{
    "015.F": {
        "short_name": "AILERON THERAP. DL-,001",
        "long_name": "Aileron Therapeutics, Inc.",
        "summary": "Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Watertown, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.aileronrx.com",
        "market_cap": "Small Cap"
    },
    "01P.F": {
        "short_name": "MEDPACE HOLDINGS  DL-,01",
        "long_name": "Medpace Holdings, Inc.",
        "summary": "Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45227",
        "website": "http://www.medpace.com",
        "market_cap": "Mid Cap"
    },
    "04IC.F": {
        "short_name": "INVIVO THERAPEU.DL-,00001",
        "long_name": "InVivo Therapeutics Holdings Corp.",
        "summary": "InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). The company is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.invivotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "07X.F": {
        "short_name": "ANNOVIS BIO INC. DL-,0001",
        "long_name": "Annovis Bio, Inc.",
        "summary": "Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Berwyn",
        "zipcode": "19312",
        "website": "http://www.annovisbio.com",
        "market_cap": "Small Cap"
    },
    "08D.F": {
        "short_name": "MIRUM PHARMAC.  DL-,0001",
        "long_name": "Mirum Pharmaceuticals, Inc.",
        "summary": "Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.mirumpharma.com",
        "market_cap": "Small Cap"
    },
    "0A3.F": {
        "short_name": "ACCELERON PHARMA DL -,001",
        "long_name": "Acceleron Pharma Inc.",
        "summary": "Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.acceleronpharma.com",
        "market_cap": "Mid Cap"
    },
    "0C1.F": {
        "short_name": "ATRECA INC.A SHS DL-,0001",
        "long_name": "Atreca, Inc.",
        "summary": "Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.atreca.com",
        "market_cap": "Small Cap"
    },
    "0C1.MU": {
        "short_name": "ATRECA INC.A SHS DL-,0001",
        "long_name": "Atreca, Inc.",
        "summary": "Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.atreca.com",
        "market_cap": "Small Cap"
    },
    "0C8.F": {
        "short_name": "CATALENT INC.  DL-,01",
        "long_name": "Catalent, Inc.",
        "summary": "Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Somerset",
        "zipcode": "08873",
        "website": "http://www.catalent.com",
        "market_cap": "Large Cap"
    },
    "0ET.F": {
        "short_name": "ESPER.THERAP.(NEW) DL-001",
        "long_name": "Esperion Therapeutics, Inc.",
        "summary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MI",
        "city": "Ann Arbor",
        "zipcode": "48108",
        "website": "http://www.esperion.com",
        "market_cap": "Small Cap"
    },
    "0F1.F": {
        "short_name": "NANOSTR.TECHNOL. DL-,0001",
        "long_name": "NanoString Technologies, Inc.",
        "summary": "NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq technologies. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; and Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma. NanoString Technologies, Inc. was founded in 2003 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98109",
        "website": "http://www.nanostring.com",
        "market_cap": "Mid Cap"
    },
    "0FY.F": {
        "short_name": "EQUILLIUM INC.  DL-,0001",
        "long_name": "Equillium, Inc.",
        "summary": "Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://equilliumbio.com",
        "market_cap": "Small Cap"
    },
    "0GT.F": {
        "short_name": "STOKE THERAPEUT.DL-,001",
        "long_name": "Stoke Therapeutics, Inc.",
        "summary": "Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Bedford",
        "zipcode": "01730",
        "website": "http://www.stoketherapeutics.com",
        "market_cap": "Small Cap"
    },
    "0HV.F": {
        "short_name": "ENVISTA HOLDINGS  DL-,01",
        "long_name": "Envista Holdings Corporation",
        "summary": "Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Brea",
        "zipcode": "92821-6208",
        "website": "http://www.envistaco.com",
        "market_cap": "Mid Cap"
    },
    "0I3.F": {
        "short_name": "AXONICS INC.",
        "long_name": "Axonics, Inc.",
        "summary": "Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.axonics.com",
        "market_cap": "Mid Cap"
    },
    "0IF.F": {
        "short_name": "LOGICBIO THERAP. DL-,0001",
        "long_name": "LogicBio Therapeutics, Inc.",
        "summary": "LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.logicbio.com",
        "market_cap": "Small Cap"
    },
    "0IGA.F": {
        "short_name": "TELIGENT INC.  DL-,01",
        "long_name": "Teligent, Inc.",
        "summary": "Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Buena",
        "zipcode": "08310",
        "website": "http://www.teligent.com",
        "market_cap": "Small Cap"
    },
    "0JS.F": {
        "short_name": "MEDMEN ENTERPRISES",
        "long_name": "MedMen Enterprises Inc.",
        "summary": "MedMen Enterprises Inc., through its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the [statemade], LuxLyte, and MedMen Red brand names. It operates 25 retail stores in 6 states. MedMen Enterprises Inc. was founded in 2010 and is headquartered in Culver City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Culver City",
        "zipcode": "90232",
        "website": "http://www.medmen.com",
        "market_cap": "Small Cap"
    },
    "0JS.SG": {
        "short_name": "MedMen Enterprises Inc. Registe",
        "long_name": "MedMen Enterprises Inc.",
        "summary": "MedMen Enterprises Inc., through its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the [statemade], LuxLyte, and MedMen Red brand names. It operates 25 retail stores in 6 states. MedMen Enterprises Inc. was founded in 2010 and is headquartered in Culver City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Culver City",
        "zipcode": "90232",
        "website": "http://www.medmen.com",
        "market_cap": "Small Cap"
    },
    "0JVN.F": {
        "short_name": "IBIO INC.  DL-,001",
        "long_name": "iBio, Inc.",
        "summary": "iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.",
        "currency": null,
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.ibioinc.com",
        "market_cap": null
    },
    "0K3.F": {
        "short_name": "TFF PHARMAC.INC.  DL-,001",
        "long_name": "TFF Pharmaceuticals, Inc.",
        "summary": "TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78746",
        "website": "http://www.tffpharma.com",
        "market_cap": "Small Cap"
    },
    "0K4.F": {
        "short_name": "AKERO THEREP.INC.DL-,0001",
        "long_name": "Akero Therapeutics, Inc.",
        "summary": "Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.akerotx.com",
        "market_cap": "Small Cap"
    },
    "0L8.F": {
        "short_name": "LANTHEUS HLDGS  DL-,01",
        "long_name": "Lantheus Holdings, Inc.",
        "summary": "Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "North Billerica",
        "zipcode": "01862",
        "website": "http://www.lantheus.com",
        "market_cap": "Small Cap"
    },
    "0M4.F": {
        "short_name": "MERSANA THERAP. DL-,0001",
        "long_name": "Mersana Therapeutics, Inc.",
        "summary": "Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.mersana.com",
        "market_cap": "Small Cap"
    },
    "0ME.F": {
        "short_name": "TWIST BIOSCIENCEDL-,00001",
        "long_name": "Twist Bioscience Corporation",
        "summary": "Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.twistbioscience.com",
        "market_cap": "Mid Cap"
    },
    "0OP.F": {
        "short_name": "OPTINOSE INC.  DL-,001",
        "long_name": "OptiNose, Inc.",
        "summary": "OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Yardley",
        "zipcode": "19067",
        "website": "http://www.optinose.com",
        "market_cap": "Small Cap"
    },
    "0OT.F": {
        "short_name": "OCULAR THERAPEUT.DL-,0001",
        "long_name": "Ocular Therapeutix, Inc.",
        "summary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Bedford",
        "zipcode": "01730",
        "website": "http://www.ocutx.com",
        "market_cap": "Small Cap"
    },
    "0P0.F": {
        "short_name": "AERIE PHARMACEUTIC.DL-001",
        "long_name": "Aerie Pharmaceuticals, Inc.",
        "summary": "Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27703",
        "website": "http://www.aeriepharma.com",
        "market_cap": "Small Cap"
    },
    "0P8.F": {
        "short_name": "PENUMBRA INC.",
        "long_name": "Penumbra, Inc.",
        "summary": "Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Alameda",
        "zipcode": "94502",
        "website": "http://www.penumbrainc.com",
        "market_cap": "Mid Cap"
    },
    "0PB.F": {
        "short_name": "PUMA BIOTECHNOLOG.DL-0001",
        "long_name": "Puma Biotechnology, Inc.",
        "summary": "Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90024",
        "website": "http://www.pumabiotechnology.com",
        "market_cap": "Small Cap"
    },
    "0PJ.F": {
        "short_name": "ALLENA PHARMAC. DL -,001",
        "long_name": "Allena Pharmaceuticals, Inc.",
        "summary": "Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Newton",
        "zipcode": "02462",
        "website": "http://www.allenapharma.com",
        "market_cap": "Small Cap"
    },
    "0QF.F": {
        "short_name": "MODERNA INC.  DL-,0001",
        "long_name": "Moderna, Inc.",
        "summary": "Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmac\u00c3\u00a9uticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.modernatx.com",
        "market_cap": "Large Cap"
    },
    "0QF.MU": {
        "short_name": "MODERNA INC.  DL-,0001",
        "long_name": "Moderna, Inc.",
        "summary": "Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmac\u00c3\u00a9uticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.modernatx.com",
        "market_cap": "Large Cap"
    },
    "0QT0.F": {
        "short_name": "GUARDI.HEALTH NEW DL-,001",
        "long_name": "Guardion Health Sciences, Inc.",
        "summary": "Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92128",
        "website": "http://www.guardionhealth.com",
        "market_cap": "Small Cap"
    },
    "0RA.MU": {
        "short_name": "RAPT THERAP. INC.DL-,0001",
        "long_name": "RAPT Therapeutics, Inc.",
        "summary": "RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.rapt.com",
        "market_cap": "Small Cap"
    },
    "0S9.F": {
        "short_name": "SYROS PHARMACEUT. DL-,001",
        "long_name": "Syros Pharmaceuticals, Inc.",
        "summary": "Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02140",
        "website": "http://www.syros.com",
        "market_cap": "Small Cap"
    },
    "0T22.F": {
        "short_name": "ONCONOVA THERAPEUT.DL-,01",
        "long_name": "Onconova Therapeutics, Inc.",
        "summary": "Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Newtown",
        "zipcode": "18940",
        "website": "http://www.onconova.com",
        "market_cap": "Small Cap"
    },
    "0VZ1.F": {
        "short_name": "ACREAGE HLDGS INC.CL.E SV",
        "long_name": "Acreage Holdings, Inc.",
        "summary": "Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.acreageholdings.com",
        "market_cap": "Small Cap"
    },
    "0VZ2.F": {
        "short_name": "ACREAGE HLDGS INC.CL.D SV",
        "long_name": "Acreage Holdings, Inc.",
        "summary": "Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.acreageholdings.com",
        "market_cap": "Small Cap"
    },
    "0WF.F": {
        "short_name": "SMILEDIRECTC. A  DL-,0001",
        "long_name": "SmileDirectClub, Inc.",
        "summary": "SmileDirectClub, Inc. operates as an oral care company. It offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a doctor, and monitoring through completion of their treatment with a network of approximately 250 state licensed orthodontists and general dentists through its teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, Spain, and Austria. It offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37219",
        "website": "http://www.smiledirectclub.com",
        "market_cap": "Mid Cap"
    },
    "0WF.MU": {
        "short_name": "SMILEDIRECTC. A  DL-,0001",
        "long_name": "SmileDirectClub, Inc.",
        "summary": "SmileDirectClub, Inc. operates as an oral care company. It offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a doctor, and monitoring through completion of their treatment with a network of approximately 250 state licensed orthodontists and general dentists through its teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, Spain, and Austria. It offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37219",
        "website": "http://www.smiledirectclub.com",
        "market_cap": "Mid Cap"
    },
    "0X4.F": {
        "short_name": "AGEX THERAPEUTI. DL0,0001",
        "long_name": "AgeX Therapeutics, Inc.",
        "summary": "AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function. The company was founded in 2017 and is based in Alameda, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Alameda",
        "zipcode": "94501",
        "website": "http://www.agexinc.com",
        "market_cap": "Small Cap"
    },
    "0ZF1.F": {
        "short_name": "GOODNESS GROWTH HLDGS INC",
        "long_name": "Vireo Health International, Inc.",
        "summary": "Vireo Health International Inc. operates as a physician-led cannabis company in the United States. It cultivates cannabis; manufactures pharmaceutical-grade cannabis extracts; and sells its products through its network of Green Goods and other retail locations, and third-party dispensaries. The company grows and/or processes cannabis in eight markets and operates 16 dispensaries. Vireo Health International Inc. is headquartered in Minneapolis, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55408",
        "website": "http://www.vireohealth.com",
        "market_cap": "Small Cap"
    },
    "0ZM.F": {
        "short_name": "HAMILTON THORNE LTD. O.N.",
        "long_name": "Hamilton Thorne Ltd.",
        "summary": "Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It offers laser products used in a range of scientific applications and in vitro fertilization (IVF) procedures; and image analysis systems used in the studies of reproductive cells in the human fertility, animal sciences, and reproductive toxicology fields. The company also provides a line of air filtration products to enhance air quality in the laboratory under the ZANDAIR brand; incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications under the Planer brand; and reproductive medicine, including clinical and laboratory equipment, and disposables, as well as installations of ART clinics under the Gynemed brand. In addition, it offers test laboratory providing services to the assisted reproductive technologies industry and laboratories under the Embryotech brand. Further, the company provides precision laser devices, imaging systems, micromanipulation systems, control rate freezers, and lab monitoring systems. It sells its products through direct sales force and distributors to pharmaceutical and biotechnology companies, animal breeding facilities, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. The company is headquartered in Beverly, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Beverly",
        "zipcode": "01915",
        "website": "http://www.hamiltonthorne.ltd",
        "market_cap": "Small Cap"
    },
    "0ZPN.F": {
        "short_name": "ZOSANO PHARM.NEW DL-,0001",
        "long_name": "Zosano Pharma Corporation",
        "summary": "Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Fremont",
        "zipcode": "94555",
        "website": "http://www.zosanopharma.com",
        "market_cap": "Small Cap"
    },
    "107.F": {
        "short_name": "BIOASIS TECHNOLOGIES INC.",
        "long_name": "Bioasis Technologies Inc.",
        "summary": "Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-002), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. has a research collaboration with Aposense Ltd. to focus on the delivery of siRNA into the brain. The company was founded in 2007 and is based in New Haven, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06510",
        "website": "http://www.bioasis.us",
        "market_cap": "Small Cap"
    },
    "109.F": {
        "short_name": "CASTLIGHT HEALT.B DL-0001",
        "long_name": "Castlight Health, Inc.",
        "summary": "Castlight Health, Inc. provides health navigation solutions for employers and health plan customers in education, manufacturing, retail, government, and technology industries in the United States. It provides Care Guidance Navigator that enables users to make better care decisions and navigate the employer-sponsored healthcare benefit programs; Wellbeing Navigator, which helps to drive engagement across an employer's benefits program; Complete Health Navigator that combines the Wellbeing Navigator and Care Guidance Navigator packages for unified user experience; and Castlight Care Guides, a high-touch navigation service. The company also offers white-labeled health navigation solutions and embedded platform technology services. In addition, it provides implementation and marketplace services. The company was formerly known as Ventana Health Services and changed its name to Castlight Health, Inc. in April 2010. Castlight Health, Inc. was incorporated in 2008 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94105",
        "website": "http://www.castlighthealth.com",
        "market_cap": "Small Cap"
    },
    "10VA.F": {
        "short_name": "IMMUNIC INC.  DL-,0001",
        "long_name": "Immunic, Inc.",
        "summary": "Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.immunic-therapeutics.com",
        "market_cap": "Small Cap"
    },
    "111N.F": {
        "short_name": "SINTX TECHS INC.  DL-,01",
        "long_name": "Sintx Technologies, Inc.",
        "summary": "Sintx Technologies, Inc., an advanced materials company, researches, develops, manufactures, and commercializes silicon nitride ceramics in the United States, Europe, and South America. It offers ceramic based solutions for various medical, industrial, and antipathogenic applications. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84119",
        "website": "http://www.sintx.com",
        "market_cap": "Small Cap"
    },
    "12V.F": {
        "short_name": "VERACYTE INC.  DL-,001",
        "long_name": "Veracyte, Inc.",
        "summary": "Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.veracyte.com",
        "market_cap": "Mid Cap"
    },
    "12X1.F": {
        "short_name": "ANAVEX LIFE SCI.  DL-,001",
        "long_name": "Anavex Life Sciences Corp.",
        "summary": "Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.anavex.com",
        "market_cap": "Small Cap"
    },
    "135A.F": {
        "short_name": "SCYNEXIS INC.  DL-,001",
        "long_name": "SCYNEXIS, Inc.",
        "summary": "SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Jersey City",
        "zipcode": "07302-6548",
        "website": "http://www.scynexis.com",
        "market_cap": "Small Cap"
    },
    "136.F": {
        "short_name": "ADAMAS PAHRMACEUT.DL-,001",
        "long_name": "Adamas Pharmaceuticals, Inc.",
        "summary": "Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.adamaspharma.com",
        "market_cap": "Small Cap"
    },
    "137.F": {
        "short_name": "ALDEYRA THERAPEUT.DL-,001",
        "long_name": "Aldeyra Therapeutics, Inc.",
        "summary": "Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.aldeyra.com",
        "market_cap": "Small Cap"
    },
    "1521.HK": {
        "short_name": "FRONTAGE",
        "long_name": "Frontage Holdings Corporation",
        "summary": "Frontage Holdings Corporation, a contract research organization, provides research, analytical, and development services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies. It offers bioanalytical services, such as method development and validation, and sample analysis services; chemistry, manufacturing, and control services, including providing assistance in drug product development and analysis, as well as delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services that include study designs, execution of studies, and interpretation of the data through structural optimization in early discovery, pharmacokinetic studies in rodents, non- GLP bioanalytical studies, etc. The company also provides safety and toxicology services comprising in-vitro and in-vivo studies; bioequivalence services, which consist of designing, coordinating, and reporting of bioequivalence studies; chemistry services comprising contract research and custom synthesis services; clinical services, such as early stage clinical, BE/BA, biometric, and data management services, as well as agrochemical services. It operates in the United States, the People's Republic of China, Britain, the Netherlands, Poland, India, Japan, Korea, Israel, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "United States",
        "state": "PA",
        "city": "Exton",
        "zipcode": "19341",
        "website": "http://www.frontagelab.com",
        "market_cap": "Small Cap"
    },
    "17K.F": {
        "short_name": "KINDRED BIOSCIENC.DL-0001",
        "long_name": "Kindred Biosciences, Inc.",
        "summary": "Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Burlingame",
        "zipcode": "94010",
        "website": "http://www.kindredbio.com",
        "market_cap": "Small Cap"
    },
    "17R.F": {
        "short_name": "TRAVERE THERAP. DL -,0001",
        "long_name": "Travere Therapeutics, Inc.",
        "summary": "Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.travere.com",
        "market_cap": "Small Cap"
    },
    "19KA.F": {
        "short_name": "CORMEDIX INC.  DL-,001",
        "long_name": "CorMedix Inc.",
        "summary": "CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Berkeley Heights",
        "zipcode": "07922",
        "website": "http://www.cormedix.com",
        "market_cap": "Small Cap"
    },
    "19P.F": {
        "short_name": "PHREESIA INC.  DL-,01",
        "long_name": "Phreesia, Inc.",
        "summary": "Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; appointments solution for online appointments, reminders, and referral tracking; and patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and PRO data for approximately 25 specialties; and life sciences solution to deliver targeted and clinically relevant marketing content to patients, as well as COVID-19 product offerings for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was founded in 2005 and is headquartered in Raleigh, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Raleigh",
        "zipcode": "27601",
        "website": "http://www.phreesia.com",
        "market_cap": "Mid Cap"
    },
    "19X.F": {
        "short_name": "AXSOME THERAPEUT. DL-0001",
        "long_name": "Axsome Therapeutics, Inc.",
        "summary": "Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10007",
        "website": "http://www.axsome.com",
        "market_cap": "Mid Cap"
    },
    "1A1.SG": {
        "short_name": "Achaogen Inc. Registered Shares",
        "long_name": "Achaogen, Inc.",
        "summary": "Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.achaogen.com",
        "market_cap": "Small Cap"
    },
    "1AQ1.SG": {
        "short_name": "Evofem Biosciences Inc. Registe",
        "long_name": "Evofem Biosciences, Inc.",
        "summary": "Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.evofem.com",
        "market_cap": "Small Cap"
    },
    "1C8.F": {
        "short_name": "VYANT BIO INC.  DL-,0001",
        "long_name": "Vyant Bio, Inc.",
        "summary": "Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cherry Hill",
        "zipcode": "08002",
        "website": "http://www.vyantbio.com",
        "market_cap": "Small Cap"
    },
    "1D5A.F": {
        "short_name": "PLX PHARMA INC.  DL -,001",
        "long_name": "PLx Pharma Inc.",
        "summary": "PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Sparta",
        "zipcode": "07871",
        "website": "http://plxpharma.com",
        "market_cap": "Small Cap"
    },
    "1FG.F": {
        "short_name": "FIBROGEN INC.  DL-,01",
        "long_name": "FibroGen, Inc.",
        "summary": "FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94158",
        "website": "http://www.fibrogen.com",
        "market_cap": "Mid Cap"
    },
    "1IJA.F": {
        "short_name": "ADICET BIO INC. DL -,0001",
        "long_name": "Adicet Bio, Inc.",
        "summary": "Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://www.adicetbio.com",
        "market_cap": "Small Cap"
    },
    "1IY.F": {
        "short_name": "MONOPAR THERAP.  -,001",
        "long_name": "Monopar Therapeutics Inc.",
        "summary": "Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Espa\u00c3\u00b1ol de Investigaci\u00c3\u00b3n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Wilmette",
        "zipcode": "60091",
        "website": "http://www.monopartx.com",
        "market_cap": "Small Cap"
    },
    "1JA2.F": {
        "short_name": "JAGUAR HEALTH  DL-,0001",
        "long_name": "Jaguar Health, Inc.",
        "summary": "Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94104",
        "website": "http://www.jaguar.health",
        "market_cap": "Small Cap"
    },
    "1JK.F": {
        "short_name": "APELLIS PHARMACT.DL-,0001",
        "long_name": "Apellis Pharmaceuticals, Inc.",
        "summary": "Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.apellis.com",
        "market_cap": "Mid Cap"
    },
    "1K9.F": {
        "short_name": "CAREDX INC.  DL-,001",
        "long_name": "CareDx, Inc",
        "summary": "CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.caredx.com",
        "market_cap": "Mid Cap"
    },
    "1LV.F": {
        "short_name": "SATSUMA PHARMACEUTICALS",
        "long_name": "Satsuma Pharmaceuticals, Inc.",
        "summary": "Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.satsumarx.com",
        "market_cap": "Small Cap"
    },
    "1LV.MU": {
        "short_name": "SATSUMA PHARMACEUTICALS",
        "long_name": "Satsuma Pharmaceuticals, Inc.",
        "summary": "Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.satsumarx.com",
        "market_cap": "Small Cap"
    },
    "1N7.F": {
        "short_name": "NEVRO CORP.  DL-,001",
        "long_name": "Nevro Corp.",
        "summary": "Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://www.nevro.com",
        "market_cap": "Mid Cap"
    },
    "1NE.F": {
        "short_name": "VERRICA PHARMAC. DL-,0001",
        "long_name": "Verrica Pharmaceuticals Inc.",
        "summary": "Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "West Chester",
        "zipcode": "19380",
        "website": "http://www.verrica.com",
        "market_cap": "Small Cap"
    },
    "1OT.F": {
        "short_name": "OVID THERAPEUTICS DL-,001",
        "long_name": "Ovid Therapeutics Inc.",
        "summary": "Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.ovidrx.com",
        "market_cap": "Small Cap"
    },
    "1P4.F": {
        "short_name": "PROTECH HOME MEDICAL NEW",
        "long_name": "Protech Home Medical Corp.",
        "summary": "Protech Home Medical Corp. provides in-home monitoring equipment, supplies, and services for patients in the United States. It offers daily and ambulatory aides; power mobility equipment; BiPAP and CPAP machines, oxygen concentrators, and ventilators; oxygen therapy; sleep apnea and PAP treatment equipment; disease management services; and home ventilator equipment, as well as rents respiratory equipment. The company was formerly known as Patient Home Monitoring Corp. and changed its name to Protech Home Medical Corp. in April 2018. Protech Home Medical Corp. was incorporated in 1993 and is headquartered in Wilder, Kentucky.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "KY",
        "city": "Wilder",
        "zipcode": "41076",
        "website": "http://www.protechhomemedical.com",
        "market_cap": "Small Cap"
    },
    "1P5.F": {
        "short_name": "PAVMED INC  DL-,001",
        "long_name": "PAVmed Inc.",
        "summary": "PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10165",
        "website": "http://www.pavmed.com",
        "market_cap": "Small Cap"
    },
    "1P5.SG": {
        "short_name": "PAVmed Inc. Registered Shares D",
        "long_name": "PAVmed Inc.",
        "summary": "PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10165",
        "website": "http://www.pavmed.com",
        "market_cap": "Small Cap"
    },
    "1R8.F": {
        "short_name": "RADIUS HEALTH INC.DL-0001",
        "long_name": "Radius Health, Inc.",
        "summary": "Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a short-wear-time transdermal patch that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.radiuspharm.com",
        "market_cap": "Small Cap"
    },
    "1RV.F": {
        "short_name": "RHYTHM PHARMAC. DL-,001",
        "long_name": "Rhythm Pharmaceuticals, Inc.",
        "summary": "Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstr\u00c3\u00b6m syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://www.rhythmtx.com",
        "market_cap": "Small Cap"
    },
    "1S1.F": {
        "short_name": "VIRIDIAN THERAPEUTICS",
        "long_name": "Viridian Therapeutics, Inc.",
        "summary": "Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80301",
        "website": "http://www.viridiantherapeutics.com",
        "market_cap": "Small Cap"
    },
    "1S7.F": {
        "short_name": "SELECTA BIOSCI. DL -,0001",
        "long_name": "Selecta Biosciences, Inc.",
        "summary": "Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://selectabio.com",
        "market_cap": "Small Cap"
    },
    "1S9.F": {
        "short_name": "SERES THERAPEUT. DL -,001",
        "long_name": "Seres Therapeutics, Inc.",
        "summary": "Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.serestherapeutics.com",
        "market_cap": "Small Cap"
    },
    "1SP.F": {
        "short_name": "SURGERY PARTNERS  DL -,01",
        "long_name": "Surgery Partners, Inc.",
        "summary": "Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through Surgical Facility Services and Ancillary Services segments. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2020, it owned or operated a portfolio of 127 surgical facilities, including 110 ambulatory surgical centers and 17 surgical hospitals in 30 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Brentwood",
        "zipcode": "37027",
        "website": "http://www.surgerypartners.com",
        "market_cap": "Mid Cap"
    },
    "1T3.F": {
        "short_name": "SYNDAX PHARMACEU.DL-,0001",
        "long_name": "Syndax Pharmaceuticals, Inc.",
        "summary": "Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.syndax.com",
        "market_cap": "Small Cap"
    },
    "1T7.F": {
        "short_name": "TRICIDA INC.  DL-,001",
        "long_name": "Tricida, Inc.",
        "summary": "Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.tricida.com",
        "market_cap": "Small Cap"
    },
    "1VT.F": {
        "short_name": "VIKING THERAPEUT.DL -,005",
        "long_name": "Viking Therapeutics, Inc.",
        "summary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00c3\u009f), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00c3\u009f for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.vikingtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "1ZU.F": {
        "short_name": "PENNANT GROUP  DL -,001",
        "long_name": "The Pennant Group, Inc.",
        "summary": "The Pennant Group, Inc. provides healthcare services in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, and meals, as well as housekeeping and assistance in the activities of daily living to seniors, who are independent or who require some support. As of February 24, 2021, the company operated 80 home health and hospice agencies; and 54 senior living communities. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "ID",
        "city": "Eagle",
        "zipcode": "83616",
        "website": "http://pennantgroup.com",
        "market_cap": "Small Cap"
    },
    "209A.F": {
        "short_name": "CATABAS.PHARM.INC. NEW",
        "long_name": "Catabasis Pharmaceuticals, Inc.",
        "summary": "Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02110",
        "website": "http://www.catabasis.com",
        "market_cap": "Small Cap"
    },
    "20D.F": {
        "short_name": "CIDARA THERAPEUT.DL-,0001",
        "long_name": "Cidara Therapeutics, Inc.",
        "summary": "Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.cidara.com",
        "market_cap": "Small Cap"
    },
    "21J.F": {
        "short_name": "JOUNCE THERAP. DL-,001",
        "long_name": "Jounce Therapeutics, Inc.",
        "summary": "Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://jouncetx.com",
        "market_cap": "Small Cap"
    },
    "22R1.F": {
        "short_name": "CONTRAFECT CORP. DL-,0001",
        "long_name": "ContraFect Corporation",
        "summary": "ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Yonkers",
        "zipcode": "10701",
        "website": "http://www.contrafect.com",
        "market_cap": "Small Cap"
    },
    "23E2.F": {
        "short_name": "EKSO BIONICS HLDGS DL-001",
        "long_name": "Ekso Bionics Holdings, Inc.",
        "summary": "Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells, and rents exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation and OttoBock Healthcare Product GmbH. The company was founded in 2005 and is headquartered in Richmond, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Richmond",
        "zipcode": "94804",
        "website": "http://www.eksobionics.com",
        "market_cap": "Small Cap"
    },
    "23I.F": {
        "short_name": "INTRA-CELLUL.THE.DL-,0001",
        "long_name": "Intra-Cellular Therapies, Inc.",
        "summary": "Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.intracellulartherapies.com",
        "market_cap": "Mid Cap"
    },
    "24OA.F": {
        "short_name": "OBALON THERAPEUT. DL-,001",
        "long_name": "Obalon Therapeutics, Inc.",
        "summary": "Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008-4410",
        "website": "http://www.obalon.com",
        "market_cap": "Small Cap"
    },
    "24PA.F": {
        "short_name": "SECOND SIGHT MED.PRODUCT.",
        "long_name": "Second Sight Medical Products, Inc.",
        "summary": "Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Sylmar",
        "zipcode": "91342",
        "website": "http://www.secondsight.com",
        "market_cap": "Small Cap"
    },
    "25K.F": {
        "short_name": "KARYOPHARM THERAP.DL-0001",
        "long_name": "Karyopharm Therapeutics Inc.",
        "summary": "Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of low-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory DLBCL. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration agreement with Curadev Pharma Pvt Ltd to identify and co-develop novel small molecules against various biological targets for the treatment of cancer; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Newton",
        "zipcode": "02459",
        "website": "http://www.karyopharm.com",
        "market_cap": "Small Cap"
    },
    "26CA.F": {
        "short_name": "IMMUNITYBIO INC. DL-,0001",
        "long_name": "ImmunityBio, Inc.",
        "summary": "ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes. ImmunityBio, Inc. was formerly known as NantCell, Inc. and changed its name to ImmunityBio, Inc. in June 2019. The company was incorporated in 2014 and is based in El Segundo, California. ImmunityBio, Inc. operates as a subsidiary of NantWorks, LLC.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "El Segundo",
        "zipcode": "90245",
        "website": "http://immunitybio.com",
        "market_cap": "Mid Cap"
    },
    "26HA.F": {
        "short_name": "HELIUS MEDICAL TECHNOLOG.",
        "long_name": "Helius Medical Technologies, Inc.",
        "summary": "Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product is Portable Neuromodulation Stimulator (PoNS), a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Newtown",
        "zipcode": "18940",
        "website": "http://heliusmedical.com",
        "market_cap": "Small Cap"
    },
    "26M.F": {
        "short_name": "MIRATI THERAPEUTICS DL-01",
        "long_name": "Mirati Therapeutics, Inc.",
        "summary": "Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.mirati.com",
        "market_cap": "Mid Cap"
    },
    "27F.F": {
        "short_name": "KALA PHARMACEUT. DL-,001",
        "long_name": "Kala Pharmaceuticals, Inc.",
        "summary": "Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.kalarx.com",
        "market_cap": "Small Cap"
    },
    "290A.F": {
        "short_name": "CHINOOK THERAP.  DL-,0001",
        "long_name": "Chinook Therapeutics, Inc.",
        "summary": "Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98102",
        "website": "http://www.chinooktx.com",
        "market_cap": "Small Cap"
    },
    "29A.F": {
        "short_name": "AMPHASTAR PHARMA.DL-,0001",
        "long_name": "Amphastar Pharmaceuticals, Inc.",
        "summary": "Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as manufactures and distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Rancho Cucamonga",
        "zipcode": "91730",
        "website": "http://www.amphastar.com",
        "market_cap": "Small Cap"
    },
    "2B3.F": {
        "short_name": "XERIS PHARMAC.  DL-,0001",
        "long_name": "Xeris Pharmaceuticals, Inc.",
        "summary": "Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60601",
        "website": "http://www.xerispharma.com",
        "market_cap": "Small Cap"
    },
    "2CB.F": {
        "short_name": "CALITHERA BIOSCIEN.DL-001",
        "long_name": "Calithera Biosciences, Inc.",
        "summary": "Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor that is in Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and CB-708, an orally administered small molecule inhibitor of CD73, as well as CB-668, an inhibitor of the enzyme IL4I1. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.calithera.com",
        "market_cap": "Small Cap"
    },
    "2CL.F": {
        "short_name": "BRIDGEBIO PHARMA  DL-,001",
        "long_name": "BridgeBio Pharma, Inc.",
        "summary": "BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); and the University of California, Davis. The company was founded in 2015 and is headquartered in Palo Alto, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Palo Alto",
        "zipcode": "94301",
        "website": "http://www.bridgebio.com",
        "market_cap": "Mid Cap"
    },
    "2CX.F": {
        "short_name": "CHEMOCENTRYX INC.",
        "long_name": "ChemoCentryx, Inc.",
        "summary": "ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Mountain View",
        "zipcode": "94043",
        "website": "http://www.chemocentryx.com",
        "market_cap": "Small Cap"
    },
    "2DE.F": {
        "short_name": "GENPREX INC  DL-,001",
        "long_name": "Genprex, Inc.",
        "summary": "Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78712-1885",
        "website": "http://www.genprex.com",
        "market_cap": "Small Cap"
    },
    "2DT.F": {
        "short_name": "AMNEAL PHMCTCLS, INC.",
        "long_name": "Amneal Pharmaceuticals, Inc.",
        "summary": "Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bridgewater",
        "zipcode": "08807",
        "website": "http://www.amneal.com",
        "market_cap": "Small Cap"
    },
    "2H0.F": {
        "short_name": "EXICURE INC.  DL-,0001",
        "long_name": "Exicure, Inc.",
        "summary": "Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA\u00c2\u0096based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60614",
        "website": "http://www.exicuretx.com",
        "market_cap": "Small Cap"
    },
    "2H51.F": {
        "short_name": "OCUGEN INC.  DL-,001",
        "long_name": "Ocugen, Inc.",
        "summary": "Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.ocugen.com",
        "market_cap": "Small Cap"
    },
    "2HA.F": {
        "short_name": "SPERO THERAP.INC. DL-,001",
        "long_name": "Spero Therapeutics, Inc.",
        "summary": "Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://sperotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "2HE.F": {
        "short_name": "HEALTHEQUITY INC.DL-,0001",
        "long_name": "HealthEquity, Inc.",
        "summary": "HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides mutual fund investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is headquartered in Draper, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Draper",
        "zipcode": "84020",
        "website": "http://www.healthequity.com",
        "market_cap": "Mid Cap"
    },
    "2IA.F": {
        "short_name": "IANTHUS CAPITAL HLDGS INC",
        "long_name": "iAnthus Capital Holdings, Inc.",
        "summary": "iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. It offers biomass products, such as pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures; cannabidiol products, such as topical creams, tinctures, and sprays, as well as products for beauty and skincare that include lotions, creams, haircare products, lip balms, and bath bombs. The company engages in the wholesale-distribution and retail of CBD products. It owns and/or operates 31 dispensaries and 10 cultivation and/or processing facilities in 9 states. The company is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10170",
        "website": "http://www.ianthus.com",
        "market_cap": "Small Cap"
    },
    "2IV.F": {
        "short_name": "INDIVIOR PLC  DL 0,10",
        "long_name": "Indivior PLC",
        "summary": "Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "VA",
        "city": "North Chesterfield",
        "zipcode": "23235",
        "website": "http://www.indivior.com",
        "market_cap": "Small Cap"
    },
    "2IVA.F": {
        "short_name": "INDIVIOR PLC ADR/5  DL 2",
        "long_name": "Indivior PLC",
        "summary": "Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "VA",
        "city": "North Chesterfield",
        "zipcode": "23235",
        "website": "http://www.indivior.com",
        "market_cap": "Small Cap"
    },
    "2JQ.F": {
        "short_name": "GRITSTONE BIO  DL-,0001",
        "long_name": "Gritstone bio, Inc.",
        "summary": "Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://gritstonebio.com",
        "market_cap": "Small Cap"
    },
    "2JQ.SG": {
        "short_name": "Gritstone Oncology Inc. Registe",
        "long_name": "Gritstone bio, Inc.",
        "summary": "Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://gritstonebio.com",
        "market_cap": "Small Cap"
    },
    "2K4.F": {
        "short_name": "PHASEBIO PHARMAC. DL-,001",
        "long_name": "PhaseBio Pharmaceuticals, Inc.",
        "summary": "PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://phasebio.com",
        "market_cap": "Small Cap"
    },
    "2K7.F": {
        "short_name": "TCR2 THERAPEUTICS  DL-,01",
        "long_name": "TCR2 Therapeutics Inc.",
        "summary": "TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies, including adult acute lymphoblastic leukemia, DLBCL, follicular lymphoma, and other non-hodgkin lymphomas that is in phase I/II clinical trial. It is also developing TC-510 for, GPC3, IL-15, and Allogenic for solid tumors, as well as DC70 for solid tumors and hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.tcr2.com",
        "market_cap": "Small Cap"
    },
    "2K7.MU": {
        "short_name": "TCR2 THERAPEUTICS  DL-,01",
        "long_name": "TCR2 Therapeutics Inc.",
        "summary": "TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies, including adult acute lymphoblastic leukemia, DLBCL, follicular lymphoma, and other non-hodgkin lymphomas that is in phase I/II clinical trial. It is also developing TC-510 for, GPC3, IL-15, and Allogenic for solid tumors, as well as DC70 for solid tumors and hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.tcr2.com",
        "market_cap": "Small Cap"
    },
    "2KZ.F": {
        "short_name": "KEZAR LIFE SCIENC.DL-,001",
        "long_name": "Kezar Life Sciences, Inc.",
        "summary": "Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.kezarlifesciences.com",
        "market_cap": "Small Cap"
    },
    "2L9.F": {
        "short_name": "BLUEPRINT MED.CORP.DL-001",
        "long_name": "Blueprint Medicines Corporation",
        "summary": "Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139-4133",
        "website": "http://www.blueprintmedicines.com",
        "market_cap": "Mid Cap"
    },
    "2LB.F": {
        "short_name": "IOVANCE BIOTHERAP.DL-,001",
        "long_name": "Iovance Biotherapeutics, Inc.",
        "summary": "Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Universit\u00c3\u00a9 de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Carlos",
        "zipcode": "94070",
        "website": "http://www.iovance.com",
        "market_cap": "Mid Cap"
    },
    "2MT.F": {
        "short_name": "ATHENEX INC.",
        "long_name": "Athenex, Inc.",
        "summary": "Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Buffalo",
        "zipcode": "14203",
        "website": "http://www.athenex.com",
        "market_cap": "Small Cap"
    },
    "2NJ.DE": {
        "short_name": "COVETRUS INC.",
        "long_name": "Covetrus, Inc.",
        "summary": "Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "ME",
        "city": "Portland",
        "zipcode": "04101",
        "website": "http://www.covetrus.com",
        "market_cap": "Mid Cap"
    },
    "2NJ.F": {
        "short_name": "COVETRUS INC.",
        "long_name": "Covetrus, Inc.",
        "summary": "Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "ME",
        "city": "Portland",
        "zipcode": "04101",
        "website": "http://www.covetrus.com",
        "market_cap": "Mid Cap"
    },
    "2PQ.F": {
        "short_name": "ORGANOGENESIS HLDGS",
        "long_name": "Organogenesis Holdings Inc.",
        "summary": "Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Canton",
        "zipcode": "02021",
        "website": "http://organogenesis.com",
        "market_cap": "Small Cap"
    },
    "2PU1.F": {
        "short_name": "PULMATRIX INC.  DL-,0001",
        "long_name": "Pulmatrix, Inc.",
        "summary": "Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.pulmatrix.com",
        "market_cap": "Small Cap"
    },
    "2Q3.F": {
        "short_name": "9 METERS BIOPHARM.DL-,001",
        "long_name": "9 Meters Biopharma, Inc.",
        "summary": "9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. 9 Meters Biopharma, Inc. has a collaboration with the Duke Clinical Research Institute to support the clinical development of NM-002. The company is headquartered in Raleigh, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Raleigh",
        "zipcode": "27615",
        "website": "http://www.9meters.com",
        "market_cap": "Small Cap"
    },
    "2Q5.SG": {
        "short_name": "Enochian Biosciences Inc Regist",
        "long_name": "Enochian Biosciences, Inc.",
        "summary": "Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90067-2012",
        "website": "http://www.enochianbio.com",
        "market_cap": "Small Cap"
    },
    "2R3.F": {
        "short_name": "REATA PHARMA INC. 0,001",
        "long_name": "Reata Pharmaceuticals, Inc.",
        "summary": "Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Plano",
        "zipcode": "75024",
        "website": "http://www.reatapharma.com",
        "market_cap": "Mid Cap"
    },
    "2RZ.F": {
        "short_name": "POSEIDA THERAP.  DL-,0001",
        "long_name": "Poseida Therapeutics, Inc.",
        "summary": "Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.poseida.com",
        "market_cap": "Small Cap"
    },
    "2SX.F": {
        "short_name": "SCPHARMACEUTIC. DL -,0001",
        "long_name": "scPharmaceuticals Inc.",
        "summary": "scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Burlington",
        "zipcode": "01803",
        "website": "http://www.scpharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "2TK.F": {
        "short_name": "ELEDON PHARMACEUT.DL-,001",
        "long_name": "Eledon Pharmaceuticals, Inc.",
        "summary": "Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92612",
        "website": "http://eledon.com",
        "market_cap": "Small Cap"
    },
    "2TX.F": {
        "short_name": "ASENSUS SURGICAL  DL-,001",
        "long_name": "Asensus Surgical, Inc.",
        "summary": "Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera; and SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. Its products also comprise instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is based in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27703",
        "website": "http://www.asensus.com",
        "market_cap": "Small Cap"
    },
    "2US.F": {
        "short_name": "NEXTCURE INC.  DL-,001",
        "long_name": "NextCure, Inc.",
        "summary": "NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Beltsville",
        "zipcode": "20705",
        "website": "http://www.nextcure.com",
        "market_cap": "Small Cap"
    },
    "2US.MU": {
        "short_name": "NEXTCURE INC.  DL-,001",
        "long_name": "NextCure, Inc.",
        "summary": "NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Beltsville",
        "zipcode": "20705",
        "website": "http://www.nextcure.com",
        "market_cap": "Small Cap"
    },
    "2VB.F": {
        "short_name": "PROVENTION BIO  DL-,0001",
        "long_name": "Provention Bio, Inc.",
        "summary": "Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. The company was incorporated in 2016 and is headquartered in Red Bank, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Red Bank",
        "zipcode": "07701",
        "website": "http://www.proventionbio.com",
        "market_cap": "Small Cap"
    },
    "2VN.F": {
        "short_name": "BIOHAVEN PHARMAC.HLDG CO.",
        "long_name": "Biohaven Pharmaceutical Holding Company Ltd.",
        "summary": "Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06510",
        "website": "http://www.biohavenpharma.com",
        "market_cap": "Mid Cap"
    },
    "2VS.F": {
        "short_name": "VERASTEM INC.  DL-,0001",
        "long_name": "Verastem, Inc.",
        "summary": "Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Needham",
        "zipcode": "02494",
        "website": "http://www.verastem.com",
        "market_cap": "Small Cap"
    },
    "2VT.F": {
        "short_name": "LIPOCINE INC.NEW DL-,0001",
        "long_name": "Lipocine Inc.",
        "summary": "Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84108",
        "website": "http://www.lipocine.com",
        "market_cap": "Small Cap"
    },
    "2W6.F": {
        "short_name": "MUSTANG BIO INC  DL-,0001",
        "long_name": "Mustang Bio, Inc.",
        "summary": "Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Worcester",
        "zipcode": "01605",
        "website": "http://www.mustangbio.com",
        "market_cap": "Small Cap"
    },
    "2W6.SG": {
        "short_name": "Mustang Bio Inc. Registered Sha",
        "long_name": "Mustang Bio, Inc.",
        "summary": "Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Worcester",
        "zipcode": "01605",
        "website": "http://www.mustangbio.com",
        "market_cap": "Small Cap"
    },
    "2X7.F": {
        "short_name": "ORTHOPEDIATRICS DL-,00025",
        "long_name": "OrthoPediatrics Corp.",
        "summary": "OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IN",
        "city": "Warsaw",
        "zipcode": "46582",
        "website": "http://www.orthopediatrics.com",
        "market_cap": "Small Cap"
    },
    "2Y3.F": {
        "short_name": "BIONANO GENOMICS DL-,0001",
        "long_name": "Bionano Genomics, Inc.",
        "summary": "Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://bionanogenomics.com",
        "market_cap": "Mid Cap"
    },
    "308.F": {
        "short_name": "CONFORMIS INC.  DL-,00001",
        "long_name": "Conformis, Inc.",
        "summary": "Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Billerica",
        "zipcode": "01821",
        "website": "http://www.conformis.com",
        "market_cap": "Small Cap"
    },
    "30J.F": {
        "short_name": "IDEAYA BIOSCIENCE  DL-,01",
        "long_name": "IDEAYA Biosciences, Inc.",
        "summary": "IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.ideayabio.com",
        "market_cap": "Small Cap"
    },
    "30J.SG": {
        "short_name": "Ideaya Biosciences Inc. Registe",
        "long_name": "IDEAYA Biosciences, Inc.",
        "summary": "IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.ideayabio.com",
        "market_cap": "Small Cap"
    },
    "31Y.F": {
        "short_name": "MORPHIC HOLDING IDL-,0001",
        "long_name": "Morphic Holding, Inc.",
        "summary": "Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4\u00c3\u009f7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing av\u00c3\u009f1 for the treatment of fibrotic diseases, and av\u00c3\u009f8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schr\u00c3\u00b6dinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.morphictx.com",
        "market_cap": "Small Cap"
    },
    "328.F": {
        "short_name": "MEIRAGTX HLDGSDL-,0000388",
        "long_name": "MeiraGTx Holdings plc",
        "summary": "MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.meiragtx.com",
        "market_cap": "Small Cap"
    },
    "32W.F": {
        "short_name": "CODIAK BIOSCIENCEDL-,0001",
        "long_name": "Codiak BioSciences, Inc.",
        "summary": "Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02140",
        "website": "http://www.codiakbio.com",
        "market_cap": "Small Cap"
    },
    "335.F": {
        "short_name": "AERPIO PHARMAC.  DL-,0001",
        "long_name": "Aerpio Pharmaceuticals, Inc.",
        "summary": "Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45242",
        "website": "http://www.aerpio.com",
        "market_cap": "Small Cap"
    },
    "335.SG": {
        "short_name": "Aerpio Pharmaceuticals Inc. Reg",
        "long_name": "Aerpio Pharmaceuticals, Inc.",
        "summary": "Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45242",
        "website": "http://www.aerpio.com",
        "market_cap": "Small Cap"
    },
    "336P.F": {
        "short_name": "HEPION PHARMACEUT. DL-,01",
        "long_name": "Hepion Pharmaceuticals, Inc.",
        "summary": "Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Edison",
        "zipcode": "08837",
        "website": "http://www.hepionpharma.com",
        "market_cap": "Small Cap"
    },
    "337.F": {
        "short_name": "CORBUS PHAR.HLDGS DL-0001",
        "long_name": "Corbus Pharmaceuticals Holdings, Inc.",
        "summary": "Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Norwood",
        "zipcode": "02062",
        "website": "http://www.corbuspharma.com",
        "market_cap": "Small Cap"
    },
    "34LA.F": {
        "short_name": "ALPINE IMMUNE SCI.DL-,001",
        "long_name": "Alpine Immune Sciences, Inc.",
        "summary": "Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98102",
        "website": "http://www.alpineimmunesciences.com",
        "market_cap": "Small Cap"
    },
    "354.F": {
        "short_name": "COLLEGIUM PHARMAC.DL-,001",
        "long_name": "Collegium Pharmaceutical, Inc.",
        "summary": "Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Stoughton",
        "zipcode": "02072",
        "website": "http://www.collegiumpharma.com",
        "market_cap": "Small Cap"
    },
    "35H.F": {
        "short_name": "HOMOLOGY MED. DL-,0001",
        "long_name": "Homology Medicines, Inc.",
        "summary": "Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Bedford",
        "zipcode": "01730",
        "website": "http://www.homologymedicines.com",
        "market_cap": "Small Cap"
    },
    "366.F": {
        "short_name": "AZURRX BIOPHARMA DL-,0001",
        "long_name": "AzurRx BioPharma, Inc.",
        "summary": "AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Delray Beach",
        "zipcode": "33445",
        "website": "http://www.azurrx.com",
        "market_cap": "Small Cap"
    },
    "36M.F": {
        "short_name": "SHOCKWAVE MEDICAL DL-,001",
        "long_name": "ShockWave Medical, Inc.",
        "summary": "ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Clara",
        "zipcode": "95054",
        "website": "http://www.shockwavemedical.com",
        "market_cap": "Mid Cap"
    },
    "37Z.F": {
        "short_name": "ALLAKOS INC. DL-,001",
        "long_name": "Allakos Inc.",
        "summary": "Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://www.allakos.com",
        "market_cap": "Mid Cap"
    },
    "38I.F": {
        "short_name": "INTELLIA THERAPEU  DL-,01",
        "long_name": "Intellia Therapeutics, Inc.",
        "summary": "Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.intelliatx.com",
        "market_cap": "Mid Cap"
    },
    "397.F": {
        "short_name": "ELOXX PHARMACEUT.  DL-,01",
        "long_name": "Eloxx Pharmaceuticals, Inc.",
        "summary": "Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.eloxxpharma.com",
        "market_cap": "Small Cap"
    },
    "39L.F": {
        "short_name": "PETIQ INC. CL. A  DL-,001",
        "long_name": "PetIQ, Inc.",
        "summary": "PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "ID",
        "city": "Eagle",
        "zipcode": "83616",
        "website": "http://www.petiq.com",
        "market_cap": "Small Cap"
    },
    "3DM.F": {
        "short_name": "KINTARA THERAP.  DL-,001",
        "long_name": "Kintara Therapeutics, Inc.",
        "summary": "Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.kintara.com",
        "market_cap": "Small Cap"
    },
    "3G0.F": {
        "short_name": "ALTIMMUNE INC.  DL-,0001",
        "long_name": "Altimmune, Inc.",
        "summary": "Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://altimmune.com",
        "market_cap": "Small Cap"
    },
    "3IP.F": {
        "short_name": "HARROW HEALTH INC. NEW",
        "long_name": "Harrow Health, Inc.",
        "summary": "Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37205",
        "website": "http://www.harrowinc.com",
        "market_cap": "Small Cap"
    },
    "3K70.F": {
        "short_name": "SILO WELLNESS INC.",
        "long_name": "Silo Wellness Inc.",
        "summary": "FlyOverture Equity Inc. doing business as Silo Wellness, engages in producing plant and fungal-based compounds for natural wellness. It offers psilocybin nasal spray made from cannabis. FlyOverture Equity Inc. was formerly known as Eighteen Fifty Equity, Inc. The company was founded in 2018 and is headquartered in Springfield, Oregon.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OR",
        "city": "Springfield",
        "zipcode": "97478",
        "website": "http://www.silowellness.com",
        "market_cap": null
    },
    "3L3.F": {
        "short_name": "TACTILE SYS TECH. DL-,001",
        "long_name": "Tactile Systems Technology, Inc.",
        "summary": "Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55416",
        "website": "http://www.tactilemedical.com",
        "market_cap": "Small Cap"
    },
    "3M4.F": {
        "short_name": "MASIMO CORP.  DL-,001",
        "long_name": "Masimo Corporation",
        "summary": "Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.masimo.com",
        "market_cap": "Large Cap"
    },
    "3O8.F": {
        "short_name": "OMEROS CORP. DL -,01",
        "long_name": "Omeros Corporation",
        "summary": "Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98119",
        "website": "http://www.omeros.com",
        "market_cap": "Small Cap"
    },
    "3T2.F": {
        "short_name": "T2 BIOSYSTEMS  DL-,001",
        "long_name": "T2 Biosystems, Inc.",
        "summary": "T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.t2biosystems.com",
        "market_cap": "Small Cap"
    },
    "41ON.F": {
        "short_name": "OUTLOOK THERAPEUT. DL-,01",
        "long_name": "Outlook Therapeutics, Inc.",
        "summary": "Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranbury",
        "zipcode": "08852",
        "website": "http://www.outlooktherapeutics.com",
        "market_cap": "Small Cap"
    },
    "41ON.SG": {
        "short_name": "Outlook Therapeutics Inc. Regis",
        "long_name": "Outlook Therapeutics, Inc.",
        "summary": "Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranbury",
        "zipcode": "08852",
        "website": "http://www.outlooktherapeutics.com",
        "market_cap": "Small Cap"
    },
    "41X.F": {
        "short_name": "ARDELYX INC.  DL-,0001",
        "long_name": "Ardelyx, Inc.",
        "summary": "Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Fremont",
        "zipcode": "94555",
        "website": "http://www.ardelyx.com",
        "market_cap": "Small Cap"
    },
    "42Z.F": {
        "short_name": "REVOLUTION MED.  DL-,0001",
        "long_name": "Revolution Medicines, Inc.",
        "summary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.revmed.com",
        "market_cap": "Mid Cap"
    },
    "43T.F": {
        "short_name": "TABULA RASA HEAL.DL-,0001",
        "long_name": "Tabula Rasa HealthCare, Inc.",
        "summary": "Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates through two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise software that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing programs or systems. The company also provides RxCompanion, a cloud-based MTM software platform designed to aid in the identification and resolution of medication and other health related problems; TruChart, a web-based electronic health record for Programs of All-Inclusive Care for the Elderly (PACE) organizations; PACElogic, which delivers real-time sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state required reporting. In addition, the company offers DoseMeRx, a decision support software; PrescribeWellness, a patient engagement center platform; and clinical pharmacist collaboration, prescription fulfillment and reminder packaging, and pharmacy cost management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2020, it served approximately 130 healthcare organizations; and 280 health plans and approximately 14,000 retail pharmacies. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Moorestown",
        "zipcode": "08057",
        "website": "http://www.tabularasahealthcare.com",
        "market_cap": "Small Cap"
    },
    "44R3.F": {
        "short_name": "PHIO PHARMACEUT. DL-,0001",
        "long_name": "Phio Pharmaceuticals Corp.",
        "summary": "Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that prevent cancer cells from inactivating T cells and attack the cancer. It has collaboration with AgonOx, Inc. on clinical development of novel immunotherapy drugs targeting key regulators of the immune response to cancer. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Marlborough",
        "zipcode": "01752",
        "website": "http://www.phiopharma.com",
        "market_cap": "Small Cap"
    },
    "45E.F": {
        "short_name": "NATERA INC.  DL-,0001",
        "long_name": "Natera, Inc.",
        "summary": "Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Carlos",
        "zipcode": "94070",
        "website": "http://www.natera.com",
        "market_cap": "Mid Cap"
    },
    "46K.F": {
        "short_name": "IRADIMED CORP.  DL-,0001",
        "long_name": "IRadimed Corporation",
        "summary": "IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Winter Springs",
        "zipcode": "32708",
        "website": "http://www.iradimed.com",
        "market_cap": "Small Cap"
    },
    "46K.SG": {
        "short_name": "iRadimed Corp. Registered Share",
        "long_name": "IRadimed Corporation",
        "summary": "IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Winter Springs",
        "zipcode": "32708",
        "website": "http://www.iradimed.com",
        "market_cap": "Small Cap"
    },
    "46L.SG": {
        "short_name": "SeaSpine Holdings Corp. Registe",
        "long_name": "SeaSpine Holdings Corporation",
        "summary": "SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and demineralized bone matrices. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive surgery, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical spine. The company has development and licensing agreement with restor3d, Inc. and 7D Surgical, Inc. to develop 3D-printed interbody devices. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008",
        "website": "http://www.seaspine.com",
        "market_cap": "Small Cap"
    },
    "471A.F": {
        "short_name": "ATYR PHARMA INC. DL -,001",
        "long_name": "aTyr Pharma, Inc.",
        "summary": "aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product ATYR1923 is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.atyrpharma.com",
        "market_cap": "Small Cap"
    },
    "47N.F": {
        "short_name": "CITIUS PHARMAC.  DL -,001",
        "long_name": "Citius Pharmaceuticals, Inc.",
        "summary": "Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranford",
        "zipcode": "07016",
        "website": "http://www.citiuspharma.com",
        "market_cap": "Small Cap"
    },
    "4875.T": {
        "short_name": "MEDICINOVA INC",
        "long_name": "MediciNova, Inc.",
        "summary": "MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://medicinova.com",
        "market_cap": "Small Cap"
    },
    "48Q.F": {
        "short_name": "X4 PHARMACEUTIC.  DL-,001",
        "long_name": "X4 Pharmaceuticals, Inc.",
        "summary": "X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenstr\u00c3\u00b6m macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02134",
        "website": "http://www.x4pharma.com",
        "market_cap": "Small Cap"
    },
    "4AB.DE": {
        "short_name": "ABBVIE INC.  DL-,01",
        "long_name": "AbbVie Inc.",
        "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh\u00c3\u00a7et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstr\u00c3\u00b6m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbvie.com",
        "market_cap": "Large Cap"
    },
    "4AB.F": {
        "short_name": "ABBVIE INC.  DL-,01",
        "long_name": "AbbVie Inc.",
        "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh\u00c3\u00a7et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstr\u00c3\u00b6m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbvie.com",
        "market_cap": "Large Cap"
    },
    "4DN.F": {
        "short_name": "DENALI THERAP.INC. DL-,01",
        "long_name": "Denali Therapeutics Inc.",
        "summary": "Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.denalitherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "4DN.MU": {
        "short_name": "DENALI THERAP.INC. DL-,01",
        "long_name": "Denali Therapeutics Inc.",
        "summary": "Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.denalitherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "4E4.F": {
        "short_name": "TRXADE GRP INC.  DL-,0001",
        "long_name": "Trxade Group, Inc.",
        "summary": "Trxade Group, Inc., together with its subsidiaries, operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc.; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services. Its principal products and services include Trxade.com, a web-based pharmaceutical marketplace; InventoryRx.com, a web-based pharmaceutical exchange platform; Pharmabayonline that provides proprietary pharmaceutical data analytics and governmental reimbursement benchmarks analysis to the United States-based independent pharmacies and pharmaceutical databases; and RxGuru, an application, which offers product information. The company also operates a retail specialty pharmacy; Delivmeds.com, a consumer-based app to provide delivery of pharmaceutical products; and Trxademso.com to assist independent retail pharmacies on pricing, distribution, and logistics. In addition, it operates Trxade Prime, which allows pharmacy members on the Trxade platform to process, consolidate, and ship purchase orders that are placed directly with Trxade suppliers; Bonum Health Hub, a virtual examination room; Bonum+, a B2B platform to purchase COVID-19 risk assessment and personal protective equipment tools; and MedCheks, a healthcare platform that lets patients consolidate and control their health data via a digital Health Passport and allows them to share their health profile, tests, and vaccination. The company is based in Land O'Lakes, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Land O'Lakes",
        "zipcode": "34639",
        "website": "http://www.trxadegroup.com",
        "market_cap": "Small Cap"
    },
    "4GB.F": {
        "short_name": "GOSSAMER BIO INC.",
        "long_name": "Gossamer Bio, Inc.",
        "summary": "Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.gossamerbio.com",
        "market_cap": "Small Cap"
    },
    "4GB.MU": {
        "short_name": "GOSSAMER BIO INC.",
        "long_name": "Gossamer Bio, Inc.",
        "summary": "Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.gossamerbio.com",
        "market_cap": "Small Cap"
    },
    "4KB.SG": {
        "short_name": "Krystal Biotech Inc. Registered",
        "long_name": "Krystal Biotech, Inc.",
        "summary": "Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Pittsburgh",
        "zipcode": "15203",
        "website": "http://www.krystalbio.com",
        "market_cap": "Small Cap"
    },
    "4LL.F": {
        "short_name": "TELADOC HEALTH INC.DL-001",
        "long_name": "Teladoc Health, Inc.",
        "summary": "Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, chronic condition management, expert medical services, behavioral health solutions, guidance and support, and platform and program services. It serves health employers, health plans, hospitals, health systems, and insurance and financial services companies. The company offers its products and services under the Teladoc, Livongo, Advance Medical, Best Doctors, BetterHelp, and HealthiestYou brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was Incorporated in 2002 and is headquartered in Purchase, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Purchase",
        "zipcode": "10577",
        "website": "http://www.teladochealth.com",
        "market_cap": "Large Cap"
    },
    "4LN2.F": {
        "short_name": "CAPRICOR THERAP.  DL-,001",
        "long_name": "Capricor Therapeutics, Inc.",
        "summary": "Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Beverly Hills",
        "zipcode": "90211",
        "website": "http://www.capricor.com",
        "market_cap": "Small Cap"
    },
    "4LS.F": {
        "short_name": "ATHERSYS INC. NEW DL-,001",
        "long_name": "Athersys, Inc.",
        "summary": "Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Cleveland",
        "zipcode": "44115-2634",
        "website": "http://www.athersys.com",
        "market_cap": "Small Cap"
    },
    "4MN.F": {
        "short_name": "MINERVA NEUROSC. DL-,0001",
        "long_name": "Minerva Neurosciences, Inc.",
        "summary": "Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.minervaneurosciences.com",
        "market_cap": "Small Cap"
    },
    "4NE1.F": {
        "short_name": "ACCOLADE INC.  DL-,0001",
        "long_name": "Accolade, Inc.",
        "summary": "Accolade, Inc. develops and provides technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and with multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. Its customers are primarily employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Plymouth Meeting",
        "zipcode": "19462",
        "website": "http://accolade.com",
        "market_cap": "Mid Cap"
    },
    "4NX1.F": {
        "short_name": "LUMOS PHARMA  DL -,01",
        "long_name": "Lumos Pharma, Inc.",
        "summary": "Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78756",
        "website": "http://www.lumos-pharma.com",
        "market_cap": "Small Cap"
    },
    "4OD.F": {
        "short_name": "ODONATE TRERAPEUT. DL-,01",
        "long_name": "Odonate Therapeutics, Inc.",
        "summary": "Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.odonate.com",
        "market_cap": "Small Cap"
    },
    "4OD.MU": {
        "short_name": "ODONATE TRERAPEUT. DL-,01",
        "long_name": "Odonate Therapeutics, Inc.",
        "summary": "Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.odonate.com",
        "market_cap": "Small Cap"
    },
    "4OR1.F": {
        "short_name": "ORGANOVO HLDGS  DL-,01",
        "long_name": "Organovo Holdings, Inc.",
        "summary": "Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Solana Beach",
        "zipcode": "92075",
        "website": "http://www.organovo.com",
        "market_cap": "Small Cap"
    },
    "4QK.F": {
        "short_name": "CODEXIS INC.  DL-,01",
        "long_name": "Codexis, Inc.",
        "summary": "Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.codexis.com",
        "market_cap": "Small Cap"
    },
    "4R8.F": {
        "short_name": "SCWORK CORP.  DL-,01",
        "long_name": "SCWorx Corp.",
        "summary": "SCWorx Corp. provides software solutions for the management of health care providers' foundational business applications in the United States. The company provides services related to repair, normalization, and interoperability of information, as well as big data analytics model that provides Web portal for display, and reporting and analysis of the information contained within the data warehouse. It also offers various software solutions and services, such as virtualized item master file repair, expansion, and automation; electronic medical record management, a module that integrates the advanced data attributes created in the item master to the electronic medical records; charge description master management(CDM), a module, which assists healthcare providers by integrating the CDM data into the workflow of the hospitals purchasing systems; contract management, a module that assists healthcare providers to establish a contract management system and to provide care to patients; request for proposal automation solution; rebate management; ScanWorx, a mobile perioperative closed loop scanning solution; and data integration and warehousing, as well as solutions for integration of acquired businesses, which enable deployment of a virtual item master files. The company sells its solutions and services to hospitals and health systems through its distribution and reseller partnerships. In addition, it provides CageTix, a ticketing platform for mixed martial arts industry. Further, the company focuses on selling rapid test kits for COVID-19; and personal protective equipment. SCWorx Corp. is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.scworx.com",
        "market_cap": "Small Cap"
    },
    "4T3A.F": {
        "short_name": "TRIPLE-S MANAG.CORP.B DL1",
        "long_name": "Triple-S Management Corporation",
        "summary": "Triple-S Management Corporation, through its subsidiaries, provides a portfolio of managed care and related products in the commercial, Medicare Advantage, and Medicaid markets. It operates through three segments: Managed Care, Life Insurance, and Property and Casualty Insurance. The company offers various managed care products, including health maintenance organization plans; preferred provider organization plans; BlueCard program; Medicare Supplement products; Medicare Advantage products; Medicaid plans; and claims processing and other administrative services to employers, individuals, and government entities. It also provides various life, accident, disability, and health insurance products, as well as annuity products primarily to individuals; and property and casualty insurance products comprising commercial multi-peril package, personal package, commercial auto, hospital malpractice, commercial liability, and commercial property primarily for small-to medium-size accounts. The company markets and distributes its products through a network of internal sales force, direct mail, independent brokers and agents, telemarketing staff, traditional media, and digital media. It holds rights to the Blue Cross and Blue Shield name and marks throughout Puerto Rico, the United States Virgin Islands, Costa Rica, the British Virgin Islands, and Anguilla. The company was founded in 1959 and is headquartered in San Juan, Puerto Rico.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PR",
        "city": "San Juan",
        "zipcode": "00920",
        "website": "http://management.grupotriples.com",
        "market_cap": "Small Cap"
    },
    "4XB.F": {
        "short_name": "XBIOTECH INC.",
        "long_name": "XBiotech Inc.",
        "summary": "XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78744",
        "website": "http://www.xbiotech.com",
        "market_cap": "Small Cap"
    },
    "4XC1.F": {
        "short_name": "KALVISTA PHARMA.  DL-,001",
        "long_name": "KalVista Pharmaceuticals, Inc.",
        "summary": "KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.kalvista.com",
        "market_cap": "Small Cap"
    },
    "5CE.F": {
        "short_name": "CERTIVE SOLUTIONS INC.",
        "long_name": "Certive Solutions Inc.",
        "summary": "Certive Solutions Inc. provides healthcare information technology solutions to hospitals and healthcare administrators in the United States. It offers revenue cycle management services. The company was formerly known as Visual Vault Corporation and changed its name to Certive Solutions Inc. in October 2013. Certive Solutions Inc. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85258",
        "website": "http://certive.com",
        "market_cap": "Small Cap"
    },
    "5EA.F": {
        "short_name": "ELANCO ANIMAL HEALTH.",
        "long_name": "Elanco Animal Health Incorporated",
        "summary": "Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IN",
        "city": "Greenfield",
        "zipcode": "46140",
        "website": "http://www.elanco.com",
        "market_cap": "Large Cap"
    },
    "5GH.DE": {
        "short_name": "GUARDANT HEALTH CL. A",
        "long_name": "Guardant Health, Inc.",
        "summary": "Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://guardanthealth.com",
        "market_cap": "Large Cap"
    },
    "5GH.F": {
        "short_name": "GUARDANT HEALTH CL. A",
        "long_name": "Guardant Health, Inc.",
        "summary": "Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://guardanthealth.com",
        "market_cap": "Large Cap"
    },
    "5HJ0.F": {
        "short_name": "HANC. JAFFE LAB.DL-,00001",
        "long_name": "Hancock Jaffe Laboratories, Inc.",
        "summary": "Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.hancockjaffe.com",
        "market_cap": "Small Cap"
    },
    "5HT.F": {
        "short_name": "HARPOON THERAPEUTICS",
        "long_name": "Harpoon Therapeutics, Inc.",
        "summary": "Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.harpoontx.com",
        "market_cap": "Small Cap"
    },
    "5JU.F": {
        "short_name": "KIROMIC BIOPHARMA INC.",
        "long_name": "Kiromic BioPharma, Inc.",
        "summary": "Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77054",
        "website": "http://www.kiromic.com",
        "market_cap": "Small Cap"
    },
    "5MC1.F": {
        "short_name": "LEAP THERAPEUTICS DL-,001",
        "long_name": "Leap Therapeutics, Inc.",
        "summary": "Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02141",
        "website": "http://www.leaptx.com",
        "market_cap": "Small Cap"
    },
    "5RT.F": {
        "short_name": "RUBIUS THERAPEUT. DL-,001",
        "long_name": "Rubius Therapeutics, Inc.",
        "summary": "Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.rubiustx.com",
        "market_cap": "Mid Cap"
    },
    "5TX.F": {
        "short_name": "SENSUS HEALTHCARE  DL-,01",
        "long_name": "Sensus Healthcare, Inc.",
        "summary": "Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary modulated robotic brachytherapy oncology therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33487",
        "website": "http://www.sensushealthcare.com",
        "market_cap": "Small Cap"
    },
    "5VA.F": {
        "short_name": "VAXCYTE INC.  DL -,001",
        "long_name": "Vaxcyte, Inc.",
        "summary": "Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.vaxcyte.com",
        "market_cap": "Small Cap"
    },
    "5VA.MU": {
        "short_name": "VAXCYTE INC.  DL -,001",
        "long_name": "Vaxcyte, Inc.",
        "summary": "Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.vaxcyte.com",
        "market_cap": "Small Cap"
    },
    "5VT.F": {
        "short_name": "VTV THERAPEUTICS A DL-,01",
        "long_name": "vTv Therapeutics Inc.",
        "summary": "vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "High Point",
        "zipcode": "27265",
        "website": "http://www.vtvtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "5WK.F": {
        "short_name": "ALIGOS THERAPEUT.  DL-,01",
        "long_name": "Aligos Therapeutics, Inc.",
        "summary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-\u00c3\u009f agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.aligos.com",
        "market_cap": "Small Cap"
    },
    "5XS2.F": {
        "short_name": "LEXAGENE HLDGS",
        "long_name": "LexaGene Holdings Inc.",
        "summary": "LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of automated genetic analyzers for pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company is headquartered in Beverly, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Beverly",
        "zipcode": "01915",
        "website": "http://www.lexagene.com",
        "market_cap": "Small Cap"
    },
    "61Y.F": {
        "short_name": "MARINUS PHARMAC.  DL-,001",
        "long_name": "Marinus Pharmaceuticals, Inc.",
        "summary": "Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Radnor",
        "zipcode": "19087",
        "website": "http://www.marinuspharma.com",
        "market_cap": "Small Cap"
    },
    "6502.F": {
        "short_name": "OPGEN INC.  DL-,01",
        "long_name": "OpGen, Inc.",
        "summary": "OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://www.opgen.com",
        "market_cap": "Small Cap"
    },
    "6598.TW": {
        "short_name": "APPLIED BIOCODE CORPORATION",
        "long_name": "Applied BioCode Corporation",
        "summary": "Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex testing products for the In-Vitro diagnostics market. The company's products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. It also develops assays, such as BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and BioCode sexually transmitted infections (STI) panels for detection of common infectious agents causing STDs, as well as MDx assays pipeline for various molecular tests. In addition, the company offers human cytokine/chemokine multiplex kits to identify relevant biomarkers; mouse premixed multiplex kits and custom panels for enhancing flexibility in experimental design allowing the user to pick and choose their own analytes panel; and rat, monkey, canine, and non-human primate cytokine/chemokine multiplex kits. Further, it provides BMB, calibration beads, and coupling kits for various bioassay applications; ELISA, a tool for the quantitative measurement of drug/protein/antibody levels in biological samples comprising cell lysate or serum; and various assay development services. The company was founded in 2016 and is based in Santa Fe Springs, California.",
        "currency": "TWD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TAI",
        "market": "tw_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Fe Springs",
        "zipcode": "90703",
        "website": "http://www.apbiocode.com",
        "market_cap": "Small Cap"
    },
    "65HA.F": {
        "short_name": "HTG MOLECUL.DIAGN.DL-,001",
        "long_name": "HTG Molecular Diagnostics, Inc.",
        "summary": "HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tucson",
        "zipcode": "85706",
        "website": "http://www.htgmolecular.com",
        "market_cap": "Small Cap"
    },
    "6819.HK": {
        "short_name": "INTELLICENTRICS",
        "long_name": "IntelliCentrics Global Holdings Ltd.",
        "summary": "IntelliCentrics Global Holdings Ltd., an investment holding company, provides credentialing services in the United States, Canada, and the United Kingdom. It primarily operates a credentialing platform for compliance and security purposes in the healthcare industry. The company's platform collects, processes, and verifies data and information in accordance with the various requirements of locations of care, including hospitals and other types of healthcare locations. It primarily provides vendor credentialing solution and medical credentialing solution through its platform, as well as add-on services. The company was formerly known as 31 Frameworks Ltd. and changed its name to IntelliCentrics Global Holdings Ltd. in February 2018. The company was founded in 2007 and is headquartered in Dallas, Texas. IntelliCentrics Global Holdings Ltd. is a subsidiary of Ocin Corp.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75028-4035",
        "website": "http://www.intellicentrics-global.com",
        "market_cap": "Small Cap"
    },
    "69BN.F": {
        "short_name": "STRONGBRIDGE BIOPH. EO 11",
        "long_name": "Strongbridge Biopharma plc",
        "summary": "Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Trevose",
        "zipcode": "19053",
        "website": "http://www.strongbridgebio.com",
        "market_cap": "Small Cap"
    },
    "6AP.F": {
        "short_name": "NEOLEUKIN TERAP. -,000001",
        "long_name": "Neoleukin Therapeutics, Inc.",
        "summary": "Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98102",
        "website": "http://www.neoleukin.com",
        "market_cap": "Small Cap"
    },
    "6C1.F": {
        "short_name": "CYTOMX THERAPEUTICS INC.",
        "long_name": "CytomX Therapeutics, Inc.",
        "summary": "CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.cytomx.com",
        "market_cap": "Small Cap"
    },
    "6CQ.F": {
        "short_name": "CRESCO LABS INC. SUB. VTG",
        "long_name": "Cresco Labs Inc.",
        "summary": "Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; flowers, popcorns, shakes, pre-rolls, and vapes under the High Supply brand; flowers, vapes, and edibles under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, ingestibles, sublingual oils, and transdermal patches under the Remedi brand, as well as cannabis products made from plants under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. It owns and operates 24 dispensaries, as well as has 5 retail licenses. The company is headquartered in Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.crescolabs.com",
        "market_cap": "Mid Cap"
    },
    "6GJ.F": {
        "short_name": "GLAUKOS CORP.  DL-,001",
        "long_name": "Glaukos Corporation",
        "summary": "Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Clemente",
        "zipcode": "92672",
        "website": "http://www.glaukos.com",
        "market_cap": "Mid Cap"
    },
    "6IO.F": {
        "short_name": "INOGEN INC.  DL -,001",
        "long_name": "Inogen, Inc.",
        "summary": "Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Goleta",
        "zipcode": "93117",
        "website": "http://www.inogen.com",
        "market_cap": "Small Cap"
    },
    "6JU.F": {
        "short_name": "BIOCARDIA INC.NEW DL-,001",
        "long_name": "BioCardia, Inc.",
        "summary": "BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Carlos",
        "zipcode": "94070",
        "website": "http://www.biocardia.com",
        "market_cap": "Small Cap"
    },
    "6KB.MU": {
        "short_name": "KINNATE BIOPHARMA -,0001",
        "long_name": "Kinnate Biopharma Inc.",
        "summary": "Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.kinnate.com",
        "market_cap": "Small Cap"
    },
    "6L6.F": {
        "short_name": "SENSEONICS HLGS.INC.-,001",
        "long_name": "Senseonics Holdings, Inc.",
        "summary": "Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Germantown",
        "zipcode": "20876-7005",
        "website": "http://www.senseonics.com",
        "market_cap": "Small Cap"
    },
    "6L7A.F": {
        "short_name": "BELLEROPHON THERAP.DL-,01",
        "long_name": "Bellerophon Therapeutics, Inc.",
        "summary": "Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Warren",
        "zipcode": "07059",
        "website": "http://www.bellerophon.com",
        "market_cap": "Small Cap"
    },
    "6L9.F": {
        "short_name": "VIEWRAY INC.",
        "long_name": "ViewRay, Inc.",
        "summary": "ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Oakwood",
        "zipcode": "44146",
        "website": "http://www.viewray.com",
        "market_cap": "Small Cap"
    },
    "6LJ.F": {
        "short_name": "MATINAS BIOPH.HLD.DL-,001",
        "long_name": "Matinas BioPharma Holdings, Inc.",
        "summary": "Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bedminster",
        "zipcode": "07921",
        "website": "http://www.matinasbiopharma.com",
        "market_cap": "Small Cap"
    },
    "6LU.F": {
        "short_name": "NOVAN INC.  DL-,0001",
        "long_name": "Novan, Inc.",
        "summary": "Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Morrisville, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560",
        "website": "http://www.novan.com",
        "market_cap": "Small Cap"
    },
    "6OM.F": {
        "short_name": "OWENS + MINOR  DL 2",
        "long_name": "Owens & Minor, Inc.",
        "summary": "Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. The company provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Richmond, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "VA",
        "city": "Richmond",
        "zipcode": "23261-7626",
        "website": "http://www.owens-minor.com",
        "market_cap": "Mid Cap"
    },
    "6T4.F": {
        "short_name": "TREVENA INC.  DL-,001",
        "long_name": "Trevena, Inc.",
        "summary": "Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Chesterbrook",
        "zipcode": "19087",
        "website": "http://www.trevena.com",
        "market_cap": "Small Cap"
    },
    "6XC1.F": {
        "short_name": "SOLENO THERAPEUT. DL-,001",
        "long_name": "Soleno Therapeutics, Inc.",
        "summary": "Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://soleno.life",
        "market_cap": "Small Cap"
    },
    "6YY.F": {
        "short_name": "SIO GENE THERAP.DL-,00001",
        "long_name": "Sio Gene Therapies Inc.",
        "summary": "Sio Gene Therapies, Inc., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was founded in 2014 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.siogtx.com",
        "market_cap": "Small Cap"
    },
    "6Z4.F": {
        "short_name": "CRINETICS PHARM. DL-,001",
        "long_name": "Crinetics Pharmaceuticals, Inc.",
        "summary": "Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.crinetics.com",
        "market_cap": "Small Cap"
    },
    "6ZY.F": {
        "short_name": "ZYNERBA PHARMACEUTIC.INC.",
        "long_name": "Zynerba Pharmaceuticals, Inc.",
        "summary": "Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Devon",
        "zipcode": "19333",
        "website": "http://zynerba.com",
        "market_cap": "Small Cap"
    },
    "700.HM": {
        "short_name": "CERTARA INC.  DL-,01",
        "long_name": "Certara, Inc.",
        "summary": "Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HAM",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.certara.com",
        "market_cap": "Mid Cap"
    },
    "72C1.F": {
        "short_name": "EIGER BIOPHARM. DL -,0001",
        "long_name": "Eiger BioPharmaceuticals, Inc.",
        "summary": "Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Palo Alto",
        "zipcode": "94306",
        "website": "http://www.eigerbio.com",
        "market_cap": "Small Cap"
    },
    "737.F": {
        "short_name": "NEXIMMUNE INC.  DL-,0001",
        "long_name": "NexImmune, Inc.",
        "summary": "NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20877",
        "website": "http://www.neximmune.com",
        "market_cap": "Small Cap"
    },
    "73C.F": {
        "short_name": "CONCERT PHARMACEUT.DL-001",
        "long_name": "Concert Pharmaceuticals, Inc.",
        "summary": "Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.concertpharma.com",
        "market_cap": "Small Cap"
    },
    "7AY1.F": {
        "short_name": "ACTINIUM PHARMAC. DL-,001",
        "long_name": "Actinium Pharmaceuticals, Inc.",
        "summary": "Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.actiniumpharma.com",
        "market_cap": "Small Cap"
    },
    "7CB1.F": {
        "short_name": "CLEVELAND BIOLABS DL-,005",
        "long_name": "Cleveland BioLabs, Inc.",
        "summary": "Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and immuno-oncology. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand; and CBL0137, a small molecule with a multi-targeted mechanism for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, Rusnano, and Everon Biosciences. The company was incorporated in 2003 and is headquartered in Buffalo, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Buffalo",
        "zipcode": "14203",
        "website": "http://www.cbiolabs.com",
        "market_cap": "Small Cap"
    },
    "7EYA.F": {
        "short_name": "EYEGATE PHARMACEUT.DL-,01",
        "long_name": "EyeGate Pharmaceuticals, Inc.",
        "summary": "EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02452",
        "website": "http://www.eyegatepharma.com",
        "market_cap": "Small Cap"
    },
    "7F0.F": {
        "short_name": "FULGENT GENETICS DL-,0001",
        "long_name": "Fulgent Genetics, Inc.",
        "summary": "Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Temple City",
        "zipcode": "91780",
        "website": "http://www.fulgentgenetics.com",
        "market_cap": "Small Cap"
    },
    "7IN.F": {
        "short_name": "INTERSECT ENT  DL-,001",
        "long_name": "Intersect ENT, Inc.",
        "summary": "Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://www.intersectent.com",
        "market_cap": "Small Cap"
    },
    "7M4.F": {
        "short_name": "MOTUS GI HLG.INC DL-,0001",
        "long_name": "Motus GI Holdings, Inc.",
        "summary": "Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with colonoscopy in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Lauderdale",
        "zipcode": "33301",
        "website": "http://www.motusgi.com",
        "market_cap": "Small Cap"
    },
    "7NSA.F": {
        "short_name": "PALISADE BIO INC. DL 0,01",
        "long_name": "Palisade Bio, Inc.",
        "summary": "Leading BioSciences, Inc. develops therapeutics to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company was founded in 2005 and is based in Carlsbad, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008",
        "website": "http://leadingbiosciences.com",
        "market_cap": "Small Cap"
    },
    "7OC.F": {
        "short_name": "ONCOCYTE CORP.",
        "long_name": "OncoCyte Corporation",
        "summary": "OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation was founded in 2009 and is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://oncocyte.com",
        "market_cap": "Small Cap"
    },
    "7OT.F": {
        "short_name": "OTONOMY INC.  DL-,001",
        "long_name": "Otonomy, Inc.",
        "summary": "Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of M\u00c3\u00a9ni\u00c3\u00a8re's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.otonomy.com",
        "market_cap": "Small Cap"
    },
    "7R8.F": {
        "short_name": "REPLIMUNE GR. INC DL-,001",
        "long_name": "Replimune Group, Inc.",
        "summary": "Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Woburn",
        "zipcode": "01801",
        "website": "http://replimune.com",
        "market_cap": "Small Cap"
    },
    "7R9B.F": {
        "short_name": "QUALIGEN THERAP. DL-,001",
        "long_name": "Qualigen Therapeutics, Inc.",
        "summary": "Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92011",
        "website": "http://www.qualigeninc.com",
        "market_cap": "Small Cap"
    },
    "7RG1.F": {
        "short_name": "REGULUS THERAPEUT.DL-,001",
        "long_name": "Regulus Therapeutics Inc.",
        "summary": "Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.regulusrx.com",
        "market_cap": "Small Cap"
    },
    "82P.F": {
        "short_name": "PACIRA BIOSCIENC. DL-,001",
        "long_name": "Pacira BioSciences, Inc.",
        "summary": "Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Parsippany",
        "zipcode": "07054",
        "website": "http://www.pacira.com",
        "market_cap": "Mid Cap"
    },
    "84C.F": {
        "short_name": "CLENE INC.",
        "long_name": "Clene Inc.",
        "summary": "Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84121",
        "website": "http://clene.com",
        "market_cap": "Small Cap"
    },
    "84P.F": {
        "short_name": "IMPEL NEUROPHARMA DL-,001",
        "long_name": "Impel NeuroPharma, Inc.",
        "summary": "Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98119",
        "website": "http://www.Impelnp.com",
        "market_cap": null
    },
    "864.F": {
        "short_name": "LIXTE BIOTECHN. HLDGS",
        "long_name": "Lixte Biotechnology Holdings, Inc.",
        "summary": "Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; pharmacologic study with the National Cancer Institute; and clinical research support agreement with City of Hope National Medical Center to carry out a Phase 1b clinical trial of its LB-100, a protein phosphatase inhibitor for small cell lung cancer. The company was incorporated in 2005 and is based in East Setauket, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "East Setauket",
        "zipcode": "11733",
        "website": "http://www.lixte.com",
        "market_cap": "Small Cap"
    },
    "8AO.F": {
        "short_name": "PANBELA THERAP.  DL-,001",
        "long_name": "Panbela Therapeutics, Inc.",
        "summary": "Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in Waconia, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Waconia",
        "zipcode": "55387",
        "website": "http://www.panbela.com",
        "market_cap": "Small Cap"
    },
    "8AP.F": {
        "short_name": "AGIOS PHARMACEUT. DL-,001",
        "long_name": "Agios Pharmaceuticals, Inc.",
        "summary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139-4169",
        "website": "http://www.agios.com",
        "market_cap": "Mid Cap"
    },
    "8AT.F": {
        "short_name": "ACLARIS THERAPEUTICS DL 1",
        "long_name": "Aclaris Therapeutics, Inc.",
        "summary": "Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Wayne",
        "zipcode": "19087",
        "website": "http://www.aclaristx.com",
        "market_cap": "Small Cap"
    },
    "8C8.SG": {
        "short_name": "Cannabis Pharmaceuticals Inc. R",
        "long_name": "Cannabics Pharmaceuticals Inc.",
        "summary": "Cannabics Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The company focuses on developing and marketing bioinformatic delivery systems for cannabinoids, personalized medicine therapies, and procedures based on cannabis originated compounds and bioinformatics tools. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, a drug sensitivity test for cannabinoid-based cancer therapies. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was founded in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Bethesda",
        "zipcode": "20814",
        "website": "http://cannabics.com",
        "market_cap": "Small Cap"
    },
    "8EM.F": {
        "short_name": "EDITAS MEDICINE  DL-,0001",
        "long_name": "Editas Medicine, Inc.",
        "summary": "Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02141",
        "website": "http://www.editasmedicine.com",
        "market_cap": "Mid Cap"
    },
    "8HH.F": {
        "short_name": "AVANOS MEDICAL INC.DL-,01",
        "long_name": "Avanos Medical, Inc.",
        "summary": "Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30004",
        "website": "http://avanos.com",
        "market_cap": "Small Cap"
    },
    "8IN.F": {
        "short_name": "SYNEOS HEALTH A  DL-,01",
        "long_name": "Syneos Health, Inc.",
        "summary": "Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560-5468",
        "website": "http://www.syneoshealth.com",
        "market_cap": "Mid Cap"
    },
    "8IY.F": {
        "short_name": "YUMANITY THERAPEUTICS INC",
        "long_name": "Yumanity Therapeutics, Inc.",
        "summary": "Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02135",
        "website": "http://www.yumanity.com",
        "market_cap": "Small Cap"
    },
    "8NE2.F": {
        "short_name": "CALADRIUS BIOSC.  DL-,001",
        "long_name": "Caladrius Biosciences, Inc.",
        "summary": "Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Basking Ridge",
        "zipcode": "07920",
        "website": "http://www.caladrius.com",
        "market_cap": "Small Cap"
    },
    "8OO.F": {
        "short_name": "HEMPFUSION WELLNES INC.",
        "long_name": "Hempfusion Wellness Inc.",
        "summary": "Hempfusion Wellness Inc., a health and wellness supplement company, manufactures, markets, and sells hemp-based cannabidiol (CBD) and probiotic products in the United States. Its products include tinctures, capsules, and topical creams and gel products under the HempFusion brand; probiotic enzymes and digestive capsules, and topical products under the Probulin brand; and HF Labs and Biome Research branded products that are versions of its hemp extract-based and probiotic products. The company sells its products through its e-commerce websites and doctor practitioners, as well as through a various food, drug, mass, and convenience market retailers. Hempfusion Wellness Inc. was founded in 2015 and is headquartered in Denver, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80202",
        "website": "http://www.hempfusion.com",
        "market_cap": "Small Cap"
    },
    "8OP.SG": {
        "short_name": "Opiant Pharmaceuticals Inc. Reg",
        "long_name": "Opiant Pharmaceuticals, Inc.",
        "summary": "Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Monica",
        "zipcode": "90401",
        "website": "http://www.opiant.com",
        "market_cap": "Small Cap"
    },
    "8STN.F": {
        "short_name": "SORRENTO THER.NEW DL-0001",
        "long_name": "Sorrento Therapeutics, Inc.",
        "summary": "Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.sorrentotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "8ZF.F": {
        "short_name": "POLAREAN IMAG.LS-,00037",
        "long_name": "Polarean Imaging plc",
        "summary": "Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of polarized Xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27713",
        "website": "http://www.polarean.com",
        "market_cap": "Small Cap"
    },
    "9CX.MU": {
        "short_name": "CELL MEDXCORP.  DL -,001",
        "long_name": "Cell MedX Corp.",
        "summary": "Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general relaxation and for the temporary relief of pain due to sore and/or aching muscles. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "NV",
        "city": "Carson City",
        "zipcode": "89706",
        "website": "http://www.cellmedx.com",
        "market_cap": "Small Cap"
    },
    "9EH.F": {
        "short_name": "EVOLENT HEALTH A  DL-,01",
        "long_name": "Evolent Health, Inc.",
        "summary": "Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients; population health performance that delivers patient-centric cost effective care; and delivery network alignments. This segment also offers specialty care management solutions that support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation, and specific market dynamics; and comprehensive health plan administrative services that helps providers assemble the complete infrastructure required to operate, manage, and capitalize on a variety of financial and administrative management services. The True Health segment operates a commercial health plan for small and large businesses in New Mexico. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "VA",
        "city": "Arlington",
        "zipcode": "22203",
        "website": "http://www.evolenthealth.com",
        "market_cap": "Small Cap"
    },
    "9EP.F": {
        "short_name": "ENANTA PHARMA.INC. DL-,01",
        "long_name": "Enanta Pharmaceuticals, Inc.",
        "summary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.enanta.com",
        "market_cap": "Small Cap"
    },
    "9PT.MU": {
        "short_name": "PLIANT THERA.INC.DL-,0001",
        "long_name": "Pliant Therapeutics, Inc.",
        "summary": "Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av\u00c3\u009f6 and av\u00c3\u009f1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective inhibitor of av\u00c3\u009f1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://pliantrx.com",
        "market_cap": "Small Cap"
    },
    "9U9.F": {
        "short_name": "UNITY BIOTECHN.  DL-,0001",
        "long_name": "Unity Biotechnology, Inc.",
        "summary": "Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.unitybiotechnology.com",
        "market_cap": "Small Cap"
    },
    "A.MX": {
        "short_name": "AGILENT TECHNOLOGIES INC",
        "long_name": "Agilent Technologies, Inc.",
        "summary": "Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Laboratories & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Clara",
        "zipcode": "95051",
        "website": "http://www.agilent.com",
        "market_cap": "Large Cap"
    },
    "A": {
        "short_name": "Agilent Technologies, Inc.",
        "long_name": "Agilent Technologies, Inc.",
        "summary": "Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Clara",
        "zipcode": "95051",
        "website": "http://www.agilent.com",
        "market_cap": "Large Cap"
    },
    "A061.F": {
        "short_name": "VIBE GROWTH CORP.",
        "long_name": "Vibe Growth Corporation",
        "summary": "Vibe Growth Corporation engages in the cultivation, production, retail, and distribution of cannabis for recreation and medicinal use in the United States, Canada, and internationally. The company operates through four segments: Dispensaries, Cultivation, Real Estate, and Canada. It operates 5 dispensaries and a cannabis greenhouse cultivation, as well as sells its products online under the Vibe By California brand. The company was formerly known as Vibe Bioscience Ltd. and changed its name to Vibe Growth Corporation in October 2020. Vibe Growth Corporation is headquartered in Sacramento, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Sacramento",
        "zipcode": "95826",
        "website": "http://www.vibebycalifornia.com",
        "market_cap": "Small Cap"
    },
    "A1BM34.SA": {
        "short_name": "ABIOMED INC DRN",
        "long_name": "Abiomed, Inc.",
        "summary": "Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Danvers",
        "zipcode": "01923",
        "website": "http://www.abiomed.com",
        "market_cap": "Large Cap"
    },
    "A1GI34.SA": {
        "short_name": "AGILENT TECHDRN",
        "long_name": "Agilent Technologies, Inc.",
        "summary": "Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Clara",
        "zipcode": "95051",
        "website": "http://www.agilent.com",
        "market_cap": "Large Cap"
    },
    "A1LG34.SA": {
        "short_name": "ALIGN TECHNODRN",
        "long_name": "Align Technology, Inc.",
        "summary": "Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85281",
        "website": "http://www.aligntech.com",
        "market_cap": "Large Cap"
    },
    "A1LN34.SA": {
        "short_name": "ALNYLAM PHARDRN",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.alnylam.com",
        "market_cap": "Large Cap"
    },
    "A1LX34.SA": {
        "short_name": "ALEXION PHARDRN",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.alexion.com",
        "market_cap": "Large Cap"
    },
    "A1MB34.SA": {
        "short_name": "AMERISOURCEBDRN",
        "long_name": "AmerisourceBergen Corporation",
        "summary": "AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "PA",
        "city": "Chesterbrook",
        "zipcode": "19087-5594",
        "website": "http://www.amerisourcebergen.com",
        "market_cap": "Large Cap"
    },
    "A1NT34.SA": {
        "short_name": "ANTHEM INC  DRN",
        "long_name": "Anthem, Inc.",
        "summary": "Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2020, it served 43 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46204",
        "website": "http://www.antheminc.com",
        "market_cap": "Large Cap"
    },
    "A41.F": {
        "short_name": "ADDUS HOMECARE CP.DL-,001",
        "long_name": "Addus HomeCare Corporation",
        "summary": "Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. As of March 9, 2021, the company served consumers through 212 offices located in 22 states. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Frisco",
        "zipcode": "75034",
        "website": "http://addus.com",
        "market_cap": "Small Cap"
    },
    "A58.F": {
        "short_name": "ANTHEM INC.  DL-,01",
        "long_name": "Anthem, Inc.",
        "summary": "Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2020, it served 43 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46204",
        "website": "http://www.antheminc.com",
        "market_cap": "Large Cap"
    },
    "A5I.F": {
        "short_name": "ATRICURE INC.  DL-,001",
        "long_name": "AtriCure, Inc.",
        "summary": "AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Mason",
        "zipcode": "45040",
        "website": "http://www.atricure.com",
        "market_cap": "Mid Cap"
    },
    "AAJ.F": {
        "short_name": "ISORAY INC.  DL-,001",
        "long_name": "Isoray, Inc.",
        "summary": "Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Richland",
        "zipcode": "99354",
        "website": "http://isoray.com",
        "market_cap": "Small Cap"
    },
    "AB3A.F": {
        "short_name": "SAREPTA THERAP.  DL-,0001",
        "long_name": "Sarepta Therapeutics, Inc.",
        "summary": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.sarepta.com",
        "market_cap": "Mid Cap"
    },
    "ABBV.BA": {
        "short_name": "ABBVIE INC",
        "long_name": "AbbVie Inc.",
        "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh\u00c3\u00a7et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstr\u00c3\u00b6m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbvie.com",
        "market_cap": null
    },
    "ABBV.MX": {
        "short_name": "ABBVIE INC",
        "long_name": "AbbVie Inc.",
        "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh\u00c3\u00a7et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstr\u00c3\u00b6m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbvie.com",
        "market_cap": "Large Cap"
    },
    "ABBV": {
        "short_name": "AbbVie Inc.",
        "long_name": "AbbVie Inc.",
        "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh\u00c3\u00a7et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstr\u00c3\u00b6m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbvie.com",
        "market_cap": "Large Cap"
    },
    "ABBV.VI": {
        "short_name": "ABBVIE INC",
        "long_name": "AbbVie Inc.",
        "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh\u00c3\u00a7et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstr\u00c3\u00b6m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbvie.com",
        "market_cap": "Large Cap"
    },
    "ABBV34.SA": {
        "short_name": "ABBVIE      DRN",
        "long_name": "AbbVie Inc.",
        "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh\u00c3\u00a7et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstr\u00c3\u00b6m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbvie.com",
        "market_cap": "Large Cap"
    },
    "ABC": {
        "short_name": "AmerisourceBergen Corporation",
        "long_name": "AmerisourceBergen Corporation",
        "summary": "AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Chesterbrook",
        "zipcode": "19087-5594",
        "website": "http://www.amerisourcebergen.com",
        "market_cap": "Large Cap"
    },
    "ABEO": {
        "short_name": "Abeona Therapeutics Inc.",
        "long_name": "Abeona Therapeutics Inc.",
        "summary": "Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.abeonatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "ABG.F": {
        "short_name": "AMERISOURCEBERGEN  DL-,01",
        "long_name": "AmerisourceBergen Corporation",
        "summary": "AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Chesterbrook",
        "zipcode": "19087-5594",
        "website": "http://www.amerisourcebergen.com",
        "market_cap": "Large Cap"
    },
    "ABIO": {
        "short_name": "ARCA biopharma, Inc.",
        "long_name": "ARCA biopharma, Inc.",
        "summary": "ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Westminster",
        "zipcode": "80021",
        "website": "http://www.arcabio.com",
        "market_cap": "Small Cap"
    },
    "ABL.DE": {
        "short_name": "ABBOTT LABS",
        "long_name": "Abbott Laboratories",
        "summary": "Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, M\u00c3\u00a9ni\u00c3\u00a8re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbott.com",
        "market_cap": "Large Cap"
    },
    "ABL.F": {
        "short_name": "ABBOTT LABS",
        "long_name": "Abbott Laboratories",
        "summary": "Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, M\u00c3\u00a9ni\u00c3\u00a8re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbott.com",
        "market_cap": "Large Cap"
    },
    "ABMC": {
        "short_name": "AMERICAN BIO MEDICA CORP",
        "long_name": "American Bio Medica Corporation",
        "summary": "American Bio Medica Corporation develops, manufactures, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides bulk test strip contract manufacturing services to non-affiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, North America, Europe, the Asia Pacific, South America, and Africa. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Kinderhook",
        "zipcode": "12106",
        "website": "http://www.abmc.com",
        "market_cap": "Small Cap"
    },
    "ABMD.MX": {
        "short_name": "ABIOMED INC",
        "long_name": "Abiomed, Inc.",
        "summary": "Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Danvers",
        "zipcode": "01923",
        "website": "http://www.abiomed.com",
        "market_cap": "Large Cap"
    },
    "ABMD": {
        "short_name": "ABIOMED, Inc.",
        "long_name": "Abiomed, Inc.",
        "summary": "Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Danvers",
        "zipcode": "01923",
        "website": "http://www.abiomed.com",
        "market_cap": "Large Cap"
    },
    "ABMT": {
        "short_name": "ADVANCED BIOMEDICAL TECHNOLOGIE",
        "long_name": "Advanced Biomedical Technologies, Inc.",
        "summary": "Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10166",
        "website": "http://abtlafleur.com",
        "market_cap": "Small Cap"
    },
    "ABT.BA": {
        "short_name": "ABBOTT LABS",
        "long_name": "Abbott Laboratories",
        "summary": "Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, M\u00c3\u00a9ni\u00c3\u00a8re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbott.com",
        "market_cap": "Large Cap"
    },
    "ABT.MX": {
        "short_name": "ABBOTT LABORATORIES",
        "long_name": "Abbott Laboratories",
        "summary": "Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, M\u00c3\u00a9ni\u00c3\u00a8re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbott.com",
        "market_cap": "Large Cap"
    },
    "ABT": {
        "short_name": "Abbott Laboratories",
        "long_name": "Abbott Laboratories",
        "summary": "Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, M\u00c3\u00a9ni\u00c3\u00a8re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbott.com",
        "market_cap": "Large Cap"
    },
    "ABT.SN": {
        "short_name": "ABBOTT LABS",
        "long_name": "Abbott Laboratories",
        "summary": "Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, M\u00c3\u00a9ni\u00c3\u00a8re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SGO",
        "market": "cl_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbott.com",
        "market_cap": "Large Cap"
    },
    "ABT.SW": {
        "short_name": "ABBOTT LABOR",
        "long_name": "Abbott Laboratories",
        "summary": "Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, M\u00c3\u00a9ni\u00c3\u00a8re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbott.com",
        "market_cap": "Large Cap"
    },
    "ABT.VI": {
        "short_name": "ABBOTT LABORATORIES",
        "long_name": "Abbott Laboratories",
        "summary": "Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, M\u00c3\u00a9ni\u00c3\u00a8re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbott.com",
        "market_cap": "Large Cap"
    },
    "ABTT34.SA": {
        "short_name": "ABBOTT      DRN",
        "long_name": "Abbott Laboratories",
        "summary": "Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, M\u00c3\u00a9ni\u00c3\u00a8re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "IL",
        "city": "North Chicago",
        "zipcode": "60064-6400",
        "website": "http://www.abbott.com",
        "market_cap": "Large Cap"
    },
    "ABUS": {
        "short_name": "Arbutus Biopharma Corporation",
        "long_name": "Arbutus Biopharma Corporation",
        "summary": "Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Warminster",
        "zipcode": "18974",
        "website": "http://www.arbutusbio.com",
        "market_cap": "Small Cap"
    },
    "ABVC": {
        "short_name": "ABVC BIOPHARMA INC",
        "long_name": "ABVC BioPharma, Inc.",
        "summary": "American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Fremont",
        "zipcode": "94538",
        "website": "http://abvcpharma.com",
        "market_cap": "Small Cap"
    },
    "AC4.F": {
        "short_name": "AUSTRALIS CAPITAL INC.",
        "long_name": "Australis Capital Inc.",
        "summary": "Australis Capital Inc. is a venture capital specializing in early-stage but not limited to equity positions and/or debt in both public and private companies, financings in exchange for royalties or other distribution streams, and control share acquisitions and buyouts. It seeks to identify and invest in United States and abroad in cannabis and real estate assets. Australis Capital Inc. is based in Las Vegas, Nevada and additional offices in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89119",
        "website": "http://www.ausa-corp.com/",
        "market_cap": "Small Cap"
    },
    "ACAD.MX": {
        "short_name": "ACADIA PHARMACEUTICALS INC",
        "long_name": "ACADIA Pharmaceuticals Inc.",
        "summary": "ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.acadia-pharm.com",
        "market_cap": "Mid Cap"
    },
    "ACAD": {
        "short_name": "ACADIA Pharmaceuticals Inc.",
        "long_name": "ACADIA Pharmaceuticals Inc.",
        "summary": "ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.acadia-pharm.com",
        "market_cap": "Mid Cap"
    },
    "ACAI": {
        "short_name": "SAFEPLUS INTL HLDGS LTD",
        "long_name": "Safeplus International Holdings Limited",
        "summary": "Safeplus International Holdings Limited develops and markets various technologies for the medical device industries. It is seeking partners to monetize its patented technologies, including biothermal power supply and pulsewidth modulation technology to enhance the performance of pacemakers and neurostimulators, and photonics and nanomaterials patents. The company was formerly known as Biophan Technologies, Inc. and changed its name to Safeplus International Holdings Limited in September 2020. Safeplus International Holdings Limited was founded in 1963 and is based in Pittsford, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Pittsford",
        "zipcode": "14534",
        "website": "http://www.biophan.com",
        "market_cap": "Small Cap"
    },
    "ACBM": {
        "short_name": "ACRO BIOMEDICAL CO LTD",
        "long_name": "Acro Biomedical Co., Ltd.",
        "summary": "Acro Biomedical Co., Ltd. develops and markets nutritional products. It sells cordycepin and cordyceps powder, a fungus used in traditional Chinese medicine; and metallothionein MT-3 elizer, a protein powder used in health supplements. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. was incorporated in 2014 and is based in Fishers, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IN",
        "city": "Fishers",
        "zipcode": "46038",
        "website": "http://acrobiomedicalco.com",
        "market_cap": "Small Cap"
    },
    "ACCA": {
        "short_name": "ACACIA DIVERSIFIED HOLDINGS INC",
        "long_name": "Acacia Diversified Holdings, Inc.",
        "summary": "Acacia Diversified Holdings, Inc. engages in the extraction and processing of high-CBD/low-THC content medical grade hemp oils from medical hemp plants in the United States. The company is also involved in the research and development of botanicals endocannabinoid nutraceuticals product line; and retail and wholesale distribution of medicinal hemp products and dietary supplements. In addition, it offers consumer products under the EUFLORIA brand name for the distribution channels. The company was formerly known as Acacia Automotive, Inc. and changed its name to Acacia Diversified Holdings, Inc. in October 2012. Acacia Diversified Holdings, Inc. was incorporated in 1984 and is based in Clearwater, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Clearwater",
        "zipcode": "33760",
        "website": "http://www.acaciadiversifiedholdings.com",
        "market_cap": "Small Cap"
    },
    "ACCD": {
        "short_name": "Accolade, Inc.",
        "long_name": "Accolade, Inc.",
        "summary": "Accolade, Inc. develops and provides technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and with multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. Its customers are primarily employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Plymouth Meeting",
        "zipcode": "19462",
        "website": "http://accolade.com",
        "market_cap": "Mid Cap"
    },
    "ACER": {
        "short_name": "Acer Therapeutics Inc.",
        "long_name": "Acer Therapeutics Inc.",
        "summary": "Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Newton",
        "zipcode": "02458",
        "website": "http://www.acertx.com",
        "market_cap": "Small Cap"
    },
    "ACET": {
        "short_name": "Adicet Bio, Inc.",
        "long_name": "Adicet Bio, Inc.",
        "summary": "Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://www.adicetbio.com",
        "market_cap": "Small Cap"
    },
    "ACGI": {
        "short_name": "AMACORE GROUP INC",
        "long_name": "The Amacore Group, Inc.",
        "summary": "The Amacore Group, Inc. provides and markets healthcare-related membership products for individuals and families. Its products include limited and major medical insurance programs, supplemental medical insurance, and discount dental and vision programs. The company also provides and markets lifestyle membership programs, including insurance discounts, discount benefit savings, ID theft, legal counsel, credit management, automotive warranties, employment protection, and a host of others. The company serves insurance carriers, financial institutions, affiliate marketers, direct marketers, insurance agents, and fortune 500 companies. It distributes its products and services through various distribution methods, such as its agent network, inbound call center, in-house sales representatives, network marketing, and affinity marketing partners, as well as through third-party direct response marketers. The Amacore Group, Inc. was formerly known as Eye Care International Inc. and changed its name to The Amacore Group, Inc. in April 2005. The company was founded in 1993 and is based in Maitland, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Maitland",
        "zipcode": "32751",
        "website": null,
        "market_cap": "Small Cap"
    },
    "ACHC": {
        "short_name": "Acadia Healthcare Company, Inc.",
        "long_name": "Acadia Healthcare Company, Inc.",
        "summary": "Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States and Puerto Rico. The company operates acute inpatient psychiatric facilities, which cares to stabilize patients that are either threat to themselves or others by hourly observation, daily intervention, and monitoring by psychiatrists; and specialty treatment facilities, including residential recovery and eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders. It also provides residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs; and outpatient community-based services, such as community-based programs that are designed to offer therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric, or chemical dependency disorders. In addition, the company provides education and children's, and adult care services. As of December 31, 2020, it operated a network of 572 behavioral healthcare facilities with approximately 18,100 beds. The company was founded in 2005 and is headquartered in Franklin, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Franklin",
        "zipcode": "37067",
        "website": "http://www.acadiahealthcare.com",
        "market_cap": "Mid Cap"
    },
    "ACNV": {
        "short_name": "ACCELERA INNOVATIONS INC",
        "long_name": "Accelera Innovations, Inc",
        "summary": "Accelera Innovations, Inc., a healthcare service company, focuses on the development of Internet-based software in the United States. The company's Accelera Technology, an Internet-based software platform enhances the functionality and performance of healthcare services through making clinical healthcare data available to healthcare consumers. It also provides billing, practice management, and administrative services to doctors and other clinicians, as well as home health services to patients in Chicago. The company was formerly known as Accelerated Acquisitions IV, Inc. and changed its name to Accelera Innovations, Inc. in October 2011. Accelera Innovations, Inc. was founded in 2008 and is based in Colorado Springs, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Colorado Springs",
        "zipcode": "80924",
        "website": "http://www.accelerainnovations.com",
        "market_cap": "Small Cap"
    },
    "ACOR": {
        "short_name": "Acorda Therapeutics, Inc.",
        "long_name": "Acorda Therapeutics, Inc.",
        "summary": "Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Ardsley",
        "zipcode": "10502",
        "website": "http://www.acorda.com",
        "market_cap": "Small Cap"
    },
    "ACRDF": {
        "short_name": "ACREAGE HOLDINGS INC",
        "long_name": "Acreage Holdings, Inc.",
        "summary": "Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.acreageholdings.com",
        "market_cap": "Small Cap"
    },
    "ACRHF": {
        "short_name": "ACREAGE HOLDINGS INC",
        "long_name": "Acreage Holdings, Inc.",
        "summary": "Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.acreageholdings.com",
        "market_cap": "Small Cap"
    },
    "ACRS": {
        "short_name": "Aclaris Therapeutics, Inc.",
        "long_name": "Aclaris Therapeutics, Inc.",
        "summary": "Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Wayne",
        "zipcode": "19087",
        "website": "http://www.aclaristx.com",
        "market_cap": "Small Cap"
    },
    "ACRX": {
        "short_name": "AcelRx Pharmaceuticals, Inc.",
        "long_name": "AcelRx Pharmaceuticals, Inc.",
        "summary": "AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.acelrx.com",
        "market_cap": "Small Cap"
    },
    "ACUR": {
        "short_name": "ACURA PHARMACEUTICALS INC",
        "long_name": "Acura Pharmaceuticals, Inc.",
        "summary": "Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Palatine",
        "zipcode": "60067",
        "website": "http://www.acurapharm.com",
        "market_cap": "Small Cap"
    },
    "ACUS": {
        "short_name": "ACUSPHERE INC",
        "long_name": "Acusphere, Inc.",
        "summary": "Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.acusphere.com",
        "market_cap": "Small Cap"
    },
    "ACXP": {
        "short_name": "Acurx Pharmaceuticals, Inc.",
        "long_name": "Acurx Pharmaceuticals, Inc.",
        "summary": "Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Staten Island",
        "zipcode": "10305",
        "website": "http://www.acurxpharma.com",
        "market_cap": "Small Cap"
    },
    "ADIL": {
        "short_name": "Adial Pharmaceuticals, Inc",
        "long_name": "Adial Pharmaceuticals, Inc.",
        "summary": "Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Charlottesville",
        "zipcode": "22901",
        "website": "http://www.adialpharma.com",
        "market_cap": "Small Cap"
    },
    "ADLI": {
        "short_name": "AMERICAN MEDICAL TECHNOLOGIES",
        "long_name": "American Medical Technologies Inc.",
        "summary": "American Medical Technologies Inc. develops, manufactures, and markets dental related equipment. The company's products include air abrasive systems, high speed curing lights, and intra-oral video cameras. It serves dentists worldwide. The company provides sales and technical support through a network of authorized distributors and dealers in North America, as well as through independent equipment representatives. American Medical Technologies Inc. was formerly known as American Dental Technologies Inc. and changed its name to American Medical Technologies Inc. in July 2000. The company was founded in 1986 and is based in Corpus Christi, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Corpus Christi",
        "zipcode": "78405",
        "website": "http://www.americanmedicaltech.com",
        "market_cap": "Small Cap"
    },
    "ADMA": {
        "short_name": "ADMA Biologics Inc",
        "long_name": "ADMA Biologics, Inc.",
        "summary": "ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Ramsey",
        "zipcode": "07446",
        "website": "http://www.admabiologics.com",
        "market_cap": "Small Cap"
    },
    "ADMP": {
        "short_name": "Adamis Pharmaceuticals Corporat",
        "long_name": "Adamis Pharmaceuticals Corporation",
        "summary": "Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.adamispharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "ADMS": {
        "short_name": "Adamas Pharmaceuticals, Inc.",
        "long_name": "Adamas Pharmaceuticals, Inc.",
        "summary": "Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.adamaspharma.com",
        "market_cap": "Small Cap"
    },
    "ADMT": {
        "short_name": "ADM TRONICS UNLIMITED INC",
        "long_name": "ADM Tronics Unlimited, Inc.",
        "summary": "ADM Tronics Unlimited, Inc., together with its subsidiary, develops, manufactures, and sells electronics for non-invasive, electrotherapeutic, and diagnostic medical devices, veterinary, and other applications in the United States, Australia, Asia, and Europe. The company offers proprietary devices for use in diagnostics and therapeutics of humans and animals; and electronic controllers for spas and hot tubs. It also provides water-based primers and adhesives; water-based coatings and resins; water-based chemical additives; and anti-static conductive paints, coatings, and other products. In addition, the company offers water-based, adhesive, and related topical formulations for use in maxillofacial prosthetic medical applications; and for professional makeup applications primarily for film, TV, and theatrical productions. Further, it provides contract manufacturing services; and research, development, regulatory, and engineering services for the design, development, and manufacturing of medical devices, electronics, and other technologies and products. The company was founded in 1969 and is headquartered in Northvale, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Northvale",
        "zipcode": "07647",
        "website": "http://www.admtronics.com",
        "market_cap": "Small Cap"
    },
    "ADPT": {
        "short_name": "Adaptive Biotechnologies Corpor",
        "long_name": "Adaptive Biotechnologies Corporation",
        "summary": "Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98102",
        "website": "http://www.adaptivebiotech.com",
        "market_cap": "Mid Cap"
    },
    "ADTX": {
        "short_name": "ADiTx Therapeutics, Inc.",
        "long_name": "ADiTx Therapeutics, Inc.",
        "summary": "ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Mountain View",
        "zipcode": "94043",
        "website": "http://www.aditxt.com",
        "market_cap": "Small Cap"
    },
    "ADUS": {
        "short_name": "Addus HomeCare Corporation",
        "long_name": "Addus HomeCare Corporation",
        "summary": "Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. As of March 9, 2021, the company served consumers through 212 offices located in 22 states. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Frisco",
        "zipcode": "75034",
        "website": "http://addus.com",
        "market_cap": "Small Cap"
    },
    "ADVM": {
        "short_name": "Adverum Biotechnologies, Inc.",
        "long_name": "Adverum Biotechnologies, Inc.",
        "summary": "Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.adverum.com",
        "market_cap": "Small Cap"
    },
    "ADVT": {
        "short_name": "ADVANTIS CORPORATION",
        "long_name": "Advantis Corp.",
        "summary": "Advantis Corp. develops and markets products focusing on medical cannabis, research, and pharmaceutical sectors. The company offers pain management and healthcare solutions. Advantis Corp. was formerly known as Ramoil Management, Ltd. and changed its name to Advantis Corp. in December 2015. Advantis Corp. is based in Newport Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newport Beach",
        "zipcode": "92660",
        "website": "http://www.advantiscorp.com",
        "market_cap": "Small Cap"
    },
    "ADXS": {
        "short_name": "Advaxis, Inc.",
        "long_name": "Advaxis, Inc.",
        "summary": "Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.advaxis.com",
        "market_cap": "Small Cap"
    },
    "ADY.F": {
        "short_name": "AMEDISYS INC.  DL-,001",
        "long_name": "Amedisys, Inc.",
        "summary": "Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "LA",
        "city": "Baton Rouge",
        "zipcode": "70816",
        "website": "http://www.amedisys.com",
        "market_cap": "Mid Cap"
    },
    "ADYX": {
        "short_name": "ADYNXX INC",
        "long_name": "Adynxx, Inc.",
        "summary": "Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94111",
        "website": "http://www.adynxx.com",
        "market_cap": "Small Cap"
    },
    "AEGY": {
        "short_name": "ALTERNATIVE ENERGY PARTNERS INC",
        "long_name": "Alternative Energy Partners, Inc.",
        "summary": "Alternative Energy Partners, Inc., a development stage company, is engaged in providing support services for medical marijuana collectives based in California. It focuses on developing PharmaJanes, a Web and phone application that allows individuals to place orders for medical marijuana through a Website and smart phone application. The company was founded in 2008 and is based in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33431",
        "website": null,
        "market_cap": "Small Cap"
    },
    "AEMD": {
        "short_name": "Aethlon Medical, Inc.",
        "long_name": "Aethlon Medical, Inc.",
        "summary": "Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.aethlonmedical.com",
        "market_cap": "Small Cap"
    },
    "AERI": {
        "short_name": "Aerie Pharmaceuticals, Inc.",
        "long_name": "Aerie Pharmaceuticals, Inc.",
        "summary": "Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27703",
        "website": "http://www.aeriepharma.com",
        "market_cap": "Small Cap"
    },
    "AEZS": {
        "short_name": "Aeterna Zentaris Inc.",
        "long_name": "Aeterna Zentaris Inc.",
        "summary": "Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "SC",
        "city": "Summerville",
        "zipcode": "29486",
        "website": "http://www.zentaris.com",
        "market_cap": "Small Cap"
    },
    "AEZS.TO": {
        "short_name": "AETERNA ZENTARIS INC",
        "long_name": "Aeterna Zentaris Inc.",
        "summary": "Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "United States",
        "state": "SC",
        "city": "Summerville",
        "zipcode": "29486",
        "website": "http://www.zentaris.com",
        "market_cap": "Small Cap"
    },
    "AFFY": {
        "short_name": "AFFYMAX INC",
        "long_name": "Affymax, Inc.",
        "summary": "Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10020",
        "website": "http://www.affymax.com",
        "market_cap": "Small Cap"
    },
    "AFIB": {
        "short_name": "Acutus Medical, Inc.",
        "long_name": "Acutus Medical, Inc.",
        "summary": "Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008",
        "website": "http://www.acutusmedical.com",
        "market_cap": "Small Cap"
    },
    "AFN.SG": {
        "short_name": "Tivity Health Inc. Registered S",
        "long_name": "Tivity Health, Inc.",
        "summary": "Tivity Health, Inc. provides fitness and health products primarily for seniors and older adults in the United States. The company offers SilverSneakers to members of Medicare Advantage, Medicare Supplement, and group retiree plans; Prime Fitness, a fitness facility access program through commercial health plans, employers, and other sponsoring organizations; virtual fitness experiences, including live instructor-led classes; and WholeHealth living program, a continuum of services related to complementary, alternative, and physical medicine. It also provides Wisely Well brand meals designed to support individuals and caregivers who are seeking meal convenience, as well as those recovering after a hospitalization or living with chronic conditions. The company was formerly known as Healthways, Inc. and changed its name to Tivity Health, Inc. in January 2017. Tivity Health, Inc. was incorporated in 1981 and is headquartered in Franklin, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Franklin",
        "zipcode": "37067",
        "website": "http://www.tivityhealth.com",
        "market_cap": "Small Cap"
    },
    "AFW.F": {
        "short_name": "ALIGN TECHNOLOGY DL-,0001",
        "long_name": "Align Technology, Inc.",
        "summary": "Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85281",
        "website": "http://www.aligntech.com",
        "market_cap": "Large Cap"
    },
    "AG8.F": {
        "short_name": "AGILENT TECHS INC. DL-,01",
        "long_name": "Agilent Technologies, Inc.",
        "summary": "Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Clara",
        "zipcode": "95051",
        "website": "http://www.agilent.com",
        "market_cap": "Large Cap"
    },
    "AGE": {
        "short_name": "AgeX Therapeutics, Inc.",
        "long_name": "AgeX Therapeutics, Inc.",
        "summary": "AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function. The company was founded in 2017 and is based in Alameda, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Alameda",
        "zipcode": "94501",
        "website": "http://www.agexinc.com",
        "market_cap": "Small Cap"
    },
    "AGEN": {
        "short_name": "Agenus Inc.",
        "long_name": "Agenus Inc.",
        "summary": "Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGF\u00c3\u009f TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421-7305",
        "website": "http://agenusbio.com",
        "market_cap": "Small Cap"
    },
    "AGHC": {
        "short_name": "AEON GLOBAL HEALTH CORP",
        "long_name": "Aeon Global Health Corp.",
        "summary": "Aeon Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States. The company operates through Laboratory Testing Services and Web-Based Software segments. Its laboratory testing services include the testing of an individual's blood, urine, or saliva for the presence of drugs or chemicals, as well as the patient's DNA profile. The company primarily offers medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. It also provides Web-based services as software as a service for Web-based revenue cycle management applications; and telehealth products and services that enable healthcare organizations to coordinate care for patients, and enhance related administrative and clinical workflows, as well as compliance with regulatory requirements. The company was formerly known as Authentidate Holding Corp. and changed its name to Aeon Global Health Corp. in January 2018. Aeon Global Health Corp. is headquartered in Gainesville, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Gainesville",
        "zipcode": "30504",
        "website": "http://www.aeonglobalhealth.com",
        "market_cap": "Small Cap"
    },
    "AGIO.MX": {
        "short_name": "AGIOS PHARMACEUTICALS INC",
        "long_name": "Agios Pharmaceuticals, Inc.",
        "summary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139-4169",
        "website": "http://www.agios.com",
        "market_cap": "Mid Cap"
    },
    "AGIO": {
        "short_name": "Agios Pharmaceuticals, Inc.",
        "long_name": "Agios Pharmaceuticals, Inc.",
        "summary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139-4169",
        "website": "http://www.agios.com",
        "market_cap": "Mid Cap"
    },
    "AGL": {
        "short_name": "agilon health, inc.",
        "long_name": "agilon health, inc.",
        "summary": "agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Long Beach",
        "zipcode": "90831",
        "website": "http://agilonhealth.com",
        "market_cap": "Large Cap"
    },
    "AGLE": {
        "short_name": "Aeglea BioTherapeutics, Inc.",
        "long_name": "Aeglea BioTherapeutics, Inc.",
        "summary": "Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78746",
        "website": "http://www.aeglea.com",
        "market_cap": "Small Cap"
    },
    "AGOL": {
        "short_name": "ANDINA GOLD CORP",
        "long_name": "Andina Gold Corp.",
        "summary": "Andina Gold Corp. focuses on gold exploration activities. The company was formerly known as Redwood Green Corp. and changed its name to Andina Gold Corp. in October 2020. Andina Gold Corp. was incorporated in 2011 and is based in Englewood, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Englewood",
        "zipcode": "80204",
        "website": "http://www.redwoodgreencorp.com",
        "market_cap": "Small Cap"
    },
    "AGRX": {
        "short_name": "Agile Therapeutics, Inc.",
        "long_name": "Agile Therapeutics, Inc.",
        "summary": "Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.agiletherapeutics.com",
        "market_cap": "Small Cap"
    },
    "AGTC": {
        "short_name": "Applied Genetic Technologies Co",
        "long_name": "Applied Genetic Technologies Corporation",
        "summary": "Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Alachua",
        "zipcode": "32615",
        "website": "http://www.agtc.com",
        "market_cap": "Small Cap"
    },
    "AGTI": {
        "short_name": "Agiliti, Inc.",
        "long_name": "Agiliti, Inc.",
        "summary": "Agiliti, Inc. provides healthcare technology management and service solutions to the healthcare industry in the United States. The company offers onsite managed services, including programs for the management, reprocessing, and logistics of medical equipment at individual facilities and integrated delivery networks to monitor and adjust equipment quantities and availability to address fluctuations in patient census and acuity; and clinical engineering services comprising maintenance, repair, and remediation solutions for various type of medical equipment, including general biomedical and diagnostic imaging equipment through supplemental and outsourced offerings. It also provides equipment solutions, which primarily provide supplemental, peak need, and per-case rental of general biomedical, specialty, and surgical equipment to acute care hospitals and alternate site providers, including premier healthcare institutions and integrated delivery networks. As of December 31, 2020, it owned or managed approximately a million units of medical equipment for approximately 7,000 national, regional, and local acute care hospitals, health system integrated delivery networks, and alternate site providers. Agiliti, Inc. was founded in 2018 and is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55439",
        "website": "http://www.agilitihealth.com",
        "market_cap": "Small Cap"
    },
    "AGTX": {
        "short_name": "AGENTIX CORP",
        "long_name": "Agentix Corp.",
        "summary": "Agentix Corp. develops and commercializes therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. The company was incorporated in 2013 and is based in Dana Point, California. Agentix Corp. is a subsidiary of Applied Biosciences Corp.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Dana Point",
        "zipcode": "92629",
        "website": "http://www.agentixcorp.com",
        "market_cap": "Small Cap"
    },
    "AHCO": {
        "short_name": "AdaptHealth Corp.",
        "long_name": "AdaptHealth Corp.",
        "summary": "AdaptHealth Corp., together with its subsidiaries, provides home healthcare equipment, medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; home medical equipment (HME) to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. It serves beneficiaries of Medicare, Medicaid, and commercial payors. The company is headquartered in Plymouth Meeting, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Plymouth Meeting",
        "zipcode": "19462",
        "website": "http://www.adapthealth.com",
        "market_cap": "Mid Cap"
    },
    "AHPI": {
        "short_name": "Allied Healthcare Products, Inc",
        "long_name": "Allied Healthcare Products, Inc.",
        "summary": "Allied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide. The company offers respiratory care/anesthesia products, including air compressors, calibration equipment, humidifiers, croup tents, and equipment dryers, as well as respiratory disposable products, such as oxygen tubing products, facemasks, cannulas, and ventilator circuits; and home respiratory care products comprising aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, portable suction equipment, and a line of respiratory disposable products. It also provides medical gas equipment, which include construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment comprising flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure, regulate, monitor, and transfer medical gases from walled piping or equipment to patients; and disposable oxygen cylinders to provide oxygen for short periods. In addition, the company offers emergency medical products that include respiratory/resuscitation products, such as demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products that include spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. It serves hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers, and others. Allied Healthcare Products, Inc. was incorporated in 1979 and is headquartered in St. Louis, Missouri.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MO",
        "city": "Saint Louis",
        "zipcode": "63110",
        "website": "http://www.alliedhpi.com",
        "market_cap": "Small Cap"
    },
    "AHROQ": {
        "short_name": "ATHERONOVA INC",
        "long_name": "AtheroNova Inc.",
        "summary": "AtheroNova Inc., a development stage company, is engaged in the research, development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. The company develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. Its lead compound includes AHRO-001, an active pharmaceutical ingredient. The company also focuses on developing various applications for its patented and patents-pending therapies in market sectors that comprise cardiovascular disease, stroke, and peripheral artery disease. AtheroNova Inc. was founded in 2006 and is based in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92612",
        "website": null,
        "market_cap": "Small Cap"
    },
    "AIKI": {
        "short_name": "AIkido Pharma Inc.",
        "long_name": "AIkido Pharma Inc.",
        "summary": "AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10020",
        "website": "http://www.aikidopharma.com",
        "market_cap": "Small Cap"
    },
    "AIM": {
        "short_name": "AIM ImmunoTech Inc.",
        "long_name": "AIM ImmunoTech Inc.",
        "summary": "AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Ocala",
        "zipcode": "34473",
        "website": "http://www.aimimmuno.com",
        "market_cap": "Small Cap"
    },
    "AIO.F": {
        "short_name": "ABIOMED INC.  DL-,01",
        "long_name": "Abiomed, Inc.",
        "summary": "Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Danvers",
        "zipcode": "01923",
        "website": "http://www.abiomed.com",
        "market_cap": "Large Cap"
    },
    "AJ81.F": {
        "short_name": "AGENUS INC.  DL-,01",
        "long_name": "Agenus Inc.",
        "summary": "Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGF\u00c3\u009f TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421-7305",
        "website": "http://agenusbio.com",
        "market_cap": "Small Cap"
    },
    "AKAOQ": {
        "short_name": "ACHAOGEN INC",
        "long_name": "Achaogen, Inc.",
        "summary": "Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.achaogen.com",
        "market_cap": "Small Cap"
    },
    "AKBA": {
        "short_name": "Akebia Therapeutics, Inc.",
        "long_name": "Akebia Therapeutics, Inc.",
        "summary": "Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.akebia.com",
        "market_cap": "Small Cap"
    },
    "AKP.F": {
        "short_name": "ANIKA THERAPEUTICS DL-,01",
        "long_name": "Anika Therapeutics, Inc.",
        "summary": "Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Bedford",
        "zipcode": "01730",
        "website": "http://www.anikatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "AKRO": {
        "short_name": "Akero Therapeutics, Inc.",
        "long_name": "Akero Therapeutics, Inc.",
        "summary": "Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.akerotx.com",
        "market_cap": "Small Cap"
    },
    "AKSY": {
        "short_name": "AKSYS LTD",
        "long_name": "Aksys Ltd.",
        "summary": "Aksys Ltd. provides hemodialysis products and services for patients suffering from end-stage renal disease, known as chronic kidney failure. The company offers an automated personal hemodialysis system, known as the Aksys PHD, a Personal Hemodialysis System (PHD System), which is designed to enable patients to perform frequent hemodialysis at alternate sites, such as their own homes. The PHD System is designed to monitor, during the treatment, various vital statistics, including the patient's blood flow rate, the amount of water removed from the patient, the length of the treatment session, and other parameters. It also evaluates the performance of the artificial kidney in removing toxins from the patient's blood prior to each treatment, as well as automatically evaluates the water treatment filters and indicates whether a replacement is required and verifies that safety systems, sensors, and alarms are operating correctly. Aksys Ltd. also provides various services, including the delivery and installation of the PHD System; technical services, including maintenance and repair of the PHD System; delivery of consumables used in dialysis, such as the water purification components and dialysate concentrate; and artificial kidney, and arterial and venous blood tubing. The company markets its products and services, primarily to healthcare providers, such as hospitals, dialysis clinics, managed care organizations, and nephrology physician groups in the United States, the United Kingdom, and Japan. Aksys Ltd. was founded in 1991 and is headquartered in Lincolnshire, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Lincolnshire",
        "zipcode": "60069",
        "website": null,
        "market_cap": "Small Cap"
    },
    "AKU": {
        "short_name": "Akumin Inc.",
        "long_name": "Akumin Inc.",
        "summary": "Akumin Inc. provides outpatient diagnostic imaging services in the United States. Its centers offer physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The company provides various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures; and online medical bill payment services. As of December 31, 2020, the company operated 127 outpatient diagnostic imaging centers located in Florida, Texas, Pennsylvania, Delaware, Georgia, Illinois, and Kansas. Akumin Inc. is headquartered in Plantation, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Plantation",
        "zipcode": "33322",
        "website": "http://www.akumin.com",
        "market_cap": "Small Cap"
    },
    "AKU.TO": {
        "short_name": "AKUMIN INC",
        "long_name": "Akumin Inc.",
        "summary": "Akumin Inc. provides outpatient diagnostic imaging services in the United States. Its centers offer physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The company provides various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures; and online medical bill payment services. As of December 31, 2020, the company operated 127 outpatient diagnostic imaging centers located in Florida, Texas, Pennsylvania, Delaware, Georgia, Illinois, and Kansas. Akumin Inc. is headquartered in Plantation, Florida.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "United States",
        "state": "FL",
        "city": "Plantation",
        "zipcode": "33322",
        "website": "http://www.akumin.com",
        "market_cap": "Small Cap"
    },
    "AKUS": {
        "short_name": "Akouos, Inc.",
        "long_name": "Akouos, Inc.",
        "summary": "Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.akouos.com",
        "market_cap": "Small Cap"
    },
    "AKYA": {
        "short_name": "Akoya BioSciences, Inc.",
        "long_name": "Akoya Biosciences, Inc.",
        "summary": "Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Marlborough",
        "zipcode": "01752",
        "website": "http://www.akoyabio.com",
        "market_cap": "Small Cap"
    },
    "AL21.F": {
        "short_name": "ALLSCRIPTS HEAL.SOL.DL-01",
        "long_name": "Allscripts Healthcare Solutions, Inc.",
        "summary": "Allscripts Healthcare Solutions, Inc., together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates in two segments: The Core Clinical and Financial Solutions; and The Data, Analytics and Care Coordination. The Core Clinical and Financial Solutions segment provides software applications for patient engagement, and integrated clinical and financial management solutions, which primarily include EHR-related software; and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Data, Analytics and Care Coordination segment offers practice reimbursement, and payer and life sciences solutions, which are primarily targeted at physician practices, payers, life sciences companies, and other healthcare stakeholders. Its solutions enable clients to transition, analyze, and coordinate care and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.allscripts.com",
        "market_cap": "Mid Cap"
    },
    "ALBO": {
        "short_name": "Albireo Pharma, Inc.",
        "long_name": "Albireo Pharma, Inc.",
        "summary": "Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02109",
        "website": "http://www.albireopharma.com",
        "market_cap": "Small Cap"
    },
    "ALDX": {
        "short_name": "Aldeyra Therapeutics, Inc.",
        "long_name": "Aldeyra Therapeutics, Inc.",
        "summary": "Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.aldeyra.com",
        "market_cap": "Small Cap"
    },
    "ALEC": {
        "short_name": "Alector, Inc.",
        "long_name": "Alector, Inc.",
        "summary": "Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.alector.com",
        "market_cap": "Small Cap"
    },
    "ALGN.MX": {
        "short_name": "ALIGN TECHNOLOGY INC",
        "long_name": "Align Technology, Inc.",
        "summary": "Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85281",
        "website": "http://www.aligntech.com",
        "market_cap": "Large Cap"
    },
    "ALGN": {
        "short_name": "Align Technology, Inc.",
        "long_name": "Align Technology, Inc.",
        "summary": "Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85281",
        "website": "http://www.aligntech.com",
        "market_cap": "Large Cap"
    },
    "ALGN.VI": {
        "short_name": "ALIGN TECHNOLOGY INC",
        "long_name": "Align Technology, Inc.",
        "summary": "Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85281",
        "website": "http://www.aligntech.com",
        "market_cap": "Large Cap"
    },
    "ALGS": {
        "short_name": "Aligos Therapeutics, Inc.",
        "long_name": "Aligos Therapeutics, Inc.",
        "summary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-\u00c3\u009f agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.aligos.com",
        "market_cap": "Small Cap"
    },
    "ALHC": {
        "short_name": "Alignment Healthcare, Inc.",
        "long_name": "Alignment Healthcare, Inc.",
        "summary": "Alignment Healthcare, Inc. provides a consumer-centric platform that delivers customized health care to seniors in the United States. It offers medicare advantage plans and health plan options to its partners and patients with customized care and service; and preferred provider organization offerings. The company was founded in 2013 and is based in Orange, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Orange",
        "zipcode": "92868",
        "website": "http://www.alignmenthealthcare.com",
        "market_cap": "Mid Cap"
    },
    "ALIM": {
        "short_name": "Alimera Sciences, Inc.",
        "long_name": "Alimera Sciences, Inc.",
        "summary": "Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30005",
        "website": "http://www.alimerasciences.com",
        "market_cap": "Small Cap"
    },
    "ALLK": {
        "short_name": "Allakos Inc.",
        "long_name": "Allakos Inc.",
        "summary": "Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://www.allakos.com",
        "market_cap": "Mid Cap"
    },
    "ALLO": {
        "short_name": "Allogene Therapeutics, Inc.",
        "long_name": "Allogene Therapeutics, Inc.",
        "summary": "Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.allogene.com",
        "market_cap": "Mid Cap"
    },
    "ALNA": {
        "short_name": "Allena Pharmaceuticals, Inc.",
        "long_name": "Allena Pharmaceuticals, Inc.",
        "summary": "Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Newton",
        "zipcode": "02462",
        "website": "http://www.allenapharma.com",
        "market_cap": "Small Cap"
    },
    "ALNY.MX": {
        "short_name": "ALNYLAM PHARMACEUTICALS INC",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.alnylam.com",
        "market_cap": "Large Cap"
    },
    "ALNY": {
        "short_name": "Alnylam Pharmaceuticals, Inc.",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.alnylam.com",
        "market_cap": "Large Cap"
    },
    "ALPN": {
        "short_name": "Alpine Immune Sciences, Inc.",
        "long_name": "Alpine Immune Sciences, Inc.",
        "summary": "Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98102",
        "website": "http://www.alpineimmunesciences.com",
        "market_cap": "Small Cap"
    },
    "ALRN": {
        "short_name": "Aileron Therapeutics, Inc.",
        "long_name": "Aileron Therapeutics, Inc.",
        "summary": "Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.aileronrx.com",
        "market_cap": "Small Cap"
    },
    "ALRT": {
        "short_name": "ALR TECHNOLOGIES INC",
        "long_name": "ALR Technologies Inc.",
        "summary": "ALR Technologies Inc. develops compliance monitoring systems that enable health care professionals to remotely monitor patient health conditions in the United States. The company's product includes Diabetes Management System, which consists of a communications software platform that enables health professionals to monitor the health progress of patients with diabetes. Its primary business markets are the providers of health insurance and the providers of disease and case management services, including the home care industry. The company was formerly known as Mo Betta Corp. and changed its name to ALR Technologies Inc. in December 1998. ALR Technologies Inc. was founded in 1987 and is headquartered in Richmond, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Richmond",
        "zipcode": "23225",
        "website": "http://www.alrt.com",
        "market_cap": "Small Cap"
    },
    "ALSE": {
        "short_name": "ALSERES PHARMACEUTICALS INC",
        "long_name": "Alseres Pharmaceuticals, Inc.",
        "summary": "Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Auburndale",
        "zipcode": "02466",
        "website": "http://www.alseres.com",
        "market_cap": "Small Cap"
    },
    "ALT": {
        "short_name": "Altimmune, Inc.",
        "long_name": "Altimmune, Inc.",
        "summary": "Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://altimmune.com",
        "market_cap": "Small Cap"
    },
    "ALT1.MX": {
        "short_name": "ALTIMMUNE INC",
        "long_name": "Altimmune, Inc.",
        "summary": "Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://altimmune.com",
        "market_cap": "Small Cap"
    },
    "ALVR": {
        "short_name": "AlloVir, Inc.",
        "long_name": "AlloVir, Inc.",
        "summary": "Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.allovir.com",
        "market_cap": "Small Cap"
    },
    "ALXN.MX": {
        "short_name": "ALEXION PHARMACEUTICAL INC",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.alexion.com",
        "market_cap": "Large Cap"
    },
    "ALXN": {
        "short_name": "Alexion Pharmaceuticals, Inc.",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.alexion.com",
        "market_cap": "Large Cap"
    },
    "ALXN.VI": {
        "short_name": "ALEXION PHARMACEUTICALS INC",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.alexion.com",
        "market_cap": "Large Cap"
    },
    "ALXO": {
        "short_name": "ALX Oncology Holdings Inc.",
        "long_name": "ALX Oncology Holdings Inc.",
        "summary": "ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Burlingame",
        "zipcode": "94010",
        "website": "http://www.alxoncology.com",
        "market_cap": "Mid Cap"
    },
    "AM6.F": {
        "short_name": "AMICUS THERAPEUTICS INC.",
        "long_name": "Amicus Therapeutics, Inc.",
        "summary": "Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19104",
        "website": "http://amicusrx.com",
        "market_cap": "Mid Cap"
    },
    "AMAR": {
        "short_name": "AMARILLO BIOSCIENCES",
        "long_name": "Amarillo Biosciences, Inc.",
        "summary": "Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Amarillo",
        "zipcode": "79110",
        "website": "http://www.amarbio.com",
        "market_cap": "Small Cap"
    },
    "AMBD": {
        "short_name": "AMERICAN MOBILE DENTAL CORP",
        "long_name": "American Mobile Dental Corp.",
        "summary": "American Mobile Dental Corp. engages in the ownership and operation of mobile dental offices in the northeast region of the United States. These mobile dental offices provide dental and health management services for consumers in economic development areas in New York. The company provides various services, including oral examinations, X-rays, dental prophylaxes, nutrition counseling, fluoride treatments, sealant, amalgam and composite restorations, stainless steel crowns, polycarbonate anterior crowns, root canal therapy for primary and permanent teeth, and extractions and minor oral surgery. It also manages dental centers that offer treatments, such as crown and bridge, molar root canals, orthodontics, and TMJ therapy, as well as various cosmetic procedures. In addition, American Mobile Dental provides dental screenings and educational materials to individuals at inner city schools, malls, health fairs, college campuses, senior citizen centers, convalescent homes, and elementary schools. The company was founded in 2000. It was formerly known as Tradepubz.com, Inc. and changed its name to American Mobile Dental Corp. in 2004. American Mobile Dental is headquartered in Mamaroneck, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Mamaroneck",
        "zipcode": "10543",
        "website": "http://www.americanmobiledental.com",
        "market_cap": "Small Cap"
    },
    "AMBS": {
        "short_name": "AMARANTUS BIOSCIENCE HLDGS INC",
        "long_name": "Amarantus BioScience Holdings, Inc.",
        "summary": "Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10005",
        "website": "http://www.amarantus.com",
        "market_cap": "Small Cap"
    },
    "AMCY": {
        "short_name": "ACS GLOBAL INC",
        "long_name": "ACS Global, Inc.",
        "summary": "ACS Global, Inc. engages in the collection, processing, and long-term storage of stem cells. The company's services would allow individuals to privately preserve their stem cells for potential future use in cell therapy. The company was formerly known as American CryoStem Corp. and changed its name to ACS Global, Inc. in June 2011. The company is based in Red Bank, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Red Bank",
        "zipcode": "07701",
        "website": "http://www.americancryostem.com",
        "market_cap": null
    },
    "AMED.MX": {
        "short_name": "AMEDISYS INC",
        "long_name": "Amedisys, Inc.",
        "summary": "Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "LA",
        "city": "Baton Rouge",
        "zipcode": "70816",
        "website": "http://www.amedisys.com",
        "market_cap": "Mid Cap"
    },
    "AMED": {
        "short_name": "Amedisys Inc",
        "long_name": "Amedisys, Inc.",
        "summary": "Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "LA",
        "city": "Baton Rouge",
        "zipcode": "70816",
        "website": "http://www.amedisys.com",
        "market_cap": "Mid Cap"
    },
    "AMEH": {
        "short_name": "Apollo Medical Holdings, Inc.",
        "long_name": "Apollo Medical Holdings, Inc.",
        "summary": "Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare management company, provides medical care services. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was founded in 1994 and is headquartered in Alhambra, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Alhambra",
        "zipcode": "91801",
        "website": "http://www.apollomed.net",
        "market_cap": "Mid Cap"
    },
    "AMG.DE": {
        "short_name": "AMGEN INC.  DL-,0001",
        "long_name": "Amgen Inc.",
        "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00c3\u00a7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "Thousand Oaks",
        "zipcode": "91320-1799",
        "website": "http://www.amgen.com",
        "market_cap": "Large Cap"
    },
    "AMG.F": {
        "short_name": "AMGEN INC.  DL-,0001",
        "long_name": "Amgen Inc.",
        "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00c3\u00a7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Thousand Oaks",
        "zipcode": "91320-1799",
        "website": "http://www.amgen.com",
        "market_cap": "Large Cap"
    },
    "AMGN.MX": {
        "short_name": "AMGEN INC",
        "long_name": "Amgen Inc.",
        "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00c3\u00a7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Thousand Oaks",
        "zipcode": "91320-1799",
        "website": "http://www.amgen.com",
        "market_cap": "Large Cap"
    },
    "AMGN": {
        "short_name": "Amgen Inc.",
        "long_name": "Amgen Inc.",
        "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00c3\u00a7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Thousand Oaks",
        "zipcode": "91320-1799",
        "website": "http://www.amgen.com",
        "market_cap": "Large Cap"
    },
    "AMGN.VI": {
        "short_name": "AMGEN INC",
        "long_name": "Amgen Inc.",
        "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00c3\u00a7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "CA",
        "city": "Thousand Oaks",
        "zipcode": "91320-1799",
        "website": "http://www.amgen.com",
        "market_cap": "Large Cap"
    },
    "AMGN34.SA": {
        "short_name": "AMGEN       DRN",
        "long_name": "Amgen Inc.",
        "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00c3\u00a7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "Thousand Oaks",
        "zipcode": "91320-1799",
        "website": "http://www.amgen.com",
        "market_cap": "Large Cap"
    },
    "AMHD": {
        "short_name": "HLK BIOTECH HOLDING GROUP INC",
        "long_name": "HLK Biotech Holding Group, Inc.",
        "summary": "HLK Biotech Holding Group, Inc., through its subsidiaries, produces and sells biodiesel. It also acquires real estate properties. The company was formerly known as Amelot Holdings, Inc. and changed its name to HLK Biotech Holding Group, Inc. in February 2018. HLK Biotech Holding Group, Inc. is headquartered in Norfolk, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Norfolk",
        "zipcode": "23517",
        "website": "http://www.amelotholdings.com",
        "market_cap": "Small Cap"
    },
    "AMHV": {
        "short_name": "AMERICAN HEMP VENTURES INC",
        "long_name": "American Hemp Ventures Inc.",
        "summary": "ASC Biosciences, Inc., a biotechnology company, develops products that restore, maintain, and improve tissue function in humans. It offers Chondrofelt, a medical device to repair articular cartilage defects caused by trauma/osteoarthritis; PeriGen, a product that regenerates peritoneum following abdominal surgery to prevent surgical adhesions; ChondroGen, a product to regenerate articular cartilage and subchondral bone in patients with cartilage damage resulting from sports injury, traumatic injury, and osteoarthritis; and RhytiGen, a product that utilizes MASCs to form connective tissue when injected under the skin. The company also provides MeniGen, a product that incorporates MASCs into a matrix for use as a universal allogeneic meniscus graft; OsteoGen, a product that utilizes MASCs in polylactic acid polymers/purchased porous bone substitutes as three-dimensional scaffolds for the healing of fractures, non-union fractures, and craniofacial defects; and DermiGen, a product that utilizes MASCs to form the cell types in skin, fibroblasts in the dermis, and keratinocytes in the epidermis. ASC Biosciences, Inc. was founded in 2015 and is based in Palm Desert, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Palm Desert",
        "zipcode": "92260",
        "website": "http://www.ascbio.com",
        "market_cap": "Small Cap"
    },
    "AMN": {
        "short_name": "AMN Healthcare Services Inc AMN",
        "long_name": "AMN Healthcare Services, Inc.",
        "summary": "AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to hospitals and healthcare facilities in the United States. The company operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. It offers travel nurse staffing under the American Mobile, Onward Healthcare, and O'Grady Peyton brands; rapid response nurse staffing and labor disruption services under the NurseChoice and HealthSource Global Staffing brands; local or per diem staffing services under Nursefinders brand; and locum tenens staffing services under the Staff Care and Locum Leaders brands. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists under the Med Travelers and Club Staffing brands; revenue cycle solutions; physician permanent placement services to hospitals, healthcare facilities, and physician practice groups; interim leadership staffing and executive search services; and recruitment process outsourcing services. In addition, it offers managed services programs; language interpretation services; vendor management systems; workforce optimization services; credentialing services; digital staffing services; and flex pool management services. AMN Healthcare Services, Inc. was founded in 1985 and is based in Dallas, Taxas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75019",
        "website": "http://www.amnhealthcare.com",
        "market_cap": "Mid Cap"
    },
    "AMPE": {
        "short_name": "Ampio Pharmaceuticals, Inc.",
        "long_name": "Ampio Pharmaceuticals, Inc.",
        "summary": "Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Englewood",
        "zipcode": "80112",
        "website": "http://www.ampiopharma.com",
        "market_cap": "Small Cap"
    },
    "AMPH": {
        "short_name": "Amphastar Pharmaceuticals, Inc.",
        "long_name": "Amphastar Pharmaceuticals, Inc.",
        "summary": "Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as manufactures and distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Rancho Cucamonga",
        "zipcode": "91730",
        "website": "http://www.amphastar.com",
        "market_cap": "Small Cap"
    },
    "AMRX": {
        "short_name": "Amneal Pharmaceuticals, Inc.",
        "long_name": "Amneal Pharmaceuticals, Inc.",
        "summary": "Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bridgewater",
        "zipcode": "08807",
        "website": "http://www.amneal.com",
        "market_cap": "Small Cap"
    },
    "AMS": {
        "short_name": "American Shared Hospital Servic",
        "long_name": "American Shared Hospital Services",
        "summary": "American Shared Hospital Services leases radiosurgery and radiation therapy equipment to health care providers. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. As of March 1, 2021, it had thirteen operating Gamma Knife units located in the United States, as well as two in South America in Lima, Peru and Guayaquil, Ecuador. The company also operates one PBRT system. American Shared Hospital Services was founded in 1980 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94111-4107",
        "website": "http://ashs.com",
        "market_cap": "Small Cap"
    },
    "AMTI": {
        "short_name": "Applied Molecular Transport Inc",
        "long_name": "Applied Molecular Transport Inc.",
        "summary": "Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.appliedmt.com",
        "market_cap": "Small Cap"
    },
    "AMWL": {
        "short_name": "American Well Corporation",
        "long_name": "American Well Corporation",
        "summary": "American Well Corporation operates as a telehealth company that enables digital delivery of care for healthcare. Its application offers urgent care; pediatrics; therapy; menopause nutrition; menopause counseling; telestroke; population health management; telepsychiatry; pregnancy and postpartum care; pregnancy and postpartum therapy; breastfeed support; and menopause care. The company also provides telemedicine equipment, including telemedicine carts, peripherals, TV kits, tablets, and kiosks. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02109",
        "website": "http://amwell.com",
        "market_cap": "Mid Cap"
    },
    "AN6.F": {
        "short_name": "ANAPTYSBIO INC.  DL-,001",
        "long_name": "AnaptysBio, Inc.",
        "summary": "AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.anaptysbio.com",
        "market_cap": "Small Cap"
    },
    "ANAB": {
        "short_name": "AnaptysBio, Inc.",
        "long_name": "AnaptysBio, Inc.",
        "summary": "AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.anaptysbio.com",
        "market_cap": "Small Cap"
    },
    "ANAS": {
        "short_name": "ALTERNATURALS INC",
        "long_name": "Alternaturals, Inc.",
        "summary": "Alternaturals, Inc. manufactures and distributes supplements and all-natural remedies that are alternatives to prescription drugs. Its products include Focamine, an all-natural focus, attention, and concentration promoter for people suffering from ADHD; and Sombium, an alternative sleep aid. The company was formerly known as Premier Mortgage Resources, Inc. and changed its name to Alternaturals, Inc. in May 2014. The company was founded in 1995 and is based in Grandville, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New Windsor",
        "zipcode": "12553",
        "website": "http://alternaturals.com",
        "market_cap": "Small Cap"
    },
    "ANEB": {
        "short_name": "Anebulo Pharmaceuticals, Inc.",
        "long_name": "Anebulo Pharmaceuticals, Inc.",
        "summary": "Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Lakeway",
        "zipcode": "78734",
        "website": "http://www.anebulo.com",
        "market_cap": "Small Cap"
    },
    "ANGN": {
        "short_name": "Angion Biomedica Corp.",
        "long_name": "Angion Biomedica Corp.",
        "summary": "Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Uniondale",
        "zipcode": "11553",
        "website": "http://www.angion.com",
        "market_cap": "Small Cap"
    },
    "ANGO": {
        "short_name": "AngioDynamics, Inc.",
        "long_name": "AngioDynamics, Inc.",
        "summary": "AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Latham",
        "zipcode": "12110",
        "website": "http://www.angiodynamics.com",
        "market_cap": "Small Cap"
    },
    "ANIK": {
        "short_name": "Anika Therapeutics Inc.",
        "long_name": "Anika Therapeutics, Inc.",
        "summary": "Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Bedford",
        "zipcode": "01730",
        "website": "http://www.anikatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "ANIP": {
        "short_name": "ANI Pharmaceuticals, Inc.",
        "long_name": "ANI Pharmaceuticals, Inc.",
        "summary": "ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Baudette",
        "zipcode": "56623",
        "website": "http://www.anipharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "ANIX": {
        "short_name": "Anixa Biosciences, Inc.",
        "long_name": "Anixa Biosciences, Inc.",
        "summary": "Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Jose",
        "zipcode": "95118",
        "website": "http://www.anixa.com",
        "market_cap": "Small Cap"
    },
    "ANNX": {
        "short_name": "Annexon, Inc.",
        "long_name": "Annexon, Inc.",
        "summary": "Annexon, Inc., a clinical-stage biopharmaceutical company, engages in developing therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its products in pipelines are focused on antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. Its products include ANX005 (IV), which is in Phase III stage with guillain-barr\u00c3\u00a9 syndrome indication, as well as in Phase II stage with warm autoimmune hemolytic anemia, huntington's disease, and amyotrophic lateral sclerosis indications; ANX007 (IVT), a Phase II candidate with geographic atrophy indication; and ANX009 (SubQ), which is in Phase I stage with autoimmune indications. The company was founded in 2011 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.annexonbio.com",
        "market_cap": "Small Cap"
    },
    "ANTH": {
        "short_name": "ANTHERA PHARMACEUTICALS INC",
        "long_name": "Anthera Pharmaceuticals, Inc.",
        "summary": "Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77002",
        "website": "http://www.anthera.com",
        "market_cap": "Small Cap"
    },
    "ANTI": {
        "short_name": "ANTIGENICS INC",
        "long_name": "Antigenics, Inc.",
        "summary": "Antigenics, Inc. is based in Huntingdon Valley, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Huntingdon Valley",
        "zipcode": "19006-5518",
        "website": "http://agenusbio.com",
        "market_cap": null
    },
    "ANTM.MX": {
        "short_name": "ANTHEM INC",
        "long_name": "Anthem, Inc.",
        "summary": "Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2020, it served 43 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46204",
        "website": "http://www.antheminc.com",
        "market_cap": "Large Cap"
    },
    "ANTM": {
        "short_name": "Anthem, Inc.",
        "long_name": "Anthem, Inc.",
        "summary": "Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2020, it served 43 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46204",
        "website": "http://www.antheminc.com",
        "market_cap": "Large Cap"
    },
    "ANTM.VI": {
        "short_name": "ANTHEM INC",
        "long_name": "Anthem, Inc.",
        "summary": "Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2020, it served 43 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46204",
        "website": "http://www.antheminc.com",
        "market_cap": "Large Cap"
    },
    "ANVS": {
        "short_name": "Annovis Bio, Inc.",
        "long_name": "Annovis Bio, Inc.",
        "summary": "Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Berwyn",
        "zipcode": "19312",
        "website": "http://www.annovisbio.com",
        "market_cap": "Small Cap"
    },
    "AOLS": {
        "short_name": "AEOLUS PHARMACEUTICALS INC",
        "long_name": "Aeolus Pharmaceuticals, Inc.",
        "summary": "Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Mission Viejo",
        "zipcode": "92691",
        "website": "http://www.aeoluspharma.com",
        "market_cap": "Small Cap"
    },
    "AP8N.F": {
        "short_name": "APTEVO THERAP.INC.DL-,001",
        "long_name": "Aptevo Therapeutics Inc.",
        "summary": "Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98121",
        "website": "http://www.aptevotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "APDN": {
        "short_name": "Applied DNA Sciences, Inc.",
        "long_name": "Applied DNA Sciences, Inc.",
        "summary": "Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications and can be used to fortify brand protection efforts, and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide definitive real-time authentication of molecular tags in the field; and CertainT Supply Chain Platform that provides proof of product claims for materials, items, or products. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Stony Brook",
        "zipcode": "11790",
        "website": "http://www.adnas.com",
        "market_cap": "Small Cap"
    },
    "APEN": {
        "short_name": "Apollo Endosurgery, Inc.",
        "long_name": "Apollo Endosurgery, Inc.",
        "summary": "Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands; and Orbera Coach, a digital and remotely delivered aftercare program. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78746",
        "website": "http://www.apolloendo.com",
        "market_cap": "Small Cap"
    },
    "APH.F": {
        "short_name": "AMPIO PHARMACEUTIC.DL-,01",
        "long_name": "Ampio Pharmaceuticals, Inc.",
        "summary": "Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Englewood",
        "zipcode": "80112",
        "website": "http://www.ampiopharma.com",
        "market_cap": "Small Cap"
    },
    "APLS": {
        "short_name": "Apellis Pharmaceuticals, Inc.",
        "long_name": "Apellis Pharmaceuticals, Inc.",
        "summary": "Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.apellis.com",
        "market_cap": "Mid Cap"
    },
    "APLT": {
        "short_name": "Applied Therapeutics, Inc.",
        "long_name": "Applied Therapeutics, Inc.",
        "summary": "Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.appliedtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "APPB": {
        "short_name": "APPLIED BIOSCIENCES CORP",
        "long_name": "Applied Biosciences Corp.",
        "summary": "Applied Biosciences Corp. focuses on the development and commercialization of novel, synthetic cannabinoid therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a range of diseases across various therapeutic areas. It is focused on investment and partnership opportunities under the Applied BioSciences brand in the medical, scientific, nutraceutical, and health and wellness markets. The company also produces health and wellness products, including creams, balms, tinctures, concentrates, and edibles under the Remedi, Remedi Plus, Herbal Pet, MTN CBD, Champ Organics, and Equine Care names. It focuses on various areas of the medical, scientific, bioceutical, hemp, and CBD industry. In addition, the company provides lab testing services. It delivers consumer and OTC THC-free CBD products to its customers in the United States and internationally. Applied Biosciences Corp. was incorporated in 2014 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.appliedbiocorp.com",
        "market_cap": "Small Cap"
    },
    "APR": {
        "short_name": "Apria, Inc.",
        "long_name": "Apria, Inc.",
        "summary": "Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. The company was incorporated in 2018 and is headquartered in Indianapolis, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46237",
        "website": "http://www.apria.com",
        "market_cap": "Small Cap"
    },
    "APRE": {
        "short_name": "Aprea Therapeutics, Inc.",
        "long_name": "Aprea Therapeutics, Inc.",
        "summary": "Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://www.aprea.com",
        "market_cap": "Small Cap"
    },
    "APTX": {
        "short_name": "Aptinyx Inc.",
        "long_name": "Aptinyx Inc.",
        "summary": "Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Evanston",
        "zipcode": "60201",
        "website": "http://www.aptinyx.com",
        "market_cap": "Small Cap"
    },
    "APVO": {
        "short_name": "Aptevo Therapeutics Inc.",
        "long_name": "Aptevo Therapeutics Inc.",
        "summary": "Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98121",
        "website": "http://www.aptevotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "APYI": {
        "short_name": "ASPYRA INC",
        "long_name": "Aspyra Inc.",
        "summary": "Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Jacksonville",
        "zipcode": "32256",
        "website": "http://www.aspyra.com",
        "market_cap": "Small Cap"
    },
    "APYX": {
        "short_name": "Apyx Medical Corporation",
        "long_name": "Apyx Medical Corporation",
        "summary": "Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Clearwater",
        "zipcode": "33760",
        "website": "http://www.apyxmedical.com",
        "market_cap": "Small Cap"
    },
    "AQST": {
        "short_name": "Aquestive Therapeutics, Inc.",
        "long_name": "Aquestive Therapeutics, Inc.",
        "summary": "Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Warren",
        "zipcode": "07059",
        "website": "http://www.aquestive.com",
        "market_cap": "Small Cap"
    },
    "ARAV": {
        "short_name": "Aravive, Inc.",
        "long_name": "Aravive, Inc.",
        "summary": "Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77098",
        "website": "http://aravive.com",
        "market_cap": "Small Cap"
    },
    "ARAY": {
        "short_name": "Accuray Incorporated",
        "long_name": "Accuray Incorporated",
        "summary": "Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Sunnyvale",
        "zipcode": "94089",
        "website": "http://www.accuray.com",
        "market_cap": "Small Cap"
    },
    "ARCT": {
        "short_name": "Arcturus Therapeutics Holdings ",
        "long_name": "Arcturus Therapeutics Holdings Inc.",
        "summary": "Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.arcturusrx.com",
        "market_cap": "Small Cap"
    },
    "ARDS": {
        "short_name": "Aridis Pharmaceuticals Inc.",
        "long_name": "Aridis Pharmaceuticals, Inc.",
        "summary": "Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Gatos",
        "zipcode": "95032",
        "website": "http://www.aridispharma.com",
        "market_cap": "Small Cap"
    },
    "ARDX": {
        "short_name": "Ardelyx, Inc.",
        "long_name": "Ardelyx, Inc.",
        "summary": "Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Fremont",
        "zipcode": "94555",
        "website": "http://www.ardelyx.com",
        "market_cap": "Small Cap"
    },
    "ARHH": {
        "short_name": "ASSURE HOLDINGS CORP",
        "long_name": "Assure Holdings Corp.",
        "summary": "Assure Holdings Corp., together with its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services primarily associated with spine and head surgeries to physicians. The company has operations in Louisiana, Michigan, Pennsylvania, Texas, Colorado, South Carolina, and Arizona, the United States. Assure Holdings Corp. is based in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80237",
        "website": "http://www.assureneuromonitoring.com",
        "market_cap": "Small Cap"
    },
    "ARMP": {
        "short_name": "Armata Pharmaceuticals, Inc.",
        "long_name": "Armata Pharmaceuticals Inc.",
        "summary": "Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Marina del Rey",
        "zipcode": "90292",
        "website": "http://www.armatapharma.com",
        "market_cap": "Small Cap"
    },
    "ARNA.MX": {
        "short_name": "ARENA PHARMACEUTICALS INC",
        "long_name": "Arena Pharmaceuticals, Inc.",
        "summary": "Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "UT",
        "city": "Park City",
        "zipcode": "84060",
        "website": "http://www.arenapharm.com",
        "market_cap": "Mid Cap"
    },
    "ARNA": {
        "short_name": "Arena Pharmaceuticals, Inc.",
        "long_name": "Arena Pharmaceuticals, Inc.",
        "summary": "Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Park City",
        "zipcode": "84060",
        "website": "http://www.arenapharm.com",
        "market_cap": "Mid Cap"
    },
    "ARNI": {
        "short_name": "ARNO THERAPEUTICS INC",
        "long_name": "Arno Therapeutics, Inc.",
        "summary": "Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Flemington",
        "zipcode": "08822",
        "website": "http://www.arnothera.com",
        "market_cap": "Small Cap"
    },
    "ARPO": {
        "short_name": "Aerpio Pharmaceuticals, Inc.",
        "long_name": "Aerpio Pharmaceuticals, Inc.",
        "summary": "Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45242",
        "website": "http://www.aerpio.com",
        "market_cap": "Small Cap"
    },
    "ARQT": {
        "short_name": "Arcutis Biotherapeutics, Inc.",
        "long_name": "Arcutis Biotherapeutics, Inc.",
        "summary": "Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Westlake Village",
        "zipcode": "91361",
        "website": "http://www.arcutis.com",
        "market_cap": "Small Cap"
    },
    "ARTH": {
        "short_name": "ARCH THERAPEUTICS INC",
        "long_name": "Arch Therapeutics, Inc.",
        "summary": "Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Framingham",
        "zipcode": "01702",
        "website": "http://www.archtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "ARTL": {
        "short_name": "Artelo Biosciences, Inc.",
        "long_name": "Artelo Biosciences, Inc.",
        "summary": "Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://www.artelobio.com",
        "market_cap": "Small Cap"
    },
    "ARVN": {
        "short_name": "Arvinas, Inc.",
        "long_name": "Arvinas, Inc.",
        "summary": "Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06511",
        "website": "http://www.arvinas.com",
        "market_cap": "Mid Cap"
    },
    "ARWR": {
        "short_name": "Arrowhead Pharmaceuticals, Inc.",
        "long_name": "Arrowhead Pharmaceuticals, Inc.",
        "summary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Pasadena",
        "zipcode": "91105",
        "website": "http://arrowheadpharma.com",
        "market_cap": "Mid Cap"
    },
    "ARYC": {
        "short_name": "ARRAYIT CORP",
        "long_name": "Arrayit Corporation",
        "summary": "Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Sunnyvale",
        "zipcode": "94085",
        "website": "http://www.arrayit.com",
        "market_cap": "Small Cap"
    },
    "ASFX": {
        "short_name": "AMERICAN SCIENTIFIC RESOURCES I",
        "long_name": "American Scientific Resources, Incorporated",
        "summary": "American Scientific Resources, Incorporated develops, manufactures, assembles, markets, and distributes medical products and devices for children and adults. It offers Thermofocus 5-in-1, a non-contact clinical thermometer; VeraTemp and VeraTemp+ non-contact thermometers; Scald Safe Water temperature disc, a warning disc that helps to ensure that a baby's bath water is at an appropriate temperature; and WhistleWatch, a flow monitoring device that allows parents to monitor their child's respiratory problems. The company also provides Kidz-Med portable ultrasonic nebulizer, which is used to treat asthma, bronchitis, allergies, and sinusitis; Kidz-Med Medicine Dispenser that consists of an orthodontic nipple attached to a medication chamber; and Kidz-Med Mommy Recorder, a voice-recording device, which allows a mother to record a message designed to calm baby when he or she is upset. In addition, it offers Bip DVDs, a video series to help children understand life events; Mebby product line that includes breast pumps, bisphenol A free baby bottles, digital scales, humidifiers, pacifiers, & sterilizers; and Wee Target, a toilet training device for young boys. Further, the company provides Disintegrator, a home needle and lancet destruction device, which enables patients who give themselves injections, including those suffering from multiple sclerosis or diabetes to properly and safely dispose of needles at home. American Scientific Resources distributes its products primarily through retail drug and grocery chains, and medical suppliers, as well as through its Web site and other on-line sites. The company is based in Weston, Florida. On February 27, 2012, an involuntary petition for liquidation under Chapter 7 was filed against American Scientific Resources, Incorporated in the US Bankruptcy Court for the Southern District of Florida. On March 28, 2012, the involuntary petition was approved by the Court. American Scientific Resources, Inc. is in liquidation.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Weston",
        "zipcode": "33326",
        "website": null,
        "market_cap": "Small Cap"
    },
    "ASMB": {
        "short_name": "Assembly Biosciences, Inc.",
        "long_name": "Assembly Biosciences, Inc.",
        "summary": "Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.assemblybio.com",
        "market_cap": "Small Cap"
    },
    "ASNB": {
        "short_name": "EKIMAS CORPORATION",
        "long_name": "EKIMAS Corporation",
        "summary": "EKIMAS Corporation develops polymer materials for use in the design and development of medical devices used for treating a range of anatomical sites and disease states. It offers polymers under the ChronoFilm, ChronoFlex, ChronoThane, ChronoPrene, ChronoSil, HydroThane, HydroMed, and PolyBlend trade names. The company also manufactures specialty hydrophilic polyurethanes. It sells its products in the United States and internationally. The company was formerly known as AdvanSource Biomaterials Corporation and changed its name to EKIMAS Corporation in March 2020. EKIMAS Corporation was founded in 1993 and is headquartered in Wilmington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Wilmington",
        "zipcode": "01887",
        "website": "http://www.advbiomaterials.com",
        "market_cap": "Small Cap"
    },
    "ASNHF": {
        "short_name": "AVIDUS MANAGEMENT GROUP",
        "long_name": "Avidus Management Group Inc.",
        "summary": "Avidus Management Group Inc. develops, acquires, and operates direct sales and network marketing companies in the consumer health and wellness market in the United States. The company also offers nutraceuticals and health aids; customized nutritional, diet, and exercise plans; and various supplements comprising natural ingredients. The company's principal products include RealW8, a weight loss supplement; and IS2, a functional beverage that supports the body's natural ability to protect, fight, and rebuild against the effects of injuries, illnesses, and diseases. Avidus Management Group Inc. provides its products to various retail vendors, individuals, and businesses. The company was formerly known as Asantae Holdings International Inc. and changed its name to Avidus Management Group Inc. in May 2013. Avidus Management Group Inc. was incorporated in 2006 and is headquartered in Mesa, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Mesa",
        "zipcode": "85209",
        "website": null,
        "market_cap": "Small Cap"
    },
    "ASRT": {
        "short_name": "Assertio Holdings, Inc.",
        "long_name": "Assertio Holdings, Inc.",
        "summary": "Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Lake Forest",
        "zipcode": "60045",
        "website": "http://www.assertiotx.com",
        "market_cap": "Small Cap"
    },
    "ASSF": {
        "short_name": "ASSISTED 4 LIVING INC",
        "long_name": "Assisted 4 Living, Inc.",
        "summary": "Assisted 4 Living, Inc., through its subsidiary, Assisted 2 Live, Inc., operates as an assisted living consulting company in the United States. It provides services in the areas of acquiring, licensing, staffing, and operating assisted living facilities. The company was incorporated in 2017 and is based in Sarasota, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Sarasota",
        "zipcode": "34240",
        "website": "http://www.assisted4living.com",
        "market_cap": "Small Cap"
    },
    "ASXC": {
        "short_name": "Asensus Surgical, Inc.",
        "long_name": "Asensus Surgical, Inc.",
        "summary": "Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera; and SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. Its products also comprise instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is based in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27703",
        "website": "http://www.asensus.com",
        "market_cap": "Small Cap"
    },
    "ASZ1.F": {
        "short_name": "ALIMERA SCIENCES  DL-,01",
        "long_name": "Alimera Sciences, Inc.",
        "summary": "Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30005",
        "website": "http://www.alimerasciences.com",
        "market_cap": "Small Cap"
    },
    "AT2.F": {
        "short_name": "ATARA BIOTHERAP. DL-,0001",
        "long_name": "Atara Biotherapeutics, Inc.",
        "summary": "Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.atarabio.com",
        "market_cap": "Small Cap"
    },
    "ATEC": {
        "short_name": "Alphatec Holdings, Inc.",
        "long_name": "Alphatec Holdings, Inc.",
        "summary": "Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008",
        "website": "http://www.atecspine.com",
        "market_cap": "Small Cap"
    },
    "ATHA": {
        "short_name": "Athira Pharma, Inc.",
        "long_name": "Athira Pharma, Inc.",
        "summary": "Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Bothell",
        "zipcode": "98011",
        "website": "http://athira.com",
        "market_cap": "Small Cap"
    },
    "ATHX": {
        "short_name": "Athersys, Inc.",
        "long_name": "Athersys, Inc.",
        "summary": "Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Cleveland",
        "zipcode": "44115-2634",
        "website": "http://www.athersys.com",
        "market_cap": "Small Cap"
    },
    "ATMS": {
        "short_name": "ARTEMIS THERAPEUTICS INC",
        "long_name": "Artemis Therapeutics Inc.",
        "summary": "Artemis Therapeutics Inc. does not have significant operations. Previously, it was engaged in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company is based in New York, New York. Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10003",
        "website": "http://www.artemis-therapeutics.com",
        "market_cap": "Small Cap"
    },
    "ATNF": {
        "short_name": "180 Life Sciences Corp.",
        "long_name": "180 Life Sciences Corp.",
        "summary": "180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://180lifesciences.com",
        "market_cap": "Small Cap"
    },
    "ATNM": {
        "short_name": "Actinium Pharmaceuticals, Inc. ",
        "long_name": "Actinium Pharmaceuticals, Inc.",
        "summary": "Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.actiniumpharma.com",
        "market_cap": "Small Cap"
    },
    "ATNX": {
        "short_name": "Athenex, Inc.",
        "long_name": "Athenex, Inc.",
        "summary": "Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Buffalo",
        "zipcode": "14203",
        "website": "http://www.athenex.com",
        "market_cap": "Small Cap"
    },
    "ATOS": {
        "short_name": "Atossa Therapeutics, Inc.",
        "long_name": "Atossa Therapeutics, Inc.",
        "summary": "Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98104",
        "website": "http://www.atossatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "ATQP.F": {
        "short_name": "VERICEL CORP.",
        "long_name": "Vericel Corporation",
        "summary": "Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://vcel.com",
        "market_cap": "Mid Cap"
    },
    "ATRA": {
        "short_name": "Atara Biotherapeutics, Inc.",
        "long_name": "Atara Biotherapeutics, Inc.",
        "summary": "Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.atarabio.com",
        "market_cap": "Small Cap"
    },
    "ATRC": {
        "short_name": "AtriCure, Inc.",
        "long_name": "AtriCure, Inc.",
        "summary": "AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Mason",
        "zipcode": "45040",
        "website": "http://www.atricure.com",
        "market_cap": "Mid Cap"
    },
    "ATRI": {
        "short_name": "Atrion Corporation",
        "long_name": "Atrion Corporation",
        "summary": "Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, mixes critical drugs, controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Allen",
        "zipcode": "75002-4211",
        "website": "http://www.atrioncorp.com",
        "market_cap": "Small Cap"
    },
    "ATRS": {
        "short_name": "Antares Pharma, Inc.",
        "long_name": "Antares Pharma, Inc.",
        "summary": "Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG. Antares Pharma, Inc. was founded in 1978 and is headquartered in Ewing, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Ewing",
        "zipcode": "08628",
        "website": "http://www.antarespharma.com",
        "market_cap": "Small Cap"
    },
    "ATRX": {
        "short_name": "ADHERA THERAPEUTICS INC",
        "long_name": "Adhera Therapeutics, Inc.",
        "summary": "Adhera Therapeutics, Inc. does not have significant operations. Previously, it was involved in the development and commercialization of drug therapeutics for chronic and acute diseases in the United States. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "LA",
        "city": "Baton Rouge",
        "zipcode": "70820",
        "website": "http://adherathera.com",
        "market_cap": "Small Cap"
    },
    "ATXI": {
        "short_name": "Avenue Therapeutics, Inc.",
        "long_name": "Avenue Therapeutics, Inc.",
        "summary": "Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.avenuetx.com",
        "market_cap": "Small Cap"
    },
    "AUGX": {
        "short_name": "AUGMEDIX INC",
        "long_name": "Augmedix, Inc.",
        "summary": "Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. It offers software that is compatible with off-the-shelf, mobile client devices, which enables clinicians to communicate with remotely located documentation specialists (RDSs). The company's services include Augmedix Live, a real time service, in which RDSs provide medical documentation and live clinical support services; and Augmedix Notes, a non-real time product where RDSs offer medical documentation based upon recorded visits. Its clients include health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94104",
        "website": "http://www.augmedix.com",
        "market_cap": "Small Cap"
    },
    "AURX": {
        "short_name": "NUO THERAPEUTICS INC",
        "long_name": "Nuo Therapeutics, Inc.",
        "summary": "Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20877",
        "website": "http://www.nuot.com",
        "market_cap": "Small Cap"
    },
    "AUSA.CN": {
        "short_name": "AustralisCap",
        "long_name": "Australis Capital Inc.",
        "summary": "Australis Capital Inc. is a venture capital specializing in early-stage but not limited to equity positions and/or debt in both public and private companies, financings in exchange for royalties or other distribution streams, and control share acquisitions and buyouts. It seeks to identify and invest in United States and abroad in cannabis and real estate assets. Australis Capital Inc. is based in Las Vegas, Nevada and additional offices in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89119",
        "website": "http://www.ausa-corp.com/",
        "market_cap": "Small Cap"
    },
    "AUSAF": {
        "short_name": "AUSTRALIS CAP INC",
        "long_name": "Australis Capital Inc.",
        "summary": "Australis Capital Inc. is a venture capital specializing in early-stage but not limited to equity positions and/or debt in both public and private companies, financings in exchange for royalties or other distribution streams, and control share acquisitions and buyouts. It seeks to identify and invest in United States and abroad in cannabis and real estate assets. Australis Capital Inc. is based in Las Vegas, Nevada and additional offices in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89119",
        "website": "http://www.ausa-corp.com/",
        "market_cap": "Small Cap"
    },
    "AVAH": {
        "short_name": "Aveanna Healthcare Holdings Inc",
        "long_name": "Aveanna Healthcare Holdings Inc.",
        "summary": "Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides private duty nursing (PDN), adult home health and hospice, home-based pediatric therapy, and enteral nutrition services in the United States. Its patient- centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children; nursing services in school settings in which our caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; unskilled nursing services; and employer of record support services, as well as in-clinic and home-based pediatric therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers a line of durable medical equipment and enteral nutrition supplies to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Atlanta",
        "zipcode": "30339",
        "website": "http://www.aveanna.com",
        "market_cap": "Mid Cap"
    },
    "AVCO": {
        "short_name": "Avalon GloboCare Corp.",
        "long_name": "Avalon GloboCare Corp.",
        "summary": "Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has a strategic partnership with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2; GE Healthcare to enhance standardized automation and bio-production for cellular medicines; and HydroPeptide, LLC to co-develop and commercialize various clinical-grade, exosome-based cosmeceutical and orthopedic products, as well as research agreement with Massachusetts Institute of Technology to develop CAR technology. It also has a collaboration agreement with the UPMC Hillman Cancer Center to advance the clinical development and production of CAR therapies using FLASH CAR technology. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Freehold",
        "zipcode": "07728",
        "website": "http://www.avalon-globocare.com",
        "market_cap": "Small Cap"
    },
    "AVEO": {
        "short_name": "AVEO Pharmaceuticals, Inc.",
        "long_name": "AVEO Pharmaceuticals, Inc.",
        "summary": "AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02108",
        "website": "http://www.aveooncology.com",
        "market_cap": "Small Cap"
    },
    "AVGR": {
        "short_name": "Avinger, Inc.",
        "long_name": "Avinger, Inc.",
        "summary": "Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.avinger.com",
        "market_cap": "Small Cap"
    },
    "AVH.AX": {
        "short_name": "AVITA MED CDI 5:1",
        "long_name": "AVITA Medical, Inc.",
        "summary": "AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United States",
        "state": "CA",
        "city": "Valencia",
        "zipcode": "91355",
        "website": "http://www.avitamedical.com",
        "market_cap": "Small Cap"
    },
    "AVHHL": {
        "short_name": "AVITA MEDICAL INC CDI 5:1",
        "long_name": "AVITA Medical, Inc.",
        "summary": "AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Valencia",
        "zipcode": "91355",
        "website": "http://www.avitamedical.com",
        "market_cap": "Small Cap"
    },
    "AVIR": {
        "short_name": "Atea Pharmaceuticals, Inc.",
        "long_name": "Atea Pharmaceuticals, Inc.",
        "summary": "Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02110",
        "website": "http://ateapharma.com",
        "market_cap": "Small Cap"
    },
    "AVMR": {
        "short_name": "AVRA MED ROBOTICS INC",
        "long_name": "AVRA Medical Robotics, Inc.",
        "summary": "AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Orlando",
        "zipcode": "32826",
        "website": "http://www.avramedicalrobotics.com",
        "market_cap": "Small Cap"
    },
    "AVNS": {
        "short_name": "Avanos Medical, Inc.",
        "long_name": "Avanos Medical, Inc.",
        "summary": "Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30004",
        "website": "http://avanos.com",
        "market_cap": "Small Cap"
    },
    "AVRO": {
        "short_name": "AVROBIO, Inc.",
        "long_name": "AVROBIO, Inc.",
        "summary": "AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.avrobio.com",
        "market_cap": "Small Cap"
    },
    "AVTI": {
        "short_name": "AVITAR INC",
        "long_name": "Avitar, Inc.",
        "summary": "Avitar, Inc. is a holding company which through its subsidiaries designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine such as crack; marijuana; and methamphetamines, including meth and ecstasy. The company also provides foam disposable products including medical-grade hydrophilic polyurethane foam disposables such as wound dressings comprising Hydrasorb, a wound dressing product for exudating wounds; and various custom foam products comprising a sinus dressing and a device used by astronauts for relieving ear pressure while in a pressurized space suit. In addition, it develops specialty wound dressings for the cardiac catheter lab market, as well as the Illizarov Dressing used for dressing external bone fixators in orthopedic procedures. The company markets its products and services to employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations through direct sales force and strategic partners, as well as through a network of distributors. Avitar, Inc. was founded in 1986 and is based in Canton, Massachusetts with Additional office in Calgary, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Canton",
        "zipcode": "02021",
        "website": null,
        "market_cap": "Small Cap"
    },
    "AVU.F": {
        "short_name": "ADVERUM BIOTECHS DL-,0001",
        "long_name": "Adverum Biotechnologies, Inc.",
        "summary": "Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.adverum.com",
        "market_cap": "Small Cap"
    },
    "AVXL": {
        "short_name": "Anavex Life Sciences Corp.",
        "long_name": "Anavex Life Sciences Corp.",
        "summary": "Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.anavex.com",
        "market_cap": "Small Cap"
    },
    "AVXT": {
        "short_name": "AVAX TECHNOLOGIES INC",
        "long_name": "AVAX Technologies, Inc.",
        "summary": "AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19130",
        "website": "http://www.avax-tech.com",
        "market_cap": "Small Cap"
    },
    "AWH": {
        "short_name": "Aspira Women's Health Inc.",
        "long_name": "Aspira Women's Health Inc.",
        "summary": "Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, the company is developing diagnostic algorithms; and a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. It has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test; and an agreement with Dana Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer. The company has a strategic alliance with Quest Diagnostics, Incorporated. It serves physician office and hospital laboratories, as well as physicians. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78738",
        "website": "http://aspirawh.com",
        "market_cap": "Small Cap"
    },
    "AX9.F": {
        "short_name": "AKEBIA THERAPEUT.DL-00001",
        "long_name": "Akebia Therapeutics, Inc.",
        "summary": "Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.akebia.com",
        "market_cap": "Small Cap"
    },
    "AXD2.F": {
        "short_name": "HERON THERAPEUTICS DL-,01",
        "long_name": "Heron Therapeutics, Inc.",
        "summary": "Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.herontx.com",
        "market_cap": "Small Cap"
    },
    "AXDX.MX": {
        "short_name": "ACCELERATE DIAGNOSTICS INC",
        "long_name": "Accelerate Diagnostics, Inc.",
        "summary": "Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tucson",
        "zipcode": "85714",
        "website": "http://acceleratediagnostics.com",
        "market_cap": "Small Cap"
    },
    "AXDX": {
        "short_name": "Accelerate Diagnostics, Inc.",
        "long_name": "Accelerate Diagnostics, Inc.",
        "summary": "Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tucson",
        "zipcode": "85714",
        "website": "http://acceleratediagnostics.com",
        "market_cap": "Small Cap"
    },
    "AXGN": {
        "short_name": "AxoGen, Inc.",
        "long_name": "AxoGen, Inc.",
        "summary": "AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Alachua",
        "zipcode": "32615",
        "website": "http://www.axogeninc.com",
        "market_cap": "Small Cap"
    },
    "AXIM": {
        "short_name": "AXIM BIOTECHNOLOGIES INC",
        "long_name": "AXIM Biotechnologies, Inc.",
        "summary": "AXIM Biotechnologies, Inc., a preclinical stage research and development company focuses on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company is developing NeuCovix, a rapid diagnostic test measuring levels of functional neutralizing antibodies to prevent SARS-CoV-2 from entering the host cells; and ImmunoPass, a rapid serological diagnostic test that measures SARS-CoV-2 neutralizing antibodies within 10 minutes. It is also developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.aximbiotech.com",
        "market_cap": "Small Cap"
    },
    "AXLA": {
        "short_name": "Axcella Health Inc.",
        "long_name": "Axcella Health Inc.",
        "summary": "Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.axcellahealth.com",
        "market_cap": "Small Cap"
    },
    "AXNX": {
        "short_name": "Axonics, Inc.",
        "long_name": "Axonics, Inc.",
        "summary": "Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.axonics.com",
        "market_cap": "Mid Cap"
    },
    "AXP.DE": {
        "short_name": "ALEXION PHARMAC. DL-,0001",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.alexion.com",
        "market_cap": "Large Cap"
    },
    "AXP.F": {
        "short_name": "ALEXION PHARMAC. DL-,0001",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.alexion.com",
        "market_cap": "Large Cap"
    },
    "AXRX": {
        "short_name": "AMEXDRUG CORPORATION",
        "long_name": "Amexdrug Corporation",
        "summary": "Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products. It is also involved in the research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices. The company operates in two segments, Distribution and Health and Beauty Products. In addition, it engages in the distribution of prescription and over-the-counter drugs, non-drug products, and health and beauty products; and private manufacturing and labeling activities. Further, the company manufactures and sells facial and body creams, arthritic pain relief medications, and hair and nail care products to pharmacies, beauty salons, beauty supply stores, and other fine shops. Amexdrug Corporation markets its products under the Sponix name. The company distributes its products through its subsidiaries primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities, and other wholesalers and retailers in the state of California. The company was formerly known as Harlyn Products, Inc. and changed its name to Amexdrug Corporation in April 2000 to reflect the change in its business to the sale of pharmaceutical products. Amexdrug Corporation was founded in 1963 and is based in Commerce, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Commerce",
        "zipcode": "90040",
        "website": "http://www.amexdrug.com",
        "market_cap": "Small Cap"
    },
    "AXSM": {
        "short_name": "Axsome Therapeutics, Inc.",
        "long_name": "Axsome Therapeutics, Inc.",
        "summary": "Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10007",
        "website": "http://www.axsome.com",
        "market_cap": "Mid Cap"
    },
    "AY2.F": {
        "short_name": "AYTU BIOPHARMA  DL -,0001",
        "long_name": "Aytu Biopharma, Inc.",
        "summary": "Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Englewood",
        "zipcode": "80112",
        "website": "http://aytubio.com",
        "market_cap": "Small Cap"
    },
    "AYR-A.CN": {
        "short_name": "Ayr Wellness",
        "long_name": "Ayr Wellness Inc.",
        "summary": "Ayr Wellness Inc., a vertically-integrated cannabis multi-state operator, cultivates, extracts, manufactures, distributes, and retails cannabis products and branded cannabis packaged goods. The company's cannabis and cannabis products include concentrates, edibles, and vaporizer products. It also provides administrative, consulting, and operations support services to licensed cannabis companies. In addition, Ayr Wellness Inc. operates medical retail dispensaries. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in New York, New York.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.ayrwellness.com",
        "market_cap": "Small Cap"
    },
    "AYRWF": {
        "short_name": "AYR WELLNESS INC",
        "long_name": "Ayr Wellness Inc.",
        "summary": "Ayr Wellness Inc., a vertically-integrated cannabis multi-state operator, cultivates, extracts, manufactures, distributes, and retails cannabis products and branded cannabis packaged goods. The company's cannabis and cannabis products include concentrates, edibles, and vaporizer products. It also provides administrative, consulting, and operations support services to licensed cannabis companies. In addition, Ayr Wellness Inc. operates medical retail dispensaries. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.ayrwellness.com",
        "market_cap": "Small Cap"
    },
    "AYTU": {
        "short_name": "Aytu BioPharma, Inc.",
        "long_name": "Aytu Biopharma, Inc.",
        "summary": "Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Englewood",
        "zipcode": "80112",
        "website": "http://aytubio.com",
        "market_cap": "Small Cap"
    },
    "AZRX": {
        "short_name": "AzurRx BioPharma, Inc.",
        "long_name": "AzurRx BioPharma, Inc.",
        "summary": "AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Delray Beach",
        "zipcode": "33445",
        "website": "http://www.azurrx.com",
        "market_cap": "Small Cap"
    },
    "AZS.F": {
        "short_name": "AMER. SHARED HOSP. SERV.",
        "long_name": "American Shared Hospital Services",
        "summary": "American Shared Hospital Services leases radiosurgery and radiation therapy equipment to health care providers. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. As of March 1, 2021, it had thirteen operating Gamma Knife units located in the United States, as well as two in South America in Lima, Peru and Guayaquil, Ecuador. The company also operates one PBRT system. American Shared Hospital Services was founded in 1980 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94111-4107",
        "website": "http://ashs.com",
        "market_cap": "Small Cap"
    },
    "AZYO": {
        "short_name": "Aziyo Biologics, Inc.",
        "long_name": "Aziyo Biologics, Inc.",
        "summary": "Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Silver Spring",
        "zipcode": "20904",
        "website": "http://www.aziyo.com",
        "market_cap": "Small Cap"
    },
    "B003.F": {
        "short_name": "BIOCEPT INC.  DL -,0001",
        "long_name": "Biocept, Inc.",
        "summary": "Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://biocept.com",
        "market_cap": "Small Cap"
    },
    "B1AX34.SA": {
        "short_name": "BAXTER INTERDRN",
        "long_name": "Baxter International Inc.",
        "summary": "Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.baxter.com",
        "market_cap": "Large Cap"
    },
    "B1DX34.SA": {
        "short_name": "BECTON DICKIDRN",
        "long_name": "Becton, Dickinson and Company",
        "summary": "Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NJ",
        "city": "Franklin Lakes",
        "zipcode": "07417-1880",
        "website": "http://www.bd.com",
        "market_cap": "Large Cap"
    },
    "B1MR34.SA": {
        "short_name": "BIOMARIN PHADRN",
        "long_name": "BioMarin Pharmaceutical Inc.",
        "summary": "BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "San Rafael",
        "zipcode": "94901",
        "website": "http://www.biomarin.com",
        "market_cap": "Large Cap"
    },
    "B5G2.F": {
        "short_name": "LATTICE BIOLOGICS LTD.",
        "long_name": "Lattice Biologics Ltd.",
        "summary": "Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MT",
        "city": "Belgrade",
        "zipcode": "59714",
        "website": "http://www.latticebiologics.com",
        "market_cap": "Small Cap"
    },
    "B7S.F": {
        "short_name": "BROOKDALE SR LVG  DL -,01",
        "long_name": "Brookdale Senior Living Inc.",
        "summary": "Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates through five segments: Independent Living, Assisted Living and Memory Care, Continuing Care Retirement Communities (CCRCs), Health Care Services, and Management Services. The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding multi-story communities and freestanding single-story communities, which offer housing and 24-hour assistance with activities of daily life to mid-acuity and frail elderly residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that offer various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and health needs. The Health Care Services segment provides home health, hospice, and outpatient therapy services. The Management Services segment operates communities under the management agreements. As of December 31, 2020, the company owned 350 communities, leased 301 communities, managed 72 communities on behalf of third parties, and 3 communities for which it has equity interest. Brookdale Senior Living Inc. is headquartered in Brentwood, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Brentwood",
        "zipcode": "37027",
        "website": "http://www.brookdale.com",
        "market_cap": "Small Cap"
    },
    "BAX.MX": {
        "short_name": "BAXTER INTERNATIONAL INC",
        "long_name": "Baxter International Inc.",
        "summary": "Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.baxter.com",
        "market_cap": "Large Cap"
    },
    "BAX": {
        "short_name": "Baxter International Inc.",
        "long_name": "Baxter International Inc.",
        "summary": "Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.baxter.com",
        "market_cap": "Large Cap"
    },
    "BAX.VI": {
        "short_name": "BAXTER INTERNATIONAL INC",
        "long_name": "Baxter International Inc.",
        "summary": "Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.baxter.com",
        "market_cap": "Large Cap"
    },
    "BBAL": {
        "short_name": "NEW YORK HEALTH CARE INC",
        "long_name": "New York Health Care, Inc.",
        "summary": "New York Health Care, Inc. operates as a home care services agency primarily in New York. The company offers various home care services, such as companionship services, homemaker/housekeeper staff, professional and practical nurses, home health aides, care givers, geriatric care, and dementia and alzheimer care services. It also provides insurance services. The company was founded in 1983 and is based in Valley Stream, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Valley Stream",
        "zipcode": "11580",
        "website": "http://www.nyhc.com",
        "market_cap": "Small Cap"
    },
    "BBI": {
        "short_name": "Brickell Biotech, Inc.",
        "long_name": "Brickell Biotech, Inc.",
        "summary": "Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80301",
        "website": "http://www.brickellbio.com",
        "market_cap": "Small Cap"
    },
    "BBIO": {
        "short_name": "BridgeBio Pharma, Inc.",
        "long_name": "BridgeBio Pharma, Inc.",
        "summary": "BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); and the University of California, Davis. The company was founded in 2015 and is headquartered in Palo Alto, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Palo Alto",
        "zipcode": "94301",
        "website": "http://www.bridgebio.com",
        "market_cap": "Mid Cap"
    },
    "BBLG": {
        "short_name": "BONE BIOLOGICS CORP",
        "long_name": "Bone Biologics Corporation",
        "summary": "Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Burlington",
        "zipcode": "01803",
        "website": "http://www.bonebiologics.com",
        "market_cap": "Small Cap"
    },
    "BCAB": {
        "short_name": "BioAtla, Inc.",
        "long_name": "BioAtla, Inc.",
        "summary": "BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.bioatla.com",
        "market_cap": "Small Cap"
    },
    "BCDA": {
        "short_name": "BioCardia, Inc.",
        "long_name": "BioCardia, Inc.",
        "summary": "BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Carlos",
        "zipcode": "94070",
        "website": "http://www.biocardia.com",
        "market_cap": "Small Cap"
    },
    "BCEL": {
        "short_name": "Atreca, Inc.",
        "long_name": "Atreca, Inc.",
        "summary": "Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.atreca.com",
        "market_cap": "Small Cap"
    },
    "BCLI": {
        "short_name": "Brainstorm Cell Therapeutics In",
        "long_name": "Brainstorm Cell Therapeutics Inc.",
        "summary": "Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.brainstorm-cell.com",
        "market_cap": "Small Cap"
    },
    "BCRX.MX": {
        "short_name": "BIOCRYST PHARMACEUTICALS INC",
        "long_name": "BioCryst Pharmaceuticals, Inc.",
        "summary": "BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27703",
        "website": "http://www.biocryst.com",
        "market_cap": "Mid Cap"
    },
    "BCRX": {
        "short_name": "BioCryst Pharmaceuticals, Inc.",
        "long_name": "BioCryst Pharmaceuticals, Inc.",
        "summary": "BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27703",
        "website": "http://www.biocryst.com",
        "market_cap": "Mid Cap"
    },
    "BD5.F": {
        "short_name": "BIODELIVERY SCIE. DL-,001",
        "long_name": "BioDelivery Sciences International, Inc.",
        "summary": "BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Raleigh",
        "zipcode": "27612",
        "website": "http://www.bdsi.com",
        "market_cap": "Small Cap"
    },
    "BDQM.F": {
        "short_name": "ALBIREO PHARMA  DL -,01",
        "long_name": "Albireo Pharma, Inc.",
        "summary": "Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02109",
        "website": "http://www.albireopharma.com",
        "market_cap": "Small Cap"
    },
    "BDSI": {
        "short_name": "BioDelivery Sciences Internatio",
        "long_name": "BioDelivery Sciences International, Inc.",
        "summary": "BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Raleigh",
        "zipcode": "27612",
        "website": "http://www.bdsi.com",
        "market_cap": "Small Cap"
    },
    "BDSX": {
        "short_name": "Biodesix, Inc.",
        "long_name": "Biodesix, Inc.",
        "summary": "Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80301",
        "website": "http://www.biodesix.com",
        "market_cap": "Small Cap"
    },
    "BDTX": {
        "short_name": "Black Diamond Therapeutics, Inc",
        "long_name": "Black Diamond Therapeutics, Inc.",
        "summary": "Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.blackdiamondtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "BDX.MX": {
        "short_name": "BECTON DICKINSON & CO",
        "long_name": "Becton, Dickinson and Company",
        "summary": "Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NJ",
        "city": "Franklin Lakes",
        "zipcode": "07417-1880",
        "website": "http://www.bd.com",
        "market_cap": "Large Cap"
    },
    "BDX": {
        "short_name": "Becton, Dickinson and Company",
        "long_name": "Becton, Dickinson and Company",
        "summary": "Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Franklin Lakes",
        "zipcode": "07417-1880",
        "website": "http://www.bd.com",
        "market_cap": "Large Cap"
    },
    "BDX.VI": {
        "short_name": "BECTON DICKINSON AND CO",
        "long_name": "Becton, Dickinson and Company",
        "summary": "Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "NJ",
        "city": "Franklin Lakes",
        "zipcode": "07417-1880",
        "website": "http://www.bd.com",
        "market_cap": "Large Cap"
    },
    "BDXB": {
        "short_name": "Becton, Dickinson and Company D",
        "long_name": "Becton, Dickinson and Company",
        "summary": "Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Franklin Lakes",
        "zipcode": "07417-1880",
        "website": "http://www.bd.com",
        "market_cap": null
    },
    "BDYS": {
        "short_name": "BODYSCAN CORP",
        "long_name": "BodyScan Corp.",
        "summary": "BodyScan Corp. offers medical imaging services that include GE-Imatron Electron Beam Tomography (EBT) scanning for coronary artery disease (CAD), lung diseases, tumors, and stones detection. The company is based in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": null,
        "market_cap": null
    },
    "BEAM": {
        "short_name": "Beam Therapeutics Inc.",
        "long_name": "Beam Therapeutics Inc.",
        "summary": "Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.beamtx.com",
        "market_cap": "Mid Cap"
    },
    "BFLY": {
        "short_name": "Butterfly Network, Inc.",
        "long_name": "Butterfly Network, Inc.",
        "summary": "Butterfly Network, Inc., a digital health company, develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; and Butterfly iQ+, a point-of-care ultrasound imaging device that connects with a smart phone or tablet. The company serves healthcare practitioners. Butterfly Network, Inc. was incorporated in 2011 and is headquartered in Guilford, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Guilford",
        "zipcode": "06437",
        "website": "http://www.butterflynetwork.com",
        "market_cap": "Mid Cap"
    },
    "BGMD": {
        "short_name": "BG MEDICINE INC",
        "long_name": "BG Medicine, Inc.",
        "summary": "BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioM\u00c3\u00a9rieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.bg-medicine.com",
        "market_cap": "Small Cap"
    },
    "BHVN": {
        "short_name": "Biohaven Pharmaceutical Holding",
        "long_name": "Biohaven Pharmaceutical Holding Company Ltd.",
        "summary": "Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06510",
        "website": "http://www.biohavenpharma.com",
        "market_cap": "Mid Cap"
    },
    "BICB": {
        "short_name": "BIO CUBE INC",
        "long_name": "BioCube, Inc.",
        "summary": "BioCube, Inc., a development stage company, focuses on the development and marketing of lithium ion batteries in North America. The company was formerly known as Alliance Network Communications Holdings, Inc. and changed its name to BioCube, Inc. in December 2010. BioCube, Inc. is based in Bohemia, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Bohemia",
        "zipcode": "11716",
        "website": null,
        "market_cap": "Small Cap"
    },
    "BICX": {
        "short_name": "BIOCORRX INC",
        "long_name": "BioCorRx Inc.",
        "summary": "BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Anaheim",
        "zipcode": "92806",
        "website": "http://www.biocorrx.com",
        "market_cap": "Small Cap"
    },
    "BIEI": {
        "short_name": "PREMIER BIOMEDICAL INC",
        "long_name": "Premier Biomedical, Inc.",
        "summary": "Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer's disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Jackson Center",
        "zipcode": "16133",
        "website": "http://www.premierbiomedical.com",
        "market_cap": "Small Cap"
    },
    "BIEL": {
        "short_name": "BIOELECTRONICS CORP",
        "long_name": "BioElectronics Corporation",
        "summary": "BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain relief; Smart Insole, a heel pain solution; Allay, a drug-free micro medical device that uses electromagnetic pulse therapy to reduce menstrual pain and discomfort; RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. The company sells its products to wholesale distributors, hospitals and clinics, and consumers. BioElectronics Corporation was founded in 2000 and is headquartered in Frederick, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Frederick",
        "zipcode": "21704",
        "website": "http://www.bielcorp.com",
        "market_cap": "Small Cap"
    },
    "BIIB.BA": {
        "short_name": "BIOGEN INC",
        "long_name": "Biogen Inc.",
        "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.biogen.com",
        "market_cap": "Large Cap"
    },
    "BIIB.MX": {
        "short_name": "BIOGEN INC",
        "long_name": "Biogen Inc.",
        "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.biogen.com",
        "market_cap": "Large Cap"
    },
    "BIIB": {
        "short_name": "Biogen Inc.",
        "long_name": "Biogen Inc.",
        "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.biogen.com",
        "market_cap": "Large Cap"
    },
    "BIIB.VI": {
        "short_name": "BIOGEN INC",
        "long_name": "Biogen Inc.",
        "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.biogen.com",
        "market_cap": "Large Cap"
    },
    "BIIB34.SA": {
        "short_name": "BIOGEN      DRN",
        "long_name": "Biogen Inc.",
        "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.biogen.com",
        "market_cap": "Large Cap"
    },
    "BIO": {
        "short_name": "Bio-Rad Laboratories, Inc.",
        "long_name": "Bio-Rad Laboratories, Inc.",
        "summary": "Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Hercules",
        "zipcode": "94547",
        "website": "http://www.bio-rad.com",
        "market_cap": "Large Cap"
    },
    "BIOAF": {
        "short_name": "BIOASIS TECHNOLOGIES INC",
        "long_name": "Bioasis Technologies Inc.",
        "summary": "Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-002), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. has a research collaboration with Aposense Ltd. to focus on the delivery of siRNA into the brain. The company was founded in 2007 and is based in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06510",
        "website": "http://www.bioasis.us",
        "market_cap": "Small Cap"
    },
    "BIOC": {
        "short_name": "Biocept, Inc.",
        "long_name": "Biocept, Inc.",
        "summary": "Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://biocept.com",
        "market_cap": "Small Cap"
    },
    "BIOL": {
        "short_name": "Biolase, Inc.",
        "long_name": "BIOLASE, Inc.",
        "summary": "BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Foothill Ranch",
        "zipcode": "92610-2811",
        "website": "http://www.biolase.com",
        "market_cap": "Small Cap"
    },
    "BIOQ": {
        "short_name": "BIOQUAL INC",
        "long_name": "Bioqual, Inc.",
        "summary": "Bioqual, Inc. provides research, development, pre-clinical, and testing/assay services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides in-vivo animal model services related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850-3336",
        "website": "http://www.bioqual.com",
        "market_cap": "Small Cap"
    },
    "BIVI": {
        "short_name": "BioVie Inc.",
        "long_name": "BioVie Inc.",
        "summary": "BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Monica",
        "zipcode": "90404",
        "website": "http://www.biovieinc.com",
        "market_cap": "Small Cap"
    },
    "BJ93.F": {
        "short_name": "BENITEC BIOPHARMA INC.",
        "long_name": "Benitec Biopharma Inc.",
        "summary": "Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Hayward",
        "zipcode": "94545",
        "website": "http://www.benitec.com",
        "market_cap": "Small Cap"
    },
    "BJX1.F": {
        "short_name": "BIOLIFE SOLUTIONS DL-,001",
        "long_name": "BioLife Solutions, Inc.",
        "summary": "BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Bothell",
        "zipcode": "98021",
        "website": "http://www.biolifesolutions.com",
        "market_cap": "Small Cap"
    },
    "BKD.F": {
        "short_name": "BRUKER CORP.  DL -,01",
        "long_name": "Bruker Corporation",
        "summary": "Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Billerica",
        "zipcode": "01821",
        "website": "http://www.bruker.com",
        "market_cap": "Large Cap"
    },
    "BKD": {
        "short_name": "Brookdale Senior Living Inc.",
        "long_name": "Brookdale Senior Living Inc.",
        "summary": "Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates through five segments: Independent Living, Assisted Living and Memory Care, Continuing Care Retirement Communities (CCRCs), Health Care Services, and Management Services. The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding multi-story communities and freestanding single-story communities, which offer housing and 24-hour assistance with activities of daily life to mid-acuity and frail elderly residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that offer various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and health needs. The Health Care Services segment provides home health, hospice, and outpatient therapy services. The Management Services segment operates communities under the management agreements. As of December 31, 2020, the company owned 350 communities, leased 301 communities, managed 72 communities on behalf of third parties, and 3 communities for which it has equity interest. Brookdale Senior Living Inc. is headquartered in Brentwood, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Brentwood",
        "zipcode": "37027",
        "website": "http://www.brookdale.com",
        "market_cap": "Small Cap"
    },
    "BKIT": {
        "short_name": "BIOHEMP INTERNATIONAL INC",
        "long_name": "BioHemp International, Inc.",
        "summary": "BioHemp International, Inc. focuses on operating in the fast-growing consumer hemp and cannabidiol (CBD) market through a strategic rollup of CBD distributors. It focuses on the creation of distribution platform for CBD providers. The company was formerly known as Blake Insomnia Therapeutics, Inc. and changed its name to BioHemp International, Inc. in June 2019. BioHemp International, Inc. was founded in 2012 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10001",
        "website": "http://www.biohempinternational.com",
        "market_cap": "Small Cap"
    },
    "BKUH": {
        "short_name": "BAKHU HOLDINGS CORPORATION",
        "long_name": "Bakhu Holdings, Corp.",
        "summary": "Bakhu Holdings, Corp. focuses on the production, manufacturing, and sale of cannabis and byproducts in the United States, Canada, Mexico, the Caribbean, and internationally. It also focuses on cannabis-related research, teaching, and education for medical and other purposes. The company was formerly known as Planet Resources, Corp. and changed its name to Bakhu Holdings, Corp. in May 2009. Bakhu Holdings, Corp. was founded in 2008 and is based in Long Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Long Beach",
        "zipcode": "90831",
        "website": "http://www.bakhuholdings.com",
        "market_cap": "Small Cap"
    },
    "BLCM": {
        "short_name": "Bellicum Pharmaceuticals, Inc.",
        "long_name": "Bellicum Pharmaceuticals, Inc.",
        "summary": "Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77098",
        "website": "http://www.bellicum.com",
        "market_cap": "Small Cap"
    },
    "BLE.F": {
        "short_name": "BLUEBIRD BIO INC.  DL-,01",
        "long_name": "bluebird bio, Inc.",
        "summary": "bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent \u00c3\u009f-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.bluebirdbio.com",
        "market_cap": "Mid Cap"
    },
    "BLFS": {
        "short_name": "BioLife Solutions, Inc.",
        "long_name": "BioLife Solutions, Inc.",
        "summary": "BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Bothell",
        "zipcode": "98021",
        "website": "http://www.biolifesolutions.com",
        "market_cap": "Small Cap"
    },
    "BLI": {
        "short_name": "Berkeley Lights, Inc.",
        "long_name": "Berkeley Lights, Inc.",
        "summary": "Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. The company was incorporated in 2011 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.berkeleylights.com",
        "market_cap": "Mid Cap"
    },
    "BLPH": {
        "short_name": "Bellerophon Therapeutics, Inc.",
        "long_name": "Bellerophon Therapeutics, Inc.",
        "summary": "Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Warren",
        "zipcode": "07059",
        "website": "http://www.bellerophon.com",
        "market_cap": "Small Cap"
    },
    "BLUE.MX": {
        "short_name": "BLUEBIRD BIO INC",
        "long_name": "bluebird bio, Inc.",
        "summary": "bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent \u00c3\u009f-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.bluebirdbio.com",
        "market_cap": "Mid Cap"
    },
    "BLUE": {
        "short_name": "bluebird bio, Inc.",
        "long_name": "bluebird bio, Inc.",
        "summary": "bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent \u00c3\u009f-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.bluebirdbio.com",
        "market_cap": "Small Cap"
    },
    "BM8.DE": {
        "short_name": "BIOMARIN PHAR.  DL-,001",
        "long_name": "BioMarin Pharmaceutical Inc.",
        "summary": "BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "San Rafael",
        "zipcode": "94901",
        "website": "http://www.biomarin.com",
        "market_cap": "Large Cap"
    },
    "BM8.F": {
        "short_name": "BIOMARIN PHAR.  DL-,001",
        "long_name": "BioMarin Pharmaceutical Inc.",
        "summary": "BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Rafael",
        "zipcode": "94901",
        "website": "http://www.biomarin.com",
        "market_cap": "Large Cap"
    },
    "BMCS": {
        "short_name": "BIOTECH MEDICS INC",
        "long_name": "BioTech Medics, Inc.",
        "summary": "BioTech Medics, Inc. operates as a medical-based holding company. The company operates medical therapeutic laser centers that treat various pain ailments affecting the muscles, nerves, and bones, as well as arthritis. It also offers SHBAN, an antiseptic hand and body sanitizer. In addition, the company develops and sells nutraceutical products, such as BioBody Balance, a liquid vitamin concentrate; and BioBody Energy Spray, a caffeine and alcohol free natural vitamin energy spray. It offers its nutraceutical products through gross retail sales. The company was incorporated in 1997 and is based in Southlake, Texas with laser pain centers in Texas, California, New Mexico, and Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Southlake",
        "zipcode": "76092-0114",
        "website": null,
        "market_cap": "Small Cap"
    },
    "BMEA": {
        "short_name": "Biomea Fusion, Inc.",
        "long_name": "Biomea Fusion, Inc. Common Stock",
        "summary": "Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.biomeafusion.com",
        "market_cap": "Small Cap"
    },
    "BMMX": {
        "short_name": "BIOMIMIX INC",
        "long_name": "Biomimix, Inc.",
        "summary": "Biomimix, Inc. operates in the life science tools and services market covering genomics, proteomics, cell biology, analytical chemistry, bioprocess development, and bioinformatics in the United States. It develops and commercializes products based on processes and systems found in nature, known as biomimicry. The company's product portfolio includes Bonegrafix products, which are bioactive substances to produce graft attributes for bone replacement and filling defects or holes in bone, or stabilizing bone during the healing process; and ocean water based skin care products to supplement skin health. It also engages in the research and development of Medusa technology, an electro-chemical process that focuses on ballast water treatment, remote potable water treatment, and hydrogen production for use with portable renewable energy platforms. The company was formerly known as C'watre International, Inc. and changed its name to Biomimix, Inc. in April 2009. Biomimix, Inc. was founded in 1986 and is based in Ashburn, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Ashburn",
        "zipcode": "20147",
        "website": "http://www.biomimix.net",
        "market_cap": null
    },
    "BMRA": {
        "short_name": "Biomerica, Inc.",
        "long_name": "Biomerica, Inc.",
        "summary": "Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.biomerica.com",
        "market_cap": "Small Cap"
    },
    "BMRN.MX": {
        "short_name": "BIOMARIN PHARMACEUTICAL",
        "long_name": "BioMarin Pharmaceutical Inc.",
        "summary": "BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Rafael",
        "zipcode": "94901",
        "website": "http://www.biomarin.com",
        "market_cap": "Large Cap"
    },
    "BMRN": {
        "short_name": "BioMarin Pharmaceutical Inc.",
        "long_name": "BioMarin Pharmaceutical Inc.",
        "summary": "BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Rafael",
        "zipcode": "94901",
        "website": "http://www.biomarin.com",
        "market_cap": "Large Cap"
    },
    "BMRN.VI": {
        "short_name": "BIOMARIN PHARMACEUTICAL INC",
        "long_name": "BioMarin Pharmaceutical Inc.",
        "summary": "BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "CA",
        "city": "San Rafael",
        "zipcode": "94901",
        "website": "http://www.biomarin.com",
        "market_cap": "Large Cap"
    },
    "BMY.MX": {
        "short_name": "BRISTOL-MYERS SQUIBB CO",
        "long_name": "Bristol-Myers Squibb Company",
        "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.bms.com",
        "market_cap": "Large Cap"
    },
    "BMY": {
        "short_name": "Bristol-Myers Squibb Company",
        "long_name": "Bristol-Myers Squibb Company",
        "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.bms.com",
        "market_cap": "Large Cap"
    },
    "BMYB34.SA": {
        "short_name": "BRISTOLMYERSDRN",
        "long_name": "Bristol-Myers Squibb Company",
        "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.bms.com",
        "market_cap": "Large Cap"
    },
    "BMYS.VI": {
        "short_name": "BRISTOL-MYERS SQUIBB CO",
        "long_name": "Bristol-Myers Squibb Company",
        "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.bms.com",
        "market_cap": "Large Cap"
    },
    "BNGO.MX": {
        "short_name": "BIONANO GENOMICS INC",
        "long_name": "Bionano Genomics, Inc.",
        "summary": "Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://bionanogenomics.com",
        "market_cap": "Mid Cap"
    },
    "BNGO": {
        "short_name": "Bionano Genomics, Inc.",
        "long_name": "Bionano Genomics, Inc.",
        "summary": "Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://bionanogenomics.com",
        "market_cap": "Small Cap"
    },
    "BNTC": {
        "short_name": "Benitec Biopharma Inc.",
        "long_name": "Benitec Biopharma Inc.",
        "summary": "Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Hayward",
        "zipcode": "94545",
        "website": "http://www.benitec.com",
        "market_cap": "Small Cap"
    },
    "BNYN": {
        "short_name": "BANYAN CORP(OREGON)",
        "long_name": "Banyan Corp.",
        "summary": "Banyan Corp., through its subsidiaries, engages in the franchising of chiropractic clinics in North America. It provides practice development training and assistance to chiropractors, as well as offers franchise support and related services to franchisees and licensees. The company also offers diagnostic testing services. Banyan Corporation provides nerve conduction velocity (NCV) testing to patients through health care professionals, such as doctors and chiropractors. The NCV testing measures the transmission of nerve impulses through the body, identifies problems in the nervous system, and enables to substantiate the cost of treatment to patients and their insurers. In addition, it manufactures and markets the VT3000, a nerve testing system for the diagnosis of neuropathies, which are diseases of the peripheral nerves and parts of the spine, as well as nerve irritation and other damage to the nervous system of a patient. The company was founded in 1978 and is based in Beverly Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Beverly Hills",
        "zipcode": "90211",
        "website": null,
        "market_cap": "Small Cap"
    },
    "BO1.F": {
        "short_name": "BIOCRYST PHARMAC.  DL-,01",
        "long_name": "BioCryst Pharmaceuticals, Inc.",
        "summary": "BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27703",
        "website": "http://www.biocryst.com",
        "market_cap": "Mid Cap"
    },
    "BOLT": {
        "short_name": "Bolt Biotherapeutics, Inc.",
        "long_name": "Bolt Biotherapeutics, Inc.",
        "summary": "Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.boltbio.com",
        "market_cap": "Small Cap"
    },
    "BOV.F": {
        "short_name": "APYX MEDICAL  DL-,001",
        "long_name": "Apyx Medical Corporation",
        "summary": "Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Clearwater",
        "zipcode": "33760",
        "website": "http://www.apyxmedical.com",
        "market_cap": "Small Cap"
    },
    "BOX.DE": {
        "short_name": "BECTON, DICKINSON  DL 1",
        "long_name": "Becton, Dickinson and Company",
        "summary": "Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "NJ",
        "city": "Franklin Lakes",
        "zipcode": "07417-1880",
        "website": "http://www.bd.com",
        "market_cap": "Large Cap"
    },
    "BOX.F": {
        "short_name": "BECTON, DICKINSON  DL 1",
        "long_name": "Becton, Dickinson and Company",
        "summary": "Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Franklin Lakes",
        "zipcode": "07417-1880",
        "website": "http://www.bd.com",
        "market_cap": "Large Cap"
    },
    "BP2M.F": {
        "short_name": "AIKIDO PHARMA  DL-,01",
        "long_name": "AIkido Pharma Inc.",
        "summary": "AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10020",
        "website": "http://www.aikidopharma.com",
        "market_cap": "Small Cap"
    },
    "BPC2.F": {
        "short_name": "TIMBER PHARMACEUT. INC.",
        "long_name": "Timber Pharmaceuticals, Inc.",
        "summary": "Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical dermatology company, focused on the development and commercialization of treatments for orphan dermatologic diseases. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Basking Ridge",
        "zipcode": "07920",
        "website": "http://www.timberpharma.com",
        "market_cap": "Small Cap"
    },
    "BPMC": {
        "short_name": "Blueprint Medicines Corporation",
        "long_name": "Blueprint Medicines Corporation",
        "summary": "Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139-4133",
        "website": "http://www.blueprintmedicines.com",
        "market_cap": "Mid Cap"
    },
    "BPSR": {
        "short_name": "BIOTECH PROD SVCS & RESEARCH IN",
        "long_name": "Organicell Regenerative Medicine, Inc.",
        "summary": "Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. Zofin contains approximately 300 growth factors, cytokines, chemokines, and 102 unique microRNAs, as well as other exosomes/nanoparticles derived from perinatal tissues. It also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. Organicell Regenerative Medicine, Inc. has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was founded in 2011 and is headquartered in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33140",
        "website": "http://www.organicell.com",
        "market_cap": "Small Cap"
    },
    "BPTH": {
        "short_name": "Bio-Path Holdings, Inc.",
        "long_name": "Bio-Path Holdings, Inc.",
        "summary": "Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Bellaire",
        "zipcode": "77401",
        "website": "http://www.biopathholdings.com",
        "market_cap": "Small Cap"
    },
    "BPXA.F": {
        "short_name": "BELLICUM PHARMA.INC.DL-01",
        "long_name": "Bellicum Pharmaceuticals, Inc.",
        "summary": "Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77098",
        "website": "http://www.bellicum.com",
        "market_cap": "Small Cap"
    },
    "BQST": {
        "short_name": "BIOQUEST CORP",
        "long_name": "BioQuest Corp.",
        "summary": "BioQuest Corp. produces and sells a range of CBD products in the retail, direct, and Internet markets in the United States. The company was formerly known as Select-TV Solutions, Inc. and changed its name to BioQuest Corp. in November 2019. BioQuest Corp. was founded in 2011 and is headquartered in Newport Beach, California. As of October 10, 2019, BioQuest Corp. operates as a subsidiary of Pillar Marketing Group, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newport Beach",
        "zipcode": "92660",
        "website": "http://www.bioquestcorp.com",
        "market_cap": "Small Cap"
    },
    "BRCK-U.CN": {
        "short_name": "BellRockBran",
        "long_name": "BellRock Brands Inc.",
        "summary": "BellRock Brands Inc. develops, markets, and sells cannabis products in the United States, Canada, and internationally. It offers cannabis infused adult-use topicals, confections, edibles, beverages, and concentrates, as well as transdermal patches, tinctures, capsules, lotions, creams, other topicals, vapes, and cosmetic serums. The company also provides branded hemp-infused products for humans and pets. Its brands include Mary's Medicinals, Mary's Nutritionals, Mary's Methods, Mary's Tails, Beezle, Dixie, Synergy, Mindset, Aceso, Therabis, D\u00c3\u00a9fonc\u00c3\u00a9, and Rebel Coast. The company was formerly known as Dixie Brands Inc. and changed its name to BellRock Brands Inc. in October 2020. BellRock Brands Inc. is headquartered in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80239",
        "website": "http://www.bellrockbrands.com",
        "market_cap": "Small Cap"
    },
    "BRKR.MX": {
        "short_name": "BRUKER CORPORATION",
        "long_name": "Bruker Corporation",
        "summary": "Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Billerica",
        "zipcode": "01821",
        "website": "http://www.bruker.com",
        "market_cap": "Large Cap"
    },
    "BRKR": {
        "short_name": "Bruker Corporation",
        "long_name": "Bruker Corporation",
        "summary": "Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Billerica",
        "zipcode": "01821",
        "website": "http://www.bruker.com",
        "market_cap": "Large Cap"
    },
    "BRM.DE": {
        "short_name": "BRISTOL-MYERS SQUIBBDL-10",
        "long_name": "Bristol-Myers Squibb Company",
        "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.bms.com",
        "market_cap": "Large Cap"
    },
    "BRM.F": {
        "short_name": "BRISTOL-MYERS SQUIBBDL-10",
        "long_name": "Bristol-Myers Squibb Company",
        "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.bms.com",
        "market_cap": "Large Cap"
    },
    "BRSF": {
        "short_name": "BRAIN SCIENTIFIC INC",
        "long_name": "Brain Scientific Inc.",
        "summary": "Brain Scientific Inc. operates as a neurodiagnostic and predictive technology platform company in the United States. The company provides a platform for data acquisition and analysis of electroencephalography (EEG) data that combines medical device technologies with cloud-based telehealth services. It also offers NeuroCap, a disposable and soft layered cap with an integrated electrode circuit that is designed to address existing problems of conventional EEG systems; and NeuroEEG, a cloud-enabled data acquisition platform for electroencephalogram activity, as well as MemoryMD Cloud, a database where brain data can be stored and analyzed. Brain Scientific Inc. was founded in 2013 and is headquartered in Bohemia, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Bohemia",
        "zipcode": "11716",
        "website": "http://www.brainscientific.com",
        "market_cap": "Small Cap"
    },
    "BRTX": {
        "short_name": "BIORESTORATIVE THERAPIES INC",
        "long_name": "BioRestorative Therapies, Inc.",
        "summary": "BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Melville",
        "zipcode": "11747",
        "website": "http://www.biorestorative.com",
        "market_cap": "Small Cap"
    },
    "BS50.F": {
        "short_name": "INOTIV INC.",
        "long_name": "Inotiv, Inc.",
        "summary": "Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IN",
        "city": "West Lafayette",
        "zipcode": "47906",
        "website": "http://www.inotivco.com",
        "market_cap": "Small Cap"
    },
    "BSEM": {
        "short_name": "BIOSTEM TECHNOLOGIES INC",
        "long_name": "BioStem Technologies, Inc.",
        "summary": "BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Pompano Beach",
        "zipcode": "33064",
        "website": "http://www.biostemtechnologies.com",
        "market_cap": "Small Cap"
    },
    "BSFA.F": {
        "short_name": "ANI PHARMACEUT.  DL-,0001",
        "long_name": "ANI Pharmaceuticals, Inc.",
        "summary": "ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Baudette",
        "zipcode": "56623",
        "website": "http://www.anipharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "BSFA.SG": {
        "short_name": "ANI Pharmaceuticals Inc. Regist",
        "long_name": "ANI Pharmaceuticals, Inc.",
        "summary": "ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Baudette",
        "zipcode": "56623",
        "website": "http://www.anipharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "BSGM": {
        "short_name": "BioSig Technologies, Inc.",
        "long_name": "BioSig Technologies, Inc.",
        "summary": "BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Westport",
        "zipcode": "06880",
        "website": "http://www.biosig.com",
        "market_cap": "Small Cap"
    },
    "BSPK": {
        "short_name": "BESPOKE EXCTRACTS INC",
        "long_name": "Bespoke Extracts, Inc.",
        "summary": "Bespoke Extracts, Inc. provides hemp-derived cannabidiol (CBD) products. The company offers CBD formulations, including manuka honey and in the form of lotions and balms; and markets CBD extracts in capsule form, topicals, and gummies. Bespoke Extracts, Inc. market its products as dietary supplements through its direct-to-consumers e-commerce store bespokeextracts.com. The company was formerly known as DiMi Telematics International, Inc. and changed its name to Bespoke Extracts, Inc. in March 2017. Bespoke Extracts, Inc. is headquartered in Sunny Isles Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Sunny Isles Beach",
        "zipcode": "33160",
        "website": "http://www.bespokeextracts.com",
        "market_cap": "Small Cap"
    },
    "BSSP": {
        "short_name": "BASSLINE PRODUCTIONS INC",
        "long_name": "Reve Technologies, Inc.",
        "summary": "Reve Technologies, Inc., a drug development company, provides advanced therapeutics for the treatment of cancer. It offers irreversible pepsin fraction (IPF), a therapeutic platform technology that is used to facilitate a range of applications. The company's solution is also used for the treatment of autoimmune diseases, such as cirrhosis and Hepatitis C. The company was founded in 2010 and is based in San Clemente, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Clemente",
        "zipcode": "92672",
        "website": "http://www.cantechpharma.com",
        "market_cap": "Small Cap"
    },
    "BSTG": {
        "short_name": "Biostage, Inc.",
        "long_name": "Biostage, Inc.",
        "summary": "Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Holliston",
        "zipcode": "01746",
        "website": "http://biostage.com",
        "market_cap": "Small Cap"
    },
    "BTAI": {
        "short_name": "BioXcel Therapeutics, Inc.",
        "long_name": "BioXcel Therapeutics, Inc.",
        "summary": "BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06511",
        "website": "http://www.bioxceltherapeutics.com",
        "market_cap": "Small Cap"
    },
    "BTCY": {
        "short_name": "BIOTRICITY INC",
        "long_name": "Biotricity, Inc.",
        "summary": "Biotricity, Inc., medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry technology, an integrated electrocardiogram (ECG) device and software solution. Biotricity, Inc. has a research partnership with the University of Calgary to determine the predictive value of ECG readings in preventative healthcare applications; and a strategic partnership with Verizon to develop EMS solutions for first responders by integrating its Bioflux solution. The company is based in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://www.biotricity.com",
        "market_cap": "Small Cap"
    },
    "BTH1.F": {
        "short_name": "BIOLASE INC.  DL -,001",
        "long_name": "BIOLASE, Inc.",
        "summary": "BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Foothill Ranch",
        "zipcode": "92610-2811",
        "website": "http://www.biolase.com",
        "market_cap": "Small Cap"
    },
    "BTHE": {
        "short_name": "BOSTON THERAPEUTICS INC",
        "long_name": "Boston Therapeutics, Inc.",
        "summary": "Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. The company's lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It also produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lawrence",
        "zipcode": "01843",
        "website": "http://www.bostonti.com",
        "market_cap": "Small Cap"
    },
    "BTI.V": {
        "short_name": "BIOASIS TECHNOLOGIES INC.",
        "long_name": "Bioasis Technologies Inc.",
        "summary": "Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-002), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. has a research collaboration with Aposense Ltd. to focus on the delivery of siRNA into the brain. The company was founded in 2007 and is based in New Haven, Connecticut.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06510",
        "website": "http://www.bioasis.us",
        "market_cap": "Small Cap"
    },
    "BTL.DE": {
        "short_name": "BAXTER INTL  DL 1",
        "long_name": "Baxter International Inc.",
        "summary": "Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.baxter.com",
        "market_cap": "Large Cap"
    },
    "BTL.F": {
        "short_name": "BAXTER INTL  DL 1",
        "long_name": "Baxter International Inc.",
        "summary": "Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.baxter.com",
        "market_cap": "Large Cap"
    },
    "BTX": {
        "short_name": "Brooklyn ImmunoTherapeutics, In",
        "long_name": "Brooklyn ImmunoTherapeutics, Inc.",
        "summary": "Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Brooklyn",
        "zipcode": "11220",
        "website": "http://www.brooklynitx.com",
        "market_cap": "Small Cap"
    },
    "BUDZ": {
        "short_name": "WEED INC",
        "long_name": "WEED, Inc.",
        "summary": "WEED, Inc., an early stage holding company, focuses on the development and application of cannabis-derived compounds for the treatment of human diseases primarily in the United States. The company was formerly known as United Mines, Inc. and changed its name to WEED, Inc. in February 2015. WEED, Inc. was incorporated in 1999 and is headquartered in Tucson, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tucson",
        "zipcode": "85750",
        "website": "http://weedincusa.com",
        "market_cap": "Small Cap"
    },
    "BUW.F": {
        "short_name": "BIO-RAD LABS INC. B  DL 1",
        "long_name": "Bio-Rad Laboratories, Inc.",
        "summary": "Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Hercules",
        "zipcode": "94547",
        "website": "http://www.bio-rad.com",
        "market_cap": "Large Cap"
    },
    "BUWA.DE": {
        "short_name": "BIO-RAD LABS INC.DL-,0001",
        "long_name": "Bio-Rad Laboratories, Inc.",
        "summary": "Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "Hercules",
        "zipcode": "94547",
        "website": "http://www.bio-rad.com",
        "market_cap": "Large Cap"
    },
    "BUWA.F": {
        "short_name": "BIO-RAD LABS INC.DL-,0001",
        "long_name": "Bio-Rad Laboratories, Inc.",
        "summary": "Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Hercules",
        "zipcode": "94547",
        "website": "http://www.bio-rad.com",
        "market_cap": "Large Cap"
    },
    "BVS": {
        "short_name": "Bioventus Inc.",
        "long_name": "Bioventus Inc.",
        "summary": "Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27703",
        "website": "http://www.bioventus.com",
        "market_cap": "Small Cap"
    },
    "BX2.F": {
        "short_name": "BIOXCEL THERAPEUT DL-,001",
        "long_name": "BioXcel Therapeutics, Inc.",
        "summary": "BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06511",
        "website": "http://www.bioxceltherapeutics.com",
        "market_cap": "Small Cap"
    },
    "BXRX": {
        "short_name": "Baudax Bio, Inc.",
        "long_name": "Baudax Bio, Inc.",
        "summary": "Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.baudaxbio.com",
        "market_cap": "Small Cap"
    },
    "BYSI": {
        "short_name": "BeyondSpring, Inc.",
        "long_name": "BeyondSpring Inc.",
        "summary": "BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10005",
        "website": "http://www.beyondspringpharma.com",
        "market_cap": "Small Cap"
    },
    "BZYR": {
        "short_name": "BURZYNSKI RESEARCH INSTITUTE IN",
        "long_name": "Burzynski Research Institute, Inc.",
        "summary": "Burzynski Research Institute, Inc. operates a research and development facility of drugs for use in the treatment of cancer in the United States. The company engages in the research, development, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons name. It also provides consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77055",
        "website": "http://www.burzynskiclinic.com",
        "market_cap": "Small Cap"
    },
    "C0I.F": {
        "short_name": "CYMABAY THERAPEUT.DL-0001",
        "long_name": "CymaBay Therapeutics, Inc.",
        "summary": "CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Newark",
        "zipcode": "94560",
        "website": "http://www.cymabay.com",
        "market_cap": "Small Cap"
    },
    "C1AH34.SA": {
        "short_name": "CARDINAL HEADRN",
        "long_name": "Cardinal Health, Inc.",
        "summary": "Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. It also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and offers pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers. In addition, this segment repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products. It also provides incontinence, nutritional delivery, wound care, cardiovascular, and endovascular products; single-use surgical drapes, gowns and apparel, and fluid suction and collection systems; urology products; operating room supplies; and electrode products. In addition, this segment distributes a range of national brand products, including medical, surgical, and laboratory products; and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "OH",
        "city": "Dublin",
        "zipcode": "43017",
        "website": "http://www.cardinalhealth.com",
        "market_cap": "Large Cap"
    },
    "C1ER34.SA": {
        "short_name": "CERNER CORP DRN",
        "long_name": "Cerner Corporation",
        "summary": "Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. It also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, the company offers a portfolio of clinical and financial health care information technology solutions, as well as departmental and care coordination solutions. Further, it provides tech-enabled services, such as implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, employee wellness programs, and third-party administrator services; and complementary hardware and devices for third parties. The company serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. Cerner Corporation was founded in 1979 and is headquartered in North Kansas City, Missouri.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MO",
        "city": "North Kansas City",
        "zipcode": "64117-2551",
        "website": "http://www.cerner.com",
        "market_cap": "Large Cap"
    },
    "C1IC34.SA": {
        "short_name": "CIGNA CORP  DRN",
        "long_name": "Cigna Corporation",
        "summary": "Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CT",
        "city": "Bloomfield",
        "zipcode": "06002",
        "website": "http://www.cigna.com",
        "market_cap": "Large Cap"
    },
    "C1NC34.SA": {
        "short_name": "CENTENE CORPDRN",
        "long_name": "Centene Corporation",
        "summary": "Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MO",
        "city": "St. Louis",
        "zipcode": "63105",
        "website": "http://www.centene.com",
        "market_cap": "Large Cap"
    },
    "C1OO34.SA": {
        "short_name": "COOPER COMPADRN",
        "long_name": "The Cooper Companies, Inc.",
        "summary": "The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "San Ramon",
        "zipcode": "94583",
        "website": "http://www.coopercos.com",
        "market_cap": "Large Cap"
    },
    "C6K.F": {
        "short_name": "CERECOR INC.  DL-,001",
        "long_name": "Cerecor Inc.",
        "summary": "Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.cerecor.com",
        "market_cap": "Small Cap"
    },
    "C6O.DE": {
        "short_name": "CLOVIS ONCOLOGY  DL-,001",
        "long_name": "Clovis Oncology, Inc.",
        "summary": "Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/\u00c3\u009f), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80301",
        "website": "http://www.clovisoncology.com",
        "market_cap": "Small Cap"
    },
    "C6O.F": {
        "short_name": "CLOVIS ONCOLOGY  DL-,001",
        "long_name": "Clovis Oncology, Inc.",
        "summary": "Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/\u00c3\u009f), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80301",
        "website": "http://www.clovisoncology.com",
        "market_cap": "Small Cap"
    },
    "C97.F": {
        "short_name": "CO-DIAGNOSTICS DL-,001",
        "long_name": "Co-Diagnostics, Inc.",
        "summary": "Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84109",
        "website": "http://www.codiagnostics.com",
        "market_cap": "Small Cap"
    },
    "C97.MU": {
        "short_name": "CO-DIAGNOSTICS DL-,001",
        "long_name": "Co-Diagnostics, Inc.",
        "summary": "Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84109",
        "website": "http://www.codiagnostics.com",
        "market_cap": "Small Cap"
    },
    "CAAOF": {
        "short_name": "INDVR BRANDS INC",
        "long_name": "INDVR Brands Inc.",
        "summary": "INDVR Brands Inc. focuses on providing management resources, and infrastructure and equipment for the production, cultivation, and dispensary operations of licensed cannabis businesses in the United States. The company offers its products under the Cannabis, The Joint, Incognito by Cannabis, Fire by Cannabis, Cannabis Prime, Fat Face Farms, Honu, and INDVR names. The company was formerly known as Cannabis One Holdings Inc. and changed its name to INDVR Brands Inc. in August 2020. INDVR Brands Inc. is headquartered in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80205",
        "website": "http://cannabisone.life",
        "market_cap": "Small Cap"
    },
    "CABA": {
        "short_name": "Cabaletta Bio, Inc.",
        "long_name": "Cabaletta Bio, Inc.",
        "summary": "Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19104",
        "website": "http://www.cabalettabio.com",
        "market_cap": "Small Cap"
    },
    "CAFS": {
        "short_name": "CAFE SERENDIPITY HOLDINGS",
        "long_name": "Caf\u00e9 Serendipity Holdings, Inc.",
        "summary": "Caf\u00c3\u00a9 Serendipity Holdings, Inc., a development stage company, focuses on building upscale turnkey franchises to the recreational and medical marijuana industry in the United States. It intends to market a product line of accessories, apparel, coffee and teas, bakery and other edibles, lotions, marijuana, and oils through a coast to coast franchise and dealer network to the recreational and the approximately 6,000 existing legal medical marijuana dispensaries. The company is based in Newport Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newport Beach",
        "zipcode": "92660",
        "website": null,
        "market_cap": "Small Cap"
    },
    "CAH.MX": {
        "short_name": "CARDINAL HEALTH INC",
        "long_name": "Cardinal Health, Inc.",
        "summary": "Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. It also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and offers pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers. In addition, this segment repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products. It also provides incontinence, nutritional delivery, wound care, cardiovascular, and endovascular products; single-use surgical drapes, gowns and apparel, and fluid suction and collection systems; urology products; operating room supplies; and electrode products. In addition, this segment distributes a range of national brand products, including medical, surgical, and laboratory products; and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "OH",
        "city": "Dublin",
        "zipcode": "43017",
        "website": "http://www.cardinalhealth.com",
        "market_cap": "Large Cap"
    },
    "CAH": {
        "short_name": "Cardinal Health, Inc.",
        "long_name": "Cardinal Health, Inc.",
        "summary": "Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. It also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and offers pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers. In addition, this segment repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products. It also provides incontinence, nutritional delivery, wound care, cardiovascular, and endovascular products; single-use surgical drapes, gowns and apparel, and fluid suction and collection systems; urology products; operating room supplies; and electrode products. In addition, this segment distributes a range of national brand products, including medical, surgical, and laboratory products; and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Dublin",
        "zipcode": "43017",
        "website": "http://www.cardinalhealth.com",
        "market_cap": "Large Cap"
    },
    "CALA": {
        "short_name": "Calithera Biosciences, Inc.",
        "long_name": "Calithera Biosciences, Inc.",
        "summary": "Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor that is in Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and CB-708, an orally administered small molecule inhibitor of CD73, as well as CB-668, an inhibitor of the enzyme IL4I1. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.calithera.com",
        "market_cap": "Small Cap"
    },
    "CANB": {
        "short_name": "CAN B CORP",
        "long_name": "Can B Corp.",
        "summary": "Can B Corp. produces and sells cannabidiol (CBD) based products in the United States. It provides CBD products derived from hemp, including oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates through its Website and vending machines, and other medical professionals. The company was formerly known as Canbiola Inc. and changed its name to Can B Corp. in February 2020. Can B Corp. was incorporated in 2005 and is based in Hicksville, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Hicksville",
        "zipcode": "11801",
        "website": "http://canbcorp.com",
        "market_cap": "Small Cap"
    },
    "CANL": {
        "short_name": "CANNLABS INC",
        "long_name": "CannLabs, Inc.",
        "summary": "CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. is based in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80210",
        "website": null,
        "market_cap": "Small Cap"
    },
    "CAPR": {
        "short_name": "Capricor Therapeutics, Inc.",
        "long_name": "Capricor Therapeutics, Inc.",
        "summary": "Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Beverly Hills",
        "zipcode": "90211",
        "website": "http://www.capricor.com",
        "market_cap": "Small Cap"
    },
    "CAPS": {
        "short_name": "CAPSTONE THERAPEUTICS CORPORATI",
        "long_name": "Capstone Therapeutics Corp.",
        "summary": "Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85281",
        "website": "http://www.capstonethx.com",
        "market_cap": "Small Cap"
    },
    "CARA": {
        "short_name": "Cara Therapeutics, Inc.",
        "long_name": "Cara Therapeutics, Inc.",
        "summary": "Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Stamford",
        "zipcode": "06902",
        "website": "http://www.caratherapeutics.com",
        "market_cap": "Small Cap"
    },
    "CASI": {
        "short_name": "CASI Pharmaceuticals, Inc.",
        "long_name": "CASI Pharmaceuticals, Inc.",
        "summary": "CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.casipharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "CATB": {
        "short_name": "Catabasis Pharmaceuticals, Inc.",
        "long_name": "Catabasis Pharmaceuticals, Inc.",
        "summary": "Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02110",
        "website": "http://www.catabasis.com",
        "market_cap": "Small Cap"
    },
    "CAVR": {
        "short_name": "CAVU RESOURCES INC",
        "long_name": "CAVU Resources Inc.",
        "summary": "CAVU Resources, Inc. operates in the information and entertainment space in the cannabis sector. It offers SoKu (Social Kush), a gamified social chat application for legal marijuana users; and MediKu (Medical Kush), a dosage tracking application for medical marijuana patients and caregivers providing personal analysis, budget managing recommendations, and costs and daily communication for result tracking. The company was formerly known as Proxity, Inc. and changed its name to CAVU Resources, Inc. in May 2009. CAVU Resources, Inc. was founded in 1995 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89146",
        "website": "http://cavuresource.com",
        "market_cap": "Small Cap"
    },
    "CBAY": {
        "short_name": "CymaBay Therapeutics Inc.",
        "long_name": "CymaBay Therapeutics, Inc.",
        "summary": "CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newark",
        "zipcode": "94560",
        "website": "http://www.cymabay.com",
        "market_cap": "Small Cap"
    },
    "CBBT": {
        "short_name": "CEREBAIN BIOTECH CORP",
        "long_name": "Cerebain Biotech Corp.",
        "summary": "Cerebain Biotech Corp., a biomedical company, focuses on the discovery of products for the treatment of Alzheimer's disease. Its products would include medical device solutions, as well as synthetic drug solutions. The company was formerly known as Discount Dental Materials, Inc. and changed its name to Cerebain Biotech Corp. in June 2014. Cerebain Biotech Corp. was incorporated in 2007 and is headquartered in Costa Mesa, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Costa Mesa",
        "zipcode": "92626",
        "website": "http://www.cerebain.com",
        "market_cap": "Small Cap"
    },
    "CBD-U.TO": {
        "short_name": "HEMPFUSION WELLNESS INC USD",
        "long_name": "Hempfusion Wellness Inc.",
        "summary": "Hempfusion Wellness Inc., a health and wellness supplement company, manufactures, markets, and sells hemp-based cannabidiol (CBD) and probiotic products in the United States. Its products include tinctures, capsules, and topical creams and gel products under the HempFusion brand; probiotic enzymes and digestive capsules, and topical products under the Probulin brand; and HF Labs and Biome Research branded products that are versions of its hemp extract-based and probiotic products. The company sells its products through its e-commerce websites and doctor practitioners, as well as through a various food, drug, mass, and convenience market retailers. Hempfusion Wellness Inc. was founded in 2015 and is headquartered in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80202",
        "website": "http://www.hempfusion.com",
        "market_cap": "Small Cap"
    },
    "CBDC": {
        "short_name": "APOTHECA BIOSCIENCES INC",
        "long_name": "Apotheca Biosciences, Inc.",
        "summary": "Apotheca Biosciences, Inc. develops cutting-edge medical products, nutraceuticals, formulations, and delivery technologies for the healthcare and consumer care industry in the United States. The company's products include transdermal, sublingual, and nasal delivery devices for dosing of cannabinoids. It also provides CBD pain cream, gel capsules, patches, and sleep tablets; and Promed, anti-aging and cosmetic products. The company was incorporated in 2014 and is based in Saint Petersburg, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Saint Petersburg",
        "zipcode": "33716",
        "website": "http://www.apothecabiosciences.com",
        "market_cap": "Small Cap"
    },
    "CBDL": {
        "short_name": "CBD LIFE SCIENCES INC",
        "long_name": "CBD Life Sciences Inc.",
        "summary": "Cre8tive Works, Inc. offers financing and services for independent entertainment projects in the United States. The company engages in financing independent media productions, including feature films, documentaries, animation, television series, Webisodes, and soundtracks; assisting independent productions with marketing and distribution; and funding and/or brokering production services (e.g. studios, post-production, software, and others). It serves independent film producers. The company was formerly known as a Rangemore Film Productions Corp. and changed its name to Cre8tive Works, Inc. in December 2013. Cre8tive Works, Inc. was founded in 2006 and is headquartered in Woodlands, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Woodlands",
        "zipcode": "77382",
        "website": "http://www.optiumcyber.com",
        "market_cap": "Small Cap"
    },
    "CBDN.CN": {
        "short_name": "CBDGlobalSci",
        "long_name": "CBD Global Sciences Inc.",
        "summary": "CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business. It offers provides biomass, CBD oil, and CBD oil products under the Aethics, CannaOil, and Strasburg Pharms brand names. The company was incorporated in 2018 and is headquartered in Lakewood, Colorado.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "CO",
        "city": "Lakewood",
        "zipcode": "80228",
        "website": "http://www.cbdglobalsciences.com",
        "market_cap": "Small Cap"
    },
    "CBDNF": {
        "short_name": "CBD GLOBAL SCIENCES INC",
        "long_name": "CBD Global Sciences Inc.",
        "summary": "CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business. It offers provides biomass, CBD oil, and CBD oil products under the Aethics, CannaOil, and Strasburg Pharms brand names. The company was incorporated in 2018 and is headquartered in Lakewood, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Lakewood",
        "zipcode": "80228",
        "website": "http://www.cbdglobalsciences.com",
        "market_cap": "Small Cap"
    },
    "CBDS": {
        "short_name": "CANNABIS SATIVA INC",
        "long_name": "Cannabis Sativa, Inc.",
        "summary": "Cannabis Sativa, Inc., through its subsidiaries, primarily provides telemedicine online referral services for customers desiring medical marijuana cards in the United States. It operates through two segments, PrestoCorp and GKMP. The company offers PrestoDoctor, an online telemedicine platform, which provides access to physicians for getting a medical marijuana recommendation using video conferencing technology; and operates as a contract manufacturer of products containing hemp-based cannabidiol (CBD). Its products under development include Recover, a deep penetrating healing balm used to relieve pain for sore muscles, joints, arthritic, and back pain; Trauma Cream, a cream for blended infusion of cannabinoids and THC; Face Garden, an antioxidant moisturizing cream for the face; Body Garden, a moisturizing body lotion; Lip Garden, an emollient balm; and cut cream. The company also offers Wild Earth Naturals and hi branded men's and women's fashion tee shirts and sweatshirts, as well as caps and coffee mugs through Website, wildearthnaturals.com; owns a patented cannabis sativa plant strain known as Ecuadorian Sativa; and owns intellectual property license for use in medical marijuana edibles and lozenges. In addition, it operates iBudtender, an application for sharing information between cannabis products, patients, and businesses. Cannabis Sativa, Inc. serves CBD and marijuana industries. The company was formerly known as Ultra Sun Corporation and changed its name to Cannabis Sativa, Inc. November 2013. Cannabis Sativa, Inc. was incorporated in 2004 and is based in Mesquite, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Mesquite",
        "zipcode": "89027",
        "website": "http://cannabissativainc.com",
        "market_cap": "Small Cap"
    },
    "CBDX": {
        "short_name": "CURATIVE BIOSCIENCES INC",
        "long_name": "Curative Biosciences, Inc.",
        "summary": "Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. It intends to manufacture and market natural health products and operate in the medical cannabis industry. The company was formerly known as Amaize Beverage Corporation and changed its name to Curative Biosciences, Inc. in August 2017. Curative Biosciences, Inc. was founded in 2009 and is based in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33131",
        "website": "http://curativebio.com",
        "market_cap": "Small Cap"
    },
    "CBGI": {
        "short_name": "CANNABUSINESS GROUP INC",
        "long_name": "The CannaBusiness Group, Inc.",
        "summary": "The CannaBusiness Group, Inc. operates as a real estate acquisition, leasing, and management company focusing on zoning issues in the United States. The company acquires commercial property or land, and leases out the facilities for customers in the agricultural, industrial, commercial, and retail sectors. It also acquires, leases, and manages a portfolio of properties. The company was formerly known as Muscle Warfare International, Inc. and changed its name to The CannaBusiness Group, Inc. in February 2014. The CannaBusiness Group, Inc. was founded in 1985 and is based in Mission Viejo, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Mission Viejo",
        "zipcode": "92691",
        "website": null,
        "market_cap": "Small Cap"
    },
    "CBGL": {
        "short_name": "CANNABIS GLOBAL INC",
        "long_name": "Cannabis Global, Inc.",
        "summary": "Cannabis Global, Inc. focuses on the development and commercialization of proprietary engineered technologies to deliver hemp extracts and cannabinoids to the human body. It also provides managerial services in areas of the regulated hemp and cannabis industries. The company was formerly known as MCTC Holdings, Inc. and changed its name to Cannabis Global, Inc. in December 2019. Cannabis Global, Inc. was incorporated in 2005 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90071",
        "website": "http://www.cannabisglobalinc.com",
        "market_cap": "Small Cap"
    },
    "CBIA": {
        "short_name": "CANOPUS BIOPHARMA INC",
        "long_name": "Canopus BioPharma Incorporated",
        "summary": "Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and changed its name in 2007. Canopus BioPharma Incorporated is based in Santa Monica, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Monica",
        "zipcode": "90401",
        "website": null,
        "market_cap": "Small Cap"
    },
    "CBIO": {
        "short_name": "Catalyst Biosciences, Inc.",
        "long_name": "Catalyst Biosciences, Inc.",
        "summary": "Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.catalystbiosciences.com",
        "market_cap": "Small Cap"
    },
    "CBJ.F": {
        "short_name": "CUMBERLAND PHARMACEURIC.",
        "long_name": "Cumberland Pharmaceuticals Inc.",
        "summary": "Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37203",
        "website": "http://www.cumberlandpharma.com",
        "market_cap": "Small Cap"
    },
    "CBLI": {
        "short_name": "Cleveland BioLabs, Inc.",
        "long_name": "Cleveland BioLabs, Inc.",
        "summary": "Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and immuno-oncology. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand; and CBL0137, a small molecule with a multi-targeted mechanism for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, Rusnano, and Everon Biosciences. The company was incorporated in 2003 and is headquartered in Buffalo, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Buffalo",
        "zipcode": "14203",
        "website": "http://www.cbiolabs.com",
        "market_cap": "Small Cap"
    },
    "CBOC.F": {
        "short_name": "CELSION CORP.  DL-,01",
        "long_name": "Celsion Corporation",
        "summary": "Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Lawrenceville",
        "zipcode": "08648",
        "website": "http://celsion.com",
        "market_cap": "Small Cap"
    },
    "CBP.CN": {
        "short_name": "CertiveSoln",
        "long_name": "Certive Solutions Inc.",
        "summary": "Certive Solutions Inc. provides healthcare information technology solutions to hospitals and healthcare administrators in the United States. It offers revenue cycle management services. The company was formerly known as Visual Vault Corporation and changed its name to Certive Solutions Inc. in October 2013. Certive Solutions Inc. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85258",
        "website": "http://certive.com",
        "market_cap": "Small Cap"
    },
    "CBSC": {
        "short_name": "CB SCIENTIFIC INC",
        "long_name": "CB Scientific, Inc.",
        "summary": "CB Scientific, Inc., through its subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The company's FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, offers compliance for patients at risk of abnormal heart rhythms and information for physicians. CB Scientific, Inc. is based in Escondido, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Escondido",
        "zipcode": "92029",
        "website": "http://cbscientificinc.com",
        "market_cap": "Small Cap"
    },
    "CCCC": {
        "short_name": "C4 Therapeutics, Inc.",
        "long_name": "C4 Therapeutics, Inc.",
        "summary": "C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.c4therapeutics.com",
        "market_cap": "Small Cap"
    },
    "CCEL": {
        "short_name": "CRYO-CELL INTERNATIONAL INC",
        "long_name": "Cryo-Cell International, Inc.",
        "summary": "Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Oldsmar",
        "zipcode": "34677",
        "website": "http://www.cryo-cell.com",
        "market_cap": "Small Cap"
    },
    "CCHW.CN": {
        "short_name": "ColumbiaCareInc",
        "long_name": "Columbia Care Inc.",
        "summary": "Columbia Care Inc. cultivates, manufactures, and provides cannabis-based health and wellness solutions, and derivative products. The company holds licenses in 19 jurisdictions in the United States and the European Union. It operates cultivation facilities, manufacturing facilities, and retail dispensaries. The company was founded in 2012 and is headquartered in New York, New York.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.col-care.com",
        "market_cap": "Small Cap"
    },
    "CCHWF": {
        "short_name": "COLUMBIA CARE INC",
        "long_name": "Columbia Care Inc.",
        "summary": "Columbia Care Inc. cultivates, manufactures, and provides cannabis-based health and wellness solutions, and derivative products. The company holds licenses in 19 jurisdictions in the United States and the European Union. It operates cultivation facilities, manufacturing facilities, and retail dispensaries. The company was founded in 2012 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.col-care.com",
        "market_cap": "Small Cap"
    },
    "CCXI": {
        "short_name": "ChemoCentryx, Inc.",
        "long_name": "ChemoCentryx, Inc.",
        "summary": "ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Mountain View",
        "zipcode": "94043",
        "website": "http://www.chemocentryx.com",
        "market_cap": "Small Cap"
    },
    "CDAK": {
        "short_name": "Codiak BioSciences, Inc.",
        "long_name": "Codiak BioSciences, Inc.",
        "summary": "Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02140",
        "website": "http://www.codiakbio.com",
        "market_cap": "Small Cap"
    },
    "CDG0.F": {
        "short_name": "ACORDA THERAP.NEW DL-,001",
        "long_name": "Acorda Therapeutics, Inc.",
        "summary": "Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Ardsley",
        "zipcode": "10502",
        "website": "http://www.acorda.com",
        "market_cap": "Small Cap"
    },
    "CDMO": {
        "short_name": "Avid Bioservices, Inc.",
        "long_name": "Avid Bioservices, Inc.",
        "summary": "Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Tustin",
        "zipcode": "92780",
        "website": "http://www.avidbio.com",
        "market_cap": "Small Cap"
    },
    "CDNA": {
        "short_name": "CareDx, Inc.",
        "long_name": "CareDx, Inc",
        "summary": "CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.caredx.com",
        "market_cap": "Mid Cap"
    },
    "CDTX": {
        "short_name": "Cidara Therapeutics, Inc.",
        "long_name": "Cidara Therapeutics, Inc.",
        "summary": "Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.cidara.com",
        "market_cap": "Small Cap"
    },
    "CDXC": {
        "short_name": "ChromaDex Corporation",
        "long_name": "ChromaDex Corporation",
        "summary": "ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90024",
        "website": "http://www.chromadex.com",
        "market_cap": "Small Cap"
    },
    "CDXI": {
        "short_name": "CARDAX INC",
        "long_name": "Cardax, Inc.",
        "summary": "Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "HI",
        "city": "Honolulu",
        "zipcode": "96822",
        "website": "http://www.cardaxpharma.com",
        "market_cap": "Small Cap"
    },
    "CDXS": {
        "short_name": "Codexis, Inc.",
        "long_name": "Codexis, Inc.",
        "summary": "Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.codexis.com",
        "market_cap": "Small Cap"
    },
    "CELC": {
        "short_name": "Celcuity Inc.",
        "long_name": "Celcuity Inc.",
        "summary": "Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55446",
        "website": "http://www.celcuity.com",
        "market_cap": "Small Cap"
    },
    "CELZ": {
        "short_name": "CREATIVE MEDICAL TECH HOLDING I",
        "long_name": "Creative Medical Technology Holdings, Inc.",
        "summary": "Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Phoenix",
        "zipcode": "85012",
        "website": "http://www.creativemedicaltechnology.com",
        "market_cap": "Small Cap"
    },
    "CEMI": {
        "short_name": "Chembio Diagnostics, Inc.",
        "long_name": "Chembio Diagnostics, Inc.",
        "summary": "Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Hauppauge",
        "zipcode": "11788",
        "website": "http://chembio.com",
        "market_cap": "Small Cap"
    },
    "CEPS.F": {
        "short_name": "CTI BIOPHARMA CORP.",
        "long_name": "CTI BioPharma Corp.",
        "summary": "CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98121",
        "website": "http://www.ctibiopharma.com",
        "market_cap": "Small Cap"
    },
    "CERC": {
        "short_name": "Cerecor Inc.",
        "long_name": "Cerecor Inc.",
        "summary": "Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.cerecor.com",
        "market_cap": "Small Cap"
    },
    "CERE": {
        "short_name": "Cerevel Therapeutics Holdings, ",
        "long_name": "Cerevel Therapeutics Holdings, Inc.",
        "summary": "Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02141",
        "website": "http://www.cerevel.com",
        "market_cap": "Mid Cap"
    },
    "CERN.MX": {
        "short_name": "CERNER CORP",
        "long_name": "Cerner Corporation",
        "summary": "Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. It also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, the company offers a portfolio of clinical and financial health care information technology solutions, as well as departmental and care coordination solutions. Further, it provides tech-enabled services, such as implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, employee wellness programs, and third-party administrator services; and complementary hardware and devices for third parties. The company serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. Cerner Corporation was founded in 1979 and is headquartered in North Kansas City, Missouri.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MO",
        "city": "North Kansas City",
        "zipcode": "64117-2551",
        "website": "http://www.cerner.com",
        "market_cap": "Large Cap"
    },
    "CERN": {
        "short_name": "Cerner Corporation",
        "long_name": "Cerner Corporation",
        "summary": "Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. It also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, the company offers a portfolio of clinical and financial health care information technology solutions, as well as departmental and care coordination solutions. Further, it provides tech-enabled services, such as implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, employee wellness programs, and third-party administrator services; and complementary hardware and devices for third parties. The company serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. Cerner Corporation was founded in 1979 and is headquartered in North Kansas City, Missouri.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MO",
        "city": "North Kansas City",
        "zipcode": "64117-2551",
        "website": "http://www.cerner.com",
        "market_cap": "Large Cap"
    },
    "CERN.VI": {
        "short_name": "CERNER CORP",
        "long_name": "Cerner Corporation",
        "summary": "Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. It also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, the company offers a portfolio of clinical and financial health care information technology solutions, as well as departmental and care coordination solutions. Further, it provides tech-enabled services, such as implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, employee wellness programs, and third-party administrator services; and complementary hardware and devices for third parties. The company serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. Cerner Corporation was founded in 1979 and is headquartered in North Kansas City, Missouri.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "MO",
        "city": "North Kansas City",
        "zipcode": "64117-2551",
        "website": "http://www.cerner.com",
        "market_cap": "Large Cap"
    },
    "CERT": {
        "short_name": "Certara, Inc.",
        "long_name": "Certara, Inc.",
        "summary": "Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.certara.com",
        "market_cap": "Mid Cap"
    },
    "CEVE": {
        "short_name": "CERES VENTURES INC",
        "long_name": "Ceres Ventures, Inc.",
        "summary": "Ceres Ventures, Inc., a development stage company, focuses on the research, development, and commercialization of clean technologies for the remediation of polluted water, soil, and air. Its technologies include BluFlow Nanoparticles, a proprietary system for formulating, producing, and deploying customizable absorbent nanoparticles to specific functionality for contaminant/chemical removal and extraction of valuable elements and compounds from water based solutions; BluFlow Advanced Ultrafiltration Technology, an automated process to recover water from waste or impure streams; and BluFlow Treatment System a water and wastewater treatment solution, which incorporates the BluFlow Nanoparticles and the BluFlow Advanced Ultrafiltration Technology to remove target elements, compounds, and pollutants, as well as purify water that may be suitable for reuse. Ceres Ventures, Inc.'s products are used in water and wastewater treatment and purification, contaminated groundwater treatment, industrial wastewater treatment, and valuable elements and compounds extraction applications. The company was formerly known as PhytoMedical Technologies, Inc. and changed its name to Ceres Ventures, Inc. in November 2011. Ceres Ventures, Inc. is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": null,
        "market_cap": "Small Cap"
    },
    "CFMS": {
        "short_name": "Conformis, Inc.",
        "long_name": "Conformis, Inc.",
        "summary": "Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Billerica",
        "zipcode": "01821",
        "website": "http://www.conformis.com",
        "market_cap": "Small Cap"
    },
    "CFRX": {
        "short_name": "ContraFect Corporation",
        "long_name": "ContraFect Corporation",
        "summary": "ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Yonkers",
        "zipcode": "10701",
        "website": "http://www.contrafect.com",
        "market_cap": "Small Cap"
    },
    "CG5.F": {
        "short_name": "COMMUNITY HEALTH SYSTEMS",
        "long_name": "Community Health Systems, Inc.",
        "summary": "Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, retail clinics, and via direct-to-consumer virtual health visits. As of December 31, 2020, it owned or leased 89 hospitals, including 87 general acute care hospitals and two stand-alone rehabilitation or psychiatric hospitals with an aggregate of 14,110 licensed beds. The company was founded in 1985 and is headquartered in Franklin, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Franklin",
        "zipcode": "37067",
        "website": "http://www.chs.net",
        "market_cap": "Small Cap"
    },
    "CGEM": {
        "short_name": "Cullinan Oncology, Inc.",
        "long_name": "Cullinan Oncology, Inc.",
        "summary": "Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.cullinanoncology.com",
        "market_cap": "Small Cap"
    },
    "CGHC": {
        "short_name": "CAPITAL GROUP HOLDINGS INC",
        "long_name": "Capital Group Holdings, Inc.",
        "summary": "Capital Group Holdings, Inc. provides health and wellness products and services in the United States. The company provides OneHealthPass, a Web-based personal health record system, which allows documents, images, and voice mail messages to be transmitted in and out of the system using various methods, including fax, voice, and file upload. It also offers patient-centric telehealth services; and operates 7 urgent care clinics located in the Phoenix, Arizona Metropolitan Area, that provide medical care services. The company was formerly known as Oasis Online Technologies, Corp. and changed its name to Capital Group Holdings, Inc. in April, 2010. Capital Group Holdings, Inc. was incorporated in 1980 and is based in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85260",
        "website": "http://www.capitalgroupholdings.com",
        "market_cap": "Small Cap"
    },
    "CGN.DE": {
        "short_name": "CIGNA CORP. NEW  DL 1",
        "long_name": "Cigna Corporation",
        "summary": "Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CT",
        "city": "Bloomfield",
        "zipcode": "06002",
        "website": "http://www.cigna.com",
        "market_cap": "Large Cap"
    },
    "CGN.F": {
        "short_name": "CIGNA CORP. NEW  DL 1",
        "long_name": "Cigna Corporation",
        "summary": "Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CT",
        "city": "Bloomfield",
        "zipcode": "06002",
        "website": "http://www.cigna.com",
        "market_cap": "Large Cap"
    },
    "CHCR": {
        "short_name": "COMPREHENSIVE CARE CORP",
        "long_name": "Advanzeon Solutions, Inc.",
        "summary": "Advanzeon Solutions, Inc., through its subsidiary, Pharmacy Value Management Solutions, Inc., administers and operates a sleep apnea program known as SleepMaster Solutions. The company was formerly known as Comprehensive Care Corporation and changed its name to Advanzeon Solutions, Inc. in January 2014. Advanzeon Solutions, Inc. was founded in 1969 and is headquartered in Tampa, Florida. On September 7, 2020, Advanzeon Solutions, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Middle District of Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33618",
        "website": "http://www.advanzeon.com",
        "market_cap": "Small Cap"
    },
    "CHE": {
        "short_name": "Chemed Corp",
        "long_name": "Chemed Corporation",
        "summary": "Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45202-4726",
        "website": "http://www.chemed.com",
        "market_cap": "Mid Cap"
    },
    "CHFS": {
        "short_name": "CHF Solutions, Inc.",
        "long_name": "CHF Solutions, Inc.",
        "summary": "CHF Solutions, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Eden Prairie",
        "zipcode": "55344",
        "website": "http://www.chf-solutions.com",
        "market_cap": "Small Cap"
    },
    "CHHL": {
        "short_name": "CHINA HOLDINGS INC",
        "long_name": "China Holdings, Inc.",
        "summary": "China Holdings, Inc., a development stage company, focuses to engage in the land and real estate development, energy, renewable energy, resources, utilities, and pharmaceutical businesses. The company, through its subsidiary, China Power, Inc., focuses on the mergers and acquisitions, investment, research and development, construction, and operation of energy, renewable energy, and environment protection projects, as well as develops renewable energy projects, pipelines in biomass energy projects, and hydropower plants in China and worldwide. China Holdings, Inc., through its another subsidiary, China Minerals Holdings, Inc., focuses to engage in the exploration, development, and production of precious and rare metals resource and properties, including vanadium, molybdenum, and uranium. In addition, the company, through its subsidiary, China Health Holdings, Inc., focuses on the development, manufacture, marketing, and distribution of pharmaceutical drugs and dietary supplements in China and worldwide. The company was formerly known as China Health Holding, Inc. and changed its name to China Holdings, Inc. in May 2007. China Holdings, Inc. was founded in 2002 and is headquartered in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89107-2001",
        "website": null,
        "market_cap": "Small Cap"
    },
    "CHMA": {
        "short_name": "Chiasma, Inc.",
        "long_name": "Chiasma, Inc.",
        "summary": "Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Needham",
        "zipcode": "02494",
        "website": "http://www.chiasma.com",
        "market_cap": "Small Cap"
    },
    "CHNC": {
        "short_name": "CHINA INFRASTRUCTURE CONSTRUCTI",
        "long_name": "China Infrastructure Construction Corp.",
        "summary": "China Infrastructure Construction Corp. offers concierge medicine through its membership-based model in the Houston Metro area, Texas. The company is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77036",
        "website": "http://www.chnc-hdh.com",
        "market_cap": "Small Cap"
    },
    "CHNG.MX": {
        "short_name": "CHANGE HEALTHCARE INC",
        "long_name": "Change Healthcare Inc.",
        "summary": "Change Healthcare Inc., an independent healthcare technology platform, provides data and analytics-driven solutions to enhance clinical, financial, administrative, and patient engagement outcomes in the United States healthcare system. It operates through three segments: Software and Analytics, Network Solutions, and Technology-Enabled Services. The Software and Analytics segment offers software and analytics solutions for financial performance, payment accuracy, clinical decision management, value-based payment, provider and consumer engagement, and imaging and clinical workflow. The Network Solutions segment enables financial, administrative, and clinical transactions; electronic business-to-business and consumer-to-business payments; and aggregation and analytics of clinical and financial data. The Technology-Enabled Services segment provides solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration, and healthcare consulting. Change Healthcare Inc. has a collaboration with Amazon Web Services, Inc. The company was founded in 2016 and is headquartered in Nashville, Tennessee.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37219",
        "website": "http://www.changehealthcare.com",
        "market_cap": "Mid Cap"
    },
    "CHNG": {
        "short_name": "Change Healthcare Inc.",
        "long_name": "Change Healthcare Inc.",
        "summary": "Change Healthcare Inc., an independent healthcare technology platform, provides data and analytics-driven solutions to enhance clinical, financial, administrative, and patient engagement outcomes in the United States healthcare system. It operates through three segments: Software and Analytics, Network Solutions, and Technology-Enabled Services. The Software and Analytics segment offers software and analytics solutions for financial performance, payment accuracy, clinical decision management, value-based payment, provider and consumer engagement, and imaging and clinical workflow. The Network Solutions segment enables financial, administrative, and clinical transactions; electronic business-to-business and consumer-to-business payments; and aggregation and analytics of clinical and financial data. The Technology-Enabled Services segment provides solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration, and healthcare consulting. Change Healthcare Inc. has a collaboration with Amazon Web Services, Inc. The company was founded in 2016 and is headquartered in Nashville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37219",
        "website": "http://www.changehealthcare.com",
        "market_cap": "Mid Cap"
    },
    "CHRS": {
        "short_name": "Coherus BioSciences, Inc.",
        "long_name": "Coherus BioSciences, Inc.",
        "summary": "Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://www.coherus.com",
        "market_cap": "Small Cap"
    },
    "CI.MX": {
        "short_name": "CIGNA CORPORATION",
        "long_name": "Cigna Corporation",
        "summary": "Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CT",
        "city": "Bloomfield",
        "zipcode": "06002",
        "website": "http://www.cigna.com",
        "market_cap": "Large Cap"
    },
    "CI": {
        "short_name": "Cigna Corporation",
        "long_name": "Cigna Corporation",
        "summary": "Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Bloomfield",
        "zipcode": "06002",
        "website": "http://www.cigna.com",
        "market_cap": "Large Cap"
    },
    "CI2.F": {
        "short_name": "CANTEL MED CORP.  DL-,10",
        "long_name": "Cantel Medical Corp.",
        "summary": "Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Little Falls",
        "zipcode": "07424-2139",
        "website": "http://www.cantelmedical.com",
        "market_cap": "Mid Cap"
    },
    "CIGN.VI": {
        "short_name": "CIGNA CORP",
        "long_name": "Cigna Corporation",
        "summary": "Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "CT",
        "city": "Bloomfield",
        "zipcode": "06002",
        "website": "http://www.cigna.com",
        "market_cap": "Large Cap"
    },
    "CKPT": {
        "short_name": "Checkpoint Therapeutics, Inc.",
        "long_name": "Checkpoint Therapeutics, Inc.",
        "summary": "Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10014",
        "website": "http://www.checkpointtx.com",
        "market_cap": "Small Cap"
    },
    "CL.CN": {
        "short_name": "CrescoLabsInc",
        "long_name": "Cresco Labs Inc.",
        "summary": "Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; flowers, popcorns, shakes, pre-rolls, and vapes under the High Supply brand; flowers, vapes, and edibles under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, ingestibles, sublingual oils, and transdermal patches under the Remedi brand, as well as cannabis products made from plants under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. It owns and operates 24 dispensaries, as well as has 5 retail licenses. The company is headquartered in Chicago, Illinois.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.crescolabs.com",
        "market_cap": "Mid Cap"
    },
    "CLAS.V": {
        "short_name": "CLARITAS PHARMACEUTICALS INC",
        "long_name": "Claritas Pharmaceuticals, Inc.",
        "summary": "Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. The company was founded in 2014 and is headquartered in San Rafael, California.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": "CA",
        "city": "San Rafael",
        "zipcode": "94903",
        "website": "http://claritaspharma.com",
        "market_cap": "Small Cap"
    },
    "CLBS": {
        "short_name": "Caladrius Biosciences, Inc.",
        "long_name": "Caladrius Biosciences, Inc.",
        "summary": "Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Basking Ridge",
        "zipcode": "07920",
        "website": "http://www.caladrius.com",
        "market_cap": "Small Cap"
    },
    "CLCS": {
        "short_name": "CELL SOURCE INC",
        "long_name": "Cell Source, Inc.",
        "summary": "Cell Source, Inc., a biotechnology company, develops cell therapy treatments. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, such as treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. The company was founded in 2011 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.cell-source.com",
        "market_cap": "Small Cap"
    },
    "CLDX": {
        "short_name": "Celldex Therapeutics, Inc.",
        "long_name": "Celldex Therapeutics, Inc.",
        "summary": "Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Hampton",
        "zipcode": "08827",
        "website": "http://www.celldex.com",
        "market_cap": "Small Cap"
    },
    "CLH.F": {
        "short_name": "CARDINAL HEALTH INC.",
        "long_name": "Cardinal Health, Inc.",
        "summary": "Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. It also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and offers pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers. In addition, this segment repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products. It also provides incontinence, nutritional delivery, wound care, cardiovascular, and endovascular products; single-use surgical drapes, gowns and apparel, and fluid suction and collection systems; urology products; operating room supplies; and electrode products. In addition, this segment distributes a range of national brand products, including medical, surgical, and laboratory products; and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Dublin",
        "zipcode": "43017",
        "website": "http://www.cardinalhealth.com",
        "market_cap": "Large Cap"
    },
    "CLM.SG": {
        "short_name": "Clearside Biomedical Inc. Regis",
        "long_name": "Clearside Biomedical, Inc.",
        "summary": "Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30005",
        "website": "http://www.clearsidebio.com",
        "market_cap": "Small Cap"
    },
    "CLNH": {
        "short_name": "CLINIGENCE HLDGS INC",
        "long_name": "Accountable Healthcare America Inc.",
        "summary": "Accountable Healthcare America Inc. provides health care services. It offers medicare management, performance metrics, cost improvement and performance improvement plans, and health management services. The company was incorporated in 2014 and is based in Fort Lauderdale, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Lauderdale",
        "zipcode": "33304",
        "website": "http://ahahealthcare.net",
        "market_cap": "Small Cap"
    },
    "CLNN": {
        "short_name": "Clene Inc.",
        "long_name": "Clene Inc.",
        "summary": "Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84121",
        "website": "http://clene.com",
        "market_cap": "Small Cap"
    },
    "CLOV": {
        "short_name": "Clover Health Investments, Corp",
        "long_name": "Clover Health Investments, Corp.",
        "summary": "Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Franklin",
        "zipcode": "37067",
        "website": "http://www.cloverhealth.com",
        "market_cap": "Mid Cap"
    },
    "CLPT": {
        "short_name": "ClearPoint Neuro Inc.",
        "long_name": "ClearPoint Neuro, Inc.",
        "summary": "ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.clearpointneuro.com",
        "market_cap": "Small Cap"
    },
    "CLRB": {
        "short_name": "Cellectar Biosciences, Inc.",
        "long_name": "Cellectar Biosciences, Inc.",
        "summary": "Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Florham Park",
        "zipcode": "07932",
        "website": "http://www.cellectar.com",
        "market_cap": "Small Cap"
    },
    "CLSD": {
        "short_name": "Clearside Biomedical, Inc.",
        "long_name": "Clearside Biomedical, Inc.",
        "summary": "Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30005",
        "website": "http://www.clearsidebio.com",
        "market_cap": "Small Cap"
    },
    "CLSH.CN": {
        "short_name": "CLSHldgsUSA",
        "long_name": "CLS Holdings USA, Inc.",
        "summary": "CLS Holdings USA, Inc., a diversified cannabis company, focuses on the extraction and conversion of cannabinoids in the United States. The company extracts various cannabinoids from the cannabis plants and converts into concentrates, such as oils, waxes, edibles, and shatters. Its concentrates are used for electronic cigarettes vaporization, and pharmaceutical and other purposes. The company also offers consulting services to cannabis-related businesses comprising growers, dispensaries, and laboratories; and toll processing services. CLS Holdings USA, Inc. was founded in 2014 and is based in Las Vegas, Nevada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89104",
        "website": "http://www.clsholdingsinc.com",
        "market_cap": "Small Cap"
    },
    "CLSH": {
        "short_name": "CLS HOLDINGS USA INC",
        "long_name": "CLS Holdings USA, Inc.",
        "summary": "CLS Holdings USA, Inc., a diversified cannabis company, focuses on the extraction and conversion of cannabinoids in the United States. The company extracts various cannabinoids from the cannabis plants and converts into concentrates, such as oils, waxes, edibles, and shatters. Its concentrates are used for electronic cigarettes vaporization, and pharmaceutical and other purposes. The company also offers consulting services to cannabis-related businesses comprising growers, dispensaries, and laboratories; and toll processing services. CLS Holdings USA, Inc. was founded in 2014 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89104",
        "website": "http://www.clsholdingsinc.com",
        "market_cap": "Small Cap"
    },
    "CLSN": {
        "short_name": "Celsion Corporation",
        "long_name": "Celsion Corporation",
        "summary": "Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Lawrenceville",
        "zipcode": "08648",
        "website": "http://celsion.com",
        "market_cap": "Small Cap"
    },
    "CLVR": {
        "short_name": "Clever Leaves Holdings Inc.",
        "long_name": "Clever Leaves Holdings Inc.",
        "summary": "Clever Leaves Holdings Inc. cultivates, extracts, manufactures, and commercializes pharmaceutical-grade cannabinoid products in Colombia, Portugal, Germany, the United States, and Canada. The company operates through two segments, Cannabinoid and Non-Cannabinoid. It also engages in the formulating, manufacturing, marketing, distributing, and selling of homeopathic and other natural remedies, wellness products, detoxification products, nutraceuticals, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors. Clever Leaves Holdings Inc. is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.cleverleaves.com",
        "market_cap": "Small Cap"
    },
    "CLVS": {
        "short_name": "Clovis Oncology, Inc.",
        "long_name": "Clovis Oncology, Inc.",
        "summary": "Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/\u00c3\u009f), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80301",
        "website": "http://www.clovisoncology.com",
        "market_cap": "Small Cap"
    },
    "CMD": {
        "short_name": "Cantel Medical Corp.",
        "long_name": "Cantel Medical Corp.",
        "summary": "Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Little Falls",
        "zipcode": "07424-2139",
        "website": "http://www.cantelmedical.com",
        "market_cap": "Mid Cap"
    },
    "CMPD": {
        "short_name": "COMPUMED INC",
        "long_name": "CompuMed, Inc.",
        "summary": "CompuMed, Inc., an enterprise telemedicine solutions company, provides clinical care services for patients and medical facilities. It offers telecardiology and teleradiology services that provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities worldwide. The company provides enterprise telemedicine solutions, such as network of specialists, cloud-based telemedicine technology, telemedicine-enabled medical devices, 24/7 call center customer support, professional, and training services; a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including electrocardiogram (ECG) devices, echocardiogram, ECG, vascular, holter, nuclear, and video consults; and reading, transcription, reporting, storage, and video consultations in the areas of Vscan, X-ray, ultrasound, mammography, computed tomography, magnetic resonance imaging, and radiologist video consults. It also offers OsteoGram software that works in combination with standard or digital X-ray equipment to support osteoporosis screening, diagnosis, and therapy monitoring. In addition, the company provides mobile ECG and ultrasound solutions that provide patients with immediate access to its board-certified specialists; and Vscan, a handheld, pocket-sized visualization tool that houses ultrasound technology, which strengthens the clinical confidence of physicians and aids in speedy diagnosis. It serves organ procurement organizations, rural healthcare, and correctional healthcare industries. CompuMed, Inc. was founded in 1973 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90045",
        "website": "http://www.compumed.net",
        "market_cap": "Small Cap"
    },
    "CMPI": {
        "short_name": "Checkmate Pharmaceuticals, Inc.",
        "long_name": "Checkmate Pharmaceuticals, Inc.",
        "summary": "Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 na\u00c3\u00afve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.checkmatepharma.com",
        "market_cap": "Small Cap"
    },
    "CMPX": {
        "short_name": "COMPASS THERAPEUTICS INC",
        "long_name": "Compass Therapeutics, Inc.",
        "summary": "Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics for treating solid tumors and hematological malignancies. The company's lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is in Phase 1b clinical trial. It also plans to initiate a second Phase 1 trial of CTX-471 in combination with trastuzumab for Her2 positive tumors, as well as with cetuximab in EGFR positive tumors. In addition, the company's product candidates include CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. Further, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02135",
        "website": "http://www.compasstherapeutics.com",
        "market_cap": "Small Cap"
    },
    "CMRX": {
        "short_name": "Chimerix, Inc.",
        "long_name": "Chimerix, Inc.",
        "summary": "Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27713",
        "website": "http://www.chimerix.com",
        "market_cap": "Small Cap"
    },
    "CMXC": {
        "short_name": "CELL MEDX CORP",
        "long_name": "Cell MedX Corp.",
        "summary": "Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general relaxation and for the temporary relief of pain due to sore and/or aching muscles. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Carson City",
        "zipcode": "89706",
        "website": "http://www.cellmedx.com",
        "market_cap": "Small Cap"
    },
    "CN2.F": {
        "short_name": "CATALYST PHARM.INC.DL-001",
        "long_name": "Catalyst Pharmaceuticals, Inc.",
        "summary": "Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Coral Gables",
        "zipcode": "33134",
        "website": "http://www.catalystpharma.com",
        "market_cap": "Small Cap"
    },
    "CNABQ": {
        "short_name": "UNITED CANNABIS CORPORATION",
        "long_name": "United Cannabis Corporation",
        "summary": "United Cannabis Corporation owns intellectual properties related to growth, production, manufacture, marketing, management, utilization, and distribution of medical and recreational marijuana, and marijuana infused products in the United States and the Cayman Islands. The company focuses on developing therapeutics, including Prana Bio Nutrient Medicinal products for supplement deficiencies related to the endocannabinoid system, including pain, neuropathy, arthritis, MS, IBS, autism, seizures, eczema, sleep, anxiety, head trauma, opioid dependency, and clinical endocannabinoid deficiencies; and Prana Aromatherapy Transdermal Roll-on line that provides targeted and large surface relief with combinations of aromatherapy. It also develops Epidiferphane, a therapeutic for the prevention of the negative side effects of chemotherapy, as well as therapeutics for the management of rheumatoid arthritis and treatment of brain cancer. The company was formerly known as MySkin, Inc. and changed its name to United Cannabis Corporation in May 2014. United Cannabis Corporation was founded in 2007 and is based in Golden, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Golden",
        "zipcode": "80401",
        "website": "http://unitedcannabis.us",
        "market_cap": "Small Cap"
    },
    "CNB.F": {
        "short_name": "FORTRESS BIOTECH  DL-,001",
        "long_name": "Fortress Biotech, Inc.",
        "summary": "Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10014",
        "website": "http://www.fortressbiotech.com",
        "market_cap": "Small Cap"
    },
    "CNB0.F": {
        "short_name": "FORTRESS BIOTECH.PRF.A 25",
        "long_name": "Fortress Biotech, Inc.",
        "summary": "Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10014",
        "website": "http://www.fortressbiotech.com",
        "market_cap": null
    },
    "CNBX": {
        "short_name": "CANNABICS PHARMACEUTICALS INC",
        "long_name": "Cannabics Pharmaceuticals Inc.",
        "summary": "Cannabics Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The company focuses on developing and marketing bioinformatic delivery systems for cannabinoids, personalized medicine therapies, and procedures based on cannabis originated compounds and bioinformatics tools. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, a drug sensitivity test for cannabinoid-based cancer therapies. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was founded in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Bethesda",
        "zipcode": "20814",
        "website": "http://cannabics.com",
        "market_cap": "Small Cap"
    },
    "CNC.MX": {
        "short_name": "CENTENE CORPORATION",
        "long_name": "Centene Corporation",
        "summary": "Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MO",
        "city": "St. Louis",
        "zipcode": "63105",
        "website": "http://www.centene.com",
        "market_cap": "Large Cap"
    },
    "CNC": {
        "short_name": "Centene Corporation",
        "long_name": "Centene Corporation",
        "summary": "Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MO",
        "city": "St. Louis",
        "zipcode": "63105",
        "website": "http://www.centene.com",
        "market_cap": "Large Cap"
    },
    "CNCE": {
        "short_name": "Concert Pharmaceuticals, Inc.",
        "long_name": "Concert Pharmaceuticals, Inc.",
        "summary": "Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.concertpharma.com",
        "market_cap": "Small Cap"
    },
    "CNMD": {
        "short_name": "CONMED Corporation",
        "long_name": "CONMED Corporation",
        "summary": "CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Largo",
        "zipcode": "33773-4908",
        "website": "http://www.conmed.com",
        "market_cap": "Mid Cap"
    },
    "CNNA": {
        "short_name": "CANN AMERICAN CORP",
        "long_name": "Cann American Corp.",
        "summary": "Cann American Corp., a development stage company, focuses on the development of Cannabis sativa strains for pets in various European Union countries. The company was formerly known as Canamed4Pets, Inc. and changed its name to Cann American Corp. in December 2019. Cann American Corp. was founded in 2004 and is based in Cloverdale, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Cloverdale",
        "zipcode": "95425",
        "website": null,
        "market_cap": "Small Cap"
    },
    "CNNC": {
        "short_name": "CANNONAU CORP",
        "long_name": "Cannonau Corp.",
        "summary": "Cannonau Corp. develops CBD based products. The company was formerly known as Pacific Blue Energy Corp. and changed its name to Cannonau Corp. in August 2019. Cannonau Corp. was founded in 2007 and is based in Skaneateles, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Skaneateles",
        "zipcode": "13252-9318",
        "website": "http://pbec.biz",
        "market_cap": "Small Cap"
    },
    "CNSC": {
        "short_name": "CANNASSIST INTL CORP",
        "long_name": "CannAssist International Corp.",
        "summary": "CannAssist International Corp. produces and sells cannabidiol (CBD) and other products. The company provides Cibidinol, a CBD product, as well as consumable and topical products in various delivery forms, including capsules, sublingual drops, films, troches, lotions, creams, sprays, powders, and suppositories. CannAssist International Corp. sells its products directly through xceptorcbd.com. The company was formerly known as Iris Grove Acquisition Corporation and changed its name to CannAssist International Corp. in May 2018. CannAssist International Corp. was incorporated in 2017 and is based in Fallbrook, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Fallbrook",
        "zipcode": "92028",
        "website": "http://xceptorcbd.com",
        "market_cap": "Small Cap"
    },
    "CNSP": {
        "short_name": "CNS Pharmaceuticals, Inc.",
        "long_name": "CNS Pharmaceuticals, Inc.",
        "summary": "CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77027",
        "website": "http://www.cnspharma.com",
        "market_cap": "Small Cap"
    },
    "CNST": {
        "short_name": "Constellation Pharmaceuticals, ",
        "long_name": "Constellation Pharmaceuticals, Inc.",
        "summary": "Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.constellationpharma.com",
        "market_cap": "Small Cap"
    },
    "CNTMF": {
        "short_name": "CANSORTIUM INC",
        "long_name": "Cansortium Inc.",
        "summary": "Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. The company engages in the cultivation, processing, retail, and distribution activities. Its medical cannabis products are offered in oral drops, capsules, suppositories, topicals, syringes, dried flower, prerolls, cartridges, and edibles. The company provides its products under the Fluent brand name. Cansortium Inc. was incorporated in 2018 and is headquartered in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33137",
        "website": "http://www.getfluent.com",
        "market_cap": "Small Cap"
    },
    "COCP": {
        "short_name": "Cocrystal Pharma, Inc.",
        "long_name": "Cocrystal Pharma, Inc.",
        "summary": "Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Bothell",
        "zipcode": "98011",
        "website": "http://www.cocrystalpharma.com",
        "market_cap": "Small Cap"
    },
    "CODX": {
        "short_name": "Co-Diagnostics, Inc.",
        "long_name": "Co-Diagnostics, Inc.",
        "summary": "Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84109",
        "website": "http://www.codiagnostics.com",
        "market_cap": "Small Cap"
    },
    "COGT": {
        "short_name": "Cogent Biosciences, Inc.",
        "long_name": "Cogent Biosciences, Inc.",
        "summary": "Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02140",
        "website": "http://www.cogentbio.com",
        "market_cap": "Small Cap"
    },
    "COLL": {
        "short_name": "Collegium Pharmaceutical, Inc.",
        "long_name": "Collegium Pharmaceutical, Inc.",
        "summary": "Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Stoughton",
        "zipcode": "02072",
        "website": "http://www.collegiumpharma.com",
        "market_cap": "Small Cap"
    },
    "COO.MX": {
        "short_name": "COOPER COS INC",
        "long_name": "The Cooper Companies, Inc.",
        "summary": "The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Ramon",
        "zipcode": "94583",
        "website": "http://www.coopercos.com",
        "market_cap": "Large Cap"
    },
    "COO": {
        "short_name": "The Cooper Companies, Inc.",
        "long_name": "The Cooper Companies, Inc.",
        "summary": "The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Ramon",
        "zipcode": "94583",
        "website": "http://www.coopercos.com",
        "market_cap": "Large Cap"
    },
    "CORT": {
        "short_name": "Corcept Therapeutics Incorporat",
        "long_name": "Corcept Therapeutics Incorporated",
        "summary": "Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://www.corcept.com",
        "market_cap": "Mid Cap"
    },
    "CORX": {
        "short_name": "CORE LITHIUM CORP",
        "long_name": "Core Lithium Corp.",
        "summary": "Core Lithium Corp., an exploration stage mining company, engages in the identification, acquisition, exploration, mining, and development of lithium assets in North America. Its principal property is the Quadra lithium claims property, which consists of 56 mineral exploration titles covering an area of approximately 7,840 acres located in the James Bay region of Northern Quebec, Canada. The company was formerly known as All American Energy Corp. and changed its name to Core Lithium Corp. in April 2018. Core Lithium Corp. was incorporated in 1994 and is based in Cincinnati, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Other",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45202",
        "website": "http://www.corelithium.com",
        "market_cap": "Small Cap"
    },
    "COSM": {
        "short_name": "COSMOS HOLDINGS INC",
        "long_name": "Cosmos Holdings Inc.",
        "summary": "Cosmos Holdings Inc., through its subsidiaries, operates as a pharmaceutical wholesaler primarily in the European Union. It imports, exports, and distributes branded pharmaceutical products, generic pharmaceutical products, prescription and non-prescription derivatives of cannabis products, over-the-counter medicines, cosmetics, nursery, dietary products, and vitamin supplements. It also develops nutraceutical products under the Sky Life Premium brand name. The company provides its products to wholesale drug distributors, hospitals, pharmacies, governmental agencies, and wholesalers and retail healthcare providers. It operates in Greece, Germany, the United Kingdom, Hungary, the Netherlands, Ireland, Libya, Poland, Italy, France, Denmark, Croatia, Turkey, Jordan, Indonesia, Georgia, Belgium, and Cyprus. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60604",
        "website": "http://www.cosmosholdingsinc.com",
        "market_cap": "Small Cap"
    },
    "CP6.F": {
        "short_name": "COOPER COS INC.  DL-,10",
        "long_name": "The Cooper Companies, Inc.",
        "summary": "The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Ramon",
        "zipcode": "94583",
        "website": "http://www.coopercos.com",
        "market_cap": "Large Cap"
    },
    "CPAI": {
        "short_name": "CHAMPION PAIN CARE CORP",
        "long_name": "Champion Pain Care Corporation",
        "summary": "Champion Pain Care Corporation operates as a pain management company in the United States. It offers the Champion Pain Care Protocol, a proprietary pain management protocol for the treatment and management of chronic pain. The company's protocol includes various treatment plans comprising physical examination by the attending doctor, blood testing, and urine drug screening; education for patients about the nature of their chronic pain; on-going interaction to support patient adherence to beneficial behavioral changes; relaxation training to reduce the effects or stress and anxiety, which can aggravate pain; amino acids and other dietary supplements to restore and maintain normal brain chemistry; and the reduction of cellular and joint inflammation. Its treatment plans also consists of the day and night time regimens to promote restorative sleep; use of electrotherapy stimulation to promote production and release of endorphin; topical medications for pain relief; and on-going counseling, telephone and on-line support, and checkups. The company was formerly known as OICCO Acquisition I, Inc. and changed its name to Champion Pain Care Corporation in August 2014. Champion Pain Care Corporation was incorporated in 2009 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10005",
        "website": "http://www.championpaincare.com",
        "market_cap": "Small Cap"
    },
    "CPH1.F": {
        "short_name": "HISTOGEN INC. DL-,0001",
        "long_name": "Histogen Inc.",
        "summary": "Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.histogen.com",
        "market_cap": "Small Cap"
    },
    "CPIX": {
        "short_name": "Cumberland Pharmaceuticals Inc.",
        "long_name": "Cumberland Pharmaceuticals Inc.",
        "summary": "Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37203",
        "website": "http://www.cumberlandpharma.com",
        "market_cap": "Small Cap"
    },
    "CPMV": {
        "short_name": "MOSAIC IMMUNOENGINEERING INC",
        "long_name": "Mosaic ImmunoEngineering Inc.",
        "summary": "Patriot Scientific Corporation operates as an intellectual-property licensing company. The company's Moore Microprocessor Patent portfolio that includes U.S. patents, as well as European and Japanese counterparts, which cover techniques that enable consumer and commercial digital systems ranging from PCs, cell phones, portable music players, communications infrastructure, medical equipment, and automobiles. Patriot Scientific Corporation is headquartered in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": null,
        "city": null,
        "zipcode": null,
        "website": "http://www.ptsc.com",
        "market_cap": "Small Cap"
    },
    "CPRX": {
        "short_name": "Catalyst Pharmaceuticals, Inc.",
        "long_name": "Catalyst Pharmaceuticals, Inc.",
        "summary": "Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Coral Gables",
        "zipcode": "33134",
        "website": "http://www.catalystpharma.com",
        "market_cap": "Small Cap"
    },
    "CPSI": {
        "short_name": "Computer Programs and Systems, ",
        "long_name": "Computer Programs and Systems, Inc.",
        "summary": "Computer Programs and Systems, Inc. provides healthcare information technology solutions and services in the United States and the Caribbean nation of St. Maarten. Its software systems include patient management software that enables a hospital to identify a patient at various points in the healthcare delivery system, as well as to collect and maintain patient information throughout the process of patient care; and financial accounting software, which offers business office applications to track and coordinate information needed for managerial decision-making. The company also provides clinical software that automates record keeping and reporting for various clinical functions, including laboratory, radiology, physical therapy, respiratory care, and pharmacy; patient care applications; and enterprise applications that support its products for use in various areas of the hospital. In addition, it offers Centriq, an intuitive user interface to centralize data from various care areas that provide the end user with a tool to view past and present patient information. Further, the company provides software solutions that promote data-driven clinical and financial outcomes for customers in the post-acute care industry; software application support, hardware maintenance, and education and related services; post-acute care support and maintenance services; revenue cycle management products and services, consulting and business management services, and managed information technology services; patient engagement and empowerment technology solutions; and system implementation and training services. It serves community hospitals and physician clinics, skilled nursing and assisted living facilities, and small specialty hospitals. Computer Programs and Systems, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "AL",
        "city": "Mobile",
        "zipcode": "36695",
        "website": "http://www.cpsi.com",
        "market_cap": "Small Cap"
    },
    "CPYT": {
        "short_name": "CAREPAYMENT TECHNOLOGIES INC",
        "long_name": "CarePayment Technologies, Inc.",
        "summary": "CarePayment Technologies, Inc. provides accounts receivable services in the United States. It offers services for accounts receivables generated by healthcare providers in connection with providing healthcare services to their patients under the CarePayment brand name. The company was formerly known as microHelix, Inc. CarePayment Technologies, Inc. was founded in 1991 and is based in Lake Oswego, Oregon.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OR",
        "city": "Lake Oswego",
        "zipcode": "97035",
        "website": "http://www.microhelix.com",
        "market_cap": "Small Cap"
    },
    "CRBP": {
        "short_name": "Corbus Pharmaceuticals Holdings",
        "long_name": "Corbus Pharmaceuticals Holdings, Inc.",
        "summary": "Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Norwood",
        "zipcode": "02062",
        "website": "http://www.corbuspharma.com",
        "market_cap": "Small Cap"
    },
    "CRDF": {
        "short_name": "Cardiff Oncology, Inc.",
        "long_name": "Cardiff Oncology, Inc.",
        "summary": "Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.cardiffoncology.com",
        "market_cap": "Small Cap"
    },
    "CRE.F": {
        "short_name": "CERNER CORP.  DL-,01",
        "long_name": "Cerner Corporation",
        "summary": "Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. It also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, the company offers a portfolio of clinical and financial health care information technology solutions, as well as departmental and care coordination solutions. Further, it provides tech-enabled services, such as implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, employee wellness programs, and third-party administrator services; and complementary hardware and devices for third parties. The company serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. Cerner Corporation was founded in 1979 and is headquartered in North Kansas City, Missouri.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MO",
        "city": "North Kansas City",
        "zipcode": "64117-2551",
        "website": "http://www.cerner.com",
        "market_cap": "Large Cap"
    },
    "CRIS": {
        "short_name": "Curis, Inc.",
        "long_name": "Curis, Inc.",
        "summary": "Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.curis.com",
        "market_cap": "Small Cap"
    },
    "CRL": {
        "short_name": "Charles River Laboratories Inte",
        "long_name": "Charles River Laboratories International, Inc.",
        "summary": "Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Wilmington",
        "zipcode": "01887",
        "website": "http://www.criver.com",
        "market_cap": "Large Cap"
    },
    "CRLBF": {
        "short_name": "CRESCO LABS INC",
        "long_name": "Cresco Labs Inc.",
        "summary": "Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; flowers, popcorns, shakes, pre-rolls, and vapes under the High Supply brand; flowers, vapes, and edibles under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, ingestibles, sublingual oils, and transdermal patches under the Remedi brand, as well as cannabis products made from plants under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. It owns and operates 24 dispensaries, as well as has 5 retail licenses. The company is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.crescolabs.com",
        "market_cap": "Mid Cap"
    },
    "CRMD": {
        "short_name": "CorMedix Inc.",
        "long_name": "CorMedix Inc.",
        "summary": "CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Berkeley Heights",
        "zipcode": "07922",
        "website": "http://www.cormedix.com",
        "market_cap": "Small Cap"
    },
    "CRNX": {
        "short_name": "Crinetics Pharmaceuticals, Inc.",
        "long_name": "Crinetics Pharmaceuticals, Inc.",
        "summary": "Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.crinetics.com",
        "market_cap": "Small Cap"
    },
    "CRTX": {
        "short_name": "Cortexyme, Inc.",
        "long_name": "Cortexyme, Inc.",
        "summary": "Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.cortexyme.com",
        "market_cap": "Small Cap"
    },
    "CRVS": {
        "short_name": "Corvus Pharmaceuticals, Inc.",
        "long_name": "Corvus Pharmaceuticals, Inc.",
        "summary": "Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Burlingame",
        "zipcode": "94010",
        "website": "http://www.corvuspharma.com",
        "market_cap": "Small Cap"
    },
    "CRVW": {
        "short_name": "CAREVIEW COMMUNICATIONS INC",
        "long_name": "CareView Communications, Inc.",
        "summary": "CareView Communications, Inc. provides products and on-demand application services for the healthcare industry in the United States. The company provides CareView Patient Safety System, a video monitoring tool to improve the practice of nursing, create a better work environment, and make the patient's hospital stay more satisfying, which is used in hospitals, nursing homes, adult living centers, and outpatient care facilities; and Caregiver Platform, which offers caregiver connect mobile application to provide a convenient and intuitive interface to capture critical workflows, such as acknowledging and documenting alert presses by the resident. It also offers CareView Connect, which provides resident monitoring products and services for the long- term care industry; an array of wearable and stationary buttons that allow a resident to summon help either for an emergency or assistance; a mobile app capable of delivering an alert to the caregiver and allows them document information around that alert; and alert management and monitoring system. CareView Communications, Inc. is based in Lewisville, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Lewisville",
        "zipcode": "75067",
        "website": "http://www.care-view.com",
        "market_cap": "Small Cap"
    },
    "CRXM": {
        "short_name": "TAXUS CARDIUM PHARMACEUTICALS G",
        "long_name": "Gene Biotherapeutics, Inc.",
        "summary": "Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies to manufacture the Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://genebiotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "CRY": {
        "short_name": "CryoLife, Inc.",
        "long_name": "CryoLife, Inc.",
        "summary": "CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Kennesaw",
        "zipcode": "30144",
        "website": "http://www.cryolife.com",
        "market_cap": "Small Cap"
    },
    "CRYO": {
        "short_name": "AMERICAN CRYOSTEM CORPORATION",
        "long_name": "American CryoStem Corporation",
        "summary": "American CryoStem Corporation develops, markets, and licenses tissue-based cellular technologies with a focus on processing, commercial bio-banking, and application development for adipose tissue and autologous adipose-derived regenerative cells. The company's products include CELLECT collection, transportation, and storage system, which is a solution for physicians to collect and deliver tissue samples; ATGRAFT adipose tissue storage service, a fat storage solution that enables physicians to provide their patients with tissue products and cell storage options; and ATCELL adipose derived stem cells. It also offers ACSelerat cell culture media products for growing human stromal cells. In addition, the company, through its ACS Laboratories division, operate human tissue processing, cryopreservation and cell culture and differentiation media development facility. Further, it provides contract manufacturing services for Autokine-CM, an anti-aging topical formulation; and autologous skin care product line. The company was founded in 1987 and is based in Eatontown, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Eatontown",
        "zipcode": "07724",
        "website": "http://www.americancryostem.com",
        "market_cap": "Small Cap"
    },
    "CSBR": {
        "short_name": "Champions Oncology, Inc.",
        "long_name": "Champions Oncology, Inc.",
        "summary": "Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Hackensack",
        "zipcode": "07601",
        "website": "http://www.championsoncology.com",
        "market_cap": "Small Cap"
    },
    "CSII": {
        "short_name": "Cardiovascular Systems, Inc.",
        "long_name": "Cardiovascular Systems, Inc.",
        "summary": "Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Saint Paul",
        "zipcode": "55112-6416",
        "website": "http://www.csi360.com",
        "market_cap": "Small Cap"
    },
    "CSLT": {
        "short_name": "Castlight Health, Inc.",
        "long_name": "Castlight Health, Inc.",
        "summary": "Castlight Health, Inc. provides health navigation solutions for employers and health plan customers in education, manufacturing, retail, government, and technology industries in the United States. It provides Care Guidance Navigator that enables users to make better care decisions and navigate the employer-sponsored healthcare benefit programs; Wellbeing Navigator, which helps to drive engagement across an employer's benefits program; Complete Health Navigator that combines the Wellbeing Navigator and Care Guidance Navigator packages for unified user experience; and Castlight Care Guides, a high-touch navigation service. The company also offers white-labeled health navigation solutions and embedded platform technology services. In addition, it provides implementation and marketplace services. The company was formerly known as Ventana Health Services and changed its name to Castlight Health, Inc. in April 2010. Castlight Health, Inc. was incorporated in 2008 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94105",
        "website": "http://www.castlighthealth.com",
        "market_cap": "Small Cap"
    },
    "CSOC": {
        "short_name": "CADUCEUS SOFTWARE SYSTEMS CORP",
        "long_name": "Caduceus Software Systems Corp.",
        "summary": "Caduceus Software Systems Corp., a development stage company, provides medical software solutions to medical professionals. The company offers a suite of medical management software applications for use in the medical industry for patient management, patient appointment scheduling, physician memorandum recording, medical symptom and ailment recording, and digital image recording. It provides Caduceus MMS, a software suite to manage an entire medical practice that consists of accounting records, patient billing, appointment scheduler, human anatomical mapping, imaging, and document editor or prescription writer modules. The company intends to market its software suite in the areas of healthcare patient information management; electronic healthcare recording; electronic medical billing systems; and contact management, and appointment scheduling and booking. Caduceus Software Systems Corp. was formerly known as Bosco Holdings Inc. and changed its name to Caduceus Software Systems Corp. in March 2011. The company was founded in 2006 and is based in Johnston, Rhode Island.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "RI",
        "city": "Johnston",
        "zipcode": "02919",
        "website": "http://www.caduceusco.com",
        "market_cap": "Small Cap"
    },
    "CSSI": {
        "short_name": "COSTAS INC",
        "long_name": "Costas, Inc.",
        "summary": "Costas, Inc., a digital media company, owns and develops Web-based consumer Internet assets and communities in the United States and India. It operates ejobresource.com, an online job portal that offers recruitment and placement services. The company also provides under graduate and graduate degree courses; and systems integration and software services. It serves the media and entertainment, agency, retail, manufacturing, financial services, and various other industries. The company was founded in 1998 and is based in Tempe, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85281",
        "website": "http://www.costasinc.com",
        "market_cap": "Small Cap"
    },
    "CSTL": {
        "short_name": "Castle Biosciences, Inc.",
        "long_name": "Castle Biosciences, Inc.",
        "summary": "Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Friendswood",
        "zipcode": "77546",
        "website": "http://castlebiosciences.com",
        "market_cap": "Small Cap"
    },
    "CSU": {
        "short_name": "Capital Senior Living Corporati",
        "long_name": "Capital Senior Living Corporation",
        "summary": "Capital Senior Living Corporation develops, owns, operates, and manages senior housing communities in the United States. The company provides independent living services, which include daily meals, transportation, social and recreational activities, laundry, housekeeping, and 24-hour staffing; and access to health screenings, periodic special services, and dietary and similar programs, as well as exercise and fitness classes. It also offers assisted living services consist of personal care services, such as assistance with activities of daily living, including ambulation, bathing, dressing, eating, grooming, personal hygiene, and monitoring or assistance with medications; support services, including meals, assistance with social and recreational activities, laundry, general housekeeping, maintenance, and transportation services; and supplemental services, which include extra transportation, personal maintenance, and extra laundry, as well as special care services for residents with various forms of dementia. In addition, the company provides memory care services; and home care services through third-party providers. As of December 31, 2020, it operated 101 senior housing communities in 22 states with an aggregate capacity of approximately 13,000 residents, including 60 owned and 12 leased senior housing communities. Capital Senior Living Corporation was founded in 1990 and is headquartered in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75254",
        "website": "http://www.capitalsenior.com",
        "market_cap": "Small Cap"
    },
    "CTHZ": {
        "short_name": "CANCER TREATMENT HOLDINGS INC",
        "long_name": "Cancer Treatment Holdings, Inc.",
        "summary": "Cancer Treatment Holdings, Inc., through its subsidiaries, engages in providing IT-enabled services; the exploitation of an invention related to the on-site production of chlorine gas and related compounds; and providing radiation therapy, diagnostic imaging, and other medical related services. The company, through a 50% interest in a joint venture, offers IT-enabled services, including medical transcriptions, billing and collecting, bookkeeping, and claims processing services. The company enables users to manufacture chlorine on-site and when needed through its device. It has a 51% interest in a radiation therapy center located in Logan, West Virginia. In addition, through its wholly owned subsidiary, CTI Management Corp., the company's president provides management services. The company is based in Carson City, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Carson City",
        "zipcode": "89703",
        "website": null,
        "market_cap": "Small Cap"
    },
    "CTIC": {
        "short_name": "CTI BioPharma Corp.",
        "long_name": "CTI BioPharma Corp.",
        "summary": "CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98121",
        "website": "http://www.ctibiopharma.com",
        "market_cap": "Small Cap"
    },
    "CTLT.MX": {
        "short_name": "CATALENT INC",
        "long_name": "Catalent, Inc.",
        "summary": "Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NJ",
        "city": "Somerset",
        "zipcode": "08873",
        "website": "http://www.catalent.com",
        "market_cap": "Large Cap"
    },
    "CTLT": {
        "short_name": "Catalent, Inc.",
        "long_name": "Catalent, Inc.",
        "summary": "Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Somerset",
        "zipcode": "08873",
        "website": "http://www.catalent.com",
        "market_cap": "Large Cap"
    },
    "CTMX": {
        "short_name": "CytomX Therapeutics, Inc.",
        "long_name": "CytomX Therapeutics, Inc.",
        "summary": "CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.cytomx.com",
        "market_cap": "Small Cap"
    },
    "CTSO": {
        "short_name": "Cytosorbents Corporation",
        "long_name": "Cytosorbents Corporation",
        "summary": "Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Monmouth Junction",
        "zipcode": "08852",
        "website": "http://www.cytosorbents.com",
        "market_cap": "Small Cap"
    },
    "CTTC": {
        "short_name": "CALMARE THERAPEUTICS INC",
        "long_name": "Calmare Therapeutics Incorporated",
        "summary": "Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Fairfield",
        "zipcode": "06824",
        "website": "http://www.calmaretherapeutics.com",
        "market_cap": "Small Cap"
    },
    "CTVEF": {
        "short_name": "CERTIVE SOLUTIONS INC",
        "long_name": "Certive Solutions Inc.",
        "summary": "Certive Solutions Inc. provides healthcare information technology solutions to hospitals and healthcare administrators in the United States. It offers revenue cycle management services. The company was formerly known as Visual Vault Corporation and changed its name to Certive Solutions Inc. in October 2013. Certive Solutions Inc. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85258",
        "website": "http://certive.com",
        "market_cap": "Small Cap"
    },
    "CTXR": {
        "short_name": "Citius Pharmaceuticals, Inc.",
        "long_name": "Citius Pharmaceuticals, Inc.",
        "summary": "Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranford",
        "zipcode": "07016",
        "website": "http://www.citiuspharma.com",
        "market_cap": "Small Cap"
    },
    "CUBT": {
        "short_name": "CURATIVE BIOTECHNOLOGY INC",
        "long_name": "Curative Biotechnology, Inc.",
        "summary": "Curative Biotechnology, Inc., doing business as Connectyx, a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33431",
        "website": "http://curativebiotech.com",
        "market_cap": "Small Cap"
    },
    "CUE": {
        "short_name": "Cue Biopharma, Inc.",
        "long_name": "Cue Biopharma, Inc.",
        "summary": "Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 would also leverage the IL-2 based CUE-100 framework and target an antigen to be selected in collaboration with LG Chem; CUE-200 framework that utilizes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences to the development of Immuno-STATs focused in the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.cuebiopharma.com",
        "market_cap": "Small Cap"
    },
    "CURA.CN": {
        "short_name": "CuraleafHoldnc.",
        "long_name": "Curaleaf Holdings, Inc.",
        "summary": "Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers oil-based formulations, such as vaporizing, cartridges, tinctures, and capsules; and ground-flower. The company also provides hemp-based CBD products. As of March 9, 2021, it operated 101 dispensaries, 23 cultivation sites, and 30 processing sites in 23 states of the United States. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "MA",
        "city": "Wakefield",
        "zipcode": "01880",
        "website": "http://www.curaleaf.com",
        "market_cap": "Mid Cap"
    },
    "CURLF": {
        "short_name": "CURALEAF HOLDINGS  INC",
        "long_name": "Curaleaf Holdings, Inc.",
        "summary": "Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers oil-based formulations, such as vaporizing, cartridges, tinctures, and capsules; and ground-flower. The company also provides hemp-based CBD products. As of March 9, 2021, it operated 101 dispensaries, 23 cultivation sites, and 30 processing sites in 23 states of the United States. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Wakefield",
        "zipcode": "01880",
        "website": "http://www.curaleaf.com",
        "market_cap": "Large Cap"
    },
    "CURR": {
        "short_name": "CURE PHARMACEUTICAL HOLDING COR",
        "long_name": "CURE Pharmaceutical Holding Corp.",
        "summary": "CURE Pharmaceutical Holding Corp., together with its subsidiaries, operates as an integrated drug delivery and development company in the United States and internationally. It focuses on the development and manufacture of drug formulation and drug delivery technologies in novel dosage forms to enhance drug efficacy, safety, and patient adherence. The company operates through two business segments: Cure and Sera Labs. It offers pharmaceutical and wellness products, including CUREfilm Blue, a sildenafil oral thin film for the treatment of erectile dysfunction; cannabinoid products with optimized pharmacokinetic profiles using microCURE and CUREfilm technology under the CUREfilm Canna name; and CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data. The company also provides CUREfilm Central Nervous System, a novel dosage form to treat disease states utilizing its proprietary CUREfilm dosage form, as well as to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. It sells wellness products through direct to consumer and wholesale channels. CURE Pharmaceutical Holding Corp. has a collaboration with Canopy Growth Corporation for the production and sale of medical cannabis. The company was founded in 2011 and is based in Oxnard, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Oxnard",
        "zipcode": "93033",
        "website": "http://www.curepharmaceutical.com",
        "market_cap": "Small Cap"
    },
    "CUSA.F": {
        "short_name": "CURIS INC.  DL-,01",
        "long_name": "Curis, Inc.",
        "summary": "Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.curis.com",
        "market_cap": "Small Cap"
    },
    "CUTR": {
        "short_name": "Cutera, Inc.",
        "long_name": "Cutera, Inc.",
        "summary": "Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company offers truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; truSculpt for the non-surgical body sculpting market; Juliet, a laser for women's intimate health; Secret RF, a fractional radio frequency microneedling device for skin revitalization; and enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions and acne scars. It also provides excel HR platform, a hair removal solution for various skin types; excel V+, a vascular and benign pigmented lesion treatment platform; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company offers GenesisPlus, CoolGlide, myQ, and skincare products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website cutera.com. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, and other qualified practitioners, as well as for physicians performing aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1988 and is headquartered in Brisbane, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Brisbane",
        "zipcode": "94005",
        "website": "http://cutera.com",
        "market_cap": "Small Cap"
    },
    "CVET": {
        "short_name": "Covetrus, Inc.",
        "long_name": "Covetrus, Inc.",
        "summary": "Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "ME",
        "city": "Portland",
        "zipcode": "04101",
        "website": "http://www.covetrus.com",
        "market_cap": "Mid Cap"
    },
    "CVHIF": {
        "short_name": "VENTURA CANNABIS AND WELLNESS C",
        "long_name": "Ventura Cannabis & Wellness Corporation",
        "summary": "Ventura Cannabis & Wellness Corporation operates as a vertically integrated cannabis product company in California. The company was formerly known as BLVD Centers Corporation and changed its name to Ventura Cannabis & Wellness Corporation in February 2019. The company was incorporated in 2013 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90017",
        "website": "http://www.venturacanna.com",
        "market_cap": "Small Cap"
    },
    "CVM": {
        "short_name": "Cel-Sci Corporation",
        "long_name": "CEL-SCI Corporation",
        "summary": "CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Vienna",
        "zipcode": "22182",
        "website": "http://cel-sci.com",
        "market_cap": "Small Cap"
    },
    "CVS.DE": {
        "short_name": "CVS HEALTH CORP.  DL-,01",
        "long_name": "CVS Health Corporation",
        "summary": "CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. Its Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. As of December 31, 2020, it operated approximately 9,900 retail locations and 1,100 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "RI",
        "city": "Woonsocket",
        "zipcode": "02895",
        "website": "http://www.cvshealth.com",
        "market_cap": "Large Cap"
    },
    "CVS.F": {
        "short_name": "CVS HEALTH CORP.  DL-,01",
        "long_name": "CVS Health Corporation",
        "summary": "CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. Its Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. As of December 31, 2020, it operated approximately 9,900 retail locations and 1,100 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "RI",
        "city": "Woonsocket",
        "zipcode": "02895",
        "website": "http://www.cvshealth.com",
        "market_cap": "Large Cap"
    },
    "CVS.MX": {
        "short_name": "CVS HEALTH CORPORATION",
        "long_name": "CVS Health Corporation",
        "summary": "CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. Its Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. As of December 31, 2020, it operated approximately 9,900 retail locations and 1,100 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "RI",
        "city": "Woonsocket",
        "zipcode": "02895",
        "website": "http://www.cvshealth.com",
        "market_cap": "Large Cap"
    },
    "CVS": {
        "short_name": "CVS Health Corporation",
        "long_name": "CVS Health Corporation",
        "summary": "CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. Its Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. As of December 31, 2020, it operated approximately 9,900 retail locations and 1,100 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "RI",
        "city": "Woonsocket",
        "zipcode": "02895",
        "website": "http://www.cvshealth.com",
        "market_cap": "Large Cap"
    },
    "CVS.SN": {
        "short_name": "CVS HEALTH CORP",
        "long_name": "CVS Health Corporation",
        "summary": "CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. Its Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. As of December 31, 2020, it operated approximately 9,900 retail locations and 1,100 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "SGO",
        "market": "cl_market",
        "country": "United States",
        "state": "RI",
        "city": "Woonsocket",
        "zipcode": "02895",
        "website": "http://www.cvshealth.com",
        "market_cap": "Large Cap"
    },
    "CVS.VI": {
        "short_name": "CVS HEALTH CORP",
        "long_name": "CVS Health Corporation",
        "summary": "CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. Its Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. As of December 31, 2020, it operated approximately 9,900 retail locations and 1,100 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "RI",
        "city": "Woonsocket",
        "zipcode": "02895",
        "website": "http://www.cvshealth.com",
        "market_cap": "Large Cap"
    },
    "CVSH34.SA": {
        "short_name": "CVS HEALTH  DRN",
        "long_name": "CVS Health Corporation",
        "summary": "CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. Its Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. As of December 31, 2020, it operated approximately 9,900 retail locations and 1,100 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "RI",
        "city": "Woonsocket",
        "zipcode": "02895",
        "website": "http://www.cvshealth.com",
        "market_cap": "Large Cap"
    },
    "CVSI": {
        "short_name": "CV SCIENCES INC",
        "long_name": "CV Sciences, Inc.",
        "summary": "CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.cvsciences.com",
        "market_cap": "Small Cap"
    },
    "CWBHF": {
        "short_name": "CHARLOTTES WEB HOLDINGS INC",
        "long_name": "Charlotte's Web Holdings, Inc.",
        "summary": "Charlotte's Web Holdings, Inc. produces and distributes hemp-based cannabidiol wellness products in the United States. The company offers products in the categories of tinctures, capsules, gummies, topicals, and pet products. It distributes its products under the Charlotte's Web name through its e-commerce website, third party e-commerce websites, as well as distributors, health practitioners, and various brick and mortar retailers. Charlotte's Web Holdings, Inc. has a collaboration between its CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program; and scientific collaboration with McLean Hospital. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was incorporated in 2018 and is headquartered in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80302",
        "website": "http://www.charlottesweb.com",
        "market_cap": "Small Cap"
    },
    "CWBR": {
        "short_name": "CohBar, Inc.",
        "long_name": "CohBar, Inc.",
        "summary": "CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://www.cohbar.com",
        "market_cap": "Small Cap"
    },
    "CWEB.TO": {
        "short_name": "CHARLOTTES WEB HOLDINGS INC",
        "long_name": "Charlotte's Web Holdings, Inc.",
        "summary": "Charlotte's Web Holdings, Inc. produces and distributes hemp-based cannabidiol wellness products in the United States. The company offers products in the categories of tinctures, capsules, gummies, topicals, and pet products. It distributes its products under the Charlotte's Web name through its e-commerce website, third party e-commerce websites, as well as distributors, health practitioners, and various brick and mortar retailers. Charlotte's Web Holdings, Inc. has a collaboration between its CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program; and scientific collaboration with McLean Hospital. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was incorporated in 2018 and is headquartered in Boulder, Colorado.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80302",
        "website": "http://www.charlottesweb.com",
        "market_cap": "Small Cap"
    },
    "CXF.F": {
        "short_name": "CHIMERIX INC.  DL -,001",
        "long_name": "Chimerix, Inc.",
        "summary": "Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27713",
        "website": "http://www.chimerix.com",
        "market_cap": "Small Cap"
    },
    "CXM.F": {
        "short_name": "CHEMED CORP.  DL 1",
        "long_name": "Chemed Corporation",
        "summary": "Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45202-4726",
        "website": "http://www.chemed.com",
        "market_cap": "Mid Cap"
    },
    "CXS.F": {
        "short_name": "CHIASMA INC.DL-,01",
        "long_name": "Chiasma, Inc.",
        "summary": "Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Needham",
        "zipcode": "02494",
        "website": "http://www.chiasma.com",
        "market_cap": "Small Cap"
    },
    "CY3B.F": {
        "short_name": "ADAMIS PHARMACEUTIC.CORP.",
        "long_name": "Adamis Pharmaceuticals Corporation",
        "summary": "Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.adamispharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "CY9D.F": {
        "short_name": "MICROBOT MEDICAL  DL-,01",
        "long_name": "Microbot Medical Inc.",
        "summary": "Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 42 issued/allowed patents and 23 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Hingham",
        "zipcode": "02043",
        "website": "http://www.microbotmedical.com",
        "market_cap": "Small Cap"
    },
    "CYCC": {
        "short_name": "Cyclacel Pharmaceuticals, Inc.",
        "long_name": "Cyclacel Pharmaceuticals, Inc.",
        "summary": "Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Berkeley Heights",
        "zipcode": "07922",
        "website": "http://www.cyclacel.com",
        "market_cap": "Small Cap"
    },
    "CYCCP": {
        "short_name": "Cyclacel Pharmaceuticals, Inc. ",
        "long_name": "Cyclacel Pharmaceuticals, Inc.",
        "summary": "Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Berkeley Heights",
        "zipcode": "07922",
        "website": "http://www.cyclacel.com",
        "market_cap": "Small Cap"
    },
    "CYCN": {
        "short_name": "Cyclerion Therapeutics, Inc.",
        "long_name": "Cyclerion Therapeutics, Inc.",
        "summary": "Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.cyclerion.com",
        "market_cap": "Small Cap"
    },
    "CYDX": {
        "short_name": "CYDUCT DIAGNOSTICS INC",
        "long_name": "CYduct Diagnostics, Inc.",
        "summary": "CYduct Diagnostics, Inc., a healthcare instrument company, develops and markets technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of disease and medical conditions. The company's products include breast endoscopy systems; 3-chip and 1-chip camera systems; cameras and accessories; endoscopic instruments, such as dissectors, graspers, scissors, needle holders, fan retractors, cautery instruments, and insufflation needles; and illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps. It also offers insufflators; laparoscopic instruments, such as general surgery, lymphadenectomy, gynecology, and thorascopy instruments; rigid scopes and accessories, including laparoscopes, operative scopes, cystoscopes, and scope trays; trocar and cannula sets, cannulas, trocars, reducer sleeves, and seals; video carts; instrument handles that include insulated handles and non-insulated handles; and veterinary instrumentation. The company was formerly known as Solos Endoscopy, Inc. and changed its name to CYduct Diagnostics, Inc. in December 2020. CYduct Diagnostics, Inc. was founded in 1986 and is based in Westport, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02136",
        "website": "http://www.solosendoscopy.com",
        "market_cap": "Small Cap"
    },
    "CYDY": {
        "short_name": "CYTODYN INC",
        "long_name": "CytoDyn Inc.",
        "summary": "CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Vancouver",
        "zipcode": "98660",
        "website": "http://www.cytodyn.com",
        "market_cap": "Small Cap"
    },
    "CYH": {
        "short_name": "Community Health Systems, Inc.",
        "long_name": "Community Health Systems, Inc.",
        "summary": "Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, retail clinics, and via direct-to-consumer virtual health visits. As of December 31, 2020, it owned or leased 89 hospitals, including 87 general acute care hospitals and two stand-alone rehabilitation or psychiatric hospitals with an aggregate of 14,110 licensed beds. The company was founded in 1985 and is headquartered in Franklin, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Franklin",
        "zipcode": "37067",
        "website": "http://www.chs.net",
        "market_cap": "Mid Cap"
    },
    "CYL.F": {
        "short_name": "CRYOLIFE INC.  DL-,01",
        "long_name": "CryoLife, Inc.",
        "summary": "CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "GA",
        "city": "Kennesaw",
        "zipcode": "30144",
        "website": "http://www.cryolife.com",
        "market_cap": "Small Cap"
    },
    "CYPS": {
        "short_name": "CYCLOPSS CORP",
        "long_name": "Cyclo3pss Corporation",
        "summary": "Cyclo3pss Corporation engages in the licensing, manufacture, sale, and installation of ozone food processing products; and ozone washing and laundry sorting and counting systems for commercial and institutional laundries. It also engages in the research and development of technologies for the sterilization and/or disinfection of certain consumer products. The company was founded in 1927 and is based in Salt Lake City, Utah. In July 2002, the Board of Directors of Cyclo3pss determined to suspend all operations of the company immediately due to an inability to locate willing investors and to secure necessary and suitable financing.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84121",
        "website": null,
        "market_cap": null
    },
    "CYTH": {
        "short_name": "Cyclo Therapeutics, Inc.",
        "long_name": "Cyclo Therapeutics, Inc.",
        "summary": "Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Gainesville",
        "zipcode": "32653",
        "website": "http://www.cyclotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "CYTK": {
        "short_name": "Cytokinetics, Incorporated",
        "long_name": "Cytokinetics, Incorporated",
        "summary": "Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.cytokinetics.com",
        "market_cap": "Small Cap"
    },
    "CYTR": {
        "short_name": "CYTRX CORP",
        "long_name": "CytRx Corporation",
        "summary": "CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90049",
        "website": "http://www.cytrx.com",
        "market_cap": "Small Cap"
    },
    "D05.F": {
        "short_name": "DECIPHERA PHARMAC. DL-,01",
        "long_name": "Deciphera Pharmaceuticals, Inc.",
        "summary": "Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.deciphera.com",
        "market_cap": "Small Cap"
    },
    "D1EX34.SA": {
        "short_name": "DEXCOM INC  DRN",
        "long_name": "DexCom, Inc.",
        "summary": "DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.dexcom.com",
        "market_cap": "Large Cap"
    },
    "D9IA.SG": {
        "short_name": "Chembio Diagnostics Inc. Regist",
        "long_name": "Chembio Diagnostics, Inc.",
        "summary": "Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Hauppauge",
        "zipcode": "11788",
        "website": "http://chembio.com",
        "market_cap": "Small Cap"
    },
    "DAP.DE": {
        "short_name": "DANAHER CORP.  DL-,01",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037-1701",
        "website": "http://www.danaher.com",
        "market_cap": "Large Cap"
    },
    "DAP.F": {
        "short_name": "DANAHER CORP.  DL-,01",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037-1701",
        "website": "http://www.danaher.com",
        "market_cap": "Large Cap"
    },
    "DARE": {
        "short_name": "Dare Bioscience, Inc.",
        "long_name": "Dar\u00e9 Bioscience, Inc.",
        "summary": "Dar\u00c3\u00a9 Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.darebioscience.com",
        "market_cap": "Small Cap"
    },
    "DAWN": {
        "short_name": "Day One Biopharmaceuticals, Inc",
        "long_name": "Day One Biopharmaceuticals, Inc.",
        "summary": "Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080-1930",
        "website": "http://dayonebio.com",
        "market_cap": "Small Cap"
    },
    "DBTX": {
        "short_name": "Decibel Therapeutics, Inc.",
        "long_name": "Decibel Therapeutics, Inc.",
        "summary": "Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02215",
        "website": "http://www.decibeltx.com",
        "market_cap": "Small Cap"
    },
    "DC4.F": {
        "short_name": "DEXCOM INC.  DL-,001",
        "long_name": "DexCom, Inc.",
        "summary": "DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.dexcom.com",
        "market_cap": "Large Cap"
    },
    "DC8.F": {
        "short_name": "DURECT CORP.  DL-,001",
        "long_name": "DURECT Corporation",
        "summary": "DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Cupertino",
        "zipcode": "95014-4166",
        "website": "http://www.durect.com",
        "market_cap": "Small Cap"
    },
    "DC8.SG": {
        "short_name": "DURECT CORP. Registered Shares ",
        "long_name": "DURECT Corporation",
        "summary": "DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Cupertino",
        "zipcode": "95014-4166",
        "website": "http://www.durect.com",
        "market_cap": "Small Cap"
    },
    "DCPH": {
        "short_name": "Deciphera Pharmaceuticals, Inc.",
        "long_name": "Deciphera Pharmaceuticals, Inc.",
        "summary": "Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.deciphera.com",
        "market_cap": "Small Cap"
    },
    "DCTH": {
        "short_name": "Delcath Systems, Inc.",
        "long_name": "Delcath Systems, Inc.",
        "summary": "Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.delcath.com",
        "market_cap": "Small Cap"
    },
    "DECN": {
        "short_name": "DECISION DIAGNOSTICS CORP",
        "long_name": "Decision Diagnostics Corp.",
        "summary": "Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Westlake Village",
        "zipcode": "91361",
        "website": "http://www.decisiondiagnostics.co",
        "market_cap": "Small Cap"
    },
    "DFFN": {
        "short_name": "Diffusion Pharmaceuticals Inc.",
        "long_name": "Diffusion Pharmaceuticals Inc.",
        "summary": "Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Charlottesville",
        "zipcode": "22902",
        "website": "http://www.diffusionpharma.com",
        "market_cap": "Small Cap"
    },
    "DGDM": {
        "short_name": "DIGITAL DEVELOPMENT PARTNERS IN",
        "long_name": "Digital Development Partners, Inc.",
        "summary": "Digital Development Partners, Inc. manufactures and sells cannabidiol (CBD) based products from industrial hemp worldwide. It offers CBD Oils and CBD-infused personal care products; gummies and pet treat; CBD-infused body butter and lip balms; bath bombs; and hand sanitizer gel and spray products under the Grizzly Creek Naturals brand name. The company also manufactures and distributes MiteXstream, a plant-based biopesticide for the eradication of spider mites. It also sells its products online through the grizzlycreeknaturals.com website. The company is based in Flower Mound, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Flower Mound",
        "zipcode": "75022",
        "website": "http://www.digitaldevelopmentpartners.com",
        "market_cap": "Small Cap"
    },
    "DGEN": {
        "short_name": "DELTAGEN INC",
        "long_name": "Deltagen Inc.",
        "summary": "Deltagen, Inc. provides drug discovery tools and services to the biopharmaceutical industry and to the academic research community in the United States. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was founded in 1997 and is headquartered in San Mateo, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Mateo",
        "zipcode": "94403",
        "website": "http://www.deltagen.com",
        "market_cap": "Small Cap"
    },
    "DGX.MX": {
        "short_name": "QUEST DIAGNOSTICS INC",
        "long_name": "Quest Diagnostics Incorporated",
        "summary": "Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NJ",
        "city": "Secaucus",
        "zipcode": "07094",
        "website": "http://www.questdiagnostics.com",
        "market_cap": "Large Cap"
    },
    "DGX": {
        "short_name": "Quest Diagnostics Incorporated",
        "long_name": "Quest Diagnostics Incorporated",
        "summary": "Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Secaucus",
        "zipcode": "07094",
        "website": "http://www.questdiagnostics.com",
        "market_cap": "Large Cap"
    },
    "DHER34.SA": {
        "short_name": "DANAHER CORPDRN",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037-1701",
        "website": "http://www.danaher.com",
        "market_cap": "Large Cap"
    },
    "DHR-PA": {
        "short_name": "Danaher Corporation 4.75% Manda",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037-1701",
        "website": "http://www.danaher.com",
        "market_cap": "Large Cap"
    },
    "DHR-PB": {
        "short_name": "Danaher Corporation 5.00% Manda",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037-1701",
        "website": "http://www.danaher.com",
        "market_cap": null
    },
    "DHR.MX": {
        "short_name": "DANAHER CORP",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037-1701",
        "website": "http://www.danaher.com",
        "market_cap": "Large Cap"
    },
    "DHR": {
        "short_name": "Danaher Corporation",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037-1701",
        "website": "http://www.danaher.com",
        "market_cap": "Large Cap"
    },
    "DHRC.VI": {
        "short_name": "DANAHER CORP",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037-1701",
        "website": "http://www.danaher.com",
        "market_cap": "Large Cap"
    },
    "DIGP": {
        "short_name": "DIGIPATH INC",
        "long_name": "DigiPath, Inc.",
        "summary": "DigiPath, Inc., together with its subsidiaries, provides cannabis and hemp lab testing services in Las Vegas to Nevada licensed medical marijuana enterprises. It also provides testing, cannabis education and training, and unbiased cannabis news coverage to the cannabis industry. The company operates as a testing laboratory facility for cannabis, cannabis infused products, hemp, and other botanical nutraceuticals to serve growers, dispensaries, caregivers, producers, patients, and end users of cannabis and botanical products. DigiPath, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89118",
        "website": "http://www.digipath.com",
        "market_cap": "Small Cap"
    },
    "DJNJ3.BA": {
        "short_name": "JOHNSON & JOHNSON",
        "long_name": "Johnson & Johnson",
        "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "NJ",
        "city": "New Brunswick",
        "zipcode": "08933",
        "website": "http://www.jnj.com",
        "market_cap": null
    },
    "DKSC": {
        "short_name": "DAKSHIDIN CORP",
        "long_name": "Dakshidin Corporation, Inc.",
        "summary": "Dakshidin Corporation, Inc., through its subsidiaries, operates as a CBD/cannabis-based medical product company. It cultivates cannabis; and operates an online sales portal for CBD products. The company also manages distribution channel programs in the retail distribution, reselling, and direct sales market segments. Dakshidin Corporation, Inc. was formerly known as Avrada, Inc. and changed its name to Dakshidin Corporation, Inc. in February 2007. The company is based in Miami, Florida with additional offices in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33172-3652",
        "website": null,
        "market_cap": "Small Cap"
    },
    "DMAC": {
        "short_name": "DiaMedica Therapeutics Inc.",
        "long_name": "DiaMedica Therapeutics Inc.",
        "summary": "DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55447",
        "website": "http://www.diamedica.com",
        "market_cap": "Small Cap"
    },
    "DMTK.MX": {
        "short_name": "DERMTECH INC",
        "long_name": "DermTech, Inc.",
        "summary": "DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://www.dermtech.com",
        "market_cap": "Small Cap"
    },
    "DMTK": {
        "short_name": "DermTech, Inc.",
        "long_name": "DermTech, Inc.",
        "summary": "DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://www.dermtech.com",
        "market_cap": "Small Cap"
    },
    "DNLI": {
        "short_name": "Denali Therapeutics Inc.",
        "long_name": "Denali Therapeutics Inc.",
        "summary": "Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.denalitherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "DP81.F": {
        "short_name": "DIFFUSION PHARMA. DL-,001",
        "long_name": "Diffusion Pharmaceuticals Inc.",
        "summary": "Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "VA",
        "city": "Charlottesville",
        "zipcode": "22902",
        "website": "http://www.diffusionpharma.com",
        "market_cap": "Small Cap"
    },
    "DP81.SG": {
        "short_name": "Diffusion Pharmaceuticals Inc.R",
        "long_name": "Diffusion Pharmaceuticals Inc.",
        "summary": "Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "VA",
        "city": "Charlottesville",
        "zipcode": "22902",
        "website": "http://www.diffusionpharma.com",
        "market_cap": "Small Cap"
    },
    "DPAT": {
        "short_name": "DENTAL PATIENT CARE AMERICA INC",
        "long_name": "Dental Patient Care America, Inc.",
        "summary": "Dental Patient Care America, Inc., through its subsidiaries, provides services to dentists and the dental industry. The company organizes dentists into a co-operative model of contractually networked dental practices, allowing member dentists to access various benefits, such as programs to purchase supplies, laboratory and operating services, insurance and employee benefits programs, opportunities for profit sharing, preferential business financing, and dental practice transition funding opportunities. It also offers various dental patient marketing programs, such as organization of member dentists into a network, which offers dental care plans to employers and groups. In addition, Dental Patient Care America, Inc. offers dental benefit plans. The company was founded in 1998 and is based in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84106",
        "website": "http://www.dentalcoop.com",
        "market_cap": "Small Cap"
    },
    "DPL.F": {
        "short_name": "DICERNA PHARMAC.DL -,0001",
        "long_name": "Dicerna Pharmaceuticals, Inc.",
        "summary": "Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://dicerna.com",
        "market_cap": "Mid Cap"
    },
    "DQS.F": {
        "short_name": "MYMD PHARMAC.INC. DL-,01",
        "long_name": "MyMD Pharmaceuticals, Inc.",
        "summary": "MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the development of drug products in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety, and sleep disorders. It commercializes MYMD-1, a novel therapeutic to impact conditions related to immunometabolic dysregulation; and SUPERA-1R, a synthetic cannabidiol that offers bioavailability and potency than botanicals. The company was incorporated in 2014 and is based in Tampa, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33606-4110",
        "website": "http://www.mymd.com",
        "market_cap": "Small Cap"
    },
    "DR6.F": {
        "short_name": "ACADIA PHARMACEUT. DL-,01",
        "long_name": "ACADIA Pharmaceuticals Inc.",
        "summary": "ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.acadia-pharm.com",
        "market_cap": "Mid Cap"
    },
    "DRIO": {
        "short_name": "DarioHealth Corp.",
        "long_name": "DarioHealth Corp.",
        "summary": "DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.mydario.com",
        "market_cap": "Small Cap"
    },
    "DRNA": {
        "short_name": "Dicerna Pharmaceuticals, Inc.",
        "long_name": "Dicerna Pharmaceuticals, Inc.",
        "summary": "Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://dicerna.com",
        "market_cap": "Small Cap"
    },
    "DROP": {
        "short_name": "FUSE SCIENCE INC",
        "long_name": "Fuse Science, Inc.",
        "summary": "Fuse Science, Inc. focuses on the development and commercialization of proprietary delivery technology for delivering energy, nutrition, and medications to humans in the United States. The company also produces and sells sports nutrition and performance products. Its products include SkyPorts, a drone support technology and energy demand network that enables long distance flight required for drone-based commerce without the need for drones to return every 15 minutes to recharge; and XTRAX, a remote monitoring system designed to measure the production of solar and other renewable energy systems, as well as transmit the data via the cellular and radio frequency, and microwave transmission network or satellite. The company was formerly known as Double Eagle Holdings, Ltd. and changed its name to Fuse Science, Inc. in December 2011. Fuse Science, Inc. was founded in 1985 and is based in Massapequa, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Massapequa",
        "zipcode": "11758",
        "website": null,
        "market_cap": "Small Cap"
    },
    "DRRX": {
        "short_name": "DURECT Corporation",
        "long_name": "DURECT Corporation",
        "summary": "DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Cupertino",
        "zipcode": "95014-4166",
        "website": "http://www.durect.com",
        "market_cap": "Small Cap"
    },
    "DRWN": {
        "short_name": "A CLEAN SLATE INC",
        "long_name": "Quantum Medical Transport, Inc.",
        "summary": "Quantum Medical Transport, Inc., doing business as Quantum Medical Data Services, operates as a medical blockchain data services company. It is developing a medical blockchain technology for secure data storage and data transfer. The company was formerly known as A Clean Slate, Inc. and changed its name to Quantum Medical Transport, Inc. in August 2015. Quantum Medical Transport, Inc. is based in Sugar Land, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Sugar Land",
        "zipcode": "77478",
        "website": "http://www.quanth.io",
        "market_cap": "Small Cap"
    },
    "DSGN": {
        "short_name": "Design Therapeutics, Inc.",
        "long_name": "Design Therapeutics, Inc.",
        "summary": "Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92011",
        "website": "http://www.designtx.com",
        "market_cap": "Small Cap"
    },
    "DSOL": {
        "short_name": "DRUG FREE SOLUTION INC",
        "long_name": "Drug Free Solution, Inc.",
        "summary": "Drug Free Solution, Inc., a lifestyle company, delivers proprietary emotional wellness technology, known as Living Breath Process. Its Living Breath Process is a three-step process that combines self-analysis, breath, and language addressing various markets, including addiction/prevention, self help, emotional wellness, and lifestyle. The company also offers the Living Breath Series of programs with products, education, and services. Its Living Breath Project, through protocols, lifestyle enhancement products, training, and education, focuses on creating community wellness centers, wellness homes, and correctional facility support networks and centers that combine various offerings to diminish addiction and incarceration rates in the United States. The company was formerly known as Living Breath Project, Inc. and changed its name to Drug Free Solution, Inc. in January 2014. Drug Free Solution, Inc. is based in El Segundo, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "El Segundo",
        "zipcode": "90245",
        "website": "http://www.drugfreesolution.com",
        "market_cap": "Small Cap"
    },
    "DTHR": {
        "short_name": "DTHERA SCIENCES",
        "long_name": "Dthera Sciences",
        "summary": "Dthera Sciences operates as a digital therapeutic company in neurodegenerative diseases. It is developing DTHR-ALZ, a medical device for the mitigation of the symptoms of agitation and depression associated with Alzheimer's disease. The company is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92126",
        "website": "http://www.dthera.com",
        "market_cap": "Small Cap"
    },
    "DTIL": {
        "short_name": "Precision BioSciences, Inc.",
        "long_name": "Precision BioSciences, Inc.",
        "summary": "Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27701",
        "website": "http://www.precisionbiosciences.com",
        "market_cap": "Small Cap"
    },
    "DTRK": {
        "short_name": "DATATRAK INTERNATIONAL INC",
        "long_name": "DATATRAK International, Inc.",
        "summary": "DATATRAK International, Inc., a technology and services company, provides unified clinical solutions and related services for the clinical trials industry. The company offers DATATRAK ONE Unified Experience, a clinical enterprise solution that allows clinical users and service providers to design, deliver, and manage clinical trials. Its products include UX CTMS 360 for planning and managing trials; UX Trial to streamline design-to-deployment process using a tool; UX EDC & Medical Coding for capturing and delivering data; UX Randomization and Trial Supply Management to randomize patients and automate supply; UX Patient Data Capture; UX Safety; and UX Training to train users and track certificates. The company also provides DATATRAK Clinical Consulting Services, such as training, support, learning center, Software as a Service hosting, standards, and trial design services. It serves contract research organizations, pharma and biotech companies, and clinical trial device companies. DATATRAK International, Inc. was founded in 1991 and is headquartered in Mayfield Heights, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Mayfield Heights",
        "zipcode": "44124",
        "website": "http://www.datatrak.com",
        "market_cap": "Small Cap"
    },
    "DUL.DE": {
        "short_name": "ALNYLAM PHARMACE.DL-,0001",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.alnylam.com",
        "market_cap": "Large Cap"
    },
    "DUL.F": {
        "short_name": "ALNYLAM PHARMACE.DL-,0001",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.alnylam.com",
        "market_cap": "Large Cap"
    },
    "DUTV": {
        "short_name": "DIGITAL UTILITIES VENTURES INC",
        "long_name": "Digital Utilities Ventures, Inc.",
        "summary": "Digital Utilities Ventures, Inc., through its wholly owned subsidiary, Torq Communications, Inc., provides real time video transport system for the Internet. It offers The New Last Mile, a first live Internet to TV/cell phone broadcasting system. The company is headquartered in Fort Lauderdale, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Lauderdale",
        "zipcode": "33311",
        "website": "http://www.duventures.com",
        "market_cap": "Small Cap"
    },
    "DVA.MX": {
        "short_name": "DAVITA INC",
        "long_name": "DaVita Inc.",
        "summary": "DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80202",
        "website": "http://www.davita.com",
        "market_cap": "Large Cap"
    },
    "DVA": {
        "short_name": "DaVita Inc.",
        "long_name": "DaVita Inc.",
        "summary": "DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80202",
        "website": "http://www.davita.com",
        "market_cap": "Large Cap"
    },
    "DVAI34.SA": {
        "short_name": "DAVITA INC  DRN",
        "long_name": "DaVita Inc.",
        "summary": "DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80202",
        "website": "http://www.davita.com",
        "market_cap": "Large Cap"
    },
    "DVAX": {
        "short_name": "Dynavax Technologies Corporatio",
        "long_name": "Dynavax Technologies Corporation",
        "summary": "Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.dynavax.com",
        "market_cap": "Small Cap"
    },
    "DVCR": {
        "short_name": "DIVERSICARE HEALTHCARE SERVICES",
        "long_name": "Diversicare Healthcare Services, Inc.",
        "summary": "Diversicare Healthcare Services, Inc. provides post-acute care services to skilled nursing centers, patients, and residents primarily in the Southeast, Midwest, and Southwest United States. The company offers skilled nursing health care services, including nutrition, recreational therapy, social, housekeeping, and laundry services; the delivery of ancillary medical services at the nursing centers; rehabilitation therapy services, such as audiology, speech, occupational, and physical therapies; and medical supplies, nutritional support, infusion therapies, and related clinical services. As of December 31, 2020, it operated 61 nursing centers with 7,250 licensed nursing beds. The company was formerly known as Advocat Inc. and changed its name to Diversicare Healthcare Services, Inc. in March 2013. Diversicare Healthcare Services, Inc. was incorporated in 1994 and is based in Brentwood, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Brentwood",
        "zipcode": "37027",
        "website": "http://www.dvcr.com",
        "market_cap": "Small Cap"
    },
    "DVLP": {
        "short_name": "GOLDEN DEVELOPING SOLUTIONS INC",
        "long_name": "Golden Developing Solutions, Inc.",
        "summary": "Golden Developing Solutions, Inc., through its subsidiaries, engages in the online retail of cannabidiol (CBD) products. It develops and operates an Internet website that offers CBD, hemp oil, and health/wellness related products, including vitamins, supplements, CBD based tinctures, vapes, soft-gels, and other products. The company was formerly known as Clean Hydrogen Producers, Ltd and changed its name to Golden Developing Solutions, Inc. in April 2017. Golden Developing Solutions, Inc. was incorporated in 1998 and is based in Lakeway, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Lakeway",
        "zipcode": "78734",
        "website": "http://goldendeveloping.com",
        "market_cap": "Small Cap"
    },
    "DXCM.MX": {
        "short_name": "DEXCOM INC",
        "long_name": "DexCom, Inc.",
        "summary": "DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.dexcom.com",
        "market_cap": "Large Cap"
    },
    "DXCM": {
        "short_name": "DexCom, Inc.",
        "long_name": "DexCom, Inc.",
        "summary": "DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.dexcom.com",
        "market_cap": "Large Cap"
    },
    "DXR": {
        "short_name": "Daxor Corporation",
        "long_name": "Daxor Corporation",
        "summary": "Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10118",
        "website": "http://www.daxor.com",
        "market_cap": "Small Cap"
    },
    "DY2.F": {
        "short_name": "DENTSPLY SIRONA  DL-,01",
        "long_name": "DENTSPLY SIRONA Inc.",
        "summary": "DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Charlotte",
        "zipcode": "28277-3607",
        "website": "http://www.dentsplysirona.com",
        "market_cap": "Large Cap"
    },
    "DYAI": {
        "short_name": "Dyadic International, Inc.",
        "long_name": "Dyadic International, Inc.",
        "summary": "Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership with Medytox, Inc. to co-develop C1 manufactured COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Jupiter",
        "zipcode": "33477-5094",
        "website": "http://www.dyadic.com",
        "market_cap": "Small Cap"
    },
    "DYF1.F": {
        "short_name": "DYNAVAX TECHS  DL-,001",
        "long_name": "Dynavax Technologies Corporation",
        "summary": "Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.dynavax.com",
        "market_cap": "Small Cap"
    },
    "DYN": {
        "short_name": "Dyne Therapeutics, Inc.",
        "long_name": "Dyne Therapeutics, Inc.",
        "summary": "Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.dyne-tx.com",
        "market_cap": "Small Cap"
    },
    "DYNT": {
        "short_name": "Dynatronics Corporation",
        "long_name": "Dynatronics Corporation",
        "summary": "Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. It offers orthopedic soft bracing products, which include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. The company also provides power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, treadmills, recumbent bikes, and other related equipment. In addition, it offers therapeutic modality devices, such as electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold therapy, compression therapy, and electrodes. Further, the company provides clinical supplies, including exercise bands and tubing, topical analgesics, lotions and gels, orthopedic bracing, paper products, athletic tapes, and other related supplies. It markets its products under the Bird & Cronin, Solaris, Hausmann, Physician's Choice, and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, and athletic trainers, sports medicine practitioners, hospitals, clinics, and consumers, as well as online. It also exports its products to approximately 30 countries. The company was founded in 1979 and is headquartered in Eagan, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Eagan",
        "zipcode": "55121",
        "website": "http://www.dynatronics.com",
        "market_cap": "Small Cap"
    },
    "DYXA.SG": {
        "short_name": "Dynatronics Corp. Registered Sh",
        "long_name": "Dynatronics Corporation",
        "summary": "Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. It offers orthopedic soft bracing products, which include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. The company also provides power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, treadmills, recumbent bikes, and other related equipment. In addition, it offers therapeutic modality devices, such as electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold therapy, compression therapy, and electrodes. Further, the company provides clinical supplies, including exercise bands and tubing, topical analgesics, lotions and gels, orthopedic bracing, paper products, athletic tapes, and other related supplies. It markets its products under the Bird & Cronin, Solaris, Hausmann, Physician's Choice, and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, and athletic trainers, sports medicine practitioners, hospitals, clinics, and consumers, as well as online. It also exports its products to approximately 30 countries. The company was founded in 1979 and is headquartered in Eagan, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Eagan",
        "zipcode": "55121",
        "website": "http://www.dynatronics.com",
        "market_cap": "Small Cap"
    },
    "E08A.F": {
        "short_name": "EXAGEN INC.  DL-,001",
        "long_name": "Exagen Inc.",
        "summary": "Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease requiring aggressive therapy, such as anti-TNF biologics; and AVISE PC4d that measures platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test that measures levels of MTXPG; and AVISE HCQ, a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Vista",
        "zipcode": "92081",
        "website": "http://www.exagen.com",
        "market_cap": "Small Cap"
    },
    "E1WL34.SA": {
        "short_name": "EDWARDS LIFEDRN",
        "long_name": "Edwards Lifesciences Corporation",
        "summary": "Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.edwards.com",
        "market_cap": "Large Cap"
    },
    "E2OM.F": {
        "short_name": "STRATA SKIN SCIENC.DL-,01",
        "long_name": "STRATA Skin Sciences, Inc.",
        "summary": "STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC excimer laser and VTRAC lamp systems that are used for the treatment of psoriasis, vitiligo, atopic dermatitis, eczema, and other skin disorders. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Horsham",
        "zipcode": "19044",
        "website": "http://www.strataskinsciences.com",
        "market_cap": "Small Cap"
    },
    "E8L.F": {
        "short_name": "GEOVAX LABS NEW  DL -,001",
        "long_name": "GeoVax Labs, Inc.",
        "summary": "GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "GA",
        "city": "Smyrna",
        "zipcode": "30080",
        "website": "http://www.geovax.com",
        "market_cap": "Small Cap"
    },
    "EAR": {
        "short_name": "Eargo, Inc.",
        "long_name": "Eargo, Inc.",
        "summary": "Eargo, Inc., a medical device company, develops and sells hearing aids to assist people with hearing loss in the United States. It sells its products through online stores. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was founded in 2010 and is headquartered in San Jose, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Jose",
        "zipcode": "95110",
        "website": "http://eargo.com",
        "market_cap": "Mid Cap"
    },
    "EBS": {
        "short_name": "Emergent Biosolutions, Inc.",
        "long_name": "Emergent BioSolutions Inc.",
        "summary": "Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20879",
        "website": "http://www.emergentbiosolutions.com",
        "market_cap": "Mid Cap"
    },
    "EBYH": {
        "short_name": "E-BUY HOME INC",
        "long_name": "Strainsforpains, Inc.",
        "summary": "Strainsforpains, Inc. operates as a medical marijuana data recommendation system. The company develops Strainsforpains app, a user-based application that scientifically determines which cannabis brand or strain is right for patients based upon personal data and strain genetics. It serves medical specialists, dispensaries, and consumers. The company was incorporated in 1990 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10001",
        "website": "http://strainsforpains.com",
        "market_cap": "Small Cap"
    },
    "EC8.F": {
        "short_name": "CONMED CORP.  DL-,01",
        "long_name": "CONMED Corporation",
        "summary": "CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Largo",
        "zipcode": "33773-4908",
        "website": "http://www.conmed.com",
        "market_cap": "Mid Cap"
    },
    "ECGI": {
        "short_name": "EVENT CARDIO GROUP INC",
        "long_name": "ECGI Holdings, Inc.",
        "summary": "ECGI Holdings, Inc., through its subsidiary, operates in the cardiac medical device innovation, patient monitoring, and cardiac event prediction industry. The company is developing cardiac monitoring device based on a wireless and leadless advance cardiac monitor. Its products include Now Cardio, a cardiac monitor that offers dual-functionality, including holter monitoring and event recording. The company was formerly known as Event Cardio Group Inc. and changed its name to ECGI Holdings, Inc. in August 2019. ECGI Holdings, Inc. is based in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90035",
        "website": "http://www.ecgiholdings.com",
        "market_cap": "Small Cap"
    },
    "ECGS": {
        "short_name": "ECO GROWTH STRATEGIES INC",
        "long_name": "Eco-Growth Strategies Inc.",
        "summary": "Eco-Growth Strategies Inc., a nutraceutical company, develops various CBD-based products. It offers CBD extraction services under the XtractionOne Plus name. The company is based in Orangevale, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Orangevale",
        "zipcode": "95662",
        "website": "http://ecogrowthstrategies.com",
        "market_cap": null
    },
    "ECIA": {
        "short_name": "ENCISION INC",
        "long_name": "Encision Inc.",
        "summary": "Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. It sells its products through a network of direct and independent sales representatives. The company was founded in 1991 and is based in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80301",
        "website": "http://www.encision.com",
        "market_cap": "Small Cap"
    },
    "ECOR": {
        "short_name": "electroCore, Inc.",
        "long_name": "electroCore, Inc.",
        "summary": "electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Rockaway",
        "zipcode": "07866",
        "website": "http://www.electrocore.com",
        "market_cap": "Small Cap"
    },
    "ECOX": {
        "short_name": "ECO INNOVATION GROUP INC",
        "long_name": "Eco Innovation Group, Inc.",
        "summary": "Eco Innovation Group, Inc. focuses on the development of power booster for home and office applications that will reduce electric bills. It also provides other energy saving related technologies. Eco Innovation Group, Inc. is based in Van Nuys, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Van Nuys",
        "zipcode": "91406",
        "website": "http://www.ecoig.com",
        "market_cap": "Small Cap"
    },
    "ECTE": {
        "short_name": "ECHO THERAPEUTICS INC",
        "long_name": "Echo Therapeutics, Inc.",
        "summary": "Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Iselin",
        "zipcode": "08830",
        "website": "http://www.echotx.com",
        "market_cap": "Small Cap"
    },
    "EDIT": {
        "short_name": "Editas Medicine, Inc.",
        "long_name": "Editas Medicine, Inc.",
        "summary": "Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02141",
        "website": "http://www.editasmedicine.com",
        "market_cap": "Mid Cap"
    },
    "EFLI": {
        "short_name": "CELLTECH INTERNATIONAL INC",
        "long_name": "New Earth Life Sciences, Inc.",
        "summary": "New Earth Life Sciences, Inc. harvests, processes, manufactures, and sells dietary supplements. Its dietary supplements are marketed under the Wild Essentials, EDGE, and GIVE brand names. The company is based in Klamath Falls, Oregon.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OR",
        "city": "Klamath Falls",
        "zipcode": "97601",
        "website": "http://www.newearth.com",
        "market_cap": "Small Cap"
    },
    "EGB.F": {
        "short_name": "ENSIGN GROUP INC. DL-,001",
        "long_name": "The Ensign Group, Inc.",
        "summary": "The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. It operates in two segments, Transitional and Skilled Services and Real Estate. The company offers transitional and skilled services, which include short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly; and physical, occupational, and speech therapies and other rehabilitative and healthcare services. It also provides standard services, such as room and board, special nutritional program, social, recreational, entertainment, and other services. In addition, the company offers senior living, as well as mobile diagnostics services; leases real estate properties; and provides other ancillary services consisting of digital x-ray, ultrasound, electrocardiogram, laboratory, sub-acute, and patient transportation services to people in their homes or at long-term care facilities. As of February 2, 2021, it operated 232 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington, and Wisconsin. The company was founded in 1999 and is based in San Juan Capistrano, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Juan Capistrano",
        "zipcode": "92675",
        "website": "http://www.ensigngroup.net",
        "market_cap": "Mid Cap"
    },
    "EGRX": {
        "short_name": "Eagle Pharmaceuticals, Inc.",
        "long_name": "Eagle Pharmaceuticals, Inc.",
        "summary": "Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Woodcliff Lake",
        "zipcode": "07677",
        "website": "http://www.eagleus.com",
        "market_cap": "Small Cap"
    },
    "EHC": {
        "short_name": "Encompass Health Corporation",
        "long_name": "Encompass Health Corporation",
        "summary": "Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment provides home health and hospice services primarily in the Southeast and Texas. Its home health services include a range of Medicare-certified home nursing services to adult patients in need of care comprising skilled nursing, medical social work, and home health aide services, as well as physical, occupational, speech therapy, and others. This segment's hospice services comprise in-home services to terminally ill patients and their families to address patients' physical needs, including pain control and symptom management, and to provide emotional and spiritual support. As of March 16, 2021, it operated 137 hospitals, 241 home health locations, and 82 hospice locations in 39 states and Puerto Rico. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was founded in 1983 and is based in Birmingham, Alabama.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "AL",
        "city": "Birmingham",
        "zipcode": "35242",
        "website": "http://www.encompasshealth.com",
        "market_cap": "Mid Cap"
    },
    "EIGR": {
        "short_name": "Eiger BioPharmaceuticals, Inc.",
        "long_name": "Eiger BioPharmaceuticals, Inc.",
        "summary": "Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Palo Alto",
        "zipcode": "94306",
        "website": "http://www.eigerbio.com",
        "market_cap": "Small Cap"
    },
    "EJU.F": {
        "short_name": "AETHLON MEDIC.NEW DL-,001",
        "long_name": "Aethlon Medical, Inc.",
        "summary": "Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.aethlonmedical.com",
        "market_cap": "Small Cap"
    },
    "EKSO": {
        "short_name": "Ekso Bionics Holdings, Inc.",
        "long_name": "Ekso Bionics Holdings, Inc.",
        "summary": "Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells, and rents exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation and OttoBock Healthcare Product GmbH. The company was founded in 2005 and is headquartered in Richmond, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Richmond",
        "zipcode": "94804",
        "website": "http://www.eksobionics.com",
        "market_cap": "Small Cap"
    },
    "ELAN": {
        "short_name": "Elanco Animal Health Incorporat",
        "long_name": "Elanco Animal Health Incorporated",
        "summary": "Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "IN",
        "city": "Greenfield",
        "zipcode": "46140",
        "website": "http://www.elanco.com",
        "market_cap": "Large Cap"
    },
    "ELDN": {
        "short_name": "Eledon Pharmaceuticals, Inc.",
        "long_name": "Eledon Pharmaceuticals, Inc.",
        "summary": "Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92612",
        "website": "http://eledon.com",
        "market_cap": "Small Cap"
    },
    "ELMD": {
        "short_name": "Electromed, Inc.",
        "long_name": "Electromed, Inc.",
        "summary": "Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of all ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was founded in 1992 and is headquartered in New Prague, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "New Prague",
        "zipcode": "56071",
        "website": "http://smartvest.com",
        "market_cap": "Small Cap"
    },
    "ELOX": {
        "short_name": "Eloxx Pharmaceuticals, Inc.",
        "long_name": "Eloxx Pharmaceuticals, Inc.",
        "summary": "Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.eloxxpharma.com",
        "market_cap": "Small Cap"
    },
    "ELTP": {
        "short_name": "ELITE PHARMACEUTICALS INC",
        "long_name": "Elite Pharmaceuticals, Inc.",
        "summary": "Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Northvale",
        "zipcode": "07647",
        "website": "http://www.elitepharma.com",
        "market_cap": "Small Cap"
    },
    "EMBT": {
        "short_name": "EMBER THERAPEUTICS INC",
        "long_name": "Ember Therapeutics, Inc.",
        "summary": "Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.embertx.com",
        "market_cap": "Small Cap"
    },
    "EMDF": {
        "short_name": "E MED FUTURE INC",
        "long_name": "XL Rent, Inc.",
        "summary": "XL Rent, Inc. manufactures and markets products designed to reduce accidental hypodermic needlestick injuries. Its products include NeedleZap, a safety device intended to help reduce accidental needlestick injuries by disintegrating the sharp portion of a hypodermic needle. The company also develops a dental parking station, which is intended to provide temporary resting place for a hypodermic syringe; and butterfly needle burner that is intended to accommodate needles not secured to a hypodermic syringe for IV's and kidney dialysis. It offers its products to healthcare professionals, law enforcement and correctional personnel, veterinarians, military, clinical researchers, hospitality, and sanitation workers. XL Rent, Inc. was formerly known as Acem Holdings, Inc. and changed its name to XL Rent, Inc. in October 2012. The company was incorporated in 1990 and is headquartered in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06511",
        "website": null,
        "market_cap": "Small Cap"
    },
    "EMED": {
        "short_name": "ELECTROMEDICAL TECHNOLOGIES INC",
        "long_name": "Electromedical Technologies, Inc.",
        "summary": "Electromedical Technologies, Inc., a bioelectronics manufacturing and marketing company, provides medical devices for pain management in the United States. Its products include WellnessPro Plus, a bioelectronics therapy prescription device to relieve chronic and acute pain. Electromedical Technologies, Inc. is headquartered in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85260",
        "website": "http://www.electromedtech.com",
        "market_cap": "Small Cap"
    },
    "EMGE": {
        "short_name": "EMERGENT HEALTH CORP",
        "long_name": "Emergent Health Corp",
        "summary": "Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally. Emergent Health Corp. is based in King of Prussia, Pennsylvania. As of August 26, 2014, Emergent Health Corp was taken private.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "King of Prussia",
        "zipcode": "19406",
        "website": null,
        "market_cap": "Small Cap"
    },
    "EMMA": {
        "short_name": "EMMAUS LIFE SCIENCES INC NEW",
        "long_name": "Emmaus Life Sciences, Inc.",
        "summary": "Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Emmaus Life Sciences, Inc. has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. is headquartered in Torrance, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Torrance",
        "zipcode": "90503",
        "website": "http://www.emmausmedical.com",
        "market_cap": "Small Cap"
    },
    "EMOR": {
        "short_name": "HEALIXA INC",
        "long_name": "Healixa Inc.",
        "summary": "Pura Vida Health, LLC, a health and wellness company, researches, develops, and sells cannabidiol and other natural ingredients based products for wellness, recovery, sports and fitness, and animals. The company was founded in 2017 and is based in Farmingdale, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Farmingdale",
        "zipcode": null,
        "website": "http://www.puravidavitamins.com",
        "market_cap": "Small Cap"
    },
    "ENCW": {
        "short_name": "ENCHANTED WORLD INC",
        "long_name": "Enchanted World Inc.",
        "summary": "Enchanted World Inc. engages in the development, manufacture, and distribution of health care products in the United States. The company offers fitness and weight loss equipment and products. The company offers BioFit infrared bike, a design for the use of infrared and exercise to reduce body fat. The BioFit engages 3,300 watts of infrared lights and offers detox, inch loss, weight loss, inflammation reduction, pain control, and enhanced calorie burn. It provides its products to wellness and weight loss centers, med spas, gyms, doctors' offices, and day spas. The company was formerly known as Cardio Infrared Technologies, Inc. and changed its name to Enchanted World Inc. in December 2014. Enchanted World Inc. is based in Henderson, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Henderson",
        "zipcode": "89052",
        "website": null,
        "market_cap": "Small Cap"
    },
    "ENDV": {
        "short_name": "ENDONOVO THERAPEUTICS INC",
        "long_name": "Endonovo Therapeutics, Inc.",
        "summary": "Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive electrocuetical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its electrocuetical medical devices are also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for the treatment central nervous system disorders, such as traumatic brain injury, acute concussions, post- concussion syndrome, and multiple sclerosis. The company has a collaboration with the Stanford University sponsored Orthopedic Shoulder and Knee Study to determine the benefits of Endonovo's tPEMF SofPulse on pain, medication levels, and physical function post-operatively. The company was founded in 2008 and is based in Woodland Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Woodland Hills",
        "zipcode": "91367",
        "website": "http://www.endonovo.com",
        "market_cap": "Small Cap"
    },
    "ENDY.TA": {
        "short_name": "ENDYMED LTD",
        "long_name": "Endymed Ltd",
        "summary": "Endymed Ltd, a medical technology company, designs, develops, and commercializes energy based medical aesthetic treatment systems for the professional and consumer markets worldwide. Its products comprise EndyMed PRO, a multi-application treatment platform; PURE 2.0 that offers professional skin tightening, body contouring, and functional resurfacing; and 3DEEP radiofrequency technology, a solution for the treatment of skin tightening, wrinkle reduction, body contouring, texture enhancement, cellulite reduction, circumferential reduction, acne and acne scar reduction, stretch mark reduction, RF micro needling, and fractional resurfacing. The company was founded in 2007 and is based in Freehold, New Jersey.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "United States",
        "state": "NJ",
        "city": "Freehold",
        "zipcode": "07728",
        "website": "http://www.endymed.com",
        "market_cap": null
    },
    "ENMN.F": {
        "short_name": "CASI PHARMAC. NEW  DL-,01",
        "long_name": "CASI Pharmaceuticals, Inc.",
        "summary": "CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.casipharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "ENOB": {
        "short_name": "Enochian Biosciences, Inc.",
        "long_name": "Enochian Biosciences, Inc.",
        "summary": "Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90067-2012",
        "website": "http://www.enochianbio.com",
        "market_cap": "Small Cap"
    },
    "ENSG": {
        "short_name": "The Ensign Group, Inc.",
        "long_name": "The Ensign Group, Inc.",
        "summary": "The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. It operates in two segments, Transitional and Skilled Services and Real Estate. The company offers transitional and skilled services, which include short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly; and physical, occupational, and speech therapies and other rehabilitative and healthcare services. It also provides standard services, such as room and board, special nutritional program, social, recreational, entertainment, and other services. In addition, the company offers senior living, as well as mobile diagnostics services; leases real estate properties; and provides other ancillary services consisting of digital x-ray, ultrasound, electrocardiogram, laboratory, sub-acute, and patient transportation services to people in their homes or at long-term care facilities. As of February 2, 2021, it operated 232 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington, and Wisconsin. The company was founded in 1999 and is based in San Juan Capistrano, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Juan Capistrano",
        "zipcode": "92675",
        "website": "http://www.ensigngroup.net",
        "market_cap": "Mid Cap"
    },
    "ENTA": {
        "short_name": "Enanta Pharmaceuticals, Inc.",
        "long_name": "Enanta Pharmaceuticals, Inc.",
        "summary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.enanta.com",
        "market_cap": "Small Cap"
    },
    "ENVB": {
        "short_name": "Enveric Biosciences, Inc.",
        "long_name": "Enveric Biosciences, Inc.",
        "summary": "Enveric Biosciences, Inc., a biotechnology company, engages in developing various cannabinoid medicines to enhance quality of life for cancer patients. It has a pipeline of development programs for radiodermatitis, glioblastoma, and chemotherapy-induced neuropathy. The company is based in Naples, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Naples",
        "zipcode": "34103",
        "website": "http://www.enveric.com",
        "market_cap": "Small Cap"
    },
    "ENZ": {
        "short_name": "Enzo Biochem, Inc.",
        "long_name": "Enzo Biochem, Inc.",
        "summary": "Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing \u00c2\u0091STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.enzo.com",
        "market_cap": "Small Cap"
    },
    "ENZC": {
        "short_name": "ENZOLYTICS INC",
        "long_name": "Enzolytics Inc.\t",
        "summary": "Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Plano",
        "zipcode": "75074",
        "website": "http://enzolytics.com",
        "market_cap": "Small Cap"
    },
    "ENZN": {
        "short_name": "ENZON PHARMACEUTICALS INC",
        "long_name": "Enzon Pharmaceuticals, Inc.",
        "summary": "Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranford",
        "zipcode": "07016",
        "website": "http://www.enzon.com",
        "market_cap": "Small Cap"
    },
    "EOLS": {
        "short_name": "Evolus, Inc. Common Stock",
        "long_name": "Evolus, Inc.",
        "summary": "Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newport Beach",
        "zipcode": "92660",
        "website": "http://www.evolus.com",
        "market_cap": "Small Cap"
    },
    "EP3.F": {
        "short_name": "ORASURE TECH",
        "long_name": "OraSure Technologies, Inc.",
        "summary": "OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Bethlehem",
        "zipcode": "18015",
        "website": "http://www.orasure.com",
        "market_cap": "Small Cap"
    },
    "EPE.F": {
        "short_name": "EPIZYME INC.  DL -,0001",
        "long_name": "Epizyme, Inc.",
        "summary": "Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.epizyme.com",
        "market_cap": "Small Cap"
    },
    "EPRSQ": {
        "short_name": "EPIRUS BIOPHARMACEUTICALS INC",
        "long_name": "EPIRUS Biopharmaceuticals, Inc.",
        "summary": "EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://epirusbiopharma.com",
        "market_cap": "Small Cap"
    },
    "EPZM": {
        "short_name": "Epizyme, Inc.",
        "long_name": "Epizyme, Inc.",
        "summary": "Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.epizyme.com",
        "market_cap": "Small Cap"
    },
    "EQ": {
        "short_name": "Equillium, Inc.",
        "long_name": "Equillium, Inc.",
        "summary": "Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://equilliumbio.com",
        "market_cap": "Small Cap"
    },
    "EQUR": {
        "short_name": "E-QURE CORP",
        "long_name": "E-Qure Corp.",
        "summary": "E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices. Its BST devices implement patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers down to complete closure and/or cure. E-Qure Corp. is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10023",
        "website": "http://www.e-qure.com",
        "market_cap": "Small Cap"
    },
    "ER4.F": {
        "short_name": "EMERGENT BIOSOLNS DL-,001",
        "long_name": "Emergent BioSolutions Inc.",
        "summary": "Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20879",
        "website": "http://www.emergentbiosolutions.com",
        "market_cap": "Mid Cap"
    },
    "ERBB": {
        "short_name": "AMERICAN GREEN INC",
        "long_name": "American Green, Inc.",
        "summary": "American Green, Inc. operates as a technology company in the medical cannabis industry in the United States. It develops retail, brand, and commercial cultivating solutions in partnership with licensed retail medical marijuana dispensaries operated under the American Green brand name. The company operates ZaZZZ, a consumer operated marijuana vending machine for automated, age-verifying dispensing of cannabis-based medicines. It also offers Jurassic Water for cannabis plants; truth lighting, a LED lighting solution; and OG tea nutrients, a specialty fertilizer product. It has collaboration agreement with Endexx Corporation to develop the Access Control Identification and Verification Vending Platform. The company was formerly known as Tranzbyte Corporation and changed its name to American Green, Inc. in May 2014. American Green, Inc. is headquartered in Tempe, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85284",
        "website": "http://www.americangreen.com",
        "market_cap": "Small Cap"
    },
    "ERGO": {
        "short_name": "ENTIA BIOSCIENCES INC",
        "long_name": "Entia Biosciences, Inc.",
        "summary": "Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OR",
        "city": "Sherwood",
        "zipcode": "97140",
        "website": "http://www.entiabio.com",
        "market_cap": "Small Cap"
    },
    "ESMC": {
        "short_name": "ESCALON MEDICAL CORP",
        "long_name": "Escalon Medical Corp.",
        "summary": "Escalon Medical Corp. develops, manufactures, markets, and distributes medical devices and pharmaceuticals in the area of ophthalmology in the United States and internationally. It offers A-Scan, which provides information about the internal structure of the eye; B-Scan, a diagnostic tool that supplies information to physicians where the media within the eye are cloudy or opaque; UBM, a high frequency/high resolution ultrasound device, which provides detailed information about the anterior segment of the eye; and pachymeter that measures the thickness of cornea. The company also provides color/fluorescein angiography digital imaging systems that are primarily used in detecting retinal problems in diabetic and elderly patients; distributes intraocular gas products, such as C3F8 and SF6, which are used by vitreoretinal surgeons as a temporary tamponade in detached retina surgery; and manufactures and distributes a patented disposable universal gas kit that delivers the gas from the canister to the patient. In addition, it offers disposable surgical packs that are used in vitreoretinal surgery; viscous fluid transfer systems and related disposable syringe products, which aid surgeons in the process of injecting and extracting silicone oil; and AXIS Image management system for managing images through the Web browser from various devices regardless of modality, manufacturer, or location. The company sells its products to medical institutions through independent sales representatives, a network of distributors, and internal sales employees. Escalon Medical Corp. was founded in 1987 and is headquartered in Wayne, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Wayne",
        "zipcode": "19087",
        "website": "http://www.escalonmedical.com",
        "market_cap": "Small Cap"
    },
    "ESPR": {
        "short_name": "Esperion Therapeutics, Inc.",
        "long_name": "Esperion Therapeutics, Inc.",
        "summary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Ann Arbor",
        "zipcode": "48108",
        "website": "http://www.esperion.com",
        "market_cap": "Small Cap"
    },
    "ESSI": {
        "short_name": "ECO SCIENCE SOLUTIONS INC",
        "long_name": "Eco Science Solutions, Inc.",
        "summary": "Eco Science Solutions, Inc. provides consumer and enterprise technology products and services for the health, wellness, and alternative medicine industry. Its services include business location, localized communications between consumers and business operators, social networking, inventory management/selection, and payment facilitation and delivery arrangement. The company's e-commerce and content platform enables health, wellness, and alternative medicine enthusiasts to locate, access, and connect with others to facilitate the research of and purchasing of eco-science friendly products. In addition, it offers Herbo app that enables consumers to find products and services, which support the intake of alternative medicines for a naturopathic way of living; and develops app for marijuana businesses and delivery services. Eco Science Solutions, Inc. was founded in 2009 and is headquartered in Makawao, Hawaii.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "HI",
        "city": "Makawao",
        "zipcode": "96768",
        "website": "http://www.useherbo.com",
        "market_cap": "Small Cap"
    },
    "ET82.F": {
        "short_name": "AETERNA ZENTARIS INC.",
        "long_name": "Aeterna Zentaris Inc.",
        "summary": "Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "SC",
        "city": "Summerville",
        "zipcode": "29486",
        "website": "http://www.zentaris.com",
        "market_cap": "Small Cap"
    },
    "ETF.SG": {
        "short_name": "ELITE PHARMACEUTICALS INC. Regi",
        "long_name": "Elite Pharmaceuticals, Inc.",
        "summary": "Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Northvale",
        "zipcode": "07647",
        "website": "http://www.elitepharma.com",
        "market_cap": "Small Cap"
    },
    "ETNB": {
        "short_name": "89bio, Inc.",
        "long_name": "89bio, Inc.",
        "summary": "89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94104",
        "website": "http://www.89bio.com",
        "market_cap": "Small Cap"
    },
    "ETON": {
        "short_name": "Eton Pharmaceuticals, Inc.",
        "long_name": "Eton Pharmaceuticals, Inc.",
        "summary": "Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Deer Park",
        "zipcode": "60010-7208",
        "website": "http://www.etonpharma.com",
        "market_cap": "Small Cap"
    },
    "ETST": {
        "short_name": "EARTH SCIENCE TECH INC",
        "long_name": "Earth Science Tech, Inc.",
        "summary": "Earth Science Tech, Inc., a biotechnology company, focuses on delivering nutraceuticals, bioceuticals, and dietary supplements in the areas of health, wellness, nutrition, supplement, cosmetic, and alternative medicine worldwide. The company focuses on delivering nutritional and dietary supplements for the treatment of chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, and aging. Its products include vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods, and other products. The company markets its products in a range of formulations and delivery forms, including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. It also offers Cannabidiol oil to retailers in the vaping industry; and cannabinoid products. In addition, the company retails health, wellness, sports nutrition, and dietary supplement products. Earth Science Tech, Inc. offers its products through its retail store located in Coral Gables, Florida, as well as through the internet. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in April 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Doral, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Doral",
        "zipcode": "33122",
        "website": "http://www.earthsciencetech.com",
        "market_cap": "Small Cap"
    },
    "ETTX": {
        "short_name": "Entasis Therapeutics Holdings I",
        "long_name": "Entasis Therapeutics Holdings Inc.",
        "summary": "Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.entasistx.com",
        "market_cap": "Small Cap"
    },
    "EU6.F": {
        "short_name": "PDS BIOTECHNOLOGY CORP.",
        "long_name": "PDS Biotechnology Corporation",
        "summary": "PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Florham Park",
        "zipcode": "07932",
        "website": "http://www.pdsbiotech.com",
        "market_cap": "Small Cap"
    },
    "EV0.F": {
        "short_name": "EVOKE PHARMA INC.DL-,0001",
        "long_name": "Evoke Pharma, Inc.",
        "summary": "Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Solana Beach",
        "zipcode": "92075",
        "website": "http://www.evokepharma.com",
        "market_cap": "Small Cap"
    },
    "EVFM": {
        "short_name": "Evofem Biosciences, Inc.",
        "long_name": "Evofem Biosciences, Inc.",
        "summary": "Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.evofem.com",
        "market_cap": "Small Cap"
    },
    "EVH": {
        "short_name": "Evolent Health, Inc",
        "long_name": "Evolent Health, Inc.",
        "summary": "Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients; population health performance that delivers patient-centric cost effective care; and delivery network alignments. This segment also offers specialty care management solutions that support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation, and specific market dynamics; and comprehensive health plan administrative services that helps providers assemble the complete infrastructure required to operate, manage, and capitalize on a variety of financial and administrative management services. The True Health segment operates a commercial health plan for small and large businesses in New Mexico. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Arlington",
        "zipcode": "22203",
        "website": "http://www.evolenthealth.com",
        "market_cap": "Small Cap"
    },
    "EVIO": {
        "short_name": "EVIO INC",
        "long_name": "EVIO, Inc.",
        "summary": "EVIO, Inc., together with its subsidiaries, provides analytical testing and advisory services to cannabis industry in the United States. The company's consulting services include advisory, product formulation, and licensing and compliance services. It also offers various testing services comprise cannabinoid potency testing, terpene analysis, pesticide testing, residual solvent screening, visual inspections, biological contaminant testing, and other services. EVIO, Inc. is headquartered in Henderson, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Henderson",
        "zipcode": "89052",
        "website": "http://eviolabs.com",
        "market_cap": "Small Cap"
    },
    "EVL.F": {
        "short_name": "EVOLUS INC.  DL-,00001",
        "long_name": "Evolus, Inc.",
        "summary": "Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Newport Beach",
        "zipcode": "92660",
        "website": "http://www.evolus.com",
        "market_cap": "Small Cap"
    },
    "EVLO": {
        "short_name": "Evelo Biosciences, Inc.",
        "long_name": "Evelo Biosciences, Inc.",
        "summary": "Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.evelobio.com",
        "market_cap": "Small Cap"
    },
    "EVOK": {
        "short_name": "Evoke Pharma, Inc.",
        "long_name": "Evoke Pharma, Inc.",
        "summary": "Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Solana Beach",
        "zipcode": "92075",
        "website": "http://www.evokepharma.com",
        "market_cap": "Small Cap"
    },
    "EW.MX": {
        "short_name": "EDWARDS LIFESCIENCES CORP",
        "long_name": "Edwards Lifesciences Corporation",
        "summary": "Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.edwards.com",
        "market_cap": "Large Cap"
    },
    "EW": {
        "short_name": "Edwards Lifesciences Corporatio",
        "long_name": "Edwards Lifesciences Corporation",
        "summary": "Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.edwards.com",
        "market_cap": "Large Cap"
    },
    "EWL.DE": {
        "short_name": "EDWARDS LIFESCIENCES",
        "long_name": "Edwards Lifesciences Corporation",
        "summary": "Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.edwards.com",
        "market_cap": "Large Cap"
    },
    "EWL.F": {
        "short_name": "EDWARDS LIFESCIENCES",
        "long_name": "Edwards Lifesciences Corporation",
        "summary": "Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.edwards.com",
        "market_cap": "Large Cap"
    },
    "EWLL": {
        "short_name": "EWELLNESS HEALTHCARE CORP",
        "long_name": "eWellness Healthcare Corporation",
        "summary": "eWellness Healthcare Corporation, a physical therapy telehealth company, offers real-time distance monitored assessments and treatments. It provides PHZIO platform, which enables patients to engage with live or on-demand video for digital telehealth assessments and treatments from home or office. The company is based in Fort Lauderdale, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Lauderdale",
        "zipcode": "33301",
        "website": "http://www.ewellnesshealth.com",
        "market_cap": "Small Cap"
    },
    "EWLS.VI": {
        "short_name": "EDWARDS LIFESCIENCES CORP",
        "long_name": "Edwards Lifesciences Corporation",
        "summary": "Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.edwards.com",
        "market_cap": "Large Cap"
    },
    "EWTX": {
        "short_name": "Edgewise Therapeutics, Inc.",
        "long_name": "Edgewise Therapeutics, Inc.",
        "summary": "Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80303",
        "website": "http://www.edgewisetx.com",
        "market_cap": "Small Cap"
    },
    "EX9.DE": {
        "short_name": "EXELIXIS INC.  DL-,01",
        "long_name": "Exelixis, Inc.",
        "summary": "Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "Alameda",
        "zipcode": "94502",
        "website": "http://www.exelixis.com",
        "market_cap": "Mid Cap"
    },
    "EX9.F": {
        "short_name": "EXELIXIS INC.  DL-,01",
        "long_name": "Exelixis, Inc.",
        "summary": "Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Alameda",
        "zipcode": "94502",
        "website": "http://www.exelixis.com",
        "market_cap": "Mid Cap"
    },
    "EXAS": {
        "short_name": "Exact Sciences Corporation",
        "long_name": "Exact Sciences Corporation",
        "summary": "Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WI",
        "city": "Madison",
        "zipcode": "53719",
        "website": "http://www.exactsciences.com",
        "market_cap": "Large Cap"
    },
    "EXDI": {
        "short_name": "EXACTUS INC",
        "long_name": "Exactus, Inc.",
        "summary": "Exactus, Inc. produces and supplies hemp and hemp-derived products in the United States. It provides cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products to the cosmetic, wellness, food, beverage, pharmaceutical, and pet industries. The company's specialty ingredients include CBD, CBG, CBN, and CBC isolates; CBD and CBG distillates; CBD water-soluble; CBD and CBG biomass; CBD AND CBG flowers; and CBD crude oil. It also provides a range of custom manufactured specialty cannabinoid products, such as skincare products, pain creams, tinctures, bath bombs, soft gels, balms, pet products, supplements, and other products. The company is based in Delray Beach, Florida. Exactus, Inc. is a subsidiary of Ceed2Med, LLC.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Delray Beach",
        "zipcode": "33483",
        "website": "http://www.exactushemp.com",
        "market_cap": "Small Cap"
    },
    "EXEL": {
        "short_name": "Exelixis, Inc.",
        "long_name": "Exelixis, Inc.",
        "summary": "Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Alameda",
        "zipcode": "94502",
        "website": "http://www.exelixis.com",
        "market_cap": "Mid Cap"
    },
    "EXHI": {
        "short_name": "EXLITES HOLDINGS INTERNATIONAL ",
        "long_name": "Exlites Holdings International, Inc.",
        "summary": "Exlites Holdings International, Inc. engages in the consumer health care market and durable medical supply businesses. It offers consumer products, such as battery operated heated steering wheel products, electronic hot and cold packs, spring loaded shoe insoles, and other consumer products. The company is also involved in contract manufacturing of medical supplies and devices to hospitals, nursing homes, and assisted living facilities, as well as for individuals. Exlites Holdings International, Inc. distributes its products to consumer and medical distributors through catalogs and retailers, as well as directly to consumer venues. The company was founded in 1979 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84111",
        "website": "http://exlitesholdings.com",
        "market_cap": "Small Cap"
    },
    "EXK.F": {
        "short_name": "EXACT SCIEN.  DL-,01",
        "long_name": "Exact Sciences Corporation",
        "summary": "Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WI",
        "city": "Madison",
        "zipcode": "53719",
        "website": "http://www.exactsciences.com",
        "market_cap": "Large Cap"
    },
    "EXMT": {
        "short_name": "ANYTHING TECHNOLOGIES MEDIA INC",
        "long_name": "Anything Technologies Media, Inc.",
        "summary": "Anything Technologies Media, Inc. provides media duplication/replication and fulfillment services. The company offers duplication and replication services for DVDs, Blu-ray discs, and CDs; and USB duplication and printing services. It also provides supply chain solutions fulfillment and mailing services, custom silk-screen/offset media printing and packaging, and DVD and Blu-ray authoring/encoding services; and Website hosting, design, and SEO services. The company was formerly known as Exchange Mobile Telecommunications Corp. and changed its name to Anything Technologies Media, Inc. in September 2010. Anything Technologies Media, Inc. was founded in 1997 and is based in Ione, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Ione",
        "zipcode": "95640",
        "website": "http://www.anythingtechnologiesmedia.com",
        "market_cap": "Small Cap"
    },
    "EYEG": {
        "short_name": "Eyegate Pharmaceuticals, Inc.",
        "long_name": "EyeGate Pharmaceuticals, Inc.",
        "summary": "EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02452",
        "website": "http://www.eyegatepharma.com",
        "market_cap": "Small Cap"
    },
    "EYEN": {
        "short_name": "Eyenovia, Inc.",
        "long_name": "Eyenovia, Inc.",
        "summary": "Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print (MAP) platform technology. The company focuses on to develop clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its pipelines focus on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates in pipeline include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.eyenovia.com",
        "market_cap": "Small Cap"
    },
    "EYES": {
        "short_name": "Second Sight Medical Products, ",
        "long_name": "Second Sight Medical Products, Inc.",
        "summary": "Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Sylmar",
        "zipcode": "91342",
        "website": "http://www.secondsight.com",
        "market_cap": "Small Cap"
    },
    "EYPT": {
        "short_name": "EyePoint Pharmaceuticals, Inc.",
        "long_name": "EyePoint Pharmaceuticals, Inc.",
        "summary": "EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://eyepointpharma.com",
        "market_cap": "Small Cap"
    },
    "EZ1.F": {
        "short_name": "ENZON PHARMACEUT.  DL-,01",
        "long_name": "Enzon Pharmaceuticals, Inc.",
        "summary": "Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranford",
        "zipcode": "07016",
        "website": "http://www.enzon.com",
        "market_cap": "Small Cap"
    },
    "EZB.F": {
        "short_name": "ENZO BIOCHEM. INC. DL-,01",
        "long_name": "Enzo Biochem, Inc.",
        "summary": "Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing \u00c2\u0091STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.enzo.com",
        "market_cap": "Small Cap"
    },
    "F2KA.F": {
        "short_name": "DIAMEDICA THERAPEUT.",
        "long_name": "DiaMedica Therapeutics Inc.",
        "summary": "DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55447",
        "website": "http://www.diamedica.com",
        "market_cap": "Small Cap"
    },
    "F6T.F": {
        "short_name": "FATE THERAPEUTICS DL-,001",
        "long_name": "Fate Therapeutics, Inc.",
        "summary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.fatetherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "FAD2.F": {
        "short_name": "ADVAXIS INC.  DL-,01",
        "long_name": "Advaxis, Inc.",
        "summary": "Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.advaxis.com",
        "market_cap": "Small Cap"
    },
    "FAGI": {
        "short_name": "FULL ALLIANCE GROUP INC",
        "long_name": "Full Alliance Group, Inc.",
        "summary": "Beverly Hills Group, Inc. operates an institution that recognizes and honors noteworthy individuals, movies, and film scores for their contributions to the motion picture industry. The company honors and commemorates movies and individuals, whether living or deceased, for their works and contributions to the history of motion pictures. It also operates a facility that exhibits rotating displays, memorabilia, portraitures, and live vignettes to entertain and educate the public about the people and processes involved in filmmaking. In addition, the company broadcasts the event on television. The company was founded in 2000 and is based in Palm Springs, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Palm Springs",
        "zipcode": "92262",
        "website": "http://motionpicturehalloffame.info",
        "market_cap": "Small Cap"
    },
    "FATE": {
        "short_name": "Fate Therapeutics, Inc.",
        "long_name": "Fate Therapeutics, Inc.",
        "summary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.fatetherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "FBIO": {
        "short_name": "Fortress Biotech, Inc.",
        "long_name": "Fortress Biotech, Inc.",
        "summary": "Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10014",
        "website": "http://www.fortressbiotech.com",
        "market_cap": "Small Cap"
    },
    "FBIOP": {
        "short_name": "Fortress Biotech, Inc. - 9.375%",
        "long_name": "Fortress Biotech, Inc.",
        "summary": "Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10014",
        "website": "http://www.fortressbiotech.com",
        "market_cap": "Small Cap"
    },
    "FBRX": {
        "short_name": "Forte Biosciences, Inc.",
        "long_name": "Forte Biosciences, Inc.",
        "summary": "Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Torrance",
        "zipcode": "90502",
        "website": "http://www.fortebiorx.com/home/default.aspx",
        "market_cap": "Small Cap"
    },
    "FCHS": {
        "short_name": "FIRST CHOICE HEALTHCARE SOLUTIO",
        "long_name": "First Choice Healthcare Solutions, Inc.",
        "summary": "First Choice Healthcare Solutions, Inc., through its subsidiaries, provides healthcare services in the United States. Its network of non-physician-owned medical centers offer musculoskeletal and rehabilitative care services specializing in orthopaedics, spine surgery, interventional pain management, and ambulatory surgical care. The company also provides ancillary and diagnostic services comprising magnetic resonance imaging, X-ray, durable medical equipment, and physical/occupational therapy. In addition, it subleases 29,629 square feet of commercial office space to affiliated and nonaffiliated tenants. The company is headquartered in Melbourne, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Melbourne",
        "zipcode": "32901",
        "website": "http://www.myfchs.com",
        "market_cap": "Small Cap"
    },
    "FDBH": {
        "short_name": "FOUNDERS BAY HOLDINGS",
        "long_name": "Founders Bay Holdings",
        "summary": "Founders Bay Holdings and its subsidiaries provide medical diagnostic services. The company develops, operates, and administers the use of magnetic resonance imaging equipment in medical diagnostic centers, which provide medical diagnostic services to health maintenance organizations, preferred provider organizations, trade unions, clinics, and other health care providers. The company was incorporated in 1986 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89102",
        "website": "http://fbaytech.com",
        "market_cap": "Small Cap"
    },
    "FDMT": {
        "short_name": "4D Molecular Therapeutics, Inc.",
        "long_name": "4D Molecular Therapeutics, Inc.",
        "summary": "4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.4dmoleculartherapeutics.com",
        "market_cap": "Small Cap"
    },
    "FDV.F": {
        "short_name": "STAR EQ.HLDG  DL -,0001",
        "long_name": "Star Equity Holdings, Inc.",
        "summary": "Star Equity Holdings, Inc. provides healthcare solutions in the United States and internationally. It operates through four segments: Diagnostic Services, Diagnostic Imaging, Building and Construction, and Real Estate and Investments. The company offers imaging and monitoring services to healthcare providers; and contract diagnostic imaging, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to cardiologists, internal medicine physicians, family practice physicians, hospitals, IDNs, and federal institutions. It also develops, sells, and maintains solid-state gamma cameras; imaging systems, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; and manages and finances real estate assets and investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CT",
        "city": "Old Greenwich",
        "zipcode": "06870",
        "website": "http://www.starequity.com",
        "market_cap": "Small Cap"
    },
    "FENC": {
        "short_name": "Fennec Pharmaceuticals Inc.",
        "long_name": "Fennec Pharmaceuticals Inc.",
        "summary": "Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Research Triangle Park",
        "zipcode": "27709",
        "website": "http://www.fennecpharma.com",
        "market_cap": "Small Cap"
    },
    "FFNT.CN": {
        "short_name": "4FrontVentCorp",
        "long_name": "4Front Ventures Corp.",
        "summary": "4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates in two segments, THC Cannabis and CBD Wellness. It produces and sells cannabis and CBD. As of December 31, 2020, it operated 5 dispensaries in Massachusetts, Illinois, Michigan primarily under the MISSION brand name. In addition, the company sells equipment, supplies, and intellectual property to cannabis producers; imports and sale equipment and supplies; leases real estate properties to cannabis producers; offers consulting services; and operates cannabis dispensaries. 4Front Ventures Corp. was founded in 2011 and is headquartered in Phoenix, Arizona.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "AZ",
        "city": "Phoenix",
        "zipcode": "85018",
        "website": "http://4frontventures.com",
        "market_cap": "Small Cap"
    },
    "FFNTF": {
        "short_name": "4FRONT VENTURES CORP",
        "long_name": "4Front Ventures Corp.",
        "summary": "4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates in two segments, THC Cannabis and CBD Wellness. It produces and sells cannabis and CBD. As of December 31, 2020, it operated 5 dispensaries in Massachusetts, Illinois, Michigan primarily under the MISSION brand name. In addition, the company sells equipment, supplies, and intellectual property to cannabis producers; imports and sale equipment and supplies; leases real estate properties to cannabis producers; offers consulting services; and operates cannabis dispensaries. 4Front Ventures Corp. was founded in 2011 and is headquartered in Phoenix, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Phoenix",
        "zipcode": "85018",
        "website": "http://4frontventures.com",
        "market_cap": "Small Cap"
    },
    "FGEN.MX": {
        "short_name": "FIBROGEN INC",
        "long_name": "FibroGen, Inc.",
        "summary": "FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94158",
        "website": "http://www.fibrogen.com",
        "market_cap": "Mid Cap"
    },
    "FGEN": {
        "short_name": "FibroGen, Inc",
        "long_name": "FibroGen, Inc.",
        "summary": "FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94158",
        "website": "http://www.fibrogen.com",
        "market_cap": "Small Cap"
    },
    "FHTX": {
        "short_name": "Foghorn Therapeutics Inc.",
        "long_name": "Foghorn Therapeutics Inc.",
        "summary": "Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://foghorntx.com",
        "market_cap": "Small Cap"
    },
    "FITX": {
        "short_name": "CREATIVE EDGE NUTRITION INC",
        "long_name": "Creative Edge Nutrition, Inc.",
        "summary": "Creative Edge Nutrition, Inc. develops and sells a portfolio of health\u00c2\u0096oriented nutrition products. The company offers products in the categories of weight loss, metabolic enhancement, recovery/well-being, muscle enhancement and stimulation, and natural line. Its products include MetaBolic Xtreme, a product for weight loss; Hyper-Infusion, a pre-workout powder to enhance endurance and strength; Alpha-Drive, a product for post cycle therapy; Amino Plex, an intra-workout recovery catalyst; Chia Plex, a product for health and well being; and Hemp Nutra Tea and Nutra Coffee additives. The company was formerly known as Laufer Bridge Enterprises Inc. and changed its name to Creative Edge Nutrition, Inc. in April 2012. Creative Edge Nutrition, Inc. is based in Madison Heights, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Madison Heights",
        "zipcode": "48071",
        "website": "http://www.cenergynutrition.com",
        "market_cap": "Small Cap"
    },
    "FIXX": {
        "short_name": "Homology Medicines, Inc.",
        "long_name": "Homology Medicines, Inc.",
        "summary": "Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Bedford",
        "zipcode": "01730",
        "website": "http://www.homologymedicines.com",
        "market_cap": "Small Cap"
    },
    "FLB.F": {
        "short_name": "FLUIDIGM CORP.  DL -,001",
        "long_name": "Fluidigm Corporation",
        "summary": "Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.fluidigm.com",
        "market_cap": "Small Cap"
    },
    "FLDM": {
        "short_name": "Fluidigm Corporation",
        "long_name": "Fluidigm Corporation",
        "summary": "Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.fluidigm.com",
        "market_cap": "Small Cap"
    },
    "FLGT.MX": {
        "short_name": "FULGENT GENETICS INC",
        "long_name": "Fulgent Genetics, Inc.",
        "summary": "Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Temple City",
        "zipcode": "91780",
        "website": "http://www.fulgentgenetics.com",
        "market_cap": "Mid Cap"
    },
    "FLGT": {
        "short_name": "Fulgent Genetics, Inc.",
        "long_name": "Fulgent Genetics, Inc.",
        "summary": "Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Temple City",
        "zipcode": "91780",
        "website": "http://www.fulgentgenetics.com",
        "market_cap": "Mid Cap"
    },
    "FLXN": {
        "short_name": "Flexion Therapeutics, Inc.",
        "long_name": "Flexion Therapeutics, Inc.",
        "summary": "Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Burlington",
        "zipcode": "01803",
        "website": "http://www.flexiontherapeutics.com",
        "market_cap": "Small Cap"
    },
    "FMTX": {
        "short_name": "Forma Therapeutics Holdings, In",
        "long_name": "Forma Therapeutics Holdings, Inc.",
        "summary": "Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.formatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "FMW.F": {
        "short_name": "VERU INC.  DL-,01",
        "long_name": "Veru Inc.",
        "summary": "Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33127",
        "website": "http://www.verupharma.com",
        "market_cap": "Small Cap"
    },
    "FNAM": {
        "short_name": "EVOLUTIONARY GENOMICS INC",
        "long_name": "Evolutionary Genomics, Inc.",
        "summary": "Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Castle Rock",
        "zipcode": "80108",
        "website": "http://www.evolgen.com",
        "market_cap": "Small Cap"
    },
    "FNCH": {
        "short_name": "Finch Therapeutics Group, Inc.",
        "long_name": "Finch Therapeutics Group, Inc.",
        "summary": "Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Somerville",
        "zipcode": "02143",
        "website": "http://www.finchtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "FOAA.F": {
        "short_name": "FONAR CORP. NEW  DL-,0001",
        "long_name": "FONAR Corporation",
        "summary": "FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates four diagnostic imaging facilities in Florida; and manages 35 MRI scanning facilities, including 22 facilities located in New York and 13 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was founded in 1978 and is based in Melville, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Melville",
        "zipcode": "11747",
        "website": "http://www.fonar.com",
        "market_cap": "Small Cap"
    },
    "FOLD.MX": {
        "short_name": "AMICUS THERAPEUTICS INC",
        "long_name": "Amicus Therapeutics, Inc.",
        "summary": "Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19104",
        "website": "http://amicusrx.com",
        "market_cap": "Mid Cap"
    },
    "FOLD": {
        "short_name": "Amicus Therapeutics, Inc.",
        "long_name": "Amicus Therapeutics, Inc.",
        "summary": "Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19104",
        "website": "http://amicusrx.com",
        "market_cap": "Mid Cap"
    },
    "FONR": {
        "short_name": "Fonar Corporation",
        "long_name": "FONAR Corporation",
        "summary": "FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates four diagnostic imaging facilities in Florida; and manages 35 MRI scanning facilities, including 22 facilities located in New York and 13 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was founded in 1978 and is based in Melville, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Melville",
        "zipcode": "11747",
        "website": "http://www.fonar.com",
        "market_cap": "Small Cap"
    },
    "FORA": {
        "short_name": "Forian Inc.",
        "long_name": "Forian Inc.",
        "summary": "Forian Inc. provides a suite of SaaS solutions, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the life sciences and healthcare payor and provider segments, as well as cannabis manufacturers, dispensaries, cultivators, and regulators. The company is headquartered in Newtown, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Newtown",
        "zipcode": "18940",
        "website": "http://forian.com",
        "market_cap": "Small Cap"
    },
    "FORU": {
        "short_name": "FORU HOLDINGS INC",
        "long_name": "ForU Holdings, Inc.",
        "summary": "ForU Holdings, Inc., a wellness solutions company, through its subsidiaries, provides nutritional products and healthcare services. The company engages in researching and developing branded consumer products in the health and wellness space, including functional food and beverages; providing a suite of in-home non-medical and medical staffing and services, including light housekeeping and transportation, nurse and doctor visits, occupational and physical therapy, and other clinical services; and operating Wish Upon A Hero (WUAH), an online community that connects people in need with people who can help. It is also involved in the development of an orally administered product for the treatment of pediatric diarrhea in India; and provision of DNA customized nutritional supplements, skin care, and gene modulating weight management products through self-directed businesses. The company was formerly known as Capsalus Corp. and changed its name to ForU Holdings, Inc. in July 2014. ForU Holdings, Inc. is headquartered in Barrington, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Barrington",
        "zipcode": "60010",
        "website": null,
        "market_cap": "Small Cap"
    },
    "FP11.F": {
        "short_name": "SALARIUM PHARMA. DL-,0001",
        "long_name": "Salarius Pharmaceuticals, Inc.",
        "summary": "Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77021",
        "website": "http://www.salariuspharma.com",
        "market_cap": "Small Cap"
    },
    "FPMI": {
        "short_name": "FLUOROPHARMA MEDICAL INC",
        "long_name": "FluoroPharma Medical, Inc.",
        "summary": "FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Montclair",
        "zipcode": "07042",
        "website": "http://www.fluoropharma.com",
        "market_cap": "Small Cap"
    },
    "FREQ": {
        "short_name": "Frequency Therapeutics, Inc.",
        "long_name": "Frequency Therapeutics, Inc.",
        "summary": "Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Woburn, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Woburn",
        "zipcode": "01801",
        "website": "http://www.frequencytx.com",
        "market_cap": "Small Cap"
    },
    "FRX.TO": {
        "short_name": "FENNEC PHARMACEUTICALS INC",
        "long_name": "Fennec Pharmaceuticals Inc.",
        "summary": "Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "United States",
        "state": "NC",
        "city": "Research Triangle Park",
        "zipcode": "27709",
        "website": "http://www.fennecpharma.com",
        "market_cap": "Small Cap"
    },
    "FSPM": {
        "short_name": "FUSION PHARM INC",
        "long_name": "FusionPharm, Inc.",
        "summary": "FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. Its PharmPods cultivation container system is used in the indoor plant cultivation. The company also offers its products to businesses, universities, and individuals to cultivate various plants. FusionPharm, Inc. was formerly known as Baby Bee Bright Corp. and changed its name to FusionPharm, Inc. in April 2011. The company was founded in 1998 and is based in Commerce City, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Commerce City",
        "zipcode": "80022",
        "website": "http://www.fusionpharminc.com",
        "market_cap": "Small Cap"
    },
    "FTEG": {
        "short_name": "FOR THE EARTH CORPORATION",
        "long_name": "For The Earth Corp.",
        "summary": "For the Earth Corporation manufactures and sells consumable household products in the United States and internationally. The company provides a range of laundry detergents, household cleansers, fabric softeners, dryer sheets, dishwashing detergents, and other cleaning products under its own and private label in retail chains. It also provides Litter To Go, a disposable cat litter box made from corrugated material that contains ready-to-use litter; and What Odor?, a biodegradable and non-toxic odor-eliminating spray, as well as other pet supplies, including treats and toys, stylish feeders, and odor/stain-eliminating solutions. For the Earth Corporation sells its products to retail customers; industrial customers comprising hotel, nursing homes, restaurants, and professional sports teams; and direct-to consumers. The company was formerly known as Medjet Inc. and changed its name to For the Earth Corporation in January 2011. For the Earth Corporation was founded in 1993 and is headquartered in Phoenix, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Phoenix",
        "zipcode": "85012",
        "website": "http://ftegco.com",
        "market_cap": "Small Cap"
    },
    "FULC": {
        "short_name": "Fulcrum Therapeutics, Inc.",
        "long_name": "Fulcrum Therapeutics, Inc.",
        "summary": "Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and \u00c3\u009f-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.fulcrumtx.com",
        "market_cap": "Small Cap"
    },
    "FVE": {
        "short_name": "Five Star Senior Living Inc.",
        "long_name": "Five Star Senior Living Inc.",
        "summary": "Five Star Senior Living Inc. operates and manages senior living communities in the United States. It operates through Senior Living, and Rehabilitation and Wellness segments. Its senior living communities comprise independent living communities, assisted living communities, continuing care retirement communities (CCRCs), skilled nursing facilities (SNFs), and an active adult community. The company offers nursing and healthcare services; and rehabilitation and wellness services. As of December 31, 2020, it operated 268 senior living communities consisting of 29,271 living units comprising 243 primarily independent and assisted living communities with 28,316 living units, and 9 SNFs with 955 living units located in 31 states. The company was formerly known as Five Star Quality Care, Inc. and changed its name to Five Star Senior Living Inc. in March 2017. Five Star Senior Living Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Newton",
        "zipcode": "02458-2076",
        "website": "http://www.fivestarseniorliving.com",
        "market_cap": "Small Cap"
    },
    "FWDG": {
        "short_name": "FUTUREWORLD CORP",
        "long_name": "FutureWorld Corp.",
        "summary": "FutureWorld Corp., together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of hemp/cannabis products, services, and technologies worldwide. The company provides smart sensor technology, communication network, surveillance security, data analysis for smart cultivation, and consultation for the industrial hemp and legal medicinal marijuana. It offers personal and professional tetrahydrocannabinoil and Cannabidiol test kits; pharmaceutical grade CBD oil solutions; URVape vaporizer pens, which are oil vaporizers for the e-cigarette, cannabis, and herbal vaping industry; CaNNaLyTiX, a dashboard controller system that allows various computer systems to be integrated throughout a cultivator's infrastructures; CaNNaTRAK, the barcode and RFID tracking systems for keeping seed to sale tracking of hemp/cannabis; and SPIDer (secure perimeter intrusion detection network), a system to meet the needs of theft and malicious attacks. The company also provides SmartSense, which offers wireless security and smart sensor mesh network for precision agriculture, irrigation systems, and greenhouses for the hemp industry; SmartNergy that offers tools to analyze various aspects of a cultivator's energy usage; and CaNNaBoX machine, which operates with the swipe of a card to verify identity, age, and prescription information of a medical marijuana patient before releasing measured packages of marijuana. Its target customers include consumers via Internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, affiliate sales, and master distributors. The company was formerly known as FutureWorld Energy, Inc. and changed its name to FutureWorld Corp. in June 2014. FutureWorld Corp. was founded in 2002 and is based in Saint Petersburg, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Saint Petersburg",
        "zipcode": "33704",
        "website": null,
        "market_cap": "Small Cap"
    },
    "FZMD": {
        "short_name": "FUSE MEDICAL INC",
        "long_name": "Fuse Medical, Inc.",
        "summary": "Fuse Medical, Inc. manufactures and distributes medical device implants in the United States. The company offers orthopedic implants, including internal and external fixation products for foot and ankle; upper and lower extremity plating and total joint reconstruction implants; soft tissue fixation and augmentation for sports medicine procedures; full spinal implants for trauma, degenerative disc disease, and deformity indications; and various osteo-biologics, and regenerative and amniotic tissues, which comprise human allografts, synthetic skin and substitute bone materials, tendons, and regenerative tissues and fluids. The company serves hospitals, medical facilities, and sub-distributors. Fuse Medical, Inc. is based in Richardson, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Richardson",
        "zipcode": "75080",
        "website": "http://www.fusemedical.com",
        "market_cap": "Small Cap"
    },
    "FZRQ.F": {
        "short_name": "IMMUNE PHARMAC.  DL-,0001",
        "long_name": "Immune Pharmaceuticals, Inc.",
        "summary": "Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Fort Lee",
        "zipcode": "07024",
        "website": "http://www.immunepharma.com",
        "market_cap": "Small Cap"
    },
    "G1H.F": {
        "short_name": "G1 THERAPEUTICS  DL-,0001",
        "long_name": "G1 Therapeutics, Inc.",
        "summary": "G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Research Triangle Park",
        "zipcode": "27709",
        "website": "http://www.g1therapeutics.com",
        "market_cap": "Small Cap"
    },
    "G5B.F": {
        "short_name": "GLOBAL BL.THERAP.  DL-,01",
        "long_name": "Global Blood Therapeutics, Inc.",
        "summary": "Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.gbt.com",
        "market_cap": "Mid Cap"
    },
    "G67.F": {
        "short_name": "GREENLANE HLDGS A  DL-,01",
        "long_name": "Greenlane Holdings, Inc.",
        "summary": "Greenlane Holdings, Inc. sells cannabis accessories, child-resistant packaging, and specialty vaporization products in the United States, Canada, Europe, Australia, and South America. The company provides vaporizers, liquid nicotine, storage solutions, pipes, apparel lines, and consumption accessories, as well as bubblers, rigs, and other smoking and vaporization related accessories and merchandise. It offers its products under the VIBES rolling papers, Pollen Gear, the Marley Natural accessory line, Aerospaced & Groove grinders, K. Haring Glass Collections, Eyce specialty silicone smoking products, and Higher Standards brands. The company also operates e-commerce websites, such as Vapor.com, Higherstandards.com, Aerospaced.com, Canada.vapor.com, Vaposhop.com, and others. It serves smoke shops, dispensaries, and specialty retail stores. The company was founded in 2005 and is headquartered in Boca Raton, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33487",
        "website": "http://www.gnln.com",
        "market_cap": "Small Cap"
    },
    "G67.SG": {
        "short_name": "Greenlane Holdings Inc. Registe",
        "long_name": "Greenlane Holdings, Inc.",
        "summary": "Greenlane Holdings, Inc. sells cannabis accessories, child-resistant packaging, and specialty vaporization products in the United States, Canada, Europe, Australia, and South America. The company provides vaporizers, liquid nicotine, storage solutions, pipes, apparel lines, and consumption accessories, as well as bubblers, rigs, and other smoking and vaporization related accessories and merchandise. It offers its products under the VIBES rolling papers, Pollen Gear, the Marley Natural accessory line, Aerospaced & Groove grinders, K. Haring Glass Collections, Eyce specialty silicone smoking products, and Higher Standards brands. The company also operates e-commerce websites, such as Vapor.com, Higherstandards.com, Aerospaced.com, Canada.vapor.com, Vaposhop.com, and others. It serves smoke shops, dispensaries, and specialty retail stores. The company was founded in 2005 and is headquartered in Boca Raton, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33487",
        "website": "http://www.gnln.com",
        "market_cap": "Small Cap"
    },
    "GALT": {
        "short_name": "Galectin Therapeutics Inc.",
        "long_name": "Galectin Therapeutics Inc.",
        "summary": "Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Norcross",
        "zipcode": "30071",
        "website": "http://galectintherapeutics.com",
        "market_cap": "Small Cap"
    },
    "GANX": {
        "short_name": "Gain Therapeutics, Inc.",
        "long_name": "GT Gain Therapeutics SA",
        "summary": "Gain Therapeutics, Inc., a development stage biotechnology company, engages in developing various therapeutics to treat diseases caused by protein misfolding. It focuses rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, treating the underlying disease. It is developing structurally targeted allosteric regulator candidates in various preclinical studies to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Bethesda",
        "zipcode": "20814",
        "website": "http://www.gaintherapeutics.com",
        "market_cap": "Small Cap"
    },
    "GB8A.SG": {
        "short_name": "Generex Biotechnol.Corp.(Del.)R",
        "long_name": "Generex Biotechnology Corporation",
        "summary": "Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Miramar",
        "zipcode": "33025",
        "website": "http://generex.com/index.html",
        "market_cap": "Small Cap"
    },
    "GBI1.F": {
        "short_name": "GENOCEA BIOSCIENC.DL-,001",
        "long_name": "Genocea Biosciences, Inc.",
        "summary": "Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02140",
        "website": "http://www.genocea.com",
        "market_cap": "Small Cap"
    },
    "GBIM": {
        "short_name": "GLOBEIMMUNE INC",
        "long_name": "GlobeImmune, Inc.",
        "summary": "GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Louisville",
        "zipcode": "80027",
        "website": "http://www.globeimmune.com",
        "market_cap": "Small Cap"
    },
    "GBIO": {
        "short_name": "Generation Bio Co.",
        "long_name": "Generation Bio Co.",
        "summary": "Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://generationbio.com",
        "market_cap": "Small Cap"
    },
    "GBLX": {
        "short_name": "GB SCIENCES INC",
        "long_name": "GB Sciences, Inc.",
        "summary": "GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89118-6876",
        "website": "http://www.gbsciences.com",
        "market_cap": "Small Cap"
    },
    "GBMB.F": {
        "short_name": "INOVIO PHARMACEUTICAL INC",
        "long_name": "Inovio Pharmaceuticals, Inc.",
        "summary": "Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Plymouth Meeting",
        "zipcode": "19462",
        "website": "http://www.inovio.com",
        "market_cap": "Small Cap"
    },
    "GBS": {
        "short_name": "GBS Inc.",
        "long_name": "GBS Inc.",
        "summary": "GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.gbs.inc",
        "market_cap": "Small Cap"
    },
    "GBT": {
        "short_name": "Global Blood Therapeutics, Inc.",
        "long_name": "Global Blood Therapeutics, Inc.",
        "summary": "Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.gbt.com",
        "market_cap": "Mid Cap"
    },
    "GBY.DE": {
        "short_name": "SANGAMO THERAP.INC.DL-,01",
        "long_name": "Sangamo Therapeutics, Inc.",
        "summary": "Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "Brisbane",
        "zipcode": "94005",
        "website": "http://www.sangamo.com",
        "market_cap": "Small Cap"
    },
    "GBY.F": {
        "short_name": "SANGAMO THERAP.INC.DL-,01",
        "long_name": "Sangamo Therapeutics, Inc.",
        "summary": "Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Brisbane",
        "zipcode": "94005",
        "website": "http://www.sangamo.com",
        "market_cap": "Small Cap"
    },
    "GCAN": {
        "short_name": "GREATER CANNABIS CO INC",
        "long_name": "The Greater Cannabis Company, Inc.",
        "summary": "The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer product, and pharmaceutical companies. The company was founded in 2014 and is based in Baltimore, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Baltimore",
        "zipcode": "21208",
        "website": "http://www.gcanrx.com",
        "market_cap": "Small Cap"
    },
    "GDRX": {
        "short_name": "GoodRx Holdings, Inc.",
        "long_name": "GoodRx Holdings, Inc.",
        "summary": "GoodRx Holdings, Inc., through its subsidiaries, provides information and tools to enables consumers compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that can be used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Monica",
        "zipcode": "90404",
        "website": "http://www.goodrx.com",
        "market_cap": "Large Cap"
    },
    "GEATF": {
        "short_name": "RADIKO HOLDINGS CORP",
        "long_name": "Radiko Holdings Corp.",
        "summary": "Radiko Holdings Corp., together with its subsidiaries, focuses on cannabis industries in the United States and internationally. The company also manufactures and distributes a range of cannabis infused edibles and tinctures under the La Vida Verde brand; a range of wholesale flower, packaged flower, pre-rolls, and concentrates under the Skunk Feather brand; a range of cannabis, infused, chocolates, and edible cannabis consumables gummies, and capsules under the name the Blank Brand; and supplements under the Baseline brand. The company was formerly known as International Cannabrands Inc. and changed its name to Radiko Holdings Corp. in July 2020. The company is headquartered in Des Moines, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Des Moines",
        "zipcode": "98198",
        "website": "http://www.radikoholdings.com",
        "market_cap": "Small Cap"
    },
    "GEG": {
        "short_name": "Great Elm Group, Inc.",
        "long_name": "Great Elm Group, Inc.",
        "summary": "Great Elm Group, Inc. operates in durable medical equipment, investment management, and real estate businesses. It distributes respiratory care equipment, including positive air pressure equipment and supplies, ventilators and oxygen equipment, and replacement parts, as well as provides sleep study services; and rents medical equipment. The company also offers investment management services. In addition, it engages in the real estate activities. The company was formerly known as Great Elm Capital Group, Inc. and changed its name to Great Elm Group, Inc. in December 2020. Great Elm Group, Inc. was founded in 1994 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02453",
        "website": "http://www.greatelmgroup.com",
        "market_cap": "Small Cap"
    },
    "GENH": {
        "short_name": "GENERATION HEMP INC",
        "long_name": "Generation Hemp, Inc.",
        "summary": "Generation Hemp Inc. engages in leasing industrial warehouse located in Denver, Colorado. The company was formerly known as Home Treasure Finders, Inc. and changed its name to Generation Hemp Inc. in August 2019. Generation Hemp Inc. was incorporated in 2008 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75209",
        "website": "http://www.genhempinc.com",
        "market_cap": "Small Cap"
    },
    "GENN": {
        "short_name": "Genesis Healthcare, Inc.",
        "long_name": "Genesis Healthcare, Inc.",
        "summary": "Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2020, it provided inpatient services through a network of approximately 341 skilled nursing facilities and assisted/senior living communities in 24 states; and supplied rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 42 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Kennett Square",
        "zipcode": "19348",
        "website": "http://www.genesishcc.com",
        "market_cap": "Small Cap"
    },
    "GERN": {
        "short_name": "Geron Corporation",
        "long_name": "Geron Corporation",
        "summary": "Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.geron.com",
        "market_cap": "Small Cap"
    },
    "GGBXF": {
        "short_name": "GREEN GROWTH BRANDS INC",
        "long_name": "Green Growth Brands Inc.",
        "summary": "Green Growth Brands Inc., together with its subsidiaries, engages in the cultivation, processing, production, distribution, and retailing of cannabis and cannabidiol (CBD)-infused consumer products in the United States. It provides medical and retail marijuana products to various dispensaries; and CBD-infused personal care and beauty products, such as therapeutic, face care, body care, shower and bathroom, and sleep products through shops, e-commerce, and wholesale channels. The company offers its products under the CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne brand names. The company was formerly known as Xanthic Biopharma Inc. and changed its name to Green Growth Brands Inc. in January 2019. Green Growth Brands Inc. was founded in 1968 and is based in Columbus, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Columbus",
        "zipcode": "43219",
        "website": "http://www.greengrowthbrands.com",
        "market_cap": "Small Cap"
    },
    "GH.MX": {
        "short_name": "GUARDANT HEALTH INC",
        "long_name": "Guardant Health, Inc.",
        "summary": "Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://guardanthealth.com",
        "market_cap": "Large Cap"
    },
    "GH": {
        "short_name": "Guardant Health, Inc.",
        "long_name": "Guardant Health, Inc.",
        "summary": "Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://guardanthealth.com",
        "market_cap": "Large Cap"
    },
    "GHDN.F": {
        "short_name": "BRAINSTORM C.NEW DL-,0001",
        "long_name": "Brainstorm Cell Therapeutics Inc.",
        "summary": "Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.brainstorm-cell.com",
        "market_cap": "Small Cap"
    },
    "GHSI": {
        "short_name": "Guardion Health Sciences, Inc.",
        "long_name": "Guardion Health Sciences, Inc.",
        "summary": "Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92128",
        "website": "http://www.guardionhealth.com",
        "market_cap": "Small Cap"
    },
    "GHST": {
        "short_name": "GHOST TECHNOLOGY INC",
        "long_name": "GHST World Inc.",
        "summary": "GHST World Inc. engages in the marketing and sale of technologically enhanced sports equipment. It also holds a portfolio of 119 art paintings and reproductions. In addition, the company focuses on the research and development of technology and products designed to connect households and other electronic devices using the Internet. The company is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10152",
        "website": "http://www.ghstinternational.com",
        "market_cap": "Small Cap"
    },
    "GILD.BA": {
        "short_name": "GILEAD SCIENCES",
        "long_name": "Gilead Sciences, Inc.",
        "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.gilead.com",
        "market_cap": "Large Cap"
    },
    "GILD.MI": {
        "short_name": "GILEAD SCIENCES",
        "long_name": "Gilead Sciences, Inc.",
        "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MIL",
        "market": "it_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.gilead.com",
        "market_cap": "Large Cap"
    },
    "GILD.MX": {
        "short_name": "GILEAD SCIENCES INC",
        "long_name": "Gilead Sciences, Inc.",
        "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.gilead.com",
        "market_cap": "Large Cap"
    },
    "GILD": {
        "short_name": "Gilead Sciences, Inc.",
        "long_name": "Gilead Sciences, Inc.",
        "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.gilead.com",
        "market_cap": "Large Cap"
    },
    "GILD.SN": {
        "short_name": "GILEAD SCIENCES",
        "long_name": "Gilead Sciences, Inc.",
        "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SGO",
        "market": "cl_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.gilead.com",
        "market_cap": "Large Cap"
    },
    "GILD.VI": {
        "short_name": "GILEAD SCIENCES INC",
        "long_name": "Gilead Sciences, Inc.",
        "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.gilead.com",
        "market_cap": "Large Cap"
    },
    "GILD34.SA": {
        "short_name": "GILEAD      DRN",
        "long_name": "Gilead Sciences, Inc.",
        "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.gilead.com",
        "market_cap": "Large Cap"
    },
    "GIS.DE": {
        "short_name": "GILEAD SCIENCES  DL-,001",
        "long_name": "Gilead Sciences, Inc.",
        "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.gilead.com",
        "market_cap": "Large Cap"
    },
    "GIS.F": {
        "short_name": "GILEAD SCIENCES  DL-,001",
        "long_name": "Gilead Sciences, Inc.",
        "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.gilead.com",
        "market_cap": "Large Cap"
    },
    "GKO.F": {
        "short_name": "GLYCOMIMETICS INC. DL-001",
        "long_name": "GlycoMimetics, Inc.",
        "summary": "GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://glycomimetics.com",
        "market_cap": "Small Cap"
    },
    "GKOS": {
        "short_name": "Glaukos Corporation",
        "long_name": "Glaukos Corporation",
        "summary": "Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Clemente",
        "zipcode": "92672",
        "website": "http://www.glaukos.com",
        "market_cap": "Mid Cap"
    },
    "GLPH": {
        "short_name": "GALA PHARMACEUTICAL INC",
        "long_name": "Gala Pharmaceutical, Inc.",
        "summary": "Gala Pharmaceutical, Inc. focuses on the research, development, and commercialization of products derived from the hemp and cannabis plant. The company also provides genetic fingerprinting and sequencing services for various crop species. In addition, it offers consulting services on testing and manufacturing lab designs and SOPs, as well as services to customers for building turnkey labs, drug formulations, and troubleshooting. The company was formerly known as Gala Global Inc. and changed its name to Gala Pharmaceutical, Inc. in January 2018. Gala Pharmaceutical, Inc. was founded in 2010 and is based in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92612",
        "website": "http://www.galapharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "GLSI": {
        "short_name": "Greenwich LifeSciences, Inc.",
        "long_name": "Greenwich LifeSciences, Inc.",
        "summary": "Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Stafford",
        "zipcode": "77477",
        "website": "http://greenwichlifesciences.com",
        "market_cap": "Small Cap"
    },
    "GLYC": {
        "short_name": "GlycoMimetics, Inc.",
        "long_name": "GlycoMimetics, Inc.",
        "summary": "GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://glycomimetics.com",
        "market_cap": "Small Cap"
    },
    "GM0N.F": {
        "short_name": "GLOBUS MED.A NEW DL -,001",
        "long_name": "Globus Medical, Inc.",
        "summary": "Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Its offers spine products, such as consists of traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products, comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue based products; and COALITION, COALITION MIS, COALITION AGX, MONUMENT, MAGNIFY-S, HEDRON IATM, HEDRON ICTM, INDEPENDENCE, INDEPENDENCE MIS, FORTIFY and XPAND families, SABLETM, RISE, RISE INTRALIF, RISE-L, ELSA, ELSA ATP, RASS, ALTERA, ARIEL, LATIS, CALIBER and CALIBER-L products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Audubon",
        "zipcode": "19403",
        "website": "http://www.globusmedical.com",
        "market_cap": "Mid Cap"
    },
    "GMED.MX": {
        "short_name": "GLOBUS MED INC",
        "long_name": "Globus Medical, Inc.",
        "summary": "Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Its offers spine products, such as consists of traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products, comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue based products; and COALITION, COALITION MIS, COALITION AGX, MONUMENT, MAGNIFY-S, HEDRON IATM, HEDRON ICTM, INDEPENDENCE, INDEPENDENCE MIS, FORTIFY and XPAND families, SABLETM, RISE, RISE INTRALIF, RISE-L, ELSA, ELSA ATP, RASS, ALTERA, ARIEL, LATIS, CALIBER and CALIBER-L products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "PA",
        "city": "Audubon",
        "zipcode": "19403",
        "website": "http://www.globusmedical.com",
        "market_cap": "Mid Cap"
    },
    "GMED": {
        "short_name": "Globus Medical, Inc.",
        "long_name": "Globus Medical, Inc.",
        "summary": "Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Its offers spine products, such as consists of traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products, comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue based products; and COALITION, COALITION MIS, COALITION AGX, MONUMENT, MAGNIFY-S, HEDRON IATM, HEDRON ICTM, INDEPENDENCE, INDEPENDENCE MIS, FORTIFY and XPAND families, SABLETM, RISE, RISE INTRALIF, RISE-L, ELSA, ELSA ATP, RASS, ALTERA, ARIEL, LATIS, CALIBER and CALIBER-L products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Audubon",
        "zipcode": "19403",
        "website": "http://www.globusmedical.com",
        "market_cap": "Mid Cap"
    },
    "GMTX": {
        "short_name": "Gemini Therapeutics, Inc.",
        "long_name": "Gemini Therapeutics, Inc.",
        "summary": "Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.geminitherapeutics.com",
        "market_cap": "Small Cap"
    },
    "GMVP": {
        "short_name": "GRIDIRON BIONUTRIENTS INC",
        "long_name": "Gridiron BioNutrients, Inc.",
        "summary": "Gridiron BioNutrients, Inc. develops, markets, and sells cannabidiol products. The company offers capsules, oil, gummies, concentrates, water, beverages, hemp tinctures, and salves. It sells its products under the Gridiron BioNutrients and Gridiron MVP names through an online platform. Gridiron BioNutrients, Inc. was founded in 2017 and is based in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85251",
        "website": "http://gridironmvp.com",
        "market_cap": "Small Cap"
    },
    "GNBT": {
        "short_name": "GENEREX BIOTECHNOLOGY CORP",
        "long_name": "Generex Biotechnology Corporation",
        "summary": "Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miramar",
        "zipcode": "33025",
        "website": "http://generex.com/index.html",
        "market_cap": "Small Cap"
    },
    "GNCA": {
        "short_name": "Genocea Biosciences, Inc.",
        "long_name": "Genocea Biosciences, Inc.",
        "summary": "Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02140",
        "website": "http://www.genocea.com",
        "market_cap": "Small Cap"
    },
    "GNF.F": {
        "short_name": "GENMARK DIAGNOST.DL-,0001",
        "long_name": "GenMark Diagnostics, Inc.",
        "summary": "GenMark Diagnostics, Inc. designs and manufactures multiplex molecular diagnostic solutions to enhance patient care, improve quality metrics, and reduce the total cost-of-care for laboratory professionals, healthcare providers, and customers in the United States and internationally. It offers ePlex systems to streamline the diagnostic workflow from physician order entry to the release of the final report, automate and accelerate order entry and results reporting, notify practitioners that test results are available, enable operation on every shift, minimize system downtime and ensure patients and physicians have access to rapid test results, and reduce avoidable medical errors; ePlex software to support the needs of laboratory and healthcare systems, streamline tasks across the diagnostic process from order-to-report, improve productivity at every level, improve order-to-report turnaround time, reduce labor costs, and eliminate potential transcription errors with bi-directional LIS capabilities; XT-8 systems for processing multiple tests; ePlex panels that include respiratory pathogen and blood culture identification (BCID) Panels to identify the viral and bacterial organisms associated with upper respiratory infection, provide broad coverage of organisms that can lead to sepsis along with the resistance genes, and aid clinicians in the identification of bacterial and fungal organisms; and XT-8 panels to provide sensitive and specific respiratory virus detection with an optimized workflow to maximize laboratory efficiency. The company serves customers through distributors. GenMark Diagnostics, Inc. was formerly known as Osmetech plc and changed its name to GenMark Diagnostics, Inc. in June 2010. The company was incorporated in 2010 and is based in Carlsbad, California. As of April 21, 2021, GenMark Diagnostics, Inc. operates as a subsidiary of Roche Holding AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008-8829",
        "website": "http://www.genmarkdx.com",
        "market_cap": "Small Cap"
    },
    "GNLKQ": {
        "short_name": "GENELINK INC",
        "long_name": "GeneLink, Inc.",
        "summary": "GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Orlando",
        "zipcode": "32809",
        "website": "http://www.genelinkbio.com",
        "market_cap": "Small Cap"
    },
    "GNLN": {
        "short_name": "Greenlane Holdings, Inc.",
        "long_name": "Greenlane Holdings, Inc.",
        "summary": "Greenlane Holdings, Inc. sells cannabis accessories, child-resistant packaging, and specialty vaporization products in the United States, Canada, Europe, Australia, and South America. The company provides vaporizers, liquid nicotine, storage solutions, pipes, apparel lines, and consumption accessories, as well as bubblers, rigs, and other smoking and vaporization related accessories and merchandise. It offers its products under the VIBES rolling papers, Pollen Gear, the Marley Natural accessory line, Aerospaced & Groove grinders, K. Haring Glass Collections, Eyce specialty silicone smoking products, and Higher Standards brands. The company also operates e-commerce websites, such as Vapor.com, Higherstandards.com, Aerospaced.com, Canada.vapor.com, Vaposhop.com, and others. It serves smoke shops, dispensaries, and specialty retail stores. The company was founded in 2005 and is headquartered in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33487",
        "website": "http://www.gnln.com",
        "market_cap": "Small Cap"
    },
    "GNOW": {
        "short_name": "AMERICAN CARESOURC",
        "long_name": "American Caresource Holdings, Inc.",
        "summary": "American CareSource Holdings, Inc. provides urgent and primary care services in the United States. The company operates healthcare centers that offer non-life-threatening out-patient medical care for the treatment of acute, episodic, and chronic medical conditions. Its healthcare centers provide treatment of general medical problems, including colds, flus, ear infections, hypertension, asthma, pneumonia, urinary tract infections, and other conditions; treatment of injuries, such as fractures, dislocations, sprains, bruises, and cuts; minor non-emergent surgical procedures; diagnostic tests, such as X-rays, electrocardiograms, complete blood counts, and urinalyses; and occupational and industrial medical services, including drug testing, workers' compensation cases, and pre-employment physical examinations. It owns and operates 13 urgent and primary care centers, including 2 in Georgia, 2 in Florida, 3 in Alabama, 4 in North Carolina, and 2 in Virginia. The company was founded in 1995 and is headquartered in Atlanta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Atlanta",
        "zipcode": "30308",
        "website": "http://www.americancaresource.com",
        "market_cap": "Small Cap"
    },
    "GNPX": {
        "short_name": "Genprex, Inc.",
        "long_name": "Genprex, Inc.",
        "summary": "Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78712-1885",
        "website": "http://www.genprex.com",
        "market_cap": "Small Cap"
    },
    "GON.F": {
        "short_name": "GERON CORP. (DEL.) DL-001",
        "long_name": "Geron Corporation",
        "summary": "Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.geron.com",
        "market_cap": "Small Cap"
    },
    "GOSS": {
        "short_name": "Gossamer Bio, Inc.",
        "long_name": "Gossamer Bio, Inc.",
        "summary": "Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.gossamerbio.com",
        "market_cap": "Small Cap"
    },
    "GOV.F": {
        "short_name": "INSULET CORP.  DL -,001",
        "long_name": "Insulet Corporation",
        "summary": "Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Acton",
        "zipcode": "01720",
        "website": "http://www.insulet.com",
        "market_cap": "Large Cap"
    },
    "GOVX": {
        "short_name": "GeoVax Labs, Inc.",
        "long_name": "GeoVax Labs, Inc.",
        "summary": "GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Smyrna",
        "zipcode": "30080",
        "website": "http://www.geovax.com",
        "market_cap": "Small Cap"
    },
    "GPFT": {
        "short_name": "GRAPEFRUIT USA INC",
        "long_name": "Grapefruit USA, Inc.",
        "summary": "Grapefruit USA, Inc. focuses on manufacturing and distribution of cannabis distillates, edibles, and cannabis products. It also offers cannabis advisory services for branding, compliance, packaging, extraction, edible manufacturing, and distribution logistics efforts. The company was formerly known as Grapefruit Boulevard Investments, Inc. and changed its name to Grapefruit USA, Inc. in January 2020. Grapefruit USA, Inc. was founded in 2017 and is based in Wilmington, Delaware.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "DE",
        "city": "Wilmington",
        "zipcode": "19801",
        "website": "http://www.grapefruitblvd.com",
        "market_cap": "Small Cap"
    },
    "GRAM-U.NE": {
        "short_name": "TPCO (THE PARENT COMPANY) HOLDI",
        "long_name": "TPCO Holding Corp.",
        "summary": "TPCO Holding Corp., cultivates, manufactures, distributes, and retails cannabis in California. The company offers approximately 17 owned and licensed brands offering 250 SKUs across various factors, such as whole flower, pre-rolls, infused pre-rolls, vaporizer cartridges, concentrates, gummies, chocolate, beverages, capsules, tinctures, lozenges, topicals, and body care products. It also offers its products through Caliva.com, a direct-to-consumer e-commerce platform. The company was formerly known as Subversive Capital Acquisition Corp. and changed its name to TPCO Holding Corp. in January 2021. TPCO Holding Corp. was incorporated in 2019 and is based in San Jose, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NEO",
        "market": "ca_market",
        "country": "United States",
        "state": "CA",
        "city": "San Jose",
        "zipcode": "95125",
        "website": "http://www.theparent.co",
        "market_cap": null
    },
    "GRAMF": {
        "short_name": "TPCO HOLDING CORP",
        "long_name": "TPCO Holding Corp.",
        "summary": "TPCO Holding Corp., cultivates, manufactures, distributes, and retails cannabis in California. The company offers approximately 17 owned and licensed brands offering 250 SKUs across various factors, such as whole flower, pre-rolls, infused pre-rolls, vaporizer cartridges, concentrates, gummies, chocolate, beverages, capsules, tinctures, lozenges, topicals, and body care products. It also offers its products through Caliva.com, a direct-to-consumer e-commerce platform. The company was formerly known as Subversive Capital Acquisition Corp. and changed its name to TPCO Holding Corp. in January 2021. TPCO Holding Corp. was incorporated in 2019 and is based in San Jose, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Jose",
        "zipcode": "95125",
        "website": "http://www.theparent.co",
        "market_cap": null
    },
    "GRAY": {
        "short_name": "Graybug Vision, Inc.",
        "long_name": "Graybug Vision, Inc.",
        "summary": "Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://www.graybug.vision",
        "market_cap": "Small Cap"
    },
    "GRCU": {
        "short_name": "GREEN CURES & BOTANICAL DIST IN",
        "long_name": "Green Cures & Botanical Distribution Inc.",
        "summary": "Green Cures & Botanical Distribution Inc. operates various services and products in the medical marijuana and botanical industry. It focuses on the production, distribution, and management of cannabis-derived products. The company's products comprise nutritional supplements, vitamins, minerals, herbs/botanicals, sports nutrition, and specialty products. It also provides online community portals that supply public with information and resources regarding the benefits of cannabis-derived products. Green Cures & Botanical Distribution Inc. is based in Inglewood, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Inglewood",
        "zipcode": "90304",
        "website": "http://greencurescorp.com",
        "market_cap": "Small Cap"
    },
    "GRLB": {
        "short_name": "GL BRANDS INC",
        "long_name": "GL Brands, Inc.",
        "summary": "GL Brands, Inc., a hemp consumer packaged goods company, engages in the development and commercialization of cannabinoid-rich products for health and well-being in the United States, Mexico, and internationally. The company offers various cannabinoid products made from organic industrial hemp, including tinctures, gel caps, edibles, topicals, vape cartridges, capsules, and beverages under the Green Lotus and IrieCBD brand names. It markets products through direct-to-store sales and direct-to-consumer models, as well as through distribution partnerships. The company was formerly known as Freedom Leaf, Inc. and changed its name to GL Brands, Inc. in November 2019. GL Brands, Inc. was incorporated in 2013 and is headquartered in Addison, Texas. On December 17, 2020, GL Brands, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Addison",
        "zipcode": "75001",
        "website": "http://www.glbrands.com",
        "market_cap": "Small Cap"
    },
    "GRPS": {
        "short_name": "GOLD RIVER PRODUCTIONS INC",
        "long_name": "Gold River Productions, Inc.",
        "summary": "Gold River Productions, Inc. manufactures and sells plastic composite products in the United States. Its products are used in commercial and recreational vehicle, housing and construction, marine, and other industries. The company is based in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84121",
        "website": null,
        "market_cap": "Small Cap"
    },
    "GRST": {
        "short_name": "ETHEMA HEALTH CORPORATION",
        "long_name": "Ethema Health Corporation",
        "summary": "Ethema Health Corporation, together with its subsidiaries, operates substance abuse treatment center. The company operates through two segments, Rental Operations and In-Patient Services. It also operates Addiction Recovery Institute of America in West Palm Beach, Florida. The company was formerly known as GreeneStone Healthcare Corporation and changed its name to Ethema Health Corporation in April 2017. Ethema Health Corporation is based in West Palm Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "West Palm Beach",
        "zipcode": "33406",
        "website": "http://ethemahealth.com",
        "market_cap": "Small Cap"
    },
    "GRTS": {
        "short_name": "Gritstone Oncology, Inc.",
        "long_name": "Gritstone bio, Inc.",
        "summary": "Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://gritstonebio.com",
        "market_cap": "Small Cap"
    },
    "GRTX": {
        "short_name": "Galera Therapeutics, Inc.",
        "long_name": "Galera Therapeutics, Inc.",
        "summary": "Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.galeratx.com",
        "market_cap": "Small Cap"
    },
    "GRYN": {
        "short_name": "GREEN HYGIENICS HLDGS INC",
        "long_name": "Green Hygienics Holdings Inc.",
        "summary": "Green Hygienics Holdings, Inc., a development stage company, intends to cultivate and process industrial hemp for extracting cannabidiol. The company was formerly known as Takedown Entertainment Inc. and changed its name to Green Hygienics Holdings Inc. in July 2012. Green Hygienics Holdings Inc. was founded in 2008 and is based in Poway, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Poway",
        "zipcode": "92064",
        "website": "http://www.greenhygienics.com",
        "market_cap": "Small Cap"
    },
    "GS3.F": {
        "short_name": "CBD GLOBAL SCIENCES INC.",
        "long_name": "CBD Global Sciences Inc.",
        "summary": "CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business. It offers provides biomass, CBD oil, and CBD oil products under the Aethics, CannaOil, and Strasburg Pharms brand names. The company was incorporated in 2018 and is headquartered in Lakewood, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Lakewood",
        "zipcode": "80228",
        "website": "http://www.cbdglobalsciences.com",
        "market_cap": "Small Cap"
    },
    "GSAC": {
        "short_name": "GELSTAT CORPORATION",
        "long_name": "GelStat Corp.",
        "summary": "GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation is headquartered in Palm City, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Palm City",
        "zipcode": "34990",
        "website": "http://www.gelstat.com",
        "market_cap": "Small Cap"
    },
    "GSRX": {
        "short_name": "GSRX INDUSTRIES INC",
        "long_name": "GSRX Industries Inc.",
        "summary": "GSRX Industries Inc., through its subsidiaries, engages in acquiring, developing, and operating retail cannabis dispensaries. It operates five cannabis dispensaries under the Green Spirit RX name in Puerto Rico; and a dispensary under The Green Room name in California. The company also owns and operates GetPureAndNatural.com, an e-commerce site that offers a range of hemp extract products. In addition, it focuses on the extraction, manufacture, distribution, and delivery of cannabis and cannabinoid products. The company was formerly known as Green Spirit Industries Inc. and changed its name to GSRX Industries Inc. in July 2018. GSRX Industries Inc. is headquartered in Dorado, Puerto Rico.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PR",
        "city": "Dorado",
        "zipcode": "00646",
        "website": "http://www.gsrxindustries.com",
        "market_cap": "Small Cap"
    },
    "GTBIF": {
        "short_name": "GREEN THUMB INDUSTRIES INC",
        "long_name": "Green Thumb Industries Inc.",
        "summary": "Green Thumb Industries Inc. manufactures, distributes, and sells various cannabis products for medical and adult-use in the United States. It offers cannabis flower; and processed and packaged products, including concentrates, edibles, and topical and other cannabis products under the Rythm, Dogwalkers, The Feel Collection, incredibles, Dr. Solomon's, Beboe, and other brands. The company distributes its products primarily to third-party retail stores, as well as sells finished products directly to consumers in its own retail stores. As of March 25, 2021, it owned and operated 55 retail stores in the United States. The company was founded in 2014 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.gtigrows.com",
        "market_cap": "Mid Cap"
    },
    "GTBP": {
        "short_name": "GT Biopharma, Inc.",
        "long_name": "GT Biopharma, Inc.",
        "summary": "GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Beverly Hills",
        "zipcode": "90212",
        "website": "http://www.gtbiopharma.com",
        "market_cap": "Small Cap"
    },
    "GTHP": {
        "short_name": "GUIDED THERAPEUTICS INC",
        "long_name": "Guided Therapeutics, Inc.",
        "summary": "Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Norcross",
        "zipcode": "30092",
        "website": "http://www.guidedinc.com",
        "market_cap": "Small Cap"
    },
    "GTHR": {
        "short_name": "GENETHERA INC",
        "long_name": "GeneThera, Inc.",
        "summary": "GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatment for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avian paratuberculosis infection. The company is based in Westminster, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Westminster",
        "zipcode": "80035",
        "website": "http://www.genethera.net",
        "market_cap": "Small Cap"
    },
    "GTHX": {
        "short_name": "G1 Therapeutics, Inc.",
        "long_name": "G1 Therapeutics, Inc.",
        "summary": "G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Research Triangle Park",
        "zipcode": "27709",
        "website": "http://www.g1therapeutics.com",
        "market_cap": "Small Cap"
    },
    "GTII.CN": {
        "short_name": "GreenThumb",
        "long_name": "Green Thumb Industries Inc.",
        "summary": "Green Thumb Industries Inc. manufactures, distributes, and sells various cannabis products for medical and adult-use in the United States. It offers cannabis flower; and processed and packaged products, including concentrates, edibles, and topical and other cannabis products under the Rythm, Dogwalkers, The Feel Collection, incredibles, Dr. Solomon's, Beboe, and other brands. The company distributes its products primarily to third-party retail stores, as well as sells finished products directly to consumers in its own retail stores. As of March 25, 2021, it owned and operated 55 retail stores in the United States. The company was founded in 2014 and is headquartered in Chicago, Illinois.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.gtigrows.com",
        "market_cap": "Mid Cap"
    },
    "GTS": {
        "short_name": "Triple-S Management Corporation",
        "long_name": "Triple-S Management Corporation",
        "summary": "Triple-S Management Corporation, through its subsidiaries, provides a portfolio of managed care and related products in the commercial, Medicare Advantage, and Medicaid markets. It operates through three segments: Managed Care, Life Insurance, and Property and Casualty Insurance. The company offers various managed care products, including health maintenance organization plans; preferred provider organization plans; BlueCard program; Medicare Supplement products; Medicare Advantage products; Medicaid plans; and claims processing and other administrative services to employers, individuals, and government entities. It also provides various life, accident, disability, and health insurance products, as well as annuity products primarily to individuals; and property and casualty insurance products comprising commercial multi-peril package, personal package, commercial auto, hospital malpractice, commercial liability, and commercial property primarily for small-to medium-size accounts. The company markets and distributes its products through a network of internal sales force, direct mail, independent brokers and agents, telemarketing staff, traditional media, and digital media. It holds rights to the Blue Cross and Blue Shield name and marks throughout Puerto Rico, the United States Virgin Islands, Costa Rica, the British Virgin Islands, and Anguilla. The company was founded in 1959 and is headquartered in San Juan, Puerto Rico.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "PR",
        "city": "San Juan",
        "zipcode": "00920",
        "website": "http://management.grupotriples.com",
        "market_cap": "Small Cap"
    },
    "GTU2.F": {
        "short_name": "ONCTERNAL THERAP.  DL-,01",
        "long_name": "Oncternal Therapeutics, Inc.",
        "summary": "Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. The company is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.oncternal.com",
        "market_cap": "Small Cap"
    },
    "GVDI": {
        "short_name": "GOLDEN VALLEY DEVELOPMENT INC",
        "long_name": "Golden Valley Development, Inc",
        "summary": "Golden Valley Development, Inc, through its subsidiaries, manufactures and markets patented products in the health care and home consumer markets sectors. Its products include Percuguard and Cutstop used as finger guards which protect finger and thumbs from accidental cuts from knives and other sharp implements. The company is also engaged in the media consultancy practice wherein entertainment and sports industry companies, investors, personalities, and other figures are identified and brought to participate in joint venture marketing and entertainment projects being developed. Golden Valley Development, Inc was founded in 2004 and is based in Clearwater, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Clearwater",
        "zipcode": "33756",
        "website": null,
        "market_cap": "Small Cap"
    },
    "GWHP": {
        "short_name": "GLOBAL WHOLEHEALTH PARTNERS COR",
        "long_name": "Global WholeHealth Partners Corporation",
        "summary": "Global WholeHealth Partners Corporation manufactures and markets various in vitro diagnostic test kits in the United States. It offers rapid diagnostic tests, such as the CoVid-19 test, whole blood Ebola test, whole blood Zika test, whole blood rapid TB test, and various other tests for over-the-counter or consumer-use, as well as point-of-care, which includes hospitals, physicians' offices, and medical clinics. The company was incorporated in 2013 and is based in San Clemente, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Clemente",
        "zipcode": "92673",
        "website": "http://gwhpcorp.com",
        "market_cap": "Small Cap"
    },
    "GX1N.F": {
        "short_name": "MARKER THERAPEUT.  DL-,01",
        "long_name": "Marker Therapeutics, Inc.",
        "summary": "Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77027",
        "website": "http://www.markertherapeutics.com",
        "market_cap": "Small Cap"
    },
    "H1CA34.SA": {
        "short_name": "HCA HEALTHCADRN",
        "long_name": "HCA Healthcare, Inc.",
        "summary": "HCA Healthcare, Inc., through its subsidiaries, operates as a health care services company in the United States. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, and adolescent and adult alcohol and drug abuse treatment and counseling. In addition, the company operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. As of December 31, 2020, it operated 185 hospitals, which included 178 general, acute care hospitals, as well as five psychiatric hospitals and two rehabilitation hospitals; 121 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37203",
        "website": "http://www.hcahealthcare.com",
        "market_cap": "Large Cap"
    },
    "H1OL34.SA": {
        "short_name": "HOLOGIC INC DRN",
        "long_name": "Hologic, Inc.",
        "summary": "Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Marlborough",
        "zipcode": "01752",
        "website": "http://www.hologic.com",
        "market_cap": "Large Cap"
    },
    "H1SI34.SA": {
        "short_name": "HENRY SCHEINDRN",
        "long_name": "Henry Schein, Inc.",
        "summary": "Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates in two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NY",
        "city": "Melville",
        "zipcode": "11747",
        "website": "http://www.henryschein.com",
        "market_cap": "Large Cap"
    },
    "H1UM34.SA": {
        "short_name": "HUMANA INC  DRN",
        "long_name": "Humana Inc.",
        "summary": "Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "KY",
        "city": "Louisville",
        "zipcode": "40202",
        "website": "http://www.humana.com",
        "market_cap": "Large Cap"
    },
    "H3AA.SG": {
        "short_name": "Biostage Inc. Registered Shares",
        "long_name": "Biostage, Inc.",
        "summary": "Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Holliston",
        "zipcode": "01746",
        "website": "http://biostage.com",
        "market_cap": "Small Cap"
    },
    "H3D.F": {
        "short_name": "SONNET BIOTH.H.I.DL-,0001",
        "long_name": "Sonnet BioTherapeutics Holdings, Inc.",
        "summary": "Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.sonnetbio.com",
        "market_cap": "Small Cap"
    },
    "HADV": {
        "short_name": "HEALTH ADVANCE INC",
        "long_name": "Health Advance Inc.",
        "summary": "Health Advance Inc., a development stage company, operates as an on-line retailer of home medical products in Canada and the United States. It intends to offers aids to daily living, ambulatory, bath safety, core wound care, diabetic, enteral nutrition-feeding, home diagnostics, incontinence, orthopedic, ostomy, pain management, professional use and diagnostic, respiratory, tracheostomy care, specialty wound care, and women-infant products. The company's product portfolio would also include bed accessories, catheters, diagnostic equipment, lift chairs/geri chairs, IV supplies, needles/syringes, patient lifts and acc, personal protection products/gloves, scooters and accessories, seating/cushions, specialty medical equipment and accessories, urological/collection devices, wheelchairs accessories. It focuses on operating leadingmedicalproducts.com, an e-commerce site for the retail community and health care community. The company intends to serve health care professionals, medical distributors, and consumers. Health Advance Inc. was founded in 2010 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89103",
        "website": "http://www.healthadvanceinc.com",
        "market_cap": "Small Cap"
    },
    "HAE": {
        "short_name": "Haemonetics Corporation",
        "long_name": "Haemonetics Corporation",
        "summary": "Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02110",
        "website": "http://www.haemonetics.com",
        "market_cap": "Mid Cap"
    },
    "HALB": {
        "short_name": "HALBERD CORP",
        "long_name": "Halberd Corporation",
        "summary": "Halberd Corporation researches and develops antibodies and devices for the prevention, detection, and treatment of Covid-19 through laboratory, hospital, and clinical trials. It offers patented extracorporeal treatment that is applicable to various blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Jackson Center",
        "zipcode": "16133",
        "website": "http://www.halberdcorporation.com",
        "market_cap": "Small Cap"
    },
    "HALO": {
        "short_name": "Halozyme Therapeutics, Inc.",
        "long_name": "Halozyme Therapeutics, Inc.",
        "summary": "Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.halozyme.com",
        "market_cap": "Mid Cap"
    },
    "HARP": {
        "short_name": "Harpoon Therapeutics, Inc.",
        "long_name": "Harpoon Therapeutics, Inc.",
        "summary": "Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.harpoontx.com",
        "market_cap": "Small Cap"
    },
    "HARV.CN": {
        "short_name": "HarvestHealth",
        "long_name": "Harvest Health & Recreation Inc.",
        "summary": "Harvest Health and Recreation, Inc., together with its subsidiaries, cultivates, processes, sells, and retails inhalable, ingestible, and topical cannabis products in the United States. The company offers cannabis oil products; inhalables, including flower, dabbable concentrates, pre-filled vaporizer pens, and cartridges; and capsules, tinctures, and cannabis product edibles, including chocolates, gummies, mints, fruit chews, and dissolvable mouth strips under the Avenue, CBX SCIENCES, EVOLAB, ALCHEMY, CHROMA, CO2LORS, GOODSUN, MODERN FLOWER, and ROLL ONE brand names. It also operates retail dispensaries that sell proprietary and third-party cannabis products to patients and customers; and provides support services and financing to a Utah licensed medical cannabis cultivator. Harvest Health and Recreation, Inc. was founded in 2011 and is headquartered in Tempe, Arizona.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85281",
        "website": "http://www.harvesthoc.com",
        "market_cap": "Small Cap"
    },
    "HAZ.F": {
        "short_name": "HAEMONETICS CORP.  DL-,01",
        "long_name": "Haemonetics Corporation",
        "summary": "Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02110",
        "website": "http://www.haemonetics.com",
        "market_cap": "Mid Cap"
    },
    "HB9.F": {
        "short_name": "HILL-ROM HOLDINGS INC.",
        "long_name": "Hill-Rom Holdings, Inc.",
        "summary": "Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, patient mobility solutions, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising non-invasive devices that provide respiratory support and assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include tables, lights, and pendants; and positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. It sells and rents products to acute and extended care facilities through direct sales force and distributors; sells and rents products directly to patients in the home; and sells products to primary care facilities through distributors. Hill-Rom Holdings, Inc. was founded in 1915 and is headquartered in Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60601",
        "website": "http://www.hillrom.com",
        "market_cap": "Mid Cap"
    },
    "HBI.F": {
        "short_name": "HARVARD BIOSCIENCE DL-,01",
        "long_name": "Harvard Bioscience, Inc.",
        "summary": "Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Holliston",
        "zipcode": "01746",
        "website": "http://www.harvardbioscience.com",
        "market_cap": "Small Cap"
    },
    "HBIO": {
        "short_name": "Harvard Bioscience, Inc.",
        "long_name": "Harvard Bioscience, Inc.",
        "summary": "Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Holliston",
        "zipcode": "01746",
        "website": "http://www.harvardbioscience.com",
        "market_cap": "Small Cap"
    },
    "HBOR.CN": {
        "short_name": "Harborside",
        "long_name": "Harborside Inc.",
        "summary": "Harborside Inc. cultivates, manufactures, distributes, and sells cannabis and cannabis products. The company owns and operates three retail dispensaries in California and Oregon; and a dispensary under a management services agreement. It also operates a 47 acres of cultivation facility located in Salinas, California. The company sells its products under the Harborside, Harborside Farms, Harborside Farms Reserve, and KEY brands. The company was founded in 2006 and is headquartered in Oakland, California.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "CA",
        "city": "Oakland",
        "zipcode": "94606",
        "website": "http://www.investharborside.com",
        "market_cap": "Small Cap"
    },
    "HBORF": {
        "short_name": "HARBORSIDE INC",
        "long_name": "Harborside Inc.",
        "summary": "Harborside Inc. cultivates, manufactures, distributes, and sells cannabis and cannabis products. The company owns and operates three retail dispensaries in California and Oregon; and a dispensary under a management services agreement. It also operates a 47 acres of cultivation facility located in Salinas, California. The company sells its products under the Harborside, Harborside Farms, Harborside Farms Reserve, and KEY brands. The company was founded in 2006 and is headquartered in Oakland, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Oakland",
        "zipcode": "94606",
        "website": "http://www.investharborside.com",
        "market_cap": "Small Cap"
    },
    "HBRM": {
        "short_name": "HERBORIUM GROUP INC",
        "long_name": "Herborium Group, Inc.",
        "summary": "Herborium Group, Inc., a botanical therapeutics company, develops, licenses, and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. It offers dermatology products, which include AcnEase, herbal medicinal product for enhancing conditions associated with hormonal acne and multiple symptoms of Rosacea; and AcnEase Skin Management System for the treatment of acne marks/scars. The company also provides sexual health and performance products that are non-prescriptive alternatives to selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, and surgical procedures, including hysterectomy. In addition, it offers energy restoration products, such as Lasting Energy, a herbal supplement to decrease the symptoms associated with hangovers and eliminating jet-lag; and for treating overall depletion of energy due to competitive sports, high levels of stress, and extensive sexual activities, as well as other long term or temporary physical demands. Further, the company provides Liver Activator Series for the treatment of liver damage; ProstAid, a natural product focuses on Benign Prostate Hyperplasia; and CardioVitae, a fermentation based product using a Lucidium derived cell line targeting cardio-pulmonary insufficiencies. Herborium Group, Inc. sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. The company was founded in 2000 and is headquartered in Fort Lee, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Fort Lee",
        "zipcode": "07024",
        "website": "http://www.herborium.com",
        "market_cap": "Small Cap"
    },
    "HCA.MX": {
        "short_name": "HCA HEALTHCARE INC",
        "long_name": "HCA Healthcare, Inc.",
        "summary": "HCA Healthcare, Inc., through its subsidiaries, operates as a health care services company in the United States. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, and adolescent and adult alcohol and drug abuse treatment and counseling. In addition, the company operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. As of December 31, 2020, it operated 185 hospitals, which included 178 general, acute care hospitals, as well as five psychiatric hospitals and two rehabilitation hospitals; 121 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37203",
        "website": "http://www.hcahealthcare.com",
        "market_cap": "Large Cap"
    },
    "HCA": {
        "short_name": "HCA Healthcare, Inc.",
        "long_name": "HCA Healthcare, Inc.",
        "summary": "HCA Healthcare, Inc., through its subsidiaries, operates as a health care services company in the United States. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, and adolescent and adult alcohol and drug abuse treatment and counseling. In addition, the company operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. As of December 31, 2020, it operated 185 hospitals, which included 178 general, acute care hospitals, as well as five psychiatric hospitals and two rehabilitation hospitals; 121 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37203",
        "website": "http://www.hcahealthcare.com",
        "market_cap": "Large Cap"
    },
    "HCAT": {
        "short_name": "Health Catalyst, Inc",
        "long_name": "Health Catalyst, Inc.",
        "summary": "Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. The company was founded in 2008 and is headquartered in South Jordan, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "South Jordan",
        "zipcode": "84095",
        "website": "http://www.healthcatalyst.com",
        "market_cap": "Mid Cap"
    },
    "HCLC": {
        "short_name": "HEALTH-CHEM CORP",
        "long_name": "Health-Chem Corporation",
        "summary": "Health-Chem Corporation, through its subsidiary, Transderm Laboratories Corporation, engages in the research, development, manufacture, and marketing of transdermal drug delivery systems in the United States. It offers transdermal nitroglycerin patches used for transdermal relief of the vascular and cardiovascular symptoms related to angina pectoris (chest pain). The company also conducts research and development activities for third parties on a contract basis. Health-Chem Corporation markets its products directly to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations, as well as indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit management companies. The company was founded in 1970 and is based in Emigsville, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Emigsville",
        "zipcode": "17318",
        "website": null,
        "market_cap": "Small Cap"
    },
    "HCQ.F": {
        "short_name": "AMN HEALTHCARE SVS DL-,01",
        "long_name": "AMN Healthcare Services, Inc.",
        "summary": "AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to hospitals and healthcare facilities in the United States. The company operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. It offers travel nurse staffing under the American Mobile, Onward Healthcare, and O'Grady Peyton brands; rapid response nurse staffing and labor disruption services under the NurseChoice and HealthSource Global Staffing brands; local or per diem staffing services under Nursefinders brand; and locum tenens staffing services under the Staff Care and Locum Leaders brands. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists under the Med Travelers and Club Staffing brands; revenue cycle solutions; physician permanent placement services to hospitals, healthcare facilities, and physician practice groups; interim leadership staffing and executive search services; and recruitment process outsourcing services. In addition, it offers managed services programs; language interpretation services; vendor management systems; workforce optimization services; credentialing services; digital staffing services; and flex pool management services. AMN Healthcare Services, Inc. was founded in 1985 and is based in Dallas, Taxas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75019",
        "website": "http://www.amnhealthcare.com",
        "market_cap": "Mid Cap"
    },
    "HCSG": {
        "short_name": "Healthcare Services Group, Inc.",
        "long_name": "Healthcare Services Group, Inc.",
        "summary": "Healthcare Services Group, Inc. provides management, administrative, and operating services to the housekeeping, laundry, linen, facility maintenance, and dietary service departments of nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States. It operates through two segments, Housekeeping and Dietary. The Housekeeping segment engages in the cleaning, disinfecting, and sanitizing of resident rooms and common areas of client's facility, as well as laundering and processing of the bed linens, uniforms, resident personal clothing, and other assorted linen items utilized at a client's facility. The Dietary segment provides food purchasing, meal preparation, and professional dietitian services, which include the development of menus that meet the dietary needs of residents. This segment also offers clinical consulting services to facilities. As of December 31, 2020, the company provided its services to approximately 3,000 facilities. Healthcare Services Group, Inc. was incorporated in 1976 and is based in Bensalem, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Bensalem",
        "zipcode": "19020",
        "website": "http://www.hcsgcorp.com",
        "market_cap": "Mid Cap"
    },
    "HCYT": {
        "short_name": "H CYTE INC",
        "long_name": "H-CYTE, Inc.",
        "summary": "H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute biologics for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33602",
        "website": "http://www.hcyte.com",
        "market_cap": "Small Cap"
    },
    "HDP1.F": {
        "short_name": "ARROWHEAD PHARMAC. DL-,01",
        "long_name": "Arrowhead Pharmaceuticals, Inc.",
        "summary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Pasadena",
        "zipcode": "91105",
        "website": "http://arrowheadpharma.com",
        "market_cap": "Mid Cap"
    },
    "HDVY": {
        "short_name": "HEALTH DISCOVERY CORPORATION",
        "long_name": "Health Discovery Corporation",
        "summary": "Health Discovery Corporation operates as a pattern recognition company that uses mathematical techniques to analyze data to uncover patterns primarily in the field of molecular diagnostics in the United States. Its intellectual property includes Support Vector Machines (SVM), which are mathematical algorithms; and biomarkers that are biological indicators or genetic expression signatures of certain disease states, as well as Fractal Genomic Modeling technology. The company was incorporated in 2001 and is based in Atlanta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Atlanta",
        "zipcode": "30319",
        "website": "http://www.healthdiscoverycorp.com",
        "market_cap": "Small Cap"
    },
    "HE6.F": {
        "short_name": "OAK STR.HEALTH  DL-,001",
        "long_name": "Oak Street Health, Inc.",
        "summary": "Oak Street Health, Inc., together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2020, it operated 79 centers in Illinois, Indiana, Michigan, Mississippi, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, and Texas. The company was founded in 2012 and is headquartered in Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60603",
        "website": "http://www.oakstreethealth.com",
        "market_cap": "Large Cap"
    },
    "HEME": {
        "short_name": "HEALTHMED SERVICES LTD",
        "long_name": "Healthmed Services Ltd.",
        "summary": "Healthmed Services Ltd. provides communications technology to provide individuals, companies, and health-provider organizations with telephone and Web-based access to medical advice, information, and products and services. The company was founded in 2000 and is based in Temecula, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Temecula",
        "zipcode": "92590",
        "website": "http://www.healthmedservicesltd.com",
        "market_cap": "Small Cap"
    },
    "HEMP": {
        "short_name": "HEMP INC",
        "long_name": "Hemp, Inc",
        "summary": "Hemp, Inc. focuses on the provision of industrial hemp. The company is involved in processing and farming industrial hemp; extracting hemp CBD oil; and educating and empowering hemp farmers and entrepreneurs with knowledge, processing, infrastructure, and support. It also engages in the sale of hemp accessories, such as extractors, harvesters, storage bags, containers, fertilizer, soil amendments, humidifiers, dehumidifiers, balers, greenhouses, and greenhouse equipment; and drying, trimming, curing, storing, and brokering for other farmers harvesting hemp, as well as provision of research and development, hemp consulting, and educational entertainment services. The company was formerly known as Marijuana, Inc. and changed its name to Hemp, Inc. in June 2012. Hemp, Inc. was founded in 2008 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89123",
        "website": "http://www.hempinc.com",
        "market_cap": "Small Cap"
    },
    "HEPA": {
        "short_name": "Hepion Pharmaceuticals, Inc.",
        "long_name": "Hepion Pharmaceuticals, Inc.",
        "summary": "Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Edison",
        "zipcode": "08837",
        "website": "http://www.hepionpharma.com",
        "market_cap": "Small Cap"
    },
    "HESG": {
        "short_name": "HEALTH SCIENCES GROUP INC",
        "long_name": "Health Sciences Group, Inc.",
        "summary": "Health Sciences Group Inc., through its subsidiaries, provides various products used in nutritional supplements and functional foods and beverages in the United States. It primarily offers Shugr, a zero-calorie sugar substitute that tastes and bakes like cane sugar; and Sequesterol Advance Cardio Formula, a proprietary blend of clinically studied ingredients for the maintenance of cardiovascular health and a free-flowing circulatory system. The company also offers Aplevia, an antioxidant derived from apple peels; and Edible Sponges, an open-cell hydrocolloid product. It sells its products primarily through mass market retailers, such as mass merchandisers, drug stores, supermarkets, and discount stores, as well as through healthcare professionals and practitioners, and other media. Health Sciences Group was founded in 1996 as Centurion Properties Development Corporation and changed its name to iGoHealthy.com in 2000. It changed its name to Health Sciences Group, Inc. in 2001. The company is based in Newport Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newport Beach",
        "zipcode": "92660",
        "website": null,
        "market_cap": "Small Cap"
    },
    "HEWA": {
        "short_name": "HEALTHWAREHOUSE.COM INC",
        "long_name": "HealthWarehouse.com, Inc.",
        "summary": "HealthWarehouse.com, Inc. operates an online and mail order pharmacy. The company markets a range of generic, brand name, and pet prescription medicines, as well as over-the-counter (OTC) medications and products. It sells its products in 50 states and the District of Columbia in the United States to focus on the out-of-pocket prescription drug market. The company sells prescription medications and OTC products to individual consumers over the Internet. HealthWarehouse.com, Inc. is headquartered in Florence, Kentucky.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "KY",
        "city": "Florence",
        "zipcode": "41042",
        "website": "http://www.healthwarehouse.com",
        "market_cap": "Small Cap"
    },
    "HGEN": {
        "short_name": "Humanigen, Inc.",
        "long_name": "Humanigen, Inc.",
        "summary": "Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Burlingame",
        "zipcode": "94005",
        "website": "http://www.humanigen.com",
        "market_cap": "Small Cap"
    },
    "HGF2.F": {
        "short_name": "CATALYST BIOSC.  DL -,01",
        "long_name": "Catalyst Biosciences, Inc.",
        "summary": "Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.catalystbiosciences.com",
        "market_cap": "Small Cap"
    },
    "HIRU": {
        "short_name": "HIRU CORPORATION",
        "long_name": "Hiru Corporation",
        "summary": "Hiru Corporation, through its subsidiary, produces Chinese herbs for the naturopathic industry in China. It manufactures herbal supplements containing ginseng. The company sells and distributes pharmaceuticals, health and beauty products, dietary and herbal supplements, and other healthcare products. It manufactures approximately 120 extracts used in traditional Chinese medicine. Hiru Corporation sells its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies in China. Hiru Corporation was formerly known as Phoenix Restaurant Group, Inc. and changed its name to Hiru Corporation in November 2008. The company is based in Henderson, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Henderson",
        "zipcode": "89014",
        "website": null,
        "market_cap": "Small Cap"
    },
    "HITC": {
        "short_name": "HEALTHCARE INTEGRATED TECH INC",
        "long_name": "Healthcare Integrated Technologies, Inc.",
        "summary": "Healthcare Integrated Technologies, Inc.through its subsidiary, develops healthcare technology solutions to integrate and automate the continuing care, home care, and professional healthcare spaces. The company's product include SafeSpace, an ambient fall detection solution for continuing care communities and at home use. It provides healthcare services, and health and safety monitoring equipment; and integrated solution for the professional healthcare community that integrates electronic health records, remote patient monitoring, telehealth, and other items. The company was formerly known as Grasshopper Staffing, Inc. and changed its name to Healthcare Integrated Technologies, Inc. in May 2018. Healthcare Integrated Technologies, Inc. was founded in 2013 and is based in Knoxville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Knoxville",
        "zipcode": "37919",
        "website": null,
        "market_cap": "Small Cap"
    },
    "HJLI": {
        "short_name": "Hancock Jaffe Laboratories, Inc",
        "long_name": "Hancock Jaffe Laboratories, Inc.",
        "summary": "Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.hancockjaffe.com",
        "market_cap": "Small Cap"
    },
    "HL5.F": {
        "short_name": "HEALTHSTREAM INC.  DL-,01",
        "long_name": "HealthStream, Inc.",
        "summary": "HealthStream, Inc. provides workforce and provider solutions for healthcare organizations in the United States. It operates through two segments, Workforce Solutions and Provider Solutions. The company offers workforce solutions, including software-as-a-service (SaaS) based services and subscription-based solutions to meet the range of its clinical development, talent management, training, certification, scheduling, competency assessment, performance appraisal, and other needs, as well as implementation and account management services. It also provides applications for learning, compensation management, succession planning, competency management, disclosure management, simulation-based education, quality management, and industry training. In addition, the company offers VerityStream that delivers enterprise-class solutions to transform the healthcare provider experience for ambulatory surgery centers, urgent care facilities, clinics, medical groups, and other healthcare organizations; EchoCredentialing and MSOW platforms that manage medical staff credentialing, enrollment, and privileging processes for hospitals; and EchoOneApp, a provider enrollment platform for medical groups. Further, it provides CredentialMyDoc, a credentialing and enrollment SaaS solution for medical groups and surgery centers; CredentialStream, a SaaS-based provider credentialing, privileging, and enrollment solution; and NurseGrid Mobile for nurse managers. The company offers its solutions in healthcare industry companies that include private, not-for-profit, and government entities, as well as pharmaceutical and medical device companies through direct sales teams. HealthStream, Inc. was incorporated in 1990 and is headquartered in Nashville, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37203",
        "website": "http://www.healthstream.com",
        "market_cap": "Small Cap"
    },
    "HLMB": {
        "short_name": "SWIFTSURE INTL INC",
        "long_name": "Swiftsure International, Inc.",
        "summary": "Swiftsure International, Inc. is a holding company operating through its subsidiary that operates as a contract research company. It offers various services for the design, placement, performance, and management of clinical trial programs. The company's service capabilities include design of protocols, operations manuals, identification and recruitment of trial investigators, initiation of sites, monitoring, site visits and collection of data, interpretation of trial results, and report preparation. It offers services to support research and development of biotechnology, pharmaceutical, and medical device companies in the United States and Canada. The company was formerly known as Holmes Biopharma, Inc. and changed the name to Swiftsure International, Inc. in September, 2010. The company was founded in 1998 and is based in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85258",
        "website": "http://www.swiftsureinternational.com",
        "market_cap": "Small Cap"
    },
    "HLTT": {
        "short_name": "HEALTHTECH SOLUTIONS INC",
        "long_name": "Healthtech Solutions Inc.",
        "summary": "Healthtech Solutions, Inc. engages in the creation and commercialization of cloud-based software for ultrasound scans in the United States. It is also involved in the development of medical therapies for the treatment of disease or injury, such as damage resulting from COVID-19 infection; and acquisition or investment in integrative medical diagnostic or therapeutic software or devices. The company was incorporated in 1985 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10004",
        "website": null,
        "market_cap": "Small Cap"
    },
    "HLUN": {
        "short_name": "HEALTHEUNIVERSE INC",
        "long_name": "HEALTHeUNIVERSE, Inc.",
        "summary": "Healtheuniverse, Inc., a biotechnology development company, engages in the research, development, and commercialization of biopharmaceutical, biomedical, nutraceutical, and cosmeceutical products. The company develops stem cell and regenerative medicine therapies utilizing non-embryonic adult stem cells for use in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. It also provides consulting services to various businesses in the areas of marketing, business organization, and raising capital for business ventures. The company was founded in 2001 and is headquartered in Covina, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Covina",
        "zipcode": "91722",
        "website": null,
        "market_cap": "Small Cap"
    },
    "HLYK": {
        "short_name": "HEALTHLYNKED CORP",
        "long_name": "HealthLynked Corp.",
        "summary": "HealthLynked Corp. operates a cloud-based patient information network and record archiving system in the United States. It operates through four divisions: Health Services, Digital HealthCare, Accountable Care Organization/Managed Service Organization (ACO/MSO), and Medical Distribution. The Health Services division provides obstetrical and gynecological medical services to patients; functional medicine focusing on neurodegenerative diseases, such as Alzheimer's, Parkinson's, and multiple sclerosis; and Bridging the Gap Physical Therapy, a physical therapy practice to speed patients' recovery and manage pain without pain medication or surgery. The Digital HealthCare division operates HealthLynked Network, which enables patients and doctors to keep track of medical information via Internet in a cloud-based system; and enables patients to enter a detailed online personal medical history, including past surgical history, medications, allergies, and family medical history. This segment also offers online scheduling function for patients to book appointments with providers. The ACO/MSO division operates an ACO and MSO that assists physician practices in providing care to patients via the Medicare Shared Savings Program; and offers contracted consulting services to healthcare providers and other ACOs. The Medical Distribution Division operates as a virtual distributor of discounted medical supplies selling to consumers and medical practice. The company was incorporated in 2014 and is headquartered in Naples, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Naples",
        "zipcode": "34108",
        "website": "http://www.healthlynked.com",
        "market_cap": "Small Cap"
    },
    "HMGN": {
        "short_name": "HEMAGEN DIAGNOSTICS INC",
        "long_name": "Hemagen Diagnostics, Inc.",
        "summary": "Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines. In addition, the company provides veterinary diagnostic products, such as equipment, reagents, supplies, accessories, and electrodes in chemistry, hematology, and electrolyte areas. It sells its products directly, as well as through distributors to various laboratories, hospitals, and blood banks. The company was founded in 1985 and is based in Columbia, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Columbia",
        "zipcode": "21045",
        "website": "http://www.hemagen.com",
        "market_cap": "Small Cap"
    },
    "HMPQ": {
        "short_name": "HEMP AMERICANA INC",
        "long_name": "HempAmericana, Inc",
        "summary": "HempAmericana, Inc. researches, develops, and sells products made of industrial hemp in the United States. It provides hemp-based concrete, hemp bags, hemp seeds for consumption, hemp clothing, and hemp rolling paper products. HempAmericana, Inc. was founded in 2014 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10007",
        "website": "http://www.hempamericana.com",
        "market_cap": "Small Cap"
    },
    "HNGR": {
        "short_name": "Hanger, Inc.",
        "long_name": "Hanger, Inc.",
        "summary": "Hanger, Inc. provides orthotic and prosthetic (O&P) services; and distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings in the United States. It operates through two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and provides payor network contracting services to other O&P providers. The Products & Services segment distributes O&P parts, componentry, and devices to independent O&P providers; and develops specialized rehabilitation technologies and provides evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2020, the company operated approximately 704 patient care clinics, and 112 satellite locations in 46 states and the District of Columbia. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78758",
        "website": "http://www.hanger.com",
        "market_cap": "Small Cap"
    },
    "HO1.F": {
        "short_name": "HOLOGIC INC.  DL-,01",
        "long_name": "Hologic, Inc.",
        "summary": "Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Marlborough",
        "zipcode": "01752",
        "website": "http://www.hologic.com",
        "market_cap": "Large Cap"
    },
    "HOLX.MX": {
        "short_name": "HOLOGIC INC",
        "long_name": "Hologic, Inc.",
        "summary": "Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Marlborough",
        "zipcode": "01752",
        "website": "http://www.hologic.com",
        "market_cap": "Large Cap"
    },
    "HOLX": {
        "short_name": "Hologic, Inc.",
        "long_name": "Hologic, Inc.",
        "summary": "Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Marlborough",
        "zipcode": "01752",
        "website": "http://www.hologic.com",
        "market_cap": "Large Cap"
    },
    "HOLX.VI": {
        "short_name": "HOLOGIC INC",
        "long_name": "Hologic, Inc.",
        "summary": "Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "MA",
        "city": "Marlborough",
        "zipcode": "01752",
        "website": "http://www.hologic.com",
        "market_cap": "Large Cap"
    },
    "HOOK": {
        "short_name": "HOOKIPA Pharma Inc.",
        "long_name": "HOOKIPA Pharma Inc.",
        "summary": "HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10118",
        "website": "http://www.hookipapharma.com",
        "market_cap": "Small Cap"
    },
    "HOTH": {
        "short_name": "Hoth Therapeutics, Inc.",
        "long_name": "Hoth Therapeutics, Inc.",
        "summary": "Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zyl\u00c3\u00b6 Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10020",
        "website": "http://www.hoththerapeutics.com",
        "market_cap": "Small Cap"
    },
    "HOWL": {
        "short_name": "Werewolf Therapeutics, Inc.",
        "long_name": "Werewolf Therapeutics, Inc.",
        "summary": "Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02138",
        "website": "http://werewolftx.com",
        "market_cap": "Small Cap"
    },
    "HPMM": {
        "short_name": "HEMP NATURALS INC",
        "long_name": "Hemp Naturals, Inc.",
        "summary": "Hemp Naturals, Inc., an early stage company, focuses on researching, developing, acquiring, and selling products made of industrial hemp. The company offers rolling papers through 25 retail outlets, which include gas stations, convenience stores, tobacco shops, and liquor stores. It also intends to offer consumer goods that are made of industrial hemp and/or the non-psychoactive ingredients of the cannabis plant, such as nutritional hemp health supplements, hemp shakes and/or foods, and beauty supply products, as well as hemp clothing. Hemp Naturals, Inc. was incorporated in 2015 and is based in Sunny Isles Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Sunny Isles Beach",
        "zipcode": "33160",
        "website": "http://www.hempofnaturals.com",
        "market_cap": "Small Cap"
    },
    "HPST": {
        "short_name": "HEMPSTRACT INC",
        "long_name": "Hempstract, Inc.",
        "summary": "Hempstract, Inc. produces and sells cannabidiol (CBD) and cannabigerol solutions in the United States. It offers CBD isolate powder and distillate oil. The company was formerly known as Riverdale Oil and Gas Corporation and changed its name to Hempstract, Inc. in November 2020. Hempstract, Inc. is based in Warden, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Warden",
        "zipcode": "98857-0665",
        "website": "http://www.hempstractlabs.com",
        "market_cap": null
    },
    "HQ10.F": {
        "short_name": "ARCA BIOPHARMA  DL-,01",
        "long_name": "ARCA biopharma, Inc.",
        "summary": "ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Westminster",
        "zipcode": "80021",
        "website": "http://www.arcabio.com",
        "market_cap": "Small Cap"
    },
    "HQ8F.F": {
        "short_name": "APOLLO ENDOSURGERY DL-,01",
        "long_name": "Apollo Endosurgery, Inc.",
        "summary": "Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands; and Orbera Coach, a digital and remotely delivered aftercare program. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78746",
        "website": "http://www.apolloendo.com",
        "market_cap": "Small Cap"
    },
    "HQDA": {
        "short_name": "HQDA ELDERLY LIFE NETWORK CORP",
        "long_name": "HQDA Elderly Life Network Corp.",
        "summary": "HQDA Elderly Life Network Corp. focuses on providing senior housing and retirement services and products in China. The company was formerly known as Hartford Retirement Network Corp. and changed its name to HQDA Elderly Life Network Corp. in June 2018. The company was founded in 2004 and is headquartered in Rosemead, California. HQDA Elderly Life Network Corp. is a subsidiary of HQDA International Holdings Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Rosemead",
        "zipcode": "91770",
        "website": "http://www.hqda.net",
        "market_cap": "Small Cap"
    },
    "HQY": {
        "short_name": "HealthEquity, Inc.",
        "long_name": "HealthEquity, Inc.",
        "summary": "HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides mutual fund investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is headquartered in Draper, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Draper",
        "zipcode": "84020",
        "website": "http://www.healthequity.com",
        "market_cap": "Mid Cap"
    },
    "HRAA": {
        "short_name": "HEALTH REVENUE ASSURANCE HLGDS ",
        "long_name": "Health Revenue Assurance Holdings, Inc.",
        "summary": "Health Revenue Assurance Holdings, Inc. provides revenue cycle services for healthcare providers in the United States. It offers revenue cycle data analysis, contract, and outsourced coding services; and billing, coding and compliance audits, coding education, coding consulting, physician coding, and ICD-10 education and transition services. The company was founded in 2001 and is headquartered in Plantation, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Plantation",
        "zipcode": "33322",
        "website": null,
        "market_cap": "Small Cap"
    },
    "HRC": {
        "short_name": "Hill-Rom Holdings Inc",
        "long_name": "Hill-Rom Holdings, Inc.",
        "summary": "Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, patient mobility solutions, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising non-invasive devices that provide respiratory support and assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include tables, lights, and pendants; and positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. It sells and rents products to acute and extended care facilities through direct sales force and distributors; sells and rents products directly to patients in the home; and sells products to primary care facilities through distributors. Hill-Rom Holdings, Inc. was founded in 1915 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60601",
        "website": "http://www.hillrom.com",
        "market_cap": "Mid Cap"
    },
    "HRMY": {
        "short_name": "Harmony Biosciences Holdings, I",
        "long_name": "Harmony Biosciences Holdings, Inc.",
        "summary": "Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Plymouth Meeting",
        "zipcode": "19462",
        "website": "http://www.harmonybiosciences.com",
        "market_cap": "Small Cap"
    },
    "HROW": {
        "short_name": "Harrow Health, Inc.",
        "long_name": "Harrow Health, Inc.",
        "summary": "Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37205",
        "website": "http://www.harrowinc.com",
        "market_cap": "Small Cap"
    },
    "HRTT": {
        "short_name": "HEART TRONICS INC",
        "long_name": "Heart Tronics, Inc.",
        "summary": "Heart Tronics, Inc., a medical device company, engages in the research, development, and marketing of medical devices in the United States. Its medical devices are used to monitor and measure physiological signals in order to detect diseases that impact an individual's health. The company offers Fidelity 100 Monitor System, an integrated system in which its component Model 100 Patient Module collects, processes, and amplifies electrocardiogram (ECG) signals from that patient through a set of 10 electrodes that are wirelessly transmitted to the laptop computer. Its products in the development stage include Fidelity 350 Holter Monitor, an ambulatory Holter monitor that collects ECG data of arrhythmia and transient heart disease, while the patient carries out daily activities away from the physician's office or hospital. The company's products in the development stage also consist of Fidelity 200 Event Recording System/Heart Tempo Card, a non-prescription heart monitoring device, which is used as an early-detection device by patients who desire to monitor their condition. Its products also include Cardiac Vest, a lightweight, close-fitting vest or undergarment made of stretchable material in which the electrodes are stitched into the fabric; and Fidelity 400 Intracardiac Monitor that applies its proprietary physiological signal acquisition and amplification technology to read intracardiac signals procured from intracardiac catheter. The company was formerly known as Signalife, Inc. and changed its name to Heart Tronics, Inc. in November 2008. Heart Tronics, Inc. was incorporated in 1987 is headquartered in Studio City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Studio City",
        "zipcode": "91607",
        "website": null,
        "market_cap": "Small Cap"
    },
    "HRTX": {
        "short_name": "Heron Therapeutics, Inc.",
        "long_name": "Heron Therapeutics, Inc.",
        "summary": "Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.herontx.com",
        "market_cap": "Small Cap"
    },
    "HRVSF": {
        "short_name": "HARVEST HEALTH AND RECREATION I",
        "long_name": "Harvest Health & Recreation Inc.",
        "summary": "Harvest Health and Recreation, Inc., together with its subsidiaries, cultivates, processes, sells, and retails inhalable, ingestible, and topical cannabis products in the United States. The company offers cannabis oil products; inhalables, including flower, dabbable concentrates, pre-filled vaporizer pens, and cartridges; and capsules, tinctures, and cannabis product edibles, including chocolates, gummies, mints, fruit chews, and dissolvable mouth strips under the Avenue, CBX SCIENCES, EVOLAB, ALCHEMY, CHROMA, CO2LORS, GOODSUN, MODERN FLOWER, and ROLL ONE brand names. It also operates retail dispensaries that sell proprietary and third-party cannabis products to patients and customers; and provides support services and financing to a Utah licensed medical cannabis cultivator. Harvest Health and Recreation, Inc. was founded in 2011 and is headquartered in Tempe, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tempe",
        "zipcode": "85281",
        "website": "http://www.harvesthoc.com",
        "market_cap": "Small Cap"
    },
    "HS1.F": {
        "short_name": "HEALTHCARE SVCS GRP.DL-01",
        "long_name": "Healthcare Services Group, Inc.",
        "summary": "Healthcare Services Group, Inc. provides management, administrative, and operating services to the housekeeping, laundry, linen, facility maintenance, and dietary service departments of nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States. It operates through two segments, Housekeeping and Dietary. The Housekeeping segment engages in the cleaning, disinfecting, and sanitizing of resident rooms and common areas of client's facility, as well as laundering and processing of the bed linens, uniforms, resident personal clothing, and other assorted linen items utilized at a client's facility. The Dietary segment provides food purchasing, meal preparation, and professional dietitian services, which include the development of menus that meet the dietary needs of residents. This segment also offers clinical consulting services to facilities. As of December 31, 2020, the company provided its services to approximately 3,000 facilities. Healthcare Services Group, Inc. was incorporated in 1976 and is based in Bensalem, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Bensalem",
        "zipcode": "19020",
        "website": "http://www.hcsgcorp.com",
        "market_cap": "Mid Cap"
    },
    "HS2.F": {
        "short_name": "HENRY SCHEIN INC.  DL-,01",
        "long_name": "Henry Schein, Inc.",
        "summary": "Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates in two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Melville",
        "zipcode": "11747",
        "website": "http://www.henryschein.com",
        "market_cap": "Large Cap"
    },
    "HSIC": {
        "short_name": "Henry Schein, Inc.",
        "long_name": "Henry Schein, Inc.",
        "summary": "Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates in two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Melville",
        "zipcode": "11747",
        "website": "http://www.henryschein.com",
        "market_cap": "Large Cap"
    },
    "HSIC.VI": {
        "short_name": "HENRY SCHEIN INC",
        "long_name": "Henry Schein, Inc.",
        "summary": "Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates in two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "NY",
        "city": "Melville",
        "zipcode": "11747",
        "website": "http://www.henryschein.com",
        "market_cap": "Large Cap"
    },
    "HSKA": {
        "short_name": "Heska Corporation",
        "long_name": "Heska Corporation",
        "summary": "Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Additionally, the company provides a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Loveland",
        "zipcode": "80538",
        "website": "http://www.heska.com",
        "market_cap": "Mid Cap"
    },
    "HSKN.F": {
        "short_name": "HESKA RESTR. NEW DL-,001",
        "long_name": "Heska Corporation",
        "summary": "Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Additionally, the company provides a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Loveland",
        "zipcode": "80538",
        "website": "http://www.heska.com",
        "market_cap": "Mid Cap"
    },
    "HSM.TO": {
        "short_name": "HELIUS MEDICAL TECHNOLOGIES INC",
        "long_name": "Helius Medical Technologies, Inc.",
        "summary": "Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product is Portable Neuromodulation Stimulator (PoNS), a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "United States",
        "state": "PA",
        "city": "Newtown",
        "zipcode": "18940",
        "website": "http://heliusmedical.com",
        "market_cap": "Small Cap"
    },
    "HSOA.F": {
        "short_name": "ENCOMP.HEALT.CORP. DL-,01",
        "long_name": "Encompass Health Corporation",
        "summary": "Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment provides home health and hospice services primarily in the Southeast and Texas. Its home health services include a range of Medicare-certified home nursing services to adult patients in need of care comprising skilled nursing, medical social work, and home health aide services, as well as physical, occupational, speech therapy, and others. This segment's hospice services comprise in-home services to terminally ill patients and their families to address patients' physical needs, including pain control and symptom management, and to provide emotional and spiritual support. As of March 16, 2021, it operated 137 hospitals, 241 home health locations, and 82 hospice locations in 39 states and Puerto Rico. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was founded in 1983 and is based in Birmingham, Alabama.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "AL",
        "city": "Birmingham",
        "zipcode": "35242",
        "website": "http://www.encompasshealth.com",
        "market_cap": "Mid Cap"
    },
    "HSTC": {
        "short_name": "HST GLOBAL INC",
        "long_name": "HST Global, Inc.",
        "summary": "HST Global, Inc., an integrated health and wellness biotechnology company, develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer worldwide. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancers and other life-threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Hampton",
        "zipcode": "23666",
        "website": "http://www.hstglobal.com",
        "market_cap": "Small Cap"
    },
    "HSTI": {
        "short_name": "HIGH SIERRA TECHNOLOGIES INC",
        "long_name": "High Sierra Technologies, Inc.",
        "summary": "High Sierra Technologies, Inc. focuses on the development of patents and other products used in the processing of recreational cannabis and industrial hemp. It intends to offer its products for smoking and/or ingestion in various forms. The company is based in Reno, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Reno",
        "zipcode": "89519",
        "website": null,
        "market_cap": "Small Cap"
    },
    "HSTM": {
        "short_name": "HealthStream, Inc.",
        "long_name": "HealthStream, Inc.",
        "summary": "HealthStream, Inc. provides workforce and provider solutions for healthcare organizations in the United States. It operates through two segments, Workforce Solutions and Provider Solutions. The company offers workforce solutions, including software-as-a-service (SaaS) based services and subscription-based solutions to meet the range of its clinical development, talent management, training, certification, scheduling, competency assessment, performance appraisal, and other needs, as well as implementation and account management services. It also provides applications for learning, compensation management, succession planning, competency management, disclosure management, simulation-based education, quality management, and industry training. In addition, the company offers VerityStream that delivers enterprise-class solutions to transform the healthcare provider experience for ambulatory surgery centers, urgent care facilities, clinics, medical groups, and other healthcare organizations; EchoCredentialing and MSOW platforms that manage medical staff credentialing, enrollment, and privileging processes for hospitals; and EchoOneApp, a provider enrollment platform for medical groups. Further, it provides CredentialMyDoc, a credentialing and enrollment SaaS solution for medical groups and surgery centers; CredentialStream, a SaaS-based provider credentialing, privileging, and enrollment solution; and NurseGrid Mobile for nurse managers. The company offers its solutions in healthcare industry companies that include private, not-for-profit, and government entities, as well as pharmaceutical and medical device companies through direct sales teams. HealthStream, Inc. was incorporated in 1990 and is headquartered in Nashville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37203",
        "website": "http://www.healthstream.com",
        "market_cap": "Small Cap"
    },
    "HSTO": {
        "short_name": "Histogen Inc.",
        "long_name": "Histogen Inc.",
        "summary": "Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.histogen.com",
        "market_cap": "Small Cap"
    },
    "HTBX": {
        "short_name": "Heat Biologics, Inc.",
        "long_name": "Heat Biologics, Inc.",
        "summary": "Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560",
        "website": "http://www.heatbio.com",
        "market_cap": "Small Cap"
    },
    "HTD.F": {
        "short_name": "CORCEPT THERAPEUTICS INC.",
        "long_name": "Corcept Therapeutics Incorporated",
        "summary": "Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://www.corcept.com",
        "market_cap": "Mid Cap"
    },
    "HTGM": {
        "short_name": "HTG Molecular Diagnostics, Inc.",
        "long_name": "HTG Molecular Diagnostics, Inc.",
        "summary": "HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Tucson",
        "zipcode": "85706",
        "website": "http://www.htgmolecular.com",
        "market_cap": "Small Cap"
    },
    "HTL.V": {
        "short_name": "HAMILTON THORNE LTD",
        "long_name": "Hamilton Thorne Ltd.",
        "summary": "Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It offers laser products used in a range of scientific applications and in vitro fertilization (IVF) procedures; and image analysis systems used in the studies of reproductive cells in the human fertility, animal sciences, and reproductive toxicology fields. The company also provides a line of air filtration products to enhance air quality in the laboratory under the ZANDAIR brand; incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications under the Planer brand; and reproductive medicine, including clinical and laboratory equipment, and disposables, as well as installations of ART clinics under the Gynemed brand. In addition, it offers test laboratory providing services to the assisted reproductive technologies industry and laboratories under the Embryotech brand. Further, the company provides precision laser devices, imaging systems, micromanipulation systems, control rate freezers, and lab monitoring systems. It sells its products through direct sales force and distributors to pharmaceutical and biotechnology companies, animal breeding facilities, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. The company is headquartered in Beverly, Massachusetts.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": "MA",
        "city": "Beverly",
        "zipcode": "01915",
        "website": "http://www.hamiltonthorne.ltd",
        "market_cap": "Small Cap"
    },
    "HTLZF": {
        "short_name": "HAMILTON THORNE LTD",
        "long_name": "Hamilton Thorne Ltd.",
        "summary": "Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It offers laser products used in a range of scientific applications and in vitro fertilization (IVF) procedures; and image analysis systems used in the studies of reproductive cells in the human fertility, animal sciences, and reproductive toxicology fields. The company also provides a line of air filtration products to enhance air quality in the laboratory under the ZANDAIR brand; incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications under the Planer brand; and reproductive medicine, including clinical and laboratory equipment, and disposables, as well as installations of ART clinics under the Gynemed brand. In addition, it offers test laboratory providing services to the assisted reproductive technologies industry and laboratories under the Embryotech brand. Further, the company provides precision laser devices, imaging systems, micromanipulation systems, control rate freezers, and lab monitoring systems. It sells its products through direct sales force and distributors to pharmaceutical and biotechnology companies, animal breeding facilities, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. The company is headquartered in Beverly, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Beverly",
        "zipcode": "01915",
        "website": "http://www.hamiltonthorne.ltd",
        "market_cap": "Small Cap"
    },
    "HTW.MU": {
        "short_name": "NATL HEALTHCARE CORP.",
        "long_name": "National HealthCare Corporation",
        "summary": "National HealthCare Corporation operates, manages, and provides services to skilled nursing facilities, assisted living facilities, independent living facilities, home health care programs, and a behavioral health hospital. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. The company's medical specialty units comprise memory care units and subacute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living centers offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. It also owns, leases, and manages independent living facilities that provide specially designed residential units for the active and ambulatory elderly, as well as offers various ancillary services for its residents, including restaurants, activity rooms, and social areas. In addition, it provides health care programs that offer skilled services, such as infusion, wound care and physical, occupational, and speech therapies; operates pharmacies; offers managed care insurance, management, accounting, financial, and insurance, as well as geriatric behavioral health services; and leases its properties to third party operators. As of December 31, 2020, the company operated 75 skilled nursing facilities with 9,463 licensed beds; 24 assisted living facilities; 5 independent living facilities; 35 homecare programs; and 4 pharmacy locations, as well as a 16-bed behavioral health hospital. National HealthCare Corporation was founded in 1971 and is based in Murfreesboro, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Murfreesboro",
        "zipcode": "37130",
        "website": "http://www.nhccare.com",
        "market_cap": "Small Cap"
    },
    "HUM.F": {
        "short_name": "HUMANA INC.  DL-,166",
        "long_name": "Humana Inc.",
        "summary": "Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "KY",
        "city": "Louisville",
        "zipcode": "40202",
        "website": "http://www.humana.com",
        "market_cap": "Large Cap"
    },
    "HUM.MX": {
        "short_name": "HUMANA INC",
        "long_name": "Humana Inc.",
        "summary": "Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "KY",
        "city": "Louisville",
        "zipcode": "40202",
        "website": "http://www.humana.com",
        "market_cap": "Large Cap"
    },
    "HUM": {
        "short_name": "Humana Inc.",
        "long_name": "Humana Inc.",
        "summary": "Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "KY",
        "city": "Louisville",
        "zipcode": "40202",
        "website": "http://www.humana.com",
        "market_cap": "Large Cap"
    },
    "HWT1.F": {
        "short_name": "ICAD INC.  DL-,01",
        "long_name": "iCAD, Inc.",
        "summary": "iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NH",
        "city": "Nashua",
        "zipcode": "03062",
        "website": "http://www.icadmed.com",
        "market_cap": "Small Cap"
    },
    "HXB2.F": {
        "short_name": "AIM IMMUNOTECH INC.",
        "long_name": "AIM ImmunoTech Inc.",
        "summary": "AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Ocala",
        "zipcode": "34473",
        "website": "http://www.aimimmuno.com",
        "market_cap": "Small Cap"
    },
    "HXXB.F": {
        "short_name": "IDERA PHARMAC.  DL-,001",
        "long_name": "Idera Pharmaceuticals, Inc.",
        "summary": "Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Exton",
        "zipcode": "19341",
        "website": "http://www.iderapharma.com",
        "market_cap": "Small Cap"
    },
    "HY1N.F": {
        "short_name": "ONTRAK INC.  DL -,0001",
        "long_name": "Ontrak, Inc.",
        "summary": "Ontrak, Inc. operates as an artificial intelligence powered, virtualized outpatient healthcare treatment company that provides in-person or telehealth intervention services to health plans and other third-party payors. Its Ontrak PRE (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends care pathways that people are willing to follow, and engages people who aren't getting the care they need. The company's technology-enabled, OnTrak, program is designed to treat health plan members with unaddressed behavioral health conditions that cause or exacerbate chronic medical diseases, such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was founded in 2003 and is headquartered in Santa Monica, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Monica",
        "zipcode": "90404",
        "website": "http://www.ontrak-inc.com",
        "market_cap": "Small Cap"
    },
    "HYEX": {
        "short_name": "HEALTHY EXTRACTS INC",
        "long_name": "Healthy Extracts Inc.",
        "summary": "Healthy Extracts Inc., through its subsidiaries, researches, develops, and markets natural plant-based formulations in the United States and internationally. It offers heart health nutritional products; and neuro-products under the KETONOMICS name that enhance brain health, including memory, cognition, focus, and neuro-energy. The company also provides bergamot products in capsule form under the BergaMet Pro+, BergaMet Mega+O, BergaMet HERHEART, BergaMet Cholesterol Command, and BergaMet SPORTSHEART products labels. It distributes bergamot products through its website and distribution sites. The company was formerly known as Grey Cloak Tech Inc. and changed its name to Healthy Extracts Inc. in October 2020. Healthy Extracts Inc. was incorporated in 2014 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89113",
        "website": "http://healthyextractsinc.com",
        "market_cap": "Small Cap"
    },
    "I02.F": {
        "short_name": "IMAC HOLDINGS  DL-,001",
        "long_name": "IMAC Holdings, Inc.",
        "summary": "IMAC Holdings, Inc. provides orthopedic therapies through a chain of innovative medical advancements and care regeneration centers in the United States. Its outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. As of December 31, 2020, the company operated 16 outpatient clinics in Kentucky, Missouri, Tennessee, Illinois, and Florida. IMAC Holdings, Inc. was founded in 2000 and is based in Brentwood, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Brentwood",
        "zipcode": "37027",
        "website": "http://www.imacregeneration.com",
        "market_cap": "Small Cap"
    },
    "I1DX34.SA": {
        "short_name": "IDEXX LABORADRN",
        "long_name": "IDEXX Laboratories, Inc.",
        "summary": "IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "ME",
        "city": "Westbrook",
        "zipcode": "04092",
        "website": "http://www.idexx.com",
        "market_cap": "Large Cap"
    },
    "I1LM34.SA": {
        "short_name": "ILLUMINA INCDRN",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.illumina.com",
        "market_cap": "Large Cap"
    },
    "I1NC34.SA": {
        "short_name": "INCYTE CORP DRN",
        "long_name": "Incyte Corporation",
        "summary": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat na\u00c3\u00afve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "DE",
        "city": "Wilmington",
        "zipcode": "19803",
        "website": "http://www.incyte.com",
        "market_cap": "Large Cap"
    },
    "I1QV34.SA": {
        "short_name": "IQVIA HOLDINDRN",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CT",
        "city": "Danbury",
        "zipcode": "06810",
        "website": "http://www.iqvia.com",
        "market_cap": "Large Cap"
    },
    "I1SR34.SA": {
        "short_name": "INTUITIVE SUDRN",
        "long_name": "Intuitive Surgical, Inc.",
        "summary": "Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "Sunnyvale",
        "zipcode": "94086-5304",
        "website": "http://www.intuitive.com",
        "market_cap": "Large Cap"
    },
    "I25.F": {
        "short_name": "IRHYTHM TECHN.INC.DL-,001",
        "long_name": "iRhythm Technologies, Inc.",
        "summary": "iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94103",
        "website": "http://www.irhythmtech.com",
        "market_cap": "Small Cap"
    },
    "I3F.F": {
        "short_name": "INFINITY PHARMAC. DL-,001",
        "long_name": "Infinity Pharmaceuticals, Inc.",
        "summary": "Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02138",
        "website": "http://www.infi.com",
        "market_cap": "Small Cap"
    },
    "I4P.F": {
        "short_name": "INTERCEPT PHARMAC.DL-,001",
        "long_name": "Intercept Pharmaceuticals, Inc.",
        "summary": "Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10001",
        "website": "http://www.interceptpharma.com",
        "market_cap": "Small Cap"
    },
    "I5X.F": {
        "short_name": "PRECIGEN INC.",
        "long_name": "Precigen, Inc.",
        "summary": "Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Germantown",
        "zipcode": "20876",
        "website": "http://www.precigen.com",
        "market_cap": "Small Cap"
    },
    "I76.F": {
        "short_name": "IRONWOOD PHARMA.A DL-,001",
        "long_name": "Ironwood Pharmaceuticals, Inc.",
        "summary": "Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02110",
        "website": "http://www.ironwoodpharma.com",
        "market_cap": "Small Cap"
    },
    "I9DN.F": {
        "short_name": "ARBUTUS BIOPHARMA",
        "long_name": "Arbutus Biopharma Corporation",
        "summary": "Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Warminster",
        "zipcode": "18974",
        "website": "http://www.arbutusbio.com",
        "market_cap": "Small Cap"
    },
    "IAGX": {
        "short_name": "IMAGENETIX INC",
        "long_name": "Imagenetix, Inc.",
        "summary": "Imagenetix, Inc. develops, formulates, and markets proprietary and natural based nutritional supplements, and over-the-counter topical creams and skin care products. Its primary product is Celadrin, a product formulation for joint health. The company also licenses its intellectual property to third parties. Imagenetix, Inc. markets its products through various channels of distribution, including direct and mass marketing companies, nutritional newsletters, and medical and nutritional oriented professionals; medical newsletters; and direct response radio and television. The company was founded in 1996 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92127",
        "website": "http://www.imagenetix.net",
        "market_cap": "Small Cap"
    },
    "IAN.CN": {
        "short_name": "iAnthus Capital",
        "long_name": "iAnthus Capital Holdings, Inc.",
        "summary": "iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. It offers biomass products, such as pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures; cannabidiol products, such as topical creams, tinctures, and sprays, as well as products for beauty and skincare that include lotions, creams, haircare products, lip balms, and bath bombs. The company engages in the wholesale-distribution and retail of CBD products. It owns and/or operates 31 dispensaries and 10 cultivation and/or processing facilities in 9 states. The company is headquartered in New York, New York.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10170",
        "website": "http://www.ianthus.com",
        "market_cap": "Small Cap"
    },
    "IART": {
        "short_name": "Integra LifeSciences Holdings C",
        "long_name": "Integra LifeSciences Holdings Corporation",
        "summary": "Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.integralife.com",
        "market_cap": "Mid Cap"
    },
    "IB3A.F": {
        "short_name": "IONIC BRANDS CORP.",
        "long_name": "Ionic Brands Corp.",
        "summary": "Ionic Brands Corp. provides cannabis related services in Washington and Oregon. The company manufacture and distribute hard goods, such as cartridges, applicators, pens, jars, etc. under the IONIC brand name. The company is headquartered in Tacoma, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Tacoma",
        "zipcode": "98402",
        "website": "http://www.ionicbrands.com",
        "market_cap": "Small Cap"
    },
    "IBIO": {
        "short_name": "iBio, Inc.",
        "long_name": "iBio, Inc.",
        "summary": "iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.ibioinc.com",
        "market_cap": "Small Cap"
    },
    "IBPB.F": {
        "short_name": "BIO-PATH HLDGS INC.",
        "long_name": "Bio-Path Holdings, Inc.",
        "summary": "Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Bellaire",
        "zipcode": "77401",
        "website": "http://www.biopathholdings.com",
        "market_cap": "Small Cap"
    },
    "IBRX": {
        "short_name": "ImmunityBio, Inc.",
        "long_name": "ImmunityBio, Inc.",
        "summary": "ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes. ImmunityBio, Inc. was formerly known as NantCell, Inc. and changed its name to ImmunityBio, Inc. in June 2019. The company was incorporated in 2014 and is based in El Segundo, California. ImmunityBio, Inc. operates as a subsidiary of NantWorks, LLC.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "El Segundo",
        "zipcode": "90245",
        "website": "http://immunitybio.com",
        "market_cap": "Mid Cap"
    },
    "IBX.AX": {
        "short_name": "IMAGIONBIO FPO",
        "long_name": "Imagion Biosystems Limited",
        "summary": "Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://imagionbiosystems.com",
        "market_cap": "Small Cap"
    },
    "IBXXF": {
        "short_name": "IMAGION BIOSYSTEMS LIMITED",
        "long_name": "Imagion Biosystems Limited",
        "summary": "Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://imagionbiosystems.com",
        "market_cap": "Small Cap"
    },
    "IC7.F": {
        "short_name": "ICU MEDICAL INC.  DL-,10",
        "long_name": "ICU Medical, Inc.",
        "summary": "ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Clemente",
        "zipcode": "92673",
        "website": "http://www.icumed.com",
        "market_cap": "Mid Cap"
    },
    "ICAD": {
        "short_name": "icad inc.",
        "long_name": "iCAD, Inc.",
        "summary": "iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NH",
        "city": "Nashua",
        "zipcode": "03062",
        "website": "http://www.icadmed.com",
        "market_cap": "Small Cap"
    },
    "ICBU": {
        "short_name": "IMD COMPANIES INC",
        "long_name": "iMD Companies, Inc.",
        "summary": "iMD Companies, Inc. is a holding company which, through its subsidiaries, manufactures, markets, and distributes equipment for the hydroponics industry.  It also develops and manufactures environmental controllers. iMD Companies, Inc. is based in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33625",
        "website": "http://imdcompanies.com",
        "market_cap": "Small Cap"
    },
    "ICCC": {
        "short_name": "ImmuCell Corporation",
        "long_name": "ImmuCell Corporation",
        "summary": "ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "ME",
        "city": "Portland",
        "zipcode": "04103",
        "website": "http://immucell.com",
        "market_cap": "Small Cap"
    },
    "ICCO": {
        "short_name": "INTERCARE DX INC",
        "long_name": "InterCare DX, Inc.",
        "summary": "InterCare DX, Inc. operates as a biomedical and other software products development and services company. It creates, publishes, and markets software products that are embedded with sound, text, and video for relaxation training and stress management. The company also develops an integrated Internet-ready and RFID enabled applications, which target education, hospitality, legal system, human capital, and healthcare industry markets. Its products comprise e-Learning Integrated Technology Enterprise Systems for integrated tuition, boarding and lodging management, enterprise vendor portal, customer relationship management, enterprise budgeting, and financial management, as well as other tools used in administering education at all levels; InterCare Clinical Explorer, a software application designed to integrate virtually all aspects of the healthcare enterprise; and InterCare Vascular Diagnostic Center to measure vascular health in patients before exhibiting symptoms. The company was formerly known as InterCare Diagnostics. InterCare DX, Inc. was founded in 1991 and is based in Hawthorne, California. InterCare DX, Inc.is a subsidiary of Meridian Holdings, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Hawthorne",
        "zipcode": "90250",
        "website": "http://www.intercare.com",
        "market_cap": "Small Cap"
    },
    "ICCT": {
        "short_name": "ICORECONNECT INC",
        "long_name": "iCoreConnect Inc.",
        "summary": "iCoreConnect Inc. builds cloud-based communications systems primarily for the healthcare sector in the United States. The company offers cloud based software products. Its products include iCoreExchange that enables hospitals, physician practices and dental practices, and other healthcare professionals to transfer patient health information; iCoreCodeGenius that provides the coding standards for the 10th revision of the international statistical classification of diseases and related health problems; iCoreSecure, an encrypted email to protect personal and financial data; and iCoreMD and iCoreDental software platforms for the medical and dental communities. The company's products also comprise iCoreMobile, an electronic health record software platform for mobile medical and dental care centers; iCoreHuddle, a tool to instantly reveal the revenue potential of each patient; iCoreRx, a compliant electronic ePrescription software; and IT Managed services. It also offers consulting services for physician and dental practices. The company was formerly known as iMedicor, Inc. and changed its name to iCoreConnect Inc. in June 2017. iCoreConnect Inc. was incorporated in 2001 and is headquartered in Winter Garden, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Winter Garden",
        "zipcode": "34786",
        "website": "http://www.icoreconnect.com",
        "market_cap": "Small Cap"
    },
    "ICPT": {
        "short_name": "Intercept Pharmaceuticals, Inc.",
        "long_name": "Intercept Pharmaceuticals, Inc.",
        "summary": "Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10001",
        "website": "http://www.interceptpharma.com",
        "market_cap": "Small Cap"
    },
    "ICUI": {
        "short_name": "ICU Medical, Inc.",
        "long_name": "ICU Medical, Inc.",
        "summary": "ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Clemente",
        "zipcode": "92673",
        "website": "http://www.icumed.com",
        "market_cap": "Mid Cap"
    },
    "ICY.F": {
        "short_name": "INCYTE  DL-,001",
        "long_name": "Incyte Corporation",
        "summary": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat na\u00c3\u00afve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "DE",
        "city": "Wilmington",
        "zipcode": "19803",
        "website": "http://www.incyte.com",
        "market_cap": "Large Cap"
    },
    "IDCN": {
        "short_name": "INDOCAN RESOURCES INC",
        "long_name": "Indocan Resources Inc.",
        "summary": "Indocan Resources Inc., a real estate holding company, invests in coastal vacation rental and commercial properties. The company was incorporated in 1994 and is based in Emerald Isle, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Emerald Isle",
        "zipcode": "28594",
        "website": "http://indocanresources.com",
        "market_cap": "Small Cap"
    },
    "IDP.DE": {
        "short_name": "BIOGEN INC. DL -,0005",
        "long_name": "Biogen Inc.",
        "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.biogen.com",
        "market_cap": "Large Cap"
    },
    "IDP.F": {
        "short_name": "BIOGEN INC. DL -,0005",
        "long_name": "Biogen Inc.",
        "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.biogen.com",
        "market_cap": "Large Cap"
    },
    "IDRA": {
        "short_name": "Idera Pharmaceuticals, Inc.",
        "long_name": "Idera Pharmaceuticals, Inc.",
        "summary": "Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Exton",
        "zipcode": "19341",
        "website": "http://www.iderapharma.com",
        "market_cap": "Small Cap"
    },
    "IDVR.CN": {
        "short_name": "INDVRBrands",
        "long_name": "INDVR Brands Inc.",
        "summary": "INDVR Brands Inc. focuses on providing management resources, and infrastructure and equipment for the production, cultivation, and dispensary operations of licensed cannabis businesses in the United States. The company offers its products under the Cannabis, The Joint, Incognito by Cannabis, Fire by Cannabis, Cannabis Prime, Fat Face Farms, Honu, and INDVR names. The company was formerly known as Cannabis One Holdings Inc. and changed its name to INDVR Brands Inc. in August 2020. INDVR Brands Inc. is headquartered in Denver, Colorado.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80205",
        "website": "http://cannabisone.life",
        "market_cap": "Small Cap"
    },
    "IDXG": {
        "short_name": "Interpace Biosciences, Inc.",
        "long_name": "Interpace Biosciences, Inc.",
        "summary": "Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Parsippany",
        "zipcode": "07054",
        "website": "http://www.interpace.com",
        "market_cap": "Small Cap"
    },
    "IDXX.MX": {
        "short_name": "IDEXX LABORATORIES INC",
        "long_name": "IDEXX Laboratories, Inc.",
        "summary": "IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "ME",
        "city": "Westbrook",
        "zipcode": "04092",
        "website": "http://www.idexx.com",
        "market_cap": "Large Cap"
    },
    "IDXX": {
        "short_name": "IDEXX Laboratories, Inc.",
        "long_name": "IDEXX Laboratories, Inc.",
        "summary": "IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "ME",
        "city": "Westbrook",
        "zipcode": "04092",
        "website": "http://www.idexx.com",
        "market_cap": "Large Cap"
    },
    "IDXX.VI": {
        "short_name": "IDEXX LABORATORIES INC",
        "long_name": "IDEXX Laboratories, Inc.",
        "summary": "IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "ME",
        "city": "Westbrook",
        "zipcode": "04092",
        "website": "http://www.idexx.com",
        "market_cap": "Large Cap"
    },
    "IDYA": {
        "short_name": "IDEAYA Biosciences, Inc.",
        "long_name": "IDEAYA Biosciences, Inc.",
        "summary": "IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.ideayabio.com",
        "market_cap": "Small Cap"
    },
    "IGMS": {
        "short_name": "IGM Biosciences, Inc.",
        "long_name": "IGM Biosciences, Inc.",
        "summary": "IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Mountain View",
        "zipcode": "94043",
        "website": "http://igmbio.com",
        "market_cap": "Small Cap"
    },
    "IGNT": {
        "short_name": "INGEN TECHNOLOGIES INC",
        "long_name": "Ingen Technologies, Inc.",
        "summary": "Ingen Technologies, Inc., a medical device manufacturing company, manufactures medical products for the respiratory industry in United States. The company manufactures medical equipment for patients suffering with chronic obstructive pulmonary disease; and oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademark name. Its Oxyview is a pneumatic metering device that displays and confirms the oxygen flow rate near the patient. Ingen Technologies, Inc. was founded in 1999 and is based in Riverside, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Riverside",
        "zipcode": "92503",
        "website": "http://www.ingen-tech.com",
        "market_cap": "Small Cap"
    },
    "IGPK": {
        "short_name": "INTEGRATED CANNABIS SOLUTIONS I",
        "long_name": "Integrated Cannabis Solutions, Inc.",
        "summary": "Integrated Cannabis Solutions, Inc. focuses on the growing and processing of hemp in the United States. The company intends to sell processed material in the form of Cannabidiol (CBD) or isolate to manufacturers or pharmaceutical companies for their manufacture, distribution, and sale of CBD related products, such as edibles for human consumption, vitamins, multi-vitamins, and topical products for human use comprises oils, tinctures, creams, oils and salves, and vaping liquids. Further, it is planning to promote and assist in the establishment of a co-op with local farmers for establishing a consistent supply of biomass and enter into long term purchase contracts. The company was formerly known as Integrated Parking Solutions, Inc. and changed its name to Integrated Cannabis Solutions, Inc. in April 2014. Integrated Cannabis Solutions, Inc. was founded in 2003 and is headquartered in Clermont, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Coconut Creek",
        "zipcode": "33073",
        "website": "http://www.igpk.org",
        "market_cap": "Small Cap"
    },
    "IGRW": {
        "short_name": "INTERACTIVE HEALTH NETWORK",
        "long_name": "Interactive Health Network",
        "summary": "Interactive Health Network, doing business as House of Mohan, distributes incense in the United States. Incense is composed of aromatic biotic materials, which release fragrant smoke when burned. It distributes 70 flavors, designer scents, zodiac signs scents, and a line of charcoal and natural herb incense. The company was formerly known as HPC POS System, Corp. and changed its name to Interactive Health Network in April 2014. Interactive Health Network was founded in 1995 and is based in Washington, District of Columbia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20012",
        "website": null,
        "market_cap": "Small Cap"
    },
    "IHAI": {
        "short_name": "INNOVATIVE HOLDINGS ALLIANCE IN",
        "long_name": "Innovative Holdings Alliance, Inc.",
        "summary": "Innovative Holdings Alliance, Inc., a medical technology holding company, offers personal care products in North America. The company offers arthritis cream product, a topical ointment that is used for site specific applications to provide temporary relief of pain and inflammation associated with arthritis and other musculoskeletal conditions. The company was formerly known as Innovative Health Sciences, Inc. and changed its name to Innovative Holdings Alliance, Inc. in May 2011. Innovative Holdings Alliance, Inc. was founded in 1996 and is based in Alpharetta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30039",
        "website": null,
        "market_cap": "Small Cap"
    },
    "IHTI": {
        "short_name": "INTEGRATIVE HEALTH TECHNOLOGIES",
        "long_name": "Integrative Health Technologies, Inc.",
        "summary": "Integrative Health Technologies, Inc. provides fee-based clinical trials, research and development, and consulting and testing services to the healthcare and nutritional industries. The company maintains a database that contains more than 30,000 tests and dates back more than 20 years which tracks the footprints of diseases. It also operates mobile and stationary dual energy x-ray absorptiometry (DEXA) body composition scanning units for measuring total body and regional bone densities, and body fat and lean mass. In addition, the company provides blood chemistry testing report that provides 43 chemistries, including HDL, LDL, C-reactive protein, thyroid, electrolytes, red and white blood cell counts, and glucose, etc. Integrative Health Technologies, Inc. was founded in 1999 and is based in San Antonio, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "San Antonio",
        "zipcode": "78209",
        "website": "http://ihtresearch.com",
        "market_cap": "Small Cap"
    },
    "IIN": {
        "short_name": "IntriCon Corporation",
        "long_name": "IntriCon Corporation",
        "summary": "IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. It offers micro-miniature products, microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components, and assemblies and software solutions for medical devices, hearing healthcare, and professional audio communication devices markets. The company also provides micro coils for surgical navigation clinical applications, such as interventional pulmonology, and electrophysiology; joint engineering and manufacturing services for complex medical devices, including catheters covering a range of applications for cardiology, peripheral vascular, neurology, radiology, and pulmonology; bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system; and safety needle products for original equipment manufacturing customers. In addition, it offers professional audio headset products used for emergency response needs in the fire, law enforcement, safety, aviation, and military markets; and a line of miniature ear-and head-worn devices used by performers and support staff in the music and stage performance markets. The company sells its hearing device products, and medical and professional audio communications products directly to hearing instrument manufacturers, distributors, and partnerships; and microphone products to the radio communication and professional audio industries, as well as markets and sells hearing aid devices directly to consumers through direct mail advertising, Internet, and call center. The company was formerly known as Selas Corporation of America and changed its name to IntriCon Corporation. The company was incorporated in 1930 and is headquartered in Arden Hills, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Arden Hills",
        "zipcode": "55112",
        "website": "http://www.intricon.com",
        "market_cap": "Small Cap"
    },
    "IKMA": {
        "short_name": "INTELAKARE MARKETING INC",
        "long_name": "IntelaKare Marketing, Inc.",
        "summary": "IntelaKare Marketing, Inc. provides online retail services for food products and home appliances. The company is based in Citra, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Citra",
        "zipcode": "32113",
        "website": null,
        "market_cap": "Small Cap"
    },
    "IKNA": {
        "short_name": "Ikena Oncology, Inc.",
        "long_name": "Ikena Oncology, Inc.",
        "summary": "Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://ikenaoncology.com",
        "market_cap": "Small Cap"
    },
    "IKT": {
        "short_name": "Inhibikase Therapeutics, Inc.",
        "long_name": "Inhibikase Therapeutics, Inc.",
        "summary": "Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It is also developing IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Atlanta",
        "zipcode": "30339",
        "website": "http://www.inhibikase.com",
        "market_cap": "Small Cap"
    },
    "IL3.F": {
        "short_name": "INTEGR.LIFES.HLDGS DL-,01",
        "long_name": "Integra LifeSciences Holdings Corporation",
        "summary": "Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.integralife.com",
        "market_cap": "Mid Cap"
    },
    "ILMN.MX": {
        "short_name": "ILLUMINA INC",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.illumina.com",
        "market_cap": "Large Cap"
    },
    "ILMN": {
        "short_name": "Illumina, Inc.",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.illumina.com",
        "market_cap": "Large Cap"
    },
    "ILMN.VI": {
        "short_name": "ILLUMINA INC",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.illumina.com",
        "market_cap": "Large Cap"
    },
    "ILU.DE": {
        "short_name": "ILLUMINA INC.  DL-,01",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.illumina.com",
        "market_cap": "Large Cap"
    },
    "ILU.F": {
        "short_name": "ILLUMINA INC.  DL-,01",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.illumina.com",
        "market_cap": "Large Cap"
    },
    "IM8N.F": {
        "short_name": "INSMED INC.  DL-,01",
        "long_name": "Insmed Incorporated",
        "summary": "Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bridgewater",
        "zipcode": "08807-1704",
        "website": "http://www.insmed.com",
        "market_cap": "Mid Cap"
    },
    "IM8N.SG": {
        "short_name": "Insmed Inc. Registered Shares D",
        "long_name": "Insmed Incorporated",
        "summary": "Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bridgewater",
        "zipcode": "08807-1704",
        "website": "http://www.insmed.com",
        "market_cap": "Mid Cap"
    },
    "IMAC": {
        "short_name": "IMAC Holdings, Inc.",
        "long_name": "IMAC Holdings, Inc.",
        "summary": "IMAC Holdings, Inc. provides orthopedic therapies through a chain of innovative medical advancements and care regeneration centers in the United States. Its outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. As of December 31, 2020, the company operated 16 outpatient clinics in Kentucky, Missouri, Tennessee, Illinois, and Florida. IMAC Holdings, Inc. was founded in 2000 and is based in Brentwood, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Brentwood",
        "zipcode": "37027",
        "website": "http://www.imacregeneration.com",
        "market_cap": "Small Cap"
    },
    "IMGN.MX": {
        "short_name": "IMMUNOGEN INC",
        "long_name": "ImmunoGen, Inc.",
        "summary": "ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451-1477",
        "website": "http://www.immunogen.com",
        "market_cap": "Small Cap"
    },
    "IMGN": {
        "short_name": "ImmunoGen, Inc.",
        "long_name": "ImmunoGen, Inc.",
        "summary": "ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451-1477",
        "website": "http://www.immunogen.com",
        "market_cap": "Small Cap"
    },
    "IMNM": {
        "short_name": "Immunome, Inc.",
        "long_name": "Immunome, Inc.",
        "summary": "Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Exton",
        "zipcode": "19341",
        "website": "http://immunome.com",
        "market_cap": "Small Cap"
    },
    "IMNPQ": {
        "short_name": "IMMUNE PHARMACEUTICALS INC",
        "long_name": "Immune Pharmaceuticals, Inc.",
        "summary": "Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Fort Lee",
        "zipcode": "07024",
        "website": "http://www.immunepharma.com",
        "market_cap": "Small Cap"
    },
    "IMPL": {
        "short_name": "Impel NeuroPharma, Inc. Common Stock",
        "long_name": "Impel NeuroPharma, Inc. Common Stock",
        "summary": "Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98119",
        "website": "http://www.Impelnp.com",
        "market_cap": null
    },
    "IMR.AX": {
        "short_name": "IMRICOR CDI FORUS",
        "long_name": "Imricor Medical Systems, Inc.",
        "summary": "Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an electrophysiology amplifier and recording system with integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. The company also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United States",
        "state": "MN",
        "city": "Burnsville",
        "zipcode": "55337",
        "website": "http://www.imricor.com",
        "market_cap": "Small Cap"
    },
    "IMRA": {
        "short_name": "IMARA Inc.",
        "long_name": "IMARA Inc.",
        "summary": "IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and \u00c3\u009f-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://imaratx.com",
        "market_cap": "Small Cap"
    },
    "IMTH": {
        "short_name": "INNOVATIVE MEDTECH INC",
        "long_name": "Innovative MedTech Inc.",
        "summary": "Innovative MedTech Inc. provides natural and organic food products. It offers bars and pizza products. The company was formerly known as Fresh Harvest Products, Inc. and changed its name to Innovative MedTech Inc. in March 2021. Innovative MedTech Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://innovativemedtechinc.com",
        "market_cap": "Small Cap"
    },
    "IMU.DE": {
        "short_name": "IMMUNOGEN INC.  DL-,01",
        "long_name": "ImmunoGen, Inc.",
        "summary": "ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451-1477",
        "website": "http://www.immunogen.com",
        "market_cap": "Small Cap"
    },
    "IMU.F": {
        "short_name": "IMMUNOGEN INC.  DL-,01",
        "long_name": "ImmunoGen, Inc.",
        "summary": "ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451-1477",
        "website": "http://www.immunogen.com",
        "market_cap": "Small Cap"
    },
    "IMUC": {
        "short_name": "IMMUNOCELLULAR THERAPEUTICS LTD",
        "long_name": "ImmunoCellular Therapeutics, Ltd.",
        "summary": "ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Westlake Village",
        "zipcode": "91362",
        "website": "http://www.imuc.com",
        "market_cap": "Small Cap"
    },
    "IMUN": {
        "short_name": "IMMUNE THERAPEUTICS INC FLA",
        "long_name": "Immune Therapeutics, Inc.",
        "summary": "Immune Therapeutics, Inc. focuses on the development, approval, and commercialization of pharmaceutical products. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. was incorporated in 1993 and is headquartered in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Winter Park",
        "zipcode": "32792",
        "website": "http://www.immunetherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "IMUX": {
        "short_name": "Immunic, Inc.",
        "long_name": "Immunic, Inc.",
        "summary": "Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.immunic-therapeutics.com",
        "market_cap": "Small Cap"
    },
    "IMVT": {
        "short_name": "Immunovant, Inc.",
        "long_name": "Immunovant, Inc.",
        "summary": "Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10018",
        "website": "http://www.immunovant.com",
        "market_cap": "Small Cap"
    },
    "INBX": {
        "short_name": "Inhibrx, Inc.",
        "long_name": "Inhibrx, Inc.",
        "summary": "Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://inhibrx.com",
        "market_cap": "Small Cap"
    },
    "INCY.MX": {
        "short_name": "INCYTE CORPORATION",
        "long_name": "Incyte Corporation",
        "summary": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat na\u00c3\u00afve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "DE",
        "city": "Wilmington",
        "zipcode": "19803",
        "website": "http://www.incyte.com",
        "market_cap": "Large Cap"
    },
    "INCY": {
        "short_name": "Incyte Corporation",
        "long_name": "Incyte Corporation",
        "summary": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat na\u00c3\u00afve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "DE",
        "city": "Wilmington",
        "zipcode": "19803",
        "website": "http://www.incyte.com",
        "market_cap": "Large Cap"
    },
    "INCY.VI": {
        "short_name": "INCYTE CORP",
        "long_name": "Incyte Corporation",
        "summary": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat na\u00c3\u00afve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "DE",
        "city": "Wilmington",
        "zipcode": "19803",
        "website": "http://www.incyte.com",
        "market_cap": "Large Cap"
    },
    "INDV.L": {
        "short_name": "INDIVIOR PLC ORD USD0.10",
        "long_name": "Indivior PLC",
        "summary": "Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United States",
        "state": "VA",
        "city": "North Chesterfield",
        "zipcode": "23235",
        "website": "http://www.indivior.com",
        "market_cap": null
    },
    "INFI": {
        "short_name": "Infinity Pharmaceuticals, Inc.",
        "long_name": "Infinity Pharmaceuticals, Inc.",
        "summary": "Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02138",
        "website": "http://www.infi.com",
        "market_cap": "Small Cap"
    },
    "INFU": {
        "short_name": "InfuSystems Holdings, Inc.",
        "long_name": "InfuSystem Holdings Inc.",
        "summary": "InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) Services. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Rochester Hills",
        "zipcode": "48309",
        "website": "http://www.infusystem.com",
        "market_cap": "Small Cap"
    },
    "INGN": {
        "short_name": "Inogen, Inc",
        "long_name": "Inogen, Inc.",
        "summary": "Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Goleta",
        "zipcode": "93117",
        "website": "http://www.inogen.com",
        "market_cap": "Small Cap"
    },
    "INIS": {
        "short_name": "INTERNATIONAL ISOTOPES INC",
        "long_name": "International Isotopes Inc.",
        "summary": "International Isotopes, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally. It operates through four segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, and Radiological Services. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. It offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources. The Radiochemical Products segment produces and distributes various isotopically pure radiochemicals and sodium iodide I-131 generic drug product for medical, industrial, and research applications. The Radiological Services segment provides flood source disposal and gemstones processing services. The company sells its products directly to end users and distributors. International Isotopes, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "ID",
        "city": "Idaho Falls",
        "zipcode": "83401",
        "website": "http://www.intisoid.com",
        "market_cap": "Small Cap"
    },
    "INLB": {
        "short_name": "ITEM 9 LABS CORP",
        "long_name": "Item 9 Labs Corp.",
        "summary": "Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers products through licensed dispensaries to consumers in Arizona. The company is headquartered in Phoenix, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Phoenix",
        "zipcode": "85004",
        "website": "http://www.item9labscorp.com",
        "market_cap": "Small Cap"
    },
    "INMB": {
        "short_name": "INmune Bio Inc.",
        "long_name": "INmune Bio, Inc.",
        "summary": "INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://www.inmunebio.com",
        "market_cap": "Small Cap"
    },
    "INND": {
        "short_name": "INNERSCOPE HEARING TECHNOLOGIES",
        "long_name": "InnerScope Hearing Technologies, Inc.",
        "summary": "InnerScope Hearing Technologies, Inc. provides hearing aids and its hearable, and wearable personal sound amplifier products to retail hearing aid dispensing community. The company engages in the provision of manufacturing and direct-to-consumer distribution/retail of hearing aids, personal sound amplifier products, hearing related treatment therapies, doctor-formulated dietary hearing supplements, and proprietary CDB oil for treating tinnitus. It also owns and operates 11 audiological and retail hearing device clinics; and offers business to business SaaS based patient management system software program. The company was formerly known as Innerscope Advertising Agency, Inc. and changed its name to InnerScope Hearing Technologies, Inc. in August 2017. InnerScope Hearing Technologies, Inc. was incorporated in 2012 and is headquartered in Roseville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Roseville",
        "zipcode": "95661",
        "website": "http://www.innd.com",
        "market_cap": "Small Cap"
    },
    "INNV": {
        "short_name": "InnovAge Holding Corp.",
        "long_name": "InnovAge Holding Corp.",
        "summary": "InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. The company offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, dental, mental health and psychiatric, meals, and activities, as well as physical, occupational, and speech therapy; transportation to the PACE center and third-party medical appointments; and care management. It serves approximately 6,600 PACE participants in the United States of America; and operates seventeen PACE centers in Colorado, California, New Mexico, Pennsylvania, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80230",
        "website": "http://www.innovage.com",
        "market_cap": "Mid Cap"
    },
    "INO.MX": {
        "short_name": "INOVIO PHARMACEUTICALS INC",
        "long_name": "Inovio Pharmaceuticals, Inc.",
        "summary": "Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "PA",
        "city": "Plymouth Meeting",
        "zipcode": "19462",
        "website": "http://www.inovio.com",
        "market_cap": "Small Cap"
    },
    "INO": {
        "short_name": "Inovio Pharmaceuticals, Inc.",
        "long_name": "Inovio Pharmaceuticals, Inc.",
        "summary": "Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Plymouth Meeting",
        "zipcode": "19462",
        "website": "http://www.inovio.com",
        "market_cap": "Small Cap"
    },
    "INOV": {
        "short_name": "Inovalon Holdings, Inc.",
        "long_name": "Inovalon Holdings, Inc.",
        "summary": "Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare. It operates Inovalon ONE Platform, an integrated, real-time cloud native platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities. In addition, it offers advisory, implementation, and support services. The company serves health plans and provider organizations, as well as pharmaceutical, medical device, and diagnostics companies. Its platforms include information of data pertaining to approximately one million physicians; 574,000 clinical facilities; and approximately 332 million individuals and 61 billion medical events. Inovalon Holdings, Inc. was founded in 1998 and is headquartered in Bowie, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Bowie",
        "zipcode": "20716",
        "website": "http://www.inovalon.com",
        "market_cap": "Mid Cap"
    },
    "INQD": {
        "short_name": "INDOOR HARVEST CORP",
        "long_name": "Indoor Harvest Corp.",
        "summary": "Indoor Harvest Corp. focuses on leveraging technology and planning on vertical farming, building integrated agriculture, controlled environment agriculture, and aeroponic cultivation in the United States. It develops proprietary high pressure aeroponic cultivation system designs, as well as flood and drain, and floating raft designs for cannabis and other agriculture products. The company offers Modular HP-Aeroponics, Low Tide VFRack, and Shallow Raft VFRack platforms under the Indoor Harvest brand. Indoor Harvest Corp. was founded in 2011 and is based in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78739",
        "website": null,
        "market_cap": "Small Cap"
    },
    "INSM": {
        "short_name": "Insmed, Inc.",
        "long_name": "Insmed Incorporated",
        "summary": "Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bridgewater",
        "zipcode": "08807-1704",
        "website": "http://www.insmed.com",
        "market_cap": "Mid Cap"
    },
    "INSO": {
        "short_name": "INDUSTRY SOURCE CONSULTING INC",
        "long_name": "Industry Source Consulting, Inc.",
        "summary": "Industry Source Consulting, Inc. focuses on providing various management services to the legal cannabis industry in the United States and Canada. The company was formerly known as Vega Biofuels, Inc. Industry Source Consulting, Inc. was founded in 1986 and is based in Norcross, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Norcross",
        "zipcode": "30010",
        "website": "http://insoconsulting.com",
        "market_cap": null
    },
    "INSP": {
        "short_name": "Inspire Medical Systems, Inc.",
        "long_name": "Inspire Medical Systems, Inc.",
        "summary": "Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Golden Valley",
        "zipcode": "55416",
        "website": "http://www.inspiresleep.com",
        "market_cap": "Mid Cap"
    },
    "INTI": {
        "short_name": "INHIBITOR THERAPEUTICS INC",
        "long_name": "Inhibitor Therapeutics, Inc.",
        "summary": "Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33602",
        "website": "http://www.inhibitortx.com",
        "market_cap": "Small Cap"
    },
    "INTP": {
        "short_name": "INTEGRATED PHARMACEUTICALS INC",
        "long_name": "Integrated Pharmaceuticals, Inc.",
        "summary": "Integrated Pharmaceuticals, Inc. develops and produces specialty chemicals and nutraceuticals in the United States. It offers compounds and nutraceuticals that have proven therapeutic or nutritional value in humans, plants, and animals. The company also develops technologies for the production of clinically active pharmaceutical compounds, including active small molecules and recombinant DNA technology derived products. In addition, it offers calcium supplements that are used in soft drinks, coffee, tea, soup, dehydrated sauces, and beverages; and fortified bottled water. The company sells its products through distributors and retailers. The company was formerly known as Digital Caddies, Inc. and changed its name to Integrated Pharmaceuticals, Inc. in September 2011. The company was incorporated in 1969 and is based in Fitchburg, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Fitchburg",
        "zipcode": "01420",
        "website": null,
        "market_cap": "Small Cap"
    },
    "INVA": {
        "short_name": "Innoviva, Inc.",
        "long_name": "Innoviva, Inc.",
        "summary": "Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Burlingame",
        "zipcode": "94010",
        "website": "http://www.inva.com",
        "market_cap": "Small Cap"
    },
    "INVO": {
        "short_name": "INVO BioScience, Inc.",
        "long_name": "INVO Bioscience, Inc.",
        "summary": "INVO Bioscience, Inc., a medical device company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a patented intravaginal culture system used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. The company was founded in 2007 and is based in Sarasota, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Sarasota",
        "zipcode": "34240",
        "website": "http://www.invobioscience.com",
        "market_cap": "Small Cap"
    },
    "INVVY": {
        "short_name": "INDIVIOR PLC",
        "long_name": "Indivior PLC",
        "summary": "Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "North Chesterfield",
        "zipcode": "23235",
        "website": "http://www.indivior.com",
        "market_cap": "Small Cap"
    },
    "INZY": {
        "short_name": "Inozyme Pharma, Inc.",
        "long_name": "Inozyme Pharma, Inc.",
        "summary": "Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.inozyme.com",
        "market_cap": "Small Cap"
    },
    "IOM.V": {
        "short_name": "ASSURE HOLDINGS CORP",
        "long_name": "Assure Holdings Corp.",
        "summary": "Assure Holdings Corp., together with its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services primarily associated with spine and head surgeries to physicians. The company has operations in Louisiana, Michigan, Pennsylvania, Texas, Colorado, South Carolina, and Arizona, the United States. Assure Holdings Corp. is based in Denver, Colorado.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80237",
        "website": "http://www.assureneuromonitoring.com",
        "market_cap": "Small Cap"
    },
    "IONC.CN": {
        "short_name": "IonicBrands",
        "long_name": "Ionic Brands Corp.",
        "summary": "Ionic Brands Corp. provides cannabis related services in Washington and Oregon. The company manufacture and distribute hard goods, such as cartridges, applicators, pens, jars, etc. under the IONIC brand name. The company is headquartered in Tacoma, Washington.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "WA",
        "city": "Tacoma",
        "zipcode": "98402",
        "website": "http://www.ionicbrands.com",
        "market_cap": "Small Cap"
    },
    "IONKF": {
        "short_name": "IONIC BRANDS CORP",
        "long_name": "Ionic Brands Corp.",
        "summary": "Ionic Brands Corp. provides cannabis related services in Washington and Oregon. The company manufacture and distribute hard goods, such as cartridges, applicators, pens, jars, etc. under the IONIC brand name. The company is headquartered in Tacoma, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Tacoma",
        "zipcode": "98402",
        "website": "http://www.ionicbrands.com",
        "market_cap": "Small Cap"
    },
    "IONS.MX": {
        "short_name": "IONIS PHARMACEUTICALS INC",
        "long_name": "Ionis Pharmaceuticals, Inc.",
        "summary": "Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92010",
        "website": "http://www.ionispharma.com",
        "market_cap": "Mid Cap"
    },
    "IONS": {
        "short_name": "Ionis Pharmaceuticals, Inc.",
        "long_name": "Ionis Pharmaceuticals, Inc.",
        "summary": "Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92010",
        "website": "http://www.ionispharma.com",
        "market_cap": "Mid Cap"
    },
    "IOV.F": {
        "short_name": "INOVALON HLD. A DL-000025",
        "long_name": "Inovalon Holdings, Inc.",
        "summary": "Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare. It operates Inovalon ONE Platform, an integrated, real-time cloud native platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities. In addition, it offers advisory, implementation, and support services. The company serves health plans and provider organizations, as well as pharmaceutical, medical device, and diagnostics companies. Its platforms include information of data pertaining to approximately one million physicians; 574,000 clinical facilities; and approximately 332 million individuals and 61 billion medical events. Inovalon Holdings, Inc. was founded in 1998 and is headquartered in Bowie, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Bowie",
        "zipcode": "20716",
        "website": "http://www.inovalon.com",
        "market_cap": "Mid Cap"
    },
    "IOVA": {
        "short_name": "Iovance Biotherapeutics, Inc.",
        "long_name": "Iovance Biotherapeutics, Inc.",
        "summary": "Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Universit\u00c3\u00a9 de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Carlos",
        "zipcode": "94070",
        "website": "http://www.iovance.com",
        "market_cap": "Mid Cap"
    },
    "IPIX": {
        "short_name": "INNOVATION PHARMACEUTICALS INC",
        "long_name": "Innovation Pharmaceuticals Inc.",
        "summary": "Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Wakefield",
        "zipcode": "01880",
        "website": "http://www.ipharminc.com",
        "market_cap": "Small Cap"
    },
    "IQT.F": {
        "short_name": "INHIBIKASE THERAP. INC.",
        "long_name": "Inhibikase Therapeutics, Inc.",
        "summary": "Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It is also developing IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "GA",
        "city": "Atlanta",
        "zipcode": "30339",
        "website": "http://www.inhibikase.com",
        "market_cap": "Small Cap"
    },
    "IQV.MX": {
        "short_name": "IQVIA HOLDINGS INC",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CT",
        "city": "Danbury",
        "zipcode": "06810",
        "website": "http://www.iqvia.com",
        "market_cap": "Large Cap"
    },
    "IQV": {
        "short_name": "IQVIA Holdings, Inc.",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Danbury",
        "zipcode": "06810",
        "website": "http://www.iqvia.com",
        "market_cap": "Large Cap"
    },
    "IQVH.VI": {
        "short_name": "IQVIA HOLDINGS INC",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "CT",
        "city": "Danbury",
        "zipcode": "06810",
        "website": "http://www.iqvia.com",
        "market_cap": "Large Cap"
    },
    "IRIX": {
        "short_name": "IRIDEX Corporation",
        "long_name": "IRIDEX Corporation",
        "summary": "IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Mountain View",
        "zipcode": "94043",
        "website": "http://www.iridex.com",
        "market_cap": "Small Cap"
    },
    "IRMD": {
        "short_name": "iRadimed Corporation",
        "long_name": "IRadimed Corporation",
        "summary": "IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Winter Springs",
        "zipcode": "32708",
        "website": "http://www.iradimed.com",
        "market_cap": "Small Cap"
    },
    "IRTC": {
        "short_name": "iRhythm Technologies, Inc.",
        "long_name": "iRhythm Technologies, Inc.",
        "summary": "iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94103",
        "website": "http://www.irhythmtech.com",
        "market_cap": "Mid Cap"
    },
    "IRWD": {
        "short_name": "Ironwood Pharmaceuticals, Inc.",
        "long_name": "Ironwood Pharmaceuticals, Inc.",
        "summary": "Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02110",
        "website": "http://www.ironwoodpharma.com",
        "market_cap": "Small Cap"
    },
    "ISCO": {
        "short_name": "INTERNATIONAL STEM CELL CORPORA",
        "long_name": "International Stem Cell Corporation",
        "summary": "International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was incorporated in 2005 and is headquartered in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008",
        "website": "http://www.internationalstemcell.com",
        "market_cap": "Small Cap"
    },
    "ISEE": {
        "short_name": "IVERIC bio, Inc.",
        "long_name": "IVERIC bio, Inc.",
        "summary": "IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10001",
        "website": "http://ivericbio.com",
        "market_cap": "Small Cap"
    },
    "ISHI": {
        "short_name": "ISLET HLDGS INC",
        "long_name": "Islet Holdings, Inc.",
        "summary": "Islet Holdings, Inc. offers skincare products in the United States. It provides acne-prone skin products, anti-aging products, berridroxies, botanical products, eye treatments, moisturizers and creams, sensitive skin products, toners and cleansers, and specialized products. The company also distributes skincare products of various other brands. It offers products online. Islet Holdings, Inc. was formerly known as Biozhem Cosmeceuticals, Inc. and changed its name to Islet Holdings, Inc. in May 2009. The company was incorporated in 1984 and is based in Grass Valley, California. It has a customer service center in Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Grass Valley",
        "zipcode": "95949",
        "website": "http://www.revitacell.com",
        "market_cap": "Small Cap"
    },
    "ISI.F": {
        "short_name": "IONIS PHARMACEUT.  DL-001",
        "long_name": "Ionis Pharmaceuticals, Inc.",
        "summary": "Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92010",
        "website": "http://www.ionispharma.com",
        "market_cap": "Mid Cap"
    },
    "ISR": {
        "short_name": "IsoRay, Inc.",
        "long_name": "Isoray, Inc.",
        "summary": "Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Richland",
        "zipcode": "99354",
        "website": "http://isoray.com",
        "market_cap": "Small Cap"
    },
    "ISRG.MX": {
        "short_name": "INTUITIVE SURGICAL INC",
        "long_name": "Intuitive Surgical, Inc.",
        "summary": "Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Sunnyvale",
        "zipcode": "94086-5304",
        "website": "http://www.intuitive.com",
        "market_cap": "Large Cap"
    },
    "ISRG": {
        "short_name": "Intuitive Surgical, Inc.",
        "long_name": "Intuitive Surgical, Inc.",
        "summary": "Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Sunnyvale",
        "zipcode": "94086-5304",
        "website": "http://www.intuitive.com",
        "market_cap": "Large Cap"
    },
    "ISRG.VI": {
        "short_name": "INTUITIVE SURGICAL INC",
        "long_name": "Intuitive Surgical, Inc.",
        "summary": "Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "CA",
        "city": "Sunnyvale",
        "zipcode": "94086-5304",
        "website": "http://www.intuitive.com",
        "market_cap": "Large Cap"
    },
    "ITCI": {
        "short_name": "Intra-Cellular Therapies Inc.",
        "long_name": "Intra-Cellular Therapies, Inc.",
        "summary": "Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.intracellulartherapies.com",
        "market_cap": "Mid Cap"
    },
    "ITGR": {
        "short_name": "Integer Holdings Corporation",
        "long_name": "Integer Holdings Corporation",
        "summary": "Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Plano",
        "zipcode": "75024",
        "website": "http://www.integer.net",
        "market_cap": "Mid Cap"
    },
    "ITH.F": {
        "short_name": "NEKTAR THERAPEUTICS",
        "long_name": "Nektar Therapeutics",
        "summary": "Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94158",
        "website": "http://www.nektar.com",
        "market_cap": "Mid Cap"
    },
    "ITHUF": {
        "short_name": "IANTHUS CAPITAL HOLDINGS INC",
        "long_name": "iAnthus Capital Holdings, Inc.",
        "summary": "iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. It offers biomass products, such as pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures; cannabidiol products, such as topical creams, tinctures, and sprays, as well as products for beauty and skincare that include lotions, creams, haircare products, lip balms, and bath bombs. The company engages in the wholesale-distribution and retail of CBD products. It owns and/or operates 31 dispensaries and 10 cultivation and/or processing facilities in 9 states. The company is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10170",
        "website": "http://www.ianthus.com",
        "market_cap": "Small Cap"
    },
    "ITMC": {
        "short_name": "ITOCO INC",
        "long_name": "Itoco Inc.",
        "summary": "Itoco Inc. engages in the processing, production, and distribution of medical cannabis products. The company was formerly known as Itoco Mining Corporation and changed its name to Itoco Inc. in May 2018. Itoco Inc. is based in Reno, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Reno",
        "zipcode": "89501",
        "website": "http://www.itoco.net",
        "market_cap": "Small Cap"
    },
    "ITNS": {
        "short_name": "ITONIS INC",
        "long_name": "Itonis, Inc.",
        "summary": "Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line. The company was formerly known as Kenshou, Inc. and changed its name to Itonis, Inc. in December 2005. Itonis, Inc. was founded in 2005 and is headquartered in Laguna Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Laguna Hills",
        "zipcode": "92653",
        "website": "http://www.itonisholdings.com",
        "market_cap": "Small Cap"
    },
    "ITOS": {
        "short_name": "iTeos Therapeutics, Inc.",
        "long_name": "iTeos Therapeutics, Inc.",
        "summary": "Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.iteostherapeutics.com",
        "market_cap": "Small Cap"
    },
    "IUI1.F": {
        "short_name": "INTUITIVE SURGIC. DL-,001",
        "long_name": "Intuitive Surgical, Inc.",
        "summary": "Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Sunnyvale",
        "zipcode": "94086-5304",
        "website": "http://www.intuitive.com",
        "market_cap": "Large Cap"
    },
    "IUL.F": {
        "short_name": "IMMUCELL CORP.  DL-,10",
        "long_name": "ImmuCell Corporation",
        "summary": "ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "ME",
        "city": "Portland",
        "zipcode": "04103",
        "website": "http://immucell.com",
        "market_cap": "Small Cap"
    },
    "IV3.F": {
        "short_name": "INVACARE CORP.",
        "long_name": "Invacare Corporation",
        "summary": "Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company offers mobility and seating products, such as power wheelchairs under the Invacare TDX brand; custom manual wheelchairs under the Invacare, Invacare Top End, and K\u00c3\u00bcschall brand names; and seating and positioning products under the Invacare brand, as well as custom molded seat modules under the PinDot brand. It also provides lifestyle products, including pressure relieving overlays and mattress systems under the Invacare Softform and microAIR brands; safe patient handling products under the Birdie, Evo, and ISA brands; residential and institutional care beds and bed accessories, and manual wheelchairs under the Invacare brand name; and personal care products. In addition, the company offers respiratory therapy products comprising stationary oxygen concentrators under the Platinum and Perfecto2 brands; portable oxygen concentrators under the Platinum brand; and Invacare HomeFill oxygen systems. Further, it provides repair, equipment rentals, and external contracting services, as well as distributes heart rate monitors, thermometers, and nebulizers; and portable ramps. The company sells its products primarily to home medical equipment providers through retail and e-commerce channels, as well as to residential care operators, dealers, and government health service customers through its sales force, independent manufacturers' representatives, and distributors. Invacare Corporation was founded in 1885 and is headquartered in Elyria, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Elyria",
        "zipcode": "44035-4190",
        "website": "http://www.invacare.com",
        "market_cap": "Small Cap"
    },
    "IV8.F": {
        "short_name": "INVITAE CORP.  DL-,0001",
        "long_name": "Invitae Corporation",
        "summary": "Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94103",
        "website": "http://www.invitae.com",
        "market_cap": "Mid Cap"
    },
    "IVC": {
        "short_name": "Invacare Corporation",
        "long_name": "Invacare Corporation",
        "summary": "Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company offers mobility and seating products, such as power wheelchairs under the Invacare TDX brand; custom manual wheelchairs under the Invacare, Invacare Top End, and K\u00c3\u00bcschall brand names; and seating and positioning products under the Invacare brand, as well as custom molded seat modules under the PinDot brand. It also provides lifestyle products, including pressure relieving overlays and mattress systems under the Invacare Softform and microAIR brands; safe patient handling products under the Birdie, Evo, and ISA brands; residential and institutional care beds and bed accessories, and manual wheelchairs under the Invacare brand name; and personal care products. In addition, the company offers respiratory therapy products comprising stationary oxygen concentrators under the Platinum and Perfecto2 brands; portable oxygen concentrators under the Platinum brand; and Invacare HomeFill oxygen systems. Further, it provides repair, equipment rentals, and external contracting services, as well as distributes heart rate monitors, thermometers, and nebulizers; and portable ramps. The company sells its products primarily to home medical equipment providers through retail and e-commerce channels, as well as to residential care operators, dealers, and government health service customers through its sales force, independent manufacturers' representatives, and distributors. Invacare Corporation was founded in 1885 and is headquartered in Elyria, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Elyria",
        "zipcode": "44035-4190",
        "website": "http://www.invacare.com",
        "market_cap": "Small Cap"
    },
    "IVRO": {
        "short_name": "INVITRO INTERNATIONAL",
        "long_name": "InVitro International",
        "summary": "InVitro International develops test kits for non-animal testing in the United States and internationally. Its products include Irritection Assay System, an invitro test, which could be used to detect, rank, and predict the ocular and/or dermal irritation potential of cosmetics, consumer products, pharmaceuticals, and chemical raw materials; and Corrositex, an invitro test that determines chemical corrosivity. The company also provides customized technology services for Irritection Assay System installation and testing process, as well as independent testing laboratory services for irritancy and corrosivity testing requirements. Its products are principally used by the manufacturers of surfactants, petrochemicals, cosmetics, textiles, paper and pulp, pharmaceuticals, films and resins, solvents and cleaners, and other chemical raw materials. The company was founded in 1985 and is headquartered in Placentia, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Placentia",
        "zipcode": "92870",
        "website": "http://www.invitrointl.com",
        "market_cap": "Small Cap"
    },
    "IX1.F": {
        "short_name": "IDEXX LABS INC.  DL-,10",
        "long_name": "IDEXX Laboratories, Inc.",
        "summary": "IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "ME",
        "city": "Westbrook",
        "zipcode": "04092",
        "website": "http://www.idexx.com",
        "market_cap": "Large Cap"
    },
    "IX4.F": {
        "short_name": "IRIDEX CORP.  DL-,01",
        "long_name": "IRIDEX Corporation",
        "summary": "IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Mountain View",
        "zipcode": "94043",
        "website": "http://www.iridex.com",
        "market_cap": "Small Cap"
    },
    "IZQVF": {
        "short_name": "INDIVIOR PLC",
        "long_name": "Indivior PLC",
        "summary": "Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "North Chesterfield",
        "zipcode": "23235",
        "website": "http://www.indivior.com",
        "market_cap": "Small Cap"
    },
    "JAGX": {
        "short_name": "Jaguar Health, Inc.",
        "long_name": "Jaguar Health, Inc.",
        "summary": "Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94104",
        "website": "http://www.jaguar.health",
        "market_cap": "Small Cap"
    },
    "JNCE": {
        "short_name": "Jounce Therapeutics, Inc.",
        "long_name": "Jounce Therapeutics, Inc.",
        "summary": "Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://jouncetx.com",
        "market_cap": "Small Cap"
    },
    "JNJ.BA": {
        "short_name": "JOHNSON & JOHNSON",
        "long_name": "Johnson & Johnson",
        "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "NJ",
        "city": "New Brunswick",
        "zipcode": "08933",
        "website": "http://www.jnj.com",
        "market_cap": "Large Cap"
    },
    "JNJ.DE": {
        "short_name": "JOHNSON + JOHNSON  DL 1",
        "long_name": "Johnson & Johnson",
        "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "NJ",
        "city": "New Brunswick",
        "zipcode": "08933",
        "website": "http://www.jnj.com",
        "market_cap": "Large Cap"
    },
    "JNJ.F": {
        "short_name": "JOHNSON + JOHNSON  DL 1",
        "long_name": "Johnson & Johnson",
        "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "New Brunswick",
        "zipcode": "08933",
        "website": "http://www.jnj.com",
        "market_cap": "Large Cap"
    },
    "JNJ.MX": {
        "short_name": "JOHNSON & JOHNSON",
        "long_name": "Johnson & Johnson",
        "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NJ",
        "city": "New Brunswick",
        "zipcode": "08933",
        "website": "http://www.jnj.com",
        "market_cap": "Large Cap"
    },
    "JNJ": {
        "short_name": "Johnson & Johnson",
        "long_name": "Johnson & Johnson",
        "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "New Brunswick",
        "zipcode": "08933",
        "website": "http://www.jnj.com",
        "market_cap": "Large Cap"
    },
    "JNJ.SN": {
        "short_name": "JOHNSON & JOHNSON",
        "long_name": "Johnson & Johnson",
        "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SGO",
        "market": "cl_market",
        "country": "United States",
        "state": "NJ",
        "city": "New Brunswick",
        "zipcode": "08933",
        "website": "http://www.jnj.com",
        "market_cap": "Large Cap"
    },
    "JNJ.VI": {
        "short_name": "JOHNSON & JOHNSON",
        "long_name": "Johnson & Johnson",
        "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "NJ",
        "city": "New Brunswick",
        "zipcode": "08933",
        "website": "http://www.jnj.com",
        "market_cap": "Large Cap"
    },
    "JNJB34.SA": {
        "short_name": "JOHNSON     DRN",
        "long_name": "Johnson & Johnson",
        "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NJ",
        "city": "New Brunswick",
        "zipcode": "08933",
        "website": "http://www.jnj.com",
        "market_cap": "Large Cap"
    },
    "JTBK": {
        "short_name": "JETBLACK CORP",
        "long_name": "Jetblack Corp.",
        "summary": "Jetblack Corp., through its subsidiaries, operates in the cannabis industry. The company is in the process of transferring ownership and locations for a Tier 1 Marijuana Producers Licenses with OLCC. The company has finalized an agreement to begin the process of transferring ownership and locations of an Oregon Marijuana Processors License. It also applied for other licenses with OLCC, such as an Oregon Marijuana Wholesale License. Jetblack Corp. was founded in 2002 and is based in Portland, Oregon.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OR",
        "city": "Portland",
        "zipcode": "97239",
        "website": "http://www.jetblackcorp.com",
        "market_cap": "Small Cap"
    },
    "JUPW": {
        "short_name": "Jupiter Wellness, Inc.",
        "long_name": "Jupiter Wellness, Inc.",
        "summary": "Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for use in the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CaniSun, a CBD-infused sunscreen; and CaniSkin, a CBD-infused skin care lotion. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Jupiter",
        "zipcode": "33477",
        "website": "http://www.jupiterwellnessinc.com",
        "market_cap": "Small Cap"
    },
    "JUSH.CN": {
        "short_name": "JushiHdgClassB",
        "long_name": "Jushi Holdings Inc.",
        "summary": "Jushi Holdings Inc., a cannabis and hemp company, engages in the cultivation, processing, retail, and distribution of medical and adult-use products. It focuses on building a portfolio of branded cannabis and hemp-derived assets in various jurisdictions in Pennsylvania, Virginia, Ohio, Illinois, California, and Nevada. The company operates 11 retail locations under the BEYOND/HELLO retail brand, which include 8 medical dispensaries in Ardmore, Bristol, Johnstown, Philadelphia, Reading, Scranton, and West Chester, Pennsylvania; and 2 adult-use and medical dispensaries located in Sauget and Normal, Illinois. It also offers hemp-based CBD products under the Nira brand. The company was founded in 2018 and is headquartered in Boca Raton, Florida.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33431",
        "website": "http://www.jushico.com",
        "market_cap": "Small Cap"
    },
    "JUSHF": {
        "short_name": "JUSHI HOLDINGS INC",
        "long_name": "Jushi Holdings Inc.",
        "summary": "Jushi Holdings Inc., a cannabis and hemp company, engages in the cultivation, processing, retail, and distribution of medical and adult-use products. It focuses on building a portfolio of branded cannabis and hemp-derived assets in various jurisdictions in Pennsylvania, Virginia, Ohio, Illinois, California, and Nevada. The company operates 11 retail locations under the BEYOND/HELLO retail brand, which include 8 medical dispensaries in Ardmore, Bristol, Johnstown, Philadelphia, Reading, Scranton, and West Chester, Pennsylvania; and 2 adult-use and medical dispensaries located in Sauget and Normal, Illinois. It also offers hemp-based CBD products under the Nira brand. The company was founded in 2018 and is headquartered in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33431",
        "website": "http://www.jushico.com",
        "market_cap": "Small Cap"
    },
    "JYNT": {
        "short_name": "The Joint Corp.",
        "long_name": "The Joint Corp.",
        "summary": "The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of January 27, 2021, the company operated approximately 550 locations in the United States. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85260",
        "website": "http://www.thejoint.com",
        "market_cap": "Small Cap"
    },
    "K27.F": {
        "short_name": "KODIAK SCIENCES  DL-,0001",
        "long_name": "Kodiak Sciences Inc.",
        "summary": "Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Palo Alto",
        "zipcode": "94304",
        "website": "http://kodiak.com",
        "market_cap": "Mid Cap"
    },
    "KALA": {
        "short_name": "Kala Pharmaceuticals, Inc.",
        "long_name": "Kala Pharmaceuticals, Inc.",
        "summary": "Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.kalarx.com",
        "market_cap": "Small Cap"
    },
    "KALTF": {
        "short_name": "CLARITAS PHARMACEUTICALS INC",
        "long_name": "Claritas Pharmaceuticals, Inc.",
        "summary": "Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. The company was founded in 2014 and is headquartered in San Rafael, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Rafael",
        "zipcode": "94903",
        "website": "http://claritaspharma.com",
        "market_cap": "Small Cap"
    },
    "KALV": {
        "short_name": "KalVista Pharmaceuticals, Inc.",
        "long_name": "KalVista Pharmaceuticals, Inc.",
        "summary": "KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.kalvista.com",
        "market_cap": "Small Cap"
    },
    "KALY": {
        "short_name": "KALI INC",
        "long_name": "Kali, Inc.",
        "summary": "Kali, Inc., doing business as Kali-Extracts, Inc., engages in the research and development of cannabis treatments for various illnesses, diseases, and chronic pain as a symptom of various diagnoses. It provides pharmaceuticals, cannabis extracts, and health and wellness products. The company was formerly known as VLOV Inc. and changed its name to Kali, Inc. in February 2016. Kali, Inc. is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75225",
        "website": "http://www.kali-extracts.com",
        "market_cap": "Small Cap"
    },
    "KAST": {
        "short_name": "KASTEN INC",
        "long_name": "Kasten, Inc.",
        "summary": "Kasten, Inc., doing business as DAKOTA Life Sciences, operates as a biopharmaceutical company that focuses on the acquisition, development, and commercialization of pharmaceuticals designed to prevent and treat serious conditions arising in hospital and community settings. It principally focuses on delivering solutions to those people who are affected by antimicrobial resistance and who need pharmaceutical products at affordable prices. The company was incorporated in 1986 and is based in Sioux Falls, South Dakota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "SD",
        "city": "Sioux Falls",
        "zipcode": "57104",
        "website": null,
        "market_cap": "Small Cap"
    },
    "KAYS": {
        "short_name": "KAYA HLDGS INC",
        "long_name": "Kaya Holdings, Inc.",
        "summary": "Kaya Holdings, Inc., a vertically integrated legal marijuana enterprise, produces, distributes, and/or sells a range of cannabis products in the United States. The company offers flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. It also operates two retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. The company also provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Lauderdale",
        "zipcode": "33304",
        "website": "http://www.kayaholdings.com",
        "market_cap": "Small Cap"
    },
    "KDF.F": {
        "short_name": "KADMON HLDGS.INC. DL-,001",
        "long_name": "Kadmon Holdings, Inc.",
        "summary": "Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.kadmon.com",
        "market_cap": "Small Cap"
    },
    "KDMN": {
        "short_name": "Kadmon Holdings, Inc.",
        "long_name": "Kadmon Holdings, Inc.",
        "summary": "Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.kadmon.com",
        "market_cap": "Small Cap"
    },
    "KDNY": {
        "short_name": "Chinook Therapeutics, Inc.",
        "long_name": "Chinook Therapeutics, Inc.",
        "summary": "Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98102",
        "website": "http://www.chinooktx.com",
        "market_cap": "Small Cap"
    },
    "KERN": {
        "short_name": "Akerna Corp.",
        "long_name": "Akerna Corp.",
        "summary": "Akerna Corp. operates as a technology company. The company offers MJ Platform, an enterprise resource planning system to the cannabis industry; and Leaf Data Systems, a tracking system designed for government agencies. It also provides consulting services to cannabis industry; business intelligence, an infrastructure as a service tool, which delivers supply chain analytics for the cannabis, hemp, and CBD industries; and Last Call Analytics, a subscription analytics tool for alcohol brands to analyze their retail sales analytics. In addition, the company operates seed-to-sale platform that allows cultivators to track and report various stage of their cannabis growing operations, production, and sales processes. Further, it offers cannabis cultivation management and software to manage and optimize operational workflow in business analytics; and cannabis tracking technology that provides seed-to-sale-to-self data. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80202",
        "website": "http://www.akerna.com",
        "market_cap": "Small Cap"
    },
    "KGKG": {
        "short_name": "KONA GOLD BEVERAGE INC",
        "long_name": "Kona Gold Beverage, Inc.",
        "summary": "Kona Gold Beverage, Inc. develops and sells hemp and cannabidiol (CBD) products in the functional beverage and fitness markets in the United States. The company operates through two segments, Beverages and Distribution. It offers hemp energy drinks and CBD energy water; and alkaline waters, beverages for kids, energy drinks, fruit flavored sodas, low carb lemonade, healthy aloe juice drinks, and CBD-infused jellybeans. The company also sells merchandise and apparel, such as shirts, tanks, hats, and towels. It sells its products primarily to beverage distributors and resellers, retail grocery, smoke shops and specialty stores, wholesalers, merchandisers, vape shops, and convenience stores; and beverage services under the Kona Gold Hemp Energy Drinks, OOH LA LEMIN, and Highdrate names. The company was formerly known as Kona Gold Solutions, Inc. and changed its name to Kona Gold Beverage, Inc. in October 2020. Kona Gold Beverage, Inc. was incorporated in 1997 and is based in Melbourne, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Melbourne",
        "zipcode": "32934",
        "website": "http://www.konagoldhemp.com",
        "market_cap": "Small Cap"
    },
    "KIDS": {
        "short_name": "OrthoPediatrics Corp.",
        "long_name": "OrthoPediatrics Corp.",
        "summary": "OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IN",
        "city": "Warsaw",
        "zipcode": "46582",
        "website": "http://www.orthopediatrics.com",
        "market_cap": "Small Cap"
    },
    "KIN": {
        "short_name": "Kindred Biosciences, Inc.",
        "long_name": "Kindred Biosciences, Inc.",
        "summary": "Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Burlingame",
        "zipcode": "94010",
        "website": "http://www.kindredbio.com",
        "market_cap": "Small Cap"
    },
    "KK3A.F": {
        "short_name": "CYTOKINETICS INC. DL-,001",
        "long_name": "Cytokinetics, Incorporated",
        "summary": "Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.cytokinetics.com",
        "market_cap": "Small Cap"
    },
    "KLDO": {
        "short_name": "Kaleido Biosciences, Inc.",
        "long_name": "Kaleido Biosciences, Inc.",
        "summary": "Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://kaleido.com",
        "market_cap": "Small Cap"
    },
    "KLYG": {
        "short_name": "KELYNIAM GLOBAL INC",
        "long_name": "Kelyniam Global, Inc.",
        "summary": "Kelyniam Global, Inc., a medical device manufacturing company, engages in the production of custom prosthetics utilizing computer aided design, and computer aided manufacturing of advanced medical grade polymers. The company develops, manufactures, and distributes custom cranial and craniofacial fixation screws for patients requiring the reconstruction of cranial and facial structures. It serves health systems, hospitals, sales representative, and surgeons, payors, and patients. The company was formerly known as Ketner Global Investments, Inc. and changed its name to Kelyniam Global, Inc. in December 2007. The company was incorporated in 2005 and is based in Collinsville, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Collinsville",
        "zipcode": "06019",
        "website": "http://www.kelyniam.com",
        "market_cap": "Small Cap"
    },
    "KMPH": {
        "short_name": "KemPharm, Inc.",
        "long_name": "KemPharm, Inc.",
        "summary": "KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. The company was incorporated in 2006 and is headquartered in Celebration, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Celebration",
        "zipcode": "34747",
        "website": "http://kempharm.com",
        "market_cap": "Small Cap"
    },
    "KNTE": {
        "short_name": "Kinnate Biopharma Inc.",
        "long_name": "Kinnate Biopharma Inc.",
        "summary": "Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.kinnate.com",
        "market_cap": "Small Cap"
    },
    "KOAN": {
        "short_name": "RESONATE BLENDS INC",
        "long_name": "Resonate Blends, Inc.",
        "summary": "Resonate Blends, Inc., a cannabis holding company, provides cannabis-based products. It also operates an online mobile marketing platform that provides various offers, discounts, and alerts and events schedules, such as happy hours, trivia night, and other campaigns. The company was formerly known as Textmunication Holdings, Inc. and changed its name to Resonate Blends, Inc. in December 2019. Resonate Blends, Inc. is based in Calabasas, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Calabasas",
        "zipcode": "91302",
        "website": "http://www.resonateblends.com",
        "market_cap": "Small Cap"
    },
    "KOD.MX": {
        "short_name": "KODIAK SCIENCES INC",
        "long_name": "Kodiak Sciences Inc.",
        "summary": "Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Palo Alto",
        "zipcode": "94304",
        "website": "http://kodiak.com",
        "market_cap": "Mid Cap"
    },
    "KOD": {
        "short_name": "Kodiak Sciences Inc",
        "long_name": "Kodiak Sciences Inc.",
        "summary": "Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Palo Alto",
        "zipcode": "94304",
        "website": "http://kodiak.com",
        "market_cap": "Mid Cap"
    },
    "KPTI": {
        "short_name": "Karyopharm Therapeutics Inc.",
        "long_name": "Karyopharm Therapeutics Inc.",
        "summary": "Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of low-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory DLBCL. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration agreement with Curadev Pharma Pvt Ltd to identify and co-develop novel small molecules against various biological targets for the treatment of cancer; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Newton",
        "zipcode": "02459",
        "website": "http://www.karyopharm.com",
        "market_cap": "Small Cap"
    },
    "KRBP": {
        "short_name": "Kiromic BioPharma, Inc.",
        "long_name": "Kiromic BioPharma, Inc.",
        "summary": "Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77054",
        "website": "http://www.kiromic.com",
        "market_cap": "Small Cap"
    },
    "KRMD": {
        "short_name": "Repro Med Systems, Inc.",
        "long_name": "Repro Med Systems, Inc.",
        "summary": "Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Chester",
        "zipcode": "10918",
        "website": "http://www.korumedical.com",
        "market_cap": "Small Cap"
    },
    "KRON": {
        "short_name": "Kronos Bio, Inc.",
        "long_name": "Kronos Bio, Inc.",
        "summary": "Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Mateo",
        "zipcode": "94402",
        "website": "http://kronosbio.com",
        "market_cap": "Small Cap"
    },
    "KROS": {
        "short_name": "Keros Therapeutics, Inc.",
        "long_name": "Keros Therapeutics, Inc.",
        "summary": "Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.kerostx.com",
        "market_cap": "Small Cap"
    },
    "KRTX": {
        "short_name": "Karuna Therapeutics, Inc.",
        "long_name": "Karuna Therapeutics, Inc.",
        "summary": "Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02110",
        "website": "http://www.karunatx.com",
        "market_cap": "Mid Cap"
    },
    "KRYS": {
        "short_name": "Krystal Biotech, Inc.",
        "long_name": "Krystal Biotech, Inc.",
        "summary": "Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Pittsburgh",
        "zipcode": "15203",
        "website": "http://www.krystalbio.com",
        "market_cap": "Small Cap"
    },
    "KSQR": {
        "short_name": "KENDALL SQUARE RESEARCH CORPORA",
        "long_name": "Kendall Square Research Corp",
        "summary": "Kendall Square Research Corp, through its subsidiary, Luxury Kitchen Hoods LLC, manufactures specialty equipment for residential home customers. It primarily offers ventilation hoods. Kendall Square Research Corp was incorporated in 2005 and is based in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84121",
        "website": "http://www.sancuro.com",
        "market_cap": "Small Cap"
    },
    "KTRA": {
        "short_name": "Kintara Therapeutics, Inc.",
        "long_name": "Kintara Therapeutics, Inc.",
        "summary": "Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.kintara.com",
        "market_cap": "Small Cap"
    },
    "KUR.F": {
        "short_name": "KURA ONCOLOGY  DL-,0001",
        "long_name": "Kura Oncology, Inc.",
        "summary": "Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.kuraoncology.com",
        "market_cap": "Small Cap"
    },
    "KURA": {
        "short_name": "Kura Oncology, Inc.",
        "long_name": "Kura Oncology, Inc.",
        "summary": "Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.kuraoncology.com",
        "market_cap": "Small Cap"
    },
    "KYMR": {
        "short_name": "Kymera Therapeutics, Inc.",
        "long_name": "Kymera Therapeutics, Inc.",
        "summary": "Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.kymeratx.com",
        "market_cap": "Mid Cap"
    },
    "KZR": {
        "short_name": "Kezar Life Sciences, Inc.",
        "long_name": "Kezar Life Sciences, Inc.",
        "summary": "Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.kezarlifesciences.com",
        "market_cap": "Small Cap"
    },
    "L1CA34.SA": {
        "short_name": "LABORATORY CDRN",
        "long_name": "Laboratory Corporation of America Holdings",
        "summary": "Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NC",
        "city": "Burlington",
        "zipcode": "27215",
        "website": "http://www.labcorp.com",
        "market_cap": "Large Cap"
    },
    "L1Z1.F": {
        "short_name": "ALPHATEC HOLDINGS INC.",
        "long_name": "Alphatec Holdings, Inc.",
        "summary": "Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008",
        "website": "http://www.atecspine.com",
        "market_cap": "Small Cap"
    },
    "LAB.F": {
        "short_name": "LAB. CORP.OF AMER. DL-,10",
        "long_name": "Laboratory Corporation of America Holdings",
        "summary": "Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Burlington",
        "zipcode": "27215",
        "website": "http://www.labcorp.com",
        "market_cap": "Large Cap"
    },
    "LABP": {
        "short_name": "Landos Biopharma, Inc.",
        "long_name": "Landos Biopharma, Inc.",
        "summary": "Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Blacksburg",
        "zipcode": "24060-6370",
        "website": "http://landosbiopharma.com",
        "market_cap": "Small Cap"
    },
    "LANZ": {
        "short_name": "LANCER ORTHODONTICS INC",
        "long_name": "Lancer Orthodontics, Inc.",
        "summary": "Lancer Orthodontics, Inc. designs, manufactures, and markets orthodontic products for orthodontists and dentists worldwide. It offers aesthetic brackets, brackets and buccal tubes, bands, adhesives, wires, elastomerics, intraoral and extraoral appliances, instruments, and miscellaneous products. The company was founded in 1967 and is based in Vista, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Vista",
        "zipcode": "92081",
        "website": "http://www.lancerortho.com",
        "market_cap": "Small Cap"
    },
    "LAXAF": {
        "short_name": "LAXAI PHARMA LTD",
        "long_name": "Laxai Pharma, Ltd.",
        "summary": "Laxai Pharma, Ltd. offers contract research services in the United States. It provides integrated services across the drug development spectrum. The company focuses its services in the areas of biostatistics, data management (EDC, Hybrid, and Paper), CDISC consulting, medical writing, monitoring, regulatory, drug safety, and related training programs. The company was formerly known as Nexgen Biofuels Ltd. and changed its name to Laxai Pharma, Ltd. in February, 2010. Laxai Pharma, Ltd. is based in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33647",
        "website": null,
        "market_cap": "Small Cap"
    },
    "LBL.V": {
        "short_name": "LATTICE BIOLOGICS LTD",
        "long_name": "Lattice Biologics Ltd.",
        "summary": "Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": "MT",
        "city": "Belgrade",
        "zipcode": "59714",
        "website": "http://www.latticebiologics.com",
        "market_cap": "Small Cap"
    },
    "LBLTF": {
        "short_name": "LATTICE BIOLOGICS LTD",
        "long_name": "Lattice Biologics Ltd.",
        "summary": "Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MT",
        "city": "Belgrade",
        "zipcode": "59714",
        "website": "http://www.latticebiologics.com",
        "market_cap": "Small Cap"
    },
    "LBPH": {
        "short_name": "Longboard Pharmaceuticals, Inc.",
        "long_name": "Longboard Pharmaceuticals, Inc.",
        "summary": "Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.longboardpharma.com",
        "market_cap": "Small Cap"
    },
    "LCAR": {
        "short_name": "LESCARDEN INC",
        "long_name": "Lescarden Inc.",
        "summary": "Lescarden Inc. researches, tests, develops, and sells medications for the control and cure of various diseases in the United States, Europe, and South Korea. Its lead product is Catrix Wound Dressing for the management of chronic lesions and burns, as well as for non-healing wounds, including decubitus ulcers, venous stasis ulcers, and diabetic ulcers. The company also offers a line of Catrix-based wound and skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, it provides nutritional supplements, such as Bio-Cartilage and Poly-NAG, a patented glucosamine polymer; and licenses its technologies for commercialization by other companies. Lescarden Inc. was founded in 1960 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10170",
        "website": "http://www.lescarden.com",
        "market_cap": "Small Cap"
    },
    "LCDX": {
        "short_name": "CALIBER IMAGING & DIAGNOSTICS I",
        "long_name": "Caliber Imaging & Diagnostics, Inc.",
        "summary": "Caliber Imaging & Diagnostics, Inc., a medical technologies company, designs, develops, and markets imaging solutions that shows tissue at the cellular level in the United States. The company provides VivaScope 1500, a reflectance confocal imaging system that enables clinicians and researchers to capture confocal images that depict cellular structures of living tissue; and VivaScope 3000, a hand-held in vivo reflectance confocal microscope for skin imaging. It also offers VivaScan software to schedule patients for examinations, perform imaging examinations on one or more lesions during a visit, review, and report on images obtained during an examination, as well as VivaNet, a digital telepathology system. The company was formerly known as Lucid, Inc. and changed its name to Caliber Imaging & Diagnostics, Inc. in August 2012. Caliber Imaging & Diagnostics, Inc. was founded in 1991 and is headquartered in Andover, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Andover",
        "zipcode": "01810",
        "website": "http://www.caliberid.com",
        "market_cap": "Small Cap"
    },
    "LCI": {
        "short_name": "Lannett Co Inc",
        "long_name": "Lannett Company, Inc.",
        "summary": "Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was founded in 1942 and is headquartered in Philadelphia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19136",
        "website": "http://www.lannett.com",
        "market_cap": "Small Cap"
    },
    "LCTX": {
        "short_name": "Lineage Cell Therapeutics, Inc.",
        "long_name": "Lineage Cell Therapeutics, Inc.",
        "summary": "Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product for the treatment of facial lipoatrophy. In addition, the company offers various therapeutic products for the treatment of oncology, and neurological diseases and disorders, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008",
        "website": "http://www.lineagecell.com",
        "market_cap": "Small Cap"
    },
    "LEGN": {
        "short_name": "Legend Biotech Corporation",
        "long_name": "Legend Biotech Corporation",
        "summary": "Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Somerset",
        "zipcode": "08873",
        "website": "http://www.legendbiotech.com",
        "market_cap": "Mid Cap"
    },
    "LFMD": {
        "short_name": "LifeMD, Inc.",
        "long_name": "LifeMD, Inc.",
        "summary": "LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a medical device for male and female hair loss; RexMD, a men's telehealth brand offering virtual medical treatment from licensed providers for a variety of men's health needs; Nava MD, a female-oriented tele-dermatology and skincare brand that would offer virtual medical treatment from dermatologists and other providers; and iNR Wellness MD, a supplement for immune and digestive support. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.lifemd.com",
        "market_cap": "Small Cap"
    },
    "LFPI": {
        "short_name": "LIFEPOINT INC",
        "long_name": "LifePoint, Inc.",
        "summary": "LifePoint, Inc. develops, manufactures, and sells IMPACT Test System, a diagnostic testing and screening device. It serves workplaces, ambulances, pharmacies, law enforcements, and home health care markets. LifePoint, Inc. was formerly known as US Drug Testing, Inc. and changed its name to LifePoint, Inc. in February 1998. The company was incorporated in 1992 and is based in Ontario, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Ontario",
        "zipcode": "91761",
        "website": "http://www.lifepointinc.org",
        "market_cap": "Small Cap"
    },
    "LGBI": {
        "short_name": "CANNABIZ MOBILE INC",
        "long_name": "Cannabiz Mobile, Inc.",
        "summary": "Cannabiz Mobile, Inc. operates as a mobile media and marketing company for businesses in the medical marijuana industry primarily in the United States and Canada. The company markets a subscription based, in the cloud, mobile media solution that enables care givers, dispensaries, hydroponic, and ancillary product retailers to create, deploy, and analytically measure mobile marketing campaigns using various networks and devices. It also enables businesses to create customizable personal audio and video advertisements, commercials, podcasts, and presentations that are accessible through various smart phone devices; and designs generic action pages and custom mobile Websites in which the end user has the ability to save the Mobile APP to their home screen. In addition, the company provides suppliers with mobile solutions to facilitate them in running their business through the use of the company's mobile marketing software, including mobile coupons, birthday reminders, alerts mobile business cards, mobile sites, and apps. Its software also facilitates in keeping patients informed of new medicine, as well as uses SMS text as a way to communicate for appointment reminders, refills, etc.; and provides refill reminders. The company was formerly known as Lion Gold Brazil, Inc. and changed its name to Cannabiz Mobile, Inc. in June 2014. Cannabiz Mobile, Inc. is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02140",
        "website": "http://www.cannabizmobile.com",
        "market_cap": "Small Cap"
    },
    "LGDN.F": {
        "short_name": "LIGAND PHARMAC.NEW DL-001",
        "long_name": "Ligand Pharmaceuticals Incorporated",
        "summary": "Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.ligand.com",
        "market_cap": "Small Cap"
    },
    "LGND": {
        "short_name": "Ligand Pharmaceuticals Incorpor",
        "long_name": "Ligand Pharmaceuticals Incorporated",
        "summary": "Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.ligand.com",
        "market_cap": "Mid Cap"
    },
    "LGVN": {
        "short_name": "Longeveron Inc.",
        "long_name": "Longeveron Inc.",
        "summary": "Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33136",
        "website": "http://www.longeveron.com",
        "market_cap": "Small Cap"
    },
    "LH.MX": {
        "short_name": "LABORATORY CORP AMER HLDGS",
        "long_name": "Laboratory Corporation of America Holdings",
        "summary": "Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NC",
        "city": "Burlington",
        "zipcode": "27215",
        "website": "http://www.labcorp.com",
        "market_cap": "Large Cap"
    },
    "LH": {
        "short_name": "Laboratory Corporation of Ameri",
        "long_name": "Laboratory Corporation of America Holdings",
        "summary": "Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Burlington",
        "zipcode": "27215",
        "website": "http://www.labcorp.com",
        "market_cap": "Large Cap"
    },
    "LH6.F": {
        "short_name": "LHC GROUP INC.  DL -,01",
        "long_name": "LHC Group, Inc.",
        "summary": "LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company's Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services. Its Hospice Services segment provides pain and symptom management accompanied by palliative medication, emotional and spiritual support, inpatient and respite care, homemaker services, dietary counseling, family bereavement counseling, and social worker visits. The company's Home and Community-Based Services segment offers range of services, such as assistance with grooming, medication reminders, meal preparation, assistance with feeding, light housekeeping, respite care, transportation, and errand services to patients in their home or in a medical facility. Its Facility-Based Services segment serves patients suffering from respiratory failure, neuromuscular and cardiac disorders, non-healing wounds, renal disorders, cancer, head and neck injuries, and mental disorders, as well as treats patients diagnosed with musculoskeletal impairments; and operates institutional pharmacy and other non-related facilities, nursing facilities, family health center, rural health clinic, and physician practice, as well as offers physical therapy services. The company's Healthcare Innovations (HCI) Services segment provides strategic health management services to accountable care organizations. As of December 31, 2020, it operated 537 home health services locations, 120 hospice locations, 124 community-based service locations, 11 long-term acute care hospitals with 12 locations, and 12 HCI locations. The company was founded in 1994 and is based in Lafayette, Louisiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "LA",
        "city": "Lafayette",
        "zipcode": "70508",
        "website": "http://www.lhcgroup.com",
        "market_cap": "Mid Cap"
    },
    "LHCG": {
        "short_name": "LHC Group",
        "long_name": "LHC Group, Inc.",
        "summary": "LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company's Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services. Its Hospice Services segment provides pain and symptom management accompanied by palliative medication, emotional and spiritual support, inpatient and respite care, homemaker services, dietary counseling, family bereavement counseling, and social worker visits. The company's Home and Community-Based Services segment offers range of services, such as assistance with grooming, medication reminders, meal preparation, assistance with feeding, light housekeeping, respite care, transportation, and errand services to patients in their home or in a medical facility. Its Facility-Based Services segment serves patients suffering from respiratory failure, neuromuscular and cardiac disorders, non-healing wounds, renal disorders, cancer, head and neck injuries, and mental disorders, as well as treats patients diagnosed with musculoskeletal impairments; and operates institutional pharmacy and other non-related facilities, nursing facilities, family health center, rural health clinic, and physician practice, as well as offers physical therapy services. The company's Healthcare Innovations (HCI) Services segment provides strategic health management services to accountable care organizations. As of December 31, 2020, it operated 537 home health services locations, 120 hospice locations, 124 community-based service locations, 11 long-term acute care hospitals with 12 locations, and 12 HCI locations. The company was founded in 1994 and is based in Lafayette, Louisiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "LA",
        "city": "Lafayette",
        "zipcode": "70508",
        "website": "http://www.lhcgroup.com",
        "market_cap": "Mid Cap"
    },
    "LHDX": {
        "short_name": "Lucira Health, Inc.",
        "long_name": "Lucira Health, Inc.",
        "summary": "Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.lucirahealth.com",
        "market_cap": "Small Cap"
    },
    "LHU.F": {
        "short_name": "LEMAITRE VASCULAR DL -,01",
        "long_name": "LeMaitre Vascular, Inc.",
        "summary": "LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Burlington",
        "zipcode": "01803",
        "website": "http://www.lemaitre.com",
        "market_cap": "Small Cap"
    },
    "LIFE": {
        "short_name": "aTyr Pharma, Inc.",
        "long_name": "aTyr Pharma, Inc.",
        "summary": "aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product ATYR1923 is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.atyrpharma.com",
        "market_cap": "Small Cap"
    },
    "LIFS": {
        "short_name": "LIFE STEM GENETICS INC",
        "long_name": "Life Stem Genetics Inc.",
        "summary": "Life Stem Genetics Inc., a development stage company, focuses on establishing stem cell therapy based clinics worldwide. Its products and services include nutraceutical and medical supplements, and IV nutritional cocktails; stem cell banking services; stem cell treatments for degenerative conditions, hyperbaric oxygen therapy, cancer treatments, and weight loss; anti-aging stem cell therapy; anti-viral therapy; and adistem stem cell treatments for orthopedics, neurological, and lung diseases. Life Stem Genetics Inc. has a strategic collaborative agreement with American CryoStem Corporation. The company was founded in 2012 and is based in Beverly Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Beverly Hills",
        "zipcode": "90210",
        "website": null,
        "market_cap": "Small Cap"
    },
    "LILY34.SA": {
        "short_name": "LILLY       DRN",
        "long_name": "Eli Lilly and Company",
        "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46285",
        "website": "http://www.lilly.com",
        "market_cap": "Large Cap"
    },
    "LITH": {
        "short_name": "U S LITHIUM CORP",
        "long_name": "BioELife Corp.",
        "summary": "BioELife Corp. operates in cannabinoid market. It offers cannabinoid products, such as combo adult gummies with chirorub, combo tincture with chirorub, intensive relief rub, tinctures, adult gummies, premium pre-rolls, and flowers. The company was formerly known as US Lithium Corp. and changed its name to BioELife Corp. in March 2020. The company was founded in 2006 and is based in Seal Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Seal Beach",
        "zipcode": "90740",
        "website": "http://www.bioelife.com",
        "market_cap": "Small Cap"
    },
    "LIXT": {
        "short_name": "Lixte Biotechnology Holdings, I",
        "long_name": "Lixte Biotechnology Holdings, Inc.",
        "summary": "Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; pharmacologic study with the National Cancer Institute; and clinical research support agreement with City of Hope National Medical Center to carry out a Phase 1b clinical trial of its LB-100, a protein phosphatase inhibitor for small cell lung cancer. The company was incorporated in 2005 and is based in East Setauket, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "East Setauket",
        "zipcode": "11733",
        "website": "http://www.lixte.com",
        "market_cap": "Small Cap"
    },
    "LJPC": {
        "short_name": "La Jolla Pharmaceutical Company",
        "long_name": "La Jolla Pharmaceutical Company",
        "summary": "La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://lajollapharmaceutical.com",
        "market_cap": "Small Cap"
    },
    "LJPP.F": {
        "short_name": "LA JOLLA PHARM.  DL-,0001",
        "long_name": "La Jolla Pharmaceutical Company",
        "summary": "La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://lajollapharmaceutical.com",
        "market_cap": "Small Cap"
    },
    "LLBO": {
        "short_name": "LIFELINE BIOTECHNOLOGIES INC",
        "long_name": "Lifeline Biotechnologies, Inc.",
        "summary": "Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast; and OVASCOPE, an ultra slim endoscope to directly visualize the ovarian surface in the search for cancer. The company also has operations in Europe. Lifeline Biotechnologies, Inc. is headquartered in Reno, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Reno",
        "zipcode": "89502",
        "website": "http://www.lbti.co",
        "market_cap": "Small Cap"
    },
    "LLY.DE": {
        "short_name": "ELI LILLY",
        "long_name": "Eli Lilly and Company",
        "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46285",
        "website": "http://www.lilly.com",
        "market_cap": "Large Cap"
    },
    "LLY.F": {
        "short_name": "ELI LILLY",
        "long_name": "Eli Lilly and Company",
        "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46285",
        "website": "http://www.lilly.com",
        "market_cap": "Large Cap"
    },
    "LLY.MX": {
        "short_name": "ELI LILLY AND COMPANY",
        "long_name": "Eli Lilly and Company",
        "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46285",
        "website": "http://www.lilly.com",
        "market_cap": "Large Cap"
    },
    "LLY": {
        "short_name": "Eli Lilly and Company",
        "long_name": "Eli Lilly and Company",
        "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46285",
        "website": "http://www.lilly.com",
        "market_cap": "Large Cap"
    },
    "LLY.SW": {
        "short_name": "LILLY ELI",
        "long_name": "Eli Lilly and Company",
        "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46285",
        "website": "http://www.lilly.com",
        "market_cap": "Large Cap"
    },
    "LLYC.VI": {
        "short_name": "ELI LILLY CO",
        "long_name": "Eli Lilly and Company",
        "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "IN",
        "city": "Indianapolis",
        "zipcode": "46285",
        "website": "http://www.lilly.com",
        "market_cap": "Large Cap"
    },
    "LMAT": {
        "short_name": "LeMaitre Vascular, Inc.",
        "long_name": "LeMaitre Vascular, Inc.",
        "summary": "LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Burlington",
        "zipcode": "01803",
        "website": "http://www.lemaitre.com",
        "market_cap": "Small Cap"
    },
    "LMNX": {
        "short_name": "Luminex Corporation",
        "long_name": "Luminex Corporation",
        "summary": "Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78727",
        "website": "http://www.luminexcorp.com",
        "market_cap": "Small Cap"
    },
    "LMX.F": {
        "short_name": "LUMINEX CORP. DEL  DL-,01",
        "long_name": "Luminex Corporation",
        "summary": "Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78727",
        "website": "http://www.luminexcorp.com",
        "market_cap": "Small Cap"
    },
    "LN5.F": {
        "short_name": "LANNETT CO. INC.  DL-,001",
        "long_name": "Lannett Company, Inc.",
        "summary": "Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was founded in 1942 and is headquartered in Philadelphia, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19136",
        "website": "http://www.lannett.com",
        "market_cap": "Small Cap"
    },
    "LN5.SG": {
        "short_name": "LANNETT CO. INC. Registered Sha",
        "long_name": "Lannett Company, Inc.",
        "summary": "Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was founded in 1942 and is headquartered in Philadelphia, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19136",
        "website": "http://www.lannett.com",
        "market_cap": "Small Cap"
    },
    "LNSR": {
        "short_name": "LENSAR, Inc.",
        "long_name": "LENSAR, Inc.",
        "summary": "LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Orlando",
        "zipcode": "32826",
        "website": "http://www.lensar.com",
        "market_cap": "Small Cap"
    },
    "LNTH": {
        "short_name": "Lantheus Holdings, Inc.",
        "long_name": "Lantheus Holdings, Inc.",
        "summary": "Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "North Billerica",
        "zipcode": "01862",
        "website": "http://www.lantheus.com",
        "market_cap": "Small Cap"
    },
    "LO91.F": {
        "short_name": "VBI VACCINES INC.",
        "long_name": "VBI Vaccines Inc.",
        "summary": "VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.vbivaccines.com",
        "market_cap": "Small Cap"
    },
    "LOGC": {
        "short_name": "LogicBio Therapeutics, Inc.",
        "long_name": "LogicBio Therapeutics, Inc.",
        "summary": "LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.logicbio.com",
        "market_cap": "Small Cap"
    },
    "LOWL.CN": {
        "short_name": "LowellFarms",
        "long_name": "Lowell Farms Inc.",
        "summary": "Lowell Farms Inc., a cannabis company, engages in the cultivation, extraction, processing, manufacturing, branding, packaging, and wholesale distribution of cannabis products to retail dispensaries in California. The company provides flowers, vape pens, oils, extracts, chocolate edibles, mints, gummies, beverages, tinctures, and pre-rolls under the Lowell Herb Co., Lowell Smokes, Cypress Reserve, Flavor Extracts, Kaizen, House Weed, Moon, Altai, Humble Flower, Original Pot Company, CannaStripe, and Acme Elixirs brands. It also offers manufacturing, extraction, and distribution services to third-party cannabis and cannabis branding companies. The company was formerly known as Indus Holdings, Inc. and changed its name to Lowell Farms Inc. in March 2021. Lowell Farms Inc. is headquartered in Salinas, California.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "CA",
        "city": "Salinas",
        "zipcode": "93907",
        "website": "http://www.lowellfarms.com",
        "market_cap": "Small Cap"
    },
    "LOWLF": {
        "short_name": "LOWELL FARMS INC",
        "long_name": "Lowell Farms Inc.",
        "summary": "Lowell Farms Inc., a cannabis company, engages in the cultivation, extraction, processing, manufacturing, branding, packaging, and wholesale distribution of cannabis products to retail dispensaries in California. The company offers flowers, vape pens, oils, extracts, chocolate edibles, mints, gummies, beverages, tinctures, concentrates, and pre-rolls under the Lowell Herb Co., Lowell Smokes, Cypress Reserve, Flavor Extracts, Kaizen, House Weed, Moon, Altai, Humble Flower, Original Pot Company, CannaStripe, and Acme Elixirs brands. It also provides manufacturing, extraction, and distribution services to third-party cannabis and cannabis branding companies. The company was formerly known as Indus Holdings, Inc. and changed its name to Lowell Farms Inc. in March 2021. Lowell Farms Inc. was founded in 2014 and is headquartered in Salinas, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Salinas",
        "zipcode": "93907",
        "website": "http://www.lowellfarms.com",
        "market_cap": "Small Cap"
    },
    "LPCN": {
        "short_name": "Lipocine Inc.",
        "long_name": "Lipocine Inc.",
        "summary": "Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84108",
        "website": "http://www.lipocine.com",
        "market_cap": "Small Cap"
    },
    "LPTI": {
        "short_name": "LONGPORT INC",
        "long_name": "Longport, Inc.",
        "summary": "Longport, Inc. develops, manufactures, markets, and sells high resolution ultrasound imaging systems primarily in the United States. It offers EPISCAN I-200, a high frequency ultrasound imaging system that utilizes ultrasound at frequencies between 20 and 50MHz to image the skin and underlying soft tissue. The company's products are used in wound assessment, wound prevention, clinical dermatology, and aesthetics/plastics, as well as in various other applications, including burn assessment, superficial musculoskeletal imaging, and veterinary applications. It also exports its products. The company was founded in 1993 and is based in Chadds Ford, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Chadds Ford",
        "zipcode": "19317",
        "website": "http://www.longportinc.com",
        "market_cap": "Small Cap"
    },
    "LPTX": {
        "short_name": "Leap Therapeutics, Inc.",
        "long_name": "Leap Therapeutics, Inc.",
        "summary": "Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02141",
        "website": "http://www.leaptx.com",
        "market_cap": "Small Cap"
    },
    "LQDA": {
        "short_name": "Liquidia Corporation",
        "long_name": "Liquidia Corporation",
        "summary": "Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560",
        "website": "http://www.liquidia.com",
        "market_cap": "Small Cap"
    },
    "LRMR": {
        "short_name": "Larimar Therapeutics, Inc.",
        "long_name": "Larimar Therapeutics, Inc.",
        "summary": "Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Bala Cynwyd",
        "zipcode": "19004",
        "website": "http://www.larimartx.com",
        "market_cap": "Small Cap"
    },
    "LSRM.F": {
        "short_name": "CEL-SCI CORP. NEW  DL-,01",
        "long_name": "CEL-SCI Corporation",
        "summary": "CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "VA",
        "city": "Vienna",
        "zipcode": "22182",
        "website": "http://cel-sci.com",
        "market_cap": "Small Cap"
    },
    "LT3.F": {
        "short_name": "AXOGEN INC.  DL -,01",
        "long_name": "AxoGen, Inc.",
        "summary": "AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Alachua",
        "zipcode": "32615",
        "website": "http://www.axogeninc.com",
        "market_cap": "Small Cap"
    },
    "LT4.F": {
        "short_name": "LIQUIDIA CORP.  DL-,001",
        "long_name": "Liquidia Corporation",
        "summary": "Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560",
        "website": "http://www.liquidia.com",
        "market_cap": "Small Cap"
    },
    "LT4.MU": {
        "short_name": "LIQUIDIA CORP.  DL-,001",
        "long_name": "Liquidia Corporation",
        "summary": "Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560",
        "website": "http://www.liquidia.com",
        "market_cap": "Small Cap"
    },
    "LT4.SG": {
        "short_name": "Liquidia Technologies Inc. Regi",
        "long_name": "Liquidia Corporation",
        "summary": "Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560",
        "website": "http://www.liquidia.com",
        "market_cap": "Small Cap"
    },
    "LTRN": {
        "short_name": "Lantern Pharma Inc.",
        "long_name": "Lantern Pharma Inc.",
        "summary": "Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75201",
        "website": "http://www.lanternpharma.com",
        "market_cap": "Small Cap"
    },
    "LUMO": {
        "short_name": "Lumos Pharma, Inc.",
        "long_name": "Lumos Pharma, Inc.",
        "summary": "Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78756",
        "website": "http://www.lumos-pharma.com",
        "market_cap": "Small Cap"
    },
    "LUNG": {
        "short_name": "Pulmonx Corporation",
        "long_name": "Pulmonx Corporation",
        "summary": "Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://pulmonx.com",
        "market_cap": "Small Cap"
    },
    "LV1.F": {
        "short_name": "STREAMLINE HEA.SOL.DL-,01",
        "long_name": "Streamline Health Solutions, Inc.",
        "summary": "Streamline Health Solutions, Inc. provides health information technology solutions and associated services for hospitals and health systems in the United States and Canada. It provides computer software-based solutions and auditing services, which captures, aggregates, and translates structured and unstructured data to deliver predictive insights. The company also offers coding and clinical documentation improvement (CDI) solutions, which includes integrated cloud-based software suite, CDI, and abstracting and physician query; and eValuator, a cloud-based pre-bill coding analysis platform. In addition, it provides financial management solutions, including accounts receivable management, denials management, claims processing, spend management, and audit management; patient care solutions; and custom integration services for CDI/abstracting, training, and audit services. The company sells its solutions and services through direct sales force and reseller partnerships. Streamline Health Solutions, Inc. was incorporated in 1989 and is based in Alpharetta, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30009",
        "website": "http://www.streamlinehealth.net",
        "market_cap": "Small Cap"
    },
    "LVGI": {
        "short_name": "LIMITLESS VENTURE GROUP INC",
        "long_name": "Limitless Venture Group Inc.",
        "summary": "Limitless Venture Group Inc., a development stage company, produces, distributes, and markets body care, health, and alcoholic products. The company offers LIMITLESS BODY products, including BODY FRESH, a body wash; MUSCLE BUTTER, a body soothing massage butter; BODY SUGAR, a sugar body scrub; BARE SKIN, a moisturizing shave cream; and GYM SANI-T, a sanitizer. It also provides LIMITLESS HEALTH products, such as Prostaderol, a natural prostate health supplement; LipiRestorin; and Maxtlevelin, a product to increase testosterone levels. In addition, the company offers HempCore health products comprising RELAX, an anxiety relief formula; FIBER UP to remove toxins; HEALTHY HEART, a natural product that promotes cardiovascular health and helps maintain healthy cholesterol levels; BRAIN BOOST, a neurotransmitter boosting formula that assists central nervous system to deliver oxygen and nutrients to the brain; and JOINT RELEIF, an anti-inflammation joint formula used to rebuild, lubricate, and soothe aching joints. Further, it provides ready to drink alcoholic shots that include Haymaker, a vodka with lemon and tea flavors; CoCo-Puff, a vodka with chocolate and Irish cream flavors; Red Headed Slut, a vodka with peach, licorice, and cranberry flavors; Twist, a tequila with lime flavor; and Kamikaze, a vodka with orange liquor and lime flavors. The company was formerly known as Enerbrite Technologies Group Inc. and changed its name to Limitless Venture Group Inc. in February 2013. Limitless Venture Group Inc. is based in Tulsa, Oklahoma.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OK",
        "city": "Tulsa",
        "zipcode": "74105",
        "website": "http://www.lvginc.com",
        "market_cap": "Small Cap"
    },
    "LVVV": {
        "short_name": "LIVEWIRE ERGOGENICS INC",
        "long_name": "Livewire Ergogenics  Inc.",
        "summary": "LiveWire Ergogenics Inc. focuses on acquiring, managing, and licensing special purpose real estate properties to produce handcrafted and organically grown cannabis products for medical and recreational adult-use in California. The company is based in Anaheim, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Anaheim",
        "zipcode": "92806",
        "website": "http://livewireergogenics.com",
        "market_cap": "Small Cap"
    },
    "LX31.F": {
        "short_name": "LEXICON PHARM.  DL-,001",
        "long_name": "Lexicon Pharmaceuticals, Inc.",
        "summary": "Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "The Woodlands",
        "zipcode": "77381-1160",
        "website": "http://www.lexpharma.com",
        "market_cap": "Small Cap"
    },
    "LX31.MU": {
        "short_name": "LEXICON PHARM.  DL-,001",
        "long_name": "Lexicon Pharmaceuticals, Inc.",
        "summary": "Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "The Woodlands",
        "zipcode": "77381-1160",
        "website": "http://www.lexpharma.com",
        "market_cap": "Small Cap"
    },
    "LXG.V": {
        "short_name": "LEXAGENE HOLDINGS INC",
        "long_name": "LexaGene Holdings Inc.",
        "summary": "LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of automated genetic analyzers for pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company is headquartered in Beverly, Massachusetts.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": "MA",
        "city": "Beverly",
        "zipcode": "01915",
        "website": "http://www.lexagene.com",
        "market_cap": "Small Cap"
    },
    "LXRX": {
        "short_name": "Lexicon Pharmaceuticals, Inc.",
        "long_name": "Lexicon Pharmaceuticals, Inc.",
        "summary": "Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "The Woodlands",
        "zipcode": "77381-1160",
        "website": "http://www.lexpharma.com",
        "market_cap": "Small Cap"
    },
    "LXXGF": {
        "short_name": "LEXAGENE HOLDINGS INC",
        "long_name": "LexaGene Holdings Inc.",
        "summary": "LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of automated genetic analyzers for pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company is headquartered in Beverly, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Beverly",
        "zipcode": "01915",
        "website": "http://www.lexagene.com",
        "market_cap": "Small Cap"
    },
    "LYRA": {
        "short_name": "Lyra Therapeutics, Inc.",
        "long_name": "Lyra Therapeutics, Inc.",
        "summary": "Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.lyratherapeutics.com",
        "market_cap": "Small Cap"
    },
    "M1CK34.SA": {
        "short_name": "MCKESSON CORDRN",
        "long_name": "McKesson Corporation",
        "summary": "McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and solutions for life sciences companies, including offering multiple distribution channels and clinical trial access to specific patient populations through its network of oncology physicians. The segment also sells financial, operational and clinical solutions to pharmacies; and offers consulting, outsourcing, and other services. The Prescription Technology Solutions segment operates in the healthcare delivery system to connect pharmacies, providers, payers, and biopharma for next-generation patient access and adherence solutions. The International segment provides drug distribution services, specialty pharmacy, and retail and infusion care services. The Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "TX",
        "city": "Irving",
        "zipcode": "75039",
        "website": "http://www.mckesson.com",
        "market_cap": "Large Cap"
    },
    "M1RN34.SA": {
        "short_name": "MODERNA INC DRN",
        "long_name": "Moderna, Inc.",
        "summary": "Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmac\u00c3\u00a9uticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.modernatx.com",
        "market_cap": "Large Cap"
    },
    "M1TD34.SA": {
        "short_name": "METTLER-TOLEDRN",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "OH",
        "city": "Columbus",
        "zipcode": "43240",
        "website": "http://www.mt.com",
        "market_cap": "Large Cap"
    },
    "M55.F": {
        "short_name": "MACROGENICS INC.  DL-,01",
        "long_name": "MacroGenics, Inc.",
        "summary": "MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B \u00c3\u0097 CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.macrogenics.com",
        "market_cap": "Small Cap"
    },
    "M7T.AX": {
        "short_name": "MACH7 FPO",
        "long_name": "Mach7 Technologies Limited",
        "summary": "Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability solutions for healthcare enterprises worldwide. The company operates through two segments, Sale of Software Licenses and Provision of Professional Services. It offers Management Studio that enables healthcare delivery organizations to own, archive, and communicate imaging data across the enterprise and connect that data with the electronic medical record. The company's Management Studio comprises enterprise imaging platform, vendor neutral archive, communication workflow engine, routing engine, fetching engine, and migration engine products. It also provides Diagnostic Studio that includes a suite of solutions to drive specialty workflows. The company's Diagnostic Studio solutions include PACS and QC solution; and Universal Worklist. In addition, the company offers Clinical Studio, which provides access to view, navigate, review, and share patient medical data over the Web and across the enterprise. Its Clinical Studio solutions consist of clinical portal, clinical viewer, image sharing, and procedure import/export products, as well as iModality, a mobile medical image capture using smart device technology. Further, the company provides professional services, such as implementation and training, data migration, support, and maintenance services; and archive migration services. Mach7 Technologies Limited was founded in 2007 and is based in South Burlington, Vermont.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United States",
        "state": "VT",
        "city": "South Burlington",
        "zipcode": "05403",
        "website": "http://www.mach7t.com",
        "market_cap": "Small Cap"
    },
    "MACK": {
        "short_name": "Merrimack Pharmaceuticals, Inc.",
        "long_name": "Merrimack Pharmaceuticals, Inc.",
        "summary": "Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.merrimack.com",
        "market_cap": "Small Cap"
    },
    "MAH1.F": {
        "short_name": "MAGELLAN HEALTH INC.DL-01",
        "long_name": "Magellan Health, Inc.",
        "summary": "Magellan Health, Inc., together with its subsidiaries, provides healthcare management services in the United States. The company operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine. It also contracts with state Medicaid agencies, and the centers for Medicare and Medicaid services to manage care for beneficiaries under Medicaid and Medicare programs, such as healthcare and long-term support services through its network of medical and behavioral health professionals, clinics, hospitals, nursing facilities, home care agencies, and ancillary service providers. The Pharmacy Management segment comprises products and solutions that provide clinical and financial management of pharmaceuticals paid under medical and pharmacy benefit programs. Further, it offers pharmacy benefit management services, such as pharmaceutical dispensing services; pharmacy benefit administration for state Medicaid and other government sponsored programs; clinical and formulary management programs; medical pharmacy management programs; and programs for the integrated management of specialty drugs that treat complex conditions. In addition, the company provides services to managed care organizations, employers, third party administrators, state governments, and other government agencies, exchanges, brokers, and consultants. Magellan Health, Inc. was incorporated in 1969 and is headquartered in Phoenix, Arizona.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "AZ",
        "city": "Phoenix",
        "zipcode": "85034",
        "website": "http://www.magellanhealth.com",
        "market_cap": "Mid Cap"
    },
    "MAHN": {
        "short_name": "MID-ATLANTIC HOME HEALTH NETWOR",
        "long_name": "Mid-Atlantic Home Health Network, Inc.",
        "summary": "Mid-Atlantic Home Health Network, Inc. provides integrated home health products and services for the home health care industry in Virginia, Maryland, and the District of Columbia. It also provides healthcare staffing and private duty nursing services to hospitals, nursing homes, and other facilities, such as clinics, correctional facilities, and schools. Mid-Atlantic was incorporated as U-Can Resources, Inc. in 1979. The company changed its name to Petro-Sers Corporation in 1993 and to Mid-Atlantic Home Health Network, Inc. in 1994. The company is based in Manassas, Virginia. Mid-Atlantic Home Health Network, Inc. is 80% owned by Oak Springs NursingHome Limited Liability Company.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Manassas",
        "zipcode": "20109-2631",
        "website": null,
        "market_cap": "Small Cap"
    },
    "MASI.MX": {
        "short_name": "MASIMO CORPORATION",
        "long_name": "Masimo Corporation",
        "summary": "Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.masimo.com",
        "market_cap": "Large Cap"
    },
    "MASI": {
        "short_name": "Masimo Corporation",
        "long_name": "Masimo Corporation",
        "summary": "Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.masimo.com",
        "market_cap": "Large Cap"
    },
    "MASS": {
        "short_name": "908 Devices Inc.",
        "long_name": "908 Devices Inc.",
        "summary": "908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.908devices.com",
        "market_cap": "Small Cap"
    },
    "MBCI": {
        "short_name": "MABCURE INC",
        "long_name": "MabCure, Inc.",
        "summary": "MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "White Plains",
        "zipcode": "10605",
        "website": null,
        "market_cap": "Small Cap"
    },
    "MBIO": {
        "short_name": "Mustang Bio, Inc.",
        "long_name": "Mustang Bio, Inc.",
        "summary": "Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Worcester",
        "zipcode": "01605",
        "website": "http://www.mustangbio.com",
        "market_cap": "Small Cap"
    },
    "MBOT": {
        "short_name": "Microbot Medical Inc.",
        "long_name": "Microbot Medical Inc.",
        "summary": "Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 42 issued/allowed patents and 23 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Hingham",
        "zipcode": "02043",
        "website": "http://www.microbotmedical.com",
        "market_cap": "Small Cap"
    },
    "MBPC.F": {
        "short_name": "PROTAGENIC THERAP.DL -,01",
        "long_name": "Protagenic Therapeutics, Inc.",
        "summary": "Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10010",
        "website": "http://www.protagenic.com",
        "market_cap": "Small Cap"
    },
    "MBRX": {
        "short_name": "Moleculin Biotech, Inc.",
        "long_name": "Moleculin Biotech, Inc.",
        "summary": "Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77007",
        "website": "http://www.moleculin.com",
        "market_cap": "Small Cap"
    },
    "MCDA": {
        "short_name": "KMA HOLDING INC",
        "long_name": "KMA Holding, Inc.",
        "summary": "KMA Holding, Inc., through its subsidiaries, manufactures human and pet home medical test kits and emergency response mobile hospital units in the United States. The company focuses on the detection of various illnesses, such as cancer, through the analysis of blood, saliva, urine, hair, and other substances. It offers home screening medical detection test kits for drugs of abuse, sexually transmitted diseases, infectious deceases, tumor marker, and fertility. The company also provides pet home medical test kits for cancer, diabetics, and lime diseases. In addition, it offers emergency medical response mobile hospital units, which enable the provision of temporary emergency life support, and medical and pharmaceutical products and services; and communication via secured wireless technology. The company was formerly known as Macada Holding, Inc. and changed its name to KMA Holding, Inc. in March 2011. KMA Holding, Inc. was founded in 2000 and is based in Pompano Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Pompano Beach",
        "zipcode": "33064",
        "website": null,
        "market_cap": "Small Cap"
    },
    "MCET": {
        "short_name": "MULTICELL TECHNOLOGIES INC",
        "long_name": "MultiCell Technologies, Inc.",
        "summary": "MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "RI",
        "city": "Woonsocket",
        "zipcode": "02895",
        "website": null,
        "market_cap": "Small Cap"
    },
    "MCIC": {
        "short_name": "MULTICORP INTL INC",
        "long_name": "Multicorp International, Inc.",
        "summary": "Multicorp International, Inc. engages in the medical business in the United States and internationally. It offers its products and services in the tele-medicine and tele-health sectors. The company also engages in music, television shows and movie production, and Broadway style plays, as well as operates WRSO 810 AM radio station. It was formerly known as XTend Medical Corporation and changed its name to MultiCorp International, Inc. in August 2012. The company is based in Sun Valley, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Sun Valley",
        "zipcode": "91352",
        "website": "http://multicorp.international",
        "market_cap": "Small Cap"
    },
    "MCK.F": {
        "short_name": "MCKESSON  DL-,01",
        "long_name": "McKesson Corporation",
        "summary": "McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and solutions for life sciences companies, including offering multiple distribution channels and clinical trial access to specific patient populations through its network of oncology physicians. The segment also sells financial, operational and clinical solutions to pharmacies; and offers consulting, outsourcing, and other services. The Prescription Technology Solutions segment operates in the healthcare delivery system to connect pharmacies, providers, payers, and biopharma for next-generation patient access and adherence solutions. The International segment provides drug distribution services, specialty pharmacy, and retail and infusion care services. The Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Irving",
        "zipcode": "75039",
        "website": "http://www.mckesson.com",
        "market_cap": "Large Cap"
    },
    "MCK.MX": {
        "short_name": "MCKESSON CORPORATION",
        "long_name": "McKesson Corporation",
        "summary": "McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and solutions for life sciences companies, including offering multiple distribution channels and clinical trial access to specific patient populations through its network of oncology physicians. The segment also sells financial, operational and clinical solutions to pharmacies; and offers consulting, outsourcing, and other services. The Prescription Technology Solutions segment operates in the healthcare delivery system to connect pharmacies, providers, payers, and biopharma for next-generation patient access and adherence solutions. The International segment provides drug distribution services, specialty pharmacy, and retail and infusion care services. The Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "TX",
        "city": "Irving",
        "zipcode": "75039",
        "website": "http://www.mckesson.com",
        "market_cap": "Large Cap"
    },
    "MCK": {
        "short_name": "McKesson Corporation",
        "long_name": "McKesson Corporation",
        "summary": "McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and solutions for life sciences companies, including offering multiple distribution channels and clinical trial access to specific patient populations through its network of oncology physicians. The segment also sells financial, operational and clinical solutions to pharmacies; and offers consulting, outsourcing, and other services. The Prescription Technology Solutions segment operates in the healthcare delivery system to connect pharmacies, providers, payers, and biopharma for next-generation patient access and adherence solutions. The International segment provides drug distribution services, specialty pharmacy, and retail and infusion care services. The Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Irving",
        "zipcode": "75039",
        "website": "http://www.mckesson.com",
        "market_cap": "Large Cap"
    },
    "MCOA": {
        "short_name": "MARIJUANA COMPANY OF AMERICA IN",
        "long_name": "Marijuana Company of America, Inc.",
        "summary": "Marijuana Company of America, Inc., together with its subsidiaries, develops, manufactures, markets, and sells hemp and hemp-derived consumer products under the hempSMART brand name in the United States and internationally. The company's hempSMART products include hempSMART Brain, a patented and formulated personal care consumer product that combines hemp-derived cannabidiol (CBD) for brain wellness; hempSMART Pain capsules for relief of minor discomfort with physical activity; hempSMART Pain Cream for muscle relaxation; hempSMART Drops, hemp CBD oil tincture drops; hempSMART Pet Drops for cats and dogs; hempSMART Face, a facial moisturizer; and hempSMART drink mix, an industrial hemp based powderized CBD drink. It also provides financial accounting and bookkeeping, and property management consulting services for operators in states where cannabis and/or hemp is legalized for medicinal and/or recreational use. The company sells its products through its web site and affiliate marketing programs. Marijuana Company of America, Inc. has a strategic collaboration agreement with Eco Innovation Group, Inc. to enhance the company's global cannabis offering. The company was formerly known as Converge Global, Inc. and changed its name to Marijuana Company of America, Inc. in December 2015. Marijuana Company of America, Inc. was incorporated in 1985 and is headquartered in Escondido, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Escondido",
        "zipcode": "92029",
        "website": "http://www.marijuanacompanyofamerica.com",
        "market_cap": "Small Cap"
    },
    "MCRB": {
        "short_name": "Seres Therapeutics, Inc.",
        "long_name": "Seres Therapeutics, Inc.",
        "summary": "Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.serestherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "MD": {
        "short_name": "Mednax, Inc.",
        "long_name": "MEDNAX, Inc.",
        "summary": "MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of March 16, 2021, it operated a network of approximately 2,300 physicians. The company was founded in 1979 and is based in Sunrise, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Sunrise",
        "zipcode": "33323",
        "website": "http://www.mednax.com",
        "market_cap": "Mid Cap"
    },
    "MDCN": {
        "short_name": "MEDICAN ENTERPRISES INC",
        "long_name": "Medican Enterprises, Inc.",
        "summary": "Medican Enterprises, Inc., a bio-pharmaceutical company, focuses on pursuing business opportunities in the medical and recreational marijuana sector. The company intends to invest in business of growing, marketing, research and development, training, distribution, and retail sale of medical and recreational marijuana in the United States and Canada. Medican Enterprises, Inc. was founded in 1988 and is headquartered in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89120",
        "website": "http://www.medicaninc.com",
        "market_cap": "Small Cap"
    },
    "MDGL": {
        "short_name": "Madrigal Pharmaceuticals, Inc.",
        "long_name": "Madrigal Pharmaceuticals, Inc.",
        "summary": "Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-\u00c3\u009f agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "West Conshohocken",
        "zipcode": "19428",
        "website": "http://www.madrigalpharma.com",
        "market_cap": "Mid Cap"
    },
    "MDGP": {
        "short_name": "MEDGROUP INC CALIF",
        "long_name": "Medgroup Inc.",
        "summary": "Medgroup Inc. provides physical therapy facilities in hospitals, industrial medical clinics, nursing homes, and home health agencies in the United States. The company is based in Encino, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Encino",
        "zipcode": "91436-3111",
        "website": null,
        "market_cap": "Small Cap"
    },
    "MDIT": {
        "short_name": "MEDITE CANCER DIAGNOSTICS INC",
        "long_name": "Medite Cancer Diagnostics, Inc.",
        "summary": "Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Orlando",
        "zipcode": "32832",
        "website": "http://medite-group.com",
        "market_cap": "Small Cap"
    },
    "MDKM": {
        "short_name": "MDECHEM INC",
        "long_name": "MDEChem, Inc.",
        "summary": "MDEChem, Inc. provides pharmaceutical and chemical products. The company offers MaxHeal skin restoration gel, a non-steroidal and anti-inflammatory compound that provides instant relief to minor cuts, scrapes, minor burns, sunburn, and abrasions, as well as soothe itchy bites from chiggers, mosquitoes, sand fleas, black flies, and other biting insects. It also provides SANDKLENE 950, a non-toxic chemical composition, which is used in the recovery of oil from tar/oil sands. The company was founded in 1996 and is based in Floresville, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Floresville",
        "zipcode": "78114",
        "website": "http://www.mdechem.com",
        "market_cap": "Small Cap"
    },
    "MDRX": {
        "short_name": "Allscripts Healthcare Solutions",
        "long_name": "Allscripts Healthcare Solutions, Inc.",
        "summary": "Allscripts Healthcare Solutions, Inc., together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates in two segments: The Core Clinical and Financial Solutions; and The Data, Analytics and Care Coordination. The Core Clinical and Financial Solutions segment provides software applications for patient engagement, and integrated clinical and financial management solutions, which primarily include EHR-related software; and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Data, Analytics and Care Coordination segment offers practice reimbursement, and payer and life sciences solutions, which are primarily targeted at physician practices, payers, life sciences companies, and other healthcare stakeholders. Its solutions enable clients to transition, analyze, and coordinate care and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.allscripts.com",
        "market_cap": "Mid Cap"
    },
    "MDWK": {
        "short_name": "MDWERKS INC",
        "long_name": "MDwerks, Inc.",
        "summary": "MDwerks, Inc., through its subsidiaries, distributes healthcare technology solutions and provides services to the health care industry. It markets and leases digital pen technology, which includes sale of digital pens to healthcare providers, as well as provides funding to the healthcare provider industry. The company also offers FUNDwerks solutions, which electronically manage loans, loan repayments, and the movement of funds through linked bank accounts. Its customers include doctors, clinics, surgical or hospital based practices, home health care, nursing homes, and other healthcare providers. MDwerks, Inc. was founded in 2003 and is based in Deerfield Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Deerfield Beach",
        "zipcode": "33442",
        "website": null,
        "market_cap": "Small Cap"
    },
    "MDXG": {
        "short_name": "MiMedx Group, Inc",
        "long_name": "MiMedx Group, Inc.",
        "summary": "MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Marietta",
        "zipcode": "30062",
        "website": "http://www.mimedx.com",
        "market_cap": "Small Cap"
    },
    "MDXL": {
        "short_name": "MEDIXALL GROUP INC",
        "long_name": "MediXall Group, Inc.",
        "summary": "MediXall Group, Inc., together with its subsidiaries, operates a healthcare marketplace platform in the United States. The company's cloud- based MediXall.com platform connects patients with healthcare providers and wellness services, as well as provides facilities to search and compare medical, dental, and wellness services to consumers and healthcare providers. It also offers patient, cosmetic and elective procedure, commercial, and medical accounts receivable financing services to the healthcare sector. MediXall Group, Inc. was incorporated in 1998 and is based in Fort Lauderdale, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Lauderdale",
        "zipcode": "33308",
        "website": "http://www.medixall.com",
        "market_cap": "Small Cap"
    },
    "MEDD": {
        "short_name": "MEDICAL IMAGING CORP",
        "long_name": "Medical Imaging Corp.",
        "summary": "Medical Imaging Corp., through its subsidiaries, provides medical diagnostic imaging services for patients, hospitals and clinics, workers' compensation boards, and insurance companies in North America. It provides remote reading and reporting of medical diagnostic imaging scans. The company also provides magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound, nuclear medicine, digital mammography, X-ray, and bone mineral densitometry modalities. As of December 31, 2017, it operated an independent diagnostic imaging facility in Pottsville, Pennsylvania; and three diagnostic centers in Florida. The company was formerly known as Diagnostic Imaging International Corp. and changed its name to Medical Imaging Corp. in July 2014. Medical Imaging Corp. was incorporated in 2000 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89107",
        "website": "http://www.medimagingcorp.com",
        "market_cap": "Small Cap"
    },
    "MEDP.MX": {
        "short_name": "MEDPACE HOLDINGS INC",
        "long_name": "Medpace Holdings, Inc.",
        "summary": "Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45227",
        "website": "http://www.medpace.com",
        "market_cap": "Mid Cap"
    },
    "MEDP": {
        "short_name": "Medpace Holdings, Inc.",
        "long_name": "Medpace Holdings, Inc.",
        "summary": "Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45227",
        "website": "http://www.medpace.com",
        "market_cap": "Mid Cap"
    },
    "MEDS": {
        "short_name": "Trxade Group, Inc.",
        "long_name": "Trxade Group, Inc.",
        "summary": "Trxade Group, Inc., together with its subsidiaries, operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc.; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services. Its principal products and services include Trxade.com, a web-based pharmaceutical marketplace; InventoryRx.com, a web-based pharmaceutical exchange platform; Pharmabayonline that provides proprietary pharmaceutical data analytics and governmental reimbursement benchmarks analysis to the United States-based independent pharmacies and pharmaceutical databases; and RxGuru, an application, which offers product information. The company also operates a retail specialty pharmacy; Delivmeds.com, a consumer-based app to provide delivery of pharmaceutical products; and Trxademso.com to assist independent retail pharmacies on pricing, distribution, and logistics. In addition, it operates Trxade Prime, which allows pharmacy members on the Trxade platform to process, consolidate, and ship purchase orders that are placed directly with Trxade suppliers; Bonum Health Hub, a virtual examination room; Bonum+, a B2B platform to purchase COVID-19 risk assessment and personal protective equipment tools; and MedCheks, a healthcare platform that lets patients consolidate and control their health data via a digital Health Passport and allows them to share their health profile, tests, and vaccination. The company is based in Land O'Lakes, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Land O'Lakes",
        "zipcode": "34639",
        "website": "http://www.trxadegroup.com",
        "market_cap": "Small Cap"
    },
    "MEIP": {
        "short_name": "MEI Pharma, Inc.",
        "long_name": "MEI Pharma, Inc.",
        "summary": "MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.meipharma.com",
        "market_cap": "Small Cap"
    },
    "MFST": {
        "short_name": "MEDIFIRST SOLUTIONS INC",
        "long_name": "Medifirst Solutions, Inc",
        "summary": "Medifirst Solutions, Inc., a development stage company, focuses on developing products within the healthcare market for consumer and professional applications. It develops a hand-held mobile laser system, The Time Machine Series lasers to treat temporary relief of minor muscle and joint pains, stiffness, minor arthritis pain, muscle spasms, temporary increase in local blood circulation, and temporary relaxation of muscles. Medifirst Solutions, Inc. was founded in 2010 and is based in Freehold, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Freehold",
        "zipcode": "07728",
        "website": "http://www.medifirstsolutions.com",
        "market_cap": "Small Cap"
    },
    "MGLN": {
        "short_name": "Magellan Health, Inc.",
        "long_name": "Magellan Health, Inc.",
        "summary": "Magellan Health, Inc., together with its subsidiaries, provides healthcare management services in the United States. The company operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine. It also contracts with state Medicaid agencies, and the centers for Medicare and Medicaid services to manage care for beneficiaries under Medicaid and Medicare programs, such as healthcare and long-term support services through its network of medical and behavioral health professionals, clinics, hospitals, nursing facilities, home care agencies, and ancillary service providers. The Pharmacy Management segment comprises products and solutions that provide clinical and financial management of pharmaceuticals paid under medical and pharmacy benefit programs. Further, it offers pharmacy benefit management services, such as pharmaceutical dispensing services; pharmacy benefit administration for state Medicaid and other government sponsored programs; clinical and formulary management programs; medical pharmacy management programs; and programs for the integrated management of specialty drugs that treat complex conditions. In addition, the company provides services to managed care organizations, employers, third party administrators, state governments, and other government agencies, exchanges, brokers, and consultants. Magellan Health, Inc. was incorporated in 1969 and is headquartered in Phoenix, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Phoenix",
        "zipcode": "85034",
        "website": "http://www.magellanhealth.com",
        "market_cap": "Mid Cap"
    },
    "MGNX": {
        "short_name": "MacroGenics, Inc.",
        "long_name": "MacroGenics, Inc.",
        "summary": "MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B \u00c3\u0097 CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.macrogenics.com",
        "market_cap": "Mid Cap"
    },
    "MGTA": {
        "short_name": "Magenta Therapeutics, Inc.",
        "long_name": "Magenta Therapeutics, Inc.",
        "summary": "Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent prophylaxis of graft-versus-host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate potential utility of MGTA-117 for conditioning of patients receiving one or more investigational lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.magentatx.com",
        "market_cap": "Small Cap"
    },
    "MGTX": {
        "short_name": "MeiraGTx Holdings plc",
        "long_name": "MeiraGTx Holdings plc",
        "summary": "MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.meiragtx.com",
        "market_cap": "Small Cap"
    },
    "MHG.F": {
        "short_name": "MOLINA HEALTHCARE DL-,001",
        "long_name": "Molina Healthcare, Inc.",
        "summary": "Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. The company operates in two segments, Health Plans and Other. As of December 31, 2020, it served approximately 4.0 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 15 states. The company offers its health care services for its members through contracts with a network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies. Molina Healthcare, Inc. was founded in 1980 and is headquartered in Long Beach, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Long Beach",
        "zipcode": "90802",
        "website": "http://www.molinahealthcare.com",
        "market_cap": "Large Cap"
    },
    "MHTX": {
        "short_name": "MANHATTAN SCIENTIFICS INC",
        "long_name": "Manhattan Scientifics, Inc.",
        "summary": "Manhattan Scientifics, Inc., a technology incubator, develops and commercializes life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10001",
        "website": "http://www.mhtx.com",
        "market_cap": "Small Cap"
    },
    "MICR": {
        "short_name": "MICRON SOLUTIONS INC",
        "long_name": "Micron Solutions, Inc.",
        "summary": "Micron Solutions, Inc., through its subsidiary, Micron Products, Inc., operates as a contract manufacturing organization that produces medical device components requiring precision machining and injection molding in the United States and internationally. The company also manufactures components, devices, and equipment for military, law enforcement, automotive, and consumer product applications. Its products include silver/silver chloride coated and conductive resin sensors for use as consumable component parts in integrated disposable electrophysiological sensors that are used in monitoring electrical signals in various medical applications. The company also offers orthopedic implant components; thermoplastic injection molding services; and value added services, including the design, manufacture, and rehabilitation of injection molding tools. It serves original equipment manufacturers, and other contract manufacturing organizations, as well as defense industries. The company was formerly known as Arrhythmia Research Technology, Inc. and changed its name to Micron Solutions, Inc. in March 2017. Micron Solutions, Inc. is based in Fitchburg, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Fitchburg",
        "zipcode": "01420",
        "website": "http://www.micronsolutionsinc.com",
        "market_cap": "Small Cap"
    },
    "MINA.F": {
        "short_name": "SYNLOGIC INC.  DL-,001",
        "long_name": "Synlogic, Inc.",
        "summary": "Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.synlogictx.com",
        "market_cap": "Small Cap"
    },
    "MIRM": {
        "short_name": "Mirum Pharmaceuticals, Inc.",
        "long_name": "Mirum Pharmaceuticals, Inc.",
        "summary": "Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.mirumpharma.com",
        "market_cap": "Small Cap"
    },
    "MITI": {
        "short_name": "MITESCO INC",
        "long_name": "Mitesco, Inc.",
        "summary": "Mitesco, Inc. operates medical clinics under the The Good Clinic name in North East Minneapolis, the United States. It offers wellness coaching, behavioral health care, episodic care, dermatologic services, and supplements. The company was formerly known as True Nature Holding, Inc. and changed its name to Mitesco, Inc. in April 2020. Mitesco, Inc. is based in Minnetonka, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minnetonka",
        "zipcode": "55305",
        "website": "http://www.mitescoinc.com",
        "market_cap": "Small Cap"
    },
    "MJC.F": {
        "short_name": "ANTARES PHA.  DL-,01",
        "long_name": "Antares Pharma, Inc.",
        "summary": "Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG. Antares Pharma, Inc. was founded in 1978 and is headquartered in Ewing, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Ewing",
        "zipcode": "08628",
        "website": "http://www.antarespharma.com",
        "market_cap": "Small Cap"
    },
    "MJNA": {
        "short_name": "MEDICAL MARIJUANA INC",
        "long_name": "Medical Marijuana, Inc.",
        "summary": "Medical Marijuana, Inc., an investment holding company, operates in the cannabinoid-based nutraceutical industry. It focuses on the development, sale, and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol (CBD) and other products containing CBD-rich hemp oil; treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products; and nonpsychoactive cannabidiol products. The company is also involved in the research and development of new therapeutic agents that are designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants; dietary supplements, skin care products, and prescription-based hemp oil under the Kannaway and HempMeds brands; and proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods for the medicinal cannabinoid industry. In addition, it offers RSHO oil for the treatment of various illnesses and conditions; and plant-based, non-GMO pet products for health and wellness, play and wear, and environmentally-friendly supplies. Medical Marijuana, Inc. was incorporated in 2005 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92191",
        "website": "http://www.medicalmarijuanainc.com",
        "market_cap": "Small Cap"
    },
    "MJNE": {
        "short_name": "MJ HOLDINGS INC",
        "long_name": "MJ Holdings, Inc.",
        "summary": "MJ Holdings, Inc. operates in the medical marijuana business in Nevada. It offers cultivation and production management, consulting, and asset and infrastructure development services for the cannabis industry. The company is headquartered in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89139",
        "website": "http://www.mjholdingsinc.com",
        "market_cap": "Small Cap"
    },
    "MJTV": {
        "short_name": "MICHAEL JAMES ENTERPRISES INC",
        "long_name": "MJ Biotech, Inc.",
        "summary": "MJ Biotech, Inc. produces and distributes medical hemp based CBD infused teas and herbs. It sells its products in wellness stores, as well as through its e-commerce Website. The company was formerly known as Michael James Enterprises, Inc. and changed its name to MJ Biotech, Inc. in April 2017. MJ Biotech, Inc. was founded in 2010 and is based in Boynton Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boynton Beach",
        "zipcode": "33426",
        "website": "http://www.mjbiotech.us",
        "market_cap": "Small Cap"
    },
    "MLKNA": {
        "short_name": "MEDLINK INTERNATIONAL INC",
        "long_name": "MedLink International, Inc.",
        "summary": "MedLink International, Inc. engages in selling, implementing, and supporting software solutions that provide physician practices, laboratories, and other healthcare organizations access to clinical, administrative, and financial data. The company offers MedLink iSuite EHR that automates physician activities, such as prescribing, dictating, ordering lab tests and viewing results, documenting clinical encounters, and capturing charges, among others; and MedLink IX (Information eXchange), an enterprise connectivity solution that links providers and healthcare services to achieve interoperability deployed in commercial and hospital laboratories. It also provides MedLink Lab, a Web browser based lab ordering and results portal hosted on the company's virtual cloud platform; and MedLink Connect, which allows laboratory services to utilize MedLink IX to deliver laboratory results to multiple HIS and EMR, as well as Health Information networks. MedLink International sells its products through direct sales force. The company is based in Hauppauge, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Specialized Health Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Hauppauge",
        "zipcode": "11788",
        "website": "http://www.medlinkus.com",
        "market_cap": "Small Cap"
    },
    "MLND": {
        "short_name": "Millendo Therapeutics, Inc.",
        "long_name": "Millendo Therapeutics, Inc.",
        "summary": "Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Ann Arbor",
        "zipcode": "48104",
        "website": "http://www.millendo.com",
        "market_cap": "Small Cap"
    },
    "MLSS": {
        "short_name": "Milestone Scientific, Inc.",
        "long_name": "Milestone Scientific Inc.",
        "summary": "Milestone Scientific, Inc. develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent System that are used to control the flow rate of the anesthesia during the injection, which allows virtually painless injections for various dental procedures, including routine fillings, implants, root canals, and crowns. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications; CompuFlo Intra-Articular, a computer controlled injection system for administering corticosteroids and other medicaments; and Cosmetic Botulinum Injection device for the pain free injection of botulinum toxin. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific, Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Roseland",
        "zipcode": "07068",
        "website": "http://www.milestonescientific.com",
        "market_cap": "Small Cap"
    },
    "MM3.F": {
        "short_name": "MERIT MED. SYS",
        "long_name": "Merit Medical Systems, Inc.",
        "summary": "Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "South Jordan",
        "zipcode": "84095",
        "website": "http://www.merit.com",
        "market_cap": "Mid Cap"
    },
    "MM6A.F": {
        "short_name": "OPTION CARE HEALTH DL-,01",
        "long_name": "Option Care Health, Inc.",
        "summary": "Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies. It also offers infusion therapies for bleeding disorders; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications. In addition, the company offers therapies that women need to survive and thrive through high-risk pregnancies; treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; and nursing services. The company is headquartered in Bannockburn, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Bannockburn",
        "zipcode": "60015",
        "website": "http://www.optioncarehealth.com",
        "market_cap": "Mid Cap"
    },
    "MMED.NE": {
        "short_name": "MIND MEDICINE (MINDMED) INC.",
        "long_name": "Mind Medicine (MindMed) Inc.",
        "summary": "Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NEO",
        "market": "ca_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10007",
        "website": "http://www.mindmed.co",
        "market_cap": "Small Cap"
    },
    "MMEN.CN": {
        "short_name": "MedMenInc",
        "long_name": "MedMen Enterprises Inc.",
        "summary": "MedMen Enterprises Inc., through its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the [statemade], LuxLyte, and MedMen Red brand names. It operates 25 retail stores in 6 states. MedMen Enterprises Inc. was founded in 2010 and is headquartered in Culver City, California.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "CA",
        "city": "Culver City",
        "zipcode": "90232",
        "website": "http://www.medmen.com",
        "market_cap": "Small Cap"
    },
    "MMIA.F": {
        "short_name": "MEI PHARMA INC.",
        "long_name": "MEI Pharma, Inc.",
        "summary": "MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.meipharma.com",
        "market_cap": "Small Cap"
    },
    "MMNFF": {
        "short_name": "MEDMEN ENTERPRISES INC",
        "long_name": "MedMen Enterprises Inc.",
        "summary": "MedMen Enterprises Inc., through its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the [statemade], LuxLyte, and MedMen Red brand names. It operates 25 retail stores in 6 states. MedMen Enterprises Inc. was founded in 2010 and is headquartered in Culver City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Culver City",
        "zipcode": "90232",
        "website": "http://www.medmen.com",
        "market_cap": "Small Cap"
    },
    "MMSI": {
        "short_name": "Merit Medical Systems, Inc.",
        "long_name": "Merit Medical Systems, Inc.",
        "summary": "Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "South Jordan",
        "zipcode": "84095",
        "website": "http://www.merit.com",
        "market_cap": "Mid Cap"
    },
    "MMTC": {
        "short_name": "MICRO IMAGING TECH INC",
        "long_name": "Micro Imaging Technology, Inc.",
        "summary": "Micro Imaging Technology, Inc., a development stage company, engages in the development of fluid monitoring systems for water monitoring, food processing, and clinical applications in the United States. The company is developing a non-biologically based system utilizing both proprietary hardware and software to determine the specific specie of an unknown microbe present in a fluid with a high degree of statistical probability. It would analyze a sample presented to it and compares its characteristics to a library of known microbe characteristics on file. The company was formerly known as Electropure, Inc. and changed its name to Micro Imaging Technology, Inc. in November 2005. Micro Imaging Technology, Inc. was founded in 1979 and is headquartered in San Clemente, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Clemente",
        "zipcode": "92673",
        "website": "http://www.micro-identification.com",
        "market_cap": "Small Cap"
    },
    "MNFSF": {
        "short_name": "MANIFESTSEVEN HOLDINGS CORPORAT",
        "long_name": "ManifestSeven Holdings Corporation",
        "summary": "ManifestSeven Holdings Corporation operates an integrated omnichannel platform for legal cannabis, merging compliant distribution with a retail. It owns and operates retail operations located in various metro markets, including brick-and-mortar dispensaries, local on-demand delivery services, e-commerce, and subscription offerings. The company is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.manifest7.com",
        "market_cap": "Small Cap"
    },
    "MNKD": {
        "short_name": "MannKind Corporation",
        "long_name": "MannKind Corporation",
        "summary": "MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Westlake Village",
        "zipcode": "91362",
        "website": "http://www.mannkindcorp.com",
        "market_cap": "Small Cap"
    },
    "MNMD": {
        "short_name": "Mind Medicine (MindMed) Inc. - ",
        "long_name": "Mind Medicine (MindMed) Inc.",
        "summary": "Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10007",
        "website": "http://www.mindmed.co",
        "market_cap": "Small Cap"
    },
    "MNOV": {
        "short_name": "MediciNova, Inc.",
        "long_name": "MediciNova, Inc.",
        "summary": "MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://medicinova.com",
        "market_cap": "Small Cap"
    },
    "MNPR": {
        "short_name": "Monopar Therapeutics Inc.",
        "long_name": "Monopar Therapeutics Inc.",
        "summary": "Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Espa\u00c3\u00b1ol de Investigaci\u00c3\u00b3n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Wilmette",
        "zipcode": "60091",
        "website": "http://www.monopartx.com",
        "market_cap": "Small Cap"
    },
    "MNZO": {
        "short_name": "MANZO PHARMACEUTIC INC",
        "long_name": "Manzo Pharmaceuticals, Inc.",
        "summary": "Manzo Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and testing of patented and non-patented solutions and remedies. The company is involved in developing Lacto-Freedom, a patented probiotic, which aids in the digestion of lactose containing foods primarily for people with lactose intolerance; and a natural remedy for colic in babies. It was formerly known as Fortune Oil & Gas, Inc. and changed its name to Manzo Pharmaceuticals, Inc. in September 2014. Manzo Pharmaceuticals, Inc. is based in Milford, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Milford",
        "zipcode": "18337",
        "website": "http://www.lactofreedom.com",
        "market_cap": "Small Cap"
    },
    "MODD": {
        "short_name": "MODULAR MEDICAL INC",
        "long_name": "Modular Medical, Inc.",
        "summary": "Modular Medical, Inc., a development stage medical device company, focuses on design, development, and commercialization of insulin pumps for insulin dependent people with diabetes. Its hardware technology allows people with diabetes to receive their daily insulin through continuous basal delivery and bolus delivery. The company is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92127",
        "website": "http://www.modular-medical.com",
        "market_cap": "Small Cap"
    },
    "MODV": {
        "short_name": "ModivCare Inc.",
        "long_name": "ModivCare Inc.",
        "summary": "ModivCare Inc., a technology-enabled healthcare services company, provides a suite of integrated supportive care solutions for public and private payors and patients. It offers non-emergency medical transportation services for Medicaid or Medicare eligible members, whose limited mobility or financial resources hinder their ability to access necessary healthcare and social services. The company also provides in-home and on-site care optimization services, including comprehensive health assessments through a network of community-based clinicians and a fleet of mobile health clinics. The company was formerly known as The Providence Service Corporation and changed its name to ModivCare Inc. in January 2021. The company was founded in 1996 and is headquartered in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80237",
        "website": "http://www.modivcare.com",
        "market_cap": "Mid Cap"
    },
    "MOH": {
        "short_name": "Molina Healthcare Inc",
        "long_name": "Molina Healthcare, Inc.",
        "summary": "Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. The company operates in two segments, Health Plans and Other. As of December 31, 2020, it served approximately 4.0 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 15 states. The company offers its health care services for its members through contracts with a network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies. Molina Healthcare, Inc. was founded in 1980 and is headquartered in Long Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Long Beach",
        "zipcode": "90802",
        "website": "http://www.molinahealthcare.com",
        "market_cap": "Large Cap"
    },
    "MOLA.F": {
        "short_name": "MOLECULIN BIOTECH DL-,001",
        "long_name": "Moleculin Biotech, Inc.",
        "summary": "Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77007",
        "website": "http://www.moleculin.com",
        "market_cap": "Small Cap"
    },
    "MORF": {
        "short_name": "Morphic Holding, Inc.",
        "long_name": "Morphic Holding, Inc.",
        "summary": "Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4\u00c3\u009f7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing av\u00c3\u009f1 for the treatment of fibrotic diseases, and av\u00c3\u009f8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schr\u00c3\u00b6dinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.morphictx.com",
        "market_cap": "Mid Cap"
    },
    "MOST": {
        "short_name": "MOBILESMITH INC",
        "long_name": "MobileSmith, Inc.",
        "summary": "MobileSmith, Inc. develops software applications for the healthcare industry in the United States. Its product portfolio includes PeriOp Patient Adherence, an EMR integrated mobile app-based set of pre and postoperative instructions that establish a clinical procedure management process between a patient and a healthcare provider; COVID Response Mobile Apps, a healthcare mobile apps supporting COVID-19 communications challenges for hospitals and their communities; and COVIDClear that assess and track the COVID-19 status of the workforce. The company was formerly known as Smart Online, Inc. and changed its name to MobileSmith, Inc. in July 2013. MobileSmith, Inc. was incorporated in 1993 and is headquartered in Raleigh, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Raleigh",
        "zipcode": "27607",
        "website": "http://www.mobilesmith.com",
        "market_cap": "Small Cap"
    },
    "MOTS": {
        "short_name": "Motus GI Holdings, Inc.",
        "long_name": "Motus GI Holdings, Inc.",
        "summary": "Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with colonoscopy in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Lauderdale",
        "zipcode": "33301",
        "website": "http://www.motusgi.com",
        "market_cap": "Small Cap"
    },
    "MOVE": {
        "short_name": "Movano Inc.",
        "long_name": "Movano Inc.",
        "summary": "Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Pleasanton",
        "zipcode": "94588",
        "website": "http://movano.com",
        "market_cap": "Small Cap"
    },
    "MP6N.F": {
        "short_name": "MERRIMACK PHAR.NEW DL-,01",
        "long_name": "Merrimack Pharmaceuticals, Inc.",
        "summary": "Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.merrimack.com",
        "market_cap": "Small Cap"
    },
    "MP6N.SG": {
        "short_name": "Merrimack Pharmaceuticals Inc.R",
        "long_name": "Merrimack Pharmaceuticals, Inc.",
        "summary": "Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.merrimack.com",
        "market_cap": "Small Cap"
    },
    "MPHMF": {
        "short_name": "CALLITAS HEALTH INC",
        "long_name": "Callitas Health Inc.",
        "summary": "Callitas Health Inc. provides over the counter consumer health and wellness products in the United States and Canada. It offers C-103, a reformulation of Orlistat for the treatment of obesity; ToConceive, a fertility enhancing moisturizer; and Extrinsa for female sexual dysfunction solutions, as well as focuses on developing cannabinoid delivery technologies. The company was formerly known as M Pharmaceutical Inc. and changed its name to Callitas Health Inc. in September 2017. Callitas Health Inc. was founded in 2003 and is headquartered in Newport, Kentucky.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "KY",
        "city": "Newport",
        "zipcode": "41071",
        "website": "http://callitas.com",
        "market_cap": "Small Cap"
    },
    "MPLN": {
        "short_name": "MultiPlan Corporation",
        "long_name": "MultiPlan Corporation",
        "summary": "MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services, which reduce medical costs through data-driven algorithms that detect claims over-charges and recommend or negotiate reimbursement; network-based services that reduce medical costs through contracted discounts with healthcare providers; and payment integrity services, which reduce medical costs by identifying and removing improper and unnecessary charges paid during the claim. It also provides health benefit plans, which features reference-based pricing and tools to engage health plan members and providers to make the use of benefits before and after care delivery. The company serves national insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, third party administrators, insurance bill review companies, Taft-Hartley plans, and other entities that pay medical bills in the commercial healthcare, government, workers' compensation, and auto medical markets. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10003",
        "website": "http://www.multiplan.us",
        "market_cap": "Mid Cap"
    },
    "MPM.F": {
        "short_name": "MICRON SOLUTIONS  DL-,001",
        "long_name": "Micron Solutions, Inc.",
        "summary": "Micron Solutions, Inc., through its subsidiary, Micron Products, Inc., operates as a contract manufacturing organization that produces medical device components requiring precision machining and injection molding in the United States and internationally. The company also manufactures components, devices, and equipment for military, law enforcement, automotive, and consumer product applications. Its products include silver/silver chloride coated and conductive resin sensors for use as consumable component parts in integrated disposable electrophysiological sensors that are used in monitoring electrical signals in various medical applications. The company also offers orthopedic implant components; thermoplastic injection molding services; and value added services, including the design, manufacture, and rehabilitation of injection molding tools. It serves original equipment manufacturers, and other contract manufacturing organizations, as well as defense industries. The company was formerly known as Arrhythmia Research Technology, Inc. and changed its name to Micron Solutions, Inc. in March 2017. Micron Solutions, Inc. is based in Fitchburg, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Fitchburg",
        "zipcode": "01420",
        "website": "http://www.micronsolutionsinc.com",
        "market_cap": "Small Cap"
    },
    "MR4.F": {
        "short_name": "MERIDIAN BIO",
        "long_name": "Meridian Bioscience, Inc.",
        "summary": "Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45244",
        "website": "http://www.meridianbioscience.com",
        "market_cap": "Small Cap"
    },
    "MRCK34.SA": {
        "short_name": "MERCK       DRN",
        "long_name": "Merck & Co., Inc.",
        "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NJ",
        "city": "Kenilworth",
        "zipcode": "07033",
        "website": "http://www.merck.com",
        "market_cap": "Large Cap"
    },
    "MRK.BA": {
        "short_name": "MERCK & CO INC",
        "long_name": "Merck & Co., Inc.",
        "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "NJ",
        "city": "Kenilworth",
        "zipcode": "07033",
        "website": "http://www.merck.com",
        "market_cap": "Large Cap"
    },
    "MRK.MX": {
        "short_name": "MERCK & CO INC",
        "long_name": "Merck & Co., Inc.",
        "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NJ",
        "city": "Kenilworth",
        "zipcode": "07033",
        "website": "http://www.merck.com",
        "market_cap": "Large Cap"
    },
    "MRK.PA": {
        "short_name": "MERCK AND CO INC",
        "long_name": "Merck & Co., Inc.",
        "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Kenilworth",
        "zipcode": "07033",
        "website": "http://www.merck.com",
        "market_cap": "Large Cap"
    },
    "MRK": {
        "short_name": "Merck & Company, Inc.",
        "long_name": "Merck & Co., Inc.",
        "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Kenilworth",
        "zipcode": "07033",
        "website": "http://www.merck.com",
        "market_cap": "Large Cap"
    },
    "MRK.SN": {
        "short_name": "MERCK & CO INC",
        "long_name": "Merck & Co., Inc.",
        "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SGO",
        "market": "cl_market",
        "country": "United States",
        "state": "NJ",
        "city": "Kenilworth",
        "zipcode": "07033",
        "website": "http://www.merck.com",
        "market_cap": "Large Cap"
    },
    "MRK.VI": {
        "short_name": "MERCK & CO. INC.",
        "long_name": "Merck & Co., Inc.",
        "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "NJ",
        "city": "Kenilworth",
        "zipcode": "07033",
        "website": "http://www.merck.com",
        "market_cap": "Large Cap"
    },
    "MRKR": {
        "short_name": "Marker Therapeutics, Inc.",
        "long_name": "Marker Therapeutics, Inc.",
        "summary": "Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77027",
        "website": "http://www.markertherapeutics.com",
        "market_cap": "Small Cap"
    },
    "MRMD": {
        "short_name": "MARIMED INC",
        "long_name": "MariMed Inc.",
        "summary": "MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. It offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and drink powder mixes under the brand Kalm Fusion; and natural fruit chews under the Betty's Eddies brand, and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Norwood",
        "zipcode": "02062",
        "website": "http://www.marimedinc.com",
        "market_cap": "Small Cap"
    },
    "MRNA.MX": {
        "short_name": "MODERNA INC",
        "long_name": "Moderna, Inc.",
        "summary": "Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmac\u00c3\u00a9uticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.modernatx.com",
        "market_cap": "Large Cap"
    },
    "MRNA": {
        "short_name": "Moderna, Inc.",
        "long_name": "Moderna, Inc.",
        "summary": "Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmac\u00c3\u00a9uticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.modernatx.com",
        "market_cap": "Large Cap"
    },
    "MRNS": {
        "short_name": "Marinus Pharmaceuticals, Inc.",
        "long_name": "Marinus Pharmaceuticals, Inc.",
        "summary": "Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Radnor",
        "zipcode": "19087",
        "website": "http://www.marinuspharma.com",
        "market_cap": "Small Cap"
    },
    "MRPI": {
        "short_name": "MERA PHARMACEUTICALS INC",
        "long_name": "Mera Pharmaceuticals, Inc.",
        "summary": "Mera Pharmaceuticals, Inc. primarily develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology. It produces various substances and bioactive compounds that have applications in a range of commercial areas, including human nutrition, pharmaceuticals, and other commodities, such as bio-diesel. The company's products include ASTAFACTOR, a nutraceutical and source of natural astaxanthin; SALMON ESSENTIALS, a combination of astaxanthin and omega-3 fatty acids; and KONA SEA SALT. It markets its products to mass retail outlets in Hawaii through distribution arrangements with companies. The company also operates a chain of professional martial arts studios. Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Pembroke Pines, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Pembroke Pines",
        "zipcode": "33029",
        "website": "http://www.merapharma.com",
        "market_cap": "Small Cap"
    },
    "MRPS": {
        "short_name": "MICROPHONICS INC",
        "long_name": "Microphonics, Inc.",
        "summary": "Microphonics Inc. develops, manufactures, and markets ultrasound diagnostic and detection equipments and speech recognition systems for industrial, manufacturing, governmental, agricultural, automotive, professional racing, and medical markets. The company deploys its ultrasound and electronic technology for acoustical ultrasound of mechanical diagnostic evaluations. Microphonics Inc. is based in Nashville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37228",
        "website": null,
        "market_cap": null
    },
    "MRSN": {
        "short_name": "Mersana Therapeutics, Inc.",
        "long_name": "Mersana Therapeutics, Inc.",
        "summary": "Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.mersana.com",
        "market_cap": "Small Cap"
    },
    "MRTX": {
        "short_name": "Mirati Therapeutics, Inc.",
        "long_name": "Mirati Therapeutics, Inc.",
        "summary": "Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.mirati.com",
        "market_cap": "Mid Cap"
    },
    "MRVI": {
        "short_name": "Maravai LifeSciences Holdings, ",
        "long_name": "Maravai LifeSciences Holdings, Inc.",
        "summary": "Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry, immunofluorescence, and glycobiology. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.maravai.com",
        "market_cap": "Mid Cap"
    },
    "MRVT": {
        "short_name": "MIRAVANT MEDICAL TECHNOLOGY",
        "long_name": "Miravant Medical Technologies Inc.",
        "summary": "Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Barbara",
        "zipcode": "93117",
        "website": null,
        "market_cap": "Small Cap"
    },
    "MRZM": {
        "short_name": "MARIZYME INC",
        "long_name": "Marizyme, Inc.",
        "summary": "Marizyme, Inc., a development stage company, focuses on life science technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform, which includes MB101 for complex wounds and burns; MB102 for acute ischemic stroke; MB104 for deep vein thrombosis; and MB105 for dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Jupiter",
        "zipcode": "33458",
        "website": "http://www.marizyme.com",
        "market_cap": "Small Cap"
    },
    "MSGP": {
        "short_name": "MEDSMART GROUP INC",
        "long_name": "MedSmart Group Inc.",
        "summary": "MedSmart Group Inc. owns and operates a professional network of MedSmart wellness centers specializing in anti-aging treatments. Its services include testosterone replacement therapy, cryogen therapy, hormone restoration, hypothyroidism, allergies, high cholesterol, hypertension, diabetes, Smart Diet, vein treatment, laser hair removal, hair loss treatment, Medi-Fast program, and erectile dysfunction treatment. MedSmart Group Inc. is based in Bay Harbor Islands, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Bay Harbor Islands",
        "zipcode": "33154",
        "website": "http://medsmartgroup.com",
        "market_cap": "Small Cap"
    },
    "MSON": {
        "short_name": "MISONIX, Inc.",
        "long_name": "Misonix, Inc.",
        "summary": "Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Farmingdale",
        "zipcode": "11735",
        "website": "http://www.misonix.com",
        "market_cap": "Small Cap"
    },
    "MSRT": {
        "short_name": "MASSROOTS INC",
        "long_name": "MassRoots, Inc.",
        "summary": "MassRoots, Inc., together with its subsidiaries, operates a technology platform for the cannabis industry in the United States. The company operates www.MassRoots.com, which enables users to share their cannabis content, follow their favorite dispensaries, and stay connected with the legalization movement, as well as enables cannabis consumers to find products, connect with other enthusiasts, and deliver fresh content that informs audience. MassRoots, Inc. was incorporated in 2013 and is based in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80202",
        "website": "http://www.massroots.com",
        "market_cap": "Small Cap"
    },
    "MSVN.CN": {
        "short_name": "Manifest7Co",
        "long_name": "ManifestSeven Holdings Corporation",
        "summary": "ManifestSeven Holdings Corporation operates an integrated omnichannel platform for legal cannabis, merging compliant distribution with a retail. It owns and operates retail operations located in various metro markets, including brick-and-mortar dispensaries, local on-demand delivery services, e-commerce, and subscription offerings. The company is headquartered in Irvine, California.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.manifest7.com",
        "market_cap": "Small Cap"
    },
    "MTB0.F": {
        "short_name": "CARECLOUD INC.  DL-,001",
        "long_name": "CareCloud, Inc.",
        "summary": "CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. It operates through two segments, Healthcare IT and Practice Management. The company's Software-as-a-Service platform includes revenue cycle management, practice management, electronic health record, business intelligence, telehealth, and patient experience management solutions, as well as complementary software tools and business services for medical groups and health systems. It serves physicians, nurses, nurse practitioners, physician assistants, and other clinicians that render bills for their services. The company was formerly known as MTBC, Inc. and changed its name to CareCloud, Inc. in March 2021. CareCloud, Inc. was founded in 1999 and is headquartered in Somerset, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Somerset",
        "zipcode": "08873",
        "website": "http://www.carecloud.com",
        "market_cap": "Small Cap"
    },
    "MTBB.F": {
        "short_name": "CARECLOUD INC.PREF. SR. A",
        "long_name": "CareCloud, Inc.",
        "summary": "CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. It operates through two segments, Healthcare IT and Practice Management. The company's Software-as-a-Service platform includes revenue cycle management, practice management, electronic health record, business intelligence, telehealth, and patient experience management solutions, as well as complementary software tools and business services for medical groups and health systems. It serves physicians, nurses, nurse practitioners, physician assistants, and other clinicians that render bills for their services. The company was formerly known as MTBC, Inc. and changed its name to CareCloud, Inc. in March 2021. CareCloud, Inc. was founded in 1999 and is headquartered in Somerset, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Somerset",
        "zipcode": "08873",
        "website": "http://www.carecloud.com",
        "market_cap": null
    },
    "MTBC": {
        "short_name": "CareCloud, Inc.",
        "long_name": "CareCloud, Inc.",
        "summary": "CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. It operates through two segments, Healthcare IT and Practice Management. The company's Software-as-a-Service platform includes revenue cycle management, practice management, electronic health record, business intelligence, telehealth, and patient experience management solutions, as well as complementary software tools and business services for medical groups and health systems. It serves physicians, nurses, nurse practitioners, physician assistants, and other clinicians that render bills for their services. The company was formerly known as MTBC, Inc. and changed its name to CareCloud, Inc. in March 2021. CareCloud, Inc. was founded in 1999 and is headquartered in Somerset, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Somerset",
        "zipcode": "08873",
        "website": "http://www.carecloud.com",
        "market_cap": "Small Cap"
    },
    "MTBCP": {
        "short_name": "CareCloud, Inc. - 11% Series A ",
        "long_name": "CareCloud, Inc.",
        "summary": "CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. It operates through two segments, Healthcare IT and Practice Management. The company's Software-as-a-Service platform includes revenue cycle management, practice management, electronic health record, business intelligence, telehealth, and patient experience management solutions, as well as complementary software tools and business services for medical groups and health systems. It serves physicians, nurses, nurse practitioners, physician assistants, and other clinicians that render bills for their services. The company was formerly known as MTBC, Inc. and changed its name to CareCloud, Inc. in March 2021. CareCloud, Inc. was founded in 1999 and is headquartered in Somerset, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Somerset",
        "zipcode": "08873",
        "website": "http://www.carecloud.com",
        "market_cap": "Small Cap"
    },
    "MTCR": {
        "short_name": "Metacrine, Inc.",
        "long_name": "Metacrine, Inc.",
        "summary": "Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.metacrine.com",
        "market_cap": "Small Cap"
    },
    "MTD.MX": {
        "short_name": "METTLER-TOLEDO INTERNATIONAL IN",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "OH",
        "city": "Columbus",
        "zipcode": "43240",
        "website": "http://www.mt.com",
        "market_cap": "Large Cap"
    },
    "MTD": {
        "short_name": "Mettler-Toledo International, I",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Columbus",
        "zipcode": "43240",
        "website": "http://www.mt.com",
        "market_cap": "Large Cap"
    },
    "MTEM": {
        "short_name": "Molecular Templates, Inc.",
        "long_name": "Molecular Templates, Inc.",
        "summary": "Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78729",
        "website": "http://www.mtem.com",
        "market_cap": "Small Cap"
    },
    "MTNB": {
        "short_name": "Matinas Biopharma Holdings, Inc",
        "long_name": "Matinas BioPharma Holdings, Inc.",
        "summary": "Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bedminster",
        "zipcode": "07921",
        "website": "http://www.matinasbiopharma.com",
        "market_cap": "Small Cap"
    },
    "MTO.DE": {
        "short_name": "METTLER-TOLEDO INTL",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "OH",
        "city": "Columbus",
        "zipcode": "43240",
        "website": "http://www.mt.com",
        "market_cap": "Large Cap"
    },
    "MTO.F": {
        "short_name": "METTLER-TOLEDO INTL",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Columbus",
        "zipcode": "43240",
        "website": "http://www.mt.com",
        "market_cap": "Large Cap"
    },
    "MTST": {
        "short_name": "METASTAT INC",
        "long_name": "MetaStat, Inc.",
        "summary": "MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company's therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.metastat.com",
        "market_cap": "Small Cap"
    },
    "MX9.F": {
        "short_name": "MISONIX INC.  DL-,01",
        "long_name": "Misonix, Inc.",
        "summary": "Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Farmingdale",
        "zipcode": "11735",
        "website": "http://www.misonix.com",
        "market_cap": "Small Cap"
    },
    "MXCL.L": {
        "short_name": "MAXCYTE INC COM STK USD0.01 (DI",
        "long_name": "MaxCyte, Inc.",
        "summary": "MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://www.maxcyte.com",
        "market_cap": null
    },
    "MXCT.L": {
        "short_name": "MAXCYTE INC COM STK USD0.01 (DI",
        "long_name": "MaxCyte, Inc.",
        "summary": "MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://www.maxcyte.com",
        "market_cap": null
    },
    "MYD.DE": {
        "short_name": "MYRIAD GENETICS  DL-,01",
        "long_name": "Myriad Genetics, Inc.",
        "summary": "Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84108",
        "website": "http://myriad.com",
        "market_cap": "Mid Cap"
    },
    "MYD.F": {
        "short_name": "MYRIAD GENETICS  DL-,01",
        "long_name": "Myriad Genetics, Inc.",
        "summary": "Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84108",
        "website": "http://myriad.com",
        "market_cap": "Mid Cap"
    },
    "MYE0.F": {
        "short_name": "MAXCYTE INC  DL-,01",
        "long_name": "MaxCyte, Inc.",
        "summary": "MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://www.maxcyte.com",
        "market_cap": "Small Cap"
    },
    "MYGN": {
        "short_name": "Myriad Genetics, Inc.",
        "long_name": "Myriad Genetics, Inc.",
        "summary": "Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84108",
        "website": "http://myriad.com",
        "market_cap": "Mid Cap"
    },
    "MYHI": {
        "short_name": "MOUNTAIN HIGH ACQUISITIONS",
        "long_name": "Mountain High Acquisitions Corp.",
        "summary": "Mountain High Acquisitions Corp focuses on the acquisition and development of businesses and other assets within the hemp industry. The company is based in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85254",
        "website": "http://www.mountainhighac.com",
        "market_cap": "Small Cap"
    },
    "MYMD": {
        "short_name": "MyMD Pharmaceuticals, Inc.",
        "long_name": "MyMD Pharmaceuticals, Inc.",
        "summary": "MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the development of drug products in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety, and sleep disorders. It commercializes MYMD-1, a novel therapeutic to impact conditions related to immunometabolic dysregulation; and SUPERA-1R, a synthetic cannabidiol that offers bioavailability and potency than botanicals. The company was incorporated in 2014 and is based in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33606-4110",
        "website": "http://www.mymd.com",
        "market_cap": "Small Cap"
    },
    "MYO": {
        "short_name": "Myomo Inc.",
        "long_name": "Myomo, Inc.",
        "summary": "Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02114",
        "website": "http://www.myomo.com",
        "market_cap": "Small Cap"
    },
    "MZEIQ": {
        "short_name": "MEDIZONE INTERNATIONAL",
        "long_name": "Medizone International, Inc.",
        "summary": "Medizone International, Inc. develops, manufactures, and sells disinfection systems in the United States and internationally. It offers AsepticSure system, a disinfection system that is used in medical facilities, such as hospitals, clinics, physician's offices, outpatient surgical centers, and long-term care facilities; food industry; bio-safety labs; athletic facilities, such as gyms and locker rooms, as well as sports equipment; and mortuaries, bio-defense and response to pandemics, building remediation, tissue labs, sporting venues, and hotels, as well as clean rooms to disinfect hard and non-porous surfaces. The company was founded in 1986 and is based in Kalamazoo, Michigan. On May 8, 2018, Medizone International, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Kalamazoo",
        "zipcode": "49007",
        "website": "http://www.medizoneint.com",
        "market_cap": "Small Cap"
    },
    "N18A.F": {
        "short_name": "NEMAURA MED. INC. DL-,001",
        "long_name": "Nemaura Medical Inc.",
        "summary": "Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://nemauramedical.com",
        "market_cap": "Small Cap"
    },
    "N1BI34.SA": {
        "short_name": "NEUROCRINE BDRN",
        "long_name": "Neurocrine Biosciences, Inc.",
        "summary": "Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL \u00c2\u0096 Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.neurocrine.com",
        "market_cap": "Mid Cap"
    },
    "N4CN.F": {
        "short_name": "PARATEK PHARMAC.  DL-,001",
        "long_name": "Paratek Pharmaceuticals, Inc.",
        "summary": "Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://paratekpharma.com",
        "market_cap": "Small Cap"
    },
    "NAFS": {
        "short_name": "NORTH AMERICA FRAC SAND INC",
        "long_name": "North America Frac Sand, Inc.",
        "summary": "North America Frac Sand, Inc., doing business as Voycare, provides telemedicine and medical tourism services in the United States. It enables overseas patients gain access to health care primarily in the fields of oncology, in vitro fertilization, cosmetic surgery, and wellness. The company primarily serves Chinese outbound travelers to North and South America. The company was founded in 2019 and is based in Covina, California with office in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Covina",
        "zipcode": "91724",
        "website": "http://voycare.com",
        "market_cap": "Small Cap"
    },
    "NAOV": {
        "short_name": "NanoVibronix, Inc.",
        "long_name": "NanoVibronix, Inc.",
        "summary": "NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Elmsford",
        "zipcode": "10523",
        "website": "http://www.nanovibronix.com",
        "market_cap": "Small Cap"
    },
    "NARI": {
        "short_name": "Inari Medical, Inc.",
        "long_name": "Inari Medical, Inc.",
        "summary": "Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It offers ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.inarimedical.com",
        "market_cap": "Mid Cap"
    },
    "NAUT": {
        "short_name": "Nautilus Biotechnology, Inc.",
        "long_name": "Nautilus Biotechnology, Inc.",
        "summary": "Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It operates Nautilus Proteomic Analysis Platform, an integrated single-molecule protein analysis platform that leverages a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to potentially identify and quantify the proteome. The company was incorporated in 2016 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98109",
        "website": "http://www.nautilus.bio",
        "market_cap": "Small Cap"
    },
    "NAVB": {
        "short_name": "Navidea Biopharmaceuticals, Inc",
        "long_name": "Navidea Biopharmaceuticals, Inc.",
        "summary": "Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Dublin",
        "zipcode": "43017-3552",
        "website": "http://www.navidea.com",
        "market_cap": "Small Cap"
    },
    "NB11.DE": {
        "short_name": "VAXART INC.  DL-,10",
        "long_name": "Vaxart, Inc.",
        "summary": "Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://vaxart.com",
        "market_cap": "Small Cap"
    },
    "NB11.F": {
        "short_name": "VAXART INC.  DL-,10",
        "long_name": "Vaxart, Inc.",
        "summary": "Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://vaxart.com",
        "market_cap": "Small Cap"
    },
    "NB3.F": {
        "short_name": "NEUROCRINE BIOSCI. DL-001",
        "long_name": "Neurocrine Biosciences, Inc.",
        "summary": "Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL \u00c2\u0096 Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.neurocrine.com",
        "market_cap": "Mid Cap"
    },
    "NBCO": {
        "short_name": "NEON BLOOM INC",
        "long_name": "Neon Bloom, Inc.",
        "summary": "Neon Bloom, Inc. is a principal investment firm specializing in acquisitions. The firm primarily invests in innovative agriculture and ancillary technology products and services across the globe. Neon Bloom, Inc was founded in 2015 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10005",
        "website": "http://www.neonbloominc.com",
        "market_cap": "Small Cap"
    },
    "NBGV": {
        "short_name": "NEWBRIDGE GLOBAL VENTURES INC",
        "long_name": "NewBridge Global Ventures, Inc.",
        "summary": "NewBridge Global Ventures, Inc., through its subsidiaries, cultivates, manufactures, and distributes medical and recreational cannabis products in California. It also offers consulting services to cultivators, processors, and retail brands, as well as engages in the real estate holding business. The company is based in Alameda, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Alameda",
        "zipcode": "94501",
        "website": "http://www.newbridgegv.com",
        "market_cap": "Small Cap"
    },
    "NBIO": {
        "short_name": "NASCENT BIOTECH INC",
        "long_name": "Nascent Biotech, Inc.",
        "summary": "Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company has a research collaboration agreement with Manhattan BioSolutions, Inc. to initiate a vaccine program for the prevention of COVID-19 or other viral infections; and a collaboration with Hoag Family Cancer Institute and Pickup Family Neurosciences Institute for the testing of antibody brain cancer drug. The company is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.nascentbiotech.com",
        "market_cap": "Small Cap"
    },
    "NBIX": {
        "short_name": "Neurocrine Biosciences, Inc.",
        "long_name": "Neurocrine Biosciences, Inc.",
        "summary": "Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL \u00c2\u0096 Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.neurocrine.com",
        "market_cap": "Mid Cap"
    },
    "NBSE": {
        "short_name": "NeuBase Therapeutics, Inc.",
        "long_name": "NeuBase Therapeutics, Inc.",
        "summary": "NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Pittsburgh",
        "zipcode": "15219",
        "website": "http://www.neubasetherapeutics.com",
        "market_cap": "Small Cap"
    },
    "NBY": {
        "short_name": "NovaBay Pharmaceuticals, Inc.",
        "long_name": "NovaBay Pharmaceuticals, Inc.",
        "summary": "NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx Clinical Reset, a gentle and soothing facial spray; and NeutroPhase and PhaseOne for the wound care market. It also offers KN95 Masks. The company sells its products through distribution partners, as well as offers Avenova and CelleRx Clinical Reset through online sales channels. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.novabay.com",
        "market_cap": "Small Cap"
    },
    "NBYB.SG": {
        "short_name": "Northwest Biotherapeutics Inc.R",
        "long_name": "Northwest Biotherapeutics, Inc.",
        "summary": "Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Bethesda",
        "zipcode": "20814",
        "website": "http://www.nwbio.com",
        "market_cap": "Small Cap"
    },
    "NDRA": {
        "short_name": "ENDRA Life Sciences Inc.",
        "long_name": "ENDRA Life Sciences Inc.",
        "summary": "ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Ann Arbor",
        "zipcode": "48105-1570",
        "website": "http://www.endrainc.com",
        "market_cap": "Small Cap"
    },
    "NEL.F": {
        "short_name": "NANTHEALTH INC.  DL-,0001",
        "long_name": "NantHealth, Inc.",
        "summary": "NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States and internationally. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans and CMS for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers GPS Cancer, a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing; Omics Core, an in-vitro diagnostic built on a custom-targeted whole exome sequencing platform; and Quadris, a data solution that includes multi-data analysis, reporting, and professional service. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Culver City, California. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Culver City",
        "zipcode": "90232",
        "website": "http://nanthealth.com",
        "market_cap": "Small Cap"
    },
    "NEO.MX": {
        "short_name": "NEOGENOMICS INC",
        "long_name": "NeoGenomics, Inc.",
        "summary": "NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Myers",
        "zipcode": "33913",
        "website": "http://www.neogenomics.com",
        "market_cap": "Mid Cap"
    },
    "NEO": {
        "short_name": "NeoGenomics, Inc.",
        "long_name": "NeoGenomics, Inc.",
        "summary": "NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Myers",
        "zipcode": "33913",
        "website": "http://www.neogenomics.com",
        "market_cap": "Mid Cap"
    },
    "NEOG": {
        "short_name": "Neogen Corporation",
        "long_name": "Neogen Corporation",
        "summary": "Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Lansing",
        "zipcode": "48912",
        "website": "http://www.neogen.com",
        "market_cap": "Mid Cap"
    },
    "NEPH": {
        "short_name": "Nephros, Inc.",
        "long_name": "Nephros, Inc.",
        "summary": "Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "South Orange",
        "zipcode": "07079",
        "website": "http://www.nephros.com",
        "market_cap": "Small Cap"
    },
    "NERV": {
        "short_name": "Minerva Neurosciences, Inc",
        "long_name": "Minerva Neurosciences, Inc.",
        "summary": "Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.minervaneurosciences.com",
        "market_cap": "Small Cap"
    },
    "NEUN": {
        "short_name": "NEUROGENESIS",
        "long_name": "Neurogenesis, Inc.",
        "summary": "Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "League City",
        "zipcode": "77573",
        "website": "http://www.neurogenesis.com",
        "market_cap": "Small Cap"
    },
    "NEXI": {
        "short_name": "NexImmune, Inc.",
        "long_name": "NexImmune, Inc.",
        "summary": "NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20877",
        "website": "http://www.neximmune.com",
        "market_cap": "Small Cap"
    },
    "NG2.F": {
        "short_name": "NEOGEN CORP.  DL-,16",
        "long_name": "Neogen Corporation",
        "summary": "Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MI",
        "city": "Lansing",
        "zipcode": "48912",
        "website": "http://www.neogen.com",
        "market_cap": "Mid Cap"
    },
    "NG9.F": {
        "short_name": "NEOGENOMICSINC.  DL-,001",
        "long_name": "NeoGenomics, Inc.",
        "summary": "NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Myers",
        "zipcode": "33913",
        "website": "http://www.neogenomics.com",
        "market_cap": "Mid Cap"
    },
    "NGM": {
        "short_name": "NGM Biopharmaceuticals, Inc.",
        "long_name": "NGM Biopharmaceuticals, Inc.",
        "summary": "NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase Ib clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase II clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438, which are in preclinical investigational studies for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.ngmbio.com",
        "market_cap": "Mid Cap"
    },
    "NGMC": {
        "short_name": "NEXT GENERATION MGMT CORP",
        "long_name": "Next Generation Management Corp.",
        "summary": "Next Generation Management Corp. operates a medical marijuana dispensary in Hollywood, California. It provides dispensary management services to the medical marijuana industry, including site location selection, dispensary build out, staffing, staff and manager training, security services, and financial advice. It also Dispensary Management Service package, a suite of industry specific software that offers seed to sale controls and regulatory agency compliance featuring the BiotrackTHC application suite. The company was formerly known as Next Generation Energy Corp. and changed its name to Next Generation Management Corp. in June 2014. Next Generation Management Corp. was founded in 1980 and is based in Annandale, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Annandale",
        "zipcode": "22003",
        "website": "http://www.nextgenmanagementcorp.com",
        "market_cap": "Small Cap"
    },
    "NH": {
        "short_name": "NantHealth, Inc.",
        "long_name": "NantHealth, Inc.",
        "summary": "NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States and internationally. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans and CMS for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers GPS Cancer, a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing; Omics Core, an in-vitro diagnostic built on a custom-targeted whole exome sequencing platform; and Quadris, a data solution that includes multi-data analysis, reporting, and professional service. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Culver City, California. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Culver City",
        "zipcode": "90232",
        "website": "http://nanthealth.com",
        "market_cap": "Small Cap"
    },
    "NHC": {
        "short_name": "National HealthCare Corporation",
        "long_name": "National HealthCare Corporation",
        "summary": "National HealthCare Corporation operates, manages, and provides services to skilled nursing facilities, assisted living facilities, independent living facilities, home health care programs, and a behavioral health hospital. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. The company's medical specialty units comprise memory care units and subacute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living centers offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. It also owns, leases, and manages independent living facilities that provide specially designed residential units for the active and ambulatory elderly, as well as offers various ancillary services for its residents, including restaurants, activity rooms, and social areas. In addition, it provides health care programs that offer skilled services, such as infusion, wound care and physical, occupational, and speech therapies; operates pharmacies; offers managed care insurance, management, accounting, financial, and insurance, as well as geriatric behavioral health services; and leases its properties to third party operators. As of December 31, 2020, the company operated 75 skilled nursing facilities with 9,463 licensed beds; 24 assisted living facilities; 5 independent living facilities; 35 homecare programs; and 4 pharmacy locations, as well as a 16-bed behavioral health hospital. National HealthCare Corporation was founded in 1971 and is based in Murfreesboro, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Murfreesboro",
        "zipcode": "37130",
        "website": "http://www.nhccare.com",
        "market_cap": "Small Cap"
    },
    "NHLG": {
        "short_name": "NATIONAL HEALTHCARE LOGISTICS",
        "long_name": "National Healthcare Logistics Inc.",
        "summary": "National Healthcare Logistics Inc. engages in contracting with healthcare providers to reengineer logistical processes for supply chain management. The company, formerly known as BCH Systems, Inc, was incorporated in 1999 and changed its name to National Healthcare Logistics Inc. in 2005. National Healthcare Logistics Inc. is based in Cleveland, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Cleveland",
        "zipcode": "37364",
        "website": null,
        "market_cap": "Small Cap"
    },
    "NJTC.F": {
        "short_name": "POLARITYTE INC.  DL-,001",
        "long_name": "PolarityTE, Inc.",
        "summary": "PolarityTE, Inc., a biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates through two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and OsteoTE. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84104",
        "website": "http://www.polarityte.com",
        "market_cap": "Small Cap"
    },
    "NK8.F": {
        "short_name": "NUVASIVE INC.  DL-,001",
        "long_name": "NuVasive, Inc.",
        "summary": "NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process. In addition, it provides MAGEC, a spinal bracing and distraction system, Precice limb lengthening system, and various other products for treating specialized orthopedic procedures; onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries; and cervical artificial disc technology for cervical total disc replacement procedures. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.nuvasive.com",
        "market_cap": "Mid Cap"
    },
    "NKB2.F": {
        "short_name": "TG THERAPEUTICS  DL -,001",
        "long_name": "TG Therapeutics, Inc.",
        "summary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10014",
        "website": "http://www.tgtherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "NKTR": {
        "short_name": "Nektar Therapeutics",
        "long_name": "Nektar Therapeutics",
        "summary": "Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94158",
        "website": "http://www.nektar.com",
        "market_cap": "Mid Cap"
    },
    "NKTX": {
        "short_name": "Nkarta, Inc.",
        "long_name": "Nkarta, Inc.",
        "summary": "Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.nkartatx.com",
        "market_cap": "Small Cap"
    },
    "NLAB": {
        "short_name": "NUONCOLOGY LABORATORIES INC",
        "long_name": "NuOncology Labs, Inc.",
        "summary": "NuOncology Labs, Inc. engages in the research, development, testing, and licensing of cancer treatments, and medical and agricultural compounds; and the delivery of predictive chemosensitivity tests, as of December 31, 1998. It served surgeons, oncologists, pathologists, hospitals, health maintenance organizations, community health centers, and third party insurance companies in the United States. The company is based in Virginia Beach, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Virginia Beach",
        "zipcode": "23455",
        "website": null,
        "market_cap": "Small Cap"
    },
    "NLBS": {
        "short_name": "NUTRALIFE BIOSCIENCES INC",
        "long_name": "NutraLife BioSciences, Inc.",
        "summary": "NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil, topical lotions and oils, massage oils, and internal pet products. The company also offers NutraHemp CBD products, including oral sprays, tinctures, pet drops, pain balms, and face creams; and NutraSpray oral spray products for sleep support and weight loss; and an appetite suppressant, as well as dietary and other products, such as sanitizer products. NutraLife BioSciences, Inc. sells its products through nutralifebiosciences.com, as well as through private label distributors, online retailers, and retail outlets. The company was formerly known as NutraFuels, Inc. and changed its name to NutraLife BioSciences, Inc. in March 2019. NutraLife BioSciences, Inc. was incorporated in 2010 and is based in Coconut Creek, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Coconut Creek",
        "zipcode": "33073",
        "website": "http://www.nutralifebiosciences.com",
        "market_cap": "Small Cap"
    },
    "NLTX": {
        "short_name": "Neoleukin Therapeutics, Inc.",
        "long_name": "Neoleukin Therapeutics, Inc.",
        "summary": "Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98102",
        "website": "http://www.neoleukin.com",
        "market_cap": "Small Cap"
    },
    "NLZ.F": {
        "short_name": "NEUROMETRIX INC.  DL-0001",
        "long_name": "NeuroMetrix, Inc.",
        "summary": "NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Woburn",
        "zipcode": "01801",
        "website": "http://www.neurometrix.com",
        "market_cap": "Small Cap"
    },
    "NM4.F": {
        "short_name": "NATUS MEDICAL INC. DL-001",
        "long_name": "Natus Medical Incorporated",
        "summary": "Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; balance assessment systems to evaluate patients with balance disorders. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was founded in 1987 and is headquartered in Pleasanton, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Pleasanton",
        "zipcode": "94566",
        "website": "http://www.natus.com",
        "market_cap": "Small Cap"
    },
    "NMRD": {
        "short_name": "Nemaura Medical Inc.",
        "long_name": "Nemaura Medical Inc.",
        "summary": "Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://nemauramedical.com",
        "market_cap": "Small Cap"
    },
    "NMTC": {
        "short_name": "NeuroOne Medical Technologies C",
        "long_name": "NeuroOne Medical Technologies Corporation",
        "summary": "NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. The company is based in Eden Prairie, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Eden Prairie",
        "zipcode": "55344",
        "website": "http://www.n1mtc.com",
        "market_cap": "Small Cap"
    },
    "NMTR": {
        "short_name": "9 Meters Biopharma, Inc.",
        "long_name": "9 Meters Biopharma, Inc.",
        "summary": "9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. 9 Meters Biopharma, Inc. has a collaboration with the Duke Clinical Research Institute to support the clinical development of NM-002. The company is headquartered in Raleigh, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Raleigh",
        "zipcode": "27615",
        "website": "http://www.9meters.com",
        "market_cap": "Small Cap"
    },
    "NMXS": {
        "short_name": "NET MEDICAL XPRESS SOLUTIONS IN",
        "long_name": "Net Medical Xpress Solutions, Inc.",
        "summary": "Net Medical Xpress Solutions, Inc. develops and markets Internet technology-based software solutions. It offers software products and services, such as telemedicine building block, an online service for doctors, offices, hospitals, and clinics for telemedicine services; digital paper, a paper form and turns into an online fill-out list; and single pane of glass software that allows a provider to be connected into a video conference with a patient. The company also provides electronic prescription system for physicians in private practice; electronic prior authorization system, which connects to health plans and pharmacies to verify prior authorization requirements related to medical tests, procedures, devices, and drugs that require pre-approval by insurers; and Electronic Medical Records (EMR) that provides the ability to connect with 43 various hospital EMR systems. In addition, it offers hardware products, such as Web real time communications, an advanced televideo conferencing system, as well as medical cart and various net medical USB digital diagnosing tools. Further, the company provides video clinical services, such as neurology and stroke assessment, behavioral assessment, and critical care; diagnostic services, including radiology and cardiology; and video primary care services. Additionally, it provides management and administrative services, such as credentialing, call center, recruiting and staffing, and professional liability insurance services; software hosting and maintenance, and custom programming; scanning services; and consulting, training, and installation services. The company was formerly known as New Mexico Software, Inc. and changed its name to Net Medical Xpress Solutions, Inc. in January 2013. Net Medical Xpress Solutions, Inc. was founded in 1980 and is based in Albuquerque, New Mexico.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NM",
        "city": "Albuquerque",
        "zipcode": "87113",
        "website": "http://netmedical.com",
        "market_cap": "Small Cap"
    },
    "NNBP": {
        "short_name": "NANOBAC PHARMACEUTICALS INC",
        "long_name": "Nanobac Pharmaceuticals, Incorporated",
        "summary": "Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases. Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33607",
        "website": null,
        "market_cap": "Small Cap"
    },
    "NNFN.F": {
        "short_name": "MANNKIND CORP. NEW DL-,01",
        "long_name": "MannKind Corporation",
        "summary": "MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Westlake Village",
        "zipcode": "91362",
        "website": "http://www.mannkindcorp.com",
        "market_cap": "Small Cap"
    },
    "NNLX": {
        "short_name": "NANOLOGIX INC",
        "long_name": "NanoLogix, Inc.",
        "summary": "NanoLogix, Inc., a biotechnology company, provides live cell and rapid diagnostics test kits that detects viable bacteria and other microorganisms. The company's products include BioNanoPore kit, which employs a water permeable membrane that works with organic and inorganic molecules, as well as proteins; and FlatPack Petri Plates that are used for the isolation and cultivation of various fastidious and non-fastidious microorganisms, as well as displays growth of aerobic and anaerobic microorganisms. Its products are used in medical, national defense, homeland security, pharmaceutical, industrial, veterinary, and environmental testing applications. The company sells its products to established medical and scientific entities, including laboratories, medical institutions, universities, businesses, and research establishments. NanoLogix, Inc. is based in Hubbard, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Hubbard",
        "zipcode": "44425",
        "website": "http://nanologix.com",
        "market_cap": "Small Cap"
    },
    "NNRX": {
        "short_name": "NUTRANOMICS INC",
        "long_name": "Nutranomics, Inc.",
        "summary": "Nutranomics, Inc. engages in the research, development, and sale of nutritional food products. It offers approximately 480 nutritional supplements, including formulating vitamin, mineral, herbal, and probiotic supplements. The company provides Nutritional Blood Analysis, a tool to examine the customer's blood cells on a video monitor, live, in real time; and the patented Assimilation Enhancing System that improves the absorption of nutrients. In addition, it offers educational services, including various types of analyses, trainings, certifications, and group presentations to individuals and industry professionals. The company distributes its products through sales representatives throughout North America and Asia, as well as through retail stores. Nutranomics, Inc. has a strategic partnership with Terra-Formance, LLC. The company was founded in 1995 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84020",
        "website": "http://www.nutranomics.com",
        "market_cap": "Small Cap"
    },
    "NNVC": {
        "short_name": "NanoViricides, Inc.",
        "long_name": "NanoViricides, Inc.",
        "summary": "NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Shelton",
        "zipcode": "06484",
        "website": "http://www.nanoviricides.com",
        "market_cap": "Small Cap"
    },
    "NO1A.F": {
        "short_name": "NAVIDEA BIOPHARM. DL-,001",
        "long_name": "Navidea Biopharmaceuticals, Inc.",
        "summary": "Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Dublin",
        "zipcode": "43017-3552",
        "website": "http://www.navidea.com",
        "market_cap": "Small Cap"
    },
    "NOTV": {
        "short_name": "Inotiv, Inc.",
        "long_name": "Inotiv, Inc.",
        "summary": "Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IN",
        "city": "West Lafayette",
        "zipcode": "47906",
        "website": "http://www.inotivco.com",
        "market_cap": "Small Cap"
    },
    "NOUV": {
        "short_name": "NOUVEAU LIFE PHARMACEUTICALS IN",
        "long_name": "Nouveau Life Pharmaceuticals, Inc.",
        "summary": "Nouveau Life Pharmaceuticals, Inc., a development stage company, engages in the development of nutraceuticals products. It provides natural alternatives and prescription drugs. The company was formerly known as Hybrid Fuels, Inc. and changed its name to Nouveau Life Pharmaceuticals, Inc. in May 2012. Nouveau Life Pharmaceuticals, Inc. was incorporated in 1998 and is based in Ft. Lauderdale, Florida. Nouveau Life Pharmaceuticals, Inc. operates as a subsidiary of EMG Marketing Solutions, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Ft. Lauderdale",
        "zipcode": "33301",
        "website": null,
        "market_cap": "Small Cap"
    },
    "NOVC": {
        "short_name": "NOVATION COMPANIES INC",
        "long_name": "Novation Companies, Inc.",
        "summary": "Novation Companies, Inc., through its subsidiary, Healthcare Staffing, Inc., provides outsourced health care staffing and related services in Georgia. It also offers its services to hospitals, schools, crisis units, clinics, doctors' offices, prisons, and various privately owned businesses. The company was formerly known as NovaStar Financial, Inc. and changed its name to Novation Companies, Inc. in May 2012. Novation Companies, Inc. was founded in 1996 and is based in Kansas City, Missouri.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MO",
        "city": "Kansas City",
        "zipcode": "64114",
        "website": "http://novationcompanies.com",
        "market_cap": "Small Cap"
    },
    "NOVN": {
        "short_name": "Novan, Inc.",
        "long_name": "Novan, Inc.",
        "summary": "Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Morrisville, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560",
        "website": "http://www.novan.com",
        "market_cap": "Small Cap"
    },
    "NPCE": {
        "short_name": "Neuropace, Inc.",
        "long_name": "NeuroPace, Inc.",
        "summary": "NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Mountain View",
        "zipcode": "94043",
        "website": "http://www.neuropace.com",
        "market_cap": "Small Cap"
    },
    "NPHC": {
        "short_name": "NUTRA PHARMA CORP",
        "long_name": "Nutra Pharma Corp.",
        "summary": "Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, as well as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress; Pet Pain-Away, an over-the-counter pain reliever to treat pain in cats and dogs; Luxury Feet, an over-the-counter pain reliever to treat foot pain from high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, a topical therapy for chronic pain for use in equine industry. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases, including human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was founded in 2000 and is based in Plantation, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Plantation",
        "zipcode": "33313",
        "website": "http://www.nutrapharma.com",
        "market_cap": "Small Cap"
    },
    "NPTX": {
        "short_name": "NEUROPATHIX INC",
        "long_name": "Neuropathix, Inc.",
        "summary": "Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary cannabinoid product platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Doylestown",
        "zipcode": "18902",
        "website": "http://neuropathix.com",
        "market_cap": "Small Cap"
    },
    "NR1A.SG": {
        "short_name": "National Research Corp. Registe",
        "long_name": "National Research Corporation",
        "summary": "National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "NE",
        "city": "Lincoln",
        "zipcode": "68508",
        "website": "http://nrchealth.com",
        "market_cap": "Small Cap"
    },
    "NRBO": {
        "short_name": "NeuroBo Pharmaceuticals, Inc.",
        "long_name": "NeuroBo Pharmaceuticals, Inc.",
        "summary": "NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://www.neurobopharma.com",
        "market_cap": "Small Cap"
    },
    "NRC.F": {
        "short_name": "NEURONETICS INC.  DL-,01",
        "long_name": "Neuronetics, Inc.",
        "summary": "Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.neurostar.com",
        "market_cap": "Small Cap"
    },
    "NRC": {
        "short_name": "National Research Corporation",
        "long_name": "National Research Corporation",
        "summary": "National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NE",
        "city": "Lincoln",
        "zipcode": "68508",
        "website": "http://nrchealth.com",
        "market_cap": "Small Cap"
    },
    "NRCD": {
        "short_name": "NASHVILLE RECORDS INC",
        "long_name": "Nashville Records, Inc.",
        "summary": "Nashville Records, Inc. engages in the production, marketing and distribution of recorded county music on the Nashville Records label. The company is based in Nashville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37212",
        "website": "http://www.nashvillerecords.com",
        "market_cap": null
    },
    "NRIX": {
        "short_name": "Nurix Therapeutics, Inc.",
        "long_name": "Nurix Therapeutics, Inc.",
        "summary": "Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94158",
        "website": "http://www.nurixtx.com",
        "market_cap": "Small Cap"
    },
    "NRTSF": {
        "short_name": "NOBILIS HEALTH CORPORATION",
        "long_name": "Nobilis Health Corp.",
        "summary": "Nobilis Health Corp. owns and manages ambulatory surgical centers (ASCs), and acute-care and surgical hospitals in the United States. It operates through two segments, Medical Services and Marketing. The company's healthcare facilities provides surgical procedures in various clinical specialties, including orthopedic surgery, podiatric, vein and vascular, pain management, gastro- intestinal, gynecology, and general, as well as ear, nose, and throat. It also provides marketing services, patient education services, and patient care co-ordination management services to third party facilities and physicians. As of December 4, 2017, it operated 32 locations, including 5 hospitals, 14 ASCs, and 13 multi-specialty clinics. The company was formerly known as Northstar Healthcare Inc. and changed its name to Nobilis Health Corp. in December 2014. Nobilis Health Corp. was founded in 2007 and is based in Houston, Texas. On October 21, 2019, Nobilis Health Corp. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with Northstar Healthcare Holdings, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77079",
        "website": "http://www.nobilishealth.com",
        "market_cap": "Small Cap"
    },
    "NRXP": {
        "short_name": "NRX Pharmaceuticals, Inc.",
        "long_name": "NRx Pharmaceuticals, Inc.",
        "summary": "NRx Pharmaceuticals, Inc. a clinical-stage, small molecule pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "DE",
        "city": "Wilmington",
        "zipcode": "19801",
        "website": "http://www.neurorxpharma.com",
        "market_cap": "Small Cap"
    },
    "NSPX": {
        "short_name": "INSPYR THERAPEUTIC",
        "long_name": "Inspyr Therapeutics, Inc.",
        "summary": "Inspyr Therapeutics, Inc., a pharmaceutical company, focuses on the research and development of therapeutics for the treatment of cancer. Its immune-oncology lead asset is RT-AR001, an adenosine A2B receptor antagonist for tumor infiltration. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was incorporated in 2003 and is based in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Westlake Village",
        "zipcode": "91360",
        "website": "http://www.inspyrtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "NSTG": {
        "short_name": "NanoString Technologies, Inc.",
        "long_name": "NanoString Technologies, Inc.",
        "summary": "NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq technologies. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; and Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma. NanoString Technologies, Inc. was founded in 2003 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98109",
        "website": "http://www.nanostring.com",
        "market_cap": "Mid Cap"
    },
    "NSTM": {
        "short_name": "NOVELSTEM INTERNATIONAL CORP",
        "long_name": "NovelStem International Corp.",
        "summary": "NovelStem International Corp. focuses on developing and commercialization of diagnostic technology that can predict patients' resistance to chemotherapy allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. It has a collaboration agreement with NewStem Ltd. for stem-cell technology platform in cancer immunotherapy and COVID-19 resistance. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from advertising services to stem cell-based diagnostics for cancer chemotherapies. The company was founded in 1993 and is headquartered in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33431",
        "website": "http://www.novelstem.com",
        "market_cap": "Small Cap"
    },
    "NTII": {
        "short_name": "NEUROBIOLOGICAL TECHNOLOGIES IN",
        "long_name": "Neurobiological Technologies, Inc.",
        "summary": "Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in October 2009. Previously, it focused on developing investigational drugs for the treatment of human diseases. The company was founded in 1987 and is based in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": null,
        "market_cap": "Small Cap"
    },
    "NTLA": {
        "short_name": "Intellia Therapeutics, Inc.",
        "long_name": "Intellia Therapeutics, Inc.",
        "summary": "Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.intelliatx.com",
        "market_cap": "Mid Cap"
    },
    "NTR.F": {
        "short_name": "SPECTRUM PHARMACEUT. NEW",
        "long_name": "Spectrum Pharmaceuticals, Inc.",
        "summary": "Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NV",
        "city": "Henderson",
        "zipcode": "89052",
        "website": "http://www.sppirx.com",
        "market_cap": "Small Cap"
    },
    "NTRA": {
        "short_name": "Natera, Inc.",
        "long_name": "Natera, Inc.",
        "summary": "Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Carlos",
        "zipcode": "94070",
        "website": "http://www.natera.com",
        "market_cap": "Mid Cap"
    },
    "NTRB": {
        "short_name": "NUTRIBAND INC",
        "long_name": "Nutriband Inc.",
        "summary": "Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Orlando",
        "zipcode": "32801",
        "website": "http://nutriband.com",
        "market_cap": "Small Cap"
    },
    "NTRR": {
        "short_name": "NEUTRA CORP",
        "long_name": "Neutra Corp.",
        "summary": "Neutra Corp., through its subsidiaries, provides hemp-based health and nutritional products. It offers CBD tincture, lotion, and salve. The company was founded in 2011 and is based in Sugar Land, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Sugar Land",
        "zipcode": "77478",
        "website": "http://www.neutrainc.com",
        "market_cap": "Small Cap"
    },
    "NTUS": {
        "short_name": "Natus Medical Incorporated",
        "long_name": "Natus Medical Incorporated",
        "summary": "Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; balance assessment systems to evaluate patients with balance disorders. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was founded in 1987 and is headquartered in Pleasanton, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Pleasanton",
        "zipcode": "94566",
        "website": "http://www.natus.com",
        "market_cap": "Small Cap"
    },
    "NUGS": {
        "short_name": "CANNABIS STRATEGIC VENTURES",
        "long_name": "Cannabis Strategic Ventures",
        "summary": "Cannabis Strategic Ventures engages in the cultivation of marijuana products in the United States. It incubates, develops, and partners within the cannabis and ancillary sectors. The company is based in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90014",
        "website": "http://www.cannabisstrategic.com",
        "market_cap": "Small Cap"
    },
    "NUGX": {
        "short_name": "NUGENEREX IMMUNO-ONCOLOGY INC",
        "long_name": "NuGenerex Immuno-Oncology, Inc.",
        "summary": "NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miramar",
        "zipcode": "33025",
        "website": "http://www.generex.com/nugenerex-family-of-companies",
        "market_cap": "Small Cap"
    },
    "NUMD": {
        "short_name": "NU-MED PLUS INC",
        "long_name": "Nu-Med Plus, Inc.",
        "summary": "Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. It develops a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device to deliver nitric oxide gas, and a nitric oxide system that can be used for research applications. The company serves hospitals, health systems, and the medical community. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84111",
        "website": "http://www.nu-medplus.com",
        "market_cap": "Small Cap"
    },
    "NUNZ": {
        "short_name": "NUNZIA PHARMACEUTICAL CORPORATI",
        "long_name": "Nunzia Pharmaceutical Corporation",
        "summary": "Nunzia Pharmaceutical Corporation operates as a pharmaceutical and nutraceutical company. It owns the right to manufacture, market, and distribute a drug, NUNZIA that treats autism, fragile X, ADHD, and PTSD. The company was founded in 1986 and is based in Long Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Long Beach",
        "zipcode": "90813",
        "website": "http://www.nunziapharma.com",
        "market_cap": "Small Cap"
    },
    "NURO": {
        "short_name": "NeuroMetrix, Inc.",
        "long_name": "NeuroMetrix, Inc.",
        "summary": "NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Woburn",
        "zipcode": "01801",
        "website": "http://www.neurometrix.com",
        "market_cap": "Small Cap"
    },
    "NUVA": {
        "short_name": "NuVasive, Inc.",
        "long_name": "NuVasive, Inc.",
        "summary": "NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process. In addition, it provides MAGEC, a spinal bracing and distraction system, Precice limb lengthening system, and various other products for treating specialized orthopedic procedures; onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries; and cervical artificial disc technology for cervical total disc replacement procedures. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.nuvasive.com",
        "market_cap": "Mid Cap"
    },
    "NUVB": {
        "short_name": "Nuvation Bio Inc.",
        "long_name": "Nuvation Bio Inc.",
        "summary": "Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.nuvationbio.com",
        "market_cap": "Mid Cap"
    },
    "NUWE": {
        "short_name": "Nuwellis, Inc.",
        "long_name": "Nuwellis, Inc.",
        "summary": "Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Eden Prairie",
        "zipcode": "55344",
        "website": "http://www.nuwellis.com",
        "market_cap": "Small Cap"
    },
    "NV4P.F": {
        "short_name": "CELLECTAR BIOSC.DL-,00001",
        "long_name": "Cellectar Biosciences, Inc.",
        "summary": "Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Florham Park",
        "zipcode": "07932",
        "website": "http://www.cellectar.com",
        "market_cap": "Small Cap"
    },
    "NVAX.MX": {
        "short_name": "NOVAVAX INC",
        "long_name": "Novavax, Inc.",
        "summary": "Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://www.novavax.com",
        "market_cap": "Large Cap"
    },
    "NVAX": {
        "short_name": "Novavax, Inc.",
        "long_name": "Novavax, Inc.",
        "summary": "Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://www.novavax.com",
        "market_cap": "Large Cap"
    },
    "NVIV": {
        "short_name": "InVivo Therapeutics Holdings Co",
        "long_name": "InVivo Therapeutics Holdings Corp.",
        "summary": "InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). The company is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.invivotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "NVOS": {
        "short_name": "Novo Integrated Sciences, Inc.",
        "long_name": "Novo Integrated Sciences, Inc.",
        "summary": "Novo Integrated Sciences, Inc., together with its subsidiaries, provides primary healthcare services. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics including pediatric, adult, and geriatric populations. In addition, the company offers specialty treatment and recovery programs derived from motor vehicle accident injuries, long-term disability cases, corporate wellness, and job-site injuries. Further, it also provides cold laser therapeutics, shockwave therapy, custom bracing and orthotics, custom compression therapy/stockings, and lymphatic drainage treatment. The company offers medical technology services, such as telemedicine and remote patient monitoring. It operates 16 owned clinics, a contracted network of 102 affiliate clinics, and 220 eldercare related care homes, as well as retirement homes and community-based locations in Canada. The company was incorporated in 2000 and is based in Bellevue, Washington. Novo Integrated Sciences, Inc. is a subsidiary of ALMC-ASAP Holdings, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Bellevue",
        "zipcode": "98004",
        "website": "http://novointegrated.com",
        "market_cap": "Small Cap"
    },
    "NVRO": {
        "short_name": "Nevro Corp.",
        "long_name": "Nevro Corp.",
        "summary": "Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://www.nevro.com",
        "market_cap": "Mid Cap"
    },
    "NVST": {
        "short_name": "Envista Holdings Corporation",
        "long_name": "Envista Holdings Corporation",
        "summary": "Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Brea",
        "zipcode": "92821-6208",
        "website": "http://www.envistaco.com",
        "market_cap": "Mid Cap"
    },
    "NVTA.MX": {
        "short_name": "INVITAE CORP",
        "long_name": "Invitae Corporation",
        "summary": "Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94103",
        "website": "http://www.invitae.com",
        "market_cap": "Mid Cap"
    },
    "NVTA": {
        "short_name": "Invitae Corporation",
        "long_name": "Invitae Corporation",
        "summary": "Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94103",
        "website": "http://www.invitae.com",
        "market_cap": "Mid Cap"
    },
    "NVV1.F": {
        "short_name": "NOVAVAX INC.  DL-,01",
        "long_name": "Novavax, Inc.",
        "summary": "Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://www.novavax.com",
        "market_cap": "Large Cap"
    },
    "NWBO": {
        "short_name": "NORTHWEST BIOTHERAPEUTICS INC",
        "long_name": "Northwest Biotherapeutics, Inc.",
        "summary": "Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Bethesda",
        "zipcode": "20814",
        "website": "http://www.nwbio.com",
        "market_cap": "Small Cap"
    },
    "NWCI": {
        "short_name": "NEWCARDIO INC",
        "long_name": "NewCardio, Inc.",
        "summary": "NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data. The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space. NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Branchburg",
        "zipcode": "08853",
        "website": null,
        "market_cap": "Small Cap"
    },
    "NWPN": {
        "short_name": "NOW CORPORATION",
        "long_name": "The Now Corporation",
        "summary": "The NOW Corporation, a development stage company, operates as an energy development and production company. The company engages in the ownership and operation of 250 KW wind turbine; refurbishment of existing domestic stripper oil wells; and farming, harvesting, and manufacture of hemp products. The company was founded in 1993 and is headquartered in Portland, Oregon.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OR",
        "city": "Portland",
        "zipcode": "97230",
        "website": "http://www.thenowcorporation.net",
        "market_cap": "Small Cap"
    },
    "NWYU": {
        "short_name": "NEW YOU INC",
        "long_name": "New You Inc.",
        "summary": "New You, Inc., through its subsidiary, New You LLC, develops and markets cannabidiol (CBD) hemp oil-based products. The company offers DROPS beverage or liquid CBD products; CB2 & CBD 2 Plus, a multi spectrum hemp-extracted CBD and beta-caryophyllene; Drops for pets; Caffe Canna, an organic cannabinoid-infused non-GMO dark roast coffee; and ABSORB, a root and rice flour veggie capsule. It also provides RELEASE; Drops FX, a blend of CBD and Vitamins B3, B6, B9, and B12 for use in drink or liquid; and Drops FX Sleep, a blend of CBD, gamma-amino butyric acid, melatonin, and valerian root; NanoX, a water soluble full spectrum DBD made with Purified Water; and The Cream, a topical skin cream. The company markets and sells its products through multi-level marketing and direct sales force to independent business owners. New You, Inc. is based in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92010",
        "website": "http://newyoupro.com",
        "market_cap": "Small Cap"
    },
    "NXEN.F": {
        "short_name": "SEELOS THERAPEUT. DL-,001",
        "long_name": "Seelos Therapeutics, Inc.",
        "summary": "Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://seelostherapeutics.com",
        "market_cap": "Small Cap"
    },
    "NXEN": {
        "short_name": "NEXIEN BIOPHARMA INC",
        "long_name": "Nexien BioPharma, Inc.",
        "summary": "Nexien BioPharma, a pharmaceutical company, engages in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways to address a range of medical conditions and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Glendale",
        "zipcode": "80246",
        "website": "http://www.nexienbiopharma.com",
        "market_cap": "Small Cap"
    },
    "NXGB": {
        "short_name": "NXGEN BRANDS INC",
        "long_name": "NxGen Brands Inc.",
        "summary": "NxGen Brands Inc., doing business as, LeafyWell, engages in manufacturing, distributing, and marketing various cannabidiol (CBD) supplements. It focuses on offering CBD and hemp derived gummies, oils, vape liquids, pet treats, and other products. The company is based in Davie, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Davie",
        "zipcode": "33314",
        "website": "http://www.leafywell.com",
        "market_cap": null
    },
    "NXGN": {
        "short_name": "NextGen Healthcare, Inc.",
        "long_name": "NextGen Healthcare, Inc.",
        "summary": "NextGen Healthcare, Inc. provides ambulatory-focused healthcare software and services solutions in the United States. The company offers NextGen Enterprise electronic health record (EHR), which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools. Its products also comprise NextGen Enterprise PM, a practice management (PM) solution; NextGen Office, a cloud-based EHR and PM solution; NextGen Mobile; and NextGen Electronic Healthcare Transactions. In addition, it provides population health solutions, such as NextGen Population Health Analytics, NextGen Population Health Patient Care Management, and NextGen Population Health Performance Management; and patient engagement solutions comprising NextGen Patient Portal, NextGen Self Scheduling, NextGen Patient Pay, and NextGen Virtual Visits solutions. Further, the company offers NextGen Connect Integration Engine, NextGen Health Data Hub, and NextGen Share interoperability solutions; managed services, including NextGen Managed Cloud and NextGen Revenue Cycle Management Services; professional services; and client service and support. It serves managed service organizations, independent physician associations, accountable care organizations, ambulatory care centers, and community health centers through a sales force and reseller channel. The company was formerly known as Quality Systems, Inc. and changed its name to NextGen Healthcare, Inc. in September 2018. NextGen Healthcare, Inc. was founded in 1974 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92612",
        "website": "http://www.nextgen.com",
        "market_cap": "Small Cap"
    },
    "NXGT": {
        "short_name": "NEXTELIGENT HOLDINGS INC",
        "long_name": "Nexteligent Holdings, Inc.",
        "summary": "Nexteligent Holdings, Inc. operates as an aggregator of healthcare professional services and technology firms. The company provides professional services in telemedicine, consulting, and financial management. Its Telemedicine Solutions division develops and manages remote care and technology programs aimed at containing costs, improving productivity, and enhancing the quality of medical encounters at healthcare institutions serving the eldercare sector, as well as municipalities and not-for-profit organizations. The company's Financial Services division provides end-to-end revenue cycle management solutions and denials recovery for hospital systems, doctor groups, clinics, and long term care operators. This division also offers turnkey solutions for preventative care services, such as chronic care management, annual wellness visit, transitional care management, behavioral health, and remote telemonitoring. Nexteligent Holdings, Inc. is headquartered in Avon, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Avon",
        "zipcode": "06001",
        "website": "http://www.nexteligent.com",
        "market_cap": null
    },
    "NXNN": {
        "short_name": "NEXEON MEDSYSTEMS INC",
        "long_name": "Nexeon MedSystems Inc.",
        "summary": "Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75201",
        "website": "http://www.nexeonmedsystems.com",
        "market_cap": "Small Cap"
    },
    "NXTC": {
        "short_name": "NextCure, Inc.",
        "long_name": "NextCure, Inc.",
        "summary": "NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Beltsville",
        "zipcode": "20705",
        "website": "http://www.nextcure.com",
        "market_cap": "Small Cap"
    },
    "NZW2.F": {
        "short_name": "MOLECULAR TEMPLAT.DL-,001",
        "long_name": "Molecular Templates, Inc.",
        "summary": "Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78729",
        "website": "http://www.mtem.com",
        "market_cap": "Small Cap"
    },
    "O1P.F": {
        "short_name": "OSMOTICA PHARMAC.  DL-,01",
        "long_name": "Osmotica Pharmaceuticals plc",
        "summary": "Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bridgewater",
        "zipcode": "08807",
        "website": "http://www.osmotica.com",
        "market_cap": "Small Cap"
    },
    "O2T.F": {
        "short_name": "IVERIC BIO INC.  DL-,001",
        "long_name": "IVERIC bio, Inc.",
        "summary": "IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10001",
        "website": "http://ivericbio.com",
        "market_cap": "Small Cap"
    },
    "O7PA.F": {
        "short_name": "NEUBASE THERAPEUT. DL-,01",
        "long_name": "NeuBase Therapeutics, Inc.",
        "summary": "NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Pittsburgh",
        "zipcode": "15219",
        "website": "http://www.neubasetherapeutics.com",
        "market_cap": "Small Cap"
    },
    "O8Z3.F": {
        "short_name": "SONOMA PHARMAC.  DL-,0001",
        "long_name": "Sonoma Pharmaceuticals, Inc.",
        "summary": "Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "GA",
        "city": "Woodstock",
        "zipcode": "30102",
        "website": "http://www.sonomapharma.com",
        "market_cap": "Small Cap"
    },
    "OBLN": {
        "short_name": "Obalon Therapeutics, Inc.",
        "long_name": "Obalon Therapeutics, Inc.",
        "summary": "Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008-4410",
        "website": "http://www.obalon.com",
        "market_cap": "Small Cap"
    },
    "OBMP": {
        "short_name": "ONCBIOMUNE PHARMACEUTICALS INC",
        "long_name": "Theralink Technologies, Inc.",
        "summary": "Theralink Technologies, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapy products. The company has proprietary rights to immunotherapy platform focusing on prostate and breast cancers. The company's lead product is ProscaVax, which is in phase 2 clinical trials for the treatment of prostate cancer. It is also developing targeted therapies. Theralink Technologies, Inc. has a partnership with Perthera, Inc. to facilitate and enhance access to Theralink's 32 phosphoprotein panel, the Theralink assay, for breast cancer patients. The company was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies, Inc. is based in Baton Rouge, Louisiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Golden",
        "zipcode": "80401",
        "website": "http://www.theralink.com",
        "market_cap": "Small Cap"
    },
    "OC9.F": {
        "short_name": "OMNICELL INC.  DL-,001",
        "long_name": "Omnicell, Inc.",
        "summary": "Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Mountain View",
        "zipcode": "94043",
        "website": "http://www.omnicell.com",
        "market_cap": "Mid Cap"
    },
    "OCD1.F": {
        "short_name": "CHROMADEX CORP.  DL -,001",
        "long_name": "ChromaDex Corporation",
        "summary": "ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90024",
        "website": "http://www.chromadex.com",
        "market_cap": "Small Cap"
    },
    "OCDX": {
        "short_name": "Ortho Clinical Diagnostics plc",
        "long_name": "Ortho Clinical Diagnostics Holdings plc",
        "summary": "Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Raritan",
        "zipcode": "08869",
        "website": "http://www.orthoclinicaldiagnostics.com",
        "market_cap": "Mid Cap"
    },
    "OCGN": {
        "short_name": "Ocugen, Inc.",
        "long_name": "Ocugen, Inc.",
        "summary": "Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.ocugen.com",
        "market_cap": "Small Cap"
    },
    "OCLG": {
        "short_name": "ONCOLOGIX TECH INC",
        "long_name": "Oncologix Tech, Inc.",
        "summary": "Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. It offers personal home care services, including daily living assistance, companionship, and homemaker services, as well as Alzheimer's care, home care resource planning, and medical care coordination services. The company also manufactures, markets, and distributes medical technologies and products for skilled nursing facilities, acute and critical care facilities, assisted living facilities, hospitals and medical institutions, federal agencies, home medical care industry, respiratory and therapy- physical/occupational therapy centers. In addition, it distributes and sells home medical equipment for sleep and respiratory therapies; supplies and services durable medical equipment to treat obstructive Sleep Apnea; C-PAP and BiPAP oxygen equipment, a large selection of mask interfaces; and offers personalized treatment plans, as well as monitoring and support services. The company was formerly known as BestNet Communications Corp. and changed its name to Oncologix Tech, Inc. in January 2007. Oncologix Tech, Inc. was founded in 1995 and is based in Lafayette, Louisiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "LA",
        "city": "Lafayette",
        "zipcode": "70508",
        "website": "http://www.oclghealth.com",
        "market_cap": "Small Cap"
    },
    "OCUL": {
        "short_name": "Ocular Therapeutix, Inc.",
        "long_name": "Ocular Therapeutix, Inc.",
        "summary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Bedford",
        "zipcode": "01730",
        "website": "http://www.ocutx.com",
        "market_cap": "Small Cap"
    },
    "OCUP": {
        "short_name": "Ocuphire Pharma, Inc.",
        "long_name": "Ocuphire Pharma, Inc.",
        "summary": "Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Farmington Hills",
        "zipcode": "48335",
        "website": "http://www.ocuphire.com",
        "market_cap": "Small Cap"
    },
    "OCX": {
        "short_name": "OncoCyte Corporation",
        "long_name": "OncoCyte Corporation",
        "summary": "OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation was founded in 2009 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://oncocyte.com",
        "market_cap": "Small Cap"
    },
    "ODT": {
        "short_name": "Odonate Therapeutics, Inc.",
        "long_name": "Odonate Therapeutics, Inc.",
        "summary": "Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10016",
        "website": "http://www.odonate.com",
        "market_cap": "Small Cap"
    },
    "ODYY": {
        "short_name": "ODYSSEY GROUP INTL INC",
        "long_name": "Odyssey Group International, Inc.",
        "summary": "Odyssey Group International, Inc. focuses on development, acquisition, and commercialization of medical products and health related technologies. It intends to offer medical devices. The company has development projects in three technologies, including CardioMap, a heart monitoring and screening device; Save A Life choking rescue device; and a neurosteroid drug compound intended to treat rare brain disorders. Odyssey Group International, Inc. was founded in 2014 and is based in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://theodysseygroupinternational.com",
        "market_cap": "Small Cap"
    },
    "OFIX": {
        "short_name": "Orthofix Medical Inc.",
        "long_name": "Orthofix Medical Inc.",
        "summary": "Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Lewisville",
        "zipcode": "75056",
        "website": "http://www.orthofix.com",
        "market_cap": "Small Cap"
    },
    "OGEN": {
        "short_name": "Oragenics Inc.",
        "long_name": "Oragenics, Inc.",
        "summary": "Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and production of lantibiotics, a peptide antibiotic that are naturally produced in gram-positive bacteria. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33634",
        "website": "http://www.oragenics.com",
        "market_cap": "Small Cap"
    },
    "OHAQ": {
        "short_name": "ORACLE HEALTHCARE ACQUISITION C",
        "long_name": "Oracle Healthcare Acquisition Corp.",
        "summary": "Oracle Healthcare Acquisition Corp. does not have significant operations. It intends to acquire an operating business in the healthcare industry through a merger, capital stock exchange, asset acquisition, or other similar business combination. The company focuses its search for an acquisition candidate in the segments, such as healthcare services, medical devices and products, healthcare information technology, pharmaceuticals, diagnostics, biotechnology therapeutics, and life sciences. Oracle Healthcare Acquisition Corp. was founded in 2005 and is headquartered in Greenwich, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Greenwich",
        "zipcode": "06830",
        "website": null,
        "market_cap": "Small Cap"
    },
    "OJSY": {
        "short_name": "OJSYS INC",
        "long_name": "OJsys, Inc.",
        "summary": "OJsys, Inc. develops and manufactures broadcasting receivers. Its products include satellite receiver, terrestrial receiver, IP set-top boxes, media center PC devices, and receiver-plus-DVD-RW combos. It markets its products to Europe, Japan, the Middle East, Asia, and the United States. The company was founded in 2000 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94118",
        "website": null,
        "market_cap": "Small Cap"
    },
    "OJU1.F": {
        "short_name": "ORAMED PHARMA.NEW DL-,001",
        "long_name": "Oramed Pharmaceuticals Inc.",
        "summary": "Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.oramed.com",
        "market_cap": "Small Cap"
    },
    "OLMA": {
        "short_name": "Olema Pharmaceuticals, Inc.",
        "long_name": "Olema Pharmaceuticals, Inc.",
        "summary": "Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94107",
        "website": "http://www.olema.com",
        "market_cap": "Small Cap"
    },
    "OLMM": {
        "short_name": "ONELIFE TECHNOLOGIES CORP",
        "long_name": "OneLife Technologies Corp.",
        "summary": "OneLife Technologies Corp. operates as a mobile medical hardware, software, and data collection company in the United States and internationally. The company offers a suite of medical grade tracking technologies to provide patients, physicians, nursing homes, and hospitals with real-time comprehensive health data and monitoring. Its products include Sensation, a wearable designed for the health and medical markets who want or need to track aspects of their physical health, such as heart rate, activity, sleep patterns, and location; and Tricorder that captures blood pressure, heart rate, ECG/EKG, SpO2, and temperature from a patient. The company's products also comprise Personal Data Vault that offers the user a data vault, which is the central repository of their health data. OneLife Technologies Corp. is based in Rolling Meadows, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Rolling Meadows",
        "zipcode": "60008",
        "website": "http://www.onelifetc.com",
        "market_cap": "Small Cap"
    },
    "OM": {
        "short_name": "Outset Medical, Inc.",
        "long_name": "Outset Medical, Inc.",
        "summary": "Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Jose",
        "zipcode": "95134",
        "website": "http://www.outsetmedical.com",
        "market_cap": "Mid Cap"
    },
    "OM2.F": {
        "short_name": "ORTHOFIX MED.INC.  DL-,10",
        "long_name": "Orthofix Medical Inc.",
        "summary": "Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Lewisville",
        "zipcode": "75056",
        "website": "http://www.orthofix.com",
        "market_cap": "Small Cap"
    },
    "OMCL": {
        "short_name": "Omnicell, Inc.",
        "long_name": "Omnicell, Inc.",
        "summary": "Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Mountain View",
        "zipcode": "94043",
        "website": "http://www.omnicell.com",
        "market_cap": "Mid Cap"
    },
    "OMER": {
        "short_name": "Omeros Corporation",
        "long_name": "Omeros Corporation",
        "summary": "Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98119",
        "website": "http://www.omeros.com",
        "market_cap": "Small Cap"
    },
    "OMHE": {
        "short_name": "OMNI HEALTH INC",
        "long_name": "Omni Health, Inc.",
        "summary": "Omni Health, Inc., through its subsidiary, Malecon Pharmacy, Inc., operates a pharmacy in Hialeah, Florida. It provides health, wellness, and pharmacy services; and manufactures, sells, and distributes anti-aging cream. The company is headquartered in Hialeah, Florida. Omni Health, Inc. is a subsidiary of LX Retail Group, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Hialeah",
        "zipcode": "33012",
        "website": "http://www.omnihealth.md",
        "market_cap": "Small Cap"
    },
    "OMI": {
        "short_name": "Owens & Minor, Inc.",
        "long_name": "Owens & Minor, Inc.",
        "summary": "Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. The company provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Richmond, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Richmond",
        "zipcode": "23261-7626",
        "website": "http://www.owens-minor.com",
        "market_cap": "Mid Cap"
    },
    "OMID": {
        "short_name": "OMID HLDGS INC",
        "long_name": "OMID Holdings, Inc.",
        "summary": "OMID Holdings, Inc., a health and wellness company, engages in the manufacture and sale of CBD-based products. The company is based in Phillipsburg, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Phillipsburg",
        "zipcode": null,
        "website": "http://omidholdingsinc.com",
        "market_cap": null
    },
    "OMMH": {
        "short_name": "OMNIMMUNE HLDGS INC",
        "long_name": "Omnimmune Holdings, Inc.",
        "summary": "Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77027",
        "website": null,
        "market_cap": "Small Cap"
    },
    "OMRX": {
        "short_name": "ORTHOMETRIX INC",
        "long_name": "Orthometrix, Inc.",
        "summary": "Orthometrix, Inc. develops technologies, procedures, and devices to help increase musculoskeletal mobility, as well as non-invasive technologies to treat the pain associated with osteoarthritis, plantar fasciitis, and other musculoskeletal conditions that reduce mobility. The company markets, sells, and services peripheral quantitative computed tomography bone and muscle measurement systems for research and clinical applications; patented motorized exercise systems for rehabilitation, physical therapy, and sports medicine based on patented vibration technology; human performance measurement systems for monitoring improvement in power and mobility; and extracorporeal shock wave therapy systems for non-invasive treatment of pain associated with plantar fasciitis. It also markets, sells, and services patented motorized exercise systems to professional teams, fitness centers, gyms, sports clubs, and wellness-conscious general public. The company offers bone and muscle diagnostic, bone and muscle research, rehabilitation/physical therapy, sports and fitness, and home products. It serves healthcare, veterinary, and sports and fitness markets in the United States and internationally. The company was formerly known as Norland Medical Systems, Inc. and changed its name to Orthometrix, Inc. in April 2002. Orthometrix, Inc. was founded in 1993 and is headquartered in Naples, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Naples",
        "zipcode": "34110",
        "website": null,
        "market_cap": "Small Cap"
    },
    "ONBI": {
        "short_name": "ONE BIO CORP",
        "long_name": "ONE Bio Corp.",
        "summary": "ONE Bio Corp., an agritech company, together with its subsidiaries, utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements, and organic products. The company operates through two business units, Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE business unit engages in the development, manufacture, and commercialization of bio-ecological products and over-the-counter products utilizing the extractions of tobacco leaves and various other plant materials. It produces chemical and herbal extracts for use in a range of health and wellness products, including chemical extracts comprising Solanesol and Coenzyme Q10; and herabal extracts, such as Resveratrol, 5-Hydroxytryptophan, Ganoderma Tea, and powdered and particulate fertilizers. This business unit distributes its products through independent third party distributors, universities, and hospital research centers to the bio-health industry and raw chemical intermediates industry in the People's Republic of China. The OP business unit manufactures various consumer and commercial use health and energy drinks, organic food products, and fertilizers primarily based on bamboo in the People's Republic of China. Its products include boiled bamboo shoot cans, boiled bamboo shoot cans with vacuum packing, boiled mixed vegetables, and boiled seasoned vegetables, as well as Kamameshi, a Japanese rice dish. This segment distributes its products directly to supermarket chains, hotels, hospitals, and restaurants, as well as through a network of independent third party distributors. ONE Bio Corp. exports its products to Japan, southeast Asia, Europe, and North America. The company was formerly known as ONE Holdings, Corp. and changed its name to ONE Bio Corp. in November 2009. ONE Bio Corp. was incorporated in 2000 and is headquartered in Aventura, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Aventura",
        "zipcode": "33180",
        "website": null,
        "market_cap": "Small Cap"
    },
    "ONCR": {
        "short_name": "Oncorus, Inc.",
        "long_name": "Oncorus, Inc.",
        "summary": "Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.oncorus.com",
        "market_cap": "Small Cap"
    },
    "ONCS": {
        "short_name": "OncoSec Medical Incorporated",
        "long_name": "OncoSec Medical Incorporated",
        "summary": "OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Pennington",
        "zipcode": "08534",
        "website": "http://oncosec.com",
        "market_cap": "Small Cap"
    },
    "ONCT": {
        "short_name": "Oncternal Therapeutics, Inc.",
        "long_name": "Oncternal Therapeutics, Inc.",
        "summary": "Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. The company is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.oncternal.com",
        "market_cap": "Small Cap"
    },
    "ONEM": {
        "short_name": "1Life Healthcare, Inc.",
        "long_name": "1Life Healthcare, Inc.",
        "summary": "1Life Healthcare, Inc. operates a membership-based primary care platform under the One Medical brand. The company has developed a healthcare membership model based on direct consumer enrollment, as well as employer sponsorship. Its membership model includes seamless access to digital health services paired with inviting in-office care routinely covered under health insurance programs. The company also offers administrative and managerial services pursuant to contracts with physician-owned professional corporations or One Medical Entities. As of December 31, 2020, it had approximately 549,000 members in 13 markets in the United States; and 8,000 enterprise clients. The company was incorporated in 2002 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94111",
        "website": "http://www.onemedical.com",
        "market_cap": "Mid Cap"
    },
    "ONM2.F": {
        "short_name": "ONCOSEC MEDICAL  DL-,001",
        "long_name": "OncoSec Medical Incorporated",
        "summary": "OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Pennington",
        "zipcode": "08534",
        "website": "http://oncosec.com",
        "market_cap": "Small Cap"
    },
    "ONPH": {
        "short_name": "ONCOLOGY PHARMA INC",
        "long_name": "Oncology Pharma Inc.",
        "summary": "Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94104",
        "website": "http://www.oncology-pharma.com",
        "market_cap": "Small Cap"
    },
    "ONTX": {
        "short_name": "Onconova Therapeutics, Inc.",
        "long_name": "Onconova Therapeutics, Inc.",
        "summary": "Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Newtown",
        "zipcode": "18940",
        "website": "http://www.onconova.com",
        "market_cap": "Small Cap"
    },
    "ONVO": {
        "short_name": "Organovo Holdings, Inc.",
        "long_name": "Organovo Holdings, Inc.",
        "summary": "Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Solana Beach",
        "zipcode": "92075",
        "website": "http://www.organovo.com",
        "market_cap": "Small Cap"
    },
    "OPCH": {
        "short_name": "Option Care Health, Inc.",
        "long_name": "Option Care Health, Inc.",
        "summary": "Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies. It also offers infusion therapies for bleeding disorders; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications. In addition, the company offers therapies that women need to survive and thrive through high-risk pregnancies; treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; and nursing services. The company is headquartered in Bannockburn, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Bannockburn",
        "zipcode": "60015",
        "website": "http://www.optioncarehealth.com",
        "market_cap": "Mid Cap"
    },
    "OPGN": {
        "short_name": "OpGen, Inc.",
        "long_name": "OpGen, Inc.",
        "summary": "OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Gaithersburg",
        "zipcode": "20878",
        "website": "http://www.opgen.com",
        "market_cap": "Small Cap"
    },
    "OPGX": {
        "short_name": "OPTIGENEX INC",
        "long_name": "Optigenex Inc.",
        "summary": "Optigenex Inc. engages in the manufacture and sale of healthy age management and beauty care products. The company offers AC-11, a powdered and bioactive rainforest plant extract that helps the body to repair sun and environmental stress-related damage to DNA, and slow down the process of skin aging. It serves manufacturers, distributors, and retailers worldwide in the dietary supplement, as well as anti-aging topical skin care, cosmetic, and cosmeceutical market categories. The company is based in Melissa, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Melissa",
        "zipcode": "75454",
        "website": "http://www.optigenex.com",
        "market_cap": "Small Cap"
    },
    "OPK.MX": {
        "short_name": "OPKO HEALTH INC",
        "long_name": "OPKO Health, Inc.",
        "summary": "OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33137",
        "website": "http://www.opko.com",
        "market_cap": "Mid Cap"
    },
    "OPK": {
        "short_name": "Opko Health, Inc.",
        "long_name": "OPKO Health, Inc.",
        "summary": "OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33137",
        "website": "http://www.opko.com",
        "market_cap": "Mid Cap"
    },
    "OPK.TA": {
        "short_name": "OPKO HEALTH INC",
        "long_name": "OPKO Health, Inc.",
        "summary": "OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TLV",
        "market": "il_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33137",
        "website": "http://www.opko.com",
        "market_cap": null
    },
    "OPMC": {
        "short_name": "OPTIMUMCARE CORP",
        "long_name": "Optimum Care Corporation",
        "summary": "Optimum Care Corporation provides healthcare services. The company offers various inpatient and partial hospitalization behavioral health services for patients with acute mental illness through a network of affiliated hospitals, medical centers, and community mental health centers. It also provides assisted living services in a resort atmosphere. The company was founded in 1986 and is headquartered in Laguna Niguel, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Laguna Niguel",
        "zipcode": "92677",
        "website": "http://www.optimumcare.com",
        "market_cap": "Small Cap"
    },
    "OPNT": {
        "short_name": "Opiant Pharmaceuticals, Inc.",
        "long_name": "Opiant Pharmaceuticals, Inc.",
        "summary": "Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Monica",
        "zipcode": "90401",
        "website": "http://www.opiant.com",
        "market_cap": "Small Cap"
    },
    "OPRX": {
        "short_name": "OptimizeRx Corporation",
        "long_name": "OptimizeRx Corporation",
        "summary": "OptimizeRx Corporation operates as a digital health company that provides communications solutions for life science companies, physicians, and patients. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, therapeutic support messages, and unbranded messages. The company also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, it operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, the company offers patient programs with treatment and affordability information, lifestyle and condition trackers, Internet device connectivity, forms, and surveys. OptimizeRx Corporation is headquartered in Rochester, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Rochester",
        "zipcode": "48307",
        "website": "http://www.optimizerx.com",
        "market_cap": "Small Cap"
    },
    "OPTN": {
        "short_name": "OptiNose, Inc.",
        "long_name": "OptiNose, Inc.",
        "summary": "OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Yardley",
        "zipcode": "19067",
        "website": "http://www.optinose.com",
        "market_cap": "Small Cap"
    },
    "ORCD.CN": {
        "short_name": "OrchidVentInc",
        "long_name": "Orchid Ventures, Inc.",
        "summary": "Orchid Ventures, Inc. engages in the development, manufacturing, branding, and distribution of cannabis vape products in North America. The company provides cannabis vapor devices, such as kits and cartridges. It offers its products through approximately 200 dispensaries across California and Oregon. The company also licenses its brand and proprietary hardware to licensed manufacturers and distributors. In addition, it designs and sells proprietary and patent pending hardware delivery systems to the Cannabis and CBD industries. Orchid Ventures, Inc. is headquartered in Irvine, California.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "WA",
        "city": "Vancouver",
        "zipcode": "98660",
        "website": "http://www.orchidessentials.com",
        "market_cap": "Small Cap"
    },
    "ORGO": {
        "short_name": "Organogenesis Holdings Inc.",
        "long_name": "Organogenesis Holdings Inc.",
        "summary": "Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Canton",
        "zipcode": "02021",
        "website": "http://organogenesis.com",
        "market_cap": "Mid Cap"
    },
    "ORGS": {
        "short_name": "Orgenesis Inc.",
        "long_name": "Orgenesis Inc.",
        "summary": "Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. sThe company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was incorporated in 2008 and is based in Germantown, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Germantown",
        "zipcode": "20876",
        "website": "http://www.orgenesis.com",
        "market_cap": "Small Cap"
    },
    "ORHB": {
        "short_name": "ORHUB INC",
        "long_name": "ORHub, Inc.",
        "summary": "ORHub, Inc. provides surgical software focusing on real-time surgical data analytics. The company's suite of products serves the needs of the health care industry, hospitals, patients, the government, and medical device vendors. The company provides a cloud-based software solution that captures information before, during, and after surgery. Its software applications allow hospitals and medical device vendors to utilize Web-enabled device to create an anatomical graphic depiction during surgery. The company is based in Phoenix, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Phoenix",
        "zipcode": "85044",
        "website": "http://www.orhub.com",
        "market_cap": "Small Cap"
    },
    "ORIC": {
        "short_name": "Oric Pharmaceuticals, Inc.",
        "long_name": "ORIC Pharmaceuticals, Inc.",
        "summary": "ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Astellas Pharma, Inc.; Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.oricpharma.com",
        "market_cap": "Small Cap"
    },
    "ORMP": {
        "short_name": "Oramed Pharmaceuticals Inc.",
        "long_name": "Oramed Pharmaceuticals Inc.",
        "summary": "Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.oramed.com",
        "market_cap": "Small Cap"
    },
    "ORVRD": {
        "short_name": "ORCHID VENTURES INC",
        "long_name": "Orchid Ventures, Inc.",
        "summary": "Orchid Ventures, Inc. engages in the development, manufacturing, branding, and distribution of cannabis vape products in North America. The company provides cannabis vapor devices, such as kits and cartridges. It offers its products through approximately 200 dispensaries across California and Oregon. The company also licenses its brand and proprietary hardware to licensed manufacturers and distributors. In addition, it designs and sells proprietary and patent pending hardware delivery systems to the Cannabis and CBD industries. Orchid Ventures, Inc. is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Vancouver",
        "zipcode": "98660",
        "website": "http://www.orchidessentials.com",
        "market_cap": "Small Cap"
    },
    "OSCR": {
        "short_name": "Oscar Health, Inc.",
        "long_name": "Oscar Health, Inc.",
        "summary": "Oscar Health, Inc. provides health insurance products and services to individuals, families, and businesses in the United States. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was founded in 2012 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10013",
        "website": "http://www.hioscar.com",
        "market_cap": "Mid Cap"
    },
    "OSH": {
        "short_name": "Oak Street Health, Inc.",
        "long_name": "Oak Street Health, Inc.",
        "summary": "Oak Street Health, Inc., together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2020, it operated 79 centers in Illinois, Indiana, Michigan, Mississippi, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, and Texas. The company was founded in 2012 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60603",
        "website": "http://www.oakstreethealth.com",
        "market_cap": "Large Cap"
    },
    "OSMT": {
        "short_name": "Osmotica Pharmaceuticals plc",
        "long_name": "Osmotica Pharmaceuticals plc",
        "summary": "Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bridgewater",
        "zipcode": "08807",
        "website": "http://www.osmotica.com",
        "market_cap": "Small Cap"
    },
    "OSP.AX": {
        "short_name": "OSPREY MED CDI FORUS",
        "long_name": "Osprey Medical, Inc.",
        "summary": "Osprey Medical, Inc., a commercial stage company, provides contrast reduction and monitoring technologies in the United States and internationally. It offers AVERT, AVERT Plus, DyeVert NG, DyeVert Plus System, and DyeVert Plus EZ Systems, which are used to protect patients from the harmful effects of X-ray dye used during commonly performed angiographic imaging procedures. The company was incorporated in 2005 and is headquartered in Minnetonka, Minnesota.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United States",
        "state": "MN",
        "city": "Minnetonka",
        "zipcode": "55343",
        "website": "http://www.ospreymed.com",
        "market_cap": "Small Cap"
    },
    "OSUR": {
        "short_name": "OraSure Technologies, Inc.",
        "long_name": "OraSure Technologies, Inc.",
        "summary": "OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Bethlehem",
        "zipcode": "18015",
        "website": "http://www.orasure.com",
        "market_cap": "Small Cap"
    },
    "OTIC": {
        "short_name": "Otonomy, Inc.",
        "long_name": "Otonomy, Inc.",
        "summary": "Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of M\u00c3\u00a9ni\u00c3\u00a8re's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.otonomy.com",
        "market_cap": "Small Cap"
    },
    "OTLC": {
        "short_name": "ONCOTELIC THERAPEUTICS INC",
        "long_name": "Oncotelic Therapeutics, Inc.",
        "summary": "Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Agoura Hills",
        "zipcode": "91301",
        "website": "http://www.mateon.com",
        "market_cap": "Small Cap"
    },
    "OTLK": {
        "short_name": "Outlook Therapeutics, Inc.",
        "long_name": "Outlook Therapeutics, Inc.",
        "summary": "Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranbury",
        "zipcode": "08852",
        "website": "http://www.outlooktherapeutics.com",
        "market_cap": "Small Cap"
    },
    "OTRK": {
        "short_name": "Ontrak, Inc.",
        "long_name": "Ontrak, Inc.",
        "summary": "Ontrak, Inc. operates as an artificial intelligence powered, virtualized outpatient healthcare treatment company that provides in-person or telehealth intervention services to health plans and other third-party payors. Its Ontrak PRE (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends care pathways that people are willing to follow, and engages people who aren't getting the care they need. The company's technology-enabled, OnTrak, program is designed to treat health plan members with unaddressed behavioral health conditions that cause or exacerbate chronic medical diseases, such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was founded in 2003 and is headquartered in Santa Monica, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Monica",
        "zipcode": "90404",
        "website": "http://www.ontrak-inc.com",
        "market_cap": "Small Cap"
    },
    "OTRKP": {
        "short_name": "Ontrak, Inc. - 9.50% Series A C",
        "long_name": "Ontrak, Inc.",
        "summary": "Ontrak, Inc. operates as an artificial intelligence powered, virtualized outpatient healthcare treatment company that provides in-person or telehealth intervention services to health plans and other third-party payors. Its Ontrak PRE (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends care pathways that people are willing to follow, and engages people who aren't getting the care they need. The company's technology-enabled, OnTrak, program is designed to treat health plan members with unaddressed behavioral health conditions that cause or exacerbate chronic medical diseases, such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was founded in 2003 and is headquartered in Santa Monica, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Monica",
        "zipcode": "90404",
        "website": "http://www.ontrak-inc.com",
        "market_cap": null
    },
    "OVID": {
        "short_name": "Ovid Therapeutics Inc.",
        "long_name": "Ovid Therapeutics Inc.",
        "summary": "Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.ovidrx.com",
        "market_cap": "Small Cap"
    },
    "OVIT": {
        "short_name": "ONCOVISTA INNOVATIVE THERAPIES ",
        "long_name": "OncoVista Innovative Therapies, Inc.",
        "summary": "OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "San Antonio",
        "zipcode": "78245",
        "website": "http://www.oncovista.com",
        "market_cap": "Small Cap"
    },
    "OWPC": {
        "short_name": "ONE WORLD PHARMA INC",
        "long_name": "One World Pharma, Inc.",
        "summary": "One World Pharma, Inc. focuses on producing and manufacturing raw cannabis and hemp plant ingredients for medical and industrial uses worldwide. It intends to cultivate, process, and supply crude cannabis oil, distillate, and isolate to customers' specification, as well as hemp plant biomass. The company was founded in 2017 and is headquartered in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89118",
        "website": "http://www.oneworldpharma.com",
        "market_cap": "Small Cap"
    },
    "OYST": {
        "short_name": "Oyster Point Pharma, Inc.",
        "long_name": "Oyster Point Pharma, Inc.",
        "summary": "Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.oysterpointrx.com",
        "market_cap": "Small Cap"
    },
    "P09.F": {
        "short_name": "PAC.BIOSCI.OF CAL.DL-,001",
        "long_name": "Pacific Biosciences of California, Inc.",
        "summary": "Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://www.pacb.com",
        "market_cap": "Mid Cap"
    },
    "P1KI34.SA": {
        "short_name": "PERKINELMER DRN",
        "long_name": "PerkinElmer, Inc.",
        "summary": "PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.perkinelmer.com",
        "market_cap": "Large Cap"
    },
    "P7N1.F": {
        "short_name": "SIERRA ONCOLOGY  DL-,001",
        "long_name": "Sierra Oncology, Inc.",
        "summary": "Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Mateo",
        "zipcode": "94404",
        "website": "http://www.sierraoncology.com",
        "market_cap": "Small Cap"
    },
    "P91.F": {
        "short_name": "PTC THERAPEUTICS  DL-,001",
        "long_name": "PTC Therapeutics, Inc.",
        "summary": "PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "South Plainfield",
        "zipcode": "07080",
        "website": "http://www.ptcbio.com",
        "market_cap": "Mid Cap"
    },
    "PACB": {
        "short_name": "Pacific Biosciences of Californ",
        "long_name": "Pacific Biosciences of California, Inc.",
        "summary": "Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://www.pacb.com",
        "market_cap": "Mid Cap"
    },
    "PAHC": {
        "short_name": "Phibro Animal Health Corporatio",
        "long_name": "Phibro Animal Health Corporation",
        "summary": "Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Teaneck",
        "zipcode": "07666-6712",
        "website": "http://www.pahc.com",
        "market_cap": "Small Cap"
    },
    "PALI": {
        "short_name": "Palisade Bio, Inc.",
        "long_name": "Palisade Bio, Inc.",
        "summary": "Leading BioSciences, Inc. develops therapeutics to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company was founded in 2005 and is based in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008",
        "website": "http://leadingbiosciences.com",
        "market_cap": "Small Cap"
    },
    "PAOG": {
        "short_name": "PAO GROUP INC",
        "long_name": "PAO Group, Inc.",
        "summary": "PAO Group, Inc. focuses on alternative patient care treatments. The company, through its subsidiaries, engages in the development, sale, and distribution of premium medical cannabis products for treatment of chronic and terminal patients. The company is headquartered in Sandusky, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Sandusky",
        "zipcode": "44870",
        "website": "http://www.pao.group",
        "market_cap": null
    },
    "PARD": {
        "short_name": "PONIARD PHARMACEUT",
        "long_name": "Poniard Pharmaceuticals, Inc.",
        "summary": "Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98119",
        "website": null,
        "market_cap": "Small Cap"
    },
    "PASG": {
        "short_name": "Passage Bio, Inc.",
        "long_name": "Passage Bio, Inc.",
        "summary": "Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (\u00c3\u009f-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19103",
        "website": "http://www.passagebio.com",
        "market_cap": "Small Cap"
    },
    "PASO": {
        "short_name": "PATIENT ACCESS SOLUTIONS INC",
        "long_name": "Patient Access Solutions, Inc.",
        "summary": "Patient Access Solutions, Inc. provides healthcare/financial processing solutions for the healthcare and dental industries. The company, through its merchant processing platform, provides patient eligibility, medical billing, and patient self-pay solutions. It also provides practice management, business management consulting, GAP analysis, and marketing and practice development services; and treatment services for autism, concussion, PTSD, and other biomedical conditions, as well as diagnostic testing services. Patient Access Solutions, Inc. is based in Plainview, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Plainview",
        "zipcode": "11803",
        "website": "http://www.pashealth.com",
        "market_cap": "Small Cap"
    },
    "PAVM": {
        "short_name": "PAVmed Inc.",
        "long_name": "PAVmed Inc.",
        "summary": "PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10165",
        "website": "http://www.pavmed.com",
        "market_cap": "Small Cap"
    },
    "PB8.F": {
        "short_name": "PHIBRO ANIMAL HEALTH A",
        "long_name": "Phibro Animal Health Corporation",
        "summary": "Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Teaneck",
        "zipcode": "07666-6712",
        "website": "http://www.pahc.com",
        "market_cap": "Small Cap"
    },
    "PBH": {
        "short_name": "Prestige Consumer Healthcare In",
        "long_name": "Prestige Consumer Healthcare Inc.",
        "summary": "Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids/lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. It also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, Fess nasal saline spray, and Hydralyte for oral rehydration products. The company sells through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Tarrytown",
        "zipcode": "10591",
        "website": "http://www.prestigebrands.com",
        "market_cap": "Mid Cap"
    },
    "PBIO": {
        "short_name": "PRESSURE BIOSCIENCES INC",
        "long_name": "Pressure BioSciences, Inc.",
        "summary": "Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. It serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences, Inc. has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "South Easton",
        "zipcode": "02375",
        "website": "http://www.pressurebiosciences.com",
        "market_cap": "Small Cap"
    },
    "PBLA": {
        "short_name": "Panbela Therapeutics, Inc.",
        "long_name": "Panbela Therapeutics, Inc.",
        "summary": "Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in Waconia, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Waconia",
        "zipcode": "55387",
        "website": "http://www.panbela.com",
        "market_cap": "Small Cap"
    },
    "PBS.F": {
        "short_name": "PRECISION BIOSCIENCES DL",
        "long_name": "Precision BioSciences, Inc.",
        "summary": "Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27701",
        "website": "http://www.precisionbiosciences.com",
        "market_cap": "Small Cap"
    },
    "PBSV": {
        "short_name": "PHARMA-BIO SERVICES INC",
        "long_name": "Pharma-Bio Serv, Inc.",
        "summary": "Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. It provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products in Puerto Rico, the United States, Europe, and Brazil. The company's technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PR",
        "city": "Dorado",
        "zipcode": "00646",
        "website": "http://www.pharmabioserv.com",
        "market_cap": "Small Cap"
    },
    "PBV.F": {
        "short_name": "PRESTIGE CONS.HLTH.DL-,01",
        "long_name": "Prestige Consumer Healthcare Inc.",
        "summary": "Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids/lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. It also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, Fess nasal saline spray, and Hydralyte for oral rehydration products. The company sells through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Tarrytown",
        "zipcode": "10591",
        "website": "http://www.prestigebrands.com",
        "market_cap": "Mid Cap"
    },
    "PBYI": {
        "short_name": "Puma Biotechnology Inc",
        "long_name": "Puma Biotechnology, Inc.",
        "summary": "Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90024",
        "website": "http://www.pumabiotechnology.com",
        "market_cap": "Small Cap"
    },
    "PCBK.F": {
        "short_name": "SESEN BIO INC.",
        "long_name": "Sesen Bio, Inc.",
        "summary": "Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.sesenbio.com",
        "market_cap": "Small Cap"
    },
    "PCHM": {
        "short_name": "PHARMCHEM INC",
        "long_name": "PharmChem, Inc.",
        "summary": "PharmChem, Inc. provides PharmChek Sweat Patch that is used to detect drugs of abuse. Its PharmChek Sweat Patch uses sweat as the source and offers alternative to urine testing for cocaine, opiates, amphetamines, PCP, and marijuana. The company is based in Fort Worth, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Fort Worth",
        "zipcode": "76118",
        "website": "http://www.pharmchek.com",
        "market_cap": "Small Cap"
    },
    "PCJP.F": {
        "short_name": "ABEONA THERAPEUT.  DL-,01",
        "long_name": "Abeona Therapeutics Inc.",
        "summary": "Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10019",
        "website": "http://www.abeonatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "PCNT": {
        "short_name": "POINT OF CARE NANO-TECHNOLOGY I",
        "long_name": "Point of Care Nano-Technology, Inc.",
        "summary": "Point of Care Nano-Technology, Inc. focuses on developing and manufacturing saliva-based medical diagnosis products in the United States. Point of Care Nano-Technology, Inc. has a license agreement with Lamina Equities Corporation to diagnose illness in humans via a saliva test. The company was formerly known as Unique Growing Solutions, Inc. and changed its name to Point of Care Nano-Technology, Inc. in April 2015. The company was founded in 2010 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89134",
        "website": "http://www.uniquegrowingsolutions.com",
        "market_cap": "Small Cap"
    },
    "PCRX": {
        "short_name": "Pacira BioSciences, Inc.",
        "long_name": "Pacira BioSciences, Inc.",
        "summary": "Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Parsippany",
        "zipcode": "07054",
        "website": "http://www.pacira.com",
        "market_cap": "Mid Cap"
    },
    "PCSA": {
        "short_name": "Processa Pharmaceuticals, Inc.",
        "long_name": "Processa Pharmaceuticals, Inc.",
        "summary": "Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Hanover",
        "zipcode": "21076",
        "website": "http://www.processapharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "PCVX": {
        "short_name": "Vaxcyte, Inc.",
        "long_name": "Vaxcyte, Inc.",
        "summary": "Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.vaxcyte.com",
        "market_cap": "Small Cap"
    },
    "PCYN": {
        "short_name": "PROCYON CORP",
        "long_name": "Procyon Corporation",
        "summary": "Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems primarily in the United States. The company offers advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions under the AMERIGEL brand name. It also provides Bioactive Collagen products under the HELIX3 brand name. In addition, the company offers wound care products, such as calcium alginate, foam, gauze, and hyrdocolloid dressing products; wound care kits, which include calcium alginate, collagen matrix, collagen powder, foam, and hydrogel wound care kits under the AMERX brand name; and compression garment line products under the EXTREMIT-EASE name. It sells its products through distributors to institutional customers, such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, physicians, and other health care practitioners; and retail customers through direct sales, and internet sales, as well as through independent and retail chain drug stores. Procyon Corporation was incorporated in 1987 and is based in Clearwater, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Clearwater",
        "zipcode": "33756",
        "website": "http://www.procyoncorp.com",
        "market_cap": "Small Cap"
    },
    "PCYS": {
        "short_name": "PRIMECARE SYSTEMS INC",
        "long_name": "PrimeCare Systems, Inc.",
        "summary": "PrimeCare Systems, Inc., together with its subsidiaries, engages in the creation, ownership, maintenance, and marketing of patient management systems primarily in the United States. The company offers PrimeCare Version Ten, a multitier patient management system; and CodeComplierJ, an application software program that organizes the data in the proper classification and also calculates the evaluation and management reimbursement code level for third party payers. Its principal target markets include national and local health care systems, military organizations, correctional facilities, health maintenance organizations, hospitals with outpatient services, ambulatory/outpatient medical facilities, clinics, group practices, and solo practitioners. The company also creates, owns, maintains, and markets Web sites containing secure Internet enhanced and targeted components of the PrimeCare System. Its Web sites include PrimeCareOnTheWeb.com, a physician and patient interactive Website; YourOwnDoctor.com, which provides free individual Websites for physicians, physician groups, and other health care providers who register for PrimeCareOnTheWeb; and YourOwnHealth.com, an online health and wellness Website. The company focuses on selling its products directly to at-risk healthcare entities, and through distributors and private labeling opportunities. PrimeCare Systems, Inc. was incorporated in 1994 and is based in Newport News, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Newport News",
        "zipcode": "23606",
        "website": null,
        "market_cap": "Small Cap"
    },
    "PD2.DE": {
        "short_name": "PATTERSON COS INC. DL-,01",
        "long_name": "Patterson Companies, Inc.",
        "summary": "Patterson Companies, Inc. distributes and sells dental and animal health products in the United States, the United Kingdom, and Canada. It operates through three segments; Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, hand instruments, and sterilization products; basic and advanced technology dental equipment; technology solutions, such as practice management software and e-commerce solutions; patient education systems; and office forms and stationery. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritionals, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "MN",
        "city": "Saint Paul",
        "zipcode": "55120",
        "website": "http://www.pattersoncompanies.com",
        "market_cap": "Mid Cap"
    },
    "PD2.F": {
        "short_name": "PATTERSON COS INC. DL-,01",
        "long_name": "Patterson Companies, Inc.",
        "summary": "Patterson Companies, Inc. distributes and sells dental and animal health products in the United States, the United Kingdom, and Canada. It operates through three segments; Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, hand instruments, and sterilization products; basic and advanced technology dental equipment; technology solutions, such as practice management software and e-commerce solutions; patient education systems; and office forms and stationery. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritionals, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Saint Paul",
        "zipcode": "55120",
        "website": "http://www.pattersoncompanies.com",
        "market_cap": "Mid Cap"
    },
    "PDC.F": {
        "short_name": "MEDNAX INC.  DL-,01",
        "long_name": "MEDNAX, Inc.",
        "summary": "MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of March 16, 2021, it operated a network of approximately 2,300 physicians. The company was founded in 1979 and is based in Sunrise, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Sunrise",
        "zipcode": "33323",
        "website": "http://www.mednax.com",
        "market_cap": "Mid Cap"
    },
    "PDCO": {
        "short_name": "Patterson Companies, Inc.",
        "long_name": "Patterson Companies, Inc.",
        "summary": "Patterson Companies, Inc. distributes and sells dental and animal health products in the United States, the United Kingdom, and Canada. It operates through three segments; Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, hand instruments, and sterilization products; basic and advanced technology dental equipment; technology solutions, such as practice management software and e-commerce solutions; patient education systems; and office forms and stationery. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritionals, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Saint Paul",
        "zipcode": "55120",
        "website": "http://www.pattersoncompanies.com",
        "market_cap": "Mid Cap"
    },
    "PDEX": {
        "short_name": "Pro-Dex, Inc.",
        "long_name": "Pro-Dex, Inc.",
        "summary": "Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.pro-dex.com",
        "market_cap": "Small Cap"
    },
    "PDMI": {
        "short_name": "PARADIGM MEDICAL INDUSTRIES INC",
        "long_name": "Paradigm Medical Industries, Inc.",
        "summary": "Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84123",
        "website": "http://www.paradigm-medical.com",
        "market_cap": "Small Cap"
    },
    "PDRX": {
        "short_name": "PD-RX PHARMACEUTICALS INC",
        "long_name": "PD-Rx Pharmaceuticals, Inc.",
        "summary": "PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for healthcare industry in the United States. The company offers prepackaged medications; and creams, ointments, ophthalmics, otics, liquids, and suspensions, etc. The company also provides PD-Rx Net, a web based application program designed to track prescriptions filled at the point of care and print prescription labels for prescription that filled onsite; and manual dispensing system provides 10 recordkeeping labels to match the 10 bottle trays as a convenient handling package for physician dispensing customers. In addition, it offers professional assistance by staffed pharmacists and physicians; and pharmaceutical sampling program design to reduce MCO's pharmaceutical costs and allow medical professionals to offer pre-filled prescriptions to patients free of charge. The company serves to physicians, pharmacies, and medical clinics. The company was founded in 1986 and is headquartered in Oklahoma City, Oklahoma.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OK",
        "city": "Oklahoma City",
        "zipcode": "73127",
        "website": "http://www.pdrx.com",
        "market_cap": "Small Cap"
    },
    "PDSB": {
        "short_name": "PDS Biotechnology Corporation",
        "long_name": "PDS Biotechnology Corporation",
        "summary": "PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Florham Park",
        "zipcode": "07932",
        "website": "http://www.pdsbiotech.com",
        "market_cap": "Small Cap"
    },
    "PDXN.F": {
        "short_name": "PRO-DEX INC. NEW",
        "long_name": "Pro-Dex, Inc.",
        "summary": "Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.pro-dex.com",
        "market_cap": "Small Cap"
    },
    "PECN": {
        "short_name": "PHOTOELECTRON CORP",
        "long_name": "Photoelectron Corp.",
        "summary": "Photoelectron Corporation, a technology company, engages in the development, manufacture, and marketing of miniature x-ray systems for multiple market applications. It creates and adapts miniature x-ray systems for various applications in healthcare and nonhealthcare related markets. The company offers micro-adaptive x-ray systems designed for x-ray fluorescence analysis, intravascular radiation therapy, brachytherapy, radiosurgery, intraoperative radiation therapy, and instrumentation to the industrial and medical markets through original equipment manufacturers. Photoelectron Corporation was founded in 1989 and is based in North Billerica, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "North Billerica",
        "zipcode": "01862",
        "website": null,
        "market_cap": "Small Cap"
    },
    "PEN": {
        "short_name": "Penumbra, Inc.",
        "long_name": "Penumbra, Inc.",
        "summary": "Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Alameda",
        "zipcode": "94502",
        "website": "http://www.penumbrainc.com",
        "market_cap": "Large Cap"
    },
    "PETQ": {
        "short_name": "PetIQ, Inc.",
        "long_name": "PetIQ, Inc.",
        "summary": "PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "ID",
        "city": "Eagle",
        "zipcode": "83616",
        "website": "http://www.petiq.com",
        "market_cap": "Small Cap"
    },
    "PETS": {
        "short_name": "PetMed Express, Inc.",
        "long_name": "PetMed Express, Inc.",
        "summary": "PetMed Express, Inc., together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventative, flea and tick preventative, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, strollers, and other pet supplies. It sells its products through its Internet website; telephone contact center; and direct mail/print through brochures and postcards. PetMed Express, Inc. was founded in 1996 and is headquartered in Delray Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Delray Beach",
        "zipcode": "33445",
        "website": "http://www.1800petmeds.com",
        "market_cap": "Small Cap"
    },
    "PETV": {
        "short_name": "PETVIVO HLDGS INC",
        "long_name": "PetVivo Holdings, Inc.",
        "summary": "PetVivo Holdings, Inc., a biomedical device company, engages in the licensing and commercializing medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products includes 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55439",
        "website": "http://www.petvivo.com",
        "market_cap": "Small Cap"
    },
    "PEYE": {
        "short_name": "PRECISION OPTICS INC(MASS)",
        "long_name": "Precision Optics Corporation, Inc.",
        "summary": "Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. The company offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. It also provides components and assemblies, which are designed for industrial and military use. The company markets its products to original equipment manufacturers through medical device companies. The company was founded in 1982 and is based in Gardner, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Gardner",
        "zipcode": "01440",
        "website": "http://www.poci.com",
        "market_cap": "Small Cap"
    },
    "PFE.BA": {
        "short_name": "PFIZER INC",
        "long_name": "Pfizer Inc.",
        "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.pfizer.com",
        "market_cap": "Large Cap"
    },
    "PFE.DE": {
        "short_name": "PFIZER INC.  DL-,05",
        "long_name": "Pfizer Inc.",
        "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.pfizer.com",
        "market_cap": "Large Cap"
    },
    "PFE.F": {
        "short_name": "PFIZER INC.  DL-,05",
        "long_name": "Pfizer Inc.",
        "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.pfizer.com",
        "market_cap": "Large Cap"
    },
    "PFE.MX": {
        "short_name": "PFIZER INC",
        "long_name": "Pfizer Inc.",
        "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.pfizer.com",
        "market_cap": "Large Cap"
    },
    "PFE": {
        "short_name": "Pfizer, Inc.",
        "long_name": "Pfizer Inc.",
        "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.pfizer.com",
        "market_cap": "Large Cap"
    },
    "PFE.SN": {
        "short_name": "PFIZER INC",
        "long_name": "Pfizer Inc.",
        "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SGO",
        "market": "cl_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.pfizer.com",
        "market_cap": "Large Cap"
    },
    "PFE.ST": {
        "short_name": "Pfizer Inc.",
        "long_name": "Pfizer Inc.",
        "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "STO",
        "market": "se_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.pfizer.com",
        "market_cap": "Large Cap"
    },
    "PFE.VI": {
        "short_name": "PFIZER INC",
        "long_name": "Pfizer Inc.",
        "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.pfizer.com",
        "market_cap": "Large Cap"
    },
    "PFGBQ": {
        "short_name": "PFO GLOBAL INC",
        "long_name": "PFO Global, Inc.",
        "summary": "PFO Global, Inc., together with its subsidiaries, manufactures and sells prescription lenses, finished eyewear, and vision technologies for optometrist's marketplace worldwide. It offers SmartCalc, a proprietary software used to manufacture digital lens designs; and SmartEyewear, a business-to-business online ordering software system, which allows eye care providers to provide various information for patient's eyewear package and unique use. The company also distributes distortion free polycarbonate lenses under the Resolution brand name. Its customers include opticians and optometrists for ophthalmic lenses and complete eyewear; and prescription laboratories for lenses. The company was founded in 2008 and is headquartered in Dallas, Texas. PFO Global, Inc. is a subsidiary of Carpathian Resources Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75244",
        "website": null,
        "market_cap": "Small Cap"
    },
    "PFHO": {
        "short_name": "PACIFIC HEALTH CARE ORGANIZATIO",
        "long_name": "Pacific Health Care Organization, Inc.",
        "summary": "Pacific Health Care Organization, Inc., together with its subsidiaries, provides specialty workers' compensation managed care services for self-administered employers, insurers, third party administrators, municipalities, and others industries in the United States. The company is involved in managing health care organizations (HCOs) and medical provider networks (MPNs); and negotiating legal agreements for the implementation of workers' compensation carve-outs for California clients/employers with collective bargaining units. It also offers HCO and MPN programs; medical case management services; and ancillary services, including utilization and medical bill review, lien representation, legal support, Medicare set aside, and network access services for workers' compensation claims. The company was formerly known as Clear Air, Inc. and changed its name to Pacific Health Care Organization, Inc. in January 2001. Pacific Health Care Organization, Inc. was incorporated in 1970 and is based in Newport Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newport Beach",
        "zipcode": "92660",
        "website": "http://www.pacifichealthcareorganization.com",
        "market_cap": "Small Cap"
    },
    "PFIZ34.SA": {
        "short_name": "PFIZER      DRN",
        "long_name": "Pfizer Inc.",
        "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.pfizer.com",
        "market_cap": "Large Cap"
    },
    "PFND": {
        "short_name": "PATHFINDER CELL THERAPY INC",
        "long_name": "Pathfinder Cell Therapy, Inc.",
        "summary": "Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02138",
        "website": "http://www.pathfindercelltherapy.com",
        "market_cap": "Small Cap"
    },
    "PGEN": {
        "short_name": "Precigen, Inc.",
        "long_name": "Precigen, Inc.",
        "summary": "Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Germantown",
        "zipcode": "20876",
        "website": "http://www.precigen.com",
        "market_cap": "Small Cap"
    },
    "PGF.SG": {
        "short_name": "Protagonist Therapeutics Inc. R",
        "long_name": "Protagonist Therapeutics, Inc.",
        "summary": "Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Newark",
        "zipcode": "94560-1160",
        "website": "http://www.protagonist-inc.com",
        "market_cap": "Small Cap"
    },
    "PGNY": {
        "short_name": "Progyny, Inc.",
        "long_name": "Progyny, Inc.",
        "summary": "Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10018",
        "website": "http://www.progyny.com",
        "market_cap": "Mid Cap"
    },
    "PGUZ": {
        "short_name": "PEGASUS PHARMACEUTICALS INC",
        "long_name": "Pegasus Pharmaceuticals Inc.",
        "summary": "Pegasus Pharmaceuticals Inc. manufactures and provides an advanced ECG system for the non-invasive screening of heart pathologies. The company offers HeartVue 6S System, which is a screening tool used to diagnose heart and other cardiac diseases. It serves cardiologists, general practitioners, physicians, intensive care units, hospitals, emergency rooms, clinics, fitness facilities, sports teams, and other emergency medical facilities. Pegasus Pharmaceuticals Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Palm Beach Gardens",
        "zipcode": "33410",
        "website": "http://www.pegasusbiosciences.com",
        "market_cap": "Small Cap"
    },
    "PHAS": {
        "short_name": "PhaseBio Pharmaceuticals, Inc.",
        "long_name": "PhaseBio Pharmaceuticals, Inc.",
        "summary": "PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://phasebio.com",
        "market_cap": "Small Cap"
    },
    "PHAT": {
        "short_name": "Phathom Pharmaceuticals, Inc.",
        "long_name": "Phathom Pharmaceuticals, Inc.",
        "summary": "Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Florham Park",
        "zipcode": "07932",
        "website": "http://www.phathompharma.com",
        "market_cap": "Small Cap"
    },
    "PHCG": {
        "short_name": "PURE HARVEST CORPORATE GROUP",
        "long_name": "Pure Harvest Corporate Group, Inc.",
        "summary": "Pure Harvest Corporate Group, Inc. focuses on the acquisition and operation of licensed medical and recreational marijuana dispensaries, cultivation facilities, and production facilities. It also focuses on providing cannabis and hemp-derived health and wellness products; and applying education, research and development, and technology to various sectors. The company was formerly known as Pure Harvest Cannabis Group, Inc. and changed its name to Pure Harvest Corporate Group, Inc. in June 2020. Pure Harvest Corporate Group, Inc. was founded in 2004 and is based in Greenwood Village, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Greenwood Village",
        "zipcode": "80111",
        "website": "http://www.pureharvestgroup.com",
        "market_cap": "Small Cap"
    },
    "PHIO": {
        "short_name": "Phio Pharmaceuticals Corp.",
        "long_name": "Phio Pharmaceuticals Corp.",
        "summary": "Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that prevent cancer cells from inactivating T cells and attack the cancer. It has collaboration with AgonOx, Inc. on clinical development of novel immunotherapy drugs targeting key regulators of the immune response to cancer. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Marlborough",
        "zipcode": "01752",
        "website": "http://www.phiopharma.com",
        "market_cap": "Small Cap"
    },
    "PHMB": {
        "short_name": "PHARMACOM BIOVET INC",
        "long_name": "PharmaCom BioVet, Inc.",
        "summary": "PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States. The company focuses on developing bone marrow transplantation and other cancer treatment procedures to benefit companion animals that are diagnosed with lymphoma, other different types of cancers, and other diseases that are incurable. It has licensed a series of proprietary devices and compounds that would reduce suffering in animals with cancer. The company was formerly known as ABV Gold Inc. and changed its name to PharmaCom BioVet, Inc. in August 2008. PharmaCom BioVet, Inc. was incorporated in 1995 and is headquartered in Raleigh, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Raleigh",
        "zipcode": "27609",
        "website": null,
        "market_cap": "Small Cap"
    },
    "PHPN.F": {
        "short_name": "GALECTIN THERA.  DL-,01",
        "long_name": "Galectin Therapeutics Inc.",
        "summary": "Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "GA",
        "city": "Norcross",
        "zipcode": "30071",
        "website": "http://galectintherapeutics.com",
        "market_cap": "Small Cap"
    },
    "PHR": {
        "short_name": "Phreesia, Inc.",
        "long_name": "Phreesia, Inc.",
        "summary": "Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; appointments solution for online appointments, reminders, and referral tracking; and patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and PRO data for approximately 25 specialties; and life sciences solution to deliver targeted and clinically relevant marketing content to patients, as well as COVID-19 product offerings for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was founded in 2005 and is headquartered in Raleigh, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Raleigh",
        "zipcode": "27601",
        "website": "http://www.phreesia.com",
        "market_cap": "Mid Cap"
    },
    "PHRX": {
        "short_name": "PHARMAGEN INC",
        "long_name": "Pharmagen, Inc.",
        "summary": "Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. It offers plasma derivatives for treating serious medical conditions, such as cancer, hemophilia, rheumatoid arthritis, multiple scleroses, blood disorders, hepatitis, and HIV; and specialty products for treating respiratory, oncology, cardiovascular, and hormonal syndromes. The company also manufactures and distributes health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin. In addition, it sells traditional pharmaceuticals to its distribution customers, such as antibiotics, vaccines, and other oral and injectable pharmaceuticals; and specializes in the formulation of drugs. The company was formerly known as Sunpeaks Ventures, Inc. and changed its name to Pharmagen, Inc. in January 2013. Pharmagen, Inc. is based in Silver Spring, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Silver Spring",
        "zipcode": "20910",
        "website": "http://www.pharmageninc.com",
        "market_cap": "Small Cap"
    },
    "PI6.F": {
        "short_name": "PIERIS PHARMACEUT. DL-001",
        "long_name": "Pieris Pharmaceuticals, Inc.",
        "summary": "Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-expressing solid tumors. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02109",
        "website": "http://www.pieris.com",
        "market_cap": "Small Cap"
    },
    "PINC": {
        "short_name": "Premier, Inc.",
        "long_name": "Premier, Inc.",
        "summary": "Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates through two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and document shredding services. It is also involved in the provision of the ASCEND Collaborative service for members to receive group purchasing programs, tiers, and prices, as well as managed services; SURPASS Collaborative service; STOCKD, an e-commerce platform; and PROVIDEGX program, which identifies supply sources for drugs that are on or may be at risk of being added to the national drug shortage list, or that are vulnerable to pricing volatility, as well as direct sourcing business. The Performance Services segment offers PremierConnect for members to address existing cost and quality imperatives, enable them manage a value-based care reimbursement model, and support their regulatory reporting framework; performance improvement collaborative; and consulting and insurance services. This segment's various PremierConnect domains include PremierConnect Quality & Regulatory, PremierConnect Clinical Surveillance & Safety, PremierConnect Supply Chain & ERP, PremierConnect Operations, PremierConnect Enterprise Analytics, and PREMIERCONNECT Clinical Decision Support domains. Premier, Inc. has a collaboration to develop a same-day breast cancer diagnosis and treatment model. The company was incorporated in 2013 and is headquartered in Charlotte, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Charlotte",
        "zipcode": "28277",
        "website": "http://www.premierinc.com",
        "market_cap": "Mid Cap"
    },
    "PIRS": {
        "short_name": "Pieris Pharmaceuticals, Inc.",
        "long_name": "Pieris Pharmaceuticals, Inc.",
        "summary": "Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-expressing solid tumors. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02109",
        "website": "http://www.pieris.com",
        "market_cap": "Small Cap"
    },
    "PKANF": {
        "short_name": "SIMPLY BETTER BRANDS CORP",
        "long_name": "Simply Better Brands Corp.",
        "summary": "PureK Holdings Corp. manufactures and sells hemp based cannabidiol related products in the United States. The company offers tinctures, capsules, gummies, oils, edibles, topicals, sprays, vape pens, pet treats, and bath bombs, as well as tees, hoodies, beanies, caps, and other related products. It distributes its products through e-commerce website PureKana.com, as well as through retail stores, including larger retail chains and small independent retailers; wholesalers; and various brick and mortar retailers. The company was founded in 2017 and is headquartered in Paradise Valley, Arizona. PureK Holdings Corp. is a subsidiary of Heavenly Rx Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Paradise Valley",
        "zipcode": "85253",
        "website": "http://purekana.com",
        "market_cap": "Small Cap"
    },
    "PKI.MX": {
        "short_name": "PERKINELMER INC",
        "long_name": "PerkinElmer, Inc.",
        "summary": "PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.perkinelmer.com",
        "market_cap": "Large Cap"
    },
    "PKI": {
        "short_name": "PerkinElmer, Inc.",
        "long_name": "PerkinElmer, Inc.",
        "summary": "PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.perkinelmer.com",
        "market_cap": "Large Cap"
    },
    "PKN.F": {
        "short_name": "PERKINELMER INC.  DL 1",
        "long_name": "PerkinElmer, Inc.",
        "summary": "PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.perkinelmer.com",
        "market_cap": "Large Cap"
    },
    "PKPH": {
        "short_name": "PEAK PHARMACEUTICALS INC",
        "long_name": "Peak Pharmaceuticals, Inc.",
        "summary": "Peak Pharmaceuticals, Inc. operates as a bio\u00c2\u00adpharmaceutical and nutraceutical company in the United States. The company focuses to develop, manufacture, market, and sell medicinal products based on extracts from hemp. It is involved in the development of over-the-counter, THC\u00c2\u00adfree, hemp based products for human market for the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases. The company was formerly known as Cannabis Therapy Corporation and changed its name to Peak Pharmaceuticals, Inc. in December 2014. Peak Pharmaceuticals, Inc. was incorporated in 2007 and is based in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": "85260",
        "website": null,
        "market_cap": "Small Cap"
    },
    "PKTX": {
        "short_name": "PROTOKINETIX INC",
        "long_name": "ProtoKinetix, Incorporated",
        "summary": "ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry eye diseases. The company has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Marietta",
        "zipcode": "45750",
        "website": "http://www.protokinetix.com",
        "market_cap": "Small Cap"
    },
    "PLLWF": {
        "short_name": "POLAREAN IMAGING PLC",
        "long_name": "Polarean Imaging plc",
        "summary": "Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of polarized Xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company also develops and manufactures MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27713",
        "website": "http://www.polarean.com",
        "market_cap": "Small Cap"
    },
    "PLNHF": {
        "short_name": "PLANET 13 HOLDINGS INC",
        "long_name": "Planet 13 Holdings Inc.",
        "summary": "Planet 13 Holdings Inc., a cannabis company, cultivates, produces, distributes, and markets cannabis and cannabis-infused and related products for medical and retail cannabis markets in Nevada, the United States. It also operates dispensaries that provide cannabis, cannabis extracts, and infused products. In addition, the company provides cardholder process navigation services; individual consultations; compassionate care programs; patient education services; express services; and home delivery services. Further, it operates a coffee shop and pizzeria. The company offers its products under the Planet 13, Medizin, TRENDI, Leaf & Vine, HaHa, and Dreamland Chocolates brands. Planet 13 Holdings Inc. was incorporated in 2002 and is headquartered in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89109",
        "website": "http://www.planet13holdings.com",
        "market_cap": "Small Cap"
    },
    "PLRX": {
        "short_name": "Pliant Therapeutics, Inc.",
        "long_name": "Pliant Therapeutics, Inc.",
        "summary": "Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av\u00c3\u009f6 and av\u00c3\u009f1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective inhibitor of av\u00c3\u009f1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://pliantrx.com",
        "market_cap": "Small Cap"
    },
    "PLSE": {
        "short_name": "Pulse Biosciences, Inc",
        "long_name": "Pulse Biosciences, Inc.",
        "summary": "Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Hayward",
        "zipcode": "94545",
        "website": "http://www.pulsebiosciences.com",
        "market_cap": "Small Cap"
    },
    "PLSI": {
        "short_name": "PHOENIX LIFE SCIENCES INTL LTD",
        "long_name": "Phoenix Life Sciences International Limited",
        "summary": "Phoenix Life Sciences International Limited operates as a healthcare solutions company in the United States and internationally. The company focuses on advancing research, integrating programs, and manufacturing of products that target and treat diabetes, pain, and cancers, as well as address psychological, gastrointestinal, autoimmune, neurological, and sleep disorders. It offers oral soft gel capsules, thin film dissolvable strips, transdermal patches, sublingual oral sprays, suppositories, and topical creams. The company was formerly known as Stem Bioscience, Inc. and changed its name to Phoenix Life Sciences International Limited in May 2018. Phoenix Life Sciences International Limited was incorporated in 2009 and is headquartered in Las Vegas Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89139",
        "website": "http://www.phoenixlife.co",
        "market_cap": "Small Cap"
    },
    "PLTH.CN": {
        "short_name": "Planet13Hldgs",
        "long_name": "Planet 13 Holdings Inc.",
        "summary": "Planet 13 Holdings Inc., a cannabis company, cultivates, produces, distributes, and markets cannabis and cannabis-infused and related products for medical and retail cannabis markets in Nevada, the United States. It also operates dispensaries that provide cannabis, cannabis extracts, and infused products. In addition, the company provides cardholder process navigation services; individual consultations; compassionate care programs; patient education services; express services; and home delivery services. Further, it operates a coffee shop and pizzeria. The company offers its products under the Planet 13, Medizin, TRENDI, Leaf & Vine, HaHa, and Dreamland Chocolates brands. Planet 13 Holdings Inc. was incorporated in 2002 and is headquartered in Las Vegas, Nevada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89109",
        "website": "http://www.planet13holdings.com",
        "market_cap": "Small Cap"
    },
    "PLXP": {
        "short_name": "PLx Pharma Inc.",
        "long_name": "PLx Pharma Inc.",
        "summary": "PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Sparta",
        "zipcode": "07871",
        "website": "http://plxpharma.com",
        "market_cap": "Small Cap"
    },
    "PM8.F": {
        "short_name": "PREMIER INC.  DL-,01",
        "long_name": "Premier, Inc.",
        "summary": "Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates through two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and document shredding services. It is also involved in the provision of the ASCEND Collaborative service for members to receive group purchasing programs, tiers, and prices, as well as managed services; SURPASS Collaborative service; STOCKD, an e-commerce platform; and PROVIDEGX program, which identifies supply sources for drugs that are on or may be at risk of being added to the national drug shortage list, or that are vulnerable to pricing volatility, as well as direct sourcing business. The Performance Services segment offers PremierConnect for members to address existing cost and quality imperatives, enable them manage a value-based care reimbursement model, and support their regulatory reporting framework; performance improvement collaborative; and consulting and insurance services. This segment's various PremierConnect domains include PremierConnect Quality & Regulatory, PremierConnect Clinical Surveillance & Safety, PremierConnect Supply Chain & ERP, PremierConnect Operations, PremierConnect Enterprise Analytics, and PREMIERCONNECT Clinical Decision Support domains. Premier, Inc. has a collaboration to develop a same-day breast cancer diagnosis and treatment model. The company was incorporated in 2013 and is headquartered in Charlotte, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Charlotte",
        "zipcode": "28277",
        "website": "http://www.premierinc.com",
        "market_cap": "Mid Cap"
    },
    "PMCB": {
        "short_name": "PHARMACYTE BIOTECH INC",
        "long_name": "PharmaCyte Biotech, Inc.",
        "summary": "PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. PharmaCyte Biotech, Inc. has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and a research agreement with the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Laguna Hills",
        "zipcode": "92653",
        "website": "http://www.pharmacyte.com",
        "market_cap": "Small Cap"
    },
    "PMD": {
        "short_name": "Psychemedics Corporation",
        "long_name": "Psychemedics Corporation",
        "summary": "Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual drug use over a longer period-of-time. The company provides its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was founded in 1986 and is headquartered in Acton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Acton",
        "zipcode": "01720",
        "website": "http://www.psychemedics.com",
        "market_cap": "Small Cap"
    },
    "PMDL": {
        "short_name": "PACE MEDICAL INC",
        "long_name": "Pace Medical, Inc.",
        "summary": "Pace Medical, Inc. designs and markets cardiac pacing products for medical professions in the United States and internationally. The company offers Model 4580 MICRO-PACE, a programmable and dual-chamber temporary cardiac pacemaker for multi-mode and multi-parameter operation; Model EV4543, a single-chamber temporary cardiac pacemaker that is designed to provide acute therapeutic, prophylactic, and diagnostic pacing support; and The Bedside Model 4170, a single-chamber temporary cardiac pacemaker. It also provides REF 4800 pacing analyzer, an internally powered and software-programmable device designed for continuous operation in the acute cardiac-care environment as temporary cardiac pacemaker and a pacing analyzer; and autoclavable and single-use surgical/patient extension cables and adapters. The company was founded in 1985 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": null,
        "market_cap": "Small Cap"
    },
    "PMVP": {
        "short_name": "PMV Pharmaceuticals, Inc.",
        "long_name": "PMV Pharmaceuticals, Inc.",
        "summary": "PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranbury",
        "zipcode": "08512",
        "website": "http://www.pmvpharma.com",
        "market_cap": "Small Cap"
    },
    "PNC.F": {
        "short_name": "GREAT ELM GROUP  NEW-,001",
        "long_name": "Great Elm Group, Inc.",
        "summary": "Great Elm Group, Inc. operates in durable medical equipment, investment management, and real estate businesses. It distributes respiratory care equipment, including positive air pressure equipment and supplies, ventilators and oxygen equipment, and replacement parts, as well as provides sleep study services; and rents medical equipment. The company also offers investment management services. In addition, it engages in the real estate activities. The company was formerly known as Great Elm Capital Group, Inc. and changed its name to Great Elm Group, Inc. in December 2020. Great Elm Group, Inc. was founded in 1994 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02453",
        "website": "http://www.greatelmgroup.com",
        "market_cap": "Small Cap"
    },
    "PNPL": {
        "short_name": "PINEAPPLE EXPRESS INC",
        "long_name": "Pineapple, Inc.",
        "summary": "Pineapple, Inc. provides consulting, investing in, expanding, and/or rebranding businesses in the cannabis industry. It provides capital to its canna-business clients; leases real properties to canna-businesses; and provides consulting and technologies to develop, enhance, or expand existing and newly formed infrastructures. The company also intends to create a branded chain of cannabis retail stores under the \u00c2\u0091Pineapple Express' name. In addition, it operates a branded clothing line and own the rights to sell apparel, such as T-shirts, hats, beanies, pants, shorts, baseball jerseys, jackets, sweatshirts, polo shirts, sweat pants, and other attire displaying the THC trademarked name and logo, as well as operates a Website, THC.com. Pineapple, Inc. was incorporated in 1983 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90025",
        "website": "http://pineappleinc.com",
        "market_cap": "Small Cap"
    },
    "PNTG": {
        "short_name": "The Pennant Group, Inc.",
        "long_name": "The Pennant Group, Inc.",
        "summary": "The Pennant Group, Inc. provides healthcare services in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, and meals, as well as housekeeping and assistance in the activities of daily living to seniors, who are independent or who require some support. As of February 24, 2021, the company operated 80 home health and hospice agencies; and 54 senior living communities. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "ID",
        "city": "Eagle",
        "zipcode": "83616",
        "website": "http://pennantgroup.com",
        "market_cap": "Small Cap"
    },
    "POAI": {
        "short_name": "Predictive Oncology Inc.",
        "long_name": "Predictive Oncology Inc.",
        "summary": "Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Eagan",
        "zipcode": "55121",
        "website": "http://www.predictive-oncology.com",
        "market_cap": "Small Cap"
    },
    "PODD": {
        "short_name": "Insulet Corporation",
        "long_name": "Insulet Corporation",
        "summary": "Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Acton",
        "zipcode": "01720",
        "website": "http://www.insulet.com",
        "market_cap": "Large Cap"
    },
    "POLX.L": {
        "short_name": "POLAREAN IMAGING PLC ORD GBP0.0",
        "long_name": "Polarean Imaging plc",
        "summary": "Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of polarized Xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United States",
        "state": "NC",
        "city": "Durham",
        "zipcode": "27713",
        "website": "http://www.polarean.com",
        "market_cap": null
    },
    "POSC": {
        "short_name": "POSITRON CORP",
        "long_name": "Positron Corporation",
        "summary": "Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers PET molecular imaging systems, clinical and support services, automated radiopharmaceutical systems, and radiopharmaceuticals and radioisotope processing and production. The company's Attrius system based on cardiac PET technology enables healthcare providers to more accurately diagnose heart disease, improve patient outcomes, and practice cost effective medicine. It is also focused on increasing Sr-82 supply through the processing of proton irradiated target material from domestic and foreign suppliers; and recycling Sr-82 from spent generators. Positron Corporation was founded in 1983 and is based in Westmont, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Westmont",
        "zipcode": "60559",
        "website": "http://www.positron.com",
        "market_cap": "Small Cap"
    },
    "POTN": {
        "short_name": "POTNETWORK HOLDINGS INCOR",
        "long_name": "PotNetwork Holdings, Inc.",
        "summary": "PotNetwork Holdings, Inc., through its subsidiaries, engages in the development and sale of hemp-derived CBD oil products. The company also publishes PotNetwork magazine. It sells its products through distributors and resellers, as well as through its Website. The company is based in Fort Lauderdale, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Lauderdale",
        "zipcode": "33312",
        "website": "http://www.potnetworkholding.com",
        "market_cap": "Small Cap"
    },
    "PPD": {
        "short_name": "PPD, Inc.",
        "long_name": "PPD, Inc.",
        "summary": "PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Wilmington",
        "zipcode": "28401-3331",
        "website": "http://www.ppd.com",
        "market_cap": "Large Cap"
    },
    "PPII": {
        "short_name": "COENZYME A INC",
        "long_name": "Coenzyme-A Inc.",
        "summary": "Coenzyme-A Inc. formulates and manufactures nutraceutical supplements, and skin and hair care products in the United States and internationally. It offers energy drinks and skin rejuvinating serums, as well as fat management, skin treatment, fatty acid and cholesterol metabolism, and skin rejuvenating products, as well as nutritional formulas for the support of bone, joint, ligament, cartilage, and connective tissue functions. The company also provides sports-specific, women's, and men's formulas, as well as wellness, energy, and body sculpting products. Coenzyme-A Inc. was founded in 1998 and is based in Lynnwood, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Lynnwood",
        "zipcode": "98087",
        "website": null,
        "market_cap": "Small Cap"
    },
    "PPJE": {
        "short_name": "PPJ HEALTHCARE ENTERPRISES INC",
        "long_name": "PPJ Healthcare Enterprises, Inc.",
        "summary": "PPJ Healthcare Enterprises, Inc., through its subsidiaries, provides automated healthcare reimbursement cycle, online health information digital-systems, and practice information management digital-system software to health care providers and general businesses worldwide. The company offers the Automated Biller, a medical billing system that allows physicians to bill their medical insurance claims at the point of service without data entry, coding, or billing personnel. It also provides billing, specialty medical billing, collection, and workers comp lien collection services for health care providers in the areas of pain management, anesthesia and surgery centers practices, and various specialties of medicine. The company was formerly known as PPJ Enterprise and changed its name to PPJ Healthcare Enterprises, Inc. in October 2014. PPJ Healthcare Enterprises, Inc. was founded in 2000 and is headquartered in Reno, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Reno",
        "zipcode": "89502",
        "website": "http://www.ppjenterprise.com",
        "market_cap": "Small Cap"
    },
    "PPMD": {
        "short_name": "PROTIDE PHARMACEUTICALS  INC",
        "long_name": "Protide Pharmaceuticals, Inc.",
        "summary": "Protide Pharmaceuticals, Inc. discovers, develops, and commercializes technologies and processes in the areas of clinical cell therapy, regenerative medicine, transfusion medicine, cell engineering, and transplantation in the United States and internationally. It offers serum reducers, cell culture and processing products, stem cell cryopreservatives, and stem cell and regenerative research products. The company is based in Lake Zurich, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Lake Zurich",
        "zipcode": "60047",
        "website": "http://www.protidepharma.com",
        "market_cap": "Small Cap"
    },
    "PPRG": {
        "short_name": "PATIENT PORTAL TECHNOLOGIES INC",
        "long_name": "Patient Portal Technologies, Inc.",
        "summary": "Patient Portal Technologies, Inc. provides patient relationship management solutions for healthcare facilities, patients and families, and medical personnel. It offers HEALTHCAST, a multi-channel, television network for the delivery of customized information and education to patients, visitors, and staff; MEDEX PRESCRIPTION DELIVERY, a free prescription medication delivery solution; and PHONE & TV RENTAL, an interactive communication center, and billing and collection platform. The company also provides TELCIERGE INSTANT RESPONSE that puts patients in control of non-medical needs through a single phone call; QUICK PULSE SURVEYS that provide feedback for improved operations; and MEDCLIPS, which provide condition specific video clips for internal or remote viewing before or after hospital stay. Patient Portal Technologies, Inc. is based in Baldwinsville, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Baldwinsville",
        "zipcode": "13027",
        "website": "http://www.patientportal.com",
        "market_cap": "Small Cap"
    },
    "PQIA.F": {
        "short_name": "RADNET INC.  DL-,01",
        "long_name": "RadNet, Inc.",
        "summary": "RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90025",
        "website": "http://www.radnet.com",
        "market_cap": "Small Cap"
    },
    "PQM.F": {
        "short_name": "PETMED EXPRES.INC DL-,001",
        "long_name": "PetMed Express, Inc.",
        "summary": "PetMed Express, Inc., together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventative, flea and tick preventative, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, strollers, and other pet supplies. It sells its products through its Internet website; telephone contact center; and direct mail/print through brochures and postcards. PetMed Express, Inc. was founded in 1996 and is headquartered in Delray Beach, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Delray Beach",
        "zipcode": "33445",
        "website": "http://www.1800petmeds.com",
        "market_cap": "Small Cap"
    },
    "PRAH": {
        "short_name": "PRA Health Sciences, Inc.",
        "long_name": "PRA Health Sciences, Inc.",
        "summary": "PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Raleigh",
        "zipcode": "27612",
        "website": "http://prahs.com",
        "market_cap": "Large Cap"
    },
    "PRAX": {
        "short_name": "Praxis Precision Medicines, Inc",
        "long_name": "Praxis Precision Medicines, Inc.",
        "summary": "Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.praxismedicines.com",
        "market_cap": "Small Cap"
    },
    "PRF0.F": {
        "short_name": "MODIVCARE INC. DL-,001",
        "long_name": "ModivCare Inc.",
        "summary": "ModivCare Inc., a technology-enabled healthcare services company, provides a suite of integrated supportive care solutions for public and private payors and patients. It offers non-emergency medical transportation services for Medicaid or Medicare eligible members, whose limited mobility or financial resources hinder their ability to access necessary healthcare and social services. The company also provides in-home and on-site care optimization services, including comprehensive health assessments through a network of community-based clinicians and a fleet of mobile health clinics. The company was formerly known as The Providence Service Corporation and changed its name to ModivCare Inc. in January 2021. The company was founded in 1996 and is headquartered in Denver, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80237",
        "website": "http://www.modivcare.com",
        "market_cap": "Mid Cap"
    },
    "PRLD": {
        "short_name": "Prelude Therapeutics Incorporat",
        "long_name": "Prelude Therapeutics Incorporated",
        "summary": "Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "DE",
        "city": "Wilmington",
        "zipcode": "19803",
        "website": "http://www.preludetx.com",
        "market_cap": "Small Cap"
    },
    "PROG": {
        "short_name": "Progenity, Inc.",
        "long_name": "Progenity, Inc.",
        "summary": "Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.progenity.com",
        "market_cap": "Small Cap"
    },
    "PROT": {
        "short_name": "PROTEONOMIX INC",
        "long_name": "Proteonomix, Inc.",
        "summary": "Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Hawthorne",
        "zipcode": "07506",
        "website": "http://www.proteonomix.com",
        "market_cap": "Small Cap"
    },
    "PRPH": {
        "short_name": "ProPhase Labs, Inc.",
        "long_name": "ProPhase Labs, Inc.",
        "summary": "ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Garden City, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Garden City",
        "zipcode": "11530",
        "website": "http://www.prophaselabs.com",
        "market_cap": "Small Cap"
    },
    "PRPO": {
        "short_name": "Precipio, Inc.",
        "long_name": "Precipio, Inc.",
        "summary": "Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06511",
        "website": "http://www.precipiodx.com",
        "market_cap": "Small Cap"
    },
    "PRTC.L": {
        "short_name": "PURETECH HEALTH PLC ORD 1P",
        "long_name": "PureTech Health plc",
        "summary": "PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.puretechhealth.com",
        "market_cap": null
    },
    "PRTC": {
        "short_name": "PureTech Health plc",
        "long_name": "PureTech Health plc",
        "summary": "PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.puretechhealth.com",
        "market_cap": "Small Cap"
    },
    "PRTK": {
        "short_name": "Paratek Pharmaceuticals, Inc.",
        "long_name": "Paratek Pharmaceuticals, Inc.",
        "summary": "Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://paratekpharma.com",
        "market_cap": "Small Cap"
    },
    "PRTX": {
        "short_name": "PROTALEX INC",
        "long_name": "Protalex, Inc.",
        "summary": "Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Other",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Florham Park",
        "zipcode": "07932",
        "website": "http://www.protalex.com",
        "market_cap": "Small Cap"
    },
    "PRVA": {
        "short_name": "Privia Health Group, Inc.",
        "long_name": "Privia Health Group, Inc.",
        "summary": "Privia Health Group, Inc. operates as a physician practice management and population health technology company in the United States. The company comprises regional medical groups, accountable care organizations, and specialty verticals. It offers technology and population health tools to enhance independent providers' workflows; management service organization that enables providers to reduce administrative work focus on their patients; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; physician-led accountable care organization, which engages patients, reduces inappropriate utilization, and enhances coordination and patient quality metrics to drive value-based care and transform the healthcare delivery system; and network for purchasers and payers. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. operates as a subsidiary of Brighton Health Group Holdings, LLC.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Arlington",
        "zipcode": "22203",
        "website": "http://www.priviahealth.com",
        "market_cap": "Mid Cap"
    },
    "PRVB": {
        "short_name": "Provention Bio, Inc.",
        "long_name": "Provention Bio, Inc.",
        "summary": "Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. The company was incorporated in 2016 and is headquartered in Red Bank, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Red Bank",
        "zipcode": "07701",
        "website": "http://www.proventionbio.com",
        "market_cap": "Small Cap"
    },
    "PS1.F": {
        "short_name": "COMPUTER PROGRAMS + SYS",
        "long_name": "Computer Programs and Systems, Inc.",
        "summary": "Computer Programs and Systems, Inc. provides healthcare information technology solutions and services in the United States and the Caribbean nation of St. Maarten. Its software systems include patient management software that enables a hospital to identify a patient at various points in the healthcare delivery system, as well as to collect and maintain patient information throughout the process of patient care; and financial accounting software, which offers business office applications to track and coordinate information needed for managerial decision-making. The company also provides clinical software that automates record keeping and reporting for various clinical functions, including laboratory, radiology, physical therapy, respiratory care, and pharmacy; patient care applications; and enterprise applications that support its products for use in various areas of the hospital. In addition, it offers Centriq, an intuitive user interface to centralize data from various care areas that provide the end user with a tool to view past and present patient information. Further, the company provides software solutions that promote data-driven clinical and financial outcomes for customers in the post-acute care industry; software application support, hardware maintenance, and education and related services; post-acute care support and maintenance services; revenue cycle management products and services, consulting and business management services, and managed information technology services; patient engagement and empowerment technology solutions; and system implementation and training services. It serves community hospitals and physician clinics, skilled nursing and assisted living facilities, and small specialty hospitals. Computer Programs and Systems, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "AL",
        "city": "Mobile",
        "zipcode": "36695",
        "website": "http://www.cpsi.com",
        "market_cap": "Small Cap"
    },
    "PSIQ": {
        "short_name": "PROFILE SOLUTIONS INC",
        "long_name": "Profile Solutions, Inc.",
        "summary": "Profile Solutions, Inc., through its subsidiary, Elite Products International, Inc., manufactures and distributes cannabinoid hemp extracts in the form of edibles, creams, oils, and salves. It offers edibles, such as candies, gummies, cookies, crystal pops, honey and multi-vitamins, oils, tinctures, vapes, creams, and salves, as well as a line of creams and salves for house pets. The company is headquartered in Sunrise, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Sunrise",
        "zipcode": "33351",
        "website": "http://www.profilesolutionsinc.com",
        "market_cap": "Small Cap"
    },
    "PSNL": {
        "short_name": "Personalis, Inc.",
        "long_name": "Personalis, Inc.",
        "summary": "Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://www.personalis.com",
        "market_cap": "Small Cap"
    },
    "PSTV": {
        "short_name": "PLUS THERAPEUTICS, Inc.",
        "long_name": "Plus Therapeutics, Inc.",
        "summary": "Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78756",
        "website": "http://www.plustherapeutics.com",
        "market_cap": "Small Cap"
    },
    "PSTX": {
        "short_name": "Poseida Therapeutics, Inc.",
        "long_name": "Poseida Therapeutics, Inc.",
        "summary": "Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.poseida.com",
        "market_cap": "Small Cap"
    },
    "PSYB.F": {
        "short_name": "PSYBIO THERAP.  (SUB.VT.)",
        "long_name": "PsyBio Therapeutics Corp.",
        "summary": "PsyBio Therapeutics Corp., a biotechnology company, develops formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders. It also engages in the research and development of naturally occurring tryptamines found in varieties of mushrooms, other tryptamines, and phenethylamines; and new molecular structures that do not occur in nature, as well as have therapeutics properties. PsyBio Therapeutics Corp. is headquartered in Coconut Creek, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Coconut Creek",
        "zipcode": "33073",
        "website": "http://www.psybiolife.com",
        "market_cap": "Small Cap"
    },
    "PSYB.V": {
        "short_name": "PSYBIO THERAPEUTICS CORP",
        "long_name": "PsyBio Therapeutics Corp.",
        "summary": "PsyBio Therapeutics Corp., a biotechnology company, develops formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders. It also engages in the research and development of naturally occurring tryptamines found in varieties of mushrooms, other tryptamines, and phenethylamines; and new molecular structures that do not occur in nature, as well as have therapeutics properties. PsyBio Therapeutics Corp. is headquartered in Coconut Creek, Florida.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": "FL",
        "city": "Coconut Creek",
        "zipcode": "33073",
        "website": "http://www.psybiolife.com",
        "market_cap": "Small Cap"
    },
    "PSYBF": {
        "short_name": "PSYBIO THERAPEUTICS CORP",
        "long_name": "PsyBio Therapeutics Corp.",
        "summary": "PsyBio Therapeutics Corp., a biotechnology company, develops formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders. It also engages in the research and development of naturally occurring tryptamines found in varieties of mushrooms, other tryptamines, and phenethylamines; and new molecular structures that do not occur in nature, as well as have therapeutics properties. PsyBio Therapeutics Corp. is headquartered in Coconut Creek, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Coconut Creek",
        "zipcode": "33073",
        "website": "http://www.psybiolife.com",
        "market_cap": "Small Cap"
    },
    "PTCHF": {
        "short_name": "PURETECH HEALTH PLC",
        "long_name": "PureTech Health plc",
        "summary": "PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.puretechhealth.com",
        "market_cap": "Small Cap"
    },
    "PTCT": {
        "short_name": "PTC Therapeutics, Inc.",
        "long_name": "PTC Therapeutics, Inc.",
        "summary": "PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "South Plainfield",
        "zipcode": "07080",
        "website": "http://www.ptcbio.com",
        "market_cap": "Mid Cap"
    },
    "PTE": {
        "short_name": "PolarityTE, Inc.",
        "long_name": "PolarityTE, Inc.",
        "summary": "PolarityTE, Inc., a biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates through two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and OsteoTE. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84104",
        "website": "http://www.polarityte.com",
        "market_cap": "Small Cap"
    },
    "PTGX": {
        "short_name": "Protagonist Therapeutics, Inc.",
        "long_name": "Protagonist Therapeutics, Inc.",
        "summary": "Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newark",
        "zipcode": "94560-1160",
        "website": "http://www.protagonist-inc.com",
        "market_cap": "Small Cap"
    },
    "PTLF": {
        "short_name": "PETLIFE PHARMACEUTICALS INC",
        "long_name": "Petlife Pharmaceuticals, Inc.",
        "summary": "Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90046",
        "website": null,
        "market_cap": "Small Cap"
    },
    "PTN": {
        "short_name": "Palatin Technologies, Inc.",
        "long_name": "Palatin Technologies, Inc.",
        "summary": "Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranbury",
        "zipcode": "08512",
        "website": "http://www.palatin.com",
        "market_cap": "Small Cap"
    },
    "PTNA.F": {
        "short_name": "PALATIN TECHS  DL-,01",
        "long_name": "Palatin Technologies, Inc.",
        "summary": "Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranbury",
        "zipcode": "08512",
        "website": "http://www.palatin.com",
        "market_cap": "Small Cap"
    },
    "PTPI": {
        "short_name": "Petros Pharmaceuticals, Inc.",
        "long_name": "Petros Pharmaceuticals, Inc.",
        "summary": "Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.petrospharma.com",
        "market_cap": "Small Cap"
    },
    "PTQ.V": {
        "short_name": "PROTECH HOME MEDICAL CORP",
        "long_name": "Protech Home Medical Corp.",
        "summary": "Protech Home Medical Corp. provides in-home monitoring equipment, supplies, and services for patients in the United States. It offers daily and ambulatory aides; power mobility equipment; BiPAP and CPAP machines, oxygen concentrators, and ventilators; oxygen therapy; sleep apnea and PAP treatment equipment; disease management services; and home ventilator equipment, as well as rents respiratory equipment. The company was formerly known as Patient Home Monitoring Corp. and changed its name to Protech Home Medical Corp. in April 2018. Protech Home Medical Corp. was incorporated in 1993 and is headquartered in Wilder, Kentucky.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": "KY",
        "city": "Wilder",
        "zipcode": "41076",
        "website": "http://www.protechhomemedical.com",
        "market_cap": "Small Cap"
    },
    "PTQQF": {
        "short_name": "PROTECH HOME MEDICAL CORP",
        "long_name": "Protech Home Medical Corp.",
        "summary": "Protech Home Medical Corp. provides in-home monitoring equipment, supplies, and services for patients in the United States. It offers daily and ambulatory aides; power mobility equipment; BiPAP and CPAP machines, oxygen concentrators, and ventilators; oxygen therapy; sleep apnea and PAP treatment equipment; disease management services; and home ventilator equipment, as well as rents respiratory equipment. The company was formerly known as Patient Home Monitoring Corp. and changed its name to Protech Home Medical Corp. in April 2018. Protech Home Medical Corp. was incorporated in 1993 and is headquartered in Wilder, Kentucky.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "KY",
        "city": "Wilder",
        "zipcode": "41076",
        "website": "http://www.protechhomemedical.com",
        "market_cap": "Small Cap"
    },
    "PULM": {
        "short_name": "Pulmatrix, Inc.",
        "long_name": "Pulmatrix, Inc.",
        "summary": "Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.pulmatrix.com",
        "market_cap": "Small Cap"
    },
    "PUMD": {
        "short_name": "PROUROCARE MEDICAL INC",
        "long_name": "ProUroCare Medical Inc.",
        "summary": "ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Appliances & Equipment",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Eden Prairie",
        "zipcode": "55416",
        "website": "http://www.prourocare.com",
        "market_cap": "Small Cap"
    },
    "PV3B.F": {
        "short_name": "EYEPOINT PHARMAC.  DL-,01",
        "long_name": "EyePoint Pharmaceuticals, Inc.",
        "summary": "EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://eyepointpharma.com",
        "market_cap": "Small Cap"
    },
    "PVCT": {
        "short_name": "PROVECTUS BIOPHARMACEUTICALS IN",
        "long_name": "Provectus Biopharmaceuticals, Inc.",
        "summary": "Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal disodium (cGMP RBD) for the treatment of adult solid tumor cancers, such as head and neck, breast, pancreatic, liver, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; and multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Knoxville",
        "zipcode": "37932",
        "website": "http://www.provectusbio.com",
        "market_cap": "Small Cap"
    },
    "PX91.F": {
        "short_name": "CASSAVA SCIENCES  DL-,001",
        "long_name": "Cassava Sciences, Inc.",
        "summary": "Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78731",
        "website": "http://www.cassavasciences.com",
        "market_cap": "Small Cap"
    },
    "PXY.SG": {
        "short_name": "Provectus Biopharmaceutic.Inc.R",
        "long_name": "Provectus Biopharmaceuticals, Inc.",
        "summary": "Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal disodium (cGMP RBD) for the treatment of adult solid tumor cancers, such as head and neck, breast, pancreatic, liver, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; and multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "TN",
        "city": "Knoxville",
        "zipcode": "37932",
        "website": "http://www.provectusbio.com",
        "market_cap": "Small Cap"
    },
    "PZOO": {
        "short_name": "PAZOO INC",
        "long_name": "Pazoo, Inc.",
        "summary": "Pazoo, Inc. operates as a health and wellness company. It offers laboratory testing services for marijuana. Pazoo, Inc.was formerly known as IUCSS, Inc. and changed its name to Pazoo, Inc. in May 2011. The company was founded in 2010 and is headquartered in East Hanover, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "East Hanover",
        "zipcode": "07936",
        "website": "http://www.pazoo.com",
        "market_cap": "Small Cap"
    },
    "PZRXQ": {
        "short_name": "PHASERX INC",
        "long_name": "PhaseRx, Inc.",
        "summary": "PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98119",
        "website": null,
        "market_cap": "Small Cap"
    },
    "Q1UE34.SA": {
        "short_name": "QUEST DIAGNODRN",
        "long_name": "Quest Diagnostics Incorporated",
        "summary": "Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NJ",
        "city": "Secaucus",
        "zipcode": "07094",
        "website": "http://www.questdiagnostics.com",
        "market_cap": "Large Cap"
    },
    "QBIO": {
        "short_name": "Q BIOMED INC",
        "long_name": "Q BioMed Inc.",
        "summary": "Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research for the development of novel Covid-19 therapeutics. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10017",
        "website": "http://www.qbiomed.com",
        "market_cap": "Small Cap"
    },
    "QDEL.MX": {
        "short_name": "QUIDEL CORP",
        "long_name": "Quidel Corporation",
        "summary": "Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.quidel.com",
        "market_cap": "Mid Cap"
    },
    "QDEL": {
        "short_name": "Quidel Corporation",
        "long_name": "Quidel Corporation",
        "summary": "Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.quidel.com",
        "market_cap": "Mid Cap"
    },
    "QDI.DE": {
        "short_name": "QUEST DIAGNOSTICS  DL-,01",
        "long_name": "Quest Diagnostics Incorporated",
        "summary": "Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "NJ",
        "city": "Secaucus",
        "zipcode": "07094",
        "website": "http://www.questdiagnostics.com",
        "market_cap": "Large Cap"
    },
    "QDI.F": {
        "short_name": "QUEST DIAGNOSTICS  DL-,01",
        "long_name": "Quest Diagnostics Incorporated",
        "summary": "Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Secaucus",
        "zipcode": "07094",
        "website": "http://www.questdiagnostics.com",
        "market_cap": "Large Cap"
    },
    "QEBR": {
        "short_name": "VIRTUAL MEDICAL INTERNATIONAL I",
        "long_name": "Virtual Medical International, Inc.",
        "summary": "Virtual Medical International, Inc. operates as a health wellness company in the hemp-derived CBD sector. It focuses on cultivating, harvesting, and packaging cannabis. The company provides its products under the brand name Amsterdam Caf\u00c3\u00a9: Welcome to Your Whole Health. It sells its products through company-owned retail stores and franchise stores, as well as through online. The company is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89103",
        "website": "http://www.buyamsterdamcafe.com",
        "market_cap": "Small Cap"
    },
    "QEN.F": {
        "short_name": "CENTENE CORP.  DL-,001",
        "long_name": "Centene Corporation",
        "summary": "Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MO",
        "city": "St. Louis",
        "zipcode": "63105",
        "website": "http://www.centene.com",
        "market_cap": "Large Cap"
    },
    "QL1.F": {
        "short_name": "QUIDEL CORP.  DL-,001",
        "long_name": "Quidel Corporation",
        "summary": "Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.quidel.com",
        "market_cap": "Mid Cap"
    },
    "QLGN": {
        "short_name": "Qualigen Therapeutics, Inc.",
        "long_name": "Qualigen Therapeutics, Inc.",
        "summary": "Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92011",
        "website": "http://www.qualigeninc.com",
        "market_cap": "Small Cap"
    },
    "QMDT": {
        "short_name": "QUICK-MED TECHNOLOGIES INC",
        "long_name": "Quick-Med Technologies, Inc.",
        "summary": "Quick-Med Technologies, Inc., a life sciences company, focuses on developing and commercializing proprietary broad-based technologies in medical and consumer healthcare markets. It specializes in the research and development of biomedical products and devices for antibacterial applications. The company's core technologies include Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a family of advanced polymers with antimicrobial, hemostatic, and other properties for use in a range of applications; Stay Fresh, a chemical formulation for textiles with a durable antimicrobial agent effective against an array of bacteria; and MultiStat, a family of advanced patented methods and compounds effective in skin therapy applications. It serves government agencies; and healthcare and medical, apparel and textile, and personal care companies. The company was founded in 1997 and is headquartered in Gainesville, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Gainesville",
        "zipcode": "32601",
        "website": "http://www.quickmedtech.com",
        "market_cap": "Small Cap"
    },
    "QRON": {
        "short_name": "QRONS INC",
        "long_name": "Qrons Inc.",
        "summary": "Qrons Inc., a biotechnology company, develops biotech products, treatments, and technologies that to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was incorporated in 2016 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10280",
        "website": "http://qrons.com",
        "market_cap": "Small Cap"
    },
    "QSAM": {
        "short_name": "QSAM BIOSCIENCES INC",
        "long_name": "QSAM Biosciences, Inc.",
        "summary": "QSAM Biosciences, Inc., together with its subsidiary, engages in the manufacture and sale of compost and engineered soils from waste resources in the United States. Its products are used in the agriculture, horticulture, construction, landscape, site restoration, sod and turf, Silviculture and land reclamation, and infrastructure sectors. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78759",
        "website": "http://www.q2earth.com",
        "market_cap": "Small Cap"
    },
    "QSOA.F": {
        "short_name": "SURFACE ONCOLOGY DL-,0001",
        "long_name": "Surface Oncology, Inc.",
        "summary": "Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.surfaceoncology.com",
        "market_cap": "Small Cap"
    },
    "QTRX": {
        "short_name": "Quanterix Corporation",
        "long_name": "Quanterix Corporation",
        "summary": "Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Billerica",
        "zipcode": "01821",
        "website": "http://www.quanterix.com",
        "market_cap": "Mid Cap"
    },
    "QTS.DE": {
        "short_name": "IQVIA HLDGS  DL-,01",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CT",
        "city": "Danbury",
        "zipcode": "06810",
        "website": "http://www.iqvia.com",
        "market_cap": "Large Cap"
    },
    "QTS.F": {
        "short_name": "IQVIA HLDGS  DL-,01",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CT",
        "city": "Danbury",
        "zipcode": "06810",
        "website": "http://www.iqvia.com",
        "market_cap": "Large Cap"
    },
    "QTXB": {
        "short_name": "QUANTRIX BIOMEDICAL CORPORATION",
        "long_name": "QuantRx Biomedical Corporation",
        "summary": "QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, which is available as a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad, for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. The company was incorporated in 1986 and is based in Tualatin, Oregon.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OR",
        "city": "Tualatin",
        "zipcode": "97062",
        "website": null,
        "market_cap": "Small Cap"
    },
    "QY1.F": {
        "short_name": "NEXTGEN HEALTHC.  DL-,01",
        "long_name": "NextGen Healthcare, Inc.",
        "summary": "NextGen Healthcare, Inc. provides ambulatory-focused healthcare software and services solutions in the United States. The company offers NextGen Enterprise electronic health record (EHR), which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools. Its products also comprise NextGen Enterprise PM, a practice management (PM) solution; NextGen Office, a cloud-based EHR and PM solution; NextGen Mobile; and NextGen Electronic Healthcare Transactions. In addition, it provides population health solutions, such as NextGen Population Health Analytics, NextGen Population Health Patient Care Management, and NextGen Population Health Performance Management; and patient engagement solutions comprising NextGen Patient Portal, NextGen Self Scheduling, NextGen Patient Pay, and NextGen Virtual Visits solutions. Further, the company offers NextGen Connect Integration Engine, NextGen Health Data Hub, and NextGen Share interoperability solutions; managed services, including NextGen Managed Cloud and NextGen Revenue Cycle Management Services; professional services; and client service and support. It serves managed service organizations, independent physician associations, accountable care organizations, ambulatory care centers, and community health centers through a sales force and reseller channel. The company was formerly known as Quality Systems, Inc. and changed its name to NextGen Healthcare, Inc. in September 2018. NextGen Healthcare, Inc. was founded in 1974 and is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92612",
        "website": "http://www.nextgen.com",
        "market_cap": "Small Cap"
    },
    "QYBX": {
        "short_name": "QIAN YUAN BAIXING INC",
        "long_name": "Qian Yuan Baixing, Inc.",
        "summary": "Qian Yuan Baixing, Inc. focuses on the medical equipment diagnostic and biotech business. The company was formerly known as MDCorp. and changed its name to Qian Yuan Baixing, Inc. in May 2018. Qian Yuan Baixing, Inc. was founded in 2005 and is based in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98101",
        "website": null,
        "market_cap": "Small Cap"
    },
    "R1MD34.SA": {
        "short_name": "RESMED INC  DRN",
        "long_name": "ResMed Inc.",
        "summary": "ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.resmed.com",
        "market_cap": "Large Cap"
    },
    "R3X1.F": {
        "short_name": "OCUPHIRE PHARMA DL-,0001",
        "long_name": "Ocuphire Pharma, Inc.",
        "summary": "Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MI",
        "city": "Farmington Hills",
        "zipcode": "48335",
        "website": "http://www.ocuphire.com",
        "market_cap": "Small Cap"
    },
    "R5X.F": {
        "short_name": "ACELRX PHARMACEUT. DL-,01",
        "long_name": "AcelRx Pharmaceuticals, Inc.",
        "summary": "AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.acelrx.com",
        "market_cap": "Small Cap"
    },
    "R9U2.F": {
        "short_name": "GREEN THUMB INDS",
        "long_name": "Green Thumb Industries Inc.",
        "summary": "Green Thumb Industries Inc. manufactures, distributes, and sells various cannabis products for medical and adult-use in the United States. It offers cannabis flower; and processed and packaged products, including concentrates, edibles, and topical and other cannabis products under the Rythm, Dogwalkers, The Feel Collection, incredibles, Dr. Solomon's, Beboe, and other brands. The company distributes its products primarily to third-party retail stores, as well as sells finished products directly to consumers in its own retail stores. As of March 25, 2021, it owned and operated 55 retail stores in the United States. The company was founded in 2014 and is headquartered in Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.gtigrows.com",
        "market_cap": "Mid Cap"
    },
    "RAD": {
        "short_name": "Rite Aid Corporation",
        "long_name": "Rite Aid Corporation",
        "summary": "Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment sells prescription drugs and an assortment of other merchandise, including over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, pet care, and other every day and convenience products, as well as brand and generic prescription drugs. It also operates retail clinics that provide treatment for common conditions; and provides preventative services. In addition, this segment offers healthcare coaching and disease management services. The Pharmacy Services segment provides integrated suite of pharmacy benefit management (PBM) offerings, including technology solutions, mail delivery services, specialty pharmacy, network and rebate administration, claims adjudication, and pharmacy discount programs, as well as drug benefits under the federal government's Medicare Part D program and insurance offerings for individuals and groups. This segment serves health plans, commercial employers, labor groups, and state and local governments. As of April 28, 2021, the company operated approximately 2,500 retail pharmacy locations in 17 states. Rite Aid Corporation was founded in 1962 and is headquartered in Camp Hill, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Camp Hill",
        "zipcode": "17011",
        "website": "http://www.riteaid.com",
        "market_cap": "Small Cap"
    },
    "RAFA": {
        "short_name": "RAFARMA PHARMACEUTICALS INC",
        "long_name": "Rafarma Pharmaceuticals, Inc.",
        "summary": "Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-\u00c3\u009f structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Sandy",
        "zipcode": "84070",
        "website": "http://rafarma.si",
        "market_cap": "Small Cap"
    },
    "RAH.SG": {
        "short_name": "Recro Pharma Inc. Registered Sh",
        "long_name": "Recro Pharma, Inc.",
        "summary": "Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.recrogainesville.com",
        "market_cap": "Small Cap"
    },
    "RAIN": {
        "short_name": "Rain Therapeutics Inc.",
        "long_name": "Rain Therapeutics Inc.",
        "summary": "Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newark",
        "zipcode": "94560",
        "website": "http://www.rainthera.com",
        "market_cap": "Small Cap"
    },
    "RAPT": {
        "short_name": "RAPT Therapeutics, Inc.",
        "long_name": "RAPT Therapeutics, Inc.",
        "summary": "RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.rapt.com",
        "market_cap": "Small Cap"
    },
    "RARE.MX": {
        "short_name": "ULTRAGENYX PHARMACEUTICAL INC",
        "long_name": "Ultragenyx Pharmaceutical Inc.",
        "summary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Novato",
        "zipcode": "94949",
        "website": "http://www.ultragenyx.com",
        "market_cap": "Mid Cap"
    },
    "RARE": {
        "short_name": "Ultragenyx Pharmaceutical Inc.",
        "long_name": "Ultragenyx Pharmaceutical Inc.",
        "summary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Novato",
        "zipcode": "94949",
        "website": "http://www.ultragenyx.com",
        "market_cap": "Mid Cap"
    },
    "RASP": {
        "short_name": "RASNA THERAPEUTICS INC",
        "long_name": "Rasna Therapeutics, Inc.",
        "summary": "Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia. It focuses on developing molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10170",
        "website": "http://www.rasna.com",
        "market_cap": "Small Cap"
    },
    "RB0.F": {
        "short_name": "REGENXBIO INC.  DL-,0001",
        "long_name": "REGENXBIO Inc.",
        "summary": "REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.regenxbio.com",
        "market_cap": "Small Cap"
    },
    "RCAR": {
        "short_name": "RENOVACARE INC",
        "long_name": "RenovaCare, Inc.",
        "summary": "RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Roseland, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Roseland",
        "zipcode": "07068",
        "website": "http://www.renovacareinc.com",
        "market_cap": "Small Cap"
    },
    "RCEL": {
        "short_name": "Avita Therapeutics, Inc.",
        "long_name": "AVITA Medical, Inc.",
        "summary": "AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Valencia",
        "zipcode": "91355",
        "website": "http://www.avitamedical.com",
        "market_cap": "Small Cap"
    },
    "RCHA": {
        "short_name": "RICH PHARMACEUTICALS INC",
        "long_name": "Rich Pharmaceuticals, Inc.",
        "summary": "Rich Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies in oncology. It is developing RP-323 for the treatment of Hodgkin's lymphoma, acute myelogenous leukemia, and to cause elevation of white blood cells. The company was formerly known as Nepia Inc. and changed its name to Rich Pharmaceuticals, Inc., in August 2013. Rich Pharmaceuticals, Inc. was incorporated in 2010 and is based in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90036",
        "website": "http://www.richpharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "RCKT": {
        "short_name": "Rocket Pharmaceuticals, Inc.",
        "long_name": "Rocket Pharmaceuticals, Inc.",
        "summary": "Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energ\u00c3\u00a9ticas, Medioambientales y Tecnol\u00c3\u00b3gicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cranbury",
        "zipcode": "08512",
        "website": "http://www.rocketpharma.com",
        "market_cap": "Mid Cap"
    },
    "RCM": {
        "short_name": "R1 RCM Inc.",
        "long_name": "R1 RCM Inc.",
        "summary": "R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. It also provides modular services comprising physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. It serves healthcare providers, including health systems, hospitals, and physician groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was incorporated in 2003 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60611",
        "website": "http://www.r1rcm.com",
        "market_cap": "Mid Cap"
    },
    "RCMW": {
        "short_name": "RCMW GROUP INC",
        "long_name": "RCMW Group, Inc.",
        "summary": "RCMW Group Inc. produces, manufactures, and distributes hemp-derived phytocannabinoids worldwide. The company was formerly known as Hemp Technology Inc. and changed its name to RCMW Group Inc. in February 2021. RCMW Group Inc. is based in Cheyenne, Wyoming.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WY",
        "city": "Cheyenne",
        "zipcode": "82009",
        "website": "http://hemptechnologyinc.com",
        "market_cap": "Small Cap"
    },
    "RCPIQ": {
        "short_name": "ROCK CREEK PHARMACEUTICALS INC",
        "long_name": "Rock Creek Pharmaceuticals, Inc.",
        "summary": "Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Sarasota",
        "zipcode": "34243",
        "website": "http://www.rockcreekpharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "RCUS": {
        "short_name": "Arcus Biosciences, Inc.",
        "long_name": "Arcus Biosciences, Inc.",
        "summary": "Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Hayward",
        "zipcode": "94545",
        "website": "http://www.arcusbio.com",
        "market_cap": "Mid Cap"
    },
    "RDGL": {
        "short_name": "VIVOS INC",
        "long_name": "Vivos Inc.",
        "summary": "Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 is headquartered in Richland, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Richland",
        "zipcode": "99352",
        "website": "http://www.radiogel.com",
        "market_cap": "Small Cap"
    },
    "RDKO.CN": {
        "short_name": "RadikoHldgsCorp",
        "long_name": "Radiko Holdings Corp.",
        "summary": "Radiko Holdings Corp., together with its subsidiaries, focuses on cannabis industries in the United States and internationally. The company also manufactures and distributes a range of cannabis infused edibles and tinctures under the La Vida Verde brand; a range of wholesale flower, packaged flower, pre-rolls, and concentrates under the Skunk Feather brand; a range of cannabis, infused, chocolates, and edible cannabis consumables gummies, and capsules under the name the Blank Brand; and supplements under the Baseline brand. The company was formerly known as International Cannabrands Inc. and changed its name to Radiko Holdings Corp. in July 2020. The company is headquartered in Des Moines, Washington.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "WA",
        "city": "Des Moines",
        "zipcode": "98198",
        "website": "http://www.radikoholdings.com",
        "market_cap": "Small Cap"
    },
    "RDNT": {
        "short_name": "RadNet, Inc.",
        "long_name": "RadNet, Inc.",
        "summary": "RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90025",
        "website": "http://www.radnet.com",
        "market_cap": "Small Cap"
    },
    "RDUS": {
        "short_name": "Radius Health, Inc.",
        "long_name": "Radius Health, Inc.",
        "summary": "Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a short-wear-time transdermal patch that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.radiuspharm.com",
        "market_cap": "Small Cap"
    },
    "REFG": {
        "short_name": "MEDICAL CANNABIS PAYMENT SOLUTI",
        "long_name": "Medical Cannabis Payment Solutions, Inc.",
        "summary": "Medical Cannabis Payment Solutions, Inc. develops and markets a payment system for medical cannabis transactions. Its solution assists in the state tracking of sales, collection of tax, and supervision of sales to consumers. The company was incorporated in 2013 and is based in Cheyenne, Wyoming.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WY",
        "city": "Cheyenne",
        "zipcode": "82001",
        "website": "http://paywithgo.com",
        "market_cap": "Small Cap"
    },
    "REGN.MX": {
        "short_name": "REGENERON PHARMACEUTICALS INC",
        "long_name": "Regeneron Pharmaceuticals, Inc.",
        "summary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NY",
        "city": "Tarrytown",
        "zipcode": "10591-6707",
        "website": "http://www.regeneron.com",
        "market_cap": "Large Cap"
    },
    "REGN": {
        "short_name": "Regeneron Pharmaceuticals, Inc.",
        "long_name": "Regeneron Pharmaceuticals, Inc.",
        "summary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Tarrytown",
        "zipcode": "10591-6707",
        "website": "http://www.regeneron.com",
        "market_cap": "Large Cap"
    },
    "REGN.VI": {
        "short_name": "REGENERON PHARMACEUTICALS",
        "long_name": "Regeneron Pharmaceuticals, Inc.",
        "summary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "NY",
        "city": "Tarrytown",
        "zipcode": "10591-6707",
        "website": "http://www.regeneron.com",
        "market_cap": "Large Cap"
    },
    "REGN34.SA": {
        "short_name": "REGENERON PHDRN",
        "long_name": "Regeneron Pharmaceuticals, Inc.",
        "summary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NY",
        "city": "Tarrytown",
        "zipcode": "10591-6707",
        "website": "http://www.regeneron.com",
        "market_cap": "Large Cap"
    },
    "REPH": {
        "short_name": "Recro Pharma, Inc.",
        "long_name": "Recro Pharma, Inc.",
        "summary": "Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.recrogainesville.com",
        "market_cap": "Small Cap"
    },
    "REPL": {
        "short_name": "Replimune Group, Inc.",
        "long_name": "Replimune Group, Inc.",
        "summary": "Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Woburn",
        "zipcode": "01801",
        "website": "http://replimune.com",
        "market_cap": "Small Cap"
    },
    "RETA": {
        "short_name": "Reata Pharmaceuticals, Inc.",
        "long_name": "Reata Pharmaceuticals, Inc.",
        "summary": "Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Plano",
        "zipcode": "75024",
        "website": "http://www.reatapharma.com",
        "market_cap": "Mid Cap"
    },
    "RFCS": {
        "short_name": "REFOCUS GROUP INC",
        "long_name": "Refocus Group, Inc.",
        "summary": "Refocus Group, Inc., a medical device company, engages in the research and development of treatments for human vision disorders, primarily for presbyopia. The company develops VisAbility Micro-Insert System, an investigational medical device that is in clinical trials for use in the binocular presbyopic treatment. It serves patients and eye care professionals. The company was founded in 1994 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75231",
        "website": "http://www.refocus-group.com",
        "market_cap": "Small Cap"
    },
    "RFL.F": {
        "short_name": "TYME TECHNOLOGIES DL-0001",
        "long_name": "Tyme Technologies, Inc.",
        "summary": "Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10004",
        "website": "http://www.tymeinc.com",
        "market_cap": "Small Cap"
    },
    "RFL": {
        "short_name": "Rafael Holdings, Inc.",
        "long_name": "Rafael Holdings, Inc.",
        "summary": "Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Newark",
        "zipcode": "07102",
        "website": "http://www.rafaelholdings.com",
        "market_cap": "Small Cap"
    },
    "RFL.SG": {
        "short_name": "Tyme Technologies Inc. Register",
        "long_name": "Tyme Technologies, Inc.",
        "summary": "Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10004",
        "website": "http://www.tymeinc.com",
        "market_cap": "Small Cap"
    },
    "RGBOQ": {
        "short_name": "REGEN BIOLOGICS INC",
        "long_name": "ReGen Biologics Inc.",
        "summary": "ReGen Biologics Inc. designs, develops, manufactures, and markets medical devices for the repair and generation of soft tissue in humans, primarily for orthopedic applications. The company's proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular, and drug delivery. Its products include Menaflex collagen meniscus implant device, for use in surgical procedures for the reinforcement and repair of soft tissue injuries of the medial meniscus; and SharpShooter Tissue Repair System, an instrument that allows surgeons to place needles in hard-to-reach locations of the meniscus. The company sells its products in the United States, the European Union, the Republic of South Africa, Canada, Australia, Chile, and Japan. ReGen Biologics Inc. was formerly known as Aros Corp and changed its name to ReGen Biologics Inc. in November, 2002. ReGen Biologics Inc. was founded in 1987 and is headquartered in Hackensack, New Jersey. On April 8, 2011, ReGen Biologics Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 14, 2011.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Hackensack",
        "zipcode": "07601",
        "website": null,
        "market_cap": "Small Cap"
    },
    "RGBP": {
        "short_name": "REGEN BIOPHARMA INC",
        "long_name": "Regen BioPharma, Inc.",
        "summary": "Regen BioPharma, Inc. focuses on the development of small molecule therapies for treating cancer and autoimmune disorders in the United States. The company intends to develop small molecule NR2F6 that activates to immune cell for oncology and autoimmune diseases. The company was founded in 2012 and is based in La Mesa, California. Regen BioPharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Mesa",
        "zipcode": "91942",
        "website": "http://www.regenbiopharmainc.com",
        "market_cap": "Small Cap"
    },
    "RGBPP": {
        "short_name": "REGEN BIOPHARMA INC",
        "long_name": "Regen BioPharma, Inc.",
        "summary": "Regen BioPharma, Inc. focuses on the development of small molecule therapies for treating cancer and autoimmune disorders in the United States. The company intends to develop small molecule NR2F6 that activates to immune cell for oncology and autoimmune diseases. The company was founded in 2012 and is based in La Mesa, California. Regen BioPharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Mesa",
        "zipcode": "91942",
        "website": "http://www.regenbiopharmainc.com",
        "market_cap": "Small Cap"
    },
    "RGDXQ": {
        "short_name": "RESPONSE GENETICS INC",
        "long_name": "Response Genetics, Inc",
        "summary": "Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90033",
        "website": "http://www.responsegenetics.com",
        "market_cap": "Small Cap"
    },
    "RGEN": {
        "short_name": "Repligen Corporation",
        "long_name": "Repligen Corporation",
        "summary": "Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02453",
        "website": "http://www.repligen.com",
        "market_cap": "Large Cap"
    },
    "RGIN": {
        "short_name": "REGENICIN INC",
        "long_name": "Regenicin, Inc.",
        "summary": "Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is headquartered in Little Falls, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Little Falls",
        "zipcode": "07424",
        "website": "http://www.regenicin.com",
        "market_cap": "Small Cap"
    },
    "RGLS": {
        "short_name": "Regulus Therapeutics Inc.",
        "long_name": "Regulus Therapeutics Inc.",
        "summary": "Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.regulusrx.com",
        "market_cap": "Small Cap"
    },
    "RGN.F": {
        "short_name": "REPLIGEN CORP.  DL-,01",
        "long_name": "Repligen Corporation",
        "summary": "Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02453",
        "website": "http://www.repligen.com",
        "market_cap": "Mid Cap"
    },
    "RGNX": {
        "short_name": "REGENXBIO Inc.",
        "long_name": "REGENXBIO Inc.",
        "summary": "REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.regenxbio.com",
        "market_cap": "Small Cap"
    },
    "RGRX": {
        "short_name": "REGENERX BIOPHARMACEUTICALS",
        "long_name": "RegeneRx Biopharmaceuticals, Inc.",
        "summary": "RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.regenerx.com",
        "market_cap": "Small Cap"
    },
    "RGST": {
        "short_name": "ROGUE STATION COMPANIES INC",
        "long_name": "Rogue Station Companies, Inc.",
        "summary": "NX Uranium, Inc. acquires, explores, and develops uranium and minerals. The company was formerly known as NX Capital Co. and changed its name to NX Uranium, Inc. in September 2014. NX Uranium, Inc. was founded in 2004 and is based in Baton Rouge, Louisiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "LA",
        "city": "Baton Rouge",
        "zipcode": "70816",
        "website": "http://www.nxuranium.com",
        "market_cap": "Small Cap"
    },
    "RHE": {
        "short_name": "Regional Health Properties, Inc",
        "long_name": "Regional Health Properties, Inc.",
        "summary": "Regional Health Properties, Inc., through its subsidiaries, operates as a self-managed real estate investment company that invests primarily in real estate purposed for long-term care and senior living. The company's facilities offer a range of healthcare and related services to patients and residents, including skilled nursing and assisted living services, social services, various therapy services, and other rehabilitative and healthcare services for long-term and short-stay patients and residents. As of December 31, 2020, it owned, leased, or managed 24 facilities. The company operates in Alabama, Georgia, North Carolina, Ohio, and South Carolina. Regional Health Properties, Inc. was founded in 1988 and is headquartered in Suwanee, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Suwanee",
        "zipcode": "30024",
        "website": "http://regionalhealthproperties.com",
        "market_cap": "Small Cap"
    },
    "RI2A.F": {
        "short_name": "RIGEL PHARMACEUT. DL-,001",
        "long_name": "Rigel Pharmaceuticals, Inc.",
        "summary": "Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.rigel.com",
        "market_cap": "Small Cap"
    },
    "RIGL": {
        "short_name": "Rigel Pharmaceuticals, Inc.",
        "long_name": "Rigel Pharmaceuticals, Inc.",
        "summary": "Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.rigel.com",
        "market_cap": "Small Cap"
    },
    "RKV.V": {
        "short_name": "RAKOVINA THERAPEUTICS INC",
        "long_name": "Rakovina Therapeutics Inc.",
        "summary": "Certain Worldwide Rights of NewGen Therapeutics, Inc. comprises PARP inhibitor program technology. The asset is located in the United States.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": null,
        "city": null,
        "zipcode": null,
        "website": "http://www.rakovinatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "RLAY": {
        "short_name": "Relay Therapeutics, Inc.",
        "long_name": "Relay Therapeutics, Inc.",
        "summary": "Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.relaytx.com",
        "market_cap": "Mid Cap"
    },
    "RLMD": {
        "short_name": "Relmada Therapeutics, Inc.",
        "long_name": "Relmada Therapeutics, Inc.",
        "summary": "Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.relmada.com",
        "market_cap": "Small Cap"
    },
    "RMD.AX": {
        "short_name": "RESMED CDI 10:1",
        "long_name": "ResMed Inc.",
        "summary": "ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.resmed.com",
        "market_cap": "Large Cap"
    },
    "RMD.MX": {
        "short_name": "RESMED INC",
        "long_name": "ResMed Inc.",
        "summary": "ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.resmed.com",
        "market_cap": "Large Cap"
    },
    "RMD": {
        "short_name": "ResMed Inc.",
        "long_name": "ResMed Inc.",
        "summary": "ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.resmed.com",
        "market_cap": "Large Cap"
    },
    "RMD.VI": {
        "short_name": "RESMED INC",
        "long_name": "ResMed Inc.",
        "summary": "ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.resmed.com",
        "market_cap": "Large Cap"
    },
    "RME.F": {
        "short_name": "RESMED INC.  DL-,004",
        "long_name": "ResMed Inc.",
        "summary": "ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.resmed.com",
        "market_cap": "Large Cap"
    },
    "RMEA.F": {
        "short_name": "RESMED CUFS/10 DL-,004",
        "long_name": "ResMed Inc.",
        "summary": "ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.resmed.com",
        "market_cap": "Large Cap"
    },
    "RMED": {
        "short_name": "Ra Medical Systems, Inc.",
        "long_name": "Ra Medical Systems, Inc.",
        "summary": "Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92011",
        "website": "http://www.ramed.com",
        "market_cap": "Small Cap"
    },
    "RMN.F": {
        "short_name": "MEDICINOVA  NEW  DL-,001",
        "long_name": "MediciNova, Inc.",
        "summary": "MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://medicinova.com",
        "market_cap": "Small Cap"
    },
    "RMRK": {
        "short_name": "RIMROCK GOLD CORP",
        "long_name": "Rimrock Gold Corp.",
        "summary": "Rimrock Gold Corp., through its subsidiary, focuses on the development and marketing a line of CBD oils, creams, and hemp extracts. The company was incorporated in 2007 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89103",
        "website": "http://www.rimrockgold.com",
        "market_cap": "Small Cap"
    },
    "RMSL": {
        "short_name": "REMSLEEP HOLDINGS INC",
        "long_name": "REMSleep Holdings, Inc.",
        "summary": "REMSleep Holdings, Inc. focuses on the development and distribution of products to help people affected by sleep apnea worldwide. It offers DeltaWave CPAP interface device to treat patients with sleep apnea. The company serves home care dealers, private sleep labs, Internet providers, product end users, physicians, medical group, and hospitals, as well as medical associations. REMSleep Holdings, Inc. was founded in 2007 and is headquartered in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Orlando",
        "zipcode": "32789",
        "website": "http://www.remsleeptech.com",
        "market_cap": "Small Cap"
    },
    "RMTI": {
        "short_name": "Rockwell Medical, Inc.",
        "long_name": "Rockwell Medical, Inc.",
        "summary": "Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Wixom",
        "zipcode": "48393",
        "website": "http://www.rockwellmed.com",
        "market_cap": "Small Cap"
    },
    "RN3N.F": {
        "short_name": "ARENA PHARMA.NEW DL-,0001",
        "long_name": "Arena Pharmaceuticals, Inc.",
        "summary": "Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Park City",
        "zipcode": "84060",
        "website": "http://www.arenapharm.com",
        "market_cap": "Mid Cap"
    },
    "RNA": {
        "short_name": "Avidity Biosciences, Inc.",
        "long_name": "Avidity Biosciences, Inc.",
        "summary": "Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://www.aviditybiosciences.com",
        "market_cap": "Small Cap"
    },
    "RNAZ": {
        "short_name": "Transcode Therapeutics, Inc.",
        "long_name": "TransCode Therapeutics, Inc.",
        "summary": "TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.",
        "currency": null,
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02109",
        "website": "http://www.transcodetherapeutics.com",
        "market_cap": null
    },
    "RNVA": {
        "short_name": "Rennova Health, Inc.",
        "long_name": "Rennova Health, Inc.",
        "summary": "Rennova Health, Inc., together with its subsidiaries, engages in the hospital operations in the United States. As of March 31, 2021, it owns one operating hospital in Oneida, Tennessee; and a rural clinic in Williamsburg, Kentucky. The company was founded in 2005 and is based in West Palm Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "West Palm Beach",
        "zipcode": "33401",
        "website": "http://www.rennovahealth.com",
        "market_cap": "Small Cap"
    },
    "RPD.MU": {
        "short_name": "ROYALTY PHARMA OA DL-0001",
        "long_name": "Royalty Pharma plc",
        "summary": "Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.royaltypharma.com",
        "market_cap": "Large Cap"
    },
    "RPHM": {
        "short_name": "Reneo Pharmaceuticals, Inc.",
        "long_name": "Reneo Pharmaceuticals, Inc.",
        "summary": "Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://reneopharma.com",
        "market_cap": "Small Cap"
    },
    "RPRX": {
        "short_name": "Royalty Pharma plc",
        "long_name": "Royalty Pharma plc",
        "summary": "Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.royaltypharma.com",
        "market_cap": "Large Cap"
    },
    "RSCF": {
        "short_name": "REFLECT SCIENTIFIC INC",
        "long_name": "Reflect Scientific, Inc.",
        "summary": "Reflect Scientific, Inc. designs, develops, and sells scientific equipment for the life science and manufacturing industries worldwide. The company offers Cryometrix ultra low temperature and blast freezers, which are used to store various products, including blood and cancer vaccines; and optically based chemical detection instruments for the analysis of blood for metabolic diseases. It also provides laboratory consumables and disposables, such as filtration and purification products, customized sample handling vials, electronic wiring assemblies, high temperature silicone, and graphite and vespel/graphite sealing components for use by original equipment manufacturers in the field of gas/liquid chromatography in the chemical analysis industries. Its customers include hospitals and diagnostic laboratories, pharmaceutical and biotech companies, universities, government and private sector research facilities, and chemical and industrial companies. The company is based in Orem, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Orem",
        "zipcode": "84058",
        "website": "http://www.reflectscientific.com",
        "market_cap": "Small Cap"
    },
    "RSCI": {
        "short_name": "REDWOOD SCIENTIFIC TECHNOLOGIES",
        "long_name": "Redwood Scientific Technologies, Inc.",
        "summary": "Redwood Scientific Technologies, Inc. develops and markets over-the-counter FDA registered drugs through oral strip delivery technology. The company is based in Claremont, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Claremont",
        "zipcode": "91711",
        "website": "http://www.redwoodscientific.co",
        "market_cap": "Small Cap"
    },
    "RSLS": {
        "short_name": "RESHAPE LIFESCIENCES INC",
        "long_name": "ReShape Lifesciences Inc.",
        "summary": "ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Clemente",
        "zipcode": "92673",
        "website": "http://www.reshapelifesciences.com",
        "market_cap": "Small Cap"
    },
    "RSMDF": {
        "short_name": "RESMED INC",
        "long_name": "ResMed Inc.",
        "summary": "ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92123",
        "website": "http://www.resmed.com",
        "market_cap": "Large Cap"
    },
    "RSPI": {
        "short_name": "RESPIRERX PHARMACEUTICALS INC",
        "long_name": "RespireRx Pharmaceuticals Inc.",
        "summary": "RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system's endogenous cannabinoid receptors for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, SCI, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Glen Rock",
        "zipcode": "07452",
        "website": "http://www.respirerx.com",
        "market_cap": "Small Cap"
    },
    "RT2.F": {
        "short_name": "SURGALIGN HLDGS  DL-,001",
        "long_name": "Surgalign Holdings, Inc.",
        "summary": "Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.surgalign.com",
        "market_cap": "Small Cap"
    },
    "RTA1.F": {
        "short_name": "RITE AID  DL 1",
        "long_name": "Rite Aid Corporation",
        "summary": "Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment sells prescription drugs and an assortment of other merchandise, including over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, pet care, and other every day and convenience products, as well as brand and generic prescription drugs. It also operates retail clinics that provide treatment for common conditions; and provides preventative services. In addition, this segment offers healthcare coaching and disease management services. The Pharmacy Services segment provides integrated suite of pharmacy benefit management (PBM) offerings, including technology solutions, mail delivery services, specialty pharmacy, network and rebate administration, claims adjudication, and pharmacy discount programs, as well as drug benefits under the federal government's Medicare Part D program and insurance offerings for individuals and groups. This segment serves health plans, commercial employers, labor groups, and state and local governments. As of April 28, 2021, the company operated approximately 2,500 retail pharmacy locations in 17 states. Rite Aid Corporation was founded in 1962 and is headquartered in Camp Hill, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Camp Hill",
        "zipcode": "17011",
        "website": "http://www.riteaid.com",
        "market_cap": "Small Cap"
    },
    "RTI.F": {
        "short_name": "REVANCE THERAPEUT.DL-,001",
        "long_name": "Revance Therapeutics, Inc.",
        "summary": "Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Newark",
        "zipcode": "37203",
        "website": "http://www.revance.com",
        "market_cap": "Small Cap"
    },
    "RTSL": {
        "short_name": "RAPID THERAPEUTIC SCIENCE LBRTS",
        "long_name": "Rapid Therapeutic Science Laboratories, Inc.",
        "summary": "Rapid Therapeutic Science Laboratories, Inc. holds a sublicense agreement to access to certain technology regarding the RxoidTM metered dose inhaler (TMDI). The TMDI is a medical technology that delivers medication directly to a user's blood stream through the pulmonary tract. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75240",
        "website": null,
        "market_cap": "Small Cap"
    },
    "RUBY": {
        "short_name": "Rubius Therapeutics, Inc.",
        "long_name": "Rubius Therapeutics, Inc.",
        "summary": "Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.rubiustx.com",
        "market_cap": "Mid Cap"
    },
    "RV41.F": {
        "short_name": "FENNEC PHARMACEUT.",
        "long_name": "Fennec Pharmaceuticals Inc.",
        "summary": "Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Research Triangle Park",
        "zipcode": "27709",
        "website": "http://www.fennecpharma.com",
        "market_cap": "Small Cap"
    },
    "RV6.F": {
        "short_name": "CHARL.RIV.LAB INTL DL-,01",
        "long_name": "Charles River Laboratories International, Inc.",
        "summary": "Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Wilmington",
        "zipcode": "01887",
        "website": "http://www.criver.com",
        "market_cap": "Large Cap"
    },
    "RV7.F": {
        "short_name": "HALOZYME THERAPEU.DL-,001",
        "long_name": "Halozyme Therapeutics, Inc.",
        "summary": "Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.halozyme.com",
        "market_cap": "Mid Cap"
    },
    "RVMD": {
        "short_name": "Revolution Medicines, Inc.",
        "long_name": "Revolution Medicines, Inc.",
        "summary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.revmed.com",
        "market_cap": "Mid Cap"
    },
    "RVNC": {
        "short_name": "Revance Therapeutics, Inc.",
        "long_name": "Revance Therapeutics, Inc.",
        "summary": "Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Newark",
        "zipcode": "37203",
        "website": "http://www.revance.com",
        "market_cap": "Small Cap"
    },
    "RVP": {
        "short_name": "Retractable Technologies, Inc.",
        "long_name": "Retractable Technologies, Inc.",
        "summary": "Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other medical products for the healthcare industry in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holder; allergy tray; IV safety catheter; Patient Safe syringes and Luer Caps; VanishPoint blood collection set; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Little Elm",
        "zipcode": "75068-5295",
        "website": "http://www.retractable.com",
        "market_cap": "Small Cap"
    },
    "RVPH": {
        "short_name": "Reviva Pharmaceuticals Holdings",
        "long_name": "Reviva Pharmaceuticals Holdings, Inc.",
        "summary": "Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Cupertino",
        "zipcode": "95014",
        "website": "http://www.revivapharma.com",
        "market_cap": "Small Cap"
    },
    "RWM.F": {
        "short_name": "ROCKWELL MEDICAL INC.",
        "long_name": "Rockwell Medical, Inc.",
        "summary": "Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MI",
        "city": "Wixom",
        "zipcode": "48393",
        "website": "http://www.rockwellmed.com",
        "market_cap": "Small Cap"
    },
    "RXDX": {
        "short_name": "Prometheus Biosciences, Inc.",
        "long_name": "Prometheus Biosciences, Inc.",
        "summary": "Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.prometheusbiosciences.com",
        "market_cap": "Small Cap"
    },
    "RXEI": {
        "short_name": "RXELITE INC",
        "long_name": "RxElite, Inc.",
        "summary": "RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its products include Sterile Liquid Dose products that consist of generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, and injectable drugs. The company, through its subsidiaries, also manufactures active pharmaceutical ingredients for pharmaceutical companies in the United States, Europe, and Asia. Its customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. The company has partnership agreements with Stason Pharmaceuticals, Inc.; Alkem Laboratories Limited; and Zach Systems S.p.A. RxElite is headquartered in Meridian, Idaho. RxElite Inc. operates as a subsidiary of Piramal Healthcare Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "ID",
        "city": "Meridian",
        "zipcode": "83642",
        "website": "http://www.piramalcriticalcare.com",
        "market_cap": "Small Cap"
    },
    "RXK3.F": {
        "short_name": "SELLAS LIFE SCIENCES GRP",
        "long_name": "SELLAS Life Sciences Group, Inc.",
        "summary": "SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.sellaslifesciences.com",
        "market_cap": "Small Cap"
    },
    "RXMD": {
        "short_name": "PROGRESSIVE CARE INC",
        "long_name": "Progressive Care, Inc.",
        "summary": "Progressive Care, Inc., through its subsidiary, Pharmco, LLC, provides prescription pharmaceuticals to individuals and institutions in south Florida. The company operates a retail pharmacy that specializes in the sale of anti-retroviral medications and related patient care management; the sale and rental of durable medical equipment (DME), such as hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories; and the supply of various prescription medications to long term care facilities. It also provides long term care solutions to skilled nursing facilities, assisted living facilities, retirement centers and communities, doctors' offices, and clinics. In addition, the company purchases, repackages, and dispenses prescription and non-prescription pharmaceutical products for its long term care customers. Further, it offers computerized maintenance of patient prescription histories; third party billing; consultant pharmacist services consisting of evaluation of monthly patient drug therapy and monitoring the institution's drug distribution system, as well as home service and maintenance, defective product replacements, and free home installation and instruction services; and data analytics services to support health care organizations. Progressive Care, Inc. was founded in 2005 and is based in Hallandale Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Hallandale Beach",
        "zipcode": "33009",
        "website": "http://progressivecareus.com",
        "market_cap": "Small Cap"
    },
    "RXRX": {
        "short_name": "Recursion Pharmaceuticals, Inc.",
        "long_name": "Recursion Pharmaceuticals, Inc.",
        "summary": "Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84101",
        "website": "http://www.recursion.com",
        "market_cap": "Mid Cap"
    },
    "RYI.F": {
        "short_name": "VIRACTA THERAP.I.DL-,0001",
        "long_name": "Viracta Therapeutics, Inc.",
        "summary": "Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff-by-the-Sea, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Cardiff-by-the-Sea",
        "zipcode": "92007",
        "website": "http://www.viracta.com",
        "market_cap": "Small Cap"
    },
    "RYTM.MX": {
        "short_name": "RHYTHM PHARMACEUTICALS INC",
        "long_name": "Rhythm Pharmaceuticals, Inc.",
        "summary": "Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstr\u00c3\u00b6m syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://www.rhythmtx.com",
        "market_cap": "Small Cap"
    },
    "RYTM": {
        "short_name": "Rhythm Pharmaceuticals, Inc.",
        "long_name": "Rhythm Pharmaceuticals, Inc.",
        "summary": "Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstr\u00c3\u00b6m syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02116",
        "website": "http://www.rhythmtx.com",
        "market_cap": "Small Cap"
    },
    "RZLT": {
        "short_name": "Rezolute, Inc.",
        "long_name": "Rezolute, Inc.",
        "summary": "Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://www.rezolutebio.com",
        "market_cap": "Small Cap"
    },
    "S09.F": {
        "short_name": "SUTRO BIOPHARMA  DL-,001",
        "long_name": "Sutro Biopharma, Inc.",
        "summary": "Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.sutrobio.com",
        "market_cap": "Small Cap"
    },
    "S0Z.F": {
        "short_name": "SIENTRA INC.  DL-,01",
        "long_name": "Sientra, Inc.",
        "summary": "Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States and internationally. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Barbara",
        "zipcode": "93117",
        "website": "http://sientra.com",
        "market_cap": "Small Cap"
    },
    "S1GE34.SA": {
        "short_name": "SEAGEN      DRN",
        "long_name": "Seagen Inc.",
        "summary": "Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "WA",
        "city": "Bothell",
        "zipcode": "98021",
        "website": "http://www.seagen.com",
        "market_cap": "Large Cap"
    },
    "S1K2.F": {
        "short_name": "PREDICTIV.ONCOLOGY DL-,01",
        "long_name": "Predictive Oncology Inc.",
        "summary": "Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Eagan",
        "zipcode": "55121",
        "website": "http://www.predictive-oncology.com",
        "market_cap": "Small Cap"
    },
    "S1RP34.SA": {
        "short_name": "SAREPTA THERDRN",
        "long_name": "Sarepta Therapeutics, Inc.",
        "summary": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.sarepta.com",
        "market_cap": "Mid Cap"
    },
    "S1TE34.SA": {
        "short_name": "STERIS PLC  DRN",
        "long_name": "STERIS Corporation",
        "summary": "STERIS Corporation provides infection prevention and procedural products and services. The company offers surgical equipment and image management, sterile processing equipment, surgical sterilization and instrument, surgical instrument cleaning, endoscope devices, endoscope reprocessing, medical device repair, sterility assurance monitoring, and contract sterilization services, including gamma irradiation, electron beam irradiation, x-ray irradiation, and ethylene oxide sterilization. It also provides process cleaning detergents, surface disinfectants, cleaners, washing equipment, and sterilizers. STERIS Corporation was formerly known as Innovative Medical Technologies. The company was founded in 1985 and is based in Mentor, Ohio with additional locations worldwide. STERIS Corporation operates as a subsidiary of STERIS plc.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "OH",
        "city": "Mentor",
        "zipcode": "44060",
        "website": "http://www.steris.com",
        "market_cap": "Large Cap"
    },
    "S1YK34.SA": {
        "short_name": "STRYKER CORPDRN",
        "long_name": "Stryker Corporation",
        "summary": "Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MI",
        "city": "Kalamazoo",
        "zipcode": "49002",
        "website": "http://www.stryker.com",
        "market_cap": "Large Cap"
    },
    "S24.F": {
        "short_name": "SELECT MEDIC.HLDGS CORP.",
        "long_name": "Select Medical Holdings Corporation",
        "summary": "Select Medical Holdings Corporation, through its subsidiary, Select Medical Corporation, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's Critical Illness Recovery Hospital segment consists of hospitals that provide services for heart failure, infectious disease, respiratory failure and pulmonary disease, surgery requiring prolonged recovery, renal disease, neurological events, and trauma. Its Rehabilitation Hospital segment offers therapy and rehabilitation treatments, including rehabilitative services for brain and spinal cord injuries, strokes, amputations, neurological disorders, orthopedic conditions, pediatric congenital or acquired disabilities, and cancer. The company's Outpatient Rehabilitation segment operates rehabilitation clinics that provide physical, occupational, and speech rehabilitation programs and services; and specialized programs, such as functional programs for work related injuries, hand therapy, post-concussion rehabilitation, pediatric and cancer rehabilitation, and athletic training services. Its Concentra segment operates and provides occupational health centers and contract services at employer worksites that deliver occupational medicine, physical therapy, and consumer health services, as well as provides veterans' healthcare services. As of December 31, 2020, the company operated 99 critical illness recovery hospitals in 28 states; 30 rehabilitation hospitals in 12 states; 1,788 outpatient rehabilitation clinics in 37 states and the District of Columbia; and 517 occupational health centers, and 134 onsite clinics at employer worksites states. Select Medical Holdings Corporation was founded in 1996 and is headquartered in Mechanicsburg, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Mechanicsburg",
        "zipcode": "17055",
        "website": "http://www.selectmedical.com",
        "market_cap": "Mid Cap"
    },
    "S49.F": {
        "short_name": "SUPERNUS PHARMAC.DL -,001",
        "long_name": "Supernus Pharmaceuticals, Inc.",
        "summary": "Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.supernus.com",
        "market_cap": "Small Cap"
    },
    "S6V.F": {
        "short_name": "CLARITAS PHARMACEUT. O.N.",
        "long_name": "Claritas Pharmaceuticals, Inc.",
        "summary": "Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. The company was founded in 2014 and is headquartered in San Rafael, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Rafael",
        "zipcode": "94903",
        "website": "http://claritaspharma.com",
        "market_cap": "Small Cap"
    },
    "SAGD": {
        "short_name": "SOUTH AMERICAN GOLD CORP",
        "long_name": "Sativa Growth International",
        "summary": "South American Gold Corp. focuses on acquiring and operating cannabis and tech assets. It provides medical marijuana products. The company was formerly known as Grosvenor Explorations Inc. and changed its name to South American Gold Corp. in October 2010. South American Gold Corp. was founded in 2005 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89123",
        "website": "http://www.sativagrowth.com",
        "market_cap": "Small Cap"
    },
    "SAGE": {
        "short_name": "Sage Therapeutics, Inc.",
        "long_name": "Sage Therapeutics, Inc.",
        "summary": "Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.sagerx.com",
        "market_cap": "Mid Cap"
    },
    "SANA": {
        "short_name": "Sana Biotechnology, Inc.",
        "long_name": "Sana Biotechnology, Inc.",
        "summary": "Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98020",
        "website": "http://www.sana.com",
        "market_cap": "Mid Cap"
    },
    "SAVA": {
        "short_name": "Cassava Sciences, Inc.",
        "long_name": "Cassava Sciences, Inc.",
        "summary": "Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78731",
        "website": "http://www.cassavasciences.com",
        "market_cap": "Small Cap"
    },
    "SBBC.V": {
        "short_name": "SIMPLY BETTER BRANDS CORP",
        "long_name": "Simply Better Brands Corp.",
        "summary": "PureK Holdings Corp. manufactures and sells hemp based cannabidiol related products in the United States. The company offers tinctures, capsules, gummies, oils, edibles, topicals, sprays, vape pens, pet treats, and bath bombs, as well as tees, hoodies, beanies, caps, and other related products. It distributes its products through e-commerce website PureKana.com, as well as through retail stores, including larger retail chains and small independent retailers; wholesalers; and various brick and mortar retailers. The company was founded in 2017 and is headquartered in Paradise Valley, Arizona. PureK Holdings Corp. is a subsidiary of Heavenly Rx Ltd.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "state": "AZ",
        "city": "Paradise Valley",
        "zipcode": "85253",
        "website": "http://purekana.com",
        "market_cap": "Small Cap"
    },
    "SBBP": {
        "short_name": "Strongbridge Biopharma plc",
        "long_name": "Strongbridge Biopharma plc",
        "summary": "Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Trevose",
        "zipcode": "19053",
        "website": "http://www.strongbridgebio.com",
        "market_cap": "Small Cap"
    },
    "SBTX": {
        "short_name": "Silverback Therapeutics, Inc.",
        "long_name": "Silverback Therapeutics, Inc.",
        "summary": "Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98109",
        "website": "http://www.silverbacktx.com",
        "market_cap": "Small Cap"
    },
    "SCAL": {
        "short_name": "STEM CELL AUTHORITY LTD",
        "long_name": "Stem Cell Authority, Ltd.",
        "summary": "Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoietic stem cells from the umbilical cord blood; and the Miracle Mesenchymal stem cells from the Wharton's jelly inside the umbilical cord of a newborn child. The company's technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States. Stem Cell Authority, Ltd. is based in Fairlawn, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Fairlawn",
        "zipcode": "44333",
        "website": "http://www.stemcellauthority.com",
        "market_cap": "Small Cap"
    },
    "SCIE": {
        "short_name": "SPECTRASCIENCE INC",
        "long_name": "SpectraScience, Inc.",
        "summary": "SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. It offers WavSTAT3 optical biopsy system to determine whether a colon tissue is normal, pre-cancerous, or cancerous without physically removing tissue from the body; and WavSTAT4 optical biopsy system, a colon diagnostic product that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. The company also sells mobile consoles and disposable forceps. In addition, it engages in developing an esophageal diagnosis application for the detection of pre-cancerous and cancerous tissues in various tissues of the body. The company was formerly known as GV Medical, Inc. and changed its name to SpectraScience, Inc. in October 1992. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Appliances & Equipment",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.spectrascience.com",
        "market_cap": "Small Cap"
    },
    "SCNA": {
        "short_name": "SMART CANNABIS CORP",
        "long_name": "Smart Cannabis Corp.",
        "summary": "Smart Cannabis Corp. operates in the agriculture and cannabis industries. The company, through its subsidiary, Next Generation Farming, Inc., provides turnkey, automated, commercial greenhouses systems that improve yields and decrease water consumption for cultivators of organic food and cannabis crops. The company was founded in 2010 and is based in Loomis, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Loomis",
        "zipcode": "95650",
        "website": "http://smartcannabis.com",
        "market_cap": "Small Cap"
    },
    "SCPH": {
        "short_name": "scPharmaceuticals Inc.",
        "long_name": "scPharmaceuticals Inc.",
        "summary": "scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Burlington",
        "zipcode": "01803",
        "website": "http://www.scpharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "SCPS": {
        "short_name": "Scopus BioPharma Inc.",
        "long_name": "Scopus BioPharma Inc.",
        "summary": "Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10170",
        "website": "http://scopusbiopharma.com",
        "market_cap": "Small Cap"
    },
    "SCRCQ": {
        "short_name": "SCRIPSAMERICA INC",
        "long_name": "ScripsAmerica, Inc.",
        "summary": "ScripsAmerica, Inc. develops and sells non-sterile topical and transdermal pain creams. The company also provides pharmacy dispensing services for individual doctors, as well as billing and administrative services to independent pharmacies. In addition, it distributes pharmaceutical products to independent pharmacies and other medical providers. The company was founded in 2008 and is based in Clifton, New Jersey. On February 8, 2017, the voluntary petition of ScripsAmerica, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 7, 2016.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Clifton",
        "zipcode": "07011",
        "website": "http://www.scripsamerica.com",
        "market_cap": "Small Cap"
    },
    "SCYX": {
        "short_name": "SCYNEXIS, Inc.",
        "long_name": "SCYNEXIS, Inc.",
        "summary": "SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Jersey City",
        "zipcode": "07302-6548",
        "website": "http://www.scynexis.com",
        "market_cap": "Small Cap"
    },
    "SD3.F": {
        "short_name": "SIMULATIONS PLUS  DL-,01",
        "long_name": "Simulations Plus, Inc.",
        "summary": "Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Lancaster",
        "zipcode": "93534-7059",
        "website": "http://www.simulations-plus.com",
        "market_cap": "Small Cap"
    },
    "SDC.MX": {
        "short_name": "SMILEDIRECTCLUB INC",
        "long_name": "SmileDirectClub, Inc.",
        "summary": "SmileDirectClub, Inc. operates as an oral care company. It offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a doctor, and monitoring through completion of their treatment with a network of approximately 250 state licensed orthodontists and general dentists through its teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, Spain, and Austria. It offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37219",
        "website": "http://www.smiledirectclub.com",
        "market_cap": "Mid Cap"
    },
    "SDC": {
        "short_name": "SmileDirectClub, Inc.",
        "long_name": "SmileDirectClub, Inc.",
        "summary": "SmileDirectClub, Inc. operates as an oral care company. It offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a doctor, and monitoring through completion of their treatment with a network of approximately 250 state licensed orthodontists and general dentists through its teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, Spain, and Austria. It offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Nashville",
        "zipcode": "37219",
        "website": "http://www.smiledirectclub.com",
        "market_cap": "Mid Cap"
    },
    "SDGR": {
        "short_name": "Schrodinger, Inc.",
        "long_name": "Schr\u00f6dinger, Inc.",
        "summary": "Schr\u00c3\u00b6dinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schr\u00c3\u00b6dinger, Inc. has strategic collaborations with Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas; and NVIDIA designed to harness DGX SuperPODs. . The company was incorporated in 1990 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.schrodinger.com",
        "market_cap": "Mid Cap"
    },
    "SECI": {
        "short_name": "SECTOR 10 INC",
        "long_name": "Sector 10, Inc.",
        "summary": "Sector 10, Inc., a development stage company, markets MRU \u00c2\u0096 SRU product lines and various solutions related to mobile assets. The company was founded in 2002 and is based in Bellevue, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Bellevue",
        "zipcode": "98004",
        "website": "http://www.sector10.com",
        "market_cap": "Small Cap"
    },
    "SEEL": {
        "short_name": "Seelos Therapeutics, Inc.",
        "long_name": "Seelos Therapeutics, Inc.",
        "summary": "Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://seelostherapeutics.com",
        "market_cap": "Small Cap"
    },
    "SEER": {
        "short_name": "Seer, Inc.",
        "long_name": "Seer, Inc.",
        "summary": "Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://seer.bio",
        "market_cap": "Mid Cap"
    },
    "SELB": {
        "short_name": "Selecta Biosciences, Inc.",
        "long_name": "Selecta Biosciences, Inc.",
        "summary": "Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://selectabio.com",
        "market_cap": "Small Cap"
    },
    "SEM": {
        "short_name": "Select Medical Holdings Corpora",
        "long_name": "Select Medical Holdings Corporation",
        "summary": "Select Medical Holdings Corporation, through its subsidiary, Select Medical Corporation, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's Critical Illness Recovery Hospital segment consists of hospitals that provide services for heart failure, infectious disease, respiratory failure and pulmonary disease, surgery requiring prolonged recovery, renal disease, neurological events, and trauma. Its Rehabilitation Hospital segment offers therapy and rehabilitation treatments, including rehabilitative services for brain and spinal cord injuries, strokes, amputations, neurological disorders, orthopedic conditions, pediatric congenital or acquired disabilities, and cancer. The company's Outpatient Rehabilitation segment operates rehabilitation clinics that provide physical, occupational, and speech rehabilitation programs and services; and specialized programs, such as functional programs for work related injuries, hand therapy, post-concussion rehabilitation, pediatric and cancer rehabilitation, and athletic training services. Its Concentra segment operates and provides occupational health centers and contract services at employer worksites that deliver occupational medicine, physical therapy, and consumer health services, as well as provides veterans' healthcare services. As of December 31, 2020, the company operated 99 critical illness recovery hospitals in 28 states; 30 rehabilitation hospitals in 12 states; 1,788 outpatient rehabilitation clinics in 37 states and the District of Columbia; and 517 occupational health centers, and 134 onsite clinics at employer worksites states. Select Medical Holdings Corporation was founded in 1996 and is headquartered in Mechanicsburg, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Mechanicsburg",
        "zipcode": "17055",
        "website": "http://www.selectmedical.com",
        "market_cap": "Mid Cap"
    },
    "SENS": {
        "short_name": "Senseonics Holdings, Inc.",
        "long_name": "Senseonics Holdings, Inc.",
        "summary": "Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Germantown",
        "zipcode": "20876-7005",
        "website": "http://www.senseonics.com",
        "market_cap": "Small Cap"
    },
    "SESN": {
        "short_name": "Sesen Bio, Inc.",
        "long_name": "Sesen Bio, Inc.",
        "summary": "Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.sesenbio.com",
        "market_cap": "Small Cap"
    },
    "SETO": {
        "short_name": "SETO HLDGS INC",
        "long_name": "SETO Holdings, Inc.",
        "summary": "SETO Holdings, Inc., a development stage company, provides healthcare services. Its Health division offers health care services throughout the Mid-Atlantic region of the United States. The company is developing a surgical center in Maryland and 4 diabetes clinics through its existing locations and in association with other health practitioners. The company's Hearing Care Group provides hearing health care through its 15 clinics in the Mid Atlantic region. SETO Holdings is also engaged in helping to establish a hospital facility in India. The company was founded in 2004 and is based in Hanover, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Hanover",
        "zipcode": "21076",
        "website": "http://www.setousa.com",
        "market_cap": "Small Cap"
    },
    "SEYE": {
        "short_name": "SIGNATURE EYEWEAR",
        "long_name": "Signature Eyewear, Inc.",
        "summary": "Signature Eyewear, Inc. operates as an eyewear company worldwide. The company also offers sunwear products. It offers its products under the Bobby Jones, Carmen Marc Valvo, Cutter & Buck, Dakota Smith, Hart Schaffner Marx, Hickey Freeman, Laura Ashley, Laura Ashley Girls, Michael Stars, Rough Justice, Y-Sport, and Calligraphy brands. The company was founded in 1983 and is headquartered in Inglewood, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Inglewood",
        "zipcode": "90302",
        "website": "http://www.signatureeyewear.com",
        "market_cap": "Small Cap"
    },
    "SFYC.F": {
        "short_name": "SYNTHETIC BIOLOG.DL -,001",
        "long_name": "Synthetic Biologics, Inc.",
        "summary": "Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.syntheticbiologics.com",
        "market_cap": "Small Cap"
    },
    "SG7.F": {
        "short_name": "SAGE THERAPEUTICS DL-0001",
        "long_name": "Sage Therapeutics, Inc.",
        "summary": "Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.sagerx.com",
        "market_cap": "Mid Cap"
    },
    "SG7.SG": {
        "short_name": "Sage Therapeutics Inc. Register",
        "long_name": "Sage Therapeutics, Inc.",
        "summary": "Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.sagerx.com",
        "market_cap": "Mid Cap"
    },
    "SGEN": {
        "short_name": "Seagen Inc.",
        "long_name": "Seagen Inc.",
        "summary": "Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "WA",
        "city": "Bothell",
        "zipcode": "98021",
        "website": "http://www.seagen.com",
        "market_cap": "Large Cap"
    },
    "SGFY": {
        "short_name": "Signify Health, Inc.",
        "long_name": "Signify Health, Inc.",
        "summary": "Signify Health, Inc. operates a healthcare platform that utilizes analytics, technology, and healthcare provider networks in the United States. The company operates in two segments, Home & Community Services and Episodes of Care Services. The Home & Community Services segment offers health evaluations performed within the patient's home or at a healthcare provider facility primarily to Medicare Advantage health plans; diagnostic screening and other ancillary services; and services to address healthcare concerns related to social determinants of health. The Episodes of Care Services segment provides services to enhance the healthcare delivery through developing and managing episodic payment programs in partnership with healthcare providers primarily under the Medicare Bundled Payment for Care Improvement Advanced program with Centers for Medicare and Medicaid Services; and care management services. Its customers include health plans, governments, employers, health systems, and physician groups. The company was founded in 2017 and is headquartered in Dallas, Texas with additional offices in Austin, New York, Norwalk, and Rapid City.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75244",
        "website": "http://www.signifyhealth.com",
        "market_cap": "Mid Cap"
    },
    "SGLN": {
        "short_name": "SURGLINE INTL INC",
        "long_name": "SurgLine International, Inc.",
        "summary": "Surgline International, Inc. sources and sells medical and surgical products. It offers a range of surgical instruments, including scissors, forceps, basket punches, reamers, and pulse lavages. The company also provides surgical sets, such as hand and foot, and hips and small fragments; spine products consisting of ALIF systems, anterior cervical plates, PLIF systems, TLIF systems, cervical PEEK IBFDs, and pedicle screw systems; drill system and power tools comprising cordless and pneumatic drills, chucks, sleeves, saws, hoes, charges, and batteries. In addition, it offers emergency removal devices for broken screws and implant removal; a range of endoscopes; surgical burs and blades; and medical, surgical, and dental disposables. The company sells its products under the Surg brand. It serves acute care hospitals, ambulatory surgery centers, physicians, dentists, urgent care centers, and insurers, as well as others. The company was formerly known as China Nuvo Solar Energy, Inc. and changed its name to Surgline International, Inc. in October 2011. Surgline International, Inc. is based in Newport Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Appliances & Equipment",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "West Palm Beach",
        "zipcode": "33401",
        "website": null,
        "market_cap": "Small Cap"
    },
    "SGMO": {
        "short_name": "Sangamo Therapeutics, Inc.",
        "long_name": "Sangamo Therapeutics, Inc.",
        "summary": "Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Brisbane",
        "zipcode": "94005",
        "website": "http://www.sangamo.com",
        "market_cap": "Small Cap"
    },
    "SGRY": {
        "short_name": "Surgery Partners, Inc.",
        "long_name": "Surgery Partners, Inc.",
        "summary": "Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through Surgical Facility Services and Ancillary Services segments. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2020, it owned or operated a portfolio of 127 surgical facilities, including 110 ambulatory surgical centers and 17 surgical hospitals in 30 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Brentwood",
        "zipcode": "37027",
        "website": "http://www.surgerypartners.com",
        "market_cap": "Mid Cap"
    },
    "SGTX": {
        "short_name": "Sigilon Therapeutics, Inc.",
        "long_name": "Sigilon Therapeutics, Inc.",
        "summary": "Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://sigilon.com",
        "market_cap": "Small Cap"
    },
    "SH5.MU": {
        "short_name": "SOTERA HEALTH COMPANY",
        "long_name": "Sotera Health Company",
        "summary": "Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "state": "OH",
        "city": "Broadview Heights",
        "zipcode": "44147",
        "website": "http://www.soterahealth.com",
        "market_cap": "Mid Cap"
    },
    "SHC": {
        "short_name": "Sotera Health Company",
        "long_name": "Sotera Health Company",
        "summary": "Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Broadview Heights",
        "zipcode": "44147",
        "website": "http://www.soterahealth.com",
        "market_cap": "Mid Cap"
    },
    "SHMN": {
        "short_name": "SOHM INC",
        "long_name": "SOHM, Inc.",
        "summary": "SOHM, Inc. develops, manufactures, markets, and distributes generic and private label pharmaceutical products in the United States. It offers analgesics, antibiotics, anti-cold, and anti-inflammatory drugs, as well as over-the-counter, cosmeceuticals, and nutraceutical products. The company also exports its products. SOHM, Inc. was founded in 2005 and is based in Corona, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Corona",
        "zipcode": "92880",
        "website": "http://www.sohm.com",
        "market_cap": "Small Cap"
    },
    "SHOM": {
        "short_name": "SOUTHERN HOME MED INC",
        "long_name": "Southern Home Medical, Inc.",
        "summary": "Southern Home Medical, Inc. provides healthcare services to medical institutions in the United States. It supplies breathing equipment for patients with respiratory conditions; and oxygen concentrators, portable oxygen tanks, hospital beds, alternating pressure mattresses, patient lifts, tracheotomy supplies, commodes, walkers, and wheelchairs. The company also provides medical staffing needs to hospitals, rehab centers, nursing homes, mental health centers, and other medical facilities. It supports hospitals, rehab centers, nursing homes, and other medical facilities. Southern Home Medical, Inc. is based in Greer, South Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "SC",
        "city": "Greer",
        "zipcode": "29651",
        "website": "http://www.southernhomemedical.com",
        "market_cap": "Small Cap"
    },
    "SIBN": {
        "short_name": "SI-BONE, Inc.",
        "long_name": "SI-BONE, Inc.",
        "summary": "SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Clara",
        "zipcode": "95050",
        "website": "http://si-bone.com",
        "market_cap": "Small Cap"
    },
    "SIEN": {
        "short_name": "Sientra, Inc.",
        "long_name": "Sientra, Inc.",
        "summary": "Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States and internationally. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Barbara",
        "zipcode": "93117",
        "website": "http://sientra.com",
        "market_cap": "Small Cap"
    },
    "SIGA": {
        "short_name": "SIGA Technologies Inc.",
        "long_name": "SIGA Technologies, Inc.",
        "summary": "SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was founded in 1995 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10065",
        "website": "http://www.siga.com",
        "market_cap": "Small Cap"
    },
    "SIGO": {
        "short_name": "SUNSET ISLAND GROUP INC",
        "long_name": "Sunset Island Group, Inc.",
        "summary": "Sunset Island Group, Inc., through its subsidiary, VBF Brands, engages in the cultivation of medical cannabis in California, the United States. It also offers consulting and services to clients that operate in the medical marijuana business. Sunset Island Group, Inc. was incorporated in 2005 and is based in San Clemente, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Clemente",
        "zipcode": "92672",
        "website": "http://www.sunsetislandgroup.com",
        "market_cap": "Small Cap"
    },
    "SIGY": {
        "short_name": "SIGYN THERAPEUTICS INC",
        "long_name": "Sigyn Therapeutics, Inc.",
        "summary": "Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company that treats inflammatory conditions by cytokine storm syndrome. It offers Sigyn Therapy, a blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. The company also engages in evaluating the Sigyn Therapy to address CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92108",
        "website": "http://www.sigyntherapeutics.com",
        "market_cap": "Small Cap"
    },
    "SILK": {
        "short_name": "Silk Road Medical, Inc.",
        "long_name": "Silk Road Medical, Inc",
        "summary": "Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products includes ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Sunnyvale",
        "zipcode": "94089",
        "website": "http://silkroadmed.com",
        "market_cap": "Mid Cap"
    },
    "SILO.CN": {
        "short_name": "SiloWellness",
        "long_name": "Silo Wellness Inc.",
        "summary": "FlyOverture Equity Inc. doing business as Silo Wellness, engages in producing plant and fungal-based compounds for natural wellness. It offers psilocybin nasal spray made from cannabis. FlyOverture Equity Inc. was formerly known as Eighteen Fifty Equity, Inc. The company was founded in 2018 and is headquartered in Springfield, Oregon.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "OR",
        "city": "Springfield",
        "zipcode": "97478",
        "website": "http://www.silowellness.com",
        "market_cap": null
    },
    "SILO": {
        "short_name": "SILO PHARMA INC",
        "long_name": "Silo Pharma, Inc.",
        "summary": "Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research to address conditions, such as depression, post-traumatic stress disorder, Parkinson's, and other rare neurological disorders. It also offers NFID (No Found Identification) branded apparels, which include sweatshirts, hoodies, T-shirts, jackets, and hats. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Englewood Cliffs, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Englewood Cliffs",
        "zipcode": "07632",
        "website": "http://silopharma.com",
        "market_cap": "Small Cap"
    },
    "SINT": {
        "short_name": "SiNtx Technologies, Inc.",
        "long_name": "Sintx Technologies, Inc.",
        "summary": "Sintx Technologies, Inc., an advanced materials company, researches, develops, manufactures, and commercializes silicon nitride ceramics in the United States, Europe, and South America. It offers ceramic based solutions for various medical, industrial, and antipathogenic applications. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84119",
        "website": "http://www.sintx.com",
        "market_cap": "Small Cap"
    },
    "SIOX": {
        "short_name": "Sio Gene Therapies Inc.",
        "long_name": "Sio Gene Therapies, Inc.",
        "summary": "Sio Gene Therapies, Inc., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was founded in 2014 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.siogtx.com",
        "market_cap": "Small Cap"
    },
    "SKYE": {
        "short_name": "SKYE BIOSCIENCE INC",
        "long_name": "Skye Bioscience, Inc.",
        "summary": "Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based therapeutics for the treatment of infectious diseases. The company's lead product candidate is THCVHS, which is in preclinical trials for the treatment of glaucoma. It is also developing CBDVHS that is in preclinical trials to treat various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy; and Cannabinoid Cocktail for the treatment of anti-infective diseases. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://skyebioscience.com",
        "market_cap": "Small Cap"
    },
    "SLDB": {
        "short_name": "Solid Biosciences Inc.",
        "long_name": "Solid Biosciences Inc.",
        "summary": "Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.solidbio.com",
        "market_cap": "Small Cap"
    },
    "SLDX": {
        "short_name": "STELLA DIAGNOSTICS INC",
        "long_name": "Stella Diagnostics Inc.",
        "summary": "Stella Diagnostics, Inc., a molecular diagnostics-based company, focuses on enhancing patient management strategies for people living with severe esophageal diseases. Its clinical assays offer physicians insight into the molecular properties of patients' tissue to determine if the disease is stable, progressing, or turning cancerous. The company is also developing diagnostic tools that provides molecular information for providers as compared to the screening protocols. The company was formerly known as JMP Properties, Inc. and changed its name to Stella Diagnostics, Inc. in April 2021. Stella Diagnostics, Inc. is based in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84104",
        "website": "http://www.stelladx.com",
        "market_cap": null
    },
    "SLJ.F": {
        "short_name": "INTRICON CORP.  DL 1",
        "long_name": "IntriCon Corporation",
        "summary": "IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. It offers micro-miniature products, microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components, and assemblies and software solutions for medical devices, hearing healthcare, and professional audio communication devices markets. The company also provides micro coils for surgical navigation clinical applications, such as interventional pulmonology, and electrophysiology; joint engineering and manufacturing services for complex medical devices, including catheters covering a range of applications for cardiology, peripheral vascular, neurology, radiology, and pulmonology; bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system; and safety needle products for original equipment manufacturing customers. In addition, it offers professional audio headset products used for emergency response needs in the fire, law enforcement, safety, aviation, and military markets; and a line of miniature ear-and head-worn devices used by performers and support staff in the music and stage performance markets. The company sells its hearing device products, and medical and professional audio communications products directly to hearing instrument manufacturers, distributors, and partnerships; and microphone products to the radio communication and professional audio industries, as well as markets and sells hearing aid devices directly to consumers through direct mail advertising, Internet, and call center. The company was formerly known as Selas Corporation of America and changed its name to IntriCon Corporation. The company was incorporated in 1930 and is headquartered in Arden Hills, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Arden Hills",
        "zipcode": "55112",
        "website": "http://www.intricon.com",
        "market_cap": "Small Cap"
    },
    "SLNO": {
        "short_name": "Soleno Therapeutics, Inc.",
        "long_name": "Soleno Therapeutics, Inc.",
        "summary": "Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94065",
        "website": "http://soleno.life",
        "market_cap": "Small Cap"
    },
    "SLNX": {
        "short_name": "SOLANBRIDGE GROUP INC",
        "long_name": "Solanbridge Group, Inc.",
        "summary": "Solanbridge Group, Inc. intends to produce and sell medical marijuana in Nova Scotia, Canada. It also focuses on the development and sale of CBD-infused products in Nevada, California, and Colorado. The company was founded in 2000 and is headquartered in The Woodlands, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "The Woodlands",
        "zipcode": "77380",
        "website": "http://www.solanbridgegroup.com",
        "market_cap": "Small Cap"
    },
    "SLP": {
        "short_name": "Simulations Plus, Inc.",
        "long_name": "Simulations Plus, Inc.",
        "summary": "Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Lancaster",
        "zipcode": "93534-7059",
        "website": "http://www.simulations-plus.com",
        "market_cap": "Small Cap"
    },
    "SLRX": {
        "short_name": "Salarius Pharmaceuticals, Inc.",
        "long_name": "Salarius Pharmaceuticals, Inc.",
        "summary": "Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77021",
        "website": "http://www.salariuspharma.com",
        "market_cap": "Small Cap"
    },
    "SLS": {
        "short_name": "SELLAS Life Sciences Group, Inc",
        "long_name": "SELLAS Life Sciences Group, Inc.",
        "summary": "SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.sellaslifesciences.com",
        "market_cap": "Small Cap"
    },
    "SLZ.F": {
        "short_name": "ENVERIC BIOSCI.INC.DL-,01",
        "long_name": "Enveric Biosciences, Inc.",
        "summary": "Enveric Biosciences, Inc., a biotechnology company, engages in developing various cannabinoid medicines to enhance quality of life for cancer patients. It has a pipeline of development programs for radiodermatitis, glioblastoma, and chemotherapy-induced neuropathy. The company is based in Naples, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Naples",
        "zipcode": "34103",
        "website": "http://www.enveric.com",
        "market_cap": "Small Cap"
    },
    "SMEV": {
        "short_name": "SIMULATED ENVIRONMENT CONCEPTS ",
        "long_name": "Simulated Environment Concepts, Inc.",
        "summary": "Simulated Environment Concepts, Inc. engages in the development and manufacture of medical, health, and wellness equipments in the United States and internationally. Its products include SpaCapsule, a robotic massage therapy system used for medical rehabilitation, relaxation, weight loss, slimming, cellulite management, and general wellness; and PTjetCapsule. The company also offers components, parts, accessories, and peripheral massage and health related items. Its products are used in various environments, such as corporate employee lounges, relaxation centers, gyms and health clubs, doctor's offices, hotels, tanning and beauty salons/spas, luxury accommodations, gulf clubs, ski lounges, shopping centers and malls, airports, cruise ships, luxury yachts, and homes. Simulated Environment Concepts, Inc. was founded in 1993 and is based in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33179",
        "website": null,
        "market_cap": "Small Cap"
    },
    "SMLR": {
        "short_name": "SEMLER SCIENTIFIC INC",
        "long_name": "Semler Scientific, Inc.",
        "summary": "Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Clara",
        "zipcode": "95051",
        "website": "http://www.semlerscientific.com",
        "market_cap": "Small Cap"
    },
    "SMMT": {
        "short_name": "Summit Therapeutics Inc.",
        "long_name": "Summit Therapeutics Inc.",
        "summary": "Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.summittxinc.com",
        "market_cap": "Small Cap"
    },
    "SMTI": {
        "short_name": "Sanara MedTech Inc.",
        "long_name": "Sanara MedTech Inc.",
        "summary": "Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical Activated Collagen Adjuvant powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako\u00c2\u00afs Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako\u00c2\u00afs Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako\u00c2\u00afs Antimicrobial Skin and Wound Irrigation Solution. It also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers; and PULSAR II Advanced Wound Irrigation System, a portable and no touch hydro-mechanical debridement system that removes bacteria and necrotic tissue without disrupting healthy tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Fort Worth",
        "zipcode": "76102",
        "website": "http://sanaramedtech.com",
        "market_cap": "Small Cap"
    },
    "SNDD": {
        "short_name": "REDHAWK HOLDINGS CORP",
        "long_name": "RedHawk Holdings Corp.",
        "summary": "RedHawk Holdings Corp., through its subsidiaries, engages in sale and distribution of medical devices, and sale of branded generic pharmaceutical drugs primarily in the United States and the United Kingdom. It operates in three segments: Land & Hospitality, Medical Device and Pharmaceutical, and Other Services. The company manufactures and sells Sharps and Needle Destruction Devices; carotid artery digital non-contact thermometers; and Centri Controlled Entry System, a full body X-ray scanner. It also distributes WoundClot, a bleeding control medical device; Berrcom JXB178 infrared non-contact thermometers; and Zonis. In addition, RedHawk Holdings Corp. sells a line of face masks and face shields, including a level 1 single use disposable mask, a three layer level 3 cotton masks, and KN95 and N95 masks; an anti-fog and anti-static splash protection face shield; and a line of ultraviolet sanitation lights, including tabletop and handheld devices, as well as branded generic pharmaceuticals, such as Paracetamol, Glipizide, and Omeprazole. The company serves retail pharmacies, hospitals, physicians' offices, private and public healthcare clinics, corrections facilities, schools, veterinary clinics, emergency services, first responders, municipalities, and long term care facilities. In addition, it is involved in the commercial and residential property investment and leasing activities; sale of point of entry full-body security systems; and provision of specialized financial services. The company was formerly known as Independence Energy Corp. and changed its name to RedHawk Holdings Corp. in October 2015. RedHawk Holdings Corp. was incorporated in 2005 and is headquartered in Lafayette, Louisiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "LA",
        "city": "Lafayette",
        "zipcode": "70508",
        "website": "http://www.redhawkholdingscorp.com",
        "market_cap": "Small Cap"
    },
    "SNDX": {
        "short_name": "Syndax Pharmaceuticals, Inc.",
        "long_name": "Syndax Pharmaceuticals, Inc.",
        "summary": "Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.syndax.com",
        "market_cap": "Small Cap"
    },
    "SNDZ": {
        "short_name": "SUNRIDGE INTERNATIONAL",
        "long_name": "Sunridge International, Inc.",
        "summary": "Sunridge International, Inc. manufactures and markets patented vacuum fixation devices and suction rings for the treatment of open angle and pigmentary glaucoma worldwide. It serves medical supply companies and health care providers. The company was founded in 1997 and is based in Fountain Hills, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Fountain Hills",
        "zipcode": "85268",
        "website": null,
        "market_cap": "Small Cap"
    },
    "SNGX": {
        "short_name": "Soligenix, Inc.",
        "long_name": "Soligenix, Inc.",
        "summary": "Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which has completed Phase I/II clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease and SGX201 for acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.soligenix.com",
        "market_cap": "Small Cap"
    },
    "SNNAQ": {
        "short_name": "SIENNA BIOPHARMACEUTICALS INC",
        "long_name": "Sienna Biopharmaceuticals, Inc.",
        "summary": "Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Westlake Village",
        "zipcode": "91362",
        "website": "http://www.siennabio.com",
        "market_cap": "Small Cap"
    },
    "SNNC": {
        "short_name": "SIBANNAC INC",
        "long_name": "Sibannac, Inc.",
        "summary": "Sibannac, Inc. operates as a media and management services company. It serves businesses with online marketing, advertising, sales tracking, management consulting, and other informational services. The company also provides accounting, and expense and labor management systems to assist in compliance in the regulated industry environment. Sibannac, Inc. is based in Phoenix, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Phoenix",
        "zipcode": "85016",
        "website": null,
        "market_cap": "Small Cap"
    },
    "SNOA": {
        "short_name": "Sonoma Pharmaceuticals, Inc.",
        "long_name": "Sonoma Pharmaceuticals, Inc.",
        "summary": "Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Woodstock",
        "zipcode": "30102",
        "website": "http://www.sonomapharma.com",
        "market_cap": "Small Cap"
    },
    "SNPX": {
        "short_name": "Synaptogenix, Inc.",
        "long_name": "Synaptogenix, Inc.",
        "summary": "Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10036",
        "website": "http://www.synaptogen.com",
        "market_cap": "Small Cap"
    },
    "SNSE": {
        "short_name": "Sensei Biotherapeutics, Inc.",
        "long_name": "Sensei Biotherapeutics, Inc.",
        "summary": "Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.senseibio.com",
        "market_cap": "Small Cap"
    },
    "SNWV": {
        "short_name": "SANUWAVE HEALTH INC",
        "long_name": "SANUWAVE Health, Inc.",
        "summary": "SANUWAVE Health, Inc., a shock wave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States, Europe, Canada, Asia, and the Asia Pacific. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device that has completed its Phase III clinical studies for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. It markets and sells its devices and accessories. SANUWAVE Health, Inc. was founded in 2005 and is headquartered in Suwanee, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Suwanee",
        "zipcode": "30024",
        "website": "http://www.sanuwave.com",
        "market_cap": "Small Cap"
    },
    "SNYR": {
        "short_name": "SYNERGY CHC CORP",
        "long_name": "Synergy CHC Corp.",
        "summary": "Synergy CHC Corp., a consumer health care and beauty company, markets and distributes various consumer branded products primarily in the health and wellness industry in North America. The company offers FOCUSfactor, a brain-health nutritional supplement that includes a proprietary blend of brain supporting vitamins, minerals, antioxidants, and other nutrients; Hand MD, an anti-aging skincare line formulated for the hands; and Flat Tummy brand products, including tea, shakes, lollipops, and supplements, as well as apparel, a mobile App and exercise accessories. It also provides Neuragen, a topical product that works directly at the site of the pain as opposed to oral products; Sneaky Vaunt, a backless, strapless, stick on, and push up bra; and Think Fuel, a nootropic supplement for enhancing brain function. Synergy CHC Corp. sells its products directly to wholesalers and distributors; and online through flattummyco.com, handmd.com, sneakyvaunt.com, and www.thinkfuel.com, as well as through retail distribution channels. The company was formerly known as Synergy Strips Corp. and changed its name to Synergy CHC Corp. in August 2015. Synergy CHC Corp. was founded in 2010 and is based in Westbrook, Maine.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "ME",
        "city": "Westbrook",
        "zipcode": "04092",
        "website": "http://www.synergychc.com",
        "market_cap": "Small Cap"
    },
    "SOAN": {
        "short_name": "ANGIOSOMA INC",
        "long_name": "AngioSoma, Inc.",
        "summary": "AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77042",
        "website": "http://angiosoma.com",
        "market_cap": "Small Cap"
    },
    "SOLY": {
        "short_name": "Soliton, Inc.",
        "long_name": "Soliton, Inc.",
        "summary": "Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. The company offers products for the removal of tattoos. It also develops a product for cellulite reduction, fibrotic scar treatment, and other indications. The company was incorporated in 2012 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77081",
        "website": "http://www.soliton.com",
        "market_cap": "Small Cap"
    },
    "SONN": {
        "short_name": "Sonnet BioTherapeutics Holdings",
        "long_name": "Sonnet BioTherapeutics Holdings, Inc.",
        "summary": "Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.sonnetbio.com",
        "market_cap": "Small Cap"
    },
    "SPHS": {
        "short_name": "SOPHIRIS BIO INC",
        "long_name": "Sophiris Bio, Inc.",
        "summary": "Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "La Jolla",
        "zipcode": "92037",
        "website": "http://www.sophirisbio.com",
        "market_cap": "Small Cap"
    },
    "SPIN": {
        "short_name": "SPINE INJURY SOLUTIONS INC",
        "long_name": "Spine Injury Solutions, Inc.",
        "summary": "Spine Injury Solutions, Inc., together with its subsidiaries, operates as a technology, marketing, billing, and collection company that provides diagnostic services for patients with spine injuries resulting from traumatic accidents. The company offers turnkey solutions to spine surgeons, orthopedic surgeons, and other healthcare providers for the treatment of musculo-skeletal spine injuries resulting from automobile and work-related accidents. The company was formerly known as Spine Pain Management Inc. and changed its name to Spine Injury Solutions, Inc. in October 2015. Spine Injury Solutions, Inc. was incorporated in 1998 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77092",
        "website": "http://www.spineinjurysolutions.com",
        "market_cap": "Small Cap"
    },
    "SPNE": {
        "short_name": "SeaSpine Holdings Corporation",
        "long_name": "SeaSpine Holdings Corporation",
        "summary": "SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and demineralized bone matrices. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive surgery, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical spine. The company has development and licensing agreement with restor3d, Inc. and 7D Surgical, Inc. to develop 3D-printed interbody devices. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Carlsbad",
        "zipcode": "92008",
        "website": "http://www.seaspine.com",
        "market_cap": "Small Cap"
    },
    "SPPI": {
        "short_name": "Spectrum Pharmaceuticals, Inc.",
        "long_name": "Spectrum Pharmaceuticals, Inc.",
        "summary": "Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Henderson",
        "zipcode": "89052",
        "website": "http://www.sppirx.com",
        "market_cap": "Small Cap"
    },
    "SPRB": {
        "short_name": "Spruce Biosciences, Inc.",
        "long_name": "Spruce Biosciences, Inc.",
        "summary": "Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Daly City",
        "zipcode": "94014",
        "website": "http://www.sprucebiosciences.com",
        "market_cap": "Small Cap"
    },
    "SPRO": {
        "short_name": "Spero Therapeutics, Inc.",
        "long_name": "Spero Therapeutics, Inc.",
        "summary": "Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://sperotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "SQZ": {
        "short_name": "SQZ Biotechnologies Company",
        "long_name": "SQZ Biotechnologies Company",
        "summary": "SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Watertown",
        "zipcode": "02472",
        "website": "http://www.sqzbiotech.com",
        "market_cap": "Small Cap"
    },
    "SR3.F": {
        "short_name": "STAAR SURGICAL CO. DL-,01",
        "long_name": "STAAR Surgical Company",
        "summary": "STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Lake Forest",
        "zipcode": "92630",
        "website": "http://www.staar.com",
        "market_cap": "Mid Cap"
    },
    "SRDX": {
        "short_name": "Surmodics, Inc.",
        "long_name": "Surmodics, Inc.",
        "summary": "Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Eden Prairie",
        "zipcode": "55344",
        "website": "http://www.surmodics.com",
        "market_cap": "Small Cap"
    },
    "SRGA": {
        "short_name": "Surgalign Holdings, Inc.",
        "long_name": "Surgalign Holdings, Inc.",
        "summary": "Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.surgalign.com",
        "market_cap": "Small Cap"
    },
    "SRNE": {
        "short_name": "Sorrento Therapeutics, Inc.",
        "long_name": "Sorrento Therapeutics, Inc.",
        "summary": "Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.sorrentotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "SRPT": {
        "short_name": "Sarepta Therapeutics, Inc.",
        "long_name": "Sarepta Therapeutics, Inc.",
        "summary": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.sarepta.com",
        "market_cap": "Mid Cap"
    },
    "SRRA": {
        "short_name": "Sierra Oncology, Inc.",
        "long_name": "Sierra Oncology, Inc.",
        "summary": "Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Mateo",
        "zipcode": "94404",
        "website": "http://www.sierraoncology.com",
        "market_cap": "Small Cap"
    },
    "SRRK": {
        "short_name": "Scholar Rock Holding Corporatio",
        "long_name": "Scholar Rock Holding Corporation",
        "summary": "Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1. It is developing a pipeline of novel product candidates for a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://scholarrock.com",
        "market_cap": "Small Cap"
    },
    "SRTS": {
        "short_name": "Sensus Healthcare, Inc.",
        "long_name": "Sensus Healthcare, Inc.",
        "summary": "Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary modulated robotic brachytherapy oncology therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33487",
        "website": "http://www.sensushealthcare.com",
        "market_cap": "Small Cap"
    },
    "SSKN": {
        "short_name": "Strata Skin Sciences, Inc.",
        "long_name": "STRATA Skin Sciences, Inc.",
        "summary": "STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC excimer laser and VTRAC lamp systems that are used for the treatment of psoriasis, vitiligo, atopic dermatitis, eczema, and other skin disorders. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Horsham",
        "zipcode": "19044",
        "website": "http://www.strataskinsciences.com",
        "market_cap": "Small Cap"
    },
    "SSUR": {
        "short_name": "STATSURE DIAGNOSTIC SYSTEMS INC",
        "long_name": "StatSure Diagnostic Systems, Inc.",
        "summary": "StatSure Diagnostic Systems, Inc. develops, manufactures, and markets rapid in-vitro assays for use in the detection of infectious diseases and other conditions in the United States and internationally. The company offers SURE CHECK HIV 1/2 and Clearview Complete HIV 1/ 2 tests, which are single-use diagnostic tests for visual detection of antibodies to HIV 1 and HIV 2. It also provides medical specimen collection devices. The company was founded in 1986 and is based in Brooklyn, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Brooklyn",
        "zipcode": "11230",
        "website": "http://www.statsurediagnostics.com",
        "market_cap": "Small Cap"
    },
    "SSY": {
        "short_name": "SunLink Health Systems, Inc.",
        "long_name": "SunLink Health Systems, Inc.",
        "summary": "SunLink Health Systems, Inc., through its subsidiaries, provides healthcare products and services in the southeastern United States. It operates through two segments, Healthcare Services and Pharmacy. The Healthcare Services segment owns and operates an 84-bed community hospital, which includes an 18-bed geriatric psychiatry unit and a 66-bed nursing home in Mississippi; as well as offers information technology services. This segment also owns unimproved lands. The Pharmacy segment offers institutional and non-institutional pharmacy services; and durable medical equipment products and services, which consist of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care, as well as retail pharmacy products and services. SunLink Health Systems, Inc. was founded in 1959 and is based in Atlanta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Atlanta",
        "zipcode": "30339",
        "website": "http://www.sunlinkhealth.com",
        "market_cap": "Small Cap"
    },
    "STAA": {
        "short_name": "STAAR Surgical Company",
        "long_name": "STAAR Surgical Company",
        "summary": "STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Lake Forest",
        "zipcode": "92630",
        "website": "http://www.staar.com",
        "market_cap": "Mid Cap"
    },
    "STAU": {
        "short_name": "STAR NUTRITION INC",
        "long_name": "Star Nutrition, Inc.",
        "summary": "Star Nutrition, Inc. engages in the manufacture of nutritional supplements, vitamins, and other over the counter health care products in the United States. Its products include incredisocks, incredibraces, and incredisoles used for foot and back pain. The company is based in Chico, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Chico",
        "zipcode": "95926-3948",
        "website": null,
        "market_cap": "Small Cap"
    },
    "STEM.CN": {
        "short_name": "StemHoldingsInc",
        "long_name": "Stem Holdings, Inc.",
        "summary": "Stem Holdings, Inc., together with its subsidiaries, operates as a vertically integrated cannabis operating company. It is involved in manufacture, possession, use, sale, distribution, and branding of cannabis and cannabis-infused products under the laws of the states of Oregon, Nevada, California, Massachusetts, and Oklahoma. As of December 30, 2020, the company had ownership interests in 22 state issued cannabis and hemp licenses, including 10 licenses for cannabis cultivation; 4 licenses for cannabis processing; 1 license for cannabis wholesale distribution; 1 license for hemp production and processing; 5 cannabis dispensary licenses; and 1 license that permits both dispensary and cultivation activities. Stem Holdings, Inc. was founded in 2016 and is headquartered in Boca Raton, Florida.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33431",
        "website": "http://www.stemholdings.com",
        "market_cap": "Small Cap"
    },
    "STIM": {
        "short_name": "Neuronetics, Inc.",
        "long_name": "Neuronetics, Inc.",
        "summary": "Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.neurostar.com",
        "market_cap": "Small Cap"
    },
    "STMH": {
        "short_name": "STEM HOLDINGS INC",
        "long_name": "Stem Holdings, Inc.",
        "summary": "Stem Holdings, Inc., together with its subsidiaries, operates as a vertically integrated cannabis operating company. It is involved in manufacture, possession, use, sale, distribution, and branding of cannabis and cannabis-infused products under the laws of the states of Oregon, Nevada, California, Massachusetts, and Oklahoma. As of December 30, 2020, the company had ownership interests in 22 state issued cannabis and hemp licenses, including 10 licenses for cannabis cultivation; 4 licenses for cannabis processing; 1 license for cannabis wholesale distribution; 1 license for hemp production and processing; 5 cannabis dispensary licenses; and 1 license that permits both dispensary and cultivation activities. Stem Holdings, Inc. was founded in 2016 and is headquartered in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33431",
        "website": "http://www.stemholdings.com",
        "market_cap": "Small Cap"
    },
    "STOK": {
        "short_name": "Stoke Therapeutics, Inc.",
        "long_name": "Stoke Therapeutics, Inc.",
        "summary": "Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Bedford",
        "zipcode": "01730",
        "website": "http://www.stoketherapeutics.com",
        "market_cap": "Small Cap"
    },
    "STRM": {
        "short_name": "Streamline Health Solutions, In",
        "long_name": "Streamline Health Solutions, Inc.",
        "summary": "Streamline Health Solutions, Inc. provides health information technology solutions and associated services for hospitals and health systems in the United States and Canada. It provides computer software-based solutions and auditing services, which captures, aggregates, and translates structured and unstructured data to deliver predictive insights. The company also offers coding and clinical documentation improvement (CDI) solutions, which includes integrated cloud-based software suite, CDI, and abstracting and physician query; and eValuator, a cloud-based pre-bill coding analysis platform. In addition, it provides financial management solutions, including accounts receivable management, denials management, claims processing, spend management, and audit management; patient care solutions; and custom integration services for CDI/abstracting, training, and audit services. The company sells its solutions and services through direct sales force and reseller partnerships. Streamline Health Solutions, Inc. was incorporated in 1989 and is based in Alpharetta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30009",
        "website": "http://www.streamlinehealth.net",
        "market_cap": "Small Cap"
    },
    "STRO": {
        "short_name": "Sutro Biopharma, Inc.",
        "long_name": "Sutro Biopharma, Inc.",
        "summary": "Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.sutrobio.com",
        "market_cap": "Small Cap"
    },
    "STRR": {
        "short_name": "Star Equity Holdings, Inc.",
        "long_name": "Star Equity Holdings, Inc.",
        "summary": "Star Equity Holdings, Inc. provides healthcare solutions in the United States and internationally. It operates through four segments: Diagnostic Services, Diagnostic Imaging, Building and Construction, and Real Estate and Investments. The company offers imaging and monitoring services to healthcare providers; and contract diagnostic imaging, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to cardiologists, internal medicine physicians, family practice physicians, hospitals, IDNs, and federal institutions. It also develops, sells, and maintains solid-state gamma cameras; imaging systems, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; and manages and finances real estate assets and investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Old Greenwich",
        "zipcode": "06870",
        "website": "http://www.starequity.com",
        "market_cap": "Small Cap"
    },
    "STRRP": {
        "short_name": "Star Equity Holdings, Inc. - Se",
        "long_name": "Star Equity Holdings, Inc.",
        "summary": "Star Equity Holdings, Inc. provides healthcare solutions in the United States and internationally. It operates through four segments: Diagnostic Services, Diagnostic Imaging, Building and Construction, and Real Estate and Investments. The company offers imaging and monitoring services to healthcare providers; and contract diagnostic imaging, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to cardiologists, internal medicine physicians, family practice physicians, hospitals, IDNs, and federal institutions. It also develops, sells, and maintains solid-state gamma cameras; imaging systems, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; and manages and finances real estate assets and investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Old Greenwich",
        "zipcode": "06870",
        "website": "http://www.starequity.com",
        "market_cap": null
    },
    "STSA": {
        "short_name": "Satsuma Pharmaceuticals, Inc.",
        "long_name": "Satsuma Pharmaceuticals, Inc.",
        "summary": "Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.satsumarx.com",
        "market_cap": "Small Cap"
    },
    "STSN": {
        "short_name": "STEMSATION INTERNATIONAL INC",
        "long_name": "Stemsation International, Inc.",
        "summary": "StemSation International, Inc. develops, manufactures, and distributes natural wellness products that support the stem cell and endocannabinoid systems in the human body. It offers StemRCM, a dietary supplement that supports stem cells ability to repair, renew, and restore tissues and organ function through healthy stem cell release, circulation, and migration. The company sells its products through independent wellness advocates directly to consumers. StemSation International, Inc. is headquartered in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33434",
        "website": "http://www.stemsation.global",
        "market_cap": "Small Cap"
    },
    "STTK": {
        "short_name": "Shattuck Labs, Inc.",
        "long_name": "Shattuck Labs, Inc.",
        "summary": "Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78703",
        "website": "http://www.shattucklabs.com",
        "market_cap": "Small Cap"
    },
    "STXS": {
        "short_name": "Stereotaxis, Inc.",
        "long_name": "Stereotaxis, Inc.",
        "summary": "Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "MO",
        "city": "Saint Louis",
        "zipcode": "63108",
        "website": "http://www.stereotaxis.com",
        "market_cap": "Small Cap"
    },
    "SU6.F": {
        "short_name": "SURMODICS  DL-,05",
        "long_name": "Surmodics, Inc.",
        "summary": "Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Eden Prairie",
        "zipcode": "55344",
        "website": "http://www.surmodics.com",
        "market_cap": "Small Cap"
    },
    "SUPN": {
        "short_name": "Supernus Pharmaceuticals, Inc.",
        "long_name": "Supernus Pharmaceuticals, Inc.",
        "summary": "Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.supernus.com",
        "market_cap": "Small Cap"
    },
    "SURF": {
        "short_name": "Surface Oncology, Inc.",
        "long_name": "Surface Oncology, Inc.",
        "summary": "Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.surfaceoncology.com",
        "market_cap": "Small Cap"
    },
    "SUVZ": {
        "short_name": "SUVANZA",
        "long_name": "Suvanza Pharma, LLC",
        "summary": "Suvanza Pharma, LLC operates as an early-stage biotechnology corporation and engages in the development of the skin drug delivery system, RapiDerm for dermatologic diseases. Suvanza Pharma, LLC was formerly known as Hamilton PNG and changed its name to Suvanza Pharma, LLC in March 2010. The company was founded in 2004 and is based in Miami Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami Beach",
        "zipcode": "33140",
        "website": "http://www.suvanza.com",
        "market_cap": "Small Cap"
    },
    "SVRA": {
        "short_name": "Savara, Inc.",
        "long_name": "Savara Inc.",
        "summary": "Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78746",
        "website": "http://www.savarapharma.com",
        "market_cap": "Small Cap"
    },
    "SVSO": {
        "short_name": "SHEERVISION INC",
        "long_name": "SheerVision, Inc.",
        "summary": "SheerVision, Inc. designs, develops, and manufactures loupe and headlight systems for surgical, dental, dental hygiene, and veterinary markets. Its products include flip-up, through the lens, V-RAY, infinity ultra2, ultra mini surgical headlights, and dental headlights. The company sells its products through distributors and e-commerce Website. SheerVision, Inc. was founded in 1999 and is based in Rolling Hills Estates, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Rolling Hills Estates",
        "zipcode": "90274",
        "website": "http://www.sheervision.com",
        "market_cap": "Small Cap"
    },
    "SWAV": {
        "short_name": "ShockWave Medical, Inc.",
        "long_name": "ShockWave Medical, Inc.",
        "summary": "ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Clara",
        "zipcode": "95054",
        "website": "http://www.shockwavemedical.com",
        "market_cap": "Mid Cap"
    },
    "SWNM": {
        "short_name": "SOUTHWESTERN MEDICAL SOLUTIONS ",
        "long_name": "Southwestern Medical Solutions, Inc.",
        "summary": "Southwestern Medical Solutions, Inc. engages in the research and development of medical devices. The company offers LabGuard Accucheck, a device for on-site collection/analysis and testing to provide results for on-site diagnostic testing/screening market. The company was incorporated in 2003 and is based in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33618",
        "website": null,
        "market_cap": "Small Cap"
    },
    "SWTX": {
        "short_name": "SpringWorks Therapeutics, Inc.",
        "long_name": "SpringWorks Therapeutics, Inc.",
        "summary": "SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "Stamford",
        "zipcode": "06902",
        "website": "http://www.springworkstx.com",
        "market_cap": "Mid Cap"
    },
    "SYBX": {
        "short_name": "Synlogic, Inc.",
        "long_name": "Synlogic, Inc.",
        "summary": "Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.synlogictx.com",
        "market_cap": "Small Cap"
    },
    "SYK.DE": {
        "short_name": "STRYKER CORP.  DL-,10",
        "long_name": "Stryker Corporation",
        "summary": "Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "MI",
        "city": "Kalamazoo",
        "zipcode": "49002",
        "website": "http://www.stryker.com",
        "market_cap": "Large Cap"
    },
    "SYK.F": {
        "short_name": "STRYKER CORP.  DL-,10",
        "long_name": "Stryker Corporation",
        "summary": "Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MI",
        "city": "Kalamazoo",
        "zipcode": "49002",
        "website": "http://www.stryker.com",
        "market_cap": "Large Cap"
    },
    "SYK.MX": {
        "short_name": "STRYKER CORP",
        "long_name": "Stryker Corporation",
        "summary": "Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MI",
        "city": "Kalamazoo",
        "zipcode": "49002",
        "website": "http://www.stryker.com",
        "market_cap": "Large Cap"
    },
    "SYK": {
        "short_name": "Stryker Corporation",
        "long_name": "Stryker Corporation",
        "summary": "Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Kalamazoo",
        "zipcode": "49002",
        "website": "http://www.stryker.com",
        "market_cap": "Large Cap"
    },
    "SYK.VI": {
        "short_name": "STRYKER CORP",
        "long_name": "Stryker Corporation",
        "summary": "Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "MI",
        "city": "Kalamazoo",
        "zipcode": "49002",
        "website": "http://www.stryker.com",
        "market_cap": "Large Cap"
    },
    "SYN": {
        "short_name": "Synthetic Biologics, Inc.",
        "long_name": "Synthetic Biologics, Inc.",
        "summary": "Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.syntheticbiologics.com",
        "market_cap": "Small Cap"
    },
    "SYNH": {
        "short_name": "Syneos Health, Inc.",
        "long_name": "Syneos Health, Inc.",
        "summary": "Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560-5468",
        "website": "http://www.syneoshealth.com",
        "market_cap": "Mid Cap"
    },
    "SYRS": {
        "short_name": "Syros Pharmaceuticals, Inc.",
        "long_name": "Syros Pharmaceuticals, Inc.",
        "summary": "Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02140",
        "website": "http://www.syros.com",
        "market_cap": "Small Cap"
    },
    "T051.F": {
        "short_name": "TRACON PHARMACEUT.DL-,001",
        "long_name": "TRACON Pharmaceuticals, Inc.",
        "summary": "TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.traconpharma.com",
        "market_cap": "Small Cap"
    },
    "T1CH34.SA": {
        "short_name": "BIO-TECHNE CDRN",
        "long_name": "Bio-Techne Corporation",
        "summary": "Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55413",
        "website": "http://www.bio-techne.com",
        "market_cap": "Large Cap"
    },
    "T2DH34.SA": {
        "short_name": "TELADOCHEALTDRN",
        "long_name": "Teladoc Health, Inc.",
        "summary": "Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, chronic condition management, expert medical services, behavioral health solutions, guidance and support, and platform and program services. It serves health employers, health plans, hospitals, health systems, and insurance and financial services companies. The company offers its products and services under the Teladoc, Livongo, Advance Medical, Best Doctors, BetterHelp, and HealthiestYou brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was Incorporated in 2002 and is headquartered in Purchase, New York.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NY",
        "city": "Purchase",
        "zipcode": "10577",
        "website": "http://www.teladochealth.com",
        "market_cap": "Large Cap"
    },
    "TARA": {
        "short_name": "Protara Therapeutics, Inc.",
        "long_name": "Protara Therapeutics, Inc.",
        "summary": "Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10010",
        "website": "http://www.protaratx.com",
        "market_cap": "Small Cap"
    },
    "TARS": {
        "short_name": "Tarsus Pharmaceuticals, Inc.",
        "long_name": "Tarsus Pharmaceuticals, Inc.",
        "summary": "Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92618",
        "website": "http://www.tarsusrx.com",
        "market_cap": "Small Cap"
    },
    "TAUG": {
        "short_name": "TAURIGA SCIENCES INC",
        "long_name": "Tauriga Sciences, Inc.",
        "summary": "Tauriga Sciences, Inc. produces and sells cannabidiol infused chewing gum under the Tauri-Gum brand name. It also develops anti-nausea product. The company sells its products through e-commerce, distributors, and wholesale channels. It has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 (novel coronavirus) test. Tauriga Sciences, Inc. was founded in 2001 and is headquartered in Wappingers Falls, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Wappingers Falls",
        "zipcode": "12590",
        "website": "http://www.tauriga.com",
        "market_cap": "Small Cap"
    },
    "TBH.DE": {
        "short_name": "TELEFLEX INC.  DL 1",
        "long_name": "Teleflex Incorporated",
        "summary": "Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "PA",
        "city": "Wayne",
        "zipcode": "19087-1603",
        "website": "http://www.teleflex.com",
        "market_cap": "Large Cap"
    },
    "TBH.F": {
        "short_name": "TELEFLEX INC.  DL 1",
        "long_name": "Teleflex Incorporated",
        "summary": "Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Wayne",
        "zipcode": "19087-1603",
        "website": "http://www.teleflex.com",
        "market_cap": "Large Cap"
    },
    "TBIO": {
        "short_name": "Translate Bio, Inc.",
        "long_name": "Translate Bio, Inc.",
        "summary": "Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.translate.bio",
        "market_cap": "Small Cap"
    },
    "TCCR": {
        "short_name": "TRICCAR INC",
        "long_name": "TRICCAR, Inc.",
        "summary": "TRICCAR, Inc. operates as an integrated biomedical research, development, and marketing company. The company develops bioceutical and pharmaceutical products to support the well-being of humans and animals that have common diseases. It is involved in the research, development, and clinical testing of 38 bioceutical formulations designed to support illnesses and diseases, including formulae built around a patented fruit-based calcium supplement; a weight loss and obesity supplement; a formula that helps relieve the symptoms of menopause; a fast-acting blood performance product that separates white and red blood cells; a mental focus formula to enhance attention and recall of information and beneficial to children diagnosed with attention deficit disorder; a mental acuity formula to enhance memory recall and aid in the formation of new memories; and others. The company is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89107",
        "website": "http://www.triccar.com",
        "market_cap": "Small Cap"
    },
    "TCDA": {
        "short_name": "Tricida, Inc.",
        "long_name": "Tricida, Inc.",
        "summary": "Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.tricida.com",
        "market_cap": "Small Cap"
    },
    "TCE2.F": {
        "short_name": "CELLDEX THER.  DL-,001",
        "long_name": "Celldex Therapeutics, Inc.",
        "summary": "Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Hampton",
        "zipcode": "08827",
        "website": "http://www.celldex.com",
        "market_cap": "Small Cap"
    },
    "TCMD": {
        "short_name": "Tactile Systems Technology, Inc",
        "long_name": "Tactile Systems Technology, Inc.",
        "summary": "Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55416",
        "website": "http://www.tactilemedical.com",
        "market_cap": "Small Cap"
    },
    "TCNNF": {
        "short_name": "TRULIEVE CANNABIS CORP",
        "long_name": "Trulieve Cannabis Corp.",
        "summary": "Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Quincy",
        "zipcode": "32351",
        "website": "http://www.trulieve.com",
        "market_cap": "Mid Cap"
    },
    "TCON": {
        "short_name": "TRACON Pharmaceuticals, Inc.",
        "long_name": "TRACON Pharmaceuticals, Inc.",
        "summary": "TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92122",
        "website": "http://www.traconpharma.com",
        "market_cap": "Small Cap"
    },
    "TCRR": {
        "short_name": "TCR2 Therapeutics Inc.",
        "long_name": "TCR2 Therapeutics Inc.",
        "summary": "TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies, including adult acute lymphoblastic leukemia, DLBCL, follicular lymphoma, and other non-hodgkin lymphomas that is in phase I/II clinical trial. It is also developing TC-510 for, GPC3, IL-15, and Allogenic for solid tumors, as well as DC70 for solid tumors and hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.tcr2.com",
        "market_cap": "Small Cap"
    },
    "TD5A.F": {
        "short_name": "TANDEM DIABETES NEW -,001",
        "long_name": "Tandem Diabetes Care, Inc.",
        "summary": "Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.tandemdiabetes.com",
        "market_cap": "Mid Cap"
    },
    "TDOC.MX": {
        "short_name": "TELADOC HEALTH INC",
        "long_name": "Teladoc Health, Inc.",
        "summary": "Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, chronic condition management, expert medical services, behavioral health solutions, guidance and support, and platform and program services. It serves health employers, health plans, hospitals, health systems, and insurance and financial services companies. The company offers its products and services under the Teladoc, Livongo, Advance Medical, Best Doctors, BetterHelp, and HealthiestYou brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was Incorporated in 2002 and is headquartered in Purchase, New York.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NY",
        "city": "Purchase",
        "zipcode": "10577",
        "website": "http://www.teladochealth.com",
        "market_cap": "Large Cap"
    },
    "TDOC": {
        "short_name": "Teladoc Health, Inc.",
        "long_name": "Teladoc Health, Inc.",
        "summary": "Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, chronic condition management, expert medical services, behavioral health solutions, guidance and support, and platform and program services. It serves health employers, health plans, hospitals, health systems, and insurance and financial services companies. The company offers its products and services under the Teladoc, Livongo, Advance Medical, Best Doctors, BetterHelp, and HealthiestYou brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was Incorporated in 2002 and is headquartered in Purchase, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Purchase",
        "zipcode": "10577",
        "website": "http://www.teladochealth.com",
        "market_cap": "Large Cap"
    },
    "TE1.F": {
        "short_name": "BIO-TECHNE CORP.  DL-,01",
        "long_name": "Bio-Techne Corporation",
        "summary": "Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55413",
        "website": "http://www.bio-techne.com",
        "market_cap": "Large Cap"
    },
    "TECH": {
        "short_name": "Bio-Techne Corp",
        "long_name": "Bio-Techne Corporation",
        "summary": "Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55413",
        "website": "http://www.bio-techne.com",
        "market_cap": "Large Cap"
    },
    "TELA": {
        "short_name": "TELA Bio, Inc.",
        "long_name": "TELA Bio, Inc.",
        "summary": "TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.telabio.com",
        "market_cap": "Small Cap"
    },
    "TENX": {
        "short_name": "Tenax Therapeutics, Inc.",
        "long_name": "Tenax Therapeutics, Inc.",
        "summary": "Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560",
        "website": "http://www.tenaxthera.com",
        "market_cap": "Small Cap"
    },
    "TERN": {
        "short_name": "Terns Pharmaceuticals, Inc.",
        "long_name": "Terns Pharmaceuticals, Inc.",
        "summary": "Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Foster City",
        "zipcode": "94404",
        "website": "http://www.ternspharma.com",
        "market_cap": "Small Cap"
    },
    "TFFP": {
        "short_name": "TFF Pharmaceuticals, Inc.",
        "long_name": "TFF Pharmaceuticals, Inc.",
        "summary": "TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78746",
        "website": "http://www.tffpharma.com",
        "market_cap": "Small Cap"
    },
    "TFX": {
        "short_name": "Teleflex Incorporated",
        "long_name": "Teleflex Incorporated",
        "summary": "Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Wayne",
        "zipcode": "19087-1603",
        "website": "http://www.teleflex.com",
        "market_cap": "Large Cap"
    },
    "TG1N.F": {
        "short_name": "ARMATA PHARMACEUT.",
        "long_name": "Armata Pharmaceuticals Inc.",
        "summary": "Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Marina del Rey",
        "zipcode": "90292",
        "website": "http://www.armatapharma.com",
        "market_cap": "Small Cap"
    },
    "TGGI": {
        "short_name": "TRANS GLOBAL GROUP INC",
        "long_name": "Trans Global Group, Inc.",
        "summary": "Trans Global Group, Inc., a green company, through its subsidiaries, engages in renewable energy and solar energy sector. It offers products to reduce homeowner's and business' energy consumption, lower their carbon footprint, enhance the efficiency of their energy products, and reduce energy costs. The company also provides general construction services, including building schools, condominiums, town home communities, home renovations and add-ons, housing, and other projects. In addition, it offers bonding and insurance agency services. The company was formerly known as Teletek, Inc. and changed its name to Trans Global Group, Inc. in October 2007. Trans Global Group, Inc. was incorporated in 1979 and is headquartered in Coconut Creek, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Coconut Creek",
        "zipcode": "33073",
        "website": "http://transggi.com",
        "market_cap": "Small Cap"
    },
    "TGKQ.F": {
        "short_name": "PRECIPIO INC.  DL-,01",
        "long_name": "Precipio, Inc.",
        "summary": "Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06511",
        "website": "http://www.precipiodx.com",
        "market_cap": "Small Cap"
    },
    "TGTX": {
        "short_name": "TG Therapeutics, Inc.",
        "long_name": "TG Therapeutics, Inc.",
        "summary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10014",
        "website": "http://www.tgtherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "THC": {
        "short_name": "Tenet Healthcare Corporation",
        "long_name": "Tenet Healthcare Corporation",
        "summary": "Tenet Healthcare Corporation operates as a diversified healthcare services company. The company operates in three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; quaternary care services in heart and kidney transplants; and limb-salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging, and telemedicine access services. In addition, it operates ambulatory surgery and urgent care centers, imaging centers, surgical hospitals, off-campus emergency departments, and micro-hospitals; and offers healthcare business process services in the areas of hospital and physician revenue cycle management, patient communications and engagement support, and value-based care solutions to hospitals, health systems, physician practices, employers, and other customers. As of December 31, 2020, the company operated 65 hospitals; and approximately 550 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and other care sites and clinics. Tenet Healthcare Corporation was incorporated in 1975 and is headquartered in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75254",
        "website": "http://www.tenethealth.com",
        "market_cap": "Mid Cap"
    },
    "THC1.F": {
        "short_name": "TENET HEALTHCARE  DL-,05",
        "long_name": "Tenet Healthcare Corporation",
        "summary": "Tenet Healthcare Corporation operates as a diversified healthcare services company. The company operates in three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; quaternary care services in heart and kidney transplants; and limb-salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging, and telemedicine access services. In addition, it operates ambulatory surgery and urgent care centers, imaging centers, surgical hospitals, off-campus emergency departments, and micro-hospitals; and offers healthcare business process services in the areas of hospital and physician revenue cycle management, patient communications and engagement support, and value-based care solutions to hospitals, health systems, physician practices, employers, and other customers. As of December 31, 2020, the company operated 65 hospitals; and approximately 550 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and other care sites and clinics. Tenet Healthcare Corporation was incorporated in 1975 and is headquartered in Dallas, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75254",
        "website": "http://www.tenethealth.com",
        "market_cap": "Mid Cap"
    },
    "THCT": {
        "short_name": "THC THERAPEUTICS INC",
        "long_name": "THC Therapeutics, Inc.",
        "summary": "THC Therapeutics, Inc. operates in the wellness industry. It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. The company was formerly known as Millennium Blockchain, Inc. and changed its name to THC Therapeutics, Inc. in September 2018. THC Therapeutics, Inc. was incorporated in 2007 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89135",
        "website": "http://thct.io",
        "market_cap": "Small Cap"
    },
    "THMO": {
        "short_name": "ThermoGenesis Holdings, Inc.",
        "long_name": "ThermoGenesis Holdings, Inc.",
        "summary": "ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating and retrieving stem, and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Rancho Cordova",
        "zipcode": "95742",
        "website": "http://www.thermogenesis.com",
        "market_cap": "Small Cap"
    },
    "THRP.F": {
        "short_name": "THERMOGENESIS  DL-,001",
        "long_name": "ThermoGenesis Holdings, Inc.",
        "summary": "ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating and retrieving stem, and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Rancho Cordova",
        "zipcode": "95742",
        "website": "http://www.thermogenesis.com",
        "market_cap": "Small Cap"
    },
    "TIL": {
        "short_name": "Instil Bio, Inc.",
        "long_name": "Instil Bio, Inc.",
        "summary": "Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75219",
        "website": "http://instilbio.com",
        "market_cap": "Mid Cap"
    },
    "TILT.CN": {
        "short_name": "TILTHldgsInc",
        "long_name": "TILT Holdings Inc.",
        "summary": "TILT Holdings Inc., a vertically-integrated technology and infrastructure company, provides various products and services across the cannabis industry in the United States, Canada, and Europe. It operates through five segments: Cannabis, Technology and Infrastructure, Distribution, Accessories, and Other. The Cannabis segment engages in the production, cultivation, and retail of cannabis products. The Technology and Infrastructure segment offers a range of products and services across the cannabis industry. The Distribution segment provides logistic operations and software solutions throughout the cannabis supply chain. The Accessories segment manufactures and distributes electronic and non-nicotine devices and systems. The Other segment focuses on greenhouse cultivation and CO2 extraction. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02138",
        "website": "http://www.tiltholdings.com",
        "market_cap": "Small Cap"
    },
    "TIUM-U.CN": {
        "short_name": "CansortiumInc",
        "long_name": "Cansortium Inc.",
        "summary": "Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. The company engages in the cultivation, processing, retail, and distribution activities. Its medical cannabis products are offered in oral drops, capsules, suppositories, topicals, syringes, dried flower, prerolls, cartridges, and edibles. The company provides its products under the Fluent brand name. Cansortium Inc. was incorporated in 2018 and is headquartered in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33137",
        "website": "http://www.getfluent.com",
        "market_cap": "Small Cap"
    },
    "TJ9.F": {
        "short_name": "CUTERA INC.  DL-,001",
        "long_name": "Cutera, Inc.",
        "summary": "Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company offers truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; truSculpt for the non-surgical body sculpting market; Juliet, a laser for women's intimate health; Secret RF, a fractional radio frequency microneedling device for skin revitalization; and enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions and acne scars. It also provides excel HR platform, a hair removal solution for various skin types; excel V+, a vascular and benign pigmented lesion treatment platform; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company offers GenesisPlus, CoolGlide, myQ, and skincare products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website cutera.com. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, and other qualified practitioners, as well as for physicians performing aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1988 and is headquartered in Brisbane, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Brisbane",
        "zipcode": "94005",
        "website": "http://cutera.com",
        "market_cap": "Small Cap"
    },
    "TLFE": {
        "short_name": "ELFATO INC",
        "long_name": "Elfato Inc.",
        "summary": "Elfato Inc. focuses on developing canna powder products. Its canna powder is a nano-powder derived from cannabis oil. The company was founded in 1999 and is based in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90067",
        "website": "http://canna-powder.com",
        "market_cap": "Small Cap"
    },
    "TLGT": {
        "short_name": "Teligent, Inc.",
        "long_name": "Teligent, Inc.",
        "summary": "Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was incorporated in 1977 and is based in Buena, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Buena",
        "zipcode": "08310",
        "website": "http://www.teligent.com",
        "market_cap": "Small Cap"
    },
    "TLIF": {
        "short_name": "TOCCA LIFE HLDGS INC",
        "long_name": "TOCCA Life Holdings, Inc.",
        "summary": "TOCCA Life Holdings, Inc. operates sober living facilities in Lake Worth, Lantana, and Boynton Beach, Florida. The company provides clinical toxicology testing services to monitor the illicit drug use and transforms sobriety addicted clients and the community into productive members of society. It offers sober support services; operates an addiction treatment center; provides sober life coaching and transitional living programs; conducts sports events and fitness activities; and operates house recovery residence facilities and sober living recovery residences. It offers equipment, materials, and demonstrations in the areas of cooking, cleaning, household maintenance, business etiquette, basic math, basic banking, computer skills, writing skills, life coaching, transitional living management, graphic art, information technology, marketing, television production, interest rate theories, credit cost valuation, mortgage banking, career opportunities, business models, business infrastructures, business ethics, and entrepreneurship. It also offers prepaid services, which include hygiene, linen, grocery, and other products and services online. The company was formerly known as TOCCA Life Coaching, Inc. and changed its name to TOCCA Life Holdings, Inc. in January 2015. TOCCA Life Holdings, Inc. was founded in 2013 and is based in Lake Worth, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Lake Worth",
        "zipcode": "33460",
        "website": "http://www.toccalife.com",
        "market_cap": "Small Cap"
    },
    "TLIS": {
        "short_name": "Talis Biomedical Corporation",
        "long_name": "Talis Biomedical Corporation",
        "summary": "Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://talis.bio",
        "market_cap": "Small Cap"
    },
    "TLLTF": {
        "short_name": "TILT HOLDINGS INC",
        "long_name": "TILT Holdings Inc.",
        "summary": "TILT Holdings Inc., a vertically-integrated technology and infrastructure company, provides various products and services across the cannabis industry in the United States, Canada, and Europe. It operates through five segments: Cannabis, Technology and Infrastructure, Distribution, Accessories, and Other. The Cannabis segment engages in the production, cultivation, and retail of cannabis products. The Technology and Infrastructure segment offers a range of products and services across the cannabis industry. The Distribution segment provides logistic operations and software solutions throughout the cannabis supply chain. The Accessories segment manufactures and distributes electronic and non-nicotine devices and systems. The Other segment focuses on greenhouse cultivation and CO2 extraction. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02138",
        "website": "http://www.tiltholdings.com",
        "market_cap": "Small Cap"
    },
    "TLMD": {
        "short_name": "SOC Telemed, Inc.",
        "long_name": "SOC Telemed, Inc.",
        "summary": "SOC Telemed, Inc. provides acute care telemedicine services and technology to hospitals, health systems, physician groups, and government organizations in the United States. The company's technology platform, Telemed IQ, provides telemedicine programs. Its telemedicine solutions include teleNeurology, telePulmonology, telePsychiatry, and teleICU. The company was founded in 2004 and is based in Reston, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "VA",
        "city": "Reston",
        "zipcode": "20190",
        "website": "http://www.soctelemed.com",
        "market_cap": "Small Cap"
    },
    "TLOG": {
        "short_name": "TETRALOGIC PHARMACEUTICALS CORP",
        "long_name": "TetraLogic Pharmaceuticals Corporation",
        "summary": "TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19355",
        "website": "http://www.tetralogicpharma.com",
        "market_cap": "Small Cap"
    },
    "TMBR": {
        "short_name": "Timber Pharmaceuticals, Inc.",
        "long_name": "Timber Pharmaceuticals, Inc.",
        "summary": "Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical dermatology company, focused on the development and commercialization of treatments for orphan dermatologic diseases. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Basking Ridge",
        "zipcode": "07920",
        "website": "http://www.timberpharma.com",
        "market_cap": "Small Cap"
    },
    "TMCI": {
        "short_name": "Treace Medical Concepts, Inc.",
        "long_name": "Treace Medical Concepts, Inc.",
        "summary": "Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Ponte Vedra",
        "zipcode": "32081",
        "website": "http://www.treace.com",
        "market_cap": "Small Cap"
    },
    "TMDX": {
        "short_name": "TransMedics Group, Inc.",
        "long_name": "TransMedics Group, Inc.",
        "summary": "TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Andover",
        "zipcode": "01810",
        "website": "http://www.transmedics.com",
        "market_cap": "Small Cap"
    },
    "TMO.BA": {
        "short_name": "THERMO FISHER SCIE",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon brands. The company was incorporated in 1956 and is based in Waltham, Massachusetts.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.thermofisher.com",
        "market_cap": "Large Cap"
    },
    "TMO.MX": {
        "short_name": "THERMO FISHER SCIENTIFIC INC",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon brands. The company was incorporated in 1956 and is based in Waltham, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.thermofisher.com",
        "market_cap": "Large Cap"
    },
    "TMO": {
        "short_name": "Thermo Fisher Scientific Inc",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon brands. The company was incorporated in 1956 and is based in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.thermofisher.com",
        "market_cap": "Large Cap"
    },
    "TMOF.VI": {
        "short_name": "THERMO FISHER SCIENTIFIC INC",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon brands. The company was incorporated in 1956 and is based in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.thermofisher.com",
        "market_cap": "Large Cap"
    },
    "TMOS34.SA": {
        "short_name": "THERMFISCHERDRN",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon brands. The company was incorporated in 1956 and is based in Waltham, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.thermofisher.com",
        "market_cap": "Large Cap"
    },
    "TMSH": {
        "short_name": "TRANSGLOBAL ASSETS INC",
        "long_name": "TransGlobal Assets Inc.",
        "summary": "TransGlobal Assets Inc., together with its subsidiaries, distributes motor vehicle fuel and tobacco products to retail outlets in the State of Oregon. The company was formerly known as TimeShare Holdings Inc. and changed its name to TransGlobal Assets Inc. in March 2011. TransGlobal Assets Inc. was founded in 2005 and is based in Cheyenne, Wyoming.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "WY",
        "city": "Cheyenne",
        "zipcode": "82001",
        "website": null,
        "market_cap": "Small Cap"
    },
    "TN7.F": {
        "short_name": "TITAN PHARM.(DEL) DL-,001",
        "long_name": "Titan Pharmaceuticals, Inc.",
        "summary": "Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.titanpharm.com",
        "market_cap": "Small Cap"
    },
    "TN8.DE": {
        "short_name": "THERMO FISH.SCIENTIF.DL 1",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon brands. The company was incorporated in 1956 and is based in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.thermofisher.com",
        "market_cap": "Large Cap"
    },
    "TN8.F": {
        "short_name": "THERMO FISH.SCIENTIF.DL 1",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon brands. The company was incorporated in 1956 and is based in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Waltham",
        "zipcode": "02451",
        "website": "http://www.thermofisher.com",
        "market_cap": "Large Cap"
    },
    "TNDM": {
        "short_name": "Tandem Diabetes Care, Inc.",
        "long_name": "Tandem Diabetes Care, Inc.",
        "summary": "Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.tandemdiabetes.com",
        "market_cap": "Mid Cap"
    },
    "TNXP": {
        "short_name": "Tonix Pharmaceuticals Holding C",
        "long_name": "Tonix Pharmaceuticals Holding Corp.",
        "summary": "Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Chatham",
        "zipcode": "07928",
        "website": "http://www.tonixpharma.com",
        "market_cap": "Small Cap"
    },
    "TPMR.F": {
        "short_name": "TONIX PHARMA.  DL-,001",
        "long_name": "Tonix Pharmaceuticals Holding Corp.",
        "summary": "Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Chatham",
        "zipcode": "07928",
        "website": "http://www.tonixpharma.com",
        "market_cap": "Small Cap"
    },
    "TPTX": {
        "short_name": "Turning Point Therapeutics, Inc",
        "long_name": "Turning Point Therapeutics, Inc.",
        "summary": "Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-na\u00c3\u00afve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0022, a MET/CSF1R/SRC inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in Phase 1/2 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, a preclinical ALK inhibitor for advanced non-small-cell lung cancer. The company was founded in 2013 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.tptherapeutics.com",
        "market_cap": "Mid Cap"
    },
    "TRGM": {
        "short_name": "TARGETED MEDICAL PHARMA INC",
        "long_name": "Targeted Medical Pharma, Inc.",
        "summary": "Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90077",
        "website": "http://www.targetedmedicalpharma.com",
        "market_cap": "Small Cap"
    },
    "TRHC": {
        "short_name": "Tabula Rasa HealthCare, Inc.",
        "long_name": "Tabula Rasa HealthCare, Inc.",
        "summary": "Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates through two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise software that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing programs or systems. The company also provides RxCompanion, a cloud-based MTM software platform designed to aid in the identification and resolution of medication and other health related problems; TruChart, a web-based electronic health record for Programs of All-Inclusive Care for the Elderly (PACE) organizations; PACElogic, which delivers real-time sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state required reporting. In addition, the company offers DoseMeRx, a decision support software; PrescribeWellness, a patient engagement center platform; and clinical pharmacist collaboration, prescription fulfillment and reminder packaging, and pharmacy cost management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2020, it served approximately 130 healthcare organizations; and 280 health plans and approximately 14,000 retail pharmacies. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Moorestown",
        "zipcode": "08057",
        "website": "http://www.tabularasahealthcare.com",
        "market_cap": "Small Cap"
    },
    "TRL.F": {
        "short_name": "DAVITA INC.  DL -,001",
        "long_name": "DaVita Inc.",
        "summary": "DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80202",
        "website": "http://www.davita.com",
        "market_cap": "Large Cap"
    },
    "TRTC": {
        "short_name": "TERRA TECH CORP",
        "long_name": "Terra Tech Corp.",
        "summary": "Terra Tech Corp. cultivates, produces, and retails medical and adult use cannabis products. It offers cannabis-infused baked goods, chocolates, and candies; cannabis-infused topical products, such as lotions, massage oils and balms; clones of marijuana plants; flowers and concentrates; oils, waxes, hash, shatters, and clears under the IVXX brand name; and cartridges, vape pens, and wax products. The company also operates medical marijuana retail and adult use dispensaries under the Bl\u00c3\u00bcm brand in California and Nevada. Terra Tech Corp. was founded in 2010 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.terratechcorp.com",
        "market_cap": "Small Cap"
    },
    "TRUL.CN": {
        "short_name": "TrulieveCannab",
        "long_name": "Trulieve Cannabis Corp.",
        "summary": "Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of April 19, 2021, the company operated through 86 dispensaries in the United States. The company is headquartered in Quincy, Florida.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "FL",
        "city": "Quincy",
        "zipcode": "32351",
        "website": "http://www.trulieve.com",
        "market_cap": "Mid Cap"
    },
    "TRVI": {
        "short_name": "Trevi Therapeutics, Inc.",
        "long_name": "Trevi Therapeutics, Inc.",
        "summary": "Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CT",
        "city": "New Haven",
        "zipcode": "06510",
        "website": "http://www.trevitherapeutics.com",
        "market_cap": "Small Cap"
    },
    "TRVN": {
        "short_name": "Trevena, Inc.",
        "long_name": "Trevena, Inc.",
        "summary": "Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Chesterbrook",
        "zipcode": "19087",
        "website": "http://www.trevena.com",
        "market_cap": "Small Cap"
    },
    "TSHA": {
        "short_name": "Taysha Gene Therapies, Inc.",
        "long_name": "Taysha Gene Therapies, Inc.",
        "summary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75235",
        "website": "http://www.tayshagtx.com",
        "market_cap": "Small Cap"
    },
    "TSNI": {
        "short_name": "TECHNISCAN INC",
        "long_name": "TechniScan, Inc.",
        "summary": "TechniScan, Inc., a development stage company, engages in the research, development, and commercialization of non-invasive medical imaging products for the detection and diagnosis of breast cancer. It intends to develop the Warm Bath Ultrasound system, an ultrasound-based imaging device that provides radiologists with information about the bulk properties of tissue in the breast, as well as images of the tissue structure. The company is based in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Appliances & Equipment",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84106",
        "website": null,
        "market_cap": "Small Cap"
    },
    "TSOI": {
        "short_name": "THERAPEUTIC SOLUTIONS INTL INC",
        "long_name": "Therapeutic Solutions International, Inc.",
        "summary": "Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases. The company develops a range of immune-modulatory agents to target cancers, improve maternal and fetal health, and fight periodontal disease, as well as for daily health. Its flagship products include NanoStilbene, an easily absorbed nanoemulsion of nanoparticle pterostilbene to reduce inflammatory cytokine production in cancer patients; and ProJuvenol, a synergistic blend of complex anti-aging ingredients. The company also focuses on the manufacture of devices to treat patients with obstructive sleep apnea. Therapeutic Solutions International, Inc. is based in Elk City, Idaho.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "ID",
        "city": "Elk City",
        "zipcode": "83525",
        "website": "http://www.therapeuticsolutionsint.com",
        "market_cap": "Small Cap"
    },
    "TTNP": {
        "short_name": "Titan Pharmaceuticals, Inc.",
        "long_name": "Titan Pharmaceuticals, Inc.",
        "summary": "Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.titanpharm.com",
        "market_cap": "Small Cap"
    },
    "TTOO": {
        "short_name": "T2 Biosystems, Inc.",
        "long_name": "T2 Biosystems, Inc.",
        "summary": "T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Lexington",
        "zipcode": "02421",
        "website": "http://www.t2biosystems.com",
        "market_cap": "Small Cap"
    },
    "TVTY": {
        "short_name": "Tivity Health, Inc.",
        "long_name": "Tivity Health, Inc.",
        "summary": "Tivity Health, Inc. provides fitness and health products primarily for seniors and older adults in the United States. The company offers SilverSneakers to members of Medicare Advantage, Medicare Supplement, and group retiree plans; Prime Fitness, a fitness facility access program through commercial health plans, employers, and other sponsoring organizations; virtual fitness experiences, including live instructor-led classes; and WholeHealth living program, a continuum of services related to complementary, alternative, and physical medicine. It also provides Wisely Well brand meals designed to support individuals and caregivers who are seeking meal convenience, as well as those recovering after a hospitalization or living with chronic conditions. The company was formerly known as Healthways, Inc. and changed its name to Tivity Health, Inc. in January 2017. Tivity Health, Inc. was incorporated in 1981 and is headquartered in Franklin, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TN",
        "city": "Franklin",
        "zipcode": "37067",
        "website": "http://www.tivityhealth.com",
        "market_cap": "Small Cap"
    },
    "TWSI": {
        "short_name": "TRISTAR WELLNESS SOLUTIONS INC",
        "long_name": "Tristar Wellness Solutions Inc.",
        "summary": "TriStar Wellness Solutions, Inc. develops, markets, and sells wound care products. The company also offers skincare and other products under the Beaute de Maman name for pregnant and nursing women; bleeding and wound management products for surgical, health care, consumer, and military markets; and develops and markets Delivery Devise with Invertible Diaphragm, which is a medical applicator for delivering medicants and internal devices within the body without producing injury or damage. In addition, it develops over-the-counter itch suppression products; and develops, manufactures, and markets wound care and infection control medical devices. The company was formerly known as BioPack Environmental Solutions, Inc. and changed its name to TriStar Wellness Solutions, Inc. in January 2013. TriStar Wellness Solutions, Inc. is based in Portland, Oregon. On January 15, 2016, TriStar Wellness Solutions, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Oregon.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OR",
        "city": "Portland",
        "zipcode": "97205",
        "website": "http://www.tstarwellness.com",
        "market_cap": "Small Cap"
    },
    "TWST": {
        "short_name": "Twist Bioscience Corporation",
        "long_name": "Twist Bioscience Corporation",
        "summary": "Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.twistbioscience.com",
        "market_cap": "Mid Cap"
    },
    "TXG.MX": {
        "short_name": "10X GENOMICS INC",
        "long_name": "10x Genomics, Inc.",
        "summary": "10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Pleasanton",
        "zipcode": "94588",
        "website": "http://www.10xgenomics.com",
        "market_cap": "Large Cap"
    },
    "TXG": {
        "short_name": "10x Genomics, Inc.",
        "long_name": "10x Genomics, Inc.",
        "summary": "10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Pleasanton",
        "zipcode": "94588",
        "website": "http://www.10xgenomics.com",
        "market_cap": "Large Cap"
    },
    "TXMD": {
        "short_name": "TherapeuticsMD, Inc.",
        "long_name": "TherapeuticsMD, Inc.",
        "summary": "TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17\u00c3\u009f-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33431",
        "website": "http://www.therapeuticsmd.com",
        "market_cap": "Small Cap"
    },
    "TXTM": {
        "short_name": "PROTEXT MOBILITY INC",
        "long_name": "ProText Mobility, Inc.",
        "summary": "ProText Mobility, Inc., a biotech company, engages in the development of pharmaceutical botanical medicines. Its medicines are formulated with highly-bioavailable plant extracts. The company is based in Boca Raton, Florida. ProText Mobility, Inc. is a subsidiary of Planda\u00c3\u00ad Biotechnology, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33431",
        "website": "http://www.protextm.co",
        "market_cap": "Small Cap"
    },
    "TYME": {
        "short_name": "Tyme Technologies, Inc.",
        "long_name": "Tyme Technologies, Inc.",
        "summary": "Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10004",
        "website": "http://www.tymeinc.com",
        "market_cap": "Small Cap"
    },
    "U1HS34.SA": {
        "short_name": "UNIVERSAL HEDRN",
        "long_name": "Universal Health Services, Inc.",
        "summary": "Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and/or behavioral health services. As of February 25, 2021, it owned and/or operated 360 inpatient facilities, and 39 outpatient and other facilities located in 38 states; Washington, D.C.; the United Kingdom; and Puerto Rico. The company also provides commercial health insurance services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "PA",
        "city": "King of Prussia",
        "zipcode": "19406-0958",
        "website": "http://www.uhsinc.com",
        "market_cap": "Large Cap"
    },
    "UAHC": {
        "short_name": "UNITED AMERICAN HEALTHCARE INC",
        "long_name": "United American Healthcare Corporation",
        "summary": "United American Healthcare Corporation, through its subsidiaries, provides contract manufacturing services to the medical device industry. It also focuses on the production of natural rubber. The company was incorporated in 1983 and is based in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60601",
        "website": "http://www.uahc.com",
        "market_cap": "Small Cap"
    },
    "UAVP.F": {
        "short_name": "ORAGENICS INC.  DL-,001",
        "long_name": "Oragenics, Inc.",
        "summary": "Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and production of lantibiotics, a peptide antibiotic that are naturally produced in gram-positive bacteria. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Tampa",
        "zipcode": "33634",
        "website": "http://www.oragenics.com",
        "market_cap": "Small Cap"
    },
    "UBQU": {
        "short_name": "UBIQUITECH SOFTWARE CORP",
        "long_name": "Ubiquitech Software Corp.",
        "summary": "Ubiquitech Software Corp. develops Internet marketing and sales software solutions in the United States. The company's Internet sales technologies include Blue Crush Monetization System that creates advertising platforms and improves existing platforms to increase sales; InternationalFortune.com, a lead generation portal for currency trading companies, hedge funds, and other asset managers worldwide; and Blue Crush Connect, a social network that rewards and incentivizes customers. It also operates AffiliateCashExpress.com and NeedFunded.com. Ubiquitech Software Corp. was incorporated in 2007 and is based in Denver, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Denver",
        "zipcode": "80206",
        "website": "http://ubiquitechsoftware.com",
        "market_cap": "Small Cap"
    },
    "UBX": {
        "short_name": "Unity Biotechnology, Inc.",
        "long_name": "Unity Biotechnology, Inc.",
        "summary": "Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.unitybiotechnology.com",
        "market_cap": "Small Cap"
    },
    "UCBB": {
        "short_name": "US-CHINA BIOMEDICAL TECHNOLOGY ",
        "long_name": "US-China Biomedical Technology, Inc.",
        "summary": "US-China Biomedical Technology, Inc. operates as an early stage biomedical technology and services company. The company was formerly known as Cloud Security Corporation and changed its name to US-China Biomedical Technology, Inc. in February 2018. US-China Biomedical Technology, Inc. was founded in 2010 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Irvine",
        "zipcode": "92614",
        "website": "http://www.ucbb.us",
        "market_cap": "Small Cap"
    },
    "UDJP.F": {
        "short_name": "APPLIED DNA  DL-,0001",
        "long_name": "Applied DNA Sciences, Inc.",
        "summary": "Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications and can be used to fortify brand protection efforts, and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide definitive real-time authentication of molecular tags in the field; and CertainT Supply Chain Platform that provides proof of product claims for materials, items, or products. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Stony Brook",
        "zipcode": "11790",
        "website": "http://www.adnas.com",
        "market_cap": "Small Cap"
    },
    "UEEC": {
        "short_name": "UNITED HEALTH PRODUCTS INC",
        "long_name": "United Health Products, Inc.",
        "summary": "United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. It offers HemoStyp hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. The company also provides gauze products for internal and oral surgery, and external trauma; and island dressings to support intravenous procedures, such as kidney dialysis. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, assisted living and nursing homes, veterinary hospitals, emergency medical services and fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. United Health Products, Inc. was incorporated in 1997 and is based in Henderson, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Henderson",
        "zipcode": "89052",
        "website": "http://www.unitedhealthproductsinc.com",
        "market_cap": "Small Cap"
    },
    "UG2.F": {
        "short_name": "ANGIODYNAMICS INC. DL-,01",
        "long_name": "AngioDynamics, Inc.",
        "summary": "AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NY",
        "city": "Latham",
        "zipcode": "12110",
        "website": "http://www.angiodynamics.com",
        "market_cap": "Small Cap"
    },
    "UHS.F": {
        "short_name": "UNIV. HEALTH SERV.B DL-01",
        "long_name": "Universal Health Services, Inc.",
        "summary": "Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and/or behavioral health services. As of February 25, 2021, it owned and/or operated 360 inpatient facilities, and 39 outpatient and other facilities located in 38 states; Washington, D.C.; the United Kingdom; and Puerto Rico. The company also provides commercial health insurance services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "King of Prussia",
        "zipcode": "19406-0958",
        "website": "http://www.uhsinc.com",
        "market_cap": "Large Cap"
    },
    "UHS": {
        "short_name": "Universal Health Services, Inc.",
        "long_name": "Universal Health Services, Inc.",
        "summary": "Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and/or behavioral health services. As of February 25, 2021, it owned and/or operated 360 inpatient facilities, and 39 outpatient and other facilities located in 38 states; Washington, D.C.; the United Kingdom; and Puerto Rico. The company also provides commercial health insurance services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "King of Prussia",
        "zipcode": "19406-0958",
        "website": "http://www.uhsinc.com",
        "market_cap": "Large Cap"
    },
    "ULGX": {
        "short_name": "UROLOGIX",
        "long_name": "Urologix, Inc.",
        "summary": "Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55447",
        "website": "http://www.urologix.com",
        "market_cap": "Small Cap"
    },
    "ULUR": {
        "short_name": "ULURU INC",
        "long_name": "ULURU Inc.",
        "summary": "ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. and is headquartered in Addison, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Addison",
        "zipcode": "75001",
        "website": "http://www.uluruinc.info",
        "market_cap": "Small Cap"
    },
    "UNH.BA": {
        "short_name": "UNITEDHEALTH GRP",
        "long_name": "UnitedHealth Group Incorporated",
        "summary": "UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "MN",
        "city": "Minnetonka",
        "zipcode": "55343",
        "website": "http://www.unitedhealthgroup.com",
        "market_cap": null
    },
    "UNH.DE": {
        "short_name": "UNITEDHEALTH GROUP DL-,01",
        "long_name": "UnitedHealth Group Incorporated",
        "summary": "UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "MN",
        "city": "Minnetonka",
        "zipcode": "55343",
        "website": "http://www.unitedhealthgroup.com",
        "market_cap": "Large Cap"
    },
    "UNH.F": {
        "short_name": "UNITEDHEALTH GROUP DL-,01",
        "long_name": "UnitedHealth Group Incorporated",
        "summary": "UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MN",
        "city": "Minnetonka",
        "zipcode": "55343",
        "website": "http://www.unitedhealthgroup.com",
        "market_cap": "Large Cap"
    },
    "UNH.MX": {
        "short_name": "UNITEDHEALTH GROUP INC",
        "long_name": "UnitedHealth Group Incorporated",
        "summary": "UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MN",
        "city": "Minnetonka",
        "zipcode": "55343",
        "website": "http://www.unitedhealthgroup.com",
        "market_cap": "Large Cap"
    },
    "UNH": {
        "short_name": "UnitedHealth Group Incorporated",
        "long_name": "UnitedHealth Group Incorporated",
        "summary": "UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minnetonka",
        "zipcode": "55343",
        "website": "http://www.unitedhealthgroup.com",
        "market_cap": "Large Cap"
    },
    "UNH.VI": {
        "short_name": "UNITEDHEALTH GROUP INC",
        "long_name": "UnitedHealth Group Incorporated",
        "summary": "UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "MN",
        "city": "Minnetonka",
        "zipcode": "55343",
        "website": "http://www.unitedhealthgroup.com",
        "market_cap": "Large Cap"
    },
    "UNHH34.SA": {
        "short_name": "UNITEDHEALTHDRN",
        "long_name": "UnitedHealth Group Incorporated",
        "summary": "UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MN",
        "city": "Minnetonka",
        "zipcode": "55343",
        "website": "http://www.unitedhealthgroup.com",
        "market_cap": "Large Cap"
    },
    "UNVC": {
        "short_name": "UNIVEC INC",
        "long_name": "Univec, Inc.",
        "summary": "Univec, Inc., through its subsidiaries, produces, licenses, and markets medical products in the United States and internationally. It primarily provides auto-disable and safety syringes. The company offers 1 cc AD-syringe for aspirating and non-aspirating applications, which are used for dispensing dosages of allergy, immunization, and insulin medicines. It also manufactures and markets sliding sheath syringes that are designed to protect patients and healthcare workers from needle stick injuries; and bifurcated needle safety syringes, which are used in administering smallpox vaccines in response to bio-terrorist threats. Univec markets its auto-disable syringes and sliding sheath safety syringes to private hospitals, health facilities, and distributors in the United States, as well as to governments of developing countries. In addition, it assists pharmaceutical companies in marketing, fulfillment, and tracking drug samples via an online system connecting pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Baltimore",
        "zipcode": "21202",
        "website": "http://www.univec.com",
        "market_cap": "Small Cap"
    },
    "UP0.F": {
        "short_name": "ULTRAGENYX PHARM. DL-,001",
        "long_name": "Ultragenyx Pharmaceutical Inc.",
        "summary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Novato",
        "zipcode": "94949",
        "website": "http://www.ultragenyx.com",
        "market_cap": "Mid Cap"
    },
    "UPH.F": {
        "short_name": "US PHYSIC.THERAPY  DL-,01",
        "long_name": "U.S. Physical Therapy, Inc.",
        "summary": "U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company provides industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2020, it operated 544 outpatient physical therapy clinics in 39 states; and managed 38 physical therapy facilities. The company was founded in 1990 and is based in Houston, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77042",
        "website": "http://www.usph.com",
        "market_cap": "Small Cap"
    },
    "UPPR": {
        "short_name": "UPPER STREET MARKETING INC",
        "long_name": "Upper Street Marketing Inc.",
        "summary": "Upper Street Marketing Inc. provides liquid conversion water technology for various cannabis and hemp cultivators in the United States and Canada. It also acquires and operates cannabis cultivation, dispensary, and related manufacturing operations. The company is based in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Scottsdale",
        "zipcode": null,
        "website": "http://www.upperstreetmarketing.com",
        "market_cap": "Small Cap"
    },
    "UR8.F": {
        "short_name": "UROGEN PHARMA LTD IS -,01",
        "long_name": "UroGen Pharma Ltd.",
        "summary": "UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-302 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. It also has a strategic research agreement with the Johns Hopkins University to explore the potential of checkpoint inhibitors combined with RTGel in glioblastoma multiform. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.urogen.com",
        "market_cap": "Small Cap"
    },
    "URGN": {
        "short_name": "UroGen Pharma Ltd.",
        "long_name": "UroGen Pharma Ltd.",
        "summary": "UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-302 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. It also has a strategic research agreement with the Johns Hopkins University to explore the potential of checkpoint inhibitors combined with RTGel in glioblastoma multiform. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Princeton",
        "zipcode": "08540",
        "website": "http://www.urogen.com",
        "market_cap": "Small Cap"
    },
    "USAQ": {
        "short_name": "USA EQUITIES CORP",
        "long_name": "USA Equities Corp.",
        "summary": "USA Equities Corp. focuses on healthcare, informatics, and algorithmic personalized medicine. It intends to develop digital therapeutics, behavior based remote patient monitoring, chronic care, and preventive medicines. The company also provides QHSLab, a cloud based medical office and mobile patient education solution; and distributes AllergiEnd, an allergy diagnostic and allergen immunotherapy system, and related components to non-allergy specialist physicians. Its products and information service portfolio include prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. The company was formerly known as American Biogenetic Sciences, Inc. and changed its name to USA Equities Corp. in May 2015. USA Equities Corp. was incorporated in 1983 and is based in West Palm Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "West Palm Beach",
        "zipcode": "33407",
        "website": "http://www.usaqcorp.com",
        "market_cap": "Small Cap"
    },
    "USMJ": {
        "short_name": "NORTH AMERICAN CANNABIS HLDGS I",
        "long_name": "North American Cannabis Holdings, Inc.",
        "summary": "North American Cannabis Holdings, Inc., through its subsidiaries, operates in the legal cannabis market in the United States. It conducts various pilots in the legal cannabis sector in order to explore various high growth potential business opportunities. The company also operates a destination beverage company that enables consumers to interface with staff to learn about the specific benefits of cannabis, and select healthy and refreshing cannabis infused beverages, which include custom blended hemp infused coffee, cold pressed juices, and smoothies. In addition, it offers raw hemp seeds and other hemp infused foods. North American Cannabis Holdings, Inc. was formerly known as Algae International Group, Inc. and changed its name to North American Cannabis Holdings, Inc. in June 2015. The company is based in Farmers Branch, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Farmers Branch",
        "zipcode": "75244",
        "website": "http://www.aciconglomerated.com/usmj",
        "market_cap": "Small Cap"
    },
    "USNU": {
        "short_name": "U S NEUROSURGICAL HOLDINGS INC",
        "long_name": "U.S. NeuroSurgical Holdings, Inc.",
        "summary": "U.S. NeuroSurgical Holdings, Inc., through its subsidiaries, engages in the owning and operating stereotactic radiosurgery centers that utilize gamma knife technology. The gamma knife is a stereotactic radio surgical device used to treat brain tumors and other malformations of the brain without invasive surgery. It owns and operates the Southern California Regional Gamma Knife Center at the San Antonio Regional Hospital in Upland, California. U.S. NeuroSurgical Holdings, Inc. was founded in 1993 and is based in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Rockville",
        "zipcode": "20850",
        "website": "http://www.usneuro.com",
        "market_cap": "Small Cap"
    },
    "USPH": {
        "short_name": "U.S. Physical Therapy, Inc.",
        "long_name": "U.S. Physical Therapy, Inc.",
        "summary": "U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company provides industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2020, it operated 544 outpatient physical therapy clinics in 39 states; and managed 38 physical therapy facilities. The company was founded in 1990 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Houston",
        "zipcode": "77042",
        "website": "http://www.usph.com",
        "market_cap": "Small Cap"
    },
    "USRM": {
        "short_name": "U S STEM CELL INC",
        "long_name": "U.S. Stem Cell, Inc.",
        "summary": "U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is based in Sunrise, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Sunrise",
        "zipcode": "33323",
        "website": "http://www.us-stemcell.com",
        "market_cap": "Small Cap"
    },
    "UTH.F": {
        "short_name": "UTD THERAP. (DEL.) DL-,01",
        "long_name": "United Therapeutics Corporation",
        "summary": "United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MD",
        "city": "Silver Spring",
        "zipcode": "20910",
        "website": "http://www.unither.com",
        "market_cap": "Mid Cap"
    },
    "UTHR": {
        "short_name": "United Therapeutics Corporation",
        "long_name": "United Therapeutics Corporation",
        "summary": "United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MD",
        "city": "Silver Spring",
        "zipcode": "20910",
        "website": "http://www.unither.com",
        "market_cap": "Mid Cap"
    },
    "UTMD": {
        "short_name": "Utah Medical Products, Inc.",
        "long_name": "Utah Medical Products, Inc.",
        "summary": "Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Midvale",
        "zipcode": "84047-1048",
        "website": "http://www.utahmed.com",
        "market_cap": "Small Cap"
    },
    "UXI4.F": {
        "short_name": "CYCLACEL PHARM.  DL-,001",
        "long_name": "Cyclacel Pharmaceuticals, Inc.",
        "summary": "Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Berkeley Heights",
        "zipcode": "07922",
        "website": "http://www.cyclacel.com",
        "market_cap": "Small Cap"
    },
    "V7B1.F": {
        "short_name": "ASSEMBLY BIOSCIENCES",
        "long_name": "Assembly Biosciences, Inc.",
        "summary": "Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.assemblybio.com",
        "market_cap": "Small Cap"
    },
    "V7B1.SG": {
        "short_name": "Assembly Biosciences Inc. Regis",
        "long_name": "Assembly Biosciences, Inc.",
        "summary": "Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.assemblybio.com",
        "market_cap": "Small Cap"
    },
    "VA21.F": {
        "short_name": "VAPOTHERM INC. DL-,001",
        "long_name": "Vapotherm, Inc.",
        "summary": "Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of intermittent and continuous aerosol nebulization by limiting condensate management; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is based in Exeter, New Hampshire.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NH",
        "city": "Exeter",
        "zipcode": "03833",
        "website": "http://www.vapotherm.com",
        "market_cap": "Small Cap"
    },
    "VAPO": {
        "short_name": "Vapotherm, Inc.",
        "long_name": "Vapotherm, Inc.",
        "summary": "Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of intermittent and continuous aerosol nebulization by limiting condensate management; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is based in Exeter, New Hampshire.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NH",
        "city": "Exeter",
        "zipcode": "03833",
        "website": "http://www.vapotherm.com",
        "market_cap": "Small Cap"
    },
    "VASO": {
        "short_name": "VASO CORP",
        "long_name": "Vaso Corporation",
        "summary": "Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, and GEHC and third party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment provides Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for physiological signals, such as ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsaion therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease, as well as in-service training support. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. The company was founded in 1987 and is headquartered in Plainview, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Plainview",
        "zipcode": "11803",
        "website": "http://www.vasocorporation.com",
        "market_cap": "Small Cap"
    },
    "VBIO": {
        "short_name": "VITALITY BIOPHARMA INC",
        "long_name": "Vitality Biopharma, Inc.",
        "summary": "Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug for inflammatory bowel disease and irritable bowel syndromes. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Los Angeles",
        "zipcode": "90067",
        "website": "http://www.vitality.bio",
        "market_cap": "Small Cap"
    },
    "VBIV": {
        "short_name": "VBI Vaccines, Inc.",
        "long_name": "VBI Vaccines Inc.",
        "summary": "VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02142",
        "website": "http://www.vbivaccines.com",
        "market_cap": "Small Cap"
    },
    "VBSCF": {
        "short_name": "VIBE GROWTH CORPORATION",
        "long_name": "Vibe Growth Corporation",
        "summary": "Vibe Growth Corporation engages in the cultivation, production, retail, and distribution of cannabis for recreation and medicinal use in the United States, Canada, and internationally. The company operates through four segments: Dispensaries, Cultivation, Real Estate, and Canada. It operates 5 dispensaries and a cannabis greenhouse cultivation, as well as sells its products online under the Vibe By California brand. The company was formerly known as Vibe Bioscience Ltd. and changed its name to Vibe Growth Corporation in October 2020. Vibe Growth Corporation is headquartered in Sacramento, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Sacramento",
        "zipcode": "95826",
        "website": "http://www.vibebycalifornia.com",
        "market_cap": "Small Cap"
    },
    "VCBDQ": {
        "short_name": "VITALIBIS INC",
        "long_name": "Vitalibis, Inc.",
        "summary": "Vitalibis, Inc. operates as a technology-based formulator of phytocannabinoid rich hemp products with cannabidiol, along with personal care and nutritional products. The company markets and sells consumer products under the Vitalibis brand. It also sells water soluble phytocannabinoid rich hemp powder. The company was formerly known as Sheng Ying Entertainment Corp. and changed its name to Vitalibis, Inc. in February 2018. Vitalibis, Inc. was founded in 2014 and is based in Las Vegas, Nevada. On June 15, 2020, Vitalibis, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89169",
        "website": "http://www.vitalibis.com",
        "market_cap": "Small Cap"
    },
    "VCC2.F": {
        "short_name": "BRICKELL BIOTECH  DL-,01",
        "long_name": "Brickell Biotech, Inc.",
        "summary": "Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80301",
        "website": "http://www.brickellbio.com",
        "market_cap": "Small Cap"
    },
    "VCEL": {
        "short_name": "Vericel Corporation",
        "long_name": "Vericel Corporation",
        "summary": "Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://vcel.com",
        "market_cap": "Mid Cap"
    },
    "VCNX": {
        "short_name": "Vaccinex, Inc.",
        "long_name": "Vaccinex, Inc.",
        "summary": "Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Rochester",
        "zipcode": "14620",
        "website": "http://www.vaccinex.com",
        "market_cap": "Small Cap"
    },
    "VCYT": {
        "short_name": "Veracyte, Inc.",
        "long_name": "Veracyte, Inc.",
        "summary": "Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.veracyte.com",
        "market_cap": "Mid Cap"
    },
    "VDRM": {
        "short_name": "VIADERMA INC",
        "long_name": "ViaDerma, Inc.",
        "summary": "ViaDerma, Inc. operates as a specialty pharmaceutical company. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as D\u00c3\u00a9cor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. is headquartered in Marina Del Rey, the United States.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Marina Del Rey",
        "zipcode": "90292",
        "website": "http://viadermalicensing.com",
        "market_cap": "Small Cap"
    },
    "VEE.DE": {
        "short_name": "VEEVA SYSTEMS A DL-,00001",
        "long_name": "Veeva Systems Inc.",
        "summary": "Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud, a suite of software, data, and analytics solutions, which include Veeva customer relationship management (CRM) and Veeva Medical CRM, Veeva CLM, Veeva CRM Approved Email, Veeva CRM Engage, Veeva Align, Veeva CRM Events Management, Veeva Nitro, Veeva Andi, Veeva OpenData, Veeva Link, Veeva Network Customer Master, Veeva Crossix, Veeva Data Cloud, and MyVeeva for Doctors; and Veeva Vault, a cloud-based enterprise content and data management applications for managing commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. It also provides professional and support services in the areas of implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; technical consulting services related to data migration and systems integrations; training on its solutions; and ongoing managed services that include outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "Pleasanton",
        "zipcode": "94588",
        "website": "http://www.veeva.com",
        "market_cap": "Large Cap"
    },
    "VEE.F": {
        "short_name": "VEEVA SYSTEMS A DL-,00001",
        "long_name": "Veeva Systems Inc.",
        "summary": "Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud, a suite of software, data, and analytics solutions, which include Veeva customer relationship management (CRM) and Veeva Medical CRM, Veeva CLM, Veeva CRM Approved Email, Veeva CRM Engage, Veeva Align, Veeva CRM Events Management, Veeva Nitro, Veeva Andi, Veeva OpenData, Veeva Link, Veeva Network Customer Master, Veeva Crossix, Veeva Data Cloud, and MyVeeva for Doctors; and Veeva Vault, a cloud-based enterprise content and data management applications for managing commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. It also provides professional and support services in the areas of implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; technical consulting services related to data migration and systems integrations; training on its solutions; and ongoing managed services that include outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Pleasanton",
        "zipcode": "94588",
        "website": "http://www.veeva.com",
        "market_cap": "Large Cap"
    },
    "VEEV.MX": {
        "short_name": "VEEVA SYSTEMS INC",
        "long_name": "Veeva Systems Inc.",
        "summary": "Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud, a suite of software, data, and analytics solutions, which include Veeva customer relationship management (CRM) and Veeva Medical CRM, Veeva CLM, Veeva CRM Approved Email, Veeva CRM Engage, Veeva Align, Veeva CRM Events Management, Veeva Nitro, Veeva Andi, Veeva OpenData, Veeva Link, Veeva Network Customer Master, Veeva Crossix, Veeva Data Cloud, and MyVeeva for Doctors; and Veeva Vault, a cloud-based enterprise content and data management applications for managing commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. It also provides professional and support services in the areas of implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; technical consulting services related to data migration and systems integrations; training on its solutions; and ongoing managed services that include outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "Pleasanton",
        "zipcode": "94588",
        "website": "http://www.veeva.com",
        "market_cap": "Large Cap"
    },
    "VEEV": {
        "short_name": "Veeva Systems Inc.",
        "long_name": "Veeva Systems Inc.",
        "summary": "Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud, a suite of software, data, and analytics solutions, which include Veeva customer relationship management (CRM) and Veeva Medical CRM, Veeva CLM, Veeva CRM Approved Email, Veeva CRM Engage, Veeva Align, Veeva CRM Events Management, Veeva Nitro, Veeva Andi, Veeva OpenData, Veeva Link, Veeva Network Customer Master, Veeva Crossix, Veeva Data Cloud, and MyVeeva for Doctors; and Veeva Vault, a cloud-based enterprise content and data management applications for managing commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. It also provides professional and support services in the areas of implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; technical consulting services related to data migration and systems integrations; training on its solutions; and ongoing managed services that include outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Pleasanton",
        "zipcode": "94588",
        "website": "http://www.veeva.com",
        "market_cap": "Large Cap"
    },
    "VERU": {
        "short_name": "Veru Inc.",
        "long_name": "Veru Inc.",
        "summary": "Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33127",
        "website": "http://www.verupharma.com",
        "market_cap": "Small Cap"
    },
    "VFRM": {
        "short_name": "VERITAS FARMS INC",
        "long_name": "Veritas Farms, Inc.",
        "summary": "Veritas Farms, Inc. focuses on producing, marketing, and distributing hemp oils and extracts containing phytocannabinoids. The company's products include vegan capsules, gummies, tinctures, lotions, salves, vape oils, cream, and oral syringes. It markets and sells its products under the Veritas Farms brand name, as well as through white label and private label custom formulations for distributors and retailers. The company was formerly known as SanSal Wellness Holdings, Inc. and changed its name to Veritas Farms, Inc. in February 2019. Veritas Farms, Inc. is based in Fort Lauderdale, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Fort Lauderdale",
        "zipcode": "33301",
        "website": "http://www.theveritasfarms.com",
        "market_cap": "Small Cap"
    },
    "VG2B.F": {
        "short_name": "AVINGER INC.  DL-,001",
        "long_name": "Avinger, Inc.",
        "summary": "Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Redwood City",
        "zipcode": "94063",
        "website": "http://www.avinger.com",
        "market_cap": "Small Cap"
    },
    "VGLS": {
        "short_name": "VG LIFE SCIENCES INC",
        "long_name": "VG Life Sciences Inc.",
        "summary": "VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Santa Barbara",
        "zipcode": "93101",
        "website": "http://www.vglifesciences.com",
        "market_cap": "Small Cap"
    },
    "VI4.F": {
        "short_name": "VAREX IMAGING CORP DL-,01",
        "long_name": "Varex Imaging Corporation",
        "summary": "Varex Imaging Corporation designs and manufactures X-ray imaging components. The company operates in two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components comprising X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, 3D reconstruction and computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers, and buckys (a component of X-ray units that holds X-ray film cassettes). This segment's products are used in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy, oncology, CT, cardiac, surgery, dental, computer-aided detection, and other diagnostic radiography uses. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital detectors, and high voltage connectors for use in security and industrial inspection applications, such as airport security, cargo screening at ports and borders, and nondestructive testing and examination in various applications. Varex Imaging Corporation sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, Latin America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was founded in 2016 and is based in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84104",
        "website": "http://www.vareximaging.com",
        "market_cap": "Small Cap"
    },
    "VIA.DE": {
        "short_name": "VIATRIS INC.  O.N.",
        "long_name": "Viatris Inc.",
        "summary": "Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "PA",
        "city": "Canonsburg",
        "zipcode": "15317",
        "website": "http://www.viatris.com",
        "market_cap": "Large Cap"
    },
    "VIA.F": {
        "short_name": "VIATRIS INC.  O.N.",
        "long_name": "Viatris Inc.",
        "summary": "Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Canonsburg",
        "zipcode": "15317",
        "website": "http://www.viatris.com",
        "market_cap": "Large Cap"
    },
    "VIAP": {
        "short_name": "VIA PHARMACEUTICALS INC",
        "long_name": "VIA Pharmaceuticals, Inc.",
        "summary": "VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94111",
        "website": null,
        "market_cap": "Small Cap"
    },
    "VIBE.CN": {
        "short_name": "Vibe Growth",
        "long_name": "Vibe Growth Corporation",
        "summary": "Vibe Growth Corporation engages in the cultivation, production, retail, and distribution of cannabis for recreation and medicinal use in the United States, Canada, and internationally. The company operates through four segments: Dispensaries, Cultivation, Real Estate, and Canada. It operates 5 dispensaries and a cannabis greenhouse cultivation, as well as sells its products online under the Vibe By California brand. The company was formerly known as Vibe Bioscience Ltd. and changed its name to Vibe Growth Corporation in October 2020. Vibe Growth Corporation is headquartered in Sacramento, California.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "CA",
        "city": "Sacramento",
        "zipcode": "95826",
        "website": "http://www.vibebycalifornia.com",
        "market_cap": "Small Cap"
    },
    "VICP": {
        "short_name": "VICAPSYS LIFE SCIENCES INC",
        "long_name": "Vicapsys Life Sciences, Inc.",
        "summary": "Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. VICAPSYN is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Cumming, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Cumming",
        "zipcode": "30041",
        "website": null,
        "market_cap": "Small Cap"
    },
    "VIJ.F": {
        "short_name": "VIEMED HLTHCARE INC. O.N.",
        "long_name": "Viemed Healthcare, Inc.",
        "summary": "Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "LA",
        "city": "Lafayette",
        "zipcode": "70508",
        "website": "http://www.viemed.com",
        "market_cap": "Small Cap"
    },
    "VINC": {
        "short_name": "Vincerx Pharma, Inc.",
        "long_name": "Vincerx Pharma, Inc.",
        "summary": "Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in clinical trials. Its drug candidates are in development for the treatment of solid tumors, leukemia, B-cell malignancies, lymphomas, and myelodysplastic syndrome. Vincerx Pharma, Inc. is based in Palo Alto, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Palo Alto",
        "zipcode": "94306",
        "website": "http://www.vincerx.com",
        "market_cap": "Small Cap"
    },
    "VIR": {
        "short_name": "Vir Biotechnology, Inc.",
        "long_name": "Vir Biotechnology, Inc.",
        "summary": "Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Francisco",
        "zipcode": "94158",
        "website": "http://www.vir.bio",
        "market_cap": "Mid Cap"
    },
    "VIRI": {
        "short_name": "Virios Therapeutics, Inc.",
        "long_name": "Virios Therapeutics, LLC",
        "summary": "Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30009",
        "website": "http://www.virios.com",
        "market_cap": "Small Cap"
    },
    "VIRX": {
        "short_name": "Viracta Therapeutics, Inc.",
        "long_name": "Viracta Therapeutics, Inc.",
        "summary": "Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff-by-the-Sea, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Cardiff-by-the-Sea",
        "zipcode": "92007",
        "website": "http://www.viracta.com",
        "market_cap": "Small Cap"
    },
    "VIVE": {
        "short_name": "Viveve Medical, Inc.",
        "long_name": "Viveve Medical, Inc.",
        "summary": "Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. The company was founded in 2005 and is headquartered in Englewood, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Englewood",
        "zipcode": "80112",
        "website": "http://www.viveve.com",
        "market_cap": "Small Cap"
    },
    "VIVO": {
        "short_name": "Meridian Bioscience Inc.",
        "long_name": "Meridian Bioscience, Inc.",
        "summary": "Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Cincinnati",
        "zipcode": "45244",
        "website": "http://www.meridianbioscience.com",
        "market_cap": "Small Cap"
    },
    "VKTX": {
        "short_name": "Viking Therapeutics, Inc.",
        "long_name": "Viking Therapeutics, Inc.",
        "summary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00c3\u009f), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00c3\u009f for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92130",
        "website": "http://www.vikingtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "VLON": {
        "short_name": "Vallon Pharmaceuticals Inc.",
        "long_name": "Vallon Pharmaceuticals, Inc.",
        "summary": "Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Philadelphia",
        "zipcode": "19103",
        "website": "http://www.vallon-pharma.com",
        "market_cap": "Small Cap"
    },
    "VLXC": {
        "short_name": "VELTEX CORP",
        "long_name": "Veltex Corporation",
        "summary": "Veltex Corporation focuses on the development and acquisition of companies that have modalities in the areas of health, wellness, and recovery. Its target markets include rehab and treatment centers. The company was founded in 1987 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60602",
        "website": "http://www.veltex.com",
        "market_cap": "Small Cap"
    },
    "VM4.F": {
        "short_name": "VANDA PHARMAC.INC.DL-,001",
        "long_name": "Vanda Pharmaceuticals Inc.",
        "summary": "Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037",
        "website": "http://www.vandapharma.com",
        "market_cap": "Small Cap"
    },
    "VMCS": {
        "short_name": "VISUALMED CLINICAL SOLUTIONS",
        "long_name": "VisualMED Clinical Solutions Corp.",
        "summary": "VisualMED Clinical Solutions Corp., a medical information company, distributes clinical information systems. The company provides VisualMED system, a suite of software modules that constitute a functional Clinical Information System. VisualMED is an informatics tool that enables the physician to make informed diagnostic and therapeutic decisions at the point of care. It also offers VisualMED modules, including administrative/support module that allows users with the appropriate security rights to access screens that are used to define and modify the basic architectural structure; VisualMED nursing module, which integrates all physician/nursing clinical functions at the order entry and clinical data entry levels; and VisualMED clinical module that correspond to the individual clinical specialty of medicine of the healthcare institution or a particular division or ward of the institution, such as VisualER, VisualSurgeon, VisualPediatrics, and VisualICU. In addition, the company provides electronic medical record modules, which are used by physicians, consultants, nursing staff, and paramedical staff to record patient's admission and progress notes; and VisualONCOLOGY module to oncology departments and cancer clinics. It serves hospitals, healthcare delivery organizations, and regional and national healthcare authorities. The company was formerly known as Ancona Mining Corp. and changed its name to VisualMED Clinical Solutions Corp. in November 2004. VisualMED Clinical Solutions Corp. was founded in 1999 and is based in Reno, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Reno",
        "zipcode": "89501",
        "website": null,
        "market_cap": "Small Cap"
    },
    "VMD": {
        "short_name": "Viemed Healthcare, Inc.",
        "long_name": "Viemed Healthcare, Inc.",
        "summary": "Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "LA",
        "city": "Lafayette",
        "zipcode": "70508",
        "website": "http://www.viemed.com",
        "market_cap": "Small Cap"
    },
    "VMD.TO": {
        "short_name": "VIEMED HEALTHCARE INC",
        "long_name": "Viemed Healthcare, Inc.",
        "summary": "Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "United States",
        "state": "LA",
        "city": "Lafayette",
        "zipcode": "70508",
        "website": "http://www.viemed.com",
        "market_cap": "Small Cap"
    },
    "VNDA": {
        "short_name": "Vanda Pharmaceuticals Inc.",
        "long_name": "Vanda Pharmaceuticals Inc.",
        "summary": "Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "DC",
        "city": "Washington",
        "zipcode": "20037",
        "website": "http://www.vandapharma.com",
        "market_cap": "Small Cap"
    },
    "VNM.DE": {
        "short_name": "VARIAN MEDICAL SYS  DL 1",
        "long_name": "Varian Medical Systems, Inc.",
        "summary": "Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through Oncology Systems and Proton Solutions segments. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, artificial intelligence based adaptive radiotherapy, and brachytherapy, as well as quality assurance equipment. Its products include linear accelerators, brachytherapy afterloaders, treatment accessories, and quality assurance software; and information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices, medical oncology practices, radiotherapy centers, and cancer care clinics. The company has a strategic agreement with McKesson Corp. to supply treatment delivery systems and planning, services, and radiotherapy information system solutions to its U.S. Oncology Network and Vantage Oncology affiliated sites of care; strategic partnership with Siemens AG to represent Siemens diagnostic imaging products to radiation oncology clinics in the United States and other select markets; and collaboration with Google Cloud. Varian Medical Systems, Inc. was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. The company was founded in 1948 and is headquartered in Palo Alto, California. As of April 15, 2021, Varian Medical Systems, Inc. operates as a subsidiary of Siemens Healthineers AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Appliances & Equipment",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "CA",
        "city": "Palo Alto",
        "zipcode": "94304-1038",
        "website": "http://www.varian.com",
        "market_cap": "Large Cap"
    },
    "VNRX": {
        "short_name": "VolitionRX Limited",
        "long_name": "VolitionRx Limited",
        "summary": "VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78738",
        "website": "http://www.volition.com",
        "market_cap": "Small Cap"
    },
    "VNTH": {
        "short_name": "NANO MOBILE HEALTHCARE INC",
        "long_name": "Nano Mobile Healthcare, Inc.",
        "summary": "Nano Mobile Healthcare, Inc. operates as a mobile health technology company in the United States. The company develops personalized and point-of-care screening using applications based upon chemical sensing methods. It has a strategic partnership with Theranostics Laboratory, a translational research company. The company was formerly known as Vantage mHealthcare, Inc. and changed its name to Nano Mobile Healthcare, Inc. in September 2015. Nano Mobile Healthcare, Inc. was incorporated in 2010 and is based in Boston, Massachusetts. Nano Mobile Healthcare, Inc. is a subsidiary of Nanobeak, LLC.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "62108",
        "website": "http://nanomobilehealthcare.com",
        "market_cap": "Small Cap"
    },
    "VOQP": {
        "short_name": "VIOQUEST PHARMACEUTICALS INC",
        "long_name": "VioQuest Pharmaceuticals, Inc.",
        "summary": "VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products' lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Basking Ridge",
        "zipcode": "07920",
        "website": null,
        "market_cap": "Small Cap"
    },
    "VOR": {
        "short_name": "Vor Biopharma Inc.",
        "long_name": "Vor Biopharma Inc.",
        "summary": "Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02140",
        "website": "http://www.vorbio.com",
        "market_cap": "Small Cap"
    },
    "VPA1.F": {
        "short_name": "AVEO PHARMA.NEW DL-,001",
        "long_name": "AVEO Pharmaceuticals, Inc.",
        "summary": "AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02108",
        "website": "http://www.aveooncology.com",
        "market_cap": "Small Cap"
    },
    "VPRO": {
        "short_name": "VIROPRO INC",
        "long_name": "Viropro Inc.",
        "summary": "Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis. It manufactures biologics drugs, including bio-similars for pre-clinical, and Phase I, II, and III clinical trials; offers its clients with supply of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products; owns three clones that include two in insulin therapy and one for cancer therapy; and provides contractual research and manufacturing services to biotech and biopharmaceutical companies. The company's contractual work activities include cloning, sequencing, purifying, developing, validating, and producing biopharmaceutical products and sub-products. It has operations in Canada, the United Kingdom, and Malaysia. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. The company is based in San Jose, California. Viropro Inc. is a subsidiary of Alpha Biologics Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "San Jose",
        "zipcode": "95131",
        "website": "http://www.viropro.net",
        "market_cap": "Small Cap"
    },
    "VRAY": {
        "short_name": "ViewRay, Inc.",
        "long_name": "ViewRay, Inc.",
        "summary": "ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Oakwood",
        "zipcode": "44146",
        "website": "http://www.viewray.com",
        "market_cap": "Small Cap"
    },
    "VRCA": {
        "short_name": "Verrica Pharmaceuticals Inc.",
        "long_name": "Verrica Pharmaceuticals Inc.",
        "summary": "Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "West Chester",
        "zipcode": "19380",
        "website": "http://www.verrica.com",
        "market_cap": "Small Cap"
    },
    "VRCI": {
        "short_name": "VERDE SCIENCE INC",
        "long_name": "Verde Science, Inc.",
        "summary": "Verde Science, Inc., a pharmaceutical research and development company, focuses on developing a portfolio of cannabinoid based prescription medicines for various medical conditions. The company was formerly known as Rango Energy, Inc. and changed its name to Verde Science, Inc. in May 2014. Verde Science, Inc. was founded in 2007 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Dallas",
        "zipcode": "75208",
        "website": "http://www.verdescienceinc.com",
        "market_cap": "Small Cap"
    },
    "VRDN": {
        "short_name": "Viridian Therapeutics, Inc.",
        "long_name": "Viridian Therapeutics, Inc.",
        "summary": "Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Boulder",
        "zipcode": "80301",
        "website": "http://www.viridiantherapeutics.com",
        "market_cap": "Small Cap"
    },
    "VREO.CN": {
        "short_name": "VireoHealth",
        "long_name": "Vireo Health International, Inc.",
        "summary": "Vireo Health International Inc. operates as a physician-led cannabis company in the United States. It cultivates cannabis; manufactures pharmaceutical-grade cannabis extracts; and sells its products through its network of Green Goods and other retail locations, and third-party dispensaries. The company grows and/or processes cannabis in eight markets and operates 16 dispensaries. Vireo Health International Inc. is headquartered in Minneapolis, Minnesota.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55408",
        "website": "http://www.vireohealth.com",
        "market_cap": "Small Cap"
    },
    "VREOF": {
        "short_name": "VIREO HEALTH INTERNATIONAL INC",
        "long_name": "Goodness Growth Holdings, Inc.",
        "summary": "Vireo Health International Inc. operates as a physician-led cannabis company in the United States. It cultivates cannabis; manufactures pharmaceutical-grade cannabis extracts; and sells its products through its network of Green Goods and other retail locations, and third-party dispensaries. The company grows and/or processes cannabis in eight markets and operates 16 dispensaries. Vireo Health International Inc. is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Minneapolis",
        "zipcode": "55408",
        "website": "http://www.vireohealth.com",
        "market_cap": "Small Cap"
    },
    "VREX": {
        "short_name": "Varex Imaging Corporation",
        "long_name": "Varex Imaging Corporation",
        "summary": "Varex Imaging Corporation designs and manufactures X-ray imaging components. The company operates in two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components comprising X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, 3D reconstruction and computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers, and buckys (a component of X-ray units that holds X-ray film cassettes). This segment's products are used in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy, oncology, CT, cardiac, surgery, dental, computer-aided detection, and other diagnostic radiography uses. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital detectors, and high voltage connectors for use in security and industrial inspection applications, such as airport security, cargo screening at ports and borders, and nondestructive testing and examination in various applications. Varex Imaging Corporation sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, Latin America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was founded in 2016 and is based in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "UT",
        "city": "Salt Lake City",
        "zipcode": "84104",
        "website": "http://www.vareximaging.com",
        "market_cap": "Small Cap"
    },
    "VRNO.CN": {
        "short_name": "Verano Holdings",
        "long_name": "Verano Holdings Corp.",
        "summary": "Verano Holdings Corp. operates as a vertically-integrated multi-state cannabis operator in the United States. The company produces and sells a suite of cannabis products under the portfolio of consumer brands, including Encore, Avexia, M\u00c3\u009cV, and Verano. It designs, builds, and operates dispensaries under the Zen Leaf and M\u00c3\u009cV retail brands that delivers a cannabis shopping experience in medical and adult-use markets. The company also holds, operates, manages, consults, licenses, and/or controls licenses/permits in the states of Illinois, Florida, Arizona, New Jersey, Pennsylvania, Ohio, Maryland, Massachusetts, Nevada, Michigan, Arkansas, California, Missouri, and West Virginia; and engages in the wholesale of cannabis consumer packaged goods. Verano Holdings Corp. was founded in 2017 and is headquartered in Chicago, Illinois.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.verano.com",
        "market_cap": null
    },
    "VRNOF": {
        "short_name": "VERANO HOLDINGS CORP",
        "long_name": "Verano Holdings Corp.",
        "summary": "Verano Holdings Corp. operates as a vertically-integrated multi-state cannabis operator in the United States. The company produces and sells a suite of cannabis products under the portfolio of consumer brands, including Verano, Avexia, Encore, and M\u00c3\u009cV. It designs, builds, and operates dispensaries under the Zen Leaf and M\u00c3\u009cV retail brands that delivers a cannabis shopping experience in medical and adult-use markets. The company also holds, operates, manages, consults, licenses, and/or controls licenses/permits in the states of Illinois, Maryland, New Jersey, Massachusetts, Nevada, Ohio, Pennsylvania, Michigan, Arkansas, California, Missouri, and West Virginia; and engages in the wholesale of cannabis consumer packaged goods. Verano Holdings Corp. was founded in 2017 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60654",
        "website": "http://www.verano.com",
        "market_cap": null
    },
    "VRPX": {
        "short_name": "Virpax Pharmaceuticals, Inc.",
        "long_name": "Virpax Pharmaceuticals, Inc.",
        "summary": "Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Malvern",
        "zipcode": "19380",
        "website": "http://www.virpaxpharma.com",
        "market_cap": "Small Cap"
    },
    "VRTX.MX": {
        "short_name": "VERTEX PHARMACEUTICAL",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.vrtx.com",
        "market_cap": "Large Cap"
    },
    "VRTX": {
        "short_name": "Vertex Pharmaceuticals Incorpor",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.vrtx.com",
        "market_cap": "Large Cap"
    },
    "VRTX.VI": {
        "short_name": "VERTEX PHARMACEUTICALS INC",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.vrtx.com",
        "market_cap": "Large Cap"
    },
    "VRTX34.SA": {
        "short_name": "VERTEX PHARMDRN",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.vrtx.com",
        "market_cap": "Large Cap"
    },
    "VSMD": {
        "short_name": "VASAMED INC",
        "long_name": "Vasamed, Inc.",
        "summary": "Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MN",
        "city": "Eden Prairie",
        "zipcode": "55344",
        "website": "http://www.vasamed.com",
        "market_cap": "Small Cap"
    },
    "VSTM": {
        "short_name": "Verastem, Inc.",
        "long_name": "Verastem, Inc.",
        "summary": "Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Needham",
        "zipcode": "02494",
        "website": "http://www.verastem.com",
        "market_cap": "Small Cap"
    },
    "VT6.F": {
        "short_name": "VOYAGER THERAP.  DL -,001",
        "long_name": "Voyager Therapeutics, Inc.",
        "summary": "Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.voyagertherapeutics.com",
        "market_cap": "Small Cap"
    },
    "VTEQ": {
        "short_name": "VERITEQ CORPORATION",
        "long_name": "VeriTeQ Corporation",
        "summary": "VeriTeQ Corporation operates as an online retailer of orthopedic braces, physical therapy devices, and rehabilitation equipment. It provides orthopedic braces for knee, ankle, back, wrist, shoulder, elbow, foot, and neck categories; and hot and cold therapy, electric simulation, medical tables, and ambulatory devices. The company distributes its products through Website, as well as sells to healthcare professionals, hospitals and clinics, government institutions, and school sports teams. VeriTeQ Corporation was founded in 1995 and is based in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33487",
        "website": null,
        "market_cap": "Small Cap"
    },
    "VTGN": {
        "short_name": "VistaGen Therapeutics, Inc.",
        "long_name": "VistaGen Therapeutics, Inc.",
        "summary": "VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://www.vistagen.com",
        "market_cap": "Small Cap"
    },
    "VTI.AX": {
        "short_name": "VISIONTECH CDI FORUS",
        "long_name": "Visioneering Technologies, Inc.",
        "summary": "Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in North America, Europe, and the Asia-Pacific. It offers NaturalVue, a multifocal contact lens for adults with presbyopia and children with myopia. The company was incorporated in 2008 and is headquartered in Alpharetta, Georgia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United States",
        "state": "GA",
        "city": "Alpharetta",
        "zipcode": "30009",
        "website": "http://vtivision.com",
        "market_cap": "Small Cap"
    },
    "VTRS": {
        "short_name": "Viatris Inc.",
        "long_name": "Viatris Inc.",
        "summary": "Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Canonsburg",
        "zipcode": "15317",
        "website": "http://www.viatris.com",
        "market_cap": "Large Cap"
    },
    "VTVT": {
        "short_name": "vTv Therapeutics Inc.",
        "long_name": "vTv Therapeutics Inc.",
        "summary": "vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "High Point",
        "zipcode": "27265",
        "website": "http://www.vtvtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "VVOS": {
        "short_name": "Vivos Therapeutics, Inc.",
        "long_name": "Vivos Therapeutics, Inc.",
        "summary": "Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. It caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers, and patients in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2007 and is based in Highlands Ranch, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Highlands Ranch",
        "zipcode": "80129",
        "website": "http://www.vivoslife.com",
        "market_cap": "Small Cap"
    },
    "VX1.DE": {
        "short_name": "VERTEX PHARMAC.  DL-,01",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.vrtx.com",
        "market_cap": "Large Cap"
    },
    "VX1.F": {
        "short_name": "VERTEX PHARMAC.  DL-,01",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02210",
        "website": "http://www.vrtx.com",
        "market_cap": "Large Cap"
    },
    "VXRT.MX": {
        "short_name": "VAXART INC",
        "long_name": "Vaxart, Inc.",
        "summary": "Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://vaxart.com",
        "market_cap": "Small Cap"
    },
    "VXRT": {
        "short_name": "Vaxart, Inc. - Common Stock",
        "long_name": "Vaxart, Inc.",
        "summary": "Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "South San Francisco",
        "zipcode": "94080",
        "website": "http://vaxart.com",
        "market_cap": "Small Cap"
    },
    "VYCO": {
        "short_name": "VYCOR MEDICAL  INC",
        "long_name": "Vycor Medical, Inc.",
        "summary": "Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates in two segments, Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. Vycor Medical, Inc. has a license and transition agreement with HelferApp GmbH, which grants HelferApp the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria, and Switzerland. The company primarily serves hospitals and medical professionals. Vycor Medical, Inc. was incorporated in 2005 and is headquartered in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Boca Raton",
        "zipcode": "33487",
        "website": "http://www.vycormedical.com",
        "market_cap": "Small Cap"
    },
    "VYGR.MX": {
        "short_name": "VOYAGER THERAPEUTICS INC",
        "long_name": "Voyager Therapeutics, Inc.",
        "summary": "Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.voyagertherapeutics.com",
        "market_cap": "Small Cap"
    },
    "VYGR": {
        "short_name": "Voyager Therapeutics, Inc.",
        "long_name": "Voyager Therapeutics, Inc.",
        "summary": "Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.voyagertherapeutics.com",
        "market_cap": "Small Cap"
    },
    "VYND": {
        "short_name": "VYNLEADS INC",
        "long_name": "Vynleads, Inc.",
        "summary": "Vynleads, Inc. provides health and wellness information to pre-diabetic individuals or type 2 diabetes sufferers. The company offers Lifestyle Blueprint, a digital guide that provides dietary recommendations for a very low calorie eight-week diet, as well as nutritional information. It also sells nutritional supplements; and monthly subscriptions to proprietary newsletter that covers a range of healthy living-related topics. Vynleads, Inc. was incorporated in 2015 and is headquartered in Rock Hill, South Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "SC",
        "city": "Rock Hill",
        "zipcode": "29730",
        "website": "http://www.vynleads.com",
        "market_cap": "Small Cap"
    },
    "VYNE": {
        "short_name": "VYNE Therapeutics Inc.",
        "long_name": "VYNE Therapeutics Inc.",
        "summary": "VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Bridgewater",
        "zipcode": "08807",
        "website": "http://www.vynetherapeutics.com",
        "market_cap": "Small Cap"
    },
    "VYNT": {
        "short_name": "Vyant Bio, Inc.",
        "long_name": "Vyant Bio, Inc.",
        "summary": "Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Cherry Hill",
        "zipcode": "08002",
        "website": "http://www.vyantbio.com",
        "market_cap": "Small Cap"
    },
    "W8A.F": {
        "short_name": "WALGREENS BOOTS AL.DL-,01",
        "long_name": "Walgreens Boots Alliance, Inc.",
        "summary": "Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services. As of August 31, 2020, this segment operated 9,021 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies. The Retail Pharmacy International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as through boots.com and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 550 optical practices, including 165 on a franchise basis. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in the United Kingdom, Germany, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.walgreensbootsalliance.com",
        "market_cap": "Large Cap"
    },
    "WAT": {
        "short_name": "Waters Corporation",
        "long_name": "Waters Corporation",
        "summary": "Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Milford",
        "zipcode": "01757",
        "website": "http://www.waters.com",
        "market_cap": "Large Cap"
    },
    "WATC34.SA": {
        "short_name": "WATERS CORP DRN",
        "long_name": "Waters Corporation",
        "summary": "Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "MA",
        "city": "Milford",
        "zipcode": "01757",
        "website": "http://www.waters.com",
        "market_cap": "Large Cap"
    },
    "WAZ.F": {
        "short_name": "WATERS CORP.  DL-,01",
        "long_name": "Waters Corporation",
        "summary": "Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Milford",
        "zipcode": "01757",
        "website": "http://www.waters.com",
        "market_cap": "Large Cap"
    },
    "WBA.BA": {
        "short_name": "WALGREENS BOOTS AL",
        "long_name": "Walgreens Boots Alliance, Inc.",
        "summary": "Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services. As of August 31, 2020, this segment operated 9,021 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies. The Retail Pharmacy International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as through boots.com and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 550 optical practices, including 165 on a franchise basis. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in the United Kingdom, Germany, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.walgreensbootsalliance.com",
        "market_cap": null
    },
    "WBA.MX": {
        "short_name": "WALGREENS BOOTS ALLIANCE INC",
        "long_name": "Walgreens Boots Alliance, Inc.",
        "summary": "Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services. As of August 31, 2020, this segment operated 9,021 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies. The Retail Pharmacy International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as through boots.com and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 550 optical practices, including 165 on a franchise basis. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in the United Kingdom, Germany, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.walgreensbootsalliance.com",
        "market_cap": "Large Cap"
    },
    "WBA": {
        "short_name": "Walgreens Boots Alliance, Inc.",
        "long_name": "Walgreens Boots Alliance, Inc.",
        "summary": "Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services. As of August 31, 2020, this segment operated 9,021 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies. The Retail Pharmacy International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as through boots.com and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 550 optical practices, including 165 on a franchise basis. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in the United Kingdom, Germany, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.walgreensbootsalliance.com",
        "market_cap": "Large Cap"
    },
    "WBA.VI": {
        "short_name": "WALGREENS BOOTS ALLIANCE INC",
        "long_name": "Walgreens Boots Alliance, Inc.",
        "summary": "Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services. As of August 31, 2020, this segment operated 9,021 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies. The Retail Pharmacy International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as through boots.com and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 550 optical practices, including 165 on a franchise basis. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in the United Kingdom, Germany, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.walgreensbootsalliance.com",
        "market_cap": "Large Cap"
    },
    "WCUI": {
        "short_name": "WELLNESS CTR USA INC",
        "long_name": "Wellness Center USA, Inc.",
        "summary": "Wellness Center USA, Inc. engages in the healthcare and medical businesses in the United States and internationally. It operates through Medical Devices, and Authentication and Encryption Products and Services segments. The company is primarily involved in the marketing and distribution of online sports and nutrition supplements. It also designs, develops, manufactures, markets, and distributes targeted ultraviolet phototherapy devices, including Psoria-Light that is used in targeted PUVA photochemistry and UVB phototherapy for the treatment of skin conditions, such as psoriasis, vitiligo, atopic dermatitis, seborrheic dermatitis, and leukoderma. In addition, the company offers Intelligent Microparticles, which provide technologies within the security and supply chain management vertical sectors; and ActiveDuty, a data intelligence services comprising proprietary, unprecedented, and actionable technology for industries, companies, and agencies. Wellness Center USA, Inc. was founded in 2010 and is based in Tuscon, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Hoffman Estates",
        "zipcode": "60169",
        "website": "http://www.wellnesscenterusa.com",
        "market_cap": "Small Cap"
    },
    "WEK.F": {
        "short_name": "ZIOPHARM ONCOLOGY DL-,001",
        "long_name": "ZIOPHARM Oncology, Inc.",
        "summary": "ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02129",
        "website": "http://ziopharm.com",
        "market_cap": "Small Cap"
    },
    "WEQL": {
        "short_name": "WELLQUEST MED & WELLNESS CORP",
        "long_name": "WellQuest Medical & Wellness Corporation",
        "summary": "WellQuest Medical & Wellness Corporation provides an integrated medical delivery site with family physician healthcare, preventive/wellness, and medical skin-care services. It operates medical center that provides physician-directed medical service for families and businesses, which offers a range of medical care for adults and children with digital diagnostic tests, including laboratory, X-ray, EKG, and others. The company also offers various immunizations for all ages; and weight loss program, nutritional counseling, allergy testing, fitness consulting, hormone therapy, and therapeutic massage services, as well as designs personalized treatment plans. In addition, it manufactures and sells heart support; bone and joint support; stress, mood, and sleep support; immune support; and vitamins and minerals capsules. Further, the company provides aesthetic services, which include medical spa, laser skin renewal, botox and dermal fillers, skin print technology, facials and derma sweep, Glo minerals, and teeth whitening services. Additionally, it offers corporate wellness, occupational and executive health, genetic testing, and tobacco cessation services. The company was formerly known as HQHealthQuest Medical & Wellness Centers, Ltd. and changed its name to WellQuest Medical & Wellness Corporation in April 2008. WellQuest Medical & Wellness Corporation was incorporated in 2004 and is based in Bentonville, Arkansas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AR",
        "city": "Bentonville",
        "zipcode": "72712",
        "website": "http://www.wellquestmedical.com",
        "market_cap": "Small Cap"
    },
    "WGB.F": {
        "short_name": "INTEGER HLDGS  DL-,001",
        "long_name": "Integer Holdings Corporation",
        "summary": "Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Plano",
        "zipcode": "75024",
        "website": "http://www.integer.net",
        "market_cap": "Mid Cap"
    },
    "WGBA34.SA": {
        "short_name": "WALGREENS   DRN",
        "long_name": "Walgreens Boots Alliance, Inc.",
        "summary": "Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services. As of August 31, 2020, this segment operated 9,021 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies. The Retail Pharmacy International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as through boots.com and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 550 optical practices, including 165 on a franchise basis. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in the United Kingdom, Germany, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "IL",
        "city": "Deerfield",
        "zipcode": "60015",
        "website": "http://www.walgreensbootsalliance.com",
        "market_cap": "Large Cap"
    },
    "WHSI": {
        "short_name": "WEARABLE HEALTH SOLUTIONS INC",
        "long_name": "Wearable Health Solutions, Inc.",
        "summary": "Wearable Health Solutions, Inc. provides personal response monitoring services and related products to subscribers with medical or age-related conditions in the United States. The company manufactures medical alarm devices that are used to summon help in the event of an emergency. It offers MediPendant, a medical alarm product with speaker in the pendant that enables the user to simply speak and listen directly through the pendant in the event of an emergency; and iHelp, a mobile medical alarm device that utilizes T-Mobile's 2G network to remotely locate a loved one and voice prompts, as well as a dealer portal that enables dealers to manage their own iHelp customer base. The company is also designing and developing iHelp+3G, a wearable biosensor device for health and wellness that operates on 3G network. It offers its products primarily for the elderly and physically disabled, as well as for persons living alone. The company markets its products through its Websites, medipendant.com, and ihelpalarm.com; and wholesalers, as well as distributes its products in Denmark, Ireland, Bermuda, and the People's Republic of China. The company was formerly known as Medical Alarm Concepts Holdings, Inc. and changed its name to Wearable Health Solutions, Inc. in June 2016. Wearable Health Solutions, Inc. was founded in 2008 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "Las Vegas",
        "zipcode": "89169",
        "website": "http://www.wearablehealthsolutions.com",
        "market_cap": "Small Cap"
    },
    "WINT": {
        "short_name": "Windtree Therapeutics, Inc.",
        "long_name": "Windtree Therapeutics, Inc.",
        "summary": "Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Warrington",
        "zipcode": "18976-3622",
        "website": "http://www.windtreetx.com",
        "market_cap": "Small Cap"
    },
    "WLSI": {
        "short_name": "WELLSTAR INTERNATIONAL INC",
        "long_name": "Wellstar International, Inc.",
        "summary": "Wellstar International, Inc. does not have significant operations. Previously, the company, through its subsidiary, Trillennium Medical Imaging, Inc., engaged in developing and licensing advanced thermal imaging technology in the consumer health care markets. Its technology enabled a diagnostic screening procedure for the early breast cancer detection; the differential diagnosis of pain dysfunctions, such as reflex sympathetic dystrophy, neuromuscular skeletal syndromes, and neurological disorders; and the detection of pressure ulcers, deep tissue injuries, and bed sores, as well as orthopedic applications. Wellstar International, Inc. was founded in 1997 and is based in Holland, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Holland",
        "zipcode": "43528",
        "website": null,
        "market_cap": "Small Cap"
    },
    "WMGR": {
        "short_name": "WELLNESS MATRIX GROUP INC",
        "long_name": "Wellness Matrix Group, Inc.",
        "summary": "Wellness Matrix Group, Inc. focuses on developing and designing virtual reality/AR creative artificial intelligence platform through integrating the health and wellness industry networks, and program tools. It intends to offer the doctors and methodologies with genome analysis, monitoring, and predictive modeling simulation providing a state of the art wellness program for quality of life longevity under the Wellness Matrix Group brand. The company was formerly known as Fuhuiyuan International Holdings Limited and changed its name to Wellness Matrix Group, Inc. in June 2018. Wellness Matrix Group, Inc. was incorporated in 2009 and is headquartered in Huntington Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Huntington Beach",
        "zipcode": "92647",
        "website": "http://www.wellnessmatrixgroup.com",
        "market_cap": "Small Cap"
    },
    "WORX": {
        "short_name": "SCWorx Corp.",
        "long_name": "SCWorx Corp.",
        "summary": "SCWorx Corp. provides software solutions for the management of health care providers' foundational business applications in the United States. The company provides services related to repair, normalization, and interoperability of information, as well as big data analytics model that provides Web portal for display, and reporting and analysis of the information contained within the data warehouse. It also offers various software solutions and services, such as virtualized item master file repair, expansion, and automation; electronic medical record management, a module that integrates the advanced data attributes created in the item master to the electronic medical records; charge description master management(CDM), a module, which assists healthcare providers by integrating the CDM data into the workflow of the hospitals purchasing systems; contract management, a module that assists healthcare providers to establish a contract management system and to provide care to patients; request for proposal automation solution; rebate management; ScanWorx, a mobile perioperative closed loop scanning solution; and data integration and warehousing, as well as solutions for integration of acquired businesses, which enable deployment of a virtual item master files. The company sells its solutions and services to hospitals and health systems through its distribution and reseller partnerships. In addition, it provides CageTix, a ticketing platform for mixed martial arts industry. Further, the company focuses on selling rapid test kits for COVID-19; and personal protective equipment. SCWorx Corp. is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10022",
        "website": "http://www.scworx.com",
        "market_cap": "Small Cap"
    },
    "WOWU": {
        "short_name": "WOWI INC",
        "long_name": "WOWI, Inc.",
        "summary": "WOWI, Inc., an early-stage company, engages in the business of licensing technology and intellectual property to operators and businesses in the legal cannabis industry in the United States. The company also provides packaging and labeling, as well as equipment and real property leasing services to various companies. In addition, it offers a plethora of consulting services, including proper business structure and management services in the legal cannabis space serving cultivations, growers, extractors, and dispensaries that operate legally in states that has legal medicinal and/or recreational legislation. The company is headquartered in Centennial, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Centennial",
        "zipcode": "80112",
        "website": "http://worldofweedinc.com",
        "market_cap": "Small Cap"
    },
    "WPHM": {
        "short_name": "WINSTON PHARMACEUTICALS INC",
        "long_name": "Winston Pharmaceuticals, Inc.",
        "summary": "Winston Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes therapeutics for pain management. It focuses on pain indications, such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo-and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease, as well as niche indications. Winston Pharmaceuticals, Inc. was formerly known as Winston Laboratories, Inc. and changed its name to Winston Pharmaceuticals, Inc. in November 2008. The company was incorporated in 1998 and is headquartered in Vernon Hills, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Vernon Hills",
        "zipcode": "60061",
        "website": "http://www.winstonlabs.com",
        "market_cap": "Small Cap"
    },
    "WPS.DE": {
        "short_name": "WEST PHARM.SVCS  DL-,25",
        "long_name": "West Pharmaceutical Services, Inc.",
        "summary": "West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "PA",
        "city": "Exton",
        "zipcode": "19341-0645",
        "website": "http://www.westpharma.com",
        "market_cap": "Large Cap"
    },
    "WPS.F": {
        "short_name": "WEST PHARM.SVCS  DL-,25",
        "long_name": "West Pharmaceutical Services, Inc.",
        "summary": "West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "Exton",
        "zipcode": "19341-0645",
        "website": "http://www.westpharma.com",
        "market_cap": "Large Cap"
    },
    "WSRC": {
        "short_name": "WESTERN SIERRA RESOURCE CORP",
        "long_name": "Western Sierra Resource Corporation",
        "summary": "Western Sierra Resource Corporation engages in the formulation, manufacture, infusion, packaging, and distribution of high-quality CBD products and other products derived from industrial hemp. Its products include creams, salves, ointments, tinctures, beverages, organic jams, and other health and wellness products. The company was formerly known as Western Sierra Mining Corp. and changed its name to Western Sierra Resource Corporation in September 2018. The company was founded in 1907 and is based in Lake Havasu City, Arizona. Western Sierra Resource Corporation is a subsidiary of Matchaah Holdings, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "AZ",
        "city": "Lake Havasu City",
        "zipcode": "86403",
        "website": "http://westernsierraresource.com",
        "market_cap": "Small Cap"
    },
    "WST": {
        "short_name": "West Pharmaceutical Services, I",
        "long_name": "West Pharmaceutical Services, Inc.",
        "summary": "West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Exton",
        "zipcode": "19341-0645",
        "website": "http://www.westpharma.com",
        "market_cap": "Large Cap"
    },
    "WTKN": {
        "short_name": "WELLTEK INCORP",
        "long_name": "WellTek Incorporated",
        "summary": "WellTek Incorporated operates as a health, fitness, and wellness company that provides solutions to address obesity, and chronic neck and back pain in the United States. It engages in the manufacture, market, and distribution of medical, rehabilitation, and exercise equipment. The company also involves in building a network of medical back and neck rehabilitation centers offering a proprietary program to managed care companies, self-insured employer groups, and federal government agencies. In addition, it operates a social networking site, which allows in reaching, engaging, and influencing health and wellness conscious consumers with new and existing brand assets, technologies, products, and services. WellTek Incorporated was founded in 2003 and is headquartered in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Orlando",
        "zipcode": "32801",
        "website": "http://www.welltekinc.com",
        "market_cap": "Small Cap"
    },
    "WWHC": {
        "short_name": "W WORLD CORP",
        "long_name": "W World Corp.",
        "summary": "W World Corp., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat a range of metabolic and nervous system disorders. The company focuses on the disorders of the brain-gut axis, pain/inflammation, and autoimmune, as well as gout disorders. Its lead compounds under clinically development include Levotofisopam, a non-sedating agent for the treatment of Gout; and Dextofisopam, a non-serotonergic agent, which has completed Phase IIa and Phase IIb clinical trials for the treatment of irritable bowel syndrome. The company was founded in 1990 and is headquartered in North Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "NV",
        "city": "North Las Vegas",
        "zipcode": "89084",
        "website": "http://www.pharmoscorp.com",
        "market_cap": "Small Cap"
    },
    "X0M.F": {
        "short_name": "XOMA CORP.PRF.SH.SER.A 25",
        "long_name": "XOMA Corporation",
        "summary": "XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.xoma.com",
        "market_cap": null
    },
    "X0M1.F": {
        "short_name": "XOMA CORP.  DL -,0005",
        "long_name": "XOMA Corporation",
        "summary": "XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.xoma.com",
        "market_cap": "Small Cap"
    },
    "XAIR": {
        "short_name": "Beyond Air, Inc.",
        "long_name": "Beyond Air, Inc.",
        "summary": "Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Garden City",
        "zipcode": "11530",
        "website": "http://www.beyondair.net",
        "market_cap": "Small Cap"
    },
    "XBIO": {
        "short_name": "Xenetic Biosciences, Inc.",
        "long_name": "Xenetic Biosciences, Inc.",
        "summary": "Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Framingham",
        "zipcode": "01701",
        "website": "http://www.xeneticbio.com",
        "market_cap": "Small Cap"
    },
    "XBIT": {
        "short_name": "XBiotech Inc.",
        "long_name": "XBiotech Inc.",
        "summary": "XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78744",
        "website": "http://www.xbiotech.com",
        "market_cap": "Small Cap"
    },
    "XCRT": {
        "short_name": "XCELERATE INC",
        "long_name": "Xcelerate Inc.",
        "summary": "Xcelerate Inc., through its subsidiaries, provides dental services in the United States. The company operates a network of dental providers, the Dental Referral, who provide dental services through the network to union members in accordance with arrangements between UDC and various labor unions. It also manages the operation of a general dental practice. The company is based in Coral Springs, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "FL",
        "city": "Coral Springs",
        "zipcode": "33071",
        "website": "http://www.xcelerate.global",
        "market_cap": "Small Cap"
    },
    "XCUR": {
        "short_name": "Exicure, Inc.",
        "long_name": "Exicure, Inc.",
        "summary": "Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA\u00c2\u0096based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60614",
        "website": "http://www.exicuretx.com",
        "market_cap": "Small Cap"
    },
    "XCY.F": {
        "short_name": "OPKO HEALTH INC.  DL-,01",
        "long_name": "OPKO Health, Inc.",
        "summary": "OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "FL",
        "city": "Miami",
        "zipcode": "33137",
        "website": "http://www.opko.com",
        "market_cap": "Mid Cap"
    },
    "XE7C.F": {
        "short_name": "CARDIFF ONCOLOG. DL-,0001",
        "long_name": "Cardiff Oncology, Inc.",
        "summary": "Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "San Diego",
        "zipcode": "92121",
        "website": "http://www.cardiffoncology.com",
        "market_cap": "Small Cap"
    },
    "XE9.F": {
        "short_name": "XENCOR INC.  DL-,01",
        "long_name": "Xencor, Inc.",
        "summary": "Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestl\u00c3\u00a9 S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Monrovia",
        "zipcode": "91016",
        "website": "http://www.xencor.com",
        "market_cap": "Mid Cap"
    },
    "XEJ.F": {
        "short_name": "ACCURAY INC.  DL -,001",
        "long_name": "Accuray Incorporated",
        "summary": "Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "Sunnyvale",
        "zipcode": "94089",
        "website": "http://www.accuray.com",
        "market_cap": "Small Cap"
    },
    "XENO": {
        "short_name": "XENO TRANSPLANTS CORPORATION",
        "long_name": "Xeno Transplants Corporation",
        "summary": "Xeno Transplants Corporation operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation. The Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species into humans, such as swine. Xeno Transplants Corporation was incorporated in 2004 and is based in Brookline, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Brookline",
        "zipcode": "02445",
        "website": null,
        "market_cap": "Small Cap"
    },
    "XENT": {
        "short_name": "Intersect ENT, Inc.",
        "long_name": "Intersect ENT, Inc.",
        "summary": "Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Menlo Park",
        "zipcode": "94025",
        "website": "http://www.intersectent.com",
        "market_cap": "Small Cap"
    },
    "XERS": {
        "short_name": "Xeris Pharmaceuticals, Inc.",
        "long_name": "Xeris Pharmaceuticals, Inc.",
        "summary": "Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "IL",
        "city": "Chicago",
        "zipcode": "60601",
        "website": "http://www.xerispharma.com",
        "market_cap": "Small Cap"
    },
    "XFOR": {
        "short_name": "X4 Pharmaceuticals, Inc.",
        "long_name": "X4 Pharmaceuticals, Inc.",
        "summary": "X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenstr\u00c3\u00b6m macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02134",
        "website": "http://www.x4pharma.com",
        "market_cap": "Small Cap"
    },
    "XGN": {
        "short_name": "Exagen Inc.",
        "long_name": "Exagen Inc.",
        "summary": "Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease requiring aggressive therapy, such as anti-TNF biologics; and AVISE PC4d that measures platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test that measures levels of MTXPG; and AVISE HCQ, a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Vista",
        "zipcode": "92081",
        "website": "http://www.exagen.com",
        "market_cap": "Small Cap"
    },
    "XLRN": {
        "short_name": "Acceleron Pharma Inc.",
        "long_name": "Acceleron Pharma Inc.",
        "summary": "Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Cambridge",
        "zipcode": "02139",
        "website": "http://www.acceleronpharma.com",
        "market_cap": "Mid Cap"
    },
    "XMPA.F": {
        "short_name": "PLUS THERAPEUTICS",
        "long_name": "Plus Therapeutics, Inc.",
        "summary": "Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78756",
        "website": "http://www.plustherapeutics.com",
        "market_cap": "Small Cap"
    },
    "XMS.F": {
        "short_name": "XTANT MEDICAL HLDGS",
        "long_name": "Xtant Medical Holdings, Inc.",
        "summary": "Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as used in conjunction with a hardware plate system. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous Fusion System; Silex Sacroiliac joint fusion system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "MT",
        "city": "Belgrade",
        "zipcode": "59714",
        "website": "http://www.xtantmedical.com",
        "market_cap": "Small Cap"
    },
    "XNCR": {
        "short_name": "Xencor, Inc.",
        "long_name": "Xencor, Inc.",
        "summary": "Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestl\u00c3\u00a9 S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Monrovia",
        "zipcode": "91016",
        "website": "http://www.xencor.com",
        "market_cap": "Mid Cap"
    },
    "XOMA": {
        "short_name": "XOMA Corporation",
        "long_name": "XOMA Corporation",
        "summary": "XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.xoma.com",
        "market_cap": "Small Cap"
    },
    "XOMAO": {
        "short_name": "XOMA Corporation - Depositary S",
        "long_name": "XOMA Corporation",
        "summary": "XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.xoma.com",
        "market_cap": null
    },
    "XRAY": {
        "short_name": "DENTSPLY SIRONA Inc.",
        "long_name": "DENTSPLY SIRONA Inc.",
        "summary": "DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Charlotte",
        "zipcode": "28277-3607",
        "website": "http://www.dentsplysirona.com",
        "market_cap": "Large Cap"
    },
    "XRAY.VI": {
        "short_name": "DENTSPLY SIRONA INC",
        "long_name": "DENTSPLY SIRONA Inc.",
        "summary": "DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "NC",
        "city": "Charlotte",
        "zipcode": "28277-3607",
        "website": "http://www.dentsplysirona.com",
        "market_cap": "Large Cap"
    },
    "XRAY34.SA": {
        "short_name": "DENTSPLY SIRDRN",
        "long_name": "DENTSPLY SIRONA Inc.",
        "summary": "DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NC",
        "city": "Charlotte",
        "zipcode": "28277-3607",
        "website": "http://www.dentsplysirona.com",
        "market_cap": "Large Cap"
    },
    "XSNX": {
        "short_name": "NOVACCESS GLOBAL INC",
        "long_name": "NovAccess Global Inc.",
        "summary": "NovAccess Global Inc., a biopharmaceutical company, engages in developing novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company is headquartered in Chesterland, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "OH",
        "city": "Chesterland",
        "zipcode": "44026",
        "website": "http://www.novaccessglobal.com",
        "market_cap": "Small Cap"
    },
    "XTNT": {
        "short_name": "Xtant Medical Holdings, Inc.",
        "long_name": "Xtant Medical Holdings, Inc.",
        "summary": "Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as used in conjunction with a hardware plate system. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous Fusion System; Silex Sacroiliac joint fusion system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "MT",
        "city": "Belgrade",
        "zipcode": "59714",
        "website": "http://www.xtantmedical.com",
        "market_cap": "Small Cap"
    },
    "XXII": {
        "short_name": "22nd Century Group, Inc.",
        "long_name": "22nd Century Group, Inc.",
        "summary": "22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "Williamsville",
        "zipcode": "14221",
        "website": "http://www.xxiicentury.com",
        "market_cap": "Small Cap"
    },
    "YAG2.F": {
        "short_name": "ATOSSA THERAPEU. DL -,015",
        "long_name": "Atossa Therapeutics, Inc.",
        "summary": "Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98104",
        "website": "http://www.atossatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "YAG2.SG": {
        "short_name": "Atossa Genetics Inc. Registered",
        "long_name": "Atossa Therapeutics, Inc.",
        "summary": "Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "state": "WA",
        "city": "Seattle",
        "zipcode": "98104",
        "website": "http://www.atossatherapeutics.com",
        "market_cap": "Small Cap"
    },
    "YB4P.F": {
        "short_name": "SAVARA INC.  DL-,001",
        "long_name": "Savara Inc.",
        "summary": "Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "TX",
        "city": "Austin",
        "zipcode": "78746",
        "website": "http://www.savarapharma.com",
        "market_cap": "Small Cap"
    },
    "YBAO": {
        "short_name": "YBCC INC",
        "long_name": "YBCC, Inc.",
        "summary": "YBCC, Inc. does not have significant operations. The company focuses on the acquisition of or merger with an existing company. Previously, it was engaged in the bio-science manufacture and research business. The company is based in Walnut, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Walnut",
        "zipcode": "91789",
        "website": "http://www.ybccinc.com",
        "market_cap": "Small Cap"
    },
    "YBOC.F": {
        "short_name": "TENAX THERAPEUTICS DL-,01",
        "long_name": "Tenax Therapeutics, Inc.",
        "summary": "Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NC",
        "city": "Morrisville",
        "zipcode": "27560",
        "website": "http://www.tenaxthera.com",
        "market_cap": "Small Cap"
    },
    "YCBD": {
        "short_name": "cbdMD, Inc.",
        "long_name": "cbdMD, Inc.",
        "summary": "cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. It owns and operates consumer hemp-based CBD brands, such as cbdMD and Paw CBD. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. It distributes its products through its e-commerce Website, third party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was founded in 2015 and is headquartered in Charlotte, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "NC",
        "city": "Charlotte",
        "zipcode": "28217",
        "website": "http://www.cbdmd.com",
        "market_cap": "Small Cap"
    },
    "YDO1.F": {
        "short_name": "MADRIGAL PHARMAC.  DL-,01",
        "long_name": "Madrigal Pharmaceuticals, Inc.",
        "summary": "Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-\u00c3\u009f agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "PA",
        "city": "West Conshohocken",
        "zipcode": "19428",
        "website": "http://www.madrigalpharma.com",
        "market_cap": "Small Cap"
    },
    "YMAB": {
        "short_name": "Y-mAbs Therapeutics, Inc.",
        "long_name": "Y-mAbs Therapeutics, Inc.",
        "summary": "Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10169",
        "website": "http://www.ymabs.com",
        "market_cap": "Small Cap"
    },
    "YMTX": {
        "short_name": "Yumanity Therapeutics, Inc.",
        "long_name": "Yumanity Therapeutics, Inc.",
        "summary": "Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02135",
        "website": "http://www.yumanity.com",
        "market_cap": "Small Cap"
    },
    "Z081.F": {
        "short_name": "ZOGENIX INC.  DL-,001",
        "long_name": "Zogenix, Inc.",
        "summary": "Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.zogenix.com",
        "market_cap": "Small Cap"
    },
    "Z1BH34.SA": {
        "short_name": "ZIMMER BIOMEDRN",
        "long_name": "Zimmer Biomet Holdings, Inc.",
        "summary": "Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "IN",
        "city": "Warsaw",
        "zipcode": "46580",
        "website": "http://www.zimmerbiomet.com",
        "market_cap": "Large Cap"
    },
    "Z1TS34.SA": {
        "short_name": "ZOETIS INC  DRN",
        "long_name": "Zoetis Inc.",
        "summary": "Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "state": "NJ",
        "city": "Parsippany",
        "zipcode": "07054",
        "website": "http://www.zoetis.com",
        "market_cap": "Large Cap"
    },
    "ZBH.MX": {
        "short_name": "ZIMMER BIOMET HOLDINGS INC",
        "long_name": "Zimmer Biomet Holdings, Inc.",
        "summary": "Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "IN",
        "city": "Warsaw",
        "zipcode": "46580",
        "website": "http://www.zimmerbiomet.com",
        "market_cap": "Large Cap"
    },
    "ZBH": {
        "short_name": "Zimmer Biomet Holdings, Inc.",
        "long_name": "Zimmer Biomet Holdings, Inc.",
        "summary": "Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "IN",
        "city": "Warsaw",
        "zipcode": "46580",
        "website": "http://www.zimmerbiomet.com",
        "market_cap": "Large Cap"
    },
    "ZBH.SW": {
        "short_name": "ZIMMER HLD",
        "long_name": "Zimmer Biomet Holdings, Inc.",
        "summary": "Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "United States",
        "state": "IN",
        "city": "Warsaw",
        "zipcode": "46580",
        "website": "http://www.zimmerbiomet.com",
        "market_cap": "Large Cap"
    },
    "ZCBD": {
        "short_name": "BODY BASICS INC",
        "long_name": "Body Basics Inc.",
        "summary": "Body Basics Inc. does not have any business operations. The company was formerly known as Platforms Wireless International Corporation and changed its name to Body Basics Inc. in January 2019. The company was incorporated in 1992 and is headquartered in Northridge, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Northridge",
        "zipcode": "91324",
        "website": null,
        "market_cap": "Small Cap"
    },
    "ZGNX": {
        "short_name": "Zogenix, Inc.",
        "long_name": "Zogenix, Inc.",
        "summary": "Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "EmeryVille",
        "zipcode": "94608",
        "website": "http://www.zogenix.com",
        "market_cap": "Small Cap"
    },
    "ZIM.F": {
        "short_name": "ZIMMER BIOMET HLDGS DL-01",
        "long_name": "Zimmer Biomet Holdings, Inc.",
        "summary": "Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "IN",
        "city": "Warsaw",
        "zipcode": "46580",
        "website": "http://www.zimmerbiomet.com",
        "market_cap": "Large Cap"
    },
    "ZIOP": {
        "short_name": "ZIOPHARM Oncology Inc",
        "long_name": "ZIOPHARM Oncology, Inc.",
        "summary": "ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MA",
        "city": "Boston",
        "zipcode": "02129",
        "website": "http://ziopharm.com",
        "market_cap": "Small Cap"
    },
    "ZIVO": {
        "short_name": "Zivo Bioscience, Inc.",
        "long_name": "ZIVO Bioscience, Inc.",
        "summary": "ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Keego Harbor, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Keego Harbor",
        "zipcode": "48320",
        "website": "http://www.zivobioscience.com",
        "market_cap": "Mid Cap"
    },
    "ZNTL": {
        "short_name": "Zentalis Pharmaceuticals, Inc.",
        "long_name": "Zentalis Pharmaceuticals, Inc.",
        "summary": "Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10018",
        "website": "http://zentalis.com",
        "market_cap": "Mid Cap"
    },
    "ZOE.DE": {
        "short_name": "ZOETIS INC. CL.A  DL -,01",
        "long_name": "Zoetis Inc.",
        "summary": "Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "state": "NJ",
        "city": "Parsippany",
        "zipcode": "07054",
        "website": "http://www.zoetis.com",
        "market_cap": "Large Cap"
    },
    "ZOE.F": {
        "short_name": "ZOETIS INC. CL.A  DL -,01",
        "long_name": "Zoetis Inc.",
        "summary": "Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "state": "NJ",
        "city": "Parsippany",
        "zipcode": "07054",
        "website": "http://www.zoetis.com",
        "market_cap": "Large Cap"
    },
    "ZOM": {
        "short_name": "Zomedica Corp.",
        "long_name": "Zomedica Corp.",
        "summary": "Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "state": "MI",
        "city": "Ann Arbor",
        "zipcode": "48108",
        "website": "http://zomedica.com",
        "market_cap": "Small Cap"
    },
    "ZOTS.VI": {
        "short_name": "ZOETIS INC",
        "long_name": "Zoetis Inc.",
        "summary": "Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "state": "NJ",
        "city": "Parsippany",
        "zipcode": "07054",
        "website": "http://www.zoetis.com",
        "market_cap": "Large Cap"
    },
    "ZSAN": {
        "short_name": "Zosano Pharma Corporation",
        "long_name": "Zosano Pharma Corporation",
        "summary": "Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "CA",
        "city": "Fremont",
        "zipcode": "94555",
        "website": "http://www.zosanopharma.com",
        "market_cap": "Small Cap"
    },
    "ZTS.MX": {
        "short_name": "ZOETIS INC",
        "long_name": "Zoetis Inc.",
        "summary": "Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "state": "NJ",
        "city": "Parsippany",
        "zipcode": "07054",
        "website": "http://www.zoetis.com",
        "market_cap": "Large Cap"
    },
    "ZTS": {
        "short_name": "Zoetis Inc.",
        "long_name": "Zoetis Inc.",
        "summary": "Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "state": "NJ",
        "city": "Parsippany",
        "zipcode": "07054",
        "website": "http://www.zoetis.com",
        "market_cap": "Large Cap"
    },
    "ZYNE": {
        "short_name": "Zynerba Pharmaceuticals, Inc.",
        "long_name": "Zynerba Pharmaceuticals, Inc.",
        "summary": "Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "state": "PA",
        "city": "Devon",
        "zipcode": "19333",
        "website": "http://zynerba.com",
        "market_cap": "Small Cap"
    },
    "ZYXI": {
        "short_name": "Zynex, Inc.",
        "long_name": "Zynex, Inc.",
        "summary": "Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "state": "CO",
        "city": "Englewood",
        "zipcode": "80112",
        "website": "http://www.zynex.com",
        "market_cap": "Small Cap"
    }
}